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A B S T R A C T
Background
Chronic plaque psoriasis is the most common type of psoriasis, and it is characterised by redness, thickness, and scaling. First-line
management of chronic plaque psoriasis is with topical treatments, including vitamin D analogues, topical corticosteroids, tar-based
preparations, dithranol, salicylic acid, and topical retinoids.
Objectives
To compare the effectiveness, tolerability, and safety of topical treatments for chronic plaque psoriasis, relative to placebo, and to
similarly compare vitamin D analogues (used alone or in combination) with other topical treatments.
Search methods
Weupdated our searches of the following databases to February 2011: the Cochrane Skin Group Specialised Register, CENTRAL inThe
Cochrane Library (2011, Issue 2), MEDLINE (from 1948), EMBASE (from 1980), Science Citation Index (from 2008), Conference
Proceedings Citation Index - Science (from 2008), BIOSIS (from 1993), Dissertation Abstracts via DialogClassic (all publication years),
and Inside Conferences (all publication years).
We identified ongoing and unpublished studies from the UK Clinical Research Network Study Portfolio and the metaRegister of
Controlled Trials. We checked the bibliographies of published studies and reviews for further references to relevant trials, and we
contacted trialists and companies for information about newly published studies.
A separate search for adverse effects was undertaken in February 2011 using MEDLINE and EMBASE (from 2005).
Final update searches for both RCTs and adverse effects were undertaken in August 2012. Although it has not been possible to
incorporate RCTs and adverse effects studies identified through these final searches within this review, we will incorporate these into
the next update.
Selection criteria
Randomised trials comparing active topical treatments against placebo or against vitamin D analogues (used alone or in combination)
in people with chronic plaque psoriasis.
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Data collection and analysis
One author extracted study data and assessed study quality. A second author checked these data. We routinely contacted trialists and
companies for missing data. We also extracted data on withdrawals and on local and systemic adverse events. We defined long-term
trials as those with a duration of at least 24 weeks.
Main results
This update added 48 trials and provided evidence on 7 new active treatments. In total, the review included 177 randomised controlled
trials, with 34,808 participants, including 26 trials of scalp psoriasis and 6 trials of inverse psoriasis, facial psoriasis, or both. The
number of included studies counted by Review Manager (RevMan) is higher than these figures (190) because we entered each study
reporting a placebo and an active comparison into the ’Characteristics of included studies’ table as 2 studies.
When used on the body, most vitamin D analogues were significantly more effective than placebo, with the standardised mean difference
(SMD) ranging from -0.67 (95% CI -1.04 to -0.30; 1 study, 119 participants) for twice-daily becocalcidiol to SMD -1.66 (95% CI -
2.66 to -0.67; 1 study, 11 participants) for once-daily paricalcitol. On a 6-point global improvement scale, these effects translate into
0.8 and 1.9 points, respectively. Most corticosteroids also performed better than placebo; potent corticosteroids (SMD -0.89; 95%
CI -1.06 to -0.72; I² statistic = 65.1%; 14 studies, 2011 participants) had smaller benefits than very potent corticosteroids (SMD -
1.56; 95% CI -1.87 to -1.26); I² statistic = 81.7%; 10 studies, 1264 participants). On a 6-point improvement scale, these benefits
equate to 1.0 and 1.8 points, respectively. Dithranol, combined treatment with vitamin D/corticosteroid, and tazarotene all performed
significantly better than placebo.
Head-to-head comparisons of vitamin D for psoriasis of the body against potent or very potent corticosteroids had mixed findings.
For both body and scalp psoriasis, combined treatment with vitamin D and corticosteroid performed significantly better than vitamin
D alone or corticosteroid alone. Vitamin D generally performed better than coal tar, but findings relative to dithranol were mixed.
When applied to psoriasis of the scalp, vitamin D was significantly less effective than both potent corticosteroids and very potent
corticosteroids. Indirect evidence from placebo-controlled trials supported these findings.
For both body and scalp psoriasis, potent corticosteroids were less likely than vitamin D to cause local adverse events, such as burning
or irritation. Combined treatment with vitamin D/corticosteroid on either the body or the scalp was tolerated as well as potent
corticosteroids, and significantly better than vitamin D alone. Only 25 trials assessed clinical cutaneous dermal atrophy; few cases were
detected, but trials reported insufficient information to determine whether assessment methods were robust. Clinical measurements of
dermal atrophy are insensitive and detect only the most severe cases. No comparison of topical agents found a significant difference in
systemic adverse effects.
Authors’ conclusions
Corticosteroids perform at least as well as vitamin D analogues, and they are associated with a lower incidence of local adverse events.
However, for people with chronic plaque psoriasis receiving long-term treatment with corticosteroids, there remains a lack of evidence
about the risk of skin dermal atrophy. Further research is required to inform long-term maintenance treatment and provide appropriate
safety data.
P L A I N L A N G U A G E S U M M A R Y
Skin treatments for chronic plaque psoriasis
Chronic plaque psoriasis is the most common type of psoriasis. Although any part of the body may be affected, the most commonly
affected sites are the elbows, knees, and scalp. ’Topical’ treatments (i.e. treatments applied to the skin) are usually tried first. These
include vitamin D products, topical corticosteroids, tar-based preparations, dithranol, salicylic acid, and vitamin A products. As chronic
plaque psoriasis is a long-term condition, it is important to find out which treatments work best and what adverse effects they have.
This review describes average benefits of different treatments, while recognising that individuals will vary in their experience of each
treatment.
The evidence was based on 177 studies, which, in total, included 34,808 people. Studies were typically about 7 weeks’ long, but
this ranged from 1 week to 52 weeks. Vitamin D products were found to work better than placebo (the base cream or ointment).
Potent topical corticosteroids (strong, e.g. betamethasone dipropionate) and very potent (very strong, e.g. clobetasol propionate) topical
corticosteroids were also effective.
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Some studies compared vitamin D products directly with potent or very potent corticosteroids. These products had similar effects when
applied to the body, but corticosteroids worked better than vitamin D for scalp psoriasis. Treatment that combined vitamin D with a
corticosteroid was more effective than vitamin D alone and more effective than the topical corticosteroid alone. Vitamin D products
generally performed better than coal tar, but studies found conflicting results when comparing vitamin D with dithranol.
Whether applied to the body or to the scalp, potent corticosteroids were less likely than vitamin D to cause ’local adverse events’,
such as skin irritation or burning, and people were therefore more likely to stop using vitamin D products. When studies examined
whether topical treatments had effects within the body (’systemic adverse events’), we found no difference between placebo and any
other treatment. However, this may be because many trials did not properly assess systemic adverse events, rather than because there
really was no difference.
More long-term studies would help doctors and people with psoriasis decide on the best way to treat this chronic condition.
B A C K G R O U N D
Description of the condition
Psoriasis is a chronic inflammatory skin disease with a prevalence
ranging from between 1% and 2% in the UK and northern Eu-
ropean populations (Hellgren 1967; Krueger 1984) to 0.1% to
0.3% in the Far East (Simons 1949) and China (Yip 1984). Pso-
riasis comprises multiple phenotypes and may be localised (e.g.
to the skin-fold areas (inverse psoriasis), the palms, or the soles)
or widespread. Types of widespread psoriasis include guttate, gen-
eralised pustular, and erythrodermic (Griffiths 2007). Chronic
plaque psoriasis may be localised or widespread and accounts for
90% of psoriasis cases (Griffiths 2007); it is characterised by red
patches of thickened skin (plaques) covered in silver scales (Figure
1). Any area of the body may be affected, but the main areas are
the knees, elbows, lower back, and scalp. There is a wide spec-
trum of disease severity from a single plaque to involvement of
more than 90% of the skin surface. Psoriasis may be classified as
’mild’, ’moderate’, or ’severe’, although these categories are dif-
ficult to define precisely (Krueger 2000). Psoriatic arthritis ac-
companies the cutaneous (skin) manifestations of psoriasis in 5%
to 30% of cases (Barisic-Drusko 1994; Krueger 1984; Salvarani
1995; Zanolli 1992). Recent improvements in the classification
criteria may reduce the wide variation in reported prevalence of
psoriatic arthritis (Taylor 2006). Psoriasis occurs in 5% of people
with Crohn’s disease (Lee 1990).
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Figure 1. Chronic plaque psoriasisSource: Dermis Dermatology Atlas Online (used with permission)
Causes
The way that psoriasis develops is complicated and appears
to be influenced by many factors, including genetic changes,
local trauma, infections, certain drugs (such as beta-blockers,
lithium, chloroquine, and non-steroidal anti-inflammatory drugs
(NSAIDs)), the duration of antipsoriatic treatments, endocrine
factors, sunlight, alcohol, smoking, and stress (Tagami 1997). The
skin lesions of psoriasis are shown in Figure 2, and they are char-
acterised by cells multiplying too quickly (epidermal hyperprolif-
eration), cells not maturing normally (abnormal keratinocyte dif-
ferentiation), and the presence of cells that cause inflammation (a
lymphocyte inflammatory infiltrate) (Barker 1991;Griffiths 2003;
Stern 1997). Psoriasis is now recognised as an immune-mediated
disorder, with tumour necrosis factor alpha (TNFα), dendritic
cells, and T-cells all contributing to its pathogenesis (Griffiths
2007a). Several genes interact with environmental factors to in-
duce the development of psoriasis, and different combinations of
changes in several genes and environmental factors can produce
the same clinical picture of psoriasis (Bhalerao 1998; Brandrup
1978; Farber 1974; Lomholt 1963; Willan 1808). A locus (plural
= loci) is the specific location of a gene on a chromosome, and its
position is defined using the letters ’p’ (for a chromosome’s short
arm) and ’q’ (for a long arm). At least nine chromosomal psoriasis
susceptibility loci were originally identified (Griffiths 2007a). The
strongest association and linkage is to a locus within the major
histocompatibility complex, the area affecting immune response
(Genetic Analysis of Psoriasis Consortium 2010; Henseler 1992;
Russell 1972; Svejgaard 1974; Tazi-Ahnini 1999a; Tazi-Ahnini
1999b; Trembath 1997).Other linkage studies have reported link-
age to 4q and17q (Matthews 1996;Tomfohrde 1994) and16q and
20q (Nair 1997; Trembath 1997). Proinflammatory CD4-positive
T helper cells produce interferon gamma (produced by Th1) or
interleukin (IL)-17 (produced by Th17). These cells interact with
dendritic cells, macrophages, mast cells, and neutrophils, causing
inflammation (Ghoreschi 2007). A meta-analysis of 3 genome-
wide association studies (GWAS) has identified 15 new suscep-
tibility loci (Tsoi 2012) for psoriasis. This brings the total num-
ber of loci associated with psoriasis to 36. Several of these loci are
involved in the regulation of the skin’s innate immune response.
They provide confirmation of the role of several existing biologic
therapies as well as new targets for drug development.
4Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. The epidermis in the skin of people with and without psoriasis
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Impact
Until identified as a single disease by von Hebra in 1841, psoriasis
was thought to be a variant of leprosy and regarded as contagious
(de Jong 1997). The misconception may persist: In a survey of
peoplewith psoriasis in 1997, almost three-quarters of respondents
reported that others thought their condition was contagious, and
a similar proportion feared swimming and taking part in sporting
activities (Watts 1998). Psoriasis can lead to social isolation (van
de Kerkhof 1997a), stigmatisation (Gupta 1998; van de Kerkhof
1997a), and fear of other people’s reactions, adversely affecting
the quality of daily life (Finlay 1994; Finlay 1995a; Finlay 1995b;
Finlay 2001; McKenna 2003; Ortonne 2000; Richards 2003;
Stern 1995). Psychological distress induced by psoriasis may also
impair the response to treatment (Fortune 2003).
Description of the intervention
Treatment of psoriasis should always be appropriate to its severity
and importance to that individual: It should never be more un-
pleasant, intolerable, or dangerous than the disease itself (Camp
1992). Topical treatments include vitamin D analogues, top-
ical corticosteroids, tar-based preparations, dithranol, salicylic
acid, and topical retinoids (Baadsgaard 1995; Corbett 1976;
Fredriksson 1980; Goeckerman 1931; Ingram 1953; Kragballe
1988; Kragballe 1989; Langner 1996; Staberg 1989; Unna 1916;
Van de Kerkhof 1996a), but there is no evidence-based ’treatment
ladder’ by which to sequence treatments (Van de Kerkhof 2008).
Emollients are generally used in a supportive role as an addition
to topical treatments, to normalise hyperproliferation, differentia-
tion, and to exert anti-inflammatory effects (Fluhr 2008). The two
classes of topical treatment for psoriasis that are most commonly
prescribed in developed countries are vitamin D analogues and
topical corticosteroids, because they are considered more cosmet-
ically acceptable than tar and dithranol preparations (Baadsgaard
1995; Kragballe 1988; Van de Kerkhof 1996a).
Topical corticosteroids (specifically glucocorticoids) are available
in four potencies: mild, moderate, potent, and very potent, which
are assessed using the vasoconstrictor assay (BMA 2012). The
benefit of topical steroids is that in cream formulations, they are
easy to apply, cosmetically acceptable, do not stain the skin, and
rarely cause irritation. There are several adverse effects of corti-
costeroids, including cutaneous atrophy, rebound after discontin-
uation of treatment, and decreasing response to the drug (tachy-
phylaxis) (du Vivier 1975; Lee 1998; Kao 2003). Glucocorticoids
(GC) exert their effects either via interaction with cell membranes
(non-genomic effects) or downstream with the genome and via in-
teraction with intracellular fluid in GC receptors and downstream
with the genome (genomic effects). The genomic effects are of two
types: “transrepression (inhibition of synthesis of regulatory pro-
teins) and transactivation (induction of the synthesis of regulatory
proteins)” (Bos 2008). Transactivation appears to mediate certain
adverse reactions, such as cutaneous atrophy. Immunomodulation
seems to be the result of GC-mediated transrepression, that is, si-
lencing of proinflammatory genes, such as TNFα. Non-steroidal
GC receptor ligands (selective GC receptor agonists) have recently
been identified andmay reduce the side-effects of GCwithout loss
of immunosuppressive effects (Bos 2008).
The naturally occurring active metabolite of vitamin D, calcitriol
(1a,25-dihydroxyvitamin D3) (Langner 1996), and two synthetic
vitamin D analogues, calcipotriol (Kragballe 1988; Kragballe
1989; Staberg 1989) and tacalcitol (1a,24-dihydroxyvitamin D3)
(Baadsgaard 1995; Van de Kerkhof 1996a), are effective when ap-
plied topically in psoriasis (Mason 2002a). These agents bind to
vitamin D receptors (VDR), which in turn bind to vitamin D-
responsive elements (VDRE) in multiple genes. ’Switching on’
(transactivation of ) these genes inhibits the multiplication of cells
and stimulates their differentiation (Figure 2). VDRs also suppress
the inflammatory component of psoriasis by inhibiting the pro-
duction of proinflammatory cytokines (small proteins that affect
cell-cell interaction), such as interleukin-1 (IL-1). Vitamin D ana-
logues all have the potential to induce abnormally high levels of
calcium in the blood serum (hypercalcaemia) and urine (hyper-
calciuria). Although calcipotriol ointment causes no elevation of
total serum calcium when used at the recommended dose of 100
g per week (Mortensen 1993), there are significant elevations in
both serum and urinary calcium when the dose is increased to
300 g per week (Bourke 1993a; Bourke 1994). Topical vitamin
D analogues are cosmetically acceptable; they are not known to
cause skin atrophy; and they are not usually associated with re-
bound when therapy is discontinued. However, at least 25% of
people are reported to have little or no response to topical vitamin
D analogues (Holick 1996; Mee 1998).
Urea or salicylic acid may be used to reduce thickness and scaling
of the skin; combination with other products can improve their
absorption. However, these can also irritate the skin. Topical im-
munosuppressants, such as methotrexate, and topical macrolac-
tams, such as tacrolimus, are relatively new treatments, and their
effectiveness, tolerability, and longer-term effects are less clear than
with the more established products. This review also considers
combination products involving any of the above treatments.
The Cochrane Library has three published Cochrane reviews of in-
terventions for psoriasis. Owen 2000 assessed the impact of anti-
streptococcal interventions for guttate and chronic plaque psoria-
sis. The review found that “although both antibiotics and tonsil-
lectomy have frequently been advocated for patients with recur-
rent guttate psoriasis or chronic plaque psoriasis, there is to date
no good evidence that either intervention is beneficial.” Chalmers
2000 reviewed all treatments, excluding antistreptococcal inter-
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ventions, for guttate psoriasis. The review identified only one rele-
vant trial and no evidence of the effectiveness of any topical inter-
ventions. Chalmers 2006 assessed interventions, including topical
treatments, for chronic palmoplantar pustulosis (a disease that is
closely related to psoriasis and used to be considered a variant of
psoriasis). Chalmers 2006 found that topical steroids under hydro-
colloid occlusionwere effective in inducing remission. In addition,
The Cochrane Library has four published Cochrane review proto-
cols, which cover interventions for nail psoriasis (Velema 2009),
interventions for scalp psoriasis (Jales 2012), phototherapy (Chen
2011), and the biological agent ustekinumab (Roberts 2011).
Why it is important to do this review
Chronic plaque psoriasis is a condition forwhich there is no known
cure, and currently, available treatments may only temporarily
clear the skin (Bonifati 1998; Griffiths 2004). Clinical practice
varies between and within different countries. By focusing on top-
ical treatments for psoriasis, either as monotherapy or in combina-
tion, this review assesses the relative effectiveness, tolerability, and
safety of these treatments and so helps to determine how best to
induce remission and delay recurrence in people receiving topical
treatment. Table 1 provides a list of acronyms used in the review.
Structure of the Review
The structure of the review is provided to facilitate navigation:
• Objectives
• Methods
• Results
• ◦ Description of the studies
◦ Risk of bias in the included studies
◦ Effects of the interventions
⋄ (1) Primary outcome measures
(a) Investigator’s Assessment of Overall Global Improvement
(IAGI)/Investigator’s Global Assessment of Disease Severity
(IGA)
(b) Total Severity Scores (TSS)
(c) Psoriasis Area and Severity Index (PASI)
(d) Patient Assessment of overall Global Improvement (PAGI)/
Patient Global Assessment of Disease Severity (PGA)
(e) Combined end point (IAGI/TSS/PASI/PAGI)
⋄ (2) Secondary outcome measures
(a) Withdrawal rates (total rate; withdrawal because of adverse
events; withdrawal because of treatment failure)
(b) Adverse events (local and systemic)
(i) Findings from the main review
(ii) Findings from the separate search for additional studies of
adverse events
(c) Quality of life measures
(d) Economic outcomes (not updated in 2011)
(e) Concordance or adherence with treatment (not updated in
2011)
• Discussion
• Authors’ conclusions
Under ’Primary outcome measures’, we report findings for each
of the 19 analyses (including sensitivity analyses). We also do this
under ’Secondary outcome measures’ for subsections (a) and (b).
We did not update the sections on Economic outcomes (2d) and
Concordance (2e) in 2011 because of resource constraints.
O B J E C T I V E S
To compare the effectiveness, tolerability, and safety of topical
treatments for chronic plaque psoriasis, relative to placebo, and to
similarly compare vitamin D analogues (used alone or in combi-
nation) with other topical treatments.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials in the review. Trials
could be either placebo-controlled or head-to-head with a vitamin
D preparation (head-to-head trials compare two active treatments
with each other). The types of study design eligible for inclusion
were as follows: parallel-group (between-patient), cross-over, and
within-patient designs. For within-patient studies, where study
participants serve as their own control, we included only those
studies that clearly adopted a left-right design, and we excluded
studies where multiple plaques were treated with more than two
products. If no useful effectiveness, withdrawal, or adverse events
data were available, either from the published paper or from spon-
sors or trialists, we excluded the study.
In addition to findings on adverse events from themain review, we
undertook separate searches for additional safety and tolerability
studies. The searches for longer-term adverse events included stud-
ies of any design that included humans (i.e. not only animals; ei-
ther humans only or humans and animals). However, studies with
fewer than 10 participants (including case reports) were not eligi-
ble for inclusion. We did not restrict the search for concordance/
adherence studies by study design (i.e. non-randomised studies
were eligible for inclusion).
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Types of participants
People of any age with chronic plaque psoriasis affecting the body,
limbs, scalp, or a combination of the aforementioned. We did not
limit participant type by area of involvement, disease severity, or
skin area treated.
Types of interventions
Topical treatments, including the following:
• vitamin D preparations, e.g. calcipotriol;
• corticosteroids, e.g. betamethasone valerate;
• coal tar;
• dithranol, also known as anthralin;
• salicylic acid;
• urea;
• topical retinoids;
• topical immunosuppressants, e.g. methotrexate;
• topical macrolactams, e.g. ascomycin derivatives, such as
tacrolimus; and
• combination products, e.g. corticosteroids with coal tar or
corticosteroids with vitamin D.
We compared topical treatments with vehicle (placebo). We also
compared vitamin D analogues with other topical treatments. We
selected vitamin D analogues for this comparison because they
are first-line treatments in many developed countries (van de
Kerkhof 1998). We based the potency of topical corticosteroids
on classifications from a previous review (Mason 2002b).
The review included any topical treatment for psoriasis, except for
products for which (a) no licence was obtained and (b) research
into the product was discontinued. The reason for this exclusion
criterion is that these products are unlikely to be of interest to
people making decisions about health care, such as policy-makers,
people with psoriasis, or clinicians. Although theymay be of inter-
est to researchers, lessons from the research into ’failed’ molecules
are likely to have been reflected in the development of subsequent
products.
Trials of systemic or ultraviolet (UV) (phototherapy) treatments
with adjunctive topical treatment were not eligible for inclusion
in the review.
Types of outcome measures
Table 2 provides an overviewof the effectiveness outcomemeasures
included in the review. We provide details of how we used the
primary outcomes to derive a ’combined end point’ in the section
’Measures of treatment effect’.
Primary outcomes
1. Investigator’s Assessment of Overall Global Improvement
(IAGI)/Investigator’s Global Assessment of Disease Severity
(IGA).
2. Total Severity Scores (TSS).
3. Psoriasis Area and Severity Index (PASI).
4. Patient Assessment of overall Global Improvement (PAGI)/
Patient Global Assessment of Disease Severity (PGA).
Secondary outcomes
1. Withdrawal rates (total rate; withdrawal due to adverse
events; withdrawal due to treatment failure).
2. Adverse events (local and systemic).
3. Quality of life measures.
4. Economic outcomes.
5. Concordance or adherence with treatment.
Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials
(RCTs) regardless of language or publication status (published,
unpublished, in press, or in progress).
Electronic searches
Search strategies used for the previous versionof the review (Mason
2009; see also Acknowledgements) were revised where appropriate
and rerun. We did not restrict the searches by body area affected.
The information specialists updated the search strategies to reflect
changes in the interfaces and MeSH (Medical Subject) headings,
as well as to incorporate terms for newly licensed products.
In February 2011, the following databases were searched for effec-
tiveness RCTs of psoriasis treatments:
• the Cochrane Skin Group Specialised Skin Register
(searched 8 February 2011) using the search strategy in
Appendix 1;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library (2011, Issue 2) using the
search strategy in Appendix 2;
• MEDLINE via OVID (from 1948) using the strategy in
Appendix 3;
• EMBASE via OVID (from 1980) using the strategy in
Appendix 4;
• Science Citation Index (SCI) via the Institute for Scientific
Information (ISI) Web of Knowledge interface (now known as
Thomson Reuters) (from 2008) using the strategy in Appendix 5;
• Conference Proceedings Citation Index - Science (CPCI-S)
via the ISI web of Knowledge interface (from 2008) using the
strategy in Appendix 5;
• BIOSIS via the DialogClassic interface (from 1993) using
the strategy in Appendix 6;
• Dissertation Abstracts via DialogClassic interface (from
inception) using the strategy in Appendix 7;
• Inside Conferences via DialogClassic interface (from
inception) using the strategy in Appendix 7;
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• System for Information on Grey Literature in Europe
(SIGLE) via WebSPIRS interface (search not updated) using the
strategy in Appendix 8;
• National Research Register (NRR) (CD-ROM interface,
issue 2004/4) using the strategy in Appendix 2; and
• the UK Clinical Research Network Study Portfolio (http://
public.ukcrn.org.uk/search/) using the strategy in Appendix 2.
To comply with Cochrane policy (stipulating that reviews must
be published within 12 months of the electronic searches being
run), further searches for this update were run on 23, 24, and 29
August 2012. Although it was not possible to incorporate RCTs
identified through this search within this review, we listed relevant
references in the ’Characteristics of studies awaiting classification’
tables. Theywill be incorporated into the next update of the review.
Searching other resources
References from published studies and reviews
We checked these for further references to relevant trials.
Unpublished literature
We routinely contacted trialists and companies for newly pub-
lished studies and missing data.
The metaRegister of Controlled Trials (http://www.controlled-
trials.com/mrct/) was searched in August 2012 for ongoing and
unpublished trials.
Adverse effects
On 2 February 2011, the following databases were searched for
studies of adverse events of specific psoriasis treatments:
• MEDLINE via OVID (see Appendix 9); and
• EMBASE via OVID (see Appendix 10).
We limited searches to English-language papers published in the
years between 2005 to 2011. In MEDLINE, the search was de-
signed to omit records with the following publication types: ’note’,
’comment’, and ’editorial’.
We also considered relevant adverse effects studies identified dur-
ing the screening for effectiveness trials.
These searches were updated in August 2012, identifying 537 new
references. We will incorporate these studies into the next update
of this review.
Concordance/adherence
We did not undertake searches for concordance/adherence in the
2011 review update because of resource constraints.
Language restrictions
There were no language restrictions when searching for effec-
tiveness RCTs or concordance/adherence studies. We restricted
searches for studies of adverse events to those published in English.
Data collection and analysis
Selection of studies
Two authors (AM and JM) screened titles and (where available)
abstracts identified from the searches, and another author (MC)
acted as an arbiter when necessary. In our protocol, we stated our
intention that we would exclude studies meeting only some of
the inclusion criteria stated above. However, this was infeasible,
because we would have needed to cite large numbers of studies
(over 1000). Therefore, we listed as excluded only those studies
that we deemed potentially eligible for inclusion and for which we
retrieved full papers, but which subsequently failed to meet the
inclusion criteria.
For the separate search for studies exploring adverse events, we
deemed studies as eligible if they addressed safety or tolerability
issues, focused on drugs included in the main review, and were
longer-term in follow-up (> 12 weeks). Short-term studies (with
follow-up < 12 weeks) were eligible for inclusion only if they were
designed specifically to consider adverse effects, tolerability, or sa-
fety. Studies that included fewer than 10 participants (including
case reports) were not eligible for inclusion.
For the separate search for studies of concordance/adherence with
treatment, studies were eligible if they addressed adherence with
topical treatment in people with any type of psoriasis. This section
was not updated because of resource constraints.
Data extraction and management
Applying methods from our original review (Mason 2002a), we
summarised the major attributes of trials, including treatment
forms, doses and duration, inclusion and exclusion criteria, level of
blinding, within-patient or between-patient (parallel-group) de-
sign, method of generation of the randomisation sequence, con-
cealment of allocation, numbers of participants randomised, base-
line comparability, loss to follow up, primary and secondary out-
comes, withdrawals, and adverse events. One reviewer (AM) ex-
tracted the data, and another reviewer (HH) checked these data.
We extracted data from trials on four primary outcomes:
1. IAGI (Investigator’s Assessment of Global Improvement) or
the IGA (Investigator’s Global Assessment of Disease Severity).
2. TSS (Total Severity Score).
3. PASI (Psoriasis Area and Severity Index).
4. PAGI (Patient Assessment of Global Improvement) or the
PGA (Patient Global Assessment of Disease Severity).
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Where available, we also extracted data on quality of life, economic
outcomes, and concordance/adherence.
In addition, we extracted data on withdrawal due to any reason,
such as adverse events or treatment failure, as well as adverse events
due to local and systemic effects.
For each outcome measure under a comparison, we included the
same treatment options regardless of data availability (see Data
and analyses). We did this for three reasons. Firstly, an inclusive
approach makes clear that there is an absence of data, not that
data have been omitted. Secondly, if data subsequently become
available when the review is updated in future, the correct structure
is in place for data entry. Thirdly, this approach ensures treatments
are always ordered identically regardless of outcome.
Assessment of risk of bias in included studies
Assessment of methodological quality
The quality assessment included an evaluation of each included
study, based on the following components, which are considered
to be associated with biased estimates of treatment effect (Juni
2001):
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - we considered this
’adequate’ if the assignment could not be foreseen;
(c)whowas blinded/not blinded (participants, clinicians, outcome
assessors); and
(d) how many participants were lost to follow up.
In addition, the quality assessment included the following:
(e) baseline assessment of the participants for age, sex, duration,
and severity of psoriasis; and
(f ) baseline comparability of intervention and control groups.
We recorded the information in the ’Characteristics of included
studies’ section.
Measures of treatment effect
Summarising primary outcomes with standardised mean
differences
We extracted data on four primary outcome measures:
• IAGI (Investigator’s Assessment of Global Improvement) or
the IGA (Investigator’s Global Assessment of Disease Severity)
• TSS (Total Severity Score)
• PASI (Psoriasis Area and Severity Index)
• PAGI (Patient Assessment of Global Improvement) or the
PGA (Patient Global Assessment of Disease Severity)
Trials often reported more than one measure, but none of the
trials reported all measures. We therefore devised a ’combined
end point’, which allowed more data to contribute to an overall
analysis and facilitated treatment comparisons. We labelled this
’super’ outcome as outcome (e) throughout the review.
We constructed the combined end point by taking IAGI (or IGA)
data when available, and failing this, TSS, PASI, or PAGI (PGA)
data in that order of availability. For PASI and TSS, some included
trials reported change scores and others reported end point scores.
In view of the mix of end point/change scores and of the variation
in scale, we analysed findings using a standardised mean difference
statistic (SMD) in a random-effects model. Table 2 summarises
the characteristics of the outcome measures.
We also expressed SMDs in physical units adjusting by the appro-
priate pooled standard deviation estimate (Table 3).
Secondary outcomes
We summarised data on adverse events, quality of life measures,
economic outcomes, and concordance as narratives. We sum-
marised withdrawal data using the risk difference (RD) metric and
pooled using a random-effects model. We felt this was more ap-
propriate than a fixed-effect model since definitions of withdrawal
and adverse events vary between trials.
Unit of analysis issues
Within-patient studies are statistically analogous to cross-over
studies, and results should be adjusted by the correlation coeffi-
cient (Section 16.4.6, Cochrane Handbook for Systematic Reviews
of Interventions; Higgins 2011). No study included in the review
reported this statistic, and we did not have access to patient-level
data, so could not estimate it directly.
On the subject of cross-over studies, the Cochrane Handbook for
Systematic Reviews of Interventions states (Section 16.4.5; Higgins
2011) the following: “A common situation is that means and stan-
dard deviations (or standard errors) are available only for mea-
surements on E [experimental group] and C [control group] sep-
arately. A simple approach to incorporating cross-over trials in a
meta-analysis is thus to take all measurements from intervention
E periods and all measurements from intervention C periods and
analyse these as if the trial were a parallel-group trial of E versus C.
This approach gives rise to a unit-of-analysis error (see Chapter 9,
Section 9.3) and should be avoided unless it can be demonstrated
that the results approximate those from a paired analysis, as de-
scribed in Section 16.4.4. The reason for this is that confidence
intervals are likely to be too wide, and the trial will receive too
little weight, with the possible consequence of disguising clinically
important heterogeneity. Nevertheless, this incorrect analysis is
conservative, in that studies are under-weighted rather than over-
weighted. While some argue against the inclusion of cross-over
trials in this way, the unit-of-analysis error might be regarded as
less serious than some other types of unit-of-analysis error.”
Consequently, we included within-patient studies as though
they were parallel-group studies, accepting that they are under-
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weighted. To explore whether it was appropriate to combine these
trials, we undertook two sensitivity analyses. First, we considered
how effect size varied for within- and between-patient studies. If
the magnitude of effect varied consistently between the two study
designs, this strongly suggested a non-zero correlation coefficient
and an appropriateness to separate the trials. Second, we used sen-
sitivity analysis to explore the impact on pooled findings of varying
the correlation coefficient (rho) for within-patient studies. This
analysis used the generic inverse variancemeasure, with SMDs and
their standard errors estimated from the formulae in the Cochrane
Handbook for Systematic Reviews of Interventions (Section 16.4.6.4)
(Higgins 2011). These estimated SMDs differ slightly from those
that RevMan estimates for continuous outcomes, even when the
correlation coefficient is zero (which is the assumption implicit in
the latter model).
The analyses found no evidence that the magnitude of effect var-
ied consistently.Within-patient trials did not consistently demon-
strate smaller or larger effects than between-patient trials. Varying
the value of rho had no significant effect on the findings: As rho
increased, the effect size increased and the confidence intervals
(usually) widened, but the magnitudes of changes were small and
non-significant at the 5% level.
In the interests of statistical purity, these trials could (a) be reported
separately or (b) be removed altogether. The drawback of option
(a) is that it makes an already complex review even more complex
and less accessible; the disadvantage of option (b) is that it removes
data that might be of interest to clinicians and people with psori-
asis. On balance, we preferred to report relevant randomised data
wherever possible to help inform pragmatic decision-making.
Dealing with missing data
We routinely contacted trialists and companies for missing data.
Where studies did not report estimates of variance, we derived
them from confidence intervals (CIs) or from P values where pos-
sible. Where we could not obtain estimates of variance, we im-
puted them deterministically by pooling the standard deviations
of treatment cohorts fully reported in trials and adjusted for scale
size.
We made separate imputations for each outcome measure (see
Table 3):
• for within-patient studies;
• for between-patient (parallel-group) studies;
• for end point scores;
• for change scores; and
• for scalp trials.
Within-patient designs are statistically analogous to cross-over
studies, and the precision of their findings within a meta-analysis
needs adjustment for within-patient correlation. We attempted to
explore this by sensitivity analysis.
Data synthesis
We analysed findings using a standardised mean difference statis-
tic (SMD) in a random-effects model. However, this model can-
not perfectly address all the sources of design complexity that
arise when summarising findings across studies. Three of the main
sources of complexity are listed below. Other sources of complex-
ity include variation in trial duration, disease severity, participant
demographics, treatment application method, dosing frequency,
drug potency and vehicle.
Study design (within- versus between-patient)
Trials were either between-patient or within-patient designs. The
former randomise participants into separate (parallel) groups; the
latter randomise treatments to the left or right side of the same
participant.Within- and between-patient trials have different vari-
ance structures. Moreover, the two responses (left and right) of
within-patient studiesmay be correlated (SeeUnit of analysis issues
for further details).
Absence of a simple one-to-one correspondence between
papers, trials, and comparisons
There were instances of single papers reporting either multiple
trials or multiple analyses within a single trial. Therefore, simple
counts of numbers of participants and numbers of studies con-
tributing data to the analysis were misleading, and we made ad-
justments accordingly (Table 4). Thus, these numbers may not
match the numbers estimated in RevMan, which does not account
for these factors.
Body area targeted for treatment
Whereas the majority of trials investigated chronic plaque pso-
riasis on the body, some trials focused on scalp psoriasis; some
reported findings for both scalp and body psoriasis; and some
were of inverse (flexural) or facial psoriasis. One trial of body and
scalp psoriasis reported overall outcomes (IAGI/PAGI), a scalp-
only outcome (TSS), and a body-only outcome (modified PASI)
(Van de Kerkhof 2002a). Ortonne 2010 reported findings sepa-
rately for treatment of the body and treatment of the face. We
previously used sensitivity analysis to investigate the scalp psoriasis
trials (Mason 2009), but in this update we analysed trials of inverse
psoriasis (comparisons 16 and 17) and scalp trials (comparisons 18
and 19) separately from the trials of body psoriasis (see Sensitivity
analysis).
Subgroup analysis and investigation of heterogeneity
We examined findings by agent class (as our primary analysis) and
individual topical agent (within-class analysis).
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When comparing trials both within and across therapeutic classes,
the summary estimates may demonstrate substantial heterogene-
ity. Ideally, we would seek to identify the reasons for individual
differences, but publications rarely report sufficient detail to make
a robust investigation feasible. Reasons might include differences
in trial design, length of follow-up, disease severity, participant
selection, adherence, adequacy of concealment of allocation, ade-
quacy of blinding, and source of funding (Mason 2002a).
The Cochrane Handbook for Systematic Reviews of Interventions ex-
plicitly endorses the combination of ’apples and oranges’ “if they
are used to contribute to a wider question about fruit” (Section
9.5.1; Higgins 2011). Our purpose was to identify whether classes
of topical treatments work and are safe. To this end, there is a
fundamental difference between heterogeneity that makes it un-
certain whether individual people with psoriasis will derive any
benefit from a treatment and heterogeneity that makes the size of a
positive benefit imprecise. Clinicians and those with psoriasis will
still value information about a treatment that is beneficial even
though its magnitude is poorly understood. However, we clearly
stated the presence of heterogeneity where it occurred and used
the Cochrane Handbook for Systematic Reviews of Interventions as a
guide to interpretation (Section 8.5.2; Higgins 2011).
Sensitivity analysis
We used a meta-analysis with a random-effects estimation both
for measures of effect and for pooling of risk differences for ad-
verse events. We quantified heterogeneity using the I² statistic. If
we identified outliers, we undertook a sensitivity analysis to inves-
tigate the implications of their exclusion on the pooled summary
statistics. In addition, we undertook sensitivity analyses to inves-
tigate the impact of within-patient versus between-patient trials,
and to explore the impact on pooled findings of varying the cor-
relation coefficient (see Unit of analysis issues). In some compar-
isons, there were no, or relatively few, studies that included both
within-patient and between-patient designs, few participants con-
tributing data, or both. We used the following criteria to help de-
cide whether we should have included an analysis in the sensitivity
analysis:
• frequently-used products in clinical practice; and
• for within-/between-patient sensitivity analysis: whether it
included both within-patient and between-patient designs
Where at least two within-patient trials were included in a pooled
comparison, we explored the potential influence of the correlation
coefficient.
Based on these criteria, we selected six comparisons (analyses 1,
2, 3, 4, 7, and 18) for sensitivity analysis. To ensure sufficient
data were available, we analysed the combined end points. These
analyses cover vitaminDanalogues, dithranol, and corticosteroids,
which are amongst the most frequently used products in clinical
practice.
Other
We involved a consumer throughout the review process to help
ensure the readability of the final review.
R E S U L T S
Description of studies
Results of the search
For this update, the RCT searches identified 3749 records:
• MEDLINE: 1312
• EMBASE: 2008
• SCI: 253
• BIOSIS: 44
• Dissertation Abstracts: 1
• Inside Conferences: 0
• CENTRAL: 70
• UK Clinical Research Network: 20
• Skin Group Specialised Register: 41
The total number of new records assessed after deduplication
against each other and previously identified records was 2637.
We added records from the searches in February 2011 to those
identified from searches run in 2008 (see Mason 2009). The total
number of records screened for this review over time is now 5414.
From the 2011 searches, we retrieved 148 papers and screened
these for eligibility. (Some papers weremultiple reports of the same
trial).
In 40 trials (some of which were consequently excluded), some or
all outcome data were missing. We contacted trialists or sponsors
to request missing data, receiving data for 25 of these trials. We
excluded trials that reported no useable outcome data. We did not
contact trialists or sponsors for missing adverse events or with-
drawal data, although some sponsors provided this spontaneously.
We included 48 new randomised controlled trials in the updated
review. Compared with the previous version of this review (Mason
2009), studies were larger (mean number of participants: 284 ver-
sus 164), had a longer treatment duration (10 weeks versus 6
weeks) and follow up (11 weeks versus 8 weeks), and were more
likely to be parallel-group in design (88% versus 63%). The new
studies were also more likely to include an active control group
(60% versus 43%) and patient-reported outcomes (44% versus
24%), and there were relatively more scalp trials (21% versus
12%). The 48 trials provided evidence on 7 new active treatments.
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Included studies
The updated review included 177 studies, with 34,808 partici-
pants.
The number of included studies counted by RevMan is 190, be-
cause we entered each study reporting a placebo and an active
comparison into the ’Characteristics of included studies’ table as
two studies.
Of the included studies, 106 of these were placebo-controlled;
84 compared treatments head-to-head, with 15 trials reporting
both placebo-controlled and head-to-head comparisons. The 15
trials reporting both head-to-head and placebo comparisons con-
tributed only once to the analysis of study characteristics, unless the
trial involved entirely distinct participants in its placebo-controlled
and active-controlled analyses. For example, the trial by Guenther
2002 compared treatments against each other (Guenther 2002
(H)) and against placebo (Guenther 2002 (P)). This study con-
tributed only once to the analysis of study characteristics (number
of participants, proportion of males, etc). However, two trials re-
ported placebo and head-to-head analyses involving entirely sepa-
rate participants (Barker 1999 (H) and Barker 1999 (P); Grattan
1997 (H) and Grattan 1997 (P)). Therefore, the total number of
studies contributing data to the analysis of study characteristics
and quality assessment was 177 (106 placebo + 84 head-to-head
-15 double-counted trials (with placebo and active comparators)
and 2 trials that each report 2 separate studies (Barker 1999 (H)
and Barker 1999 (P); Grattan 1997 (H) and Grattan 1997 (P)).
There were 26 trials of scalp psoriasis (Barrett 2005; Buckley 2008;
Cook-Bolden 2010; Duweb 2000; Elie 1983; Ellis 1988; Franz
1999; Franz 2000; Green 1994; Jarratt 2004; Jemec 2008 (H)
and Jemec 2008 (P); Kiss 1996; Klaber 1994; Klaber 2000b; Köse
1997; Kragballe 2009; Lepaw 1978; Luger 2008; Olsen 1991;
Pauporte 2004; Poulin 2010; Reygagne 2005; Shuttleworth 1998;
Tyring 2010; Van de Kerkhof 2002a; Van de Kerkhof 2009). Six
trials investigated inverse psoriasis, facial psoriasis, or both (Gribetz
2004; Kreuter 2006 (H) and Kreuter 2006 (P); Lebwohl 2004;
Liao 2007; Ortonne 2003; Ortonne 2010). One trial evaluated
psoriasis in children (Oranje 1997). Most trials were conducted
in ambulatory care settings, but four trials were of hospitalised
participants (Grattan 1997 (H) and Grattan 1997 (P); Kragballe
1991a; Monastirli 2000; Van der Vleuten 1995).
One hundred and twenty-three trials adopted a between-patient
(parallel-group) design; 53 were within-patient studies; and one
trial used both designs (Henneicke-v. Z. 1993). The trial by Levine
(Levine 2010 (H) and Levine 2010 (P)) was a within-patient trial
that randomised participants to two of seven treatment options.
Therefore, the pair-wise comparisons we analysed (e.g. calcipotriol
versus placebo) included amixture of within- and between-patient
designs: Some participants received calcipotriol on one side and
placebo on the other; other participants received calcipotriol on
one side and another active treatment on the other side.
The 177 studies included 34,808 participants. Of these studies,
133 provided data on the age of participants. The mean age of all
participants for which studies provided data was 47.2 years (range
= 2 to 97 years) (N = 28,921). Data on the gender of participants
(N=28,941)were available from140 studies.Overall, participants
were more likely to be male; the mean proportion of males was
56.7% (range = 30% to 100%).
Almost half the studies (77/177 = 44%) did not clearly report
the overall baseline severity of study participants (e.g. participants
with mild to moderate disease) (Figure 3). One hundred studies
explicitly reported baseline severity or reported sufficient infor-
mation on global severity scores, such as the mean and variation
in baseline PASI or the percentage of body surface area (BSA) af-
fected, to allow us to infer global severity using guidance on the
interpretation of severity scores (Finlay 2005; Krueger 2000). In
the 100 trials where severity was assessable, we classified partici-
pant severity as mild (5 studies), mild to moderate (36 studies),
mild to severe (6) or very severe (2 studies), moderate (12 stud-
ies), moderate to severe (27 studies), moderately severe (2 studies),
moderately severe to very severe (2 studies), and severe (8 studies).
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Seventy-seven studies provided insufficient information to allow
an assessment of clinical severity to be made; we could not make
assessments of the clinical characteristics of participants in studies
reporting only the mean PASI (with no information about varia-
tion) or reporting only localised (e.g. TSS) scores. One example
of a study that included participants with a wide range of severity
scores is the trial by Cunliffe 1992, where the mean baseline PASI
was 9.0 (suggesting moderately severe disease, according to Finlay
2005), but where individual participant scores ranged from 0.6 to
41.2. Another example is the study by Olsen 1996 (1), where par-
ticipant BSA involvement averaged 12%, but ranged from 1% to
80%. It is unclear how participant severity was distributed within
these ranges (i.e. whether these extremes were ’outliers’ or whether
a sizeable proportion of participants were clustered at the extreme
ends of the distribution).
Even where trialists classified participant severity, it was not always
clear that this was consistent with published guidance, which itself
does not always provide consistent messages. For example, Finlay
2005 states that a PASI score > 10, a BSA involvement > 10%, or
Dermatology Life Quality Index (DLQI) score > 10 constitutes
severe disease. However, Krueger 2000 argues that BSA is unreli-
able as an indicator of severity, which is better proxied by quality
of life assessments. However, the included studies rarely assessed
quality of life. Given this lack of clarity and the absence of ade-
quate severity data in around half (44%) of the included studies,
we could not use sensitivity analysis to investigate the impact of
baseline participant severity, nor could we reliably use severity to
investigate inter-study heterogeneity.
All 177 studies provided data on treatment duration (mean: 7
weeks; range = 1 to 52) and follow-up duration (mean: 9 weeks;
range = 2 to 52), where ’follow-up duration’ was defined as in-
cluding the treatment period. Commonly used outcomes assessed
by the studies included the following:
• individual signs (erythema, scaling, induration) (105/177
studies = 59%);
• Total Severity Score, Total Sign Score, or equivalent (83
studies = 47%);
• PASI (65 studies = 37%);
• IAGI/IGA (113 studies = 64%); and
• PAGI/PGA (52 studies = 29%).
Outcome measures employed by small numbers (< 5) of trials
included the following;
• Local Psoriasis Severity Index (scale not reported);
• Jacoby assessment score (0 to 7 score transformed to %
clinical improvement); and
• investigator assessment of skin staining.
Trials seldom assessed quality of life (9 trials = 5%).
Participant-reported outcomes included the following:
• overall participant assessment (relative efficacy, speed of
response, irritation, staining, ease of application);
• participant global assessment of acceptability of treatment,
participant assessment of likely adherence; and
• participant assessment of cosmetic acceptability.
We grouped placebo-controlled trials by type of treatment (e.g.
vitamin D products) and grouped head-to-head trials in a similar
way (e.g. vitamin D versus potent corticosteroid). We included 19
comparisons in the review. Since many trials did not specify par-
ticipants’ disease severity, it was not possible to use severity to in-
form pooling decisions. The primary analysis explored the results
of pooling within these 19 comparison groups using a random-ef-
fects model. In addition, we undertook sensitivity analyses for five
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comparisons using the ’combined end point’. These analyses used
pooled data to explore within- and between-patient trial variation.
In 90% (159/177) of the studies included in the review, partic-
ipants applied their own treatments. Nurses applied treatments
in 1 trial (Geilen 2000); participants’ parents delivered some care
in a trial of childhood psoriasis (Oranje 1997); and the delivery
method was unclear in 16 studies.
Excluded studies
We excluded 43 studies, of which we had newly added 16 stud-
ies in this update of the review (see ’Characteristics of excluded
studies’ tables). The most common reasons for exclusion from the
update were that the study did not report adequate data and re-
quests for missing data from trialists or sponsors were unsuccess-
ful (N = 5), or that the study did not provide a comparison of
interest (N = 6). Two studies were not randomised (Kaur 2004;
Vena 2005); one study assessed multiple plaques (Buder 2010);
and two evaluated unlicensed products that were not subsequently
marketed (Agrawal 2010; Rhemus 2006). We also excluded trials
of nail psoriasis that we had previously included (Mason 2009), as
the topic is now covered by a separate Cochrane review (de Vries
2013).
Studies awaiting classification
Update searches were run on 23, 24, and 29 August 2012. For
each database searched, we have shown below the numbers of
records identified. The total number of new records assessed (after
deduplication against each other and previously identified records)
was 1865. Relevant studies from these searches (10 references) are
listed in the Studies awaiting classification section, but we did not
include them in the main review.
• MEDLINE: 1203
• EMBASE: 1140
• SCI: 129
• BIOSIS: 37
• Dissertation Abstracts: 1
• Inside Conferences: 0
• CENTRAL: 26
• UK Clinical Research Network: 0
• Skin Group Specialised Register: 67
Ongoing studies
The metaRegister of Controlled Trials was searched for ongoing
and unpublished trials during the final searches for this review
in August 2012 http://www.controlled-trials.com/mrct/ using the
following phrases:
• “psor* AND topical NOT completed”, which retrieved 127
hits;
• “psor* AND calcipot% NOT completed”, which retrieved
7 hits;
• “psor* AND vitamin D NOT completed”, which retrieved
21 hits;
• “(psor* AND topical AND corticost%) NOT completed”,
which retrieved 63 hits; and
• “psor* AND tar NOT completed”, which retrieved 8 hits.
In total, we identified 10 potentially relevant trials. We provide
details in the ’Characteristics of ongoing studies’ tables.
Risk of bias in included studies
We extracted and tabulated data on six quality indicators. Sum-
mary findings are presented narratively, with characteristics for all
studies presented in the ’Characteristics of included studies’ ta-
bles. Figure 3 is a graphical representation of the overview of the
risk of bias. All included trials were randomised, but only 47/177
(27%) clearly reported themethod used to randomise participants.
Concealment of treatment allocation was explicitly adequate in
15 trials, but most trials (151/177 = 85%) blinded participants
to treatment allocation. Most (164/77 = 93%) trials reported loss
to follow up data, and 142 trials (80%) demonstrated that groups
were comparable at baseline.
Allocation
Of the 177 studies assessed for quality, 15 (8.5%) explicitly
achieved adequate concealment of treatment allocation (low risk
of bias). Concealment was unclear in the majority of studies (160
studies = 90.4%), so the risk of bias was also unclear. Concealment
was inadequate in 2 studies (1.1%) (high risk of bias) (Figure 3).
Blinding
Most (131/177 = 74%) studies were double-blind, with 20 stud-
ies adopting a single-blind (investigator-only) approach. Eighteen
studies were ’open’ (no blinding), and in the remaining 8 studies,
the blinding approach adopted was unclear (Figure 3). Twenty
trials explicitly stated that the outcome assessor was blinded to
treatment allocation. However, the outcome assessor will also have
been blinded in double-blind trials where the investigator also as-
sessed outcomes.
Incomplete outcome data
We defined ’loss to follow up’ as the number of enrolled partici-
pants who failed to contribute data for the analysis.
Of the 177 studies assessed for quality, 13 (7%) provided no data
on loss to follow up. For the remaining 164 studies, the mean
percentage loss to follow up was 6.1% (range = 0% to 31.5%).
Fifty-one studies reported that there was no loss to follow up. Four
studies lost more than 25% of their participants to follow-up, and
we classified them as having high risk of bias for this dimension
(Henneicke-v. Z. 1993; Lin 2007; Maier 2004; Weinstein 2003)
(see Figure 3).
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Where studies did not report estimates of variance, we derived
them from confidence intervals (CIs) or fromP values where possi-
ble. Where we could not obtain estimates of variance, we imputed
them (see Table 3). In total, we imputed estimates of variance for
at least 1 outcome measure in 45 studies (7 of which were scalp
trials); details are in the notes section of the ’Characteristics of
included studies’ tables.
Other potential sources of bias
Method of generation of the randomisation sequence
Only randomised controlled trials were eligible for inclusion in
the review. However, 130 studies (73%) did not clearly report the
randomisation method used. Fourteen studies reported a block
randomisation design, and 27 studies used computerised methods
(5 studies used both). Four reported that sequential allocation had
been used (3 of these studies were published in the 1970s); 1 study
used the toss of a coin; and another study used a sealed envelope
method. It could be argued thatwe should have excluded trialswith
sequential allocation from the review, but this might discriminate
against studies with better reporting methods in favour of those
not stating the randomisation method.
Baseline assessment of the participants for age, gender, and
clinical characteristics
We coded studies as follows: y (baseline assessments for age, gen-
der, and clinical characteristics), p (at least one type of assess-
ment), and NR (not reported or unclear). Most studies (121/177
= 68.4%) provided baseline assessments of age, gender, and clini-
cal characteristics. Forty-three studies (24.3%) provided a partial
assessment, and 13 studies (7.3%) reported no relevant data.
Baseline comparability of intervention and control groups
We coded studies as follows: y (comparability demonstrated, low
risk of bias), p (comparability partially demonstrated, risk of bias
unclear), and NR (comparability not demonstrated or unclear,
risk of bias unclear or high, depending on whether groups were
clearly non-comparable). Studies could demonstrate comparabil-
ity by reporting data for each group, by reporting the outcome of
statistical tests (e.g. P values), or both. One hundred and sixteen
studies (65.5%) demonstrated that the groups were comparable at
baseline; 27 studies (15.3%) demonstrated partial comparability;
and 34 studies (19.2%) did not clearly demonstrate comparability
between the groups. No study found that groups were non-com-
parable (high risk of bias).
Data extraction method for the review
To minimise errors and reduce potential biases being introduced
by review authors, the recommended approach is that data ex-
traction should be undertaken independently by at least two peo-
ple, preferably from complementary disciplines (Section 7.6.2,
Higgins 2011). However, in this review, one reviewer (AM) ex-
tracted the data, and another reviewer (HH) checked these data.
Effects of interventions
Primary outcome measures
The review analyses 19 comparisons. Of these, 8 are topical treat-
ment versus placebo analyses, and 11 are head-to-head analyses
of a topical treatment against a vitamin D analogue (i.e. 1 com-
monly used class of treatments). Some analyses are a ’catch all’
category; for example, analysis 6 includes ’Other treatment ver-
sus placebo’, which covers 26 treatments for body psoriasis for
which there is less research evidence (both in terms of numbers of
studies and numbers of participants contributing data). Similarly,
analysis 15 incorporates 12 head-to-head comparisons of vitamin
D analogues for body psoriasis that are not easily classified under
the other head-to-head comparisons. Scalp trials (comparisons 18
and 19) and trials of inverse psoriasis (comparisons 16 and 17) are
analysed separately from the trials of body psoriasis.
Table 4 summarises the 19 analyses. Table 2 gives details of the
outcome measures considered. The number of participants and
number of studies are adjusted manually from those reported in
the Tables and Figures to allow for within-patient studies, studies
contributing more than once to a single analysis, and studies con-
tributing to multiple analyses. Therefore, numbers of participants
and studies reported sometimes differ from the numbers estimated
by RevMan.
For each of the 19 analyses, we analysed data on 5 effectiveness
outcome measures, where available. The fifth measure is a ’com-
bined end point’ that uses data from the four primary outcome
measures.
(a) Investigator’s Assessment of Overall Global
Improvement (IAGI)/Investigator’s Global Assessment of
Disease Severity (IGA)
Analysis 1: Vitamin D analogues versus placebo
This comparison included eight vitamin D analogues for body
psoriasis (see Analysis 1.1 and Table 5). Twenty trials with 3771
participants reported IAGI data on 7 of these treatments. Thir-
teen trials were between-patient design, and 7 were within-patient
studies. Treatment duration ranged from4weeks to 12 weeks. The
pooled SMD across all treatments was -0.95 (95% CI -1.17 to -
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0.74; I² statistic = 89.0%), but there was considerable variation
between treatments, so we removed pooling across subgroups. Six
treatments were significantly more effective than placebo, with the
effect size ranging from -0.67 (becocalcidiol twice daily) to -1.66
(paricalcitol once daily). There was considerable between-study
variation in the IAGI SMD for calcitriol. The pooled effect was -
1.03 (95% CI -1.71 to -0.36), but this ranged from -0.26 (95%
CI -0.99 to 0.47) for Langner 2001 (P) to -3.11 (95% CI -3.57 to
-2.66) for Perez 1996. The magnitude of the IAGI SMD for the
Perez study was the highest across all comparisons and treatments.
For the ’combined end point’ of this analysis, we explored the im-
pact of removing this trial from the pooled findings using sensi-
tivity analysis. The presence of considerable heterogeneity within
this subgroup means that the estimated average benefit should be
interpreted with caution (Higgins 2011).
Analysis 2: Corticosteroid (potent) versus placebo
This comparison included 10 potent corticosteroids for body pso-
riasis (see Analysis 2.1 and Table 6), although no effectiveness data
were available for budesonide. Nine studies with 1867 participants
reported IAGI data on 6 of these 10 treatments. Eight trials were
between-patient design, and one was a within-patient study (Stein
2001). Treatment duration ranged from 3 to 12 weeks. The SMD
across all 6 treatments for IAGI was -1.00 (95% CI -1.18 to -0.82;
I² statistic = 57.6%). All six treatments performed statistically sig-
nificantly better than placebo.
Analysis 3: Corticosteroid (very potent) versus placebo
This comparison included three very potent corticosteroids for
treatment of psoriasis of the body (see Analysis 3.1 and Table 7).
Five studies with 515 participants reported IAGI data on 2 of the
3 treatments. There were four between-patient trials and 1 within-
patient study (Beutner 2006). Treatment duration ranged from
two to four weeks. The IAGI SMD across both treatments was
-1.87 (95% CI -2.38 to -1.36; I² statistic = 78.7%). Both clo-
betasol propionate and halobetasol performed statistically signifi-
cantly better than placebo. In Analysis 18.1, we present placebo-
controlled scalp trials of very potent corticosteroids.
Analysis 4: Dithranol versus placebo
Our reviewdid not identify any study comparing dithranol against
placebo and which reported IAGI data.
Analysis 5: Vitamin D combination products versus placebo
This comparison included treatment with combined calcipotriol
and betamethasone dipropionate used either once or twice daily
on the body (see Analysis 5.1 and Table 8). Five parallel-group
studies with 2058 participants contributed data on both dosing
options. Treatment duration ranged from four to eight weeks. The
IAGI SMDacross treatments was -1.44 (95%CI -1.76 to -1.12; I²
statistic = 89.4%), with twice-daily combination treatment (SMD
-1.90; 95%CI -2.09 to -1.71) achieving a significantly larger effect
than once-daily treatment (SMD -1.21; 95% CI -1.50 to -0.91).
However, the difference between once- and twice-daily dosing
was not statistically significant when benefit was assessed using
the PASI (see Analysis 5.3). In Analysis 18.1, we report placebo-
controlled trials of combination vitamin D/steroid treatments for
scalp psoriasis.
Analysis 6: Other treatment versus placebo
This comparison comprised all other treatments for psoriasis of the
body not included in the first five analyses; therefore, we removed
pooling. None of the studies assessed the same treatment, which
means that findings should be interpreted with caution.
In total, we included 26 treatments in this analysis (see Analysis
6.1 and Table 9). Eight studies with 364 participants reported
IAGI data on 8 of these 26 treatments. Four trials were between-
patient design, and four were within-patient studies. Treatment
duration ranged from 3 to 12 weeks.
Four treatments performed statistically significantly better than
placebo: anti-IL-8 monoclonal antibody cream; betamethasone
17-valerate 21-acetate plus tretinoin plus salicylic acid, indigo nat-
uralise 1.4% ointment, and methotrexate gel. The effect size for
the IAGI ranged from -0.56 (Sutton 2001; methotrexate gel) to -
2.14 (Lin 2008; indigo naturalise 1.4% ointment).
In four treatments, the difference relative to placebowas not statis-
tically significant: hexafluoro-1,25-dihydroxyvitamin D3, kukui
nut oil, oleum horwathiensis, and platelet aggregation activating
factor (PAF). No treatment was statistically significantly less effec-
tive than placebo.
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
This comparison included eight vitamin D analogue-potent cor-
ticosteroid contrasts for body psoriasis (see Table 10). Eight stud-
ies with 2655 participants reported IAGI data for 6 of the 8 in-
tervention-comparator contrasts (see Analysis 7.1). Seven trials
were between-patient design, and one was a within-patient study
(Medansky 1996). Treatment duration ranged from three to eight
weeks. Overall, there was no statistically significant difference be-
tween vitamin D analogues and potent corticosteroids: The SMD
across all 6 treatments for IAGI was 0.17 (95% CI -0.04 to 0.37;
I² statistic = 83.4%). In light of the high level of heterogeneity
and inconsistency across treatments (Higgins 2011). We removed
pooling. Vitamin D analogues performed statistically significantly
better than one potent corticosteroid. This finding came from a
single between-patient study in which 99 participants contributed
data (Bruce 1994). The SMD for calcipotriol against fluocinonide
0.05% ointment was -0.58 (95% CI -0.99 to -0.18; I² statistic =
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NA). Calcipotriol was statistically significantly less effective than
both diflorasone diacetate 0.05% ointment (SMD 0.27; 95% CI
0.02 to 0.52) and betamethasone dipropionate (SMD 0.43; 95%
CI 0.28 to 0.58; I² statistic = 50.3%).We found no statistically sig-
nificant difference between calcipotriol and betamethasone valer-
ate, calcitriol and betamethasone dipropionate, or calcitriol and
betamethasone valerate.
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
This comparison included one vitamin D analogue, calcipotriol
ointment, versus a very potent corticosteroid contrast, clobetasol
propionate foam, for psoriasis of the body (see Table 11 and
Analysis 8.1). One study with 42 participants reported IAGI data.
Koo 2006 was a between-patient study with a treatment duration
of two weeks, which found no significant difference between the
treatments (SMD 0.19; 95% CI -0.42 to 0.80).
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
This comparison considered vitamin D analogues-steroid combi-
nation against potent or very potent corticosteroids for body pso-
riasis (see Analysis 9.1 and Table 12). The comparison included
three contrasts: calcipotriol plus betamethasone dipropionate ver-
sus betamethasone dipropionate, calcipotriol plus betamethasone
dipropionate versus clobetasol propionate, and calcipotriol plus
clobetasol propionate versus clobetasol propionate.
Four between-patient trials reported IAGI data for 1991 partici-
pants on 2 of the 3 intervention-comparator contrasts. Treatment
duration ranged between two and eight weeks. As these treat-
ment comparisons were very different, we only pooled subtotals.
In all but one trial (Fleming 2010 (H)), combination treatment
was significantly more effective than corticosteroid alone. Three of
the four trials compared calcipotriol/betamethasone dipropionate
against betamethasone dipropionate (SMD -0.40; 95% CI -0.52
to -0.27; I² statistic = 41.8%), and one trial compared combined
treatment with calcipotriol and clobetasol against clobetasol alone
(SMD -0.69; 95% CI -1.22 to -0.15).
Analysis 10: Vitamin D alone or in combination versus
dithranol
This comparison considered vitamin D analogues against dithra-
nol (Analysis 10.1 and Table 13). We identified three interven-
tion-comparator contrasts: calcipotriol versus dithranol, calcitriol
versus dithranol, and tacalcitol versus dithranol. Five between-pa-
tient trials reported IAGI data for 1108 participants on 2 of these
3 intervention-comparator contrasts. Treatment duration ranged
from 8 weeks to 12 weeks. There was some variation in the dithra-
nol regimens employed by trials and in the baseline severity of
trial participants. These factors may help explain the high level of
heterogeneity found in the pooled results.
The SMD for the IAGI was -0.24 (95% CI -0.72 to 0.25; I²
statistic = 93.0%). The presence of considerable heterogeneity
means that the estimated average benefit should be treated with
caution and pooling was therefore removed (Higgins 2011). Data
from four trials contributed to the SMD for the calcipotriol versus
dithranol: -0.43 (95%CI -0.85 to -0.01; I² statistic = 89.3%), indi-
cating that calcipotriol was statistically significantly more effective
than dithranol. Three of these four trials found a significant dif-
ference in favour of calcipotriol (Berth Jones 1992b; Christensen
1999; Wall 1998), but the trial by Van de Kerkhof 2006 found
outpatient treatment with short contact dithranol to be signifi-
cantly more effective than calcipotriol alone.
Data fromone trial contributed to the SMDfor the calcitriol versus
dithranol: 0.51 (95%CI 0.13 to 0.88; I² statistic =NA), indicating
that dithranol was statistically significantly more effective than
calcitriol.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Our review identified three intervention-comparator contrasts in
this comparison: calcipotriol versus calcitriol, calcipotriol versus
tacalcitol, and calcipotriol versus maxacalcitol for body psoriasis
(see Analysis 11.1 and Table 14). Three trials involving 498 par-
ticipants contributed IAGI data for all 3 intervention-comparator
contrasts (one trial for each contrast). Two trials were between-
patient, and one was within-patient in design (Barker 1999 (H)).
Treatment duration ranged from 8 to 12 weeks. The SMD for
the IAGI was -0.06 (95% CI -0.51 to 0.38; I² statistic = 82.2%).
The presence of substantial heterogeneity reflects differences in the
findings from the two intervention-comparator contrasts under-
lying this statistic. We found a statistically significant difference
in favour of calcipotriol in the analysis against tacalcitol (SMD -
0.47; 95% CI -0.73 to -0.21), but there was no significant differ-
ence relative to calcitriol (SMD 0.00; 95% CI -0.25 to 0.25) or
between calcipotriol and maxacalcitol (SMD 0.43; 95% CI -0.12
to 0.98). In light of the inconsistency of results across treatments,
we only pooled subtotals (Higgins 2011).
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
Our review identified 12 intervention-comparator contrasts for
body psoriasis, involving 3 vitamin D analogues, 2 combination
products, and 7 different corticosteroids (see Analysis 12.1 and
Table 15 ). Eleven parallel-group trials involving 4791 partici-
pants contributed IAGI data for 9 of these 12 intervention-com-
parator contrasts. Treatment duration ranged from two to eight
weeks. There were no IAGI data for three contrasts: calcipotriol
versus calcipotriol plus diflucortolone valerate, calcipotriol versus
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calcipotriol plus fluocinonide acetonide, and calcitriol versus cal-
citriol plus diflucortolone valerate.
Overall, vitamin D alone appeared to be less effective than vita-
min D plus corticosteroid: The SMD for the IAGI was 0.48 (95%
CI 0.32 to 0.65; I² statistic = 86.9%). This finding applied to all
but two of the intervention-comparator contrasts: There was no
statistically significant difference between twice-daily calcipotriol
and a regimen of calcipotriol (morning) plus betamethasone valer-
ate (night time) (SMD 0.27; 95% CI -0.19 to 0.74) (Kragballe
1998b), or between once-daily calcipotriol and once-daily treat-
ment with a combined product containing calcipotriol and hydro-
cortisone (SMD 0.14; 95% CI -0.06 to 0.33) (Ortonne 2010).
The study by Ortonne 2010 also reported findings separately for
the face (see Analysis 17.1).
In light of the observed heterogeneity between the intervention-
comparator contrasts, we only pooled subtotals (Higgins 2011).
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison summarises findings on complex regimens for
body psoriasis, defined here as treatment sequences that do not
consist of a simple head-to-head comparison between two active
treatments (see Analysis 13.1 and Table 16). We identified 12
intervention-comparator contrasts, and IAGI data were available
for 10 of these. Data from 2755 participants contributed to the
IAGI analysis, based on findings from seven trials. Six of the trials
were between-patient (parallel-group) in design, and one was a
within-patient study (Austad 1998). Trial duration varied between
6 and 12 weeks. As the interventions and comparators were highly
variable and because two trials each contributed three pair-wise
contrasts, we did not pool the data.
Six intervention-comparator contrasts for which IAGI data were
available found a significant difference between regimens. A two-
week regimen with clobetasol propionate followed by four weeks’
treatment with calcipotriol was more effective than six weeks of
monotherapy with calcipotriol (SMD0.60; 95%CI 0.18 to 1.02).
All treatmentswere applied twice-daily in thiswithin-patient study
(Austad 1998).
The remaining fivemore effective regimens all involved once-daily
treatment with a combined product containing calcipotriol and
betamethasone dipropionate, and the same study (White 2006
(P)) reported three contrasts. This study involved an initial ’treat-
ment’ phase consisting of 4 weeks’ treatment with the combined
product, followed by an 8-week maintenance phase. In one main-
tenance phase, participants received placebo ointment for 8 weeks.
This was significantly less effective than maintenance with once-
daily calcipotriol (SMD 0.27; 95% CI 0.12 to 0.41), and it was
also less effective than maintenance with once-daily calcipotriol
on weekdays and the combined product at the weekend (SMD
0.51; 95% CI 0.37 to 0.66). When these two comparator regi-
mens were compared directly (White 2006 (H)), the alternating
regimen using weekday/weekend treatments during the mainte-
nance phase was significantly more effective than once-daily cal-
cipotriol for maintenance (SMD 0.26; 95% CI 0.11 to 0.40).
Kragballe 2004 compared 3 12-week treatment regimens, 2 of
which were ’complex’. When we compared these complex regi-
mens, eight weeks’ once-daily combination treatment with cal-
cipotriol and betamethasone dipropionate, followed by four weeks
of once-daily calcipotriol was significantly less effective than a reg-
imen consisting of four weeks’ once-daily combination treatment,
followed by eight weeks of once-daily calcipotriol onweekdays and
the combined product at weekends (SMD 0.24; 95% CI 0.08 to
0.40). A separate trial compared 8 weeks with tacalcitol to combi-
nation ointment for 4 weeks, followed by calcipotriol for 4 weeks
(Ortonne 2004). Participants applied all treatments once daily (at
night time). Monotherapy with tacalcitol was significantly less ef-
fective than the complex regimen (SMD 0.54; 95% CI 0.36 to
0.72).
In 4 of the 10 intervention-comparator contrasts for which IAGI
data were available, there was no significant difference in effect.
The study by Kragballe 2004 (see paragraph above) found no dif-
ference between twice-daily calcipotriol and the two comparator
complex regimens. One regimen consisted of eight weeks’ once-
daily treatment with a combined product containing calcipotriol
and betamethasone dipropionate, followed by four weeks of once-
daily calcipotriol. Relative to calcipotriol monotherapy, the SMD
for the IAGI was -0.12 (95% CI -0.29 to 0.04). When compared
with a regimen consisting of four weeks’ once-daily treatment with
a combined product containing calcipotriol and betamethasone
dipropionate, followed by eight weeks of once-daily calcipotriol
on weekdays and the combined product at weekends, twice-daily
calcipotriol appeared to be slightly less effective, although the dif-
ference was not statistically significant (SMD 0.13; 95% CI -0.04
to 0.29).
Yang 2009 compared a six-week course of twice-daily calcipotriol
with a complex routine using halometasone and calcipotriol. For
two weeks participants applied halometasone in the morning and
calcipotriol at night; over the next two weeks, halometasone was
applied twice daily at weekends and calcipotriol twice daily during
the week. For the final twoweeks, treatment reverted to twice-daily
calcipotriol. Although there was a trend in favour of the complex
regimen (SMD 0.41; 95% CI -0.05 to 0.86), the difference was
not statistically significant.
Lahfa 2003 compared two different vitaminDproducts combined
with a very potent corticosteroid. In the initial phase, participants
applied dual therapy (clobetasol propionate in the mornings and
the vitamin D analogue (calcipotriol or calcitriol) at night) until
achieving clearance or marked improvement or until 4 weeks had
elapsed. Participants then switched to amonotherapymaintenance
phasewith the vitaminDproduct for the remainder of the 12-week
study period. The IAGI results showed the 2 treatment regimens
to be equivalent: -0.19 (95% CI -0.54 to 0.16).
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Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
This comparison included active-controlled studies of psoriasis of
the body that were at least 24 weeks in duration (see Analysis
14.1 and Table 17). One longer-term placebo-controlled trial of
the body (Katz 1991a) and two long-term scalp trials (Luger
2008; Poulin 2010) did not meet the inclusion criteria for this
comparison, and they are evaluated elsewhere (Analysis 2, Analysis
19, and Analysis 18, respectively).
One trial was included in this comparison; Kragballe 2006 was a
between-patient trial that compared three 52-week regimens with
all treatments used once daily:
• first, combination treatment with calcipotriol and
betamethasone dipropionate;
• second, alternating treatment with combination therapy for
4 weeks, then calcipotriol for 4 weeks; and
• third, combination therapy for 4 weeks, then calcipotriol
for 48 weeks.
In total, 297 participants contributed IGA data to the analysis.
Data were unsuitable for pooling because the same participants
contributed to more than one analysis.
According to the investigators’ assessment, there was no significant
difference between the three long-term regimens. One year’s com-
bination therapy was not significantly better than either the alter-
nating regimen (SMD -0.09; 95% CI -0.36 to 0.18) or the regi-
men of treatment with 4 weeks of combination therapy followed
by 48 weeks of calcipotriol (SMD -0.18; 95% CI -0.47 to 0.10).
In both these comparisons, combination therapy achieved a larger
absolute benefit, but the difference was not statistically significant.
When alternating therapy was compared with the regimen of 4
weeks’ combination therapy followed by 48 weeks of calcipotriol,
the SMD for the IAGI also indicated the two regimens were not
statistically significantly different: -0.09 (95% CI -0.37 to 0.19).
Analysis 15: Vitamin D analogues versus other treatment
This comparison incorporated all other vitamin D head-to-head
comparisons of treatments for psoriasis of the body (excluding in-
verse psoriasis) that had not already been included (see Analysis
15.1 andTable 18).We included 12 intervention-comparator con-
trasts, with IAGI data available for 6 of these contrasts. Eight be-
tween-patient trials and 2 within-patient trials provided data for
1386 participants. Trial duration ranged between 4 and 12 weeks.
In light of the pharmacological diversity amongst the compara-
tors, we only pooled data within subgroups.
According to the investigator’s global assessment, twice-daily cal-
cipotriol was significantly more effective than coal tar polytherapy
(SMD -0.59; 95% CI -0.87 to -0.31; I² statistic = 0%). Once-
daily vitamin D was significantly less effective than a twice-daily
application (SMD -0.24; 95% CI -0.38 to -0.09; I² statistic =
0%). This contrast included a comparison of once- versus twice-
daily dosing of calcipotriol (SMD -0.27; 95% CI -0.48 to -0.06)
and a dosing comparison combination treatment with calcipotriol
and betamethasone dipropionate (SMD -0.20; 95% CI -0.41 to
0.00).
In the remaining four intervention-comparator contrasts, no sig-
nificant difference was found between twice-daily calcipotriol and
the comparators. This finding held for the comparison against coal
tar monotherapy (SMD -0.53; 95% CI -1.74 to 0.68; I² statistic
= 91.1%), against betamethasone dipropionate ointment and sal-
icylic acid (SMD -0.06; 95% CI -0.33 to 0.22; I² statistic = NA),
against tacrolimus ointment (SMD -0.22; 95% CI -0.60 to 0.16;
I² statistic = NA), and against vitamin B12 cream (SMD -0.55;
95% CI -1.33 to 0.24; I² statistic = NA).
Two of the three trials comparing calcipotriol with coal tar
monotherapy found a significant difference in favour of cal-
cipotriol; the other trial found a significant difference in favour
of coal tar (Alora-Palli 2010). This apparent contradiction may
reflect different formulations of coal tar, treatment durations, or
different baseline disease severity.
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of topical
treatments for inverse or facial psoriasis (see Analysis 16.1 and
Table 19). Evidence on four treatments was found in this com-
parison: the potent steroid betamethasone valerate; the vitamin
D analogue calcipotriol; and two topical calcineurin inhibitors,
pimecrolimus and tacrolimus. We only found one trial that evalu-
ated tacrolimus ointment (Lebwohl 2004), but the study did not
report any effectiveness data suitable for this review. However, the
study did contribute data on adverse events and withdrawal rates.
IAGI outcome data were available for one of the four topical treat-
ments for inverse psoriasis. One 8-week between-patient study
with 47 participants (Gribetz 2004) reported placebo-controlled
data on pimecrolimus 1% cream, which demonstrated a statisti-
cally significant difference in favour of twice-daily pimecrolimus
(SMD -1.07; 95% CI -1.69 to -0.45).
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
inverse psoriasis, which compared vitamin D with an active con-
trol (see Analysis 17.1 and Table 20). We identified five interven-
tion-comparator contrasts. Four treatments were compared with
calcipotriol: once-daily betamethasone valerate, combined treat-
ment with calcipotriol and hydrocortisone, calcitriol, and pime-
crolimus. Calcitriol was compared with tacrolimus.
Two between-patient studies contributed IAGI data from 457
study participants on2of the 5 intervention-comparator contrasts.
Trial duration ranged from six to eight weeks. When applied once
daily to inverse psoriasis, calcipotriol was significantly less effective
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than combined treatment with calcipotriol and hydrocortisone
(SMD 0.30; 95% CI 0.11 to 0.50) (Ortonne 2010). However,
there was no significant difference in effect between twice daily
treatment with calcitriol and tacrolimus (SMD 0.42; 95% CI -
0.15 to 0.98) (Liao 2007).
Analysis 18: Scalp psoriasis: placebo-controlled trials
This comparison included placebo-controlled trials of treatments
for scalp psoriasis (see Analysis 18.1 and Table 21). We included
evidence on 11 treatments in this comparison, with IAGI data
available for 9 treatments. Ten trials, 9 of which were between-pa-
tient studies, contributed data from 2472 participants. One study
was a within-patient trial (Lepaw 1978). Trial duration ranged
between two and eight weeks. IAGI data were not available for
betamethasone valerate or ciclopirox olamine shampoo.
Eight treatments for scalp psoriasis that were assessed using the
IAGI scale were significantlymore effective than placebo. The least
effective treatment was calcipotriol (SMD -0.72; 95% CI -1.28
to -0.16; I² statistic = 69.2%), and the most effective treatment
was clobetasol propionate (SMD -1.73; 95% CI -1.99 to -1.48;
I² statistic = 14.3%). Combination treatment with calcipotriol
and betamethasone dipropionate was also effective (SMD -0.97;
95% CI -1.61 to -0.32; I² statistic = 90.2%). Data from the three
very potent corticosteroids were pooled (amcinonide, clobetasol
propionate, halcinonide). The SMD across these treatments was -
1.57 (95% CI -1.85 to -1.28; I² statistic = 49.7%). Only salicylic
acid was not significantly more effective than placebo (SMD -
0.86; 95% CI -1.79 to 0.06).
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin D
product (used either as monotherapy or in combination with an-
other product) (see Analysis 19.1 and Table 22). We identified six
intervention-comparator contrasts, and IAGI data were available
for five of these contrasts. All studies were parallel-group in design
(between-patient). Ten studies contributed IAGI data from 5175
participants, and trial duration ranged from 4 to 52 weeks.
Vitamin D for scalp psoriasis was significantly less effective than
potent steroids, either alone or in combination with vitamin D.
Specifically, calcipotriol was less effective than three comparator
treatments: betamethasone dipropionate (SMD 0.48; 95% CI
0.32 to 0.64; I² statistic = 60.4%), betamethasone valerate (SMD
0.37; 95% CI 0.20 to 0.55; I² statistic = 0%), and combina-
tion treatment with calcipotriol and betamethasone dipropionate
(SMD0.64; 95%CI 0.44 to 0.84; I² statistic = 82.3%). Combina-
tion treatment (calcipotriol/betamethasone dipropionate) was sig-
nificantly more effective than betamethasone dipropionate alone
(SMD -0.18; 95% CI -0.26 to -0.10; I² statistic = 0%). The effi-
cacy of calcipotriol and coal tar polytherapy was similar: SMD -
0.24 (95% CI -0.73 to 0.25; I² statistic = 91.1%).
(b) Total Severity Scores (TSS)
Analysis 1: Vitamin D analogues versus placebo
Our review included eight vitamin D analogues for body psoriasis
in this comparison (see Analysis 1.2 andTable 5).Nineteen studies
reported TSS data with 2647 participants contributing data. Nine
trials were between-patient design, and 10 were within-patient
studies. Treatment duration ranged from 4 weeks to 12 weeks.
The average effect size across all 8 treatments for TSS was -1.04;
(95% CI -1.33 to -0.74; I² statistic = 93.0%), but two of these
treatments were not significantly more effective than placebo. The
high level of heterogeneity means that the estimated average ben-
efit should be treated with caution; there was considerable vari-
ation between effective treatments, with the TSS ranging from -
0.46 (becocalcidiol twice daily) to -2.15 (paricalcitol once daily).
Therefore, we removed pooling across subgroups (Higgins 2011).
Four studies contributed data for the SMD for the TSS of calcitriol
(SMD -1.22; 95% CI -2.38 to -0.07), but there was considerable
heterogeneity within the subgroup (I² statistic = 98.3%). One of
the studies (Van deKerkhof 1989) found no statistically significant
difference between calcitriol and placebo (SMD -0.06; 95% CI -
0.94 to 0.81), whereas the study by Perez 1996 found a large and
statistically significant difference (-4.03; 95% CI -4.56 to -3.50).
We considered this finding in more detail in the ’combined end
point’ section (e) below.
Analysis 2: Corticosteroid (potent) versus placebo
Our review included 10 potent corticosteroids for body psoriasis
in this comparison (see Analysis 2.2 and Table 6). Seven studies
reportedTSS data contributed by 553 participants on 8 of these 10
treatments. Six trials were between-patient studies, and there was
one within-patient design (Ormerod 1997). Treatment duration
ranged from 2 to 12 weeks. The average effect size across all 8
treatments for TSS was -0.77 (95%CI -1.01 to -0.52; I² statistic =
46.7%). We found all treatments, except for diflorasone diacetate,
to be statistically significantly superior to placebo: SMD -0.32;
95% CI -0.73 to 0.09).
Analysis 3: Corticosteroid (very potent) versus placebo
Of the three very potent corticosteroids for body psoriasis included
in this comparison, TSS data were available only for clobetasol
propionate (see Analysis 3.2 and Table 7). Three studies, all of
which were between-patient trials, reported TSS data for 545 par-
ticipants. Treatment duration ranged from two to four weeks. The
SMD for the TSS was -1.35 (95% CI -1.80 to -0.89; I² statistic
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= 75.3%). In Analysis 18.2, we reported TSS data on the use of
very potent steroids on the scalp.
Analysis 4: Dithranol versus placebo
This comparison considered dithranol against placebo (see
Analysis 4.2 and Table 23). Three within-patient trials reported
TSS data for 47 participants. Treatment duration ranged from
three to eight weeks. The SMD for the TSS was -1.06 (95% CI -
1.66 to -0.46; I² statistic = 37.4%).
Analysis 5: Vitamin D combination products versus placebo
Our review did not identify any trial reporting TSS data for this
comparison.
Analysis 6: Other treatment versus placebo
This comparison comprised all other treatments for body psoriasis
that were not included in the first five comparisons. None of the
studies assessed the same treatment, which means that findings
should be interpreted with caution.
In total, we included 26 treatments in this analysis (see Analysis
6.2 and Table 9). Seventeen studies with 907 participants reported
TSS data on 17 of these 26 treatments. Five trials were between-
patient design, and 12 were within-patient studies. Treatment du-
ration ranged from 3 to 12 weeks.
Ten treatments performed significantly better than placebo: anti-
IL-8 monoclonal antibody cream, calcipotriene 0.005% ointment
+ nicotinamide, fish oil plus occlusion, hexafluoro-1,25-dihydrox-
yvitamin D3, indigo naturalise 1.4% ointment, methotrexate gel,
mycophenolic acid ointment, oleum horwathiensis, PTH (1-34)
in Novasome cream®, and tazarotene. The effect size for the TSS
ranged from -0.48 (Levine 2010 (P); calcipotriene 0.005% oint-
ment + nicotinamide) to -2.31 (Holick 2003; PTH (1-34) in No-
vasome cream®).
In seven treatments, the difference relative to placebo was not sta-
tistically significant: kukui nut oil, NG-monomethyl-L-arginine
(L-NMMA) cream, nicotinamide 1.4%, polymyxin B cream, top-
ical sirolimus, topical tacrolimus, and tar.
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
There were eight vitamin D analogue-potent corticosteroid com-
parisons for body psoriasis (see Analysis 7.2 and Table 10). Six
studies with 891 participants reported TSS data for 5 of the 8 in-
tervention-comparator contrasts. Two trials were between-patient
design, and four were within-patient studies. Treatment duration
ranged from three to six weeks. The SMD across all 5 treatments
for TSS indicated that there was no significant difference between
the vitamin D derivatives and potent corticosteroid: SMD 0.11
(95% CI -0.22 to 0.44; I² statistic = 86.7%). However, there was
considerable variation between the individual contrasts underly-
ing the pooled effect. In light of this heterogeneity, we removed
pooling (Higgins 2011).
In two of the five vitamin D-potent corticosteroid comparisons,
the vitamin D analogue performed statistically significantly better
than the potent corticosteroid: The SMD for calcipotriol against
fluocinonide 0.05% ointment was -0.50 (95% CI -0.92 to -0.07;
I² statistic = NA) (Bruce 1994). Similarly, the comparison of cal-
cipotriol against betamethasone valerate showed a significant dif-
ference in favour of calcipotriol (SMD -0.26; 95% CI -0.41 to -
0.11), a finding also based on a single study (Kragballe 1991a).
In three comparisons, the vitamin D analogue was statistically sig-
nificantly less effective than the potent corticosteroid: calcipotriol
versus diflorasone diacetate (SMD 0.40; 95% CI 0.15 to 0.65),
calcitriol versus betamethasone dipropionate (SMD0.27; 95%CI
0.02 to 0.51), and tacalcitol versus betamethasone valerate (SMD
0.41; 95% CI 0.09 to 0.74).
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
Our review did not identify any study of psoriasis of the body that
compared vitamin D analogues against very potent corticosteroids
and that reported TSS data.
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
This comparison considered vitamin D analogues-steroid combi-
nation against potent or very potent corticosteroid for body pso-
riasis (see Analysis 9.2 and Table 12). One four-week between-
patient trial reported TSS data for 122 participants with moder-
ate to severe psoriasis (Menter 2009). The combined treatment
with calcipotriol and betamethasone dipropionate was found to be
significantly less effective than clobetasol propionate spray alone
(0.45; 95% CI 0.09 to 0.81).
Analysis 10: Vitamin D alone or in combination versus
dithranol
This comparison considered vitamin D analogues against dithra-
nol (see Analysis 10.2 and Table 13).We identified three interven-
tion-comparator contrasts: calcipotriol versus dithranol, calcitriol
versus dithranol, and tacalcitol versus dithranol. Three between-
patient trials and 1 within-patient trial (Grattan 1997 (H)) re-
ported TSS data for 386 participants. Treatment duration ranged
from four weeks to eight weeks. There was some variation in the
dithranol regimens employed by trials and in the baseline severity
of trial participants. These factors may help explain the substantial
heterogeneity found in the pooled results (Higgins 2011).
The SMD for the TSS was -0.27 (95%CI -0.73 to 0.20; I² statistic
= 80.6%).Data from two trials contributed to the SMD for the cal-
cipotriol versus dithranol: -0.54 (95%CI -1.16 to 0.08; I² statistic
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= 71.2%) (Christensen 1999; Grattan 1997 (H)). Data from one
trial contributed to the SMD for the calcitriol versus dithranol:
0.13 (95%CI -0.24 to 0.50; I² statistic =NA) (Hutchinson 2000).
Data from one trial contributed to the SMD for the tacalcitol
versus dithranol: -0.18 (95% CI -0.60 to 0.25; I² statistic = NA)
(Farkas 1999). Therefore, neither the summary statistic for the
TSS nor the pooled data for individual intervention-comparator
contrasts provided evidence of a statistically significant advantage
of a vitamin D analogue over dithranol or vice versa.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Our review identified three intervention-comparator contrasts for
body psoriasis in this comparison: calcipotriol versus calcitriol,
calcipotriol versus tacalcitol, and calcipotriol versus maxacalcitol
(see Analysis 11.2 and Table 14). Three trials involving 563 par-
ticipants contributed TSS data for all 3 of these intervention-
comparator contrasts. Two trials were between-patient, and one
was within-patient in design (Barker 1999 (H)). Treatment du-
ration ranged from 8 to 12 weeks. The SMD for the TSS indi-
cated that there was a statistically significant difference in favour
of calcipotriol: SMD -0.31; 95% CI -0.55 to -0.06; I² statistic
= 46.9%. When assessed by the TSS, calcipotriol was statistically
significantly more effective than calcitriol (SMD -0.32; 95% CI
-0.57 to -0.07). This finding contrasts with the IAGI assessment
from the same study, which found no significant difference (see
Ji 2008; Analysis 11.1). Calcipotriol was also significantly more
effective than tacalcitol (SMD -0.45; 95% CI -0.68 to -0.22) and
similar in efficacy relative to maxacalcitol (SMD 0.13; 95% CI -
0.41 to 0.68).
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
Our review identified 12 intervention-comparator contrasts for
body psoriasis, involving 3 vitamin D analogues, 2 combination
products, and 7 different corticosteroids (see Analysis 12.1 and
Table 15). One 4-week parallel-group trial contributed TSS data
from 301 participants for 1 of these 12 intervention-comparator
contrasts (Huang 2009). Twice-daily calcipotriol was found to be
statistically significantly less effective than once-daily treatment
with a combined product containing calcipotriol and betametha-
sone dipropionate (SMD 0.25; 95% CI 0.03 to 0.48).
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison summarises findings on complex regimens for
body psoriasis, defined here as treatment sequences that do not
consist of a simple head-to-head comparison between two active
treatments (see Analysis 13.2 and Table 16). We identified 12 in-
tervention-comparator contrasts and TSS data were available for
one of these. Data from 1 6-week within-patient trial with 46 par-
ticipants (Austad 1998) contributed to the TSS analysis. Austad
1998 compared six weeks of twice-daily calcipotriol with a regi-
men of two weeks’ treatment with clobetasol propionate followed
by four weeks with calcipotriol. The complex regimen was signif-
icantly more effective than monotherapy with calcipotriol (SMD
0.63; 95% CI 0.21 to 1.05).
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
We did not identify any relevant study that provided TSS data for
this comparison.
Analysis 15: Vitamin D analogues versus other treatment
This comparison incorporated all other vitamin D head-to-head
comparisons of treatments for psoriasis of the body (excluding in-
verse psoriasis) that had not already been included (see Analysis
15.2 andTable 18).We included 12 intervention-comparator con-
trasts, with TSS data available for 6 of these contrasts. Five be-
tween-patient trials and 2 within-patient trials provided data from
898 participants. Trial duration ranged between 6 and 12 weeks.
In light of the pharmacological diversity of the comparators, we
only pooled data within subgroups.
According to the TSS assessment, twice-daily calcipotriol was sig-
nificantly more effective than coal tar polytherapy (SMD -0.51;
95% CI -0.86 to -0.16; I² statistic = NA). In the remaining five
intervention-comparator contrasts, we found no significant dif-
ference between twice-daily calcipotriol and the comparators.
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of topical
treatments for inverse or facial psoriasis (see Analysis 16.2 and
Table 19). Evidence on four treatments was found in this com-
parison: the potent steroid betamethasone valerate; the vitamin
D analogue calcipotriol; and two topical calcineurin inhibitors,
pimecrolimus and tacrolimus. We found only one placebo-con-
trolled trial that evaluated tacrolimus ointment (Lebwohl 2004),
but the study did not report any effectiveness data suitable for this
review. However, the study did contribute data on adverse events
and withdrawal rates.
TSS data were available for one of the four topical treatments for
inverse psoriasis. One 8-week between-patient study contributed
data on pimecrolimus 1% cream from 57 participants (Gribetz
2004), 10 participants more than those with an investigator’s as-
sessment (see Analysis 16.1). Findings from the TSS were con-
sistent with those of the IAGI: the SMD for the TSS also found
a statistically significant difference in favour of twice-daily pime-
crolimus (SMD -1.37; 95% CI -1.95 to -0.79).
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Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
inverse psoriasis, which compared vitamin D with an active con-
trol (see Analysis 17.2 and Table 20). We identified five interven-
tion-comparator contrasts. Four treatments were compared with
calcipotriol: once-daily betamethasone valerate, combined treat-
ment with calcipotriol and hydrocortisone, calcitriol, and pime-
crolimus. Calcitriol was compared with tacrolimus.
Two 6-week studies contributed TSS data from 124 study partici-
pants on2of the 5 intervention-comparator contrasts. Calcipotriol
was significantly less effective than calcitriol (SMD 0.61; 95% CI
0.28 to 0.94) (Ortonne 2003). In this within-patient study, partic-
ipants applied treatments twice daily to ’sensitive areas’, including
the face, hairline, retro-auricular, and flexural areas. When they
applied treatments to the facial and genitofemoral areas, there was
no significant difference in effect between twice-daily treatment
with calcitriol and tacrolimus (SMD 0.29; 95% CI -0.27 to 0.85)
(Liao 2007). In this between-patient study, participants applied
both treatments twice daily.
Analysis 18: Scalp psoriasis: placebo-controlled trials
This comparison included placebo-controlled trials of treatments
for scalp psoriasis (see Analysis 18.2 and Table 21). We included
evidence on 11 treatments in this comparison, with TSS data
available for 10 treatments. Twelve between-patient trials con-
tributed data from 2897 participants. Trial duration ranged be-
tween two and eight weeks. TSS data were not available for halci-
nonide (classed as a very potent corticosteroid).
Eight of the 10 treatments for scalp psoriasis that were assessed
using the TSS scale were significantly more effective than placebo.
The least effective treatment was calcipotriol (SMD -0.44; 95%
CI -0.64 to -0.25; I² statistic = 0%), and the most effective were
the 2 very potent steroids, amcinonide (SMD-1.58; 95%CI -1.98
to -1.18) and clobetasol propionate (SMD -1.53; 95% CI -1.77
to -1.28; I² statistic = 46.3%). Combination treatment with cal-
cipotriol andbetamethasone dipropionatewas also effective (SMD
-0.92; 95% CI -1.42 to -0.43; I² statistic = 83.2%).
We pooled data from the two potent corticosteroids, betametha-
sone valerate and betamethasone dipropionate (SMD -1.13; 95%
CI -1.44 to -0.81; I² statistic = 52.2%). We also pooled data from
the two very potent corticosteroids, amcinonide and clobetasol
propionate (SMD -1.55; 95% CI -1.73 to -1.37; I² statistic =
19.6%).
Two treatments were not significantly different to placebo: ci-
clopirox olamine shampoo (SMD -0.07; 95% CI -0.82 to 0.68)
and salicylic acid (SMD -0.57; 95% CI -1.47 to 0.32).
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin
D product (used either as monotherapy or in combination with
another product) (see Analysis 19.2 and Table 22).
We identified six intervention-comparator contrasts, and TSS data
were available for all six of these contrasts. All studies were parallel-
group indesign (between-patient). Eleven studies contributedTSS
data from 4877 participants, and trial duration ranged from 4 to
8 weeks.
Based on Total Severity Scores, calcipotriol was significantly less
effective than betamethasone dipropionate (SMD 0.45; 95% CI
0.28 to 0.63; I² statistic = 66.3%), clobetasol propionate (SMD
0.37; 95% CI 0.05 to 0.69; I² statistic = NA), and combina-
tion treatment with calcipotriol and betamethasone dipropionate
(SMD0.70; 95%CI 0.56 to 0.84; I² statistic = 49.6%). There was
no statistically significant difference between calcipotriol and be-
tamethasone valerate (SMD 0.09; 95% CI -0.09 to 0.27; I² statis-
tic = 0%). Combination treatment (calcipotriol/betamethasone
dipropionate) was significantly more effective than betamethasone
dipropionate alone (SMD -0.19; 95% CI -0.27 to -0.11; I² statis-
tic = 0%). The efficacy of calcipotriol and coal tar polytherapy was
not significantly different (SMD -0.30; 95% CI -0.84 to 0.24; I²
statistic = 93.1%).
(c) Psoriasis Area and Severity Index (PASI)
Analysis 1: Vitamin D analogues versus placebo
Our review included eight vitamin D analogues for body psoriasis
in this comparison (see Analysis 1.3 and Table 5). Nine studies
reported PASI data, with 2357 participants contributing data on
2 (calcipotriol and tacalcitol) of these 8 treatments. Eight trials
were between-patient design, and one was a within-patient study
(Dubertret 1992). Treatment duration ranged from three weeks
to eight weeks. The average effect size across the 2 treatments
for PASI was SMD -0.58 (95% CI -0.71 to -0.45; I² statistic =
42.3%).
Analysis 2: Corticosteroid (potent) versus placebo
Our review included 10 potent corticosteroids for body psoria-
sis in this comparison (see Analysis 2.3 and Table 6). Three be-
tween-patient studies reported PASI data from 1158 participants
on once-daily or twice-daily doses of betamethasone dipropionate
(2 of the 10 potent steroid regimens considered in this group).
Trial duration ranged between four and eight weeks. The aver-
age PASI effect size across both application frequencies was -0.97
(95% CI -1.31 to -0.62; I² statistic = 79.6%).
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Analysis 3: Corticosteroid (very potent) versus placebo
Our review did not identify any study that compared very potent
corticosteroids against placebo and also reported PASI data. This
may be because whole-body application of very potent corticos-
teroids is not recommended, so a whole-body assessment measure
like the PASI is inappropriate.
Analysis 4: Dithranol versus placebo
Our review did not identify any study that compared dithranol
against placebo and also reported PASI data.
Analysis 5: Vitamin D combination products versus placebo
This comparison included treatment with combined calcipotriol
and betamethasone dipropionate used either once or twice daily
on the body (see Analysis 5.3 and Table 8). Five parallel-group
studies with 2056 participants contributed PASI data on both
dosing options. Treatment duration ranged from four to eight
weeks. The PASI SMD across treatments was -1.24 (95%CI -1.53
to -0.95; I² statistic = 87.6%). Although twice-daily combination
treatment (SMD -1.41; 95% CI -1.86 to -0.97) achieved a larger
effect than once-daily treatment (SMD -1.14; 95% CI -1.57 to
-0.70), the difference was not statistically significant at the 5%
level. This finding contrasts with the assessment of the relative
benefit of once- versus twice-daily dosing using the IAGI metric
(see Analysis 5.1).
Analysis 6: Other treatment versus placebo
This comparison comprised all other treatments for body psoriasis
that were not included in the first five comparisons; therefore, we
removed pooling. None of the studies assessed the same treatment,
which means that findings should be interpreted with caution.
In total, we included 26 treatments in this analysis (see Analysis
6.3 and Table 9). Nine studies with 529 participants reported
PASI data on 9 of these 26 treatments. Eight trials were between-
patient studies, and one was within-patient in design (Vali 2005).
Treatment duration ranged from 2 to 12 weeks.
Six treatments performed statistically significantly better than
placebo: aloe vera extract, betamethasone 17-valerate 21-acetate
plus tretinoin plus salicylic acid, a herbal skin care product, Ma-
honia aquifolium, methotrexate gel, and theophylline ointment.
Effects sizes ranged from -0.54 (95% CI -0.99 to -0.10) for the
betamethasone 17-valerate 21 product (Santoianni 2001) to -2.96
(95% CI -4.19 to -1.74) for the herbal skin care treatment (Maier
2004).
In three treatments, we found no statistically significant differ-
ence relative to placebo in the PASI assessments. These com-
prised topical caffeine (Vali 2005), dead sea salts emollient lotion
(Cheesbrough 1992), and kukui nut oil (Brown 2005).
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
Our review identified eight vitamin D analogue-potent corticos-
teroid comparisons for body psoriasis (see Analysis 7.3 and Table
10). Nine studies with 3185 participants reported PASI data for 4
of the 8 intervention-comparator contrasts. Seven trials were be-
tween-patient design, and two were within-patient studies. Treat-
ment duration ranged from four to eight weeks. The PASI SMD
across all four intervention-comparator contrasts indicated that
there was no statistically significant difference between the vita-
min D derivatives and potent corticosteroid (SMD 0.12; 95% CI
-0.07 to 0.32; I² statistic = 86.2%).
In one vitamin D analogue versus potent corticosteroid compar-
ison, the vitamin D analogue performed statistically significantly
better than the potent corticosteroid: four studies contributed data
to analysis of calcipotriol versus betamethasone valerate (SMD -
0.12; 95% CI -0.22 to -0.02; I² statistic = 0%).
In two intervention-comparator contrasts, the vitaminDanalogue
was statistically significantly less effective than the potent corti-
costeroid: Betamethasone dipropionate was more effective than
both calcipotriol (SMD 0.36; 95% CI 0.22 to 0.51; I² statistic =
49.6%) and calcitriol (SMD 0.39; 95% CI 0.14 to 0.63; I² statis-
tic = NA).
We found no statistically significant difference between cal-
cipotriol and desoxymetasone.
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
This comparison considered vitamin D analogues against very po-
tent corticosteroids for treating psoriasis of the body (see Analysis
8.3 andTable 11).We found data on one intervention-comparator
contrast: calcipotriol versus clobetasol propionate. One between-
patient trial reported PASI data for 40 participants. This trial had
a treatment duration of six weeks (Landi 1993). The SMD for
the PASI indicated that there was no statistically significant dif-
ference between the very potent corticosteroid and the vitamin D
analogue: SMD -0.32 (95% CI -0.95 to 0.30; I² statistic = NA).
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
This comparison considered vitamin D analogue-steroid combi-
nation against potent or very potent corticosteroid for body pso-
riasis (Table 12). Three between-patient trials reported PASI data
for 1876 participants (see Analysis 9.3). All 3 trials compared com-
bination treatment with calcipotriol and betamethasone dipropi-
onate with betamethasone dipropionate as monotherapy, but var-
ied in their treatment duration (4 to 8 weeks). The SMD for the
PASI was -0.44 (95% CI -0.55 to -0.33; I² statistic = 22.4%),
indicating a significantly greater effect for combination treatment.
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Analysis 10: Vitamin D alone or in combination versus
dithranol
This comparison considered vitamin D analogues against dithra-
nol (see Analysis 10.3 and Table 13).We identified three interven-
tion-comparator contrasts: calcipotriol versus dithranol, calcitriol
versus dithranol, and tacalcitol versus dithranol. Five between-pa-
tient trials reported PASI data for 796 participants. Treatment du-
ration ranged from 8 to 12 weeks. There was some variation in the
dithranol regimens employed by trials and in the baseline severity
of trial participants. These factors may explain the considerable
level of heterogeneity found in the pooled results (Higgins 2011).
The SMD for the PASI was 0.36 (95%CI -0.33 to 1.04; I² statistic
= 94.5%). Data from three trials contributed to the SMD for
the calcipotriol versus dithranol: 0.73 (95% CI -0.55 to 2.00;
I² statistic = 97.2%) (Berth Jones 1992b; Monastirli 2000; Van
de Kerkhof 2006). One of these three trials found a large and
statistically significant difference in favour of calcipotriol (Berth
Jones 1992b); Monastirli 2000 found a significant difference in
favour of dithranol, and the trial by Van de Kerkhof 2006 found
no difference between the two treatments. In the light of this
heterogeneity, we removed all pooling from this comparison.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Our review identified three intervention-comparator contrasts for
body psoriasis in this comparison: calcipotriol versus calcitriol,
calcipotriol versus tacalcitol, and calcipotriol versus maxacalcitol
(see Analysis 11.3 and Table 14). One between-patient trial in-
volving 15 participants contributed PASI data for the comparison
of calcipotriol and calcitriol (Bourke 1997). Treatment duration
was eight weeks. Although there was a trend towards a greater ef-
fect for calcipotriol, the SMD for the PASI was not statistically
significant: -1.11 (95% CI -2.22 to 0.01; I² statistic = NA).
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
Our review identified 12 intervention-comparator contrasts, in-
volving 3 vitamin D analogues, 2 combination products, and 7
different corticosteroids (see Analysis 12.3 and Table 15). Sixteen
trials involving 5703 participants contributed PASI data for 11
of these 12 intervention-comparator contrasts. Fifteen trials were
between-patient, and 1 was within-patient in design (Salmhofer
2000). Treatment duration ranged from 2 to 12 weeks.We did not
identify any PASI data for the comparison of calcipotriol against
clobetasol propionate then calcipotriol. Overall, vitamin D plus
corticosteroid appeared to bemore effective than vitamin D alone:
The SMD for the PASI was 0.47 (95% CI 0.34 to 0.59; I² statistic
= 82.3%). However, there was considerable variation between the
findings of the intervention-comparator contrasts. In light of the
observed heterogeneity, we only pooled subtotals (Higgins 2011).
In six of the intervention-comparator contrasts, the analysis of
the PASI measure found no significant difference between the
treatments. This was the case for twice-daily calcipotriol compared
with the following:
• a regimen with calcipotriol applied in the morning and the
night-time application of betamethasone valerate (Kragballe
1998b; Ruzicka 1998);
• clobetasone butyrate (Kragballe 1998b); or
• diflucortolone valerate (Salmhofer 2000).
Once-daily calcipotriol was nomore effective than combined treat-
ment with fluocinonide acetonide (Wozel 2001) or combinedwith
hydrocortisone (Ortonne 2010). Lastly, no significant difference
was found between twice-daily calcitriol and combined treatment
with diflucortolone valerate (mornings) and calcitriol (night time)
(Lee 2007).
In contrast, combined treatment with calcipotriol and betametha-
sone dipropionate was significantly more effective than twice-
daily calcipotriol alone. This finding held for regimens involv-
ing night-time applications of betamethasone dipropionate (SMD
0.46; 95% CI 0.10 to 0.82; I² statistic = NA) and for treatment
with a combined product, whether applied once daily (SMD0.52;
95% CI 0.38 to 0.67; I² statistic = 32.3%) or twice daily (SMD
0.64; 95%CI 0.46 to 0.83; I² statistic = 73.6%). Once-daily treat-
ment with the combined calcipotriol/betamethasone dipropionate
product was also significantly more effective than once-daily cal-
cipotriol (SMD 0.67; 95% CI 0.23 to 1.11; I² statistic = 87.4%)
as well as once-daily tacalcitol (SMD 0.47; 95% CI 0.25 to 0.69;
I² statistic = NA).
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison summarises findings on complex regimens for
body psoriasis, defined here as treatment sequences that do not
consist of a simple head-to-head comparison between two active
treatments (see Analysis 13.3 and Table 16). PASI data were avail-
able for 11 of the 12 intervention-comparator contrasts identified.
Data from 2991 participants contributed to the PASI analysis,
based on findings from 8 between-patient trials. Trial duration
varied between 2 and 12 weeks. Because the interventions and
comparators were highly variable and two trials each contributed
three pair-wise contrasts, we did not pool the data.
Six intervention-comparator contrasts for which PASI data were
available found a significant difference between regimens. A six-
week course of calcipotriol was compared with two different com-
plex regimens. Monotherapy with calcipotriol was significantly
less effective than two weeks of treatment with calcipotriol and flu-
ocinonide acetonide followed by four weeks of calcipotriol (SMD
0.66; 95%CI 0.01 to 1.32) (Wozel 2001). Calcipotriol monother-
apy was also less effective than treatment with calcipotriol to
which halometasone was added (SMD1.13; 95%CI 0.64 to 1.62)
(Yang 2009).Monotherapy with tacalcitol (8 weeks) was less effec-
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tive than sequential treatment with a combined calcipotriol and
betamethasone dipropionate product (4 weeks) followed by cal-
cipotriol monotherapy for a further 4 weeks (SMD 0.49; 95% CI
0.31 to 0.67) (Ortonne 2004). White 2006 (P) compared three
regimens, all of which included an initial phase in which partic-
ipants applied combination treatment with calcipotriol and be-
tamethasone dipropionate once a day for four weeks. The sub-
sequent eight-week maintenance phase using placebo ointment
was significantly less effective than maintenance with either twice-
daily calcipotriol (SMD 0.25; 95% CI 0.10 to 0.39), or mainte-
nance with calcipotriol on weekdays and combination treatment
at weekends (SMD 0.59; 95% CI 0.45 to 0.74). When the two
active maintenance regimens were compared directly, the alternat-
ing (weekday/weekend) regimenwas significantly more efficacious
(SMD 0.30; 95% CI 0.16 to 0.45) (White 2006 (H)).
In the remaining four intervention-comparator contrasts, we did
not detect any significant difference in the PASI assessments (see
Analysis 13.3). PASI assessments in the study by Kragballe 2004
found the difference between two complex regimens not to be
significant (SMD 0.15; 95% CI -0.01 to 0.30). This result was
on the borderline of significance and contrasted with the IAGI
assessment in the same study, which was statistically significant in
favour of the complex regimen (see Analysis 13.1).
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
We did not identify any relevant study that provided PASI data
for this analysis.
Analysis 15: Vitamin D analogues versus other treatment
This comparison incorporated all other vitamin D head-to-head
comparisons of treatments for psoriasis of the body (excluding in-
verse psoriasis) that had not already been included (see Analysis
15.3 andTable 18).We included 12 intervention-comparator con-
trasts, with PASI data available for 6 of these contrasts. There were
six between-patient trials and three within-patient trials, with data
for 1228 participants. Trial duration ranged between 4 and 12
weeks. In light of the pharmacological diversity of the compara-
tors, we only pooled data within subgroups (Higgins 2011).
According to the PASI assessment, twice-daily calcipotriol was
significantly more effective than coal tar polytherapy (SMD -0.63;
95%CI -1.06 to -0.20; I² statistic =NA) as well as propylthiouracil
cream (SMD -2.24; 95% CI -3.23 to -1.25; I² statistic = NA).
Twice-daily calcipotriol was not significantly more effective than
coal tar (SMD -0.10; 95% CI -1.54 to 1.35; I² statistic = 92.8%),
betamethasone dipropionate and salicylic acid (SMD -0.05; 95%
CI -0.36 to 0.26; I² statistic = NA), or vitamin B12 cream (SMD
-0.01; 95% CI -0.78 to 0.75; I² statistic = NA). The high level
of heterogeneity observed in the pooled analysis of calcipotriol
versus coal tar reflects contradictory findings from two studies,
one finding in favour of calcipotriol (Tham 1994) and the other
in favour of coal tar (Alora-Palli 2010).
When compared with once-daily dosing, twice-daily vitamin D
was borderline in demonstrating a significantly better effect (SMD
-0.12; 95% CI -0.25 to 0.00; I² statistic = 0%). The subgroups
contributing to this result were dosing comparisons of calcipotriol
(SMD -0.12; 95% CI -0.28 to 0.03; I² statistic = 0%) and com-
bination treatment with calcipotriol and betamethasone dipropi-
onate (SMD -0.12; 95% CI -0.32 to 0.09; I² statistic = NA).
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of topical
treatments for inverse or facial psoriasis (see Analysis 16.3 and
Table 19). We found evidence on four treatments in this com-
parison: the potent steroid betamethasone valerate; the vitamin
D analogue calcipotriol; and two topical calcineurin inhibitors,
pimecrolimus and tacrolimus. We only identified one placebo-
controlled trial evaluating tacrolimus ointment (Lebwohl 2004),
but the study did not report any effectiveness data suitable for this
review. However, the study did contribute data on adverse events
and withdrawal rates.
PASI datawere available for 3 of the 4 topical treatments for inverse
psoriasis, all reported by 1 4-week between-patient study with 75
participants (Kreuter 2006 (P)). In this study, participants applied
all treatments once daily. The SMD for the PASI found a statis-
tically significant difference in favour of betamethasone valerate
0.1% (SMD -2.83; 95% CI -3.79 to -1.88) as well as calcipotriol
ointment (SMD -1.08; 95% CI -1.77 to -0.40). However, PASI
data on once-daily pimecrolimus cream indicated the difference
relative to vehicle was not statistically significant (SMD -0.62;
95% CI -1.27 to 0.02).
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
inverse psoriasis, where vitamin D was compared with an active
control (see Analysis 17.3 and Table 20). We identified five inter-
vention-comparator contrasts. We compared four treatments with
calcipotriol: once-daily betamethasone valerate, combined treat-
ment with calcipotriol and hydrocortisone, calcitriol, and pime-
crolimus. Calcitriol was compared with tacrolimus.
Two between-patient studies contributed PASI data from 464
study participants on3of the 5 intervention-comparator contrasts.
Kreuter 2006 (H) found that calcipotriol was significantly less
effective than betamethasone valerate (SMD 2.02; 95% CI 1.20
to 2.84), but not significantly different in effect to pimecrolimus
(SMD -0.53; 95% CI -1.17 to 0.11). Participants in the Kreuter
2006 (H) trial applied all treatments once daily. When assessed
using the PASI, Ortonne 2010 found that calcipotriol was signif-
icantly less effective on inverse psoriasis than combined treatment
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with calcipotriol and hydrocortisone (SMD 0.32; 95% CI 0.12
to 0.51). This finding was consistent with the IAGI assessment in
the same trial (see Analysis 17.1).
Analysis 18: Scalp psoriasis: placebo-controlled trials
No PASI data were available for this comparison.
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
No PASI data were available for this comparison.
(d) Patient Assessment of overall Global Improvement
(PAGI)/Patient Global Assessment of Disease Severity
(PGA)
Analysis 1: Vitamin D analogues versus placebo
Our review included eight vitamin D analogues for body psoriasis
in this comparison, with PAGI data available for three treatments
(see Analysis 1.4 and Table 5). Five studies reported PAGI data,
all of which were between-patient design, and 1467 participants
contributed data. In all six studies, treatment duration was eight
weeks. The pooled effect across the 3 studies reporting PAGI data
was SMD -0.54; 95% CI -0.72 to -0.36; I² statistic = 55.5%.
Analysis 2: Corticosteroid (potent) versus placebo
Our review did not identify any study that compared potent cor-
ticosteroids against placebo and reported PAGI data.
Analysis 3: Corticosteroid (very potent) versus placebo
We included three very potent corticosteroids for body psoriasis in
this comparison for this outcome (see Analysis 3.4 and Table 7).
Three studies reportedPAGIdata for 283participants on2of these
3 treatments. There was one between-patient trial (Lebwohl 2002)
and two within-patient studies. In all three studies, treatment du-
ration was two weeks. The pooled effect across both treatments
for PAGI was (SMD -1.22; 95% CI -1.42 to -1.02; I² statistic =
0%). Both treatments performed statistically significantly better
than placebo. PAGI data on the use of very potent steroids on the
scalp are reported in Analysis 18.4.
Analysis 4: Dithranol versus placebo
Our reviewdid not identify any study comparing dithranol against
placebo and that reported PAGI data.
Analysis 5: Vitamin D combination products versus placebo
This comparison included treatment with combined calcipotriol
and betamethasone dipropionate used either once or twice daily
on the body (see Analysis 5.4 and Table 8). None of the studies of
twice-daily treatment reported PAGI data, but one parallel-group
study with 235 participants contributed data on once-daily treat-
ment (Langley 2011 (P)). Treatment duration was eight weeks.
The PAGI SMD was -0.69 (95% CI -0.98 to -0.40; I² statistic =
NA). Placebo-controlled trials of combination vitamin D/steroid
treatments for scalp psoriasis are reported in Analysis 18.4.
Analysis 6: Other treatment versus placebo
This comparison comprised all other treatments for body psoriasis
that we did not include in the first five comparisons; therefore, we
removed pooling. None of the studies assessed the same treatment,
which means that findings should be interpreted with caution.
In total, we included 26 treatments in this analysis (see Analysis
6.4 andTable 9). Two studies with 105 participants reported PAGI
data on 2 of these 26 treatments. Both trials were between-patient
studies. Treatment duration ranged from 3 to 12 weeks. According
to participants’ assessments (PAGI), betamethasone 17-valerate 21
acetate plus tretinoin plus salicylic acid performed significantly
better than placebo (SMD -0.80; 95% CI -1.26 to -0.35), whilst
kukui nut oil was no more effective than placebo (SMD 0.00;
95% CI -0.80 to 0.80). These findings were very similar to the
investigators’ assessments (see Analysis 6.1).
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
Our review identified eight vitamin D analogue-potent corticos-
teroid comparisons for body psoriasis (see Analysis 7.4 and Table
10). Two studies with 738 participants reported PAGI data for 1 of
these 8 comparisons.One trial was a parallel-group study (Cunliffe
1992), and onewas awithin-patient study (Kragballe 1991a), both
with a treatment duration of six weeks. The PAGI SMD indicated
that the vitamin D analogue calcipotriol was significantly more
effective than betamethasone valerate (SMD -0.26; 95% CI -0.38
to -0.14; I² statistic = 0%).
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
This comparison included one vitamin D analogue and a very po-
tent corticosteroid contrast, calcipotriol ointment versus clobeta-
sol propionate foam for body psoriasis (see Table 11 and Analysis
8.4). One study with 42 participants reported PAGI data. Koo
2006was a between-patient studywith a treatment durationof two
weeks. Findings for the participant-reported assessment (SMD
0.42; 95% CI -0.20 to 1.03) were similar, the investigators’ assess-
ment from the same study (SMD 0.19; 95% CI -0.42 to 0.80; see
Analysis 8.1).
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Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
We foundone study comparing a vitaminDanalogue-steroid com-
bination against corticosteroids for body psoriasis that reported
PAGI/PGA data (see Table 12 and Analysis 9.4). This two-week
between-patient study reported PAGI data for 65 participants
(Koo 2006), comparing combined treatment with calcipotriol and
clobetasol propionate against the very potent corticosteroid alone.
According to the participants’ assessment (PAGI), there was no
statistically significant difference between the treatment options
(SMD -0.28; 95% CI -0.80 to 0.24). This finding contrasts with
the investigators’ assessment (IAGI), which found in favour of
combination treatment (SMD -0.69; 95% CI -1.22 to -0.15) (see
Analysis 9.1).
Analysis 10: Vitamin D alone or in combination versus
dithranol
This comparison considered vitamin D analogues against dithra-
nol (see Analysis 10.4 and Table 13). We identified three inter-
vention-comparator contrasts: calcipotriol versus dithranol, cal-
citriol versus dithranol, and tacalcitol versus dithranol. PAGI data
were available only for the intervention-comparator contrast of
calcipotriol versus dithranol. Two between-patient trials reported
PAGI data for 544 participants (Berth Jones 1992b; Van de
Kerkhof 2006). Treatment duration ranged from 8 to 12 weeks.
The SMD for the PAGIwas -0.05 (95%CI -0.90 to 0.80; I² statis-
tic = 92.5%), indicating no statistically significant advantage for
calcipotriol or dithranol according to the participants’ assessment.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Our review identified three intervention-comparator contrasts for
body psoriasis in this comparison: calcipotriol versus calcitriol,
calcipotriol versus tacalcitol, and calcipotriol versus maxacalcitol
(see Analysis 11.4 and Table 14). One between-patient trial in-
volving 250 participants contributed PAGI data for the compar-
ison of calcipotriol and calcitriol (Ji 2008). Treatment duration
was 12 weeks. The SMD for the PAGI indicated that there was
no statistically significant difference between calcipotriol and cal-
citriol (SMD 0.04; 95% CI -0.21 to 0.29; I² statistic = NA). This
study used three measures to assess the effects of calcipotriol and
calcitriol. The investigators’ assessment supported the participant
assessment (no difference) (see Analysis 11.1), but the TSS found
a significant difference in favour of calcipotriol (Analysis 11.2).
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
Our review identified 12 intervention-comparator contrasts for
body psoriasis, involving 3 vitamin D analogues, 2 combination
products, and 7 different corticosteroids (see Analysis 12.4 and
Table 15). Two parallel-group trials contributed PAGI data from
399 participants for 2 of these 12 intervention-comparator con-
trasts. Treatment duration ranged between two and eight weeks.
According to the participant assessment, twice-daily calcipotriol
was significantly less effective than twice-daily treatment with cal-
cipotriol and clobetasol propionate (SMD 0.70; 95% CI 0.16 to
1.23). Treatment with tacalcitol was also less effective than treat-
ment with a combined product containing calcipotriol and be-
tamethasone dipropionate, when both treatments were applied
once daily (SMD 0.46; 95% CI 0.24 to 0.68). The pooled SMD
for these two trials (0.49; 95% CI 0.29 to 0.69; I² statistic = 0%)
gave greater weight to the comparison with tacalcitol, since this
was the larger trial (334 participants; Langley 2011 (H)).
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison summarises findings on complex regimens for
body psoriasis, defined here as treatment sequences that do not
consist of a simple head-to-head comparison between two active
treatments (see Analysis 13.4 and Table 16). We identified 12 in-
tervention-comparator contrasts and data from the Patient Assess-
ment of Global Improvement (PAGI) or Patient Global Assess-
ment of Disease Severity (PGA) were available for 7 of these. Data
from 2508 participants contributed to the PAGI analysis, based
on findings from 4 between-patient trials. Trial duration varied be-
tween 8 and 12 weeks. Because the interventions and comparators
were highly variable and two trials each contributed three pair-
wise contrasts, we did not pool the data.
Four intervention-comparator contrasts for which PAGI data were
available found a significant difference between regimens.Ortonne
2004 found that fourweeks of treatmentwith a combination prod-
uct of calcipotriol and betamethasone dipropionate, followed by
monotherapy with calcipotriol for four weeks, was significantly
more effective thanmonotherapy with tacalcitol (SMD0.54; 95%
CI 0.36 to 0.72). Findings from the patient-reported outcome
were identical to the investigators’ assessment (Analysis 13.1). The
trial by White 2006 (H)/White 2006 (P) compared three reg-
imens. All included an initial phase in which participants ap-
plied once-daily combination treatment with calcipotriol and be-
tamethasone dipropionate for four weeks, but differed in their sub-
sequent eight-week maintenance phase. According to the partici-
pants’ assessment, maintenance therapy with twice-daily placebo
ointment was significantly less effective than maintenance with
either calcipotriol ointment (SMD 0.28; 95% CI 0.13 to 0.42)
or maintenance with calcipotriol on weekdays and combination
treatment at weekends (SMD 0.71; 95% CI 0.56 to 0.85). We
compared the 2 regimens with active maintenance options di-
rectly; the alternating (weekday/weekend) approach was signifi-
cantly more effective (SMD 0.44; 95% CI 0.29 to 0.58). These
findings, based on the participants’ assessment of severity, were
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aligned with those of both the investigators’ assessment (Analysis
13.1) and the PASI assessment (Analysis 13.3).
A head-to-head comparison of two complex regimens found a
significant difference (Kragballe 2004). Once-daily combination
treatment (calcipotriol/betamethasone dipropionate) for 8 weeks
followed by once-daily calcipotriol for 4 weeks was significantly
less effective than a regimen consisting of combined treatment for 4
weeks, followed by 8 weeks of once-daily therapy with calcipotriol
onweekdays and combined therapy at weekends (SMD0.23; 95%
CI 0.07 to 0.39).
In three of the seven intervention-comparator contrasts, no sig-
nificant difference was found. Kragballe 2004 also compared 12
weeks of calcipotriol monotherapy with the 2 complex regimens
described in the paragraph above. Compared with monotherapy,
participants who applied once-daily combination treatment (cal-
cipotriol/betamethasone dipropionate) for 8 weeks followed by
once-daily calcipotriol for 4 weeks did not experience a signifi-
cantly greater improvement in their psoriasis (SMD-0.14; 95%CI
-0.30 to 0.02). Similarly, the psoriasis of participants onmonother-
apy with twice-daily calcipotriol did not improve significantly dif-
ferently compared to those who applied once-daily combination
treatment (calcipotriol/betamethasone dipropionate) for 4 weeks,
followed by 8 weeks using calcipotriol once daily (weekdays) and
combination therapy (weekends) (SMD 0.10; 95% CI -0.06 to
0.26).
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
We did not identify any relevant study that provided PAGI data
for this analysis.
Analysis 15: Vitamin D analogues versus other treatment
This comparison incorporated all other vitamin D head-to-head
comparisons of treatments for psoriasis of the body (excluding in-
verse psoriasis) that we had not already included (see Analysis 15.4
andTable 18).We included 12 intervention-comparator contrasts,
with PAGI data available for 6 of these contrasts: 3 between-pa-
tient trials and 3 within-patient trials data for 456 participants.
Trial duration ranged between 4 and 12 weeks. In light of the
pharmacological diversity of the comparators, we only pooled data
within subgroups.
According to the participants’ assessment, twice-daily calcipotriol
was significantly more effective than three comparators, with ev-
idence on each based on a single trial. Calcipotriol was more ef-
fective than coal tar both as monotherapy (SMD -1.51; 95% CI -
2.12 to -0.90; Tham 1994) and as polytherapy (SMD -0.56; 95%
CI -0.99 to -0.13; Van de Kerkhof 2002a), andmore effective than
betamethasone dipropionate and salicylic acid (SMD -0.49; 95%
CI -0.79 to -0.20; Scarpa 1994). No significant difference was
evident when calcipotriol was compared to tacrolimus ointment
(Ortonne 2006), tazarotene (Tzung 2005), or vitamin B12 cream
(Stuecker 2001).
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of topical
treatments for inverse or facial psoriasis (see Analysis 16.4 and
Table 19). We found evidence on four treatments in this com-
parison: the potent steroid betamethasone valerate; the vitamin
D analogue calcipotriol; and two topical calcineurin inhibitors,
pimecrolimus and tacrolimus. We identified only one placebo-
controlled trial evaluating tacrolimus ointment (Lebwohl 2004),
but the study did not report any effectiveness data suitable for this
review. However, the study did contribute data on adverse events
and withdrawal rates.
PAGI (patient-assessment) data were available for one of the four
topical treatments for inverse psoriasis. One 8-week between-pa-
tient study (Gribetz 2004) reported data from 47 participants.
Relative to placebo, the SMD for the PAGI found a statistically
significant difference in favour of twice-daily pimecrolimus cream
(SMD -0.65; 95% CI -1.24 to -0.06).
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
We did not identify any relevant study that provided PAGI data
for this analysis.
Analysis 18: Scalp psoriasis: placebo-controlled trials
This comparison included placebo-controlled trials of treatments
for scalp psoriasis (see Analysis 18.4 and Table 21). We included
evidence on 11 treatments in this comparison, with PAGI data
available for 5 treatments. Five between-patient trials contributed
data from 1875 participants. Trial duration ranged between three
and eight weeks.
Four of the five treatments for scalp psoriasis that were evalu-
ated using the Patient Global Assessment Scale were significantly
more effective than placebo. The least effective treatment was cal-
cipotriol (SMD-0.66; 95%CI -1.28 to -0.05; I² statistic = 74.5%),
and the most effective was betamethasone dipropionate (SMD -
1.23; 95%CI -1.43 to -1.03; I² statistic = NA). Effects for the very
potent steroid amcinonide (SMD -0.97; 95% CI -1.33 to -0.61 I²
statistic = NA) and combination treatment with calcipotriol and
betamethasone dipropionate (SMD -1.00; 95%CI -1.79 to -0.22;
I² statistic = 93.2%) fell between these two extremes. There were
no data suitable for pooling across subcategories.
Only for ciclopirox olamine shampoo was the difference relative
to placebo found to be non-significant: SMD -0.11 (95% CI -
0.86 to 0.64; I² statistic = NA).
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Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin
D product (used either as monotherapy or in combination with
another product) (see Analysis 19.4 and Table 22).
We identified six intervention-comparator contrasts, and PAGI
data were available for four of these contrasts (there were no par-
ticipant-assessed outcomes data for the comparison of calcipotriol
against either clobetasol propionate or against coal tar polyther-
apy). All studies were parallel-group in design (between-patient).
Six studies contributed PAGI data from 3742 participants, and
trial duration ranged from 4 to 8 weeks.
Based on the participant assessment scores, calcipotriol was signifi-
cantly less effective than betamethasone dipropionate (SMD0.56;
95%CI 0.31 to 0.81; I² statistic = 82.8%), betamethasone valerate
(SMD0.41; 95%CI 0.22 to 0.59; I² statistic =NA), and combina-
tion treatment with calcipotriol and betamethasone dipropionate
(SMD0.84; 95%CI 0.61 to 1.08; I² statistic = 81.5%). Combina-
tion treatment (calcipotriol/betamethasone dipropionate) was sig-
nificantly more effective than betamethasone dipropionate alone
(SMD -0.17; 95% CI -0.25 to -0.09; I² statistic = 0%).
(e) Combined end point (IAGI/TSS/PASI/PAGI)
Analysis 1: Vitamin D analogues versus placebo
Our review included eight vitamin D analogues for body psoriasis
in this comparison (see Analysis 1.5 and Table 5). Thirty stud-
ies, involving 4986 participants, contributed data. Eighteen trials
were between-patient design, and 12 were within-patient stud-
ies. Treatment duration ranged from 3 to 12 weeks. Six studies
had adequately concealed treatment allocation. The pooled effect
across all 30 studies was -0.90 (95% CI -1.07 to -0.72; I² statistic
= 87.5%), which equates to 1.03 on a 6-point IAGI scale. How-
ever, the summary statistic conceals considerable variationbetween
treatments. In two treatments, the effect was not statistically sig-
nificantly different to placebo (twice-daily calcipotriol plus occlu-
sion for 2 weeks followed by 4 weeks with no treatment, and once-
daily becocalcidiol). In treatments that were significantly more ef-
fective than placebo, the effect ranged from -0.67 (twice-daily be-
cocalcidiol) to -1.66 (once-daily paricalcitol); on a 6-point IAGI
scale, these effects translate into 0.80 and 1.91 points, respectively.
However, given the high level of heterogeneity found in the meta-
analysis, it may bemore informative to look at individual products
within the class, rather than treating this class as a single group.
We removed the pooling across the class, so that we only pooled
subtotals.
We reported placebo-controlled trials of vitamin D products for
scalp psoriasis (Analysis 18.5) and inverse psoriasis (Analysis 16.5)
elsewhere.
Sensitivity analyses
We explored differences in within-patient and between-patient
designs using one-way sensitivity analysis (Table 5). The SMD for
the 12 within-patient studies (600 participants) was -1.11 (95%
CI -1.58 to -0.64; I² statistic = 91.5%). This translates into a
change of 1.27 on a 6-point IAGI scale, slightly larger than the
effect size for all studies. The SMD for the 18 between-patient
studies (4386 participants) was -0.80 (95% CI -0.96 to -0.63; I²
statistic = 83.2%). This translates into a change of 0.91 on a 6-
point IAGI scale, slightly smaller than the effect size for the within-
patient studies.
We also used sensitivity analysis to explore the impact of varying
the correlation coefficient (rho) for the 12 within-patient studies.
As no trial in the review reported this statistic, we tested values of
0, 0.25, 0.50, and 0.75. Varying the value of rho for the within-pa-
tient studies had no significant effect on the findings: The pooled
SMD ranged from -0.85 (95% CI -1.00 to -0.71; I² statistic =
87.8%; 30 studies), when we assumed the correlation to be zero,
to -0.91 (95% CI -1.07 to -0.75; I² statistic = 93.2%; 30 studies),
when we assumed the correlation to be 0.75.
The study byPerez 1996 comparing calcitriol andplacebo reported
large and statistically significant differences for bothTSS and IAGI
outcomes. In both outcomes, the magnitude of the effect was
the largest across all comparisons and treatments. Perez 1996 was
a 10-week within-patient study involving 84 participants. The
study included people with severe disease (mean TSS at baseline:
7.6 on a 10-point scale, with at least 10% of body surface area
affected) who had previously had an unsatisfactory response to at
least 1 previous treatment including topical steroids, UVB, PUVA,
and methotrexate. The dramatic improvement observed in the
intervention group is difficult to interpret in the context of findings
from other trials, and we explored the impact of removing this
study in a sensitivity analysis. When we removed Perez 1996 from
the pooled analysis for calcitriol, the effect size was smaller but still
statistically significantly different from placebo: SMD with Perez
1996 was -0.92 (95% CI -1.54 to -0.29; I² statistic = 94.9%; 7
studies), and SMD without Perez 1996 was -0.60 (95% CI -0.78
to -0.41; I² statistic = 30%; 6 studies). On a 6-point IAGI scale,
these effect sizes equate to 1.05 and 0.68, respectively (Table 5).
The trials of calcipotriol varied by dose, treatment duration,
and dosing frequency; where trials reported more than one dose
(Kragballe 1988b) or type of vehicle (Harrington 1996a), we esti-
mated the weighted mean and standard deviation across the trial.
The effect size for twice-daily regimens was -1.02 (95% CI -1.23
to -0.82 I² statistic = 73.5%; 13 studies); this equates to 1.18 on a
6-point IAGI scale. For once-daily calcipotriol, the corresponding
figures were -0.76 (95% CI -1.13 to -0.40; I² statistic = 82.3%; 4
studies) and 0.87 on a 6-point IAGI scale. Therefore, both dos-
ing frequencies were more effective than placebo, but once-daily
applications had a smaller effect (Table 5).
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Analysis 2: Corticosteroid (potent) versus placebo
Our review identified 10 potent corticosteroids for body psoria-
sis in this comparison (see Analysis 2.5 and Table 6). The treat-
ments included three betamethasone dipropionate regimens, but
we identified no effectiveness evidence for budesonide and no
study reporting PAGI data. Therefore, 13 studies involving 2216
participants contributed data on 9 of the 10 treatments. Eleven
trials were between-patient design, and two were within-patient
studies. Treatment allocation was adequately concealed in four
studies. Treatment duration ranged from 2 to 12 weeks. Partici-
pant numbers for individual studies ranged from 9 (Wortzel 1975
(2)) to 633 (Kaufmann 2002 (P)). The pooled effect across all 13
studies was -0.89 (95% CI -1.06 to -0.72; I² statistic = 65.1%).
This equates to 1.02 on a 6-point IAGI scale. With the exception
of diflorasone diacetate (Lane 1983), all potent corticosteroids
were significantly more effective than placebo at the 5% level of
significance. We reported elsewhere placebo-controlled trials of
potent corticosteroid products for scalp psoriasis (Analysis 18.5)
and inverse psoriasis (Analysis 16.5).
Sensitivity analyses
We explored differences in within-patient and between-patient
designs using one-way sensitivity analysis (Table 6). The SMD for
the 2 within-patient studies was -1.33 (95% CI -1.78 to -0.89;
I² statistic = 0%). This translates into a change of 1.53 on a 6-
point IAGI scale, which is larger than the effect for all studies.
However, as just 48 participants contributed data to this analysis,
robust inferences cannot be drawn. The SMD for the 11 between-
patient studies (2168 participants) was -0.85 (95% CI -1.03 to -
0.67; I² statistic = 66.7%). This translates into a change of 0.98 on
a 6-point IAGI scale, slightly smaller than the effect for all studies.
We also used sensitivity analysis to explore the impact of varying
the correlation coefficient (rho) for the 2 within-patient studies.
As no trial in the review reported this statistic, we tested values of
0, 0.25, 0.50, and 0.75. Varying the value of rho for the within-
patient studies had no significant effect on the findings: the pooled
SMD ranged from -0.89 (95% CI -1.06 to -0.72; I² statistic =
77.7%; 14 studies), when we assumed the correlation was to be
zero, to -0.91 (95% CI -1.08 to -0.74; I² statistic = 80.2%; 13
studies), when we assumed the correlation to be 0.75.
Analysis 3: Corticosteroid (very potent) versus placebo
Our review identified three very potent corticosteroids for body
psoriasis in this comparison (see Analysis 3.5 and Table 7), but
effectiveness data were not available for one of these treatments
(halcinonide). Ten studies reported data for 1264 participants.
There were seven between-patient trials and three within-patient
studies. Treatment duration ranged from two to four weeks. In no
study was treatment allocation adequately concealed. The SMD
across the 2 treatments was -1.56 (95% CI -1.87 to -1.26; I²
statistic = 81.7%; 10 studies). This equates to 1.80 points on a 6-
point IAGI scale. Both clobetasol propionate (SMD -1.65; 95%
CI -2.10 to -1.20; I² statistic = 86.3%; 7 studies) and halobetasol
(SMD-1.36; 95%CI -1.65 to -1.07 I² statistic = 47.1%; 3 studies)
performed significantly better than placebo.
We reported elsewhere placebo-controlled trials of very potent
corticosteroid products for scalp psoriasis (Analysis 18.5).
Sensitivity analyses
We explored differences in within-patient and between-patient
designs using one-way sensitivity analysis (Table 7). The SMD for
the 3 within-patient studies (229 participants) was -1.52 (95% CI
-2.02 to -1.02; I² statistic = 79.3%). This translates into a change
of 1.74 on a 6-point IAGI scale. The SMD for the 7 between-
patient studies (1035 participants) was -1.58 (95% CI -1.99 to -
1.17; I² statistic = 84.4%). This translates into a change of 1.81
on a 6-point IAGI scale.
We also used sensitivity analysis to explore the impact of varying
the correlation coefficient (rho) for the 3 within-patient studies.
As no trial in the review reported this statistic, we tested values of
0, 0.25, 0.50, and 0.75. Varying the value of rho for the within-pa-
tient studies had no significant effect on the findings: The pooled
SMD ranged from -1.52 (95% CI -1.80 to -1.24; I² statistic =
81.6%; 10 studies), when we assumed the correlation to be zero,
to -1.55 (95% CI -1.80 to -1.29; I² statistic = 85.9%; 10 studies),
when we assumed the correlation to be 0.75.
Analysis 4: Dithranol versus placebo
This comparison considered dithranol against placebo (see
Analysis 4.5 and Table 23). Three within-patient trials reported
data for 47 participants. The only outcome reported by these trials
was the TSS, so results for the combined end point are identical to
the TSS results section. The types of treatment comprised the fol-
lowing: dithranol 0.1% in a carbamide (17%urea) base twice daily
(Buckley 1978), dithranol in aqueous gel (dose titration 0.1% to
2.0%) twice daily (Grattan 1997 (P)), and dithranol 2% ointment
’one minute therapy’ once daily (Jekler 1992).
Treatment duration ranged from three to eight weeks. In all three
studies, the adequacy of the concealment of treatment allocation
was unclear. The SMD for the combined end point was -1.06
(95% CI -1.66 to -0.46; I² statistic = 37.4%; 3 studies), which
equates to 1.22 on a 6-point IAGI scale. All three trials found a
statistically significant effect in favour of dithranol.
Sensitivity analysis
We used sensitivity analysis to explore the impact of varying the
correlation coefficient (rho) for the 3 within-patient studies. As no
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trial in the review reported this statistic, we tested values of 0, 0.25,
0.50, and 0.75. Varying the value of rho for the within-patient
studies had no significant effect on the findings: The pooled SMD
ranged from -0.98 (95% CI -1.56 to -0.41; I² statistic = 13.9%;
3 studies), when we assumed the correlation to be zero, to -1.17
(95% CI -1.81 to -0.52; I² statistic = 78.5%), when we assumed
the correlation to be 0.75.
Analysis 5: Vitamin D combination products versus placebo
This comparison included treatment with combined calcipotriol
and betamethasone dipropionate used either once or twice daily on
the body (see Analysis 5.5 and Table 8). As all five studies reported
IAGI data, results for the combined end point are identical to those
in Analysis 5.1. Five parallel-group studies with 2058 participants
contributed data. Treatment duration ranged from four to eight
weeks. Three trials adequately concealed treatment allocation. The
SMD for the combined end point across treatments was -1.44
(95% CI -1.76 to -1.12; I² statistic = 89.4%; 5 studies), with
twice-daily combination treatment (SMD -1.90; 95%CI -2.09 to
-1.71; 2 studies) achieving a significantly larger effect than once-
daily treatment (SMD -1.21; 95% CI -1.50 to -0.91; 3 studies).
On a 6-point IAGI scale, these equate to improvements of 2.18
and 1.39 points, respectively.
However, the PASI assessments differed from the IAGI: although
twice-daily combination treatment achieved a larger effect than
once-daily treatment (SMD -1.41 and -1.14, respectively), the
difference was not statistically significant (see Analysis 5.3).
In Analysis 18.5, we reported placebo-controlled trials of combi-
nation vitamin D/steroid treatments for scalp psoriasis.
Analysis 6: Other treatment versus placebo
This comparison comprised all other treatments for psoriasis of
the body that we did not include in the first five comparisons;
therefore, we removed pooling. None of the studies assessed the
same treatment, which means that findings should be interpreted
with caution.
In total, we included 26 treatments in this analysis (see Analysis
6.5 and Table 9). Twenty-six studies, with 1450 participants, re-
ported data on 25 of these 26 treatments. The study of omega-3-
polyunsaturated fatty acids ointment (Henneicke-v. Z. 1993) did
not report usable effectiveness data, but did contribute data to the
analysis of withdrawals. Twelve trials were between-patient design,
and 14 were within-patient studies. Treatment duration ranged
from 2 to 12 weeks. Two studies adequately concealed treatment
allocation (Levine 2010 (P); Stutz 1996).
As assessed by the combined end point, just over half the treat-
ments (13/25) performed statistically significantly better than
placebo: aloe vera cream, anti-IL-8 monoclonal antibody cream,
betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic
acid, combined treatment with calcipotriene and nicotinamide,
fish oil plus occlusion, herbal skin care products, indigo natu-
ralise 1.4% ointment,Mahonia aquifolium, methotrexate gel, my-
cophenolic acid ointment, PTH (1-34) in Novasome cream®,
tazarotene, and theophylline 1% ointment. The effect size (SMD)
for the combined end point ranged from -0.48 (Levine 2010 (P);
calcipotriene combined with nicotinamide) to -2.96 (Maier 2004;
herbal skin care products), or 0.55 to 3.40, respectively, on a 6-
point IAGI scale.
The trial of herbal skin care products enrolled just 34 participants,
of which 24 contributed data (Maier 2004), so this study is classed
as having a high risk of attrition bias (Figure 3; see Risk of bias
in included studies). The results of this study were published as
an abstract, and our searches failed to locate a full publication.
Therefore, findings should be treated with caution.
In the remaining 12 treatments, the difference relative to placebo
using the combined end point was not statistically significant.
These included topical caffeine, Dead Sea salts emollient lo-
tion, hexafluoro-1,25-dihydroxyvitamin D3, kukui nut oil, NG-
monomethyl-L-arginine (L-NMMA) cream, nicotinamide 1.4%,
oleum horwathiensis, platelet aggregation activating factor (PAF),
polymyxin B cream, topical sirolimus, topical tacrolimus, and tar.
In two treatments, findings by different outcomes were inconsis-
tent. When assessed by the TSS, hexafluoro-1,25-dihydroxyvita-
min D3 was significantly more effective than placebo (-1.13; 95%
CI -1.91 to -0.35) (Analysis 6.2), whereas the difference assessed
by the IAGI was non-significant (-0.62; 95% CI -1.35 to 0.12)
(Analysis 6.1).We based these findings on a single trial (Durakovic
2001). Similarly, the difference for oleum horwathiensis was sta-
tistically significant using the TSS (-0.77; 95% CI -1.40 to -0.14)
(Analysis 6.2) whereas the difference assessed by the IAGI was not
(-0.02; 95% CI -0.63 to 0.58) (Analysis 6.1). We also based find-
ings for this treatment on a single trial (Lassus 1991).
We reported elsewhere placebo-controlled trials of other treat-
ments for scalp psoriasis (Analysis 18.5) and inverse psoriasis
(Analysis 16.5).
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
Our review identified eight vitamin D analogue-potent corticos-
teroid comparisons for body psoriasis for this comparison (see
Analysis 7.5 and Table 10). Fourteen studies with 3542 partici-
pants reported data for these 8 intervention-comparator contrasts.
Nine trials were between-patient design, and five were within-pa-
tient studies. Treatment duration ranged from three to eightweeks.
One study adequately concealed treatment allocation (Papp 2003
(H)).
The combined end point SMD indicated that, overall, there was
no statistically significant difference between vitamin D and po-
tent corticosteroids: SMD 0.11 (95% CI -0.07 to 0.30; I² statis-
tic = 85.6%; 14 studies). There was however substantial hetero-
geneity and variation in effect underlying this summary statistic.
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Therefore, we only pooled subtotals.
The difference between the vitamin D analogue and the potent
corticosteroidwas not statistically significant for four intervention-
comparator contrasts (calcipotriol versus betamethasone valerate,
calcipotriol versus desoxymetasone, calcitriol versus betametha-
sone dipropionate, calcitriol versus betamethasone valerate). In the
comparison of calcipotriol and betamethasone valerate, the non-
significant result was borderline (SMD -0.12; 95% CI -0.26 to
0.02; I² statistic = 41.6%; 4 studies). When assessed using the
TSS (one study), PASI (four studies), and PAGI (two studies),
calcipotriol was significantly more effective than betamethasone
valerate (see Analysis 7.2, Analysis 7.3, and Analysis 7.4). There
were similar inconsistencies between the outcome assessments for
the comparison of calcitriol with betamethasone dipropionate, all
of which we based on a single study (Camarasa 2003). According
to the TSS and PASI, calcitriol was significantly less effective than
betamethasone dipropionate, but the IAGI indicated that the dif-
ference was not significant (see Analysis 7.1).
In one intervention-comparator contrast (calcipotriol versus fluo-
cinonide), the vitamin D analogue was significantly more effective
than potent corticosteroid: SMD-0.58 (95%CI: -0.99 to -0.18; I²
statistic = NA). This effect is equivalent to a gain of approximately
two-thirds of a point (0.64) on a 6-point IAGI scale. In three inter-
vention-comparator contrasts, the potent corticosteroid was sig-
nificantly more effective than the vitamin D analogue (calcipotriol
versus betamethasone dipropionate, calcipotriol versus diflorasone
diacetate, tacalcitol versus betamethasone valerate). The SMD ef-
fect sizes for these were 0.43, 0.27, and 0.41, respectively, equiva-
lent to improvements of 0.47, 0.30, and 0.45 on a 6-point IAGI
scale.
We reported elsewhere trials comparing vitaminD and potent cor-
ticosteroids for scalp psoriasis (Analysis 19.5) and inverse psoriasis
(Analysis 17.5).
Sensitivity analyses
We explored differences inwithin-patient and between-patient de-
signs using one-way sensitivity analysis (Table 10). In both types
of design, the difference between vitamin D and potent corticos-
teroid was not statistically significant, but we associated the pooled
resultswith substantial levels of heterogeneity (Higgins 2011). The
SMD for the 5 within-patient studies (554 participants) was 0.17
(95% CI -0.20 to 0.54; I² statistic = 81.9%). The SMD for the 9
between-patient studies (2988 participants) was 0.10 (95% CI -
0.11 to 0.31; I² statistic = 84.9%).
We also used sensitivity analysis to explore the impact of vary-
ing the correlation coefficient (rho) for the 5 within-patient stud-
ies. As no trial in the review reported this statistic, we tested val-
ues of 0, 0.25, 0.50, and 0.75. Varying the value of rho for the
within-patient studies had no significant effect on the findings:
The pooled SMD ranged from 0.10 (95% CI -0.08 to 0.28; I²
statistic = 90.5%; 14 studies), when we assumed the correlation
to be zero, to 0.12 (95% CI -0.06 to 0.30; I² statistic = 94.3%),
when we assumed the correlation to be 0.75.
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
This comparison considered vitamin D analogues against very po-
tent corticosteroids for body psoriasis (see Analysis 8.5 and Table
11).We found data on one intervention-comparator contrast: cal-
cipotriol versus clobetasol propionate. Two between-patient trials
reported data for 82 participants. Treatment duration ranged be-
tween two and six weeks. The adequacy of treatment allocation
was unclear in both studies. The SMD for the combined end point
indicated that there was no statistically significant difference be-
tween the vitamin D analogue and the very potent corticosteroid:
-0.06 (95% CI -0.57 to 0.44; I² statistic = 25.7%; 2 studies).
We reported elsewhere trials comparing vitaminDand very potent
corticosteroids for scalp psoriasis (Analysis 19.5).
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
This comparison considered combined treatment with vitamin D
analogues and corticosteroids against potent or very potent corti-
costeroid for body psoriasis (see Analysis 9.5 and Table 12). Five
parallel-group studies, ranging in treatment duration from 2 to 8
weeks, provided data on 2113 participants. The adequacy of the
concealment of treatment allocation was unclear in all five trials.
Effectiveness data were available for three contrasts:
• calcipotriol plus betamethasone dipropionate versus
betamethasone dipropionate;
• calcipotriol plus betamethasone dipropionate versus
clobetasol propionate; and
• calcipotriol plus clobetasol propionate versus clobetasol
propionate.
Overall, combination treatment was more effective than
monotherapy with corticosteroids: SMD -0.26 (95% CI -0.52 to
-0.00; I² statistic = 84.4%; 5 studies). This effect is equivalent to
a change of 0.29 on a 6-point IAGI scale. However, the pooled
finding masks important diversity between the three intervention-
comparator contrasts.Whenwe compared combination treatment
with calcipotriol and betamethasone dipropionate with a potent
steroid (betamethasone dipropionate alone), combination treat-
ment was more effective (SMD -0.40; 95% CI -0.52 to -0.27;
I² statistic = 41.8%; 3 studies). However, the same combination
treatment was significantly less effective than monotherapy with a
very potent steroid (clobetasol propionate) (SMD 0.45; 95% CI
0.09 to 0.81; I² statistic = NA). Calcipotriol in combination with
clobetasol propionate however was more effective than the very
potent steroid used alone (SMD -0.69; 95% CI -1.22 to -0.15; I²
statistic = NA). Therefore, we removed pooling for this analysis,
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but the findings demonstrate that combination treatment with vi-
tamin D analogue and a corticosteroid is more effective than the
same steroid used as a monotherapy.
We reported elsewhere trials comparing combination therapy
(with vitaminDandpotent corticosteroids) against potent steroids
for scalp psoriasis (Analysis 19.5).
Analysis 10: Vitamin D alone or in combination versus
dithranol
This comparison considered vitamin D analogues against dithra-
nol for body psoriasis (see Analysis 10.5 and Table 13). We iden-
tified three intervention-comparator contrasts: calcipotriol versus
dithranol, calcitriol versus dithranol, and tacalcitol versus dithra-
nol. Seven between-patient trials and one within-patient trial
(Grattan 1997 (H)) reported data for 1284 participants. We con-
sidered concealment of treatment allocation to be adequate in one
trial (Van de Kerkhof 2006). Treatment duration ranged from 4
weeks to 12 weeks. In addition, there was some variation in the
dithranol regimens employed by trials and in the baseline severity
of trial participants. These factors may explain the high level of
heterogeneity found in the pooled results.
The SMD for the combined end point was 0.09 (95% CI -0.44 to
0.63; I² statistic = 94.9%; 8 studies), indicating that there was no
evidence of a statistically significant difference in effect between
vitamin D analogues and dithranol. The pooled findings for cal-
cipotriol against dithranol (SMD 0.07; 95% CI -0.57 to 0.71; I²
statistic = 95.7%; 6 studies) and tacalcitol versus dithranol (SMD
-0.18; 95% CI -0.60 to 0.25; I² statistic = NA) were aligned with,
and drove, this result. However, the high levels of heterogeneity
mean that findings merit closer scrutiny. Six studies contributed
data from 1086 participants to the comparison of calcipotriol and
dithranol. In three of these studies, calcipotriol performed sig-
nificantly better than dithranol; two trials found significant dif-
ferences in favour of dithranol; and one study found no signifi-
cant difference between the treatments (see Analysis 10.5). A sin-
gle study of 114 participants compared calcitriol against dithra-
nol (Hutchinson 2000) and found a statistically significant differ-
ence in favour of dithranol (SMD 0.51; 95% CI 0.14 to 0.88; I²
statistic = NA). This equates to just over half a point (0.56 of a
point) improvement on a 6-point IAGI scale. However, the same
study found no significant difference between the treatments in
the assessment using the TSS (Analysis 10.2) or the PASI (Analysis
10.3).
In light of the considerable level of observed variation within and
between studies (Higgins 2011), we removed pooling from this
comparison.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Our review identified three intervention-comparator contrasts for
body psoriasis in this comparison: calcipotriol versus calcitriol,
calcipotriol versus tacalcitol, and calcipotriol versus maxacalcitol
(see Analysis 11.5 and Table 14). Four trials involving 513 partici-
pants contributed data. One trial was within-patient (Barker 1999
(H)); three were between-patient in design; and no trials demon-
strated the concealment of treatment allocation to be adequate.
Treatment duration ranged from 8 to 12 weeks.
The SMD for the combined end point indicated that there was
no statistically significant difference between the treatments: -0.17
(95% CI -0.62 to 0.27; I² statistic = 78.5%; 4 studies). When
we considered individual intervention-comparator contrasts us-
ing the combined end point, calcipotriol was more effective than
tacalcitol (SMD -0.47; 95% CI -0.73 to -0.21; I² statistic = NA),
which equates to an improvement of 0.52 on a 6-point IAGI scale.
However, there was no statistically significant difference between
calcipotriol and calcitriol (SMD -0.41; 95% CI -1.46 to 0.64; I²
statistic = 72.3%; 2 studies) or between calcipotriol and maxacal-
citol (SMD0.43; 95%CI -0.12 to 0.98; I² statistic = NA). Partici-
pants in all trials applied treatments twice daily, with the exception
of tacalcitol, which was applied once daily (Veien 1997).
Sensitivity analysis
The trial by Ji 2008 used three outcome measures to assess the
effects of calcipotriol and calcitriol. Both the investigators’ assess-
ment (Analysis 11.1) and the participants’ assessment found no
difference between the two vitamin D products (Analysis 11.4),
but the TSS found a statistically significant difference in favour of
calcipotriol (Analysis 11.2). As findings for Ji 2008 varied depend-
ing on the outcome measure used, we tested the impact of using
TSS data for the combined end point instead of IAGI data. The
sensitivity analysis demonstrated that findings were robust, both
for the SMD for the combined end point for all treatments (SMD
-0.28; 95% CI -0.66 to 0.10; I² statistic = 70.6%; 4 studies) and
for the comparison of calcipotriol and calcitriol (SMD -0.52; 95%
CI -1.19 to 0.15; I² statistic = 44.9%; 2 studies).
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
Our review identified 12 intervention-comparator contrasts for
body psoriasis, involving 3 vitamin D analogues, 2 combina-
tion products, and 7 different corticosteroids (see Analysis 12.5
and Table 15). Seventeen trials involving 5856 participants con-
tributed data. Sixteen trials were between-patient, and 1 was
within-patient in design (Salmhofer 2000). Treatment duration
ranged from 2 to 12 weeks. Four trials adequately concealed treat-
ment allocation, but concealment was inadequate in one trial (in
the other trials, insufficient data were reported to allow an assess-
ment of adequacy).
Overall, vitamin D plus corticosteroid was more effective than
vitamin D alone: The SMD for the combined end point was 0.46
(95% CI 0.33 to 0.59; I² statistic = 83.3%; 17 studies), which
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translates into half of 1 point (0.50) on a 6-point IAGI scale.
The substantial level of heterogeneity reflects not only different
dosing schedules of the intervention and comparator products, but
also the different potency of the corticosteroids and the different
vitamin D analogues evaluated; we therefore removed pooling (
Higgins 2011).
Twice-daily calcipotriol was significantly less effective than combi-
nation treatment with betamethasone dipropionate. This finding
held whether participants applied the corticosteroid separately at
night time (SMD0.56; equivalent to 0.61 on a 6-point IAGI scale)
or as a combined product used once daily or twice daily (SMD
0.43 and 0.66, respectively, translating into improvements of 0.48
and 0.73 points on a 6-point IAGI scale). Twice-daily calcipotriol
was also significantly less effective than combination treatment
with clobetasone butyrate (SMD 0.27; 95% CI 0.05 to 0.48; I²
statistic = NA; 0.29 of a point on a 6-point IAGI) or clobetasol
propionate (SMD 0.88; 95% CI 0.34 to 1.42; I² statistic = NA;
0.97 of a point on a 6-point IAGI scale). Once-daily combina-
tion treatment with calcipotriol and betamethasone dipropionate
was significantly more effective than once-daily treatment with
either calcipotriol (SMD 0.66; 95% CI 0.31 to 1.02; I² statistic =
80.9%; 2 studies) or tacalcitol (SMD 0.48; 95% CI 0.26 to 0.70;
I² statistic = NA).
In none of the 12 intervention-comparator contrasts was the vi-
tamin D analogue significantly more effective than combined vi-
tamin D plus corticosteroid. However, in five instances, there was
no significant difference between vitamin D and the comparator
(combination treatment). These included twice-daily calcipotriol
against combination treatment with betamethasone valerate or
diflucortolone valerate, once-daily calcipotriol against combina-
tion treatmentwith fluocinonide acetonide or hydrocortisone, and
twice-daily calcitriol against combination treatment with diflucor-
tolone valerate.
We reported elsewhere trials comparing vitamin D and combina-
tion therapy with vitamin D/potent corticosteroids for scalp pso-
riasis (Analysis 19.5).
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison summarises complex regimens for body psoria-
sis, defined here as treatment sequences that do not consist of a
simple head-to-head comparison between two active treatments
(see Analysis 13.5 and Table 16). Using the combined end point,
data were available for all 12 intervention-comparator contrasts
(Figure 4). Data were available from 2936 participants from 8 be-
tween-patient trials and 1 within-patient trial (Austad 1998). Trial
duration varied between 2 and 12weeks.One trial adequately con-
cealed treatment allocation. As the interventions and comparators
were highly variable and because two trials each contributed three
pair-wise contrasts, we did not pool the data.
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Figure 4. Forest plot of comparison: 13 Vitamin D alone or in combination vs. other treatments: complex
regimens, outcome: 13.5 Combined end point (IAGI/TSS/PASI/PAGI).
Seven intervention-comparator contrasts found a significant dif-
ference between regimens. Six weeks’ monotherapy with twice-
daily calcipotriol was less effective than clobetasol propionate (2
weeks) followed by 4 weeks’ monotherapy with calcipotriol (SMD
0.60; 95% CI 0.18 to 1.02) (Austad 1998). A similar effect was
evident when calcipotriol monotherapy (once daily for two weeks,
then twice daily for four weeks) was compared with two weeks of
treatmentwith calcipotriol (mornings) andfluocinonide acetonide
(evenings), followed by 4 weeks’ monotherapy with calcipotriol
(SMD 0.66; 95% CI 0.01 to 1.32) (Wozel 2001). These benefits
translated into improvements of 0.66 and 0.72 (i.e. around two-
thirds of a point) on a 6-point IAGI scale.
The 12-week trial by White 2006 (H)/White 2006 (P) compared
3 regimens; all included an initial phase in which participants ap-
plied once-daily combination treatment with calcipotriol and be-
tamethasone dipropionate for 4 weeks, but differed in their sub-
sequent 8-week maintenance phase. Maintenance therapy with
twice-daily placebo ointment was significantly less effective than
maintenance with either calcipotriol ointment (SMD 0.27; 95%
CI 0.12 to 0.41) or maintenance with calcipotriol on weekdays
and combination treatment atweekends (SMD0.51; 95%CI 0.37
to 0.66). When we directly compared the two regimens with ac-
tive maintenance options, the alternating (weekday/weekend) ap-
proach was significantly more effective (SMD 0.26; 95% CI 0.11
to 0.40). The benefits of these 3 regimens equate to an improve-
ment of 0.29, 0.56, and 0.28 of a point, respectively, on a 6-point
IAGI scale. These findings, based on the investigators’ assessment
of severity, were aligned with those of both the PASI assessment
(Analysis 13.3) and the participants’ assessment (PAGI) (Analysis
13.4).
Ortonne 2004 demonstrated that four weeks of treatment with a
combination product of calcipotriol and betamethasone dipropi-
onate followed by monotherapy with calcipotriol for four weeks
was significantly more effective than monotherapy with tacalcitol
(SMD 0.54; 95%CI 0.36 to 0.72) (0.59 on a 6-point IAGI scale).
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Findings from the investigators’ assessment (Analysis 13.1) were
aligned with the PASI assessment (Analysis 13.3) and the partici-
pants’ assessment (Analysis 13.4).
Kragballe 2004 compared 12 weeks of calcipotriol monother-
apy with 2 complex regimens, both of which involved differ-
ent sequences of combination therapy (calcipotriol/betametha-
sone dipropionate) and calcipotriol. When we directly compared
these two complex regimens, 8 weeks of combination therapy fol-
lowed by 4 weeks of once-daily calcipotriol was significantly less
effective than a routine involving 4 weeks of combination therapy
followed by 8 weeks of once-daily calcipotriol on weekdays and
combination therapy at the weekend (SMD 0.24; 95% CI 0.08 to
0.40, equivalent to 0.27 (¼ of 1 point) on a 6-point IAGI scale).
This finding was based on the investigators’ assessment (IAGI),
which was very similar to the participants’ (PAGI) assessment
(Analysis 13.4). However, the PASI found a non-significant trend
in favour of the weekday/weekend regimen (Analysis 13.3).
In five intervention-comparator contrasts, we found no significant
difference. A single study reported two of the non-significant inter-
vention-comparator contrasts: Kragballe 2004 compared 12weeks
of calcipotriol monotherapy with each of the 2 complex regimens
described in the paragraph above. Compared with monotherapy,
participants who applied once-daily combination treatment (cal-
cipotriol/betamethasone dipropionate) for 8 weeks followed by
once-daily calcipotriol for 4 weeks did not experience a signifi-
cantly greater improvement (SMD -0.12; 95% CI -0.29 to 0.04).
Similarly, the psoriasis of participants onmonotherapy with twice-
daily calcipotriol did not improve significantly more or less than
the disease in participants who applied once-daily combination
treatment (calcipotriol/betamethasone dipropionate) for 4 weeks
followed by 8 weeks using once-daily calcipotriol (weekdays) and
once-daily combination therapy (weekends) (SMD 0.13; 95% CI
-0.04 to 0.29). These findings were based on the investigators’
assessment (IAGI), which were consistent with those of the par-
ticipants (Analysis 13.4) and with the PASI assessment (Analysis
13.3).
Similarly to Kragballe 2004, Saraceno 2007 compared 12 weeks
of calcipotriol monotherapy with 4 weeks of combined therapy
followed by 8 weeks of twice-daily calcipotriol. The SMD for the
combined end point (0.29; 95% CI -0.04 to 0.62) showed a non-
significant trend in favour of the complex regimen. Yang 2009
also explored how monotherapy with calcipotriol compared with
combined vitamin D/corticosteroid treatment. A 6-week course
of monotherapy with calcipotriol was not significantly different
to a sequential regimen involving halometasone (SMD 0.41; 95%
CI -0.05 to 0.86). Lahfa 2003 found that the effect of clobetasol
propionate combined with calcipotriol was similar to the effect of
a regimen where the same corticosteroid was used in conjunction
with calcitriol: SMD -0.19 (95% CI -0.54 to 0.16).
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
This comparison included active-controlled studies of psoriasis of
the body that were at least 24 weeks in duration (see Analysis
14.5 and Table 17). One longer-term placebo-controlled trial of
the body (Katz 1991a) and two long-term scalp trials (Luger
2008; Poulin 2010) did not meet the inclusion criteria for this
comparison, so we evaluated them elsewhere (Analyses 2, 19, and
18, respectively).
This comparison included one trial, Kragballe 2006, which was a
between-patient trial that compared 3 52-week regimens with all
treatments used once daily:
• first, combination treatment with calcipotriol and
betamethasone dipropionate;
• second, alternating treatment with combination therapy for
4 weeks, then calcipotriol for 4 weeks; and
• third, combination therapy for 4 weeks, then calcipotriol
for 48 weeks.
In total, 297 participants contributed data to the analysis. The
only outcome measure from the trial that could be included in
our review was the Investigator’s Global Assessment of Disease
Severity (scored from 0, absent, to 5, severe); therefore, results
from this section are identical to those in Analysis 14.1. Data were
unsuitable for pooling because the same participants contributed
to more than one analysis. The adequacy of the concealment of
treatment allocation was unclear in this trial.
Data from the combined endpoint showed therewas no significant
difference between the three long-term regimens (Figure 5). One
year’s combination therapy was not significantly better than either
the alternating regimen (SMD -0.09; 95% CI -0.36 to 0.18) or
the regimen of treatment with 4 weeks of combination therapy
followed by 48weeks of calcipotriol (SMD -0.18; 95%CI -0.47 to
0.10). In both these comparisons, combination therapy achieved
a larger absolute benefit, but the difference was not statistically
significant. When we compared the alternating therapy with the
regimen of 4 weeks’ combination therapy followed by 48 weeks of
calcipotriol, the SMD for the IAGI also indicated the 2 regimens
were not statistically significantly different: -0.09 (95% CI -0.37
to 0.19).
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Figure 5. Forest plot of comparison: 14 Vitamin D alone or in combination vs. other treatment: long term
studies (>24wks), outcome: 14.5 Combined end point (IAGI/TSS/PASI/PAGI).
Findings were based on unpublished data supplied by the trial
sponsor. Although these data were described as ’intention-to treat’,
just 47% of the enrolled participants contributed data to the 52-
week assessment. The reasons why participants withdrew are sum-
marised in Analysis 14.6, Analysis 14.7, and Analysis 14.8.
Analysis 15: Vitamin D analogues versus other treatment
This comparison incorporated all other vitamin D head-to-head
comparisons of treatments for psoriasis of the body (excluding in-
verse psoriasis) that we had not already included (see Analysis 15.5
andTable 18).We included 12 intervention-comparator contrasts,
with data using the combined end point available for 11 of these
contrasts. No effectiveness data were available for the comparison
of calcipotriol and combined treatment with tazarotene gel plus
mometasone furoate cream (Guenther 2000), but the trial did re-
port data on withdrawal and adverse events. Thirteen between-
patient trials and 6within-patient trials provided data for the com-
bined end point from 2364 participants. Trial duration ranged be-
tween 4 and 12 weeks. Three studies adequately concealed treat-
ment allocation. In light of the pharmacological diversity of the
comparators, we only pooled data within subgroups.
In three intervention-comparator contrasts, vitamin Dwas signifi-
cantly more effective than the comparator. Specifically, twice-daily
calcipotriol was more effective than coal tar polytherapy (SMD
-0.59; 95% CI -0.87 to -0.31; I² statistic = 0%; 2 studies) and
propylthiouracil cream (SMD -2.24; 95% CI -3.23 to -1.25; I²
statistic = NA). On a 6-point IAGI scale, these equate to improve-
ments of 0.65 of a point and 2.46 points, respectively. Twice-daily
vitamin D was significantly more effective than once-daily treat-
ment (SMD -0.20; 95% CI -0.32 to -0.07; I² statistic = 0%; 3
studies), achieving an additional improvement of around 0.22 of
a point on a 6-point IAGI scale. This finding was based on dosing
assessments of 2 vitamin D products: calcipotriol (SMD -0.19;
95%CI -0.37 to -0.02; I² statistic = 12%; 2 studies) and combina-
tion treatment with calcipotriol and betamethasone dipropionate
(SMD -0.20; 95% CI -0.41 to 0.00; I² statistic = NA).
In the remaining eight intervention-comparator contrasts, we
found no significant difference between twice-daily calcipotriol
and the comparators. This finding held for the comparison against
the following products: coal tar monotherapy (SMD -0.53; 95%
CI -1.74 to 0.68; I² statistic = 91.1%; 3 studies); nicotinamide,
either alone (SMD -0.09; 95% CI -0.49 to 0.31; I² statistic: NA)
or in combination with calcipotriol (SMD 0.19; 95% CI -0.14
to 0.52; I² statistic = NA); betamethasone dipropionate ointment
and salicylic acid (SMD -0.05; 95% CI -0.26 to 0.15; I² statistic
= NA); tacrolimus ointment (SMD -0.55; 95% CI -1.28 to 0.17;
I² statistic = 75.9%; 2 studies); tazarotene (SMD -0.10; 95% CI -
0.35 to 0.16; I² statistic = 0%; 2 studies); and vitamin B12 cream
(SMD -0.55; 95% CI -1.33 to 0.24; I² statistic = NA). The addi-
tion of occlusion to calcipotriol did not significantly improve the
drug’s effectiveness (SMD -0.18; 95%CI -2.04 to 1.68; I² statistic
= 96.2%; 2 studies).
Two of the three trials comparing calcipotriol with coal tar
monotherapy found a significant difference in favour of cal-
cipotriol (De Simone 1993; Tham 1994); the other trial found
a significant difference in favour of coal tar (Alora-Palli 2010).
This apparent contradiction may reflect different formulations of
coal tar, treatment durations, or different baseline disease sever-
ity. Alora-Palli 2010 also assessed effectiveness and quality of life
over the six-week post-treatment period, finding that the coal
tar group maintained their improvement significantly better than
those treated with calcipotriol (see section (c) Quality of life mea-
sures).
The two occlusion trials used very different regimens and may
be better considered separately. Hindsén 2006 (H) compared cal-
cipotriol with occlusion (applied once weekly for 2 weeks) fol-
lowed by 4 weeks off treatment against 6 weeks of calcipotriol
monotherapy. This trial does not provide a simple assessment of
occlusion, since, additionally, treatment is withdrawn. This paral-
lel-group trial contributed data from 209 participants with mod-
erately severe disease and found monotherapy was significantly
more effective at the 6-week end point (SMD -1.11; 95% CI -
1.40 to -0.81). In the other trial, 19 participants were treated for
8 weeks with twice-daily calcipotriol on both sides of the body,
and one side was randomised to receive overnight occlusion with
polythene. Bourke 1993b found a significant difference in favour
of occlusion (SMD 0.79; 95% CI 0.13 to 1.45); the trial did not
explicitly state the severity of participants.
We reported elsewhere trials comparing vitamin D and other
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treatments for scalp psoriasis (Analysis 19.5) and inverse psoriasis
(Analysis 17.5).
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of topical
treatments for inverse or facial psoriasis (see Analysis 16.5 and
Table 19). We found evidence on four treatments in this com-
parison: the potent steroid betamethasone valerate; the vitamin
D analogue calcipotriol; and two topical calcineurin inhibitors,
pimecrolimus and tacrolimus. We identified only one placebo-
controlled trial evaluating tacrolimus ointment (Lebwohl 2004),
but the study did not report any effectiveness data suitable for this
review. However, the study did contribute data on adverse events
and withdrawal rates. We pooled only subtotals in this compari-
son.
Using the combined end point, data were available for three of the
four topical treatments for inverse psoriasis. Two between-patient
trials contributed data from 122 participants. Gribetz 2004 was a
eight-week study that evaluated twice-daily pimecrolimus cream.
The four-week trial by Kreuter 2006 (P) compared betametha-
sone valerate, calcipotriol, and pimecrolimus against placebo; all
treatments were applied once daily. Treatment allocation was ade-
quately concealed in one trial (Gribetz 2004). Therefore, we based
the findings for each treatment on a single study.
The SMD for the combined end point found a statistically sig-
nificant difference in favour of betamethasone valerate (SMD -
2.83; 95% CI -3.79 to -1.88) and calcipotriol ointment (SMD
-1.08; 95% CI -1.77 to -0.40). These equate to improvements
of 3.25 points and 1.24 points on a 6-point IAGI scale. Pime-
crolimus cream was also significantly more effective than vehicle
(SMD -0.86; 95% CI -1.30 to -0.41; I² statistic = 0%), equivalent
to almost 1 point on a 6-point IAGI. This result pooled data on
twice-daily applications for 8 weeks (SMD -1.07; 95% CI -1.69
to -0.45) and once-daily pimecrolimus cream for 4 weeks (SMD -
0.62; 95% CI -1.27 to 0.02). These findings suggest that different
dosing schedules may influence efficacy.
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for in-
verse psoriasis, where we compared vitamin D with an active con-
trol (see Analysis 17.5 and Table 20). We identified five interven-
tion-comparator contrasts. Four treatments were compared with
calcipotriol: once-daily betamethasone valerate, combined treat-
ment with calcipotriol and hydrocortisone, calcitriol, and pime-
crolimus. Calcitriol was compared with tacrolimus.
Using the combined end point, data were available for all five
intervention-comparator contrasts. Four trials, varying in duration
from 4 to 8 weeks, contributed data from 588 participants. Three
studies were between-patient trials, and one was a within-patient
study (Ortonne 2003). The adequacy of concealment of treatment
allocation was unclear in all four trials.
When applied to sensitive areas of the body, calcipotriol was sig-
nificantly less effective than three of the comparators. These in-
cluded betamethasone valerate (SMD 2.02; 95% CI 1.20 to 2.84)
(Kreuter 2006 (H)), combination treatment with calcipotriol and
hydrocortisone (SMD 0.30; 95% CI 0.11 to 0.50) (Ortonne
2010), and calcitriol (SMD 0.61; 95% CI 0.28 to 0.94) (Ortonne
2003). On a 6-point IAGI scale, the additional benefit equates to
2.22 points for betamethasone valerate, of a point for combi-
nation treatment with hydrocortisone, and of a point for cal-
citriol.
There was no significant difference between vitamin D and the
topical calcineurin inhibitors (calcipotriol versus pimecrolimus:
SMD -0.53 (95% CI -1.17 to 0.11; I² statistic = NA); calcitriol
versus tacrolimus: SMD 0.42 (95% CI -0.15 to 0.98; I² statistic
= NA)).
Analysis 18: Scalp psoriasis: placebo-controlled trials
This comparison included placebo-controlled trials of treatments
for scalp psoriasis (see Analysis 18.5, Figure 6, and Table 21).
We included evidence on 11 treatments in this comparison, with
data from the combined end point available for all 11 treatments.
Thirteen between-patient trials and 1 within-patient trial (Lepaw
1978) contributed data from 3011 participants. Trial duration
ranged between two and eight weeks. Concealment of treatment
allocation was adequate in one trial.
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Figure 6. Forest plot of comparison: 18 Scalp psoriasis: placebo-controlled trials, outcome: 18.5 Combined
end point (IAGI/TSS/PASI/PAGI).
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Two treatments were not significantly more effective than placebo.
These were ciclopirox olamine shampoo (SMD -0.07; 95% CI -
0.82 to 0.68; I² statistic = NA) and salicylic acid (SMD -0.86;
95% CI -1.79 to 0.06; I² statistic = NA). Of the nine treatments
demonstrated to be significantly more effective than placebo, cor-
ticosteroids achieved the largest effects. Two very potent corticos-
teroids, amcinonide (SMD -1.42; 95%CI -1.80 to -1.04; I² statis-
tic = NA) and clobetasol propionate (SMD -1.57; 95% CI -1.81
to -1.34; I² statistic = 43.3%; 4 studies), delivered benefits equat-
ing to almost 2 points (1.70 and 1.88 points, respectively) on a
6-point IAGI (Investigator’s Assessment of Global Improvement)
scale. Betamethasone dipropionate combined with salicylic acid
achieved a similar effect (SMD -1.48; 95% CI -2.50 to -0.47; I²
statistic = NA), translating into 1.77 point improvement on the
6-point IAGI over and above placebo.
When used asmonotherapy, the 2 potent corticosteroids evaluated
were both more effective than placebo: Betamethasone dipropi-
onate (SMD -1.09; 95% CI -1.29 to -0.90; I² statistic = 0%; 2
studies) had a smaller effect than betamethasone valerate (SMD
-1.40; 95% CI -1.75 to -1.05; I² statistic = NA), although the
difference was not statistically significant. Calcipotriol had the
smallest observed benefit (SMD -0.72; 95% CI -1.28 to -0.16;
I² statistic = 69.2%; 2 studies). When calcipotriol was combined
with betamethasone dipropionate, the pooled effect was larger
than for calcipotriol used alone (SMD -0.97; 95% CI -1.61 to -
0.32; I² statistic = 90.2%; 2 studies), or 1.16 points on a 6-point
improvement scale. Figure 6 shows that both trials found combi-
nation therapy to be significantly more effective, but Jemec 2008
(P) found a significantly larger effect (SMD -1.28; 95% CI -1.48
to -1.08) than Tyring 2010 (SMD -0.62; 95% CI -0.98 to -0.27).
Participants in the two trials contributing data to the analysis of
combination therapy differed in their ethnicity: Tyring 2010 re-
cruited 177 people of Hispanic, Latino, Black, and African Amer-
ican ethnicity; in the trial by Jemec 2008 (P), over 96% of the
1505 enrollees were white. In addition, the trial by Jemec 2008
(P) included a larger proportion of people with severe or very se-
vere disease (37% versus 20%). These factors may help explain
the considerable level of heterogeneity (Higgins 2011) observed
in the pooled effect for combination therapy.
Sensitivity analysis
We pooled data for the two potent corticosteroids, betamethasone
dipropionate and betamethasone valerate. The SMD for the com-
bined end point was -1.18 (95% CI -1.40 to -0.96; I² statistic
= 19.9%; 3 studies), equating to 1.41 points on a 6-point IAGI
scale. For the 3 very potent corticosteroids, the SMD was -1.51
(95%CI -1.70 to -1.31; I² statistic = 37.5%; 6 studies), translating
as a 1.80 point improvement over placebo on the IAGI.
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin
D product (used either as monotherapy or in combination with
another product) (see Analysis 19.5 and Table 22).
We identified six intervention-comparator contrasts, and data on
the combined end point were available for all these contrasts. All
studies were parallel-group in design (between-patient). Twelve
studies contributed data from 5413 participants. Trial duration
ranged from 4 to 8 weeks in 11 studies, but duration was 52 weeks
in one trial (Luger 2008). The adequacy of the concealment of
treatment allocation was unclear in all 12 trials.
Based on the combined end point scores, monotherapy with vi-
tamin D was consistently less effective than monotherapy with
potent or very potent corticosteroids, and it was also significantly
less effective than combination therapy with vitamin D and a po-
tent steroid. Specifically, calcipotriol was significantly less effec-
tive than betamethasone dipropionate (SMD 0.48; 95% CI 0.32
to 0.64; I² statistic = 60.4%; 2 studies), betamethasone valerate
(SMD 0.37; 95% CI 0.20 to 0.55; I² statistic = 0%; 2 studies),
and clobetasol propionate (SMD 0.37; 95% CI 0.05 to 0.69; I²
statistic = NA). On a 6-point investigators’ global assessment of
improvement (IAGI) scale, these SMDs translate into 0.62, 0.48,
and 0.48 points, respectively.
Combination treatment achieved a significantly greater bene-
fit than either calcipotriol alone or betamethasone dipropionate
alone. Calcipotriol was significantly less effective than combina-
tion treatment (SMD 0.64; 95% CI 0.44 to 0.84; I² statistic =
82.3%; 4 studies), with combined therapy delivering a benefit
equivalent to 0.83 of a point on a 6-point IAGI. Combination
treatment was significantly more effective than monotherapy with
betamethasone dipropionate (SMD -0.18; 95%CI -0.26 to -0.10;
I² statistic = 0%; 3 studies), translating into a net benefit of 0.24
of a point on a 6-point IAGI scale.
Compared with coal tar polytherapy, calcipotriol achieved a larger
benefit, though this was not statistically significant at the 5% level
(SMD-0.45; 95%CI -0.92 to 0.02; I² statistic = 89.8%; 3 studies).
(2) Secondary outcome measures
(a) Withdrawal rates (total rate; withdrawal due to adverse
events; withdrawal due to treatment failure)
Analysis 1: Vitamin D analogues versus placebo
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We pooled withdrawal data from seven of the eight vitamin D
analogues using a random-effects risk difference (RD) metric (see
Analysis 1.6, Analysis 1.7, and Analysis 1.8). There were no with-
drawal data for the comparison of calcipotriol plus occlusion ver-
sus placebo.
There was no significant difference in the pooled rate of with-
drawals from the trials for any reason (total withdrawals) (RD: -
0.02; (95% CI -0.05 to 0.00; I² statistic = 51.4%). Rates of with-
drawals due to adverse events were not statistically significantly
different (RD -0.00; 95% CI -0.02 to 0.01; I² statistic = 36.4%),
and neither were withdrawals due to treatment failure (RD -0.03;
95% CI -0.05 to 0.00; I² statistic = 81.7%). Individually, none
of the eight vitamin D analogues were significantly different to
placebo in any of the three withdrawal rates.
Analysis 2: Corticosteroid (potent) versus placebo
This comparison included 10 potent corticosteroids. No with-
drawal data were available for diflorasone diacetate, and some
withdrawal data weremissing for fluticasone propionate, mometa-
sone furoate, and betamethasone dipropionate. Where available,
we pooled data using a random-effects risk difference metric (see
Analysis 2.6, Analysis 2.7, and Analysis 2.8). There was a small
but statistically significant difference in favour of potent corticos-
teroids for withdrawals from the trials for any reason (total with-
drawals): RD -0.14 (-0.22 to -0.05; I² statistic = 81.5%). This
finding was driven by two large trials of once-daily betamethasone
dipropionate (Fleming 2010 (P); Kaufmann 2002 (P)) and two
small trials of betamethasone dipropionate used as maintenance
(weekend pulse therapy) (Katz 1987a; Katz 1991a). In the other
corticosteroids, the RD showed no statistically significant differ-
ence.
There was no significant difference in the pooled rate of with-
drawals due to adverse events (RD -0.01; 95% CI -0.05 to 0.02;
I² statistic = 60.9%). However, betamethasone dipropionate once
daily was associated with statistically significantly lower rates of
withdrawal due to adverse events than placebo (RD -0.07; 95%
CI -0.11 to -0.02; I² statistic = NA).
For the rate of withdrawals due to treatment failure (Analysis 2.8),
findings differed by treatment duration; therefore, we only pooled
subgroup data. For short-term treatments, there was no difference
relative to placebo (RD 0.00; 95% CI -0.02 to 0.02; I² statistic =
0.0%). This is the pooled effect for the placebo comparisons with
betamethasone valerate, budesonide, desonide, and hydrocorti-
sone buteprate (data on withdrawals due to treatment failure for
once-daily and twice-daily betamethasone dipropionate were not
available). For maintenance treatment with betamethasone dipro-
pionate, there was a statistically significant difference in favour of
maintenance treatment when compared with placebo: RD -0.46;
95% CI -0.61 to -0.31; I² statistic = 0.0% (Katz 1987a; Katz
1991a).
Analysis 3: Corticosteroid (very potent) versus placebo
We identified withdrawal data for two of the three very potent cor-
ticosteroids in this comparison and pooled data using a random-
effects risk difference metric (see Analysis 3.6, Analysis 3.7, and
Analysis 3.8). There were no withdrawal data available for halci-
nonide. There were no statistically significant differences between
very potent corticosteroids and placebo for any type of withdrawal
or for any individual treatment. For total withdrawals, the risk
difference was -0.05 (95% CI -0.10 to 0.01; I² statistic = 83.7%).
Differences in withdrawals due to adverse events (RD -0.00; 95%
CI -0.01 to 0.01; I² statistic = 0.0%) and withdrawals due to
treatment failure (RD -0.00; 95% CI -0.02 to 0.01); I² statistic =
13.5%) were also small and non-significant.
Analysis 4: Dithranol versus placebo
We pooled withdrawal data on dithranol versus placebo using a
random-effects risk difference metric (see Analysis 4.6, Analysis
4.7, andAnalysis 4.8). There were no statistically significant differ-
ences between dithranol and placebo for any type of withdrawal.
For total withdrawals, the risk difference was 0.00 (95% CI -0.09
to 0.09; I² statistic = 0%). Differences in withdrawals due to ad-
verse events (RD 0.00; 95% CI -0.05 to 0.05; I² statistic = 0%)
and withdrawals due to treatment failure (RD 0.00; 95%CI -0.11
to 0.11; I² statistic = 0%) were also small and non-significant.
Analysis 5: Vitamin D combination products versus placebo
We pooled data from trials of vitamin D combination products
using a random-effects risk difference (RD) metric (see Analysis
5.6, Analysis 5.7, and Analysis 5.8). In all three withdrawal mea-
sures, combined treatment - whether used once or twice daily -
was significantly less likely to lead to withdrawal from the trial.
This finding held for total withdrawals (RD -0.12; 95% CI -0.17
to -0.07; I² statistic = 59.3%), withdrawals due to adverse events
(RD -0.07; 95% CI -0.11 to -0.04; I² statistic = 55.0%), and
withdrawals due to treatment failure (RD -0.09; 95% CI -0.12 to
-0.06; I² statistic = 0%).
Analysis 6: Other treatment versus placebo
We report findings separately for 22 of the 26 treatments consid-
ered; no withdrawal data were available for four placebo compar-
isons: those involving a herbal skin care product, topical sirolimus,
topical tacrolimus, or coal tar. Data on total withdrawals were
available for 22 treatments; for withdrawals due to adverse events
or treatment failure, data were available for 18 treatments (see
Analysis 6.6, Analysis 6.7, and Analysis 6.8).
We assessed withdrawal data using a random-effects risk difference
metric. Relative to placebo, tazarotene was associated with a signif-
icantly higher rate of withdrawal due to adverse events (RD 0.07;
95%CI 0.05 to 0.10) andMahonia aquifoliumwas associated with
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a significantly lower rate of total withdrawal (i.e. withdrawal from
the trial for any reason) (RD -0.23; 95% CI -0.32 to -0.14). No
other treatment was significantly different from placebo on any of
the three withdrawal measures assessed.
Aloe vera extract 0.5% hydrophilic cream, three times per day
Sixty participants contributed data (Syed 1996). The comparison
with placebo found no statistically significant difference for aloe
vera extract, for total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Anti-IL-8 monoclonal antibody cream
Ninety-six participants contributed data (Jin 2001). For total with-
drawals, the comparison with placebo found no statistically sig-
nificant difference for anti-IL-8 monoclonal antibody cream. The
study did not report data on withdrawals due to adverse events or
treatment failure.
Betamethasone 17-valerate 21-acetate plus tretinoin plus
salicylic acid
Eighty-five participants contributed data (Santoianni 2001). The
comparison with placebo found no statistically significant differ-
ence for betamethasone 17-valerate 21-acetate plus tretinoin plus
salicylic acid for total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Caffeine (topical) 10%, three times per day
Thirty-nine participants contributed data (Vali 2005). The com-
parison with placebo found no statistically significant difference
for topical caffeine for total withdrawals, withdrawals due to ad-
verse events, or withdrawals due to treatment failure.
Calcipotriene 0.005% ointment + nicotinamide 0.05% or
0.1% or 0.7% or 1.4%, twice daily
One hundred and sixty participants contributed data (Levine 2010
(P)). The comparison with placebo found no statistically signif-
icant difference for combination therapy with calcipotriol and
nicotinamide for total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Dead Sea salts emollient lotion
Twenty-four participants contributed data (Cheesbrough 1992).
The comparison with placebo found no statistically significant
difference forDead Sea salts emollient lotion for total withdrawals,
withdrawals due to adverse events, orwithdrawals due to treatment
failure.
Fish oil plus occlusion
Twenty-five participants contributed data (Escobar 1992). The
comparison with placebo found no statistically significant differ-
ence for fish oil plus occlusion for total withdrawals, withdrawals
due to adverse events, or withdrawals due to treatment failure.
Herbal skin care (Dr Michaels® cleansing gel, ointment, and
skin conditioner), twice daily
No withdrawal data were available for this comparison.
Hexafluoro-1,25-dihydroxyvitamin D3
Fifteen participants contributed data (Durakovic 2001). The com-
parison with placebo found no statistically significant difference
for hexafluoro-1,25-dihydroxyvitamin D3 for total withdrawals,
withdrawals due to adverse events, or withdrawals due to treat-
ment failure.
Indigo naturalise 1.4% ointment
Fifty-six participants contributed data from two within-patient
trials (Lin 2007; Lin 2008). The comparison with placebo found
no statistically significant difference for indigo naturalise ointment
for total withdrawals, withdrawals due to adverse events, or with-
drawals due to treatment failure.
Kukui nut oil, three times per day
Thirty participants contributed data (Brown 2005). The compar-
ison with placebo found no statistically significant difference for
kukui nut oil for total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Mahonia aquifolium (Reliéva™), twice daily
Two hundred participants contributed data (Bernstein 2006). For
total withdrawals, the comparison with placebo found a statis-
tically significant difference for Mahonia aquifolium (RD -0.23;
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95% CI -0.32 to -0.14). The trial did not report data on with-
drawals due to adverse events or treatment failure.
Methotrexate gel
Sixty participants contributed data (Syed 2001b). The study by
Sutton 2001 on methotrexate gel did not report withdrawal data.
The comparison with placebo found no statistically significant
difference for methotrexate gel for total withdrawals, withdrawals
due to adverse events, or withdrawals due to treatment failure.
Mycophenolic acid ointment
Seven participants contributed data (Geilen 2000). The compar-
ison with placebo found no statistically significant difference for
mycophenolic acid ointment for total withdrawals, withdrawals
due to adverse events, or withdrawals due to treatment failure.
NG-monomethyl-L-arginine (L-NMMA) cream
Seventeen participants contributed data (Ormerod 2000). The
comparison with placebo found no statistically significant differ-
ence for NG-monomethyl-L-arginine (L-NMMA) cream for total
withdrawals, withdrawals due to adverse events, or withdrawals
due to treatment failure.
Nicotinamide 1.4%, twice daily
Eighty-eight participants contributed data (Levine 2010 (P)). The
comparison with placebo found no statistically significant differ-
ence for nicotinamide for total withdrawals, withdrawals due to
adverse events, or withdrawals due to treatment failure.
Oleum horwathiensis
Fifty participants contributed data (Lassus 1991). The comparison
with placebo found no statistically significant difference for oleum
horwathiensis for total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Omega-3 polyunsaturated fatty acids ointment
Seventy-three participants contributed data (Henneicke-v. Z.
1993). The comparison with placebo found no statistically signif-
icant difference for omega-3 polyunsaturated fatty acids ointment
for total withdrawals, withdrawals due to adverse events, or with-
drawals due to treatment failure.
Platelet aggregation activating factor (PAF) (Ro 24-0238)
Fifty-two participants contributed data (Wolska 1995). The com-
parison with placebo found no statistically significant difference
for platelet aggregation activating factor for total withdrawals. The
trial did not report data on withdrawals due to adverse events or
treatment failure.
Polymyxin B cream, 200,000 U/g
Fifteen participants contributed data (Stutz 1996). The compar-
ison with placebo found no statistically significant difference for
polymyxin B cream for total withdrawals. The trial did not report
data on withdrawals due to adverse events or treatment failure.
PTH (1-34) in Novasome A® liposomal cream, twice daily
Fifteen participants contributed data (Holick 2003). The com-
parison with placebo found no statistically significant difference
for PTH (1-34) in Novasome A® liposomal cream for total with-
drawals, withdrawals due to adverse events, or withdrawals due to
treatment failure.
Sirolimus (topical)
No withdrawal data were available for this comparison.
Tacrolimus ointment
No withdrawal data were available for this comparison.
Tar
No withdrawal data were available for this comparison.
Tazarotene
Two studies, with 1627 participants, contributed data (Weinstein
1996; Weinstein 2003). The comparison with placebo found
no statistically significant difference for tazarotene for total
withdrawals or withdrawals due to treatment failure. However,
tazarotene was significantly more likely to lead to withdrawal from
the trial due to adverse events (RD 0.07; 95% CI 0.05 to 0.10; I²
statistic = 0%).
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Theophylline 1% ointment, twice daily
Twenty-two participants contributed data (Papakostantinou
2005). The comparison with placebo found no statistically signif-
icant difference for theophylline ointment for total withdrawals,
withdrawals due to adverse events, or withdrawals due to treat-
ment failure.
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
Seven of the eight vitamin D analogues that were compared with
potent corticosteroids reported withdrawal data (withdrawal data
on calcipotriol versus desoxymetasone were not available) (see
Analysis 7.6, Analysis 7.7, and Analysis 7.8). We pooled with-
drawal data on these seven treatment comparison pairs using a
random-effects risk difference (RD) metric.
Relative to potent corticosteroid, there was a statistically signifi-
cant difference in total withdrawals in favour of corticosteroids:
RD 0.02 (95% CI 0.00 to 0.03; I² statistic = 0%). Pooled rates
of withdrawals due to adverse events or treatment failure were not
statistically significantly different. Regarding individual vitamin
D analogues, the only statistically significant differences in with-
drawals relative to corticosteroid were for the comparison of cal-
cipotriol against betamethasone dipropionate (total withdrawals:
RD 0.03 (95% CI 0.01 to 0.06; I² statistic = 0%); withdrawals
due to adverse events: RD 0.02 (95% CI 0.00 to 0.04; I² statistic
= NA)).
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
We pooled withdrawal data on calcipotriol against clobetasol pro-
pionate using a random-effects risk difference (RD) metric (see
Analysis 8.6, Analysis 8.7, and Analysis 8.8). Relative to the very
potent corticosteroid, we found no statistically significant differ-
ence for calcipotriol on any of the withdrawal assessments: total
withdrawals, withdrawals due to adverse events, or withdrawals
due to treatment failure.
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
We pooled withdrawal data on combination treatment (vitamin
D and a corticosteroid) against monotherapy with a corticosteroid
using a random-effects risk difference (RD) metric (see Analysis
9.6, Analysis 9.7, and Analysis 9.8).
Relative to the corticosteroid, we found no statistically significant
difference for combination treatment on total withdrawals, with-
drawals due to adverse events, or withdrawals due to treatment
failure. There were no data on the rate of withdrawals due to treat-
ment failure for the comparison of combined treatment with cal-
cipotriol and betamethasone dipropionate versus betamethasone
dipropionate monotherapy.
Analysis 10: vitamin D alone or in combination versus
dithranol
Withdrawal data were available for three intervention-comparator
pairs: calcipotriol versus dithranol, calcitriol versus dithranol, and
tacalcitol versus dithranol. We pooled these data using a random-
effects risk difference (RD) metric (see Analysis 10.6, Analysis
10.7, and Analysis 10.8). For the comparison of tacalcitol versus
dithranol, there were no data available on withdrawals due to ad-
verse events or treatment failure.
There was no statistically significant difference for total with-
drawals, either for individual intervention-comparator pairs or for
the pooled effect (RD -0.02; 95% CI -0.06 to 0.01; I² statistic =
0%). The pooled risk difference showed a significant difference in
favour of vitamin D for withdrawals due to adverse events (RD -
0.03; 95% CI -0.06 to -0.00; I² statistic = 26.3%), but no signifi-
cant difference in the rate of withdrawals due to treatment failure
(RD -0.00; 95% CI -0.02 to 0.02; I² statistic = 0%).
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
Two of the three vitamin D analogues head-to-head comparisons
reported withdrawal data (withdrawal data on calcipotriol ver-
sus tacalcitol were not available). We pooled withdrawal data on
calcipotriol versus calcitriol, and calcipotriol versus maxacalcitol,
using a random-effects risk difference (RD) metric (see Analysis
11.6, Analysis 11.7, and Analysis 11.8). We found no statistically
significant difference on any of the withdrawal assessments: total
withdrawals, withdrawals due to adverse events, or withdrawals
due to treatment failure. There was also no significant difference
in the withdrawal rates for the individual contrasts, calcipotriol
versus calcitriol, and calcipotriol versus maxacalcitol.
Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
To simplify the analysis, we summarisedwithdrawal data by group-
ing the first 10 intervention-comparator pairs in a single category:
calcipotriol versus calcipotriol and corticosteroid. The remaining
comparisonswere calcitriol versus calcitriol and corticosteroid, and
tacalcitol versus calcipotriol and corticosteroid. We pooled with-
drawal data using a random-effects risk difference (RD) metric
(see Analysis 12.6, Analysis 12.7, and Analysis 12.8). There were
no data on withdrawals due to treatment failure for the compar-
isons of combined therapy versus calcitriol or combined therapy
versus tacalcitol.
In the comparison of calcipotriol against calcipotriol plus corticos-
teroid, total withdrawals were statistically significantly different in
favour of polytherapy: RD 0.03 (95% CI 0.01 to 0.05; I² statistic
= 13.3%). We based this on findings from 4922 participants in 13
trials. Similarly, a significant difference in favour of polytherapy
was evident from the data on withdrawals due to adverse events:
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RD 0.02 (95% CI 0.01 to 0.03; I² statistic = 32.9%). However,
we found no statistically significant difference for withdrawals due
to treatment failure (RD 0.01; 95% CI -0.00 to 0.02; I² statis-
tic = 0%). When either calcitriol or tacalcitol was compared with
combination therapy, differences in total withdrawals and in with-
drawals due to adverse events were not statistically significant.
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison covers complex regimens, defined here as treat-
ment sequences that do not consist of a simple head-to-head com-
parison between two active treatments. We summarised with-
drawals rates on twelve intervention-comparator contrasts (see
Analysis 13.6, Analysis 13.7, and Analysis 13.8). There were data
on total withdrawal rates for all 12 contrasts, but data on with-
drawals due to adverse events were missing for 3 contrasts, and
there were no data on withdrawals due to treatment failure for 6
contrasts.
In the analysis of total withdrawals (Analysis 13.6), there was a
significant difference in favour of the complex regimen for four
contrasts:
• Participants were significantly more likely to withdraw from
the trial after 12 weeks of calcipotriol than participants who
received combination therapy (8 weeks) followed by calcipotriol
(4 weeks) (RD 0.05; 95% CI 0.00 to 0.10).
• Trial withdrawal rates were also significantly higher in
participants receiving 12 weeks of monotherapy with calcipotriol
than those treated with combination therapy (4 weeks) followed
by alternating calcipotriol on weekdays and combination therapy
at the weekend (8 weeks) (RD 0.08; 95% CI 0.03 to 0.13).
• After an initial 4-week phase with combination ointment,
participants who received 8 weeks’ maintenance with calcipotriol
(RD 0.08; 95% CI 0.03 to 0.14) or 8 weeks’ maintenance with
an alternating calcipotriol/combined therapy routine (RD 0.11;
95% CI 0.06 to 0.17) were significantly less likely to withdraw
than participants who used vehicle ointment for maintenance.
In the analysis ofwithdrawals due to adverse events (Analysis 13.7),
there were no significant differences between vitamin D and any
of the complex regimens.
In the analysis of withdrawals due to treatment failure (Analysis
13.8), there were significant differences in two of the six contrasts
for which we had reported data. After 12 weeks of calcipotriol,
participants were significantly more likely to withdraw from the
trial because of treatment failure than those who received combi-
nation therapy followed by calcipotriol (RD 0.21; 95% CI 0.10
to 0.33). Withdrawals due to treatment failure were more likely
in participants who received 8 weeks’ monotherapy with tacalci-
tol than those who received combination therapy followed by cal-
cipotriol (RD 0.05; 95% CI 0.02 to 0.08).
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
This comparison included active-controlled trials of psoriasis of
the body that were at least 24 weeks in duration (see Analysis 14.6,
Analysis 14.7, and Analysis 14.8). There were three intervention-
comparator contrasts, all 52 weeks in duration and all reported by
a single study (Kragballe 2006).
Participants received one of three long-term treatments:
• once-daily combined calcipotriol and betamethasone
dipropionate;
• combination therapy (4 weeks) followed by calcipotriol (for
4 weeks), rotated over 52 weeks; or
• combination therapy for 4 weeks followed by calcipotriol
for 48 weeks.
There were no significant differences between these three regimens
in any of the withdrawal assessments: total withdrawals, with-
drawals due to adverse events, or withdrawals due to treatment
failure.
Analysis 15: Vitamin D analogues versus other treatment
This comparison compared vitamin D analogue with 12 other
treatments.We assessed the results from the analyses of withdrawal
data using a random-effects risk difference (RD)metric, and we re-
port these separately (see Analysis 15.6, Analysis 15.7, andAnalysis
15.8). Withdrawal data were missing only in the head-to-head
comparison of vitamin D (alone or in combination) versus cal-
cipotriol with occlusion.
Of the remaining 11 intervention-comparator contrasts, we found
only 1 statistically significant difference in withdrawal rates: The
rate of total withdrawals was significantly lower for calcipotriol
than for tacrolimus (RD -0.13; 95% CI -0.25 to -0.01).
Calcipotriol versus coal tar
In the comparison of calcipotriol and coal tar, we found no sta-
tistically significant difference on any of the withdrawal assess-
ments: total withdrawals, withdrawals due to adverse events, or
withdrawals due to treatment failure.
Calcipotriol versus coal tar polytherapy
In the comparison of calcipotriol and coal tar polytherapy, we
found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
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Calcipotriol versus nicotinamide 1.4%, twice daily
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Calcipotriol versus calcipotriol + nicotinamide (0.05%, 0.1%,
0.7%, or 1.4%), twice daily
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Calcipotriol versus corticosteroid + salicylic acid
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure. However, the risk
difference for the withdrawal rate for adverse events was almost
statistically significant in favour of combined therapy (RD 0.05;
95% CI -0.00 to 0.10).
Calcipotriol versus propylthiouracil cream
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Calcipotriol versus tacrolimus ointment
We found no statistically significant difference in withdrawals due
to adverse events orwithdrawals due to treatment failure.However,
the rate of total withdrawals was significantly lower for calcipotriol
than for tacrolimus (RD -0.13; 95% CI -0.25 to -0.01) (Ortonne
2006).
Calcipotriol versus tazarotene
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Calcipotriol versus tazarotene gel plus mometasone furoate
cream
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Calcipotriol versus vitamin B12 cream
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Head-to-head vitamin D alone or in combination: dosing
We found no statistically significant difference on any of the with-
drawal assessments: total withdrawals, withdrawals due to adverse
events, or withdrawals due to treatment failure.
Head-to-head vitamin D alone or in combination: occlusion
We found no usable withdrawal data reported for this comparison.
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of four topical
treatments for inverse or facial psoriasis. Data on three withdrawal
rates were available for all four treatments: the potent steroid be-
tamethasone valerate; the vitamin D analogue calcipotriol; and
two topical calcineurin inhibitors, pimecrolimus and tacrolimus
(see Analysis 16.6, Analysis 16.7, and Analysis 16.8).
Relative to placebo, participants receiving topical tacrolimus were
significantly less likely to withdraw from treatment for any reason
(RD -0.17; 95% CI -0.30 to -0.03) or because of treatment failure
(RD -0.11; 95% CI -0.19 to -0.02). No other treatment was sig-
nificantly different from placebo on any of the three withdrawal
measures assessed.
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
flexural or facial psoriasis, where we compared vitamin D with an
active control (see Analysis 17.6, Analysis 17.7, andAnalysis 17.8).
We identifiedfive intervention-comparator contrasts, andnowith-
drawal data were missing. Four treatments were compared with
calcipotriol: once-daily betamethasone valerate, combined treat-
ment with calcipotriol and hydrocortisone, calcitriol, and pime-
crolimus. Calcitriol was compared with tacrolimus.
The rate of withdrawals due to adverse events was significantly
higher in people treated with calcipotriol compared to those re-
ceiving combination therapy with calcipotriol and hydrocortisone
for facial psoriasis (RD 0.06; 95% CI 0.02 to 0.11) and compared
to those receiving calcitriol (RD 0.09; 95% CI 0.01 to 0.18). We
found no other significant differences in withdrawal rates.
48Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18: Scalp psoriasis: placebo-controlled trial
This comparison included placebo-controlled trials of 11 topical
treatments for scalp psoriasis (see Analysis 18.6, Analysis 18.7, and
Analysis 18.8). All treatments had data on at least one withdrawal
measure, which we assessed using a risk difference (RD) metric.
Relative to placebo, participants treated with betamethasone
dipropionate were significantly less likely to withdraw from the
trial for any reason (total withdrawals) (RD -0.14; 95% CI -0.21
to -0.06), because of adverse events (RD -0.04; 95% CI -0.08 to
-0.00), or because of treatment failure (RD -0.10; 95% CI -0.16
to -0.05). Participants receiving combination therapy with cal-
cipotriol and betamethasone dipropionate were significantly less
likely to withdraw from the trial for any reason (total withdrawals)
(RD -0.09; 95%CI -0.16 to -0.03) or because of treatment failure
(RD -0.11; 95%CI -0.17 to -0.06).We found no other significant
differences in withdrawal rates.
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin
D product (used either as monotherapy or in combination with
another product) (see Analysis 19.6, Analysis 19.7, and Analysis
19.8). We identified six intervention-comparator contrasts. There
were no data for withdrawal due to treatment failure for one of
these contrasts (calcipotriol versus coal tar polytherapy). No other
withdrawal data were missing.
Relative to combination treatment with calcipotriol and be-
tamethasone dipropionate, calcipotriol monotherapy was associ-
ated with a significantly higher rate of total withdrawals (RD 0.11;
95% CI 0.05 to 0.18; I² statistic = 78.5%), withdrawals due to
adverse events (RD 0.06; 95% CI 0.02 to 0.09; I² statistic =
78.9%) and withdrawals due to treatment failure (RD 0.05; 95%
CI 0.01 to 0.10; I² statistic = 88.2%). Compared with betametha-
sone dipropionate, combination therapy was also significantly less
likely to result in participant withdrawal due to treatment failure
(RD -0.01; 95% CI -0.02 to -0.00; I² statistic = 0%).
Study participants treatedwith calcipotriol were significantlymore
likely to withdraw because of adverse events than participants re-
ceiving betamethasone valerate (RD 0.03; 95% CI 0.01 to 0.06;
I² statistic = 0%) or coal tar polytherapy (RD 0.08; 95% CI 0.02
to 0.14; I² statistic = NA).
(b) Adverse events (local (cutaneous) and systemic)
(i) Findings from the main review
Analysis 1: Vitamin D analogues versus placebo
We pooled data on adverse events using a random-effects risk
difference metric (see Analysis 1.9 and Analysis 1.10). There were
no adverse events data for the comparison of calcipotriol plus
occlusion versus placebo. Therefore, data were available for seven
of the eight vitamin D analogues evaluated against placebo
Of the seven vitamin D analogues evaluated against placebo, we
found only one statistically significantly difference. Twice-daily
becocalcidiol was significantly more likely to cause local adverse
events than placebo (RD 0.10; 95% CI 0.00 to 0.19). There were
no significant differences for the pooled risk difference for either
local adverse events (RD 0.00; 95% CI -0.01 to 0.02; I² statistic =
0%) or systemic adverse events (RD 0.00; 95% CI -0.01 to 0.01;
I² statistic = 0%).
Analysis 2: Corticosteroid (potent) versus placebo
We pooled data on adverse events using a random-effects risk dif-
ference metric (see Analysis 2.9 and Analysis 2.10). Data on local
adverse events were available for 7 of the 10 corticosteroids; data
on systemic adverse events were available only for betamethasone
dipropionate twice daily, betamethasone dipropionate (mainte-
nance), and mometasone furoate.
The pooled analysis of local adverse events found a significant dif-
ference in favour of corticosteroids (RD -0.04; 95% CI -0.08 to -
0.00; I² statistic = 56.2%). Among the individual potent corticos-
teroids evaluated against placebo, we found only one statistically
significantly difference. Once-daily betamethasone dipropionate
was less likely than placebo to be associated with local adverse
events: RD -0.10 (95% CI -0.15 to -0.04; I² statistic = 2.5%). We
found no significant difference in the pooled analyses of systemic
adverse events data.
Analysis 3: Corticosteroid (very potent) versus placebo
We pooled data on adverse events using a random-effects risk dif-
ference metric (see Analysis 3.9 and Analysis 3.10). The compar-
ison with placebo found no statistically significant difference for
any of the three very potent corticosteroids considered for either
local adverse events or systemic adverse events.
Analysis 4: Dithranol versus placebo
We pooled data on adverse events using a random-effects risk dif-
ference metric (see Analysis 4.9 and Analysis 4.10). The compar-
ison with placebo found no statistically significant difference for
pooled findings on local adverse events or systemic adverse events.
In one study, a significant difference in favour of placebo was evi-
dent: RD 0.40 (95% CI 0.08 to 0.72; I² statistic = NA) (Volden
1992).
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Analysis 5: Vitamin D combination products versus placebo
We pooled data on adverse events using a random-effects risk
difference metric (see Analysis 5.9 and Analysis 5.10). The rate
of local adverse events was significantly lower for combination
therapy compared with placebo (RD -0.05; 95% CI -0.08 to -
0.02; I² statistic = 10.0%). There was no significant difference in
the rate of systemic adverse events.
Analysis 6: Other treatment versus placebo
Our review reports findings separately for 22 of the 26 compar-
isons considered (see Analysis 6.9 and Analysis 6.10). No data on
adverse events were available for placebo comparisons involving
polymyxin B cream, topical sirolimus, topical tacrolimus, coal tar,
or tazarotene. Data on local adverse events were available for 22
comparisons, but data on systemic adverse events were reported
for just 9 of the 26 comparisons. We assessed data on adverse
events using a random-effects risk differencemetric. The compari-
son with placebo found no statistically significant difference in the
rate of either local or systemic adverse events for any treatment.
Analysis 7: Vitamin D analogues versus corticosteroid
(potent)
Of the eight vitamin D analogues that were compared with po-
tent corticosteroids, data on local adverse events were available
for five comparisons, and data on systemic events were available
for four comparisons (see Analysis 7.9 and Analysis 7.10). There
were no data on adverse events for calcipotriol versus desoxymeta-
sone, calcipotriol versus diflorasone diacetate, and calcitriol versus
betamethasone valerate. In addition, systemic adverse events data
were unavailable for calcipotriol versus fluocinonide. We pooled
data on adverse effects using a random-effects risk difference met-
ric.
In the comparison of individual vitamin D analogues and potent
corticosteroids, our review found one statistically significant dif-
ference in favour of potent corticosteroids. Pooled data from 3 tri-
als with 1739 participants indicated that the rate of local adverse
events was significantly higher in the calcipotriol group than in
the group receiving betamethasone dipropionate (RD 0.07; 95%
CI 0.04 to 0.09; I² statistic = 0%). This finding drove the pooled
(class) result for local adverse events (RD 0.07; 95% CI 0.02 to
0.11; I² statistic = 82.4%). Our review found no other statistically
significant differences for local or systemic adverse events in this
comparison.
Analysis 8: Vitamin D analogues versus corticosteroid (very
potent)
We pooled withdrawal data on adverse effects using a random-
effects risk difference metric (see Analysis 8.9 and Analysis 8.10).
There was no statistically significantly difference between cal-
cipotriol and clobetasol propionate, either for local adverse events
(RD -0.05; 95% CI -0.18 to 0.08) or systemic events (RD -0.05;
95% CI -0.18 to 0.08).
Analysis 9: Vitamin D combined with corticosteroid versus
corticosteroid
We pooled withdrawal data on combination treatment (vitamin
D and a corticosteroid) against monotherapy with a corticosteroid
using a random-effects risk difference metric (see Analysis 9.9 and
Analysis 9.10). No adverse events data were available for the com-
parison of combination (calcipotriol/clobetasol propionate) ther-
apy and clobetasol propionate.
The pooled analysis found no statistically significant difference in
adverse event rates between combination (calcipotriol/betametha-
sone dipropionate) therapy and betamethasone dipropionate.
There was no significant difference in local adverse events for com-
bination (calcipotriol/betamethasone) therapy and clobetasol pro-
pionate, and there were no data on systemic adverse events for this
comparison.
Analysis 10: Vitamin D alone or in combination versus
dithranol
Adverse events data were available for three intervention-compara-
tor pairs: calcipotriol versus dithranol, calcitriol versus dithranol,
and tacalcitol versus dithranol. We pooled these data using a ran-
dom-effects risk difference metric (see Analysis 10.9 and Analysis
10.10).
Vitamin D was statistically significantly less likely to cause lo-
cal adverse events (RD -0.32; 95% CI -0.43 to -0.20; I² statistic
= 84.5%), although substantial heterogeneity was evident in the
pooled statistic (Higgins 2011). This finding also held for each of
the three intervention-comparator pairs, with the effect size rang-
ing from -0.25 (calcipotriol versus dithranol) to -0.67 (calcitriol
versus dithranol). However, the analysis of systemic adverse events
found no statistically significant differences.
Analysis 11: Vitamin D alone or in combination versus other
vitamin D analogue
We reported local adverse events data on two of the vitamin D ana-
logues head-to-head comparisons (see Analysis 11.9 and Analysis
11.10). Systemic adverse events data were not available for any of
the three comparisons. We pooled data on adverse effects using a
random-effects risk difference metric. Overall, our review found
no statistically significant difference on either local or systemic ad-
verse events when comparing pooled vitamin D analogues head-
to-head. However, in the comparison of calcipotriol against cal-
citriol, the rate of local adverse events was significantly lower for
calcitriol: RD 0.07 (95% CI 0.01 to 0.14; I² statistic = NA).
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Analysis 12: Vitamin D alone or in combination versus
vitamin D + corticosteroid
To simplify the comparison, we summarised adverse events data
by grouping the first 10 intervention-comparator pairs in a single
category: calcipotriol versus calcipotriol and corticosteroid. The
remaining comparisons were 1) calcitriol versus calcitriol and 2)
corticosteroid and tacalcitol versus calcipotriol and corticosteroid.
There were no data on systemic adverse events for the comparison
of tacalcitol against calcipotriol and corticosteroid.
We pooled data on adverse effects using a random-effects risk
difference (RD) metric (see Analysis 12.9 and Analysis 12.10). In
the local adverse events comparison of vitamin D against vitamin
D plus corticosteroid, our review found a statistically significantly
difference in favour of combination therapy: RD 0.06 (95% CI
0.05 to 0.08; I² statistic = 4.1%). This finding also held for each
individual intervention-comparator pair. Our analysis found no
statistically significantly difference in the rates of systemic adverse
events.
Analysis 13: Vitamin D alone or in combination versus other
treatments: complex regimens
This comparison included 12 intervention-comparator contrasts
(see Analysis 13.9 andAnalysis 13.10).Data on local adverse events
were available for 11 contrasts, but there were no data on the com-
parison of calcipotriol (12 weeks) versus combination therapy (4
weeks) followed by calcipotriol (8 weeks). No trial in this compar-
ison reported data on systemic adverse events.
In 4 of the 11 contrasts for which data were available, the com-
plex regimen was associated with a significantly lower rate of lo-
cal adverse events than when the vitamin D analogue was used
alone. Twelve weeks of calcipotriol monotherapy was associated
with significantly higher rates of local adverse events than two
complex regimen comparators. Specifically, the rate of local ad-
verse events was higher for calcipotriol monotherapy than for a
regimen consisting of 8 weeks of combination therapy followed
by 4 weeks of once-daily calcipotriol (RD 0.11; 95% CI 0.06 to
0.17). Calcipotriol monotherapy was also more likely to be asso-
ciated with local adverse events than 4 weeks of combination ther-
apy followed by 8 weeks of once-daily calcipotriol on weekdays
and combination therapy at the weekend (RD 0.11; 95% CI 0.05
to 0.17) (Kragballe 2004). When we compared the two complex
regimens directly, the rates of cutaneous adverse events were not
significantly different.
Relative to calcipotriol, combination therapy with halometasone
and calcipotriol had a significantly lower rate of adverse events of
the skin (RD 0.26; 95% CI 0.07 to 0.45). An 8-week course of
tacalcitol had significantly higher rates of adverse events than a rou-
tine of 4 weeks’ combined (calcipotriol/betamethasone dipropi-
onate) therapy followed by 4weeks’monotherapywith calcipotriol
(RD 0.06; 95% CI 0.01 to 0.11).
There was no significant difference in the rate of local adverse
events in any of the remaining seven intervention-comparator con-
trasts.
Analysis 14: Vitamin D alone or in combination versus other
treatment: long-term studies (> 24 weeks)
This comparison included active-controlled studies of psoriasis of
the body that were at least 24 weeks in duration (see Analysis
14.9 and Analysis 14.10). No data on systemic adverse events
were reported.We included one trial in this comparison: Kragballe
2006 compared 3 52-week regimens with all treatments used once
daily.
Combination therapy with calcipotriol and betamethasone dipro-
pionate was associated with significantly lower rates of adverse
events than either of the two ’complex’ long-term regimens:
• alternating treatment with combination therapy for 4
weeks, then calcipotriol for 4 weeks (RD -0.08; 95% CI -0.17 to
-0.00); and
• combination therapy for 4 weeks, then calcipotriol for 48
weeks (RD -0.16; 95% CI -0.25 to -0.08).
The difference between the two ’complex’ regimens was not sta-
tistically significant at the 5% level (RD -0.08; 95% CI -0.17 to
0.01), although there was a trend in favour of alternating therapy.
Analysis 15: vitamin D analogues versus other treatment
A vitaminD analogue was compared with 12 other treatments (see
Analysis 15.9 and Analysis 15.10). Data on local adverse events
were available for 10 intervention-comparator contrasts, and sys-
temic adverse events data were available for 8 intervention-com-
parator contrasts.
We assessed results from the analyses of adverse events data us-
ing a random-effects risk difference metric and report these sep-
arately. For local adverse events, three intervention-comparator
contrasts were significantly different. These were the comparison
of calcipotriol against calcipotriol + nicotinamide (RD -0.17; 95%
CI -0.30 to -0.03), calcipotriol versus corticosteroid + salicylic
acid (RD 0.09; 95% CI 0.02 to 0.15), and calcipotriol versus
tacrolimus ointment (RD -0.19; 95% CI -0.37 to -0.01). No trial
that reported the rate of systemic adverse events found a significant
difference in this outcome.
Calcipotriol versus coal tar
Our review found no statistically significant difference for local or
systemic adverse events.
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Calcipotriol versus coal tar polytherapy
Our review found no statistically significant difference for local or
systemic adverse events.
Calcipotriol versus nicotinamide 1.4%, twice daily
Systemic adverse events data were not reported for this analysis.
There was no significant difference between the local adverse event
rates, although there was a trend in favour of calcipotriol (RD -
0.15; 95% CI -0.32 to 0.03; I² statistic = NA).
Calcipotriol versus calcipotriol + nicotinamide (0.05%, 0.1%,
0.7%, or 1.4%), twice daily
Systemic adverse events data were not reported for this analysis.
Monotherapy with calcipotriol was significantly less likely to cause
local adverse events than combined therapy with nicotinamide
(RD -0.17; 95% CI -0.30 to -0.03; I² statistic = NA).
Calcipotriol versus corticosteroid + salicylic acid
Relative to calcipotriol alone, combination therapy with be-
tamethasone dipropionate and salicylic acid was significantly less
likely to be associated with local adverse events (RD 0.09; 95%
CI 0.02 to 0.15). There was no significant difference in the rate
of systemic adverse events.
Calcipotriol versus propylthiouracil cream
Our review found no statistically significant difference for local or
systemic adverse events.
Calcipotriol versus tacrolimus ointment
Relative to calcipotriol, tacrolimus was associated with a signifi-
cantly higher rate of local adverse events (RD -0.19; 95% CI -
0.37 to -0.01). There was no significant difference in the rate of
systemic adverse events.
Calcipotriol versus tazarotene
Our review found no statistically significant difference for local or
systemic adverse events.
Calcipotriol versus tazarotene gel plus mometasone furoate
cream
Adverse events data were not reported for this analysis.
Calcipotriol versus vitamin B12 cream
Our review found no statistically significant difference in the rates
of local adverse events. Data on systemic adverse events were not
reported.
Head-to-head vitamin D alone or in combination: dosing
Our review found no statistically significant difference for local or
systemic adverse events.
Head-to-head vitamin D alone or in combination: occlusion
Local adverse events data were not reported for this analysis. Our
review found no statistically significant difference in the rate of
systemic adverse events.
Analysis 16: Flexural/facial psoriasis: placebo-controlled
trials
This comparison included placebo-controlled trials of four topical
treatments for inverse or facial psoriasis. Data on local adverse
events were available for all four treatments, but data on systemic
events were reported only for one treatment, i.e. the comparison of
tacrolimus against placebo (see Analysis 16.9 and Analysis 16.10).
Relative to placebo, participants receiving topical tacrolimus were
significantly less likely to report local adverse events (RD -0.17;
95% CI -0.30 to -0.03), but there was no significant difference in
the rate of systemic events. No other treatment was significantly
different from placebo.
Analysis 17: Flexural/facial psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
flexural or facial psoriasis, where vitamin D was compared with
an active control. We identified five intervention-comparator con-
trasts (see Analysis 17.9 and Analysis 17.10). Local adverse events
data were missing for the comparison of calcitriol and tacrolimus.
There were no data on systemic events for any of the five contrasts.
In people treated with calcipotriol, the rate of local adverse events
was significantly higher compared to those receiving combination
therapy with calcipotriol and hydrocortisone for facial psoriasis
(RD 0.15; 95% CI 0.08 to 0.23) and also compared to those re-
ceiving calcitriol (RD 0.09; 95% CI 0.02 to 0.17). These find-
ings aligned with the withdrawal rates for adverse events (Analysis
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17.7). We found no other significant differences in adverse events
rates.
Analysis 18: Scalp psoriasis: placebo-controlled trials
This comparison included placebo-controlled trials of 11 topi-
cal treatments for scalp psoriasis (see Analysis 18.9 and Analysis
18.10). There were no adverse events data for two treatments, be-
tamethasone valerate and amcinonide. Data on systemic events
were available for four treatments.
Relative to placebo, participants treated with betamethasone
dipropionate were significantly less likely to suffer local adverse
events (RD -0.07; 95% CI -0.13 to -0.01; I² statistic = 0%).
These findings aligned with the withdrawal rates for adverse events
(Analysis 18.7). We found no other significant differences in ad-
verse events rates.
Analysis 19: Scalp psoriasis: vitamin D alone or in
combination versus other treatment
This comparison included head-to-head trials of treatments for
scalp psoriasis in which one of the interventions was a vitamin D
product (used either as monotherapy or in combination with an-
other product) (see Analysis 19.9 and Analysis 19.10). We identi-
fied six intervention-comparator contrasts, and there were no ad-
verse events data.
Calcipotriol monotherapy was associated with a significantly
higher rate of local adverse events than five of the comparator
treatments; these included betamethasone dipropionate (RD0.07;
95% CI 0.04 to 0.11; I² statistic = 0%), betamethasone valerate
(RD 0.17; 95% CI 0.01 to 0.33; I² statistic = 76.5%), and clo-
betasol propionate (RD 0.19; 95% CI 0.10 to 0.28; I² statistic =
0%). Relative to calcipotriol, combined therapy with calcipotriol
and betamethasone dipropionate (RD 0.09; 95% CI 0.06 to 0.12;
I² statistic = 28.1%), and coal tar polytherapy (RD 0.24; 95% CI
0.15 to 0.33; I² statistic = NA), were also associated with signif-
icantly lower rates of adverse events. Compared with betametha-
sone dipropionate monotherapy, the rate of adverse events for
combined therapy with calcipotriol and betamethasone dipropi-
onate was not significantly different (RD -0.00; 95% CI -0.02 to
0.01; I² statistic = NA). There were no significant differences in
the rates of systemic adverse events.
(ii) Findings from the separate search for additional studies
of adverse events
In addition to findings on adverse events from themain review, we
undertook a separate search for additional safety and tolerability
studies. The update searches in 2011 identified 3 new literature
reviews and 12 potentially relevant records. Eight studies (reported
in seven references)met the inclusion criteria, and we excluded five
studies from the review (Breneman 2007; Carboni 2005; Feldman
2007a; Hong 2010; and Hong 2011; Jacobi 2008) in addition
to the 13 trials excluded in the previous edition of this review
(Aste 2004; Bos 2002; Floden 1975; Franssen 1999; Kang 1998;
Lebwohl 1996; Park 2002; Senter 1983; Singh 2000; Stevanovic
1977; Traulsen 2003; Uhoda 2003; Vissers 2004). Table 24 details
the characteristics and key findings of the included studies, and
Table 25 lists the excluded studies. Langner 1996 and van de
Kerkhof 1996c also reported the study by Gerritsen 2001. Two
papers reported two studies (Berth-Jones 1993; Kimball 2008),
whichwe analysed separately. Kimball 2008 was a review reporting
findings from phase II and phase III trials of clobetasol foam (we
did not locate any other reports of these studies). The study by van
de Kerkhof 2002c reported a two-phase open study of tacalcitol,
where ’responders’ to part 1 were eligible for part 2. Full results
for part 2 were not reported separately (e.g. incidence of local
adverse events was reported only for all trial participants). The
study by Lambert 2002 appeared very similar to the second phase
of the study reported by van de Kerkhof 2002c, but as there was
no explicit evidence of an association, we analysed it as a separate
trial.
Of the 29 included adverse events studies, 20 were uncontrolled
(Barnes 2000; Berth-Jones 1992c; Berth-Jones 1993; Bleiker
1998; Brodell 2011b; Cullen 1996; Gerritsen 2001 and Langner
1996; Kimball 2008 (phase II trial); Kragballe 1991b; Lambert
2002; Menter 2007; Miyachi 2002; Poyner 1993; Ramsay 1994;
Roelofzen 2010; van de Kerkhof 1997b; van de Kerkhof 2002c;
Vazquez-Lopez 2004; Veraldi 2006; Wishart 1994), 8 were ran-
domised trials (Andres 2006; Corbett 1976; Guzzo 1996; Katz
1987b; Katz 1989; Kimball 2008 (phase III trial); Lebwohl 1998b;
Lebwohl 2001), 1 was a retrospective controlled study (Heng
1990), and 1 reported a control group of people using treatment
other than calcipotriol (Berth-Jones 1993).
We did not include any of the eight RCTs in the main review. Six
RCTs did not meet the inclusion criteria for the main review, be-
cause they did not address comparisons of interest (Andres 2006;
Corbett 1976; Katz 1987b; Katz 1989; Lebwohl 1998b) or ef-
fectiveness (Guzzo 1996). We excluded one RCT from the main
review because it did not report the numbers of participants in
each arm of the trial (Lebwohl 2001). In all eight RCTs, the ad-
equacy of concealment of treatment allocation was unclear, the
method of randomisation was unclear, and all were double-blind
(participant/investigator) trials. Five of the eight trials reported
baseline comparability, with two studies demonstrating between-
group comparability in both clinical and demographic characteris-
tics (Katz 1987b; Katz 1989), two reporting differences in baseline
severity (Guzzo 1996; Lebwohl 1998b), and one with some sig-
nificant differences in demographics and clinical severity (Andres
2006). Four of the eight RCTs were placebo-controlled and six
included active controls.
Of the nine controlled studies, two were within-patient designs
(Corbett 1976; Katz 1989), and the remainder were between-
patient (parallel-group) designs.
Trials ranged in size from 10 to over 4000 participants. Treatment
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duration ranged from 2 weeks to 18 months. Loss to follow up
averaged 9.5% (range = 0% to 63%). Themean age of participants
was 48 (range = 15 to 85), and participants were more likely to be
men (mean: 55%; range = 40 to 82%). In 12 studies, the baseline
severity of participants was unclear. Remaining studies recruited
participants with mild to moderate disease (N = 4), mild to severe
disease (N = 4), moderate to severe disease (N = 6), and severe
disease (N = 3).
Study treatments included vitamin D products (18/29), topical
corticosteroids (12/29), coal tar (1/29), and tazarotene (2/29).
Some comprised of combination regimens, such as vitamin D and
corticosteroid (Lebwohl 1996; Lebwohl 1998b; Vazquez-Lopez
2004) or tazarotene and corticosteroid (Lebwohl 2001). No study
of dithranol met the inclusion criteria for the review. Twenty-one
of the studies assessed local adverse events, 18 assessed systemic
effects, and 11 studies assessed both types. Although six RCTs
reported some data on cutaneous adverse events (Andres 2006;
Corbett 1976; Katz 1987b; Katz 1989; Lebwohl 1998b), these
were neither suitable nor adequate for pooling.
Vitamin D products (N = 18)
Eleven studies evaluated local (N = 7) or systemic (N = 8) ad-
verse effects associated with calcipotriol, or both. The rate of with-
drawals due to local adverse events ranged from 4% to 14% and
the rate of adverse events ranged between 20% and 41%; larger
trials reported higher rates (weighted mean: 36%). In the 52-week
trial by Barnes 2000, facial irritation affected 30% of participants
in the early stages of the trial, but the incidence declined over time.
The incidence of systemic effects was less common: 5/8 studies
found no significant effects. Bleiker 1998’s study of inpatients with
severe disease found 5/28 developed hypercalcaemia after receiv-
ing a dose greater than 5 g/kg. The study by Berth-Jones 1993,
in which 10 trial participants received a weekly dose of 100 g of
calcipotriol for 4 weeks, found that urinary calcium increased sig-
nificantly from baseline levels.
Four studies evaluated both local and systemic adverse effects as-
sociated with tacalcitol. The rate of withdrawals due to local ad-
verse events ranged from 0% to 6%, and the rate of adverse events
ranged between 10% and 21%. Three studies found no systemic
effects. The study by van de Kerkhof 2002c found that over half
of study participants with psoriasis affecting 10% to 20% of their
body surface area exceeded the recommended daily dose of 5 g/day
(up to 13 g daily), but there was no effect on calcium homeostasis.
Systemic effects were identified in over half enrolled participants
in the trial by Miyachi 2002, but only 6/155 events were consid-
ered to be treatment-related in this uncontrolled study.
Three studies looked at adverse events associated with calcitriol
(Brodell 2011b; Gerritsen 2001; Wishart 1994). One study ex-
amined the tolerability and systemic effects of calcitriol used as
monotherapy (3 mcg/g ointment applied twice daily, as per li-
cence) (Gerritsen 2001). Three per cent of participants withdrew
due to adverse events, and 15% reported local adverse events. The
withdrawal rate due to systemic effects was low (0.4%), but 4
cases of hypercalcaemia were reported (N = 253). Mean daily use
of calcitriol in this trial was 6 g (range = 1 to 24 g). In Brodell
2011b, participants who had responded to treatment with clobe-
tasol spray then received 8 weeks of maintenance treatment with
calcitriol 3 mcg/g ointment twice-daily. Around 15% (35/235) of
participants reported burning or stinging at the end of treatment.
Wishart 1994 tested the effects of high-dose calcitriol (15 mcg/
g once-daily) on 3 groups of participants, with the quantity used
proportional to the area affected The trial recruited participants
with psoriasis affecting up to 30% of the body surface area. Mean
daily drug use ranged from 74 to 306 mcg. The study did not
observe any systemic adverse events, skin irritation, or ’clinically
relevant’ changes in vital signs, haematology, biochemistry, urine,
or electrocardiograms.
Corticosteroids (N = 12)
The 12 studies of adverse events associated with steroids adopted
a range of different study designs. Four studies had no com-
parator group (Brodell 2011b; Kimball 2008 (Phase II); Menter
2007; Vazquez-Lopez 2004). Seven studies were randomised trials
(Andres 2006; Corbett 1976; Katz 1987b; Katz 1989; Kimball
2008 (Phase III); Lebwohl 1998b; Lebwohl 2001), of which six
used active treatment controls and three were placebo-controlled.
The remaining study retrospectively compared 13 participants
who had used topical corticosteroids for between 6 months and
12 years with a ’no steroid’ group (N = 15).
Eight of the 12 corticosteroid studies assessed atrophy or preatro-
phy in people with psoriasis whowere treated with topical steroids.
Three studies explicitly described the methods used to assess atro-
phy, and some studies did not clearly state the numbers of partic-
ipants affected by atrophy or its extent.
The retrospective study by Heng 1990 compared 13 participants
who had used topical corticosteroids for between 6 months and
12 years with a ’no steroid’ group: These 15 individuals had previ-
ously used tar, UVB, or were untreated. Light microscopy revealed
no between-group differences. However, electron microscopy re-
vealed multi-layered, fragmented, and disorganised basal laminae
(the lining of the outer surface of the cell membrane) in the steroid
group; this appeared to be correlated with duration of treatment.
Fragmentation was not observed in the control group.
The 4-week study by Katz 1989 identified preatrophy in 20% of
involved plaques, using a hand-held magnifying lens. Two long-
term (26-week) studies of combination maintenance therapy with
steroids (Lebwohl 1998b; Lebwohl 2001) did not observe cuta-
neous atrophy, but neither study reported the assessment method.
A 4-week trial of clobetasol propionate for scalp psoriasis assessed
atrophy using an ultrasound probe (20 MHz) (Andres 2006). No
case of cutaneous atrophy was detected in either the gel (which
was left in) or shampoo formulations (which was rinsed out after
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15 minutes). However, there was a significantly greater reduction
in skin thickness in participants treated with the gel, compared to
the shampoo group (Andres 2006).
An uncontrolled study of clobetasol spray (Brodell 2011b) de-
tected atrophy in 7/285 participants after 4 weeks of treatment,
though the study did not describe the assessment method. A ran-
domised trial compared 2 weeks of treatment with clobetasol pro-
pionate foam (N = 253), clobetasol propionate ointment (N =
121), or placebo foam (N = 123) (Kimball 2008, Phase III). The
paper did not describe the assessment method. The trial found five
cases of skin atrophy in the clobetasol foam group and one case
in the placebo group, but the paper did not report the number of
atrophy cases in the clobetasol ointment group. COBRA (Clobex
Spray Community-Based Research Assessment) was an open-label
4-week study where 1421 people with psoriasis used clobetasol
spray 0.05% twice daily as monotherapy (Menter 2007). Cases
of telangiectasia, skin atrophy, or folliculitis each occurred in less
than 1% of participants (the study did not report the numbers
affected or the assessment method).
Four studies examined systemic effects associated with corticos-
teroids. The study by Corbett 1976 compared betamethasone
valerate with clobetasol propionate. Quantities used by study par-
ticipants were small (mean: 7 g/wk), and the study observed no
pituitary-adrenal suppression. Katz 1987b compared two ’super-
potent’ corticosteroids and identified temporary and reversible
adrenal suppression in 20% (8/40) of study participants. In the
study by Andres 2006, none of the 14 participants assigned to clo-
betasol propionate shampoo experienced hypothalamic-pituitary-
adrenal (HPA) axis suppression. Conversely, 2 of the 12 partic-
ipants in the gel group experienced HPA axis suppression. Nei-
ther formulation had an impact on ocular safety. In a phase II
study (Kimball 2008), higher levels of clobetasol were found in
the plasma tests in ointment group than in the shampoo group,
though the difference was not statistically significant.
Tazarotene (N = 2)
The study by Lebwohl 2001 compared three types of mainte-
nance therapy: tazarotene plus steroid, tazarotene plus placebo,
andplacebo alone. In this 6-month trial, therewere nowithdrawals
due to adverse events, but 24% of participants in the tazarotene/
steroid group and 29% of participants in the tazarotene/placebo
group experienced adverse events. There were no adverse events
in the placebo group, and the study did not assess systemic effects.
Veraldi 2006 evaluated short-contact treatment with tazarotene
gel in 43 participants. The study drug was applied once daily, left
for 20 minutes, and then rinsed off with water. The number of
participants reporting pruritis and burning decreased over the 45-
day study period, with 14/43 participants reporting mild pruri-
tis at the end of treatment, and the same number reporting mild
burning. The study did not assess systemic effects.
(c) Quality of life measures
Eight of the 177 studies included in the main review formally
assessed quality of life (QoL) (Alora-Palli 2010; Bernstein 2006;
Cook-Bolden 2010; Guenther 2002 (H) and Guenther 2002 (P);
Hutchinson 2000; Saraceno 2007; Van de Kerkhof 2006; Wall
1998).
The trials used different QoL measures. Alora-Palli 2010 used the
Dermatology Quality of Life Index (DLQI), and Bernstein 2006
used the Quality of Life Index. In both measures, higher scores in-
dicate poorer QoL. The trial by Guenther (2002) measured qual-
ity of life using the Psoriasis Disability Index (PDI) and the Euro-
QOL (EQ-5D and EQ-VAS), reporting it in a separate publica-
tion (van de Kerkhof 2004). Hutchinson 2000 andWall 1998 also
assessed quality of life using the Psoriasis Disability Index; Wall
1998 also used the Sickness Impact Profile (SIP). Although four
studies used the PDI to measure quality of life, they did not report
data in sufficient detail to allow pooling, so we reported findings
narratively. Four trials included participants with mild to mod-
erate disease; the other three trials included participants with at
leastmoderately severe disease. The number of participants ranged
from 60 (Alora-Palli 2010) to 828 (Guenther 2002 (P)), although
PDI scores were obtained for only 51% of participants in this trial
(van de Kerkhof 2004). Saraceno 2007 and Van de Kerkhof 2006
used the Skindex-29, with Van de Kerkhof 2006 also employing
the SF-36. One trial used a QoL instrument designed specifically
for the scalp, the Scalpdex (Cook-Bolden 2010).
Dermatology Quality of Life Index (DLQI) (N = 1)
The Dermatology Quality of Life Index (DLQI) is scored from 0
to 30, where higher scores indicate poorer QoL. Alora-Palli 2010
used the DLQI to compare calcipotriol and liquid carbonis dis-
tillate (LCD) 15% solution. Both treatments improved QoL rel-
ative to baseline, but there was no significant difference between
the groups at the end of the 12-week treatment period. Partici-
pants were followed up for 6 weeks post-treatment; in the LCD
group, quality of life continued to improve, but it deteriorated in
the calcipotriol group. There was a significant between-group dif-
ference in the DLQI scores at the 18-week follow-up assessment.
This QoL effect reflected the PASI and physician global assess-
ments, which demonstrated significantly lower recurrence rates in
the LCD group at 18 weeks.
EuroQOL (EQ-5D and EQ-VAS) (N = 1)
The EQ5D is a generic quality of life measure. van de Kerkhof
2004 reported quality of life data from the trial by Guenther 2002.
The study presented the EQ5D scores in a non-standard method,
making their interpretation problematic. EQ-VAS (scored from
1 to 100) supported findings from the PDI assessments, with
all groups improving quality of life scores relative to baseline.
However, the EQ-VAS score for the once-daily combined cal-
cipotriol/betamethasone dipropionate (plus placebo) group was
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higher (with a better quality of life) than the corresponding score
in the twice-daily group. Relative to baseline, improvements in
mean quality of life scores were statistically significant in all treat-
ment groups, but the significance of between-group differences
was not reported.
Psoriasis Disability Index (PDI) (N = 4)
In all four trials reporting this measure, there was an improvement
in mean quality of life scores for participants in every group. The
trial by Guenther 2002 found the greatest improvement (reduc-
tion in PDI from baseline, i.e. improvement in QoL) for twice-
daily combination treatment with calcipotriol and betametha-
sone (50%). Corresponding figures were as follows: once-daily
combination treatment with calcipotriol and betamethasone (plus
placebo): 41%, calcipotriol twice daily: 31%, and placebo twice
daily: 9%. In terms of absolute scores, the group using twice-daily
combination treatment with calcipotriol and betamethasone had
the best (lowest) quality of life score, followed by the once-daily
combined treatment group, calcipotriol group, and placebo group.
Relative to baseline, improvements in mean quality of life scores
were statistically significant in all treatment groups, but the statis-
tical significance of between-group differences was not reported.
In the study by Hutchinson 2000, quality of life improved from
baseline significantly more in the group treated with calcitriol rel-
ative to the dithranol group. The comparison of dithranol and cal-
cipotriol byWall 1998 found that the magnitude of the difference
was greater in the calcipotriol group, but the difference was not
statistically significant at the 5% level.
Quality of Life Index (N = 1)
Bernstein 2006 used the Quality of Life Index to compare Maho-
nia aquifolium with placebo in participants with mild to moderate
psoriasis. The index ranges from 0 to 120, with higher scores indi-
cating poorer quality of life.Mahonia aquifolium was significantly
more effective than placebo, and this was also reflected in the QoL
index.
Scalpdex (N = 1)
Cook-Bolden 2010 used the Scalpdex, a scalp dermatitis-specific
quality of life instrument comprising 23 questions, each scored 0
(never) to 100 (all the time). Relative to baseline scores, the study
found a significant improvement in QoL for participants in the
clobetasol spray arm of the trial and no significant improvement
in the placebo spray arm.
SF-36 (N = 1)
The SF-36 is a generic short-form health survey with 36 questions
covering physical andmental health. The study by Van de Kerkhof
2006 compared calcipotriol and dithranol administered in a day-
care setting. The study found no significant difference in quality
of life, either for the Skindex-29 or for the SF-36.
Sickness Impact Profile (SIP) (N = 1)
The SIP is a generic quality of life measure. Wall 1998 assessed
participants using the SIP, which has a maximum score of 136. As
with the PDI, the SIP found a statistically significant improvement
from baseline in both groups, but the between-group difference
was not statistically significant.
Skindex-29 (N = 2)
The Skindex-29 is a dermatology-specific QoL index that includes
three domains: emotions, symptoms, and functioning. Two tri-
als used the Skindex-29, both enrolling participants with mild to
moderate disease. Saraceno 2007 compared a 12-week course of
calcipotriol against 4 weeks of combination therapy (calcipotriol/
betamethasone dipropionate) followed by maintenance with cal-
cipotriol for 8 weeks. Quality of life improved in both groups rel-
ative to baseline. Van de Kerkhof 2006’s study in a day-care treat-
ment setting found no significant difference between calcipotriol
and dithranol, either for the Skindex-29 or for the SF-36.
(d) Economic outcomes
(THIS SECTION HAS NOT BEEN UPDATED)
A number of studies have looked at economic aspects of topi-
cal treatment for psoriasis. These include cost-of-illness studies
(Feldman 1997; Jenner 2002; Poyner 1999), quality-of-life stud-
ies (Leu 1985; Lundberg 1999; Ortonne 2000; Schiffner 2003;
Zachariae 2002; Zug 1995), methodological issues (Lambert
1996; Lambert 1999), willingness to pay analyses (Lundberg 1999;
Poyner 2000; Schiffner 2003), cost analysis (Feldman 2000),
and cost-effectiveness analyses (Ashcroft 2000; de Tiedra 1997;
Harrington 1995; Köse 1997; Marchetti 1998; Oh 1997; Owen
1993; Parodi 1991; Schwicker 1992; Sorensen 2002; Stern 1988).
These analyses involve a range of modelling approaches and as-
sumptions and have not been formally reviewed here, although
they were part of our original review (Mason 2002a). Our updated
review revealed no substantial variations in tolerability or effec-
tiveness for most treatment comparisons, and no trials provided
robust resource data on the consequences of managing treatment
failure. Consequently, any economic models extrapolating beyond
the duration of the trials may be largely speculative and uninfor-
mative. In the light of available data, a ’cost and consequences’
approach, in which costs and outcomes are reported separately,
may be most informative to clinical decision-makers. The relative
short-term clinical performance of topical antipsoriatic treatments
can be set against their reimbursed costs. While it is accepted that
long-term sequelae in participants not responding to treatment
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may be very important when considering overall costs and bene-
fits, there are no good comparative data on these costs with which
to distinguish between treatments (Mason 2002a).
(e) Concordance or adherence with treatment
(THIS SECTION HAS NOT BEEN UPDATED)
The separate search for studies of concordance/adherence identi-
fied 246 potentially relevant studies for screening. Of these, we
retrieved 18 papers, and we included in the review 12 papers re-
porting on 11 studies (see Table 26) (Balkrishnan 2003; Carroll
2004a; Carroll 2004b; Feldman 2007; Ferrandiz 1998; Fouere
2005; Gokdemir 2008; Richards 1999; van de Kerkhof 1998c;
van de Kerkhof 2000; van de Kerkhof 2001; Zaghloul 2004).
Some studies were pilots (e.g. Balkrishnan 2003; van de Kerkhof
1998c) for other studies (i.e. Carroll 2004a; van deKerkhof 2000).
We listed studies that did not meet the inclusion criteria in Table
27 (Atkinson 2004; Chu 2000; Gupta 2007; Lee 2006; Osborne
2002; Richards 2006; Szeimies 2004). We identified three reviews
and bibliographies were checked for further potentially relevant
studies (Gupta 2007; Lee 2006; Richards 2006). Of the 11 studies
included in the review, 2were randomised controlled trials (Carroll
2004a; Ferrandiz 1998) and 4 were questionnaire surveys Fouere
2005;Richards 1999; van deKerkhof1998; vandeKerkhof2000).
The remaining five studies were prospective experiments, of which
one included a control group (van de Kerkhof 2001). The number
of participants included in the adherence studies ranged from 10
to 1281, and the study duration ranged from 1 to 16 weeks. In
total, 11 studies enrolled 5541 participants, of which 39% were
men and the mean age was 47.0 (range = 4 to 91). Study size
ranged from 10 to 1281 participants, with the questionnaire sur-
veys reporting the largest sample sizes. Studies covered four main
issues. First, some reported methodological issues on the mea-
surement of adherence (Balkrishnan 2003; Carroll 2004a; Fouere
2005; Zaghloul 2004). Second, some studies reported adherence
rates (Balkrishnan 2003; Carroll 2004a; Fouere 2005; Richards
1999; van de Kerkhof 2000; van de Kerkhof 2001; Zaghloul
2004). Third, seven studies considered reasons for non-adherence
(Carroll 2004a; Gokdemir 2008; Fouere 2005; Richards 1999;
van de Kerkhof 1998c; van de Kerkhof 2000; Zaghloul 2004).
Fourth, three studies assessed interventions to improve adherence
(Feldman 2007; Ferrandiz 1998; van de Kerkhof 2001).
Methodological issues relating to adherence measurement
and adherence rates
Some studies used self-reported adherence rates (Gokdemir 2008;
Richards 1999; van de Kerkhof 2000; van de Kerkhof 2001;
Zaghloul 2004). In these studies, which included short-term
prospective trials and cross-sectional questionnaire surveys, rates
varied between 61% and 72%. However, other studies adopted
more objective assessment methods. The study by Fouere used
a semistructured participant questionnaire: The PMAQ-3w scale
(Patient Medication Adherence Questionnaire) asked about strict
adherence to prescribed regimen over the previous three days and
previous weekend. Using this method, the study (Fouere 2005)
deemed just 27% of participants as ’compliant’. Some studies
adopted a single-blind approach to assess electronic bottle caps (i.e.
participants were unaware that bottles were fitted with electronic
measuring devices) (Balkrishnan 2003; Carroll 2004a; Feldman
2007). Known as a ’MEMS cap’ (Medication Event Monitoring
System), the medication bottle cap was fitted with a microproces-
sor to record the time/date of every opening of the bottle. When
compared with participant logs, electronicmethods suggested that
adherence was considerably lower than rates reported by partic-
ipants. For example, Balkrishnan’s 1-week pilot study of 10 par-
ticipants found that the adherence rate was 67% by electronic as-
sessment compared with a self-reported rate of 92%. Carroll and
colleagues took this pilot study forward using an 8-week trial of
30 participants (Carroll 2004a). Adherence rates fell over time
and averaged 55% over the study period when assessed using the
MEMS cap. Twice-daily dosing was achieved on 39% of the treat-
ment days.
Reasons for non-adherence
Reasons for non-adherence comprised therapy characteristics (real
or perceived), participants’ clinical characteristics, and partici-
pants’ demographic characteristics. Regarding therapy character-
istics, the included studies identified the following as influences
on adherence: efficacy (Fouere 2005; van de Kerkhof 1998c;
van de Kerkhof 2000), side-effects (Fouere 2005; Richards 1999;
Zaghloul 2004), time for application (Fouere 2005; Gokdemir
2008; van de Kerkhof 2000), and ’messiness’ (Fouere 2005;
Richards 1999; van de Kerkhof 1998c). Adherence was higher
for topical therapy compared with systemic treatment (Zaghloul
2004), but adherence rates also varied by type of topical treat-
ment (Fouere 2005). Disease severity was inversely related to ad-
herence (Carroll 2004a; Richards 1999), although the direction
of causality is unclear. Higher adherence rates were variously asso-
ciated with female gender (Carroll 2004a; Zaghloul 2004), older
age (Carroll 2004a; Richards 1999), higher educational achieve-
ment (Gokdemir 2008), and older age of disease onset (Richards
1999), but findings onmarital status weremixed (Gokdemir 2008;
Zaghloul 2004).
Methods to improve adherence
Office visits to clinicians were found to temporarily increase ad-
herence rates (Carroll 2004a; Feldman 2007). An educational pro-
gramme designed to improve adherence had no impact on the ef-
fectiveness of treatment (Ferrandiz 1998). Van de Kerkhof ’s study
comparing ointment/cream regimen with ointment-only treat-
ment found no clear impact, with 51% of participants reporting
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better adherence with the cream/ointment option (van de Kerkhof
2001).
D I S C U S S I O N
Summary of main results
Effectiveness
This review analysed evidence from 177 studies that included
34,808 participants. We reported results separately for treatments
of the body, inverse psoriasis, and psoriasis of the scalp.
Treatments for psoriasis of the body
We analysed six placebo-controlled comparisons of treatments for
psoriasis of the body. Most treatments were significantly more ef-
fective than placebo, with the equivalent pooled effect on a 6-
point improvement (IAGI) scale ranging from 1.02 (potent corti-
costeroid) to 1.80 (very potent corticosteroid). Pooled effects indi-
cated similar improvements for vitaminDanalogues (1.03 points),
dithranol (1.22 points), and combination therapy with vitamin D
and potent corticosteroid (1.65) on a 6-point scale.
Amongst less frequently researched treatments, 13 were signifi-
cantlymore effective than placebo. For these treatments, the equiv-
alent effect on a 6-point IAGI scale ranged from 0.55 (calcipotriol
plus nicotinamide) to 3.40 (herbal skin care products). Tazarotene
achieved an equivalent improvement of 0.99 on the 6-point IAGI
scale. One small within-patient study found that tar was no more
effective than placebo (Kanzler 1993). Findings from single studies
should be treated with caution and regarded as requiring further
evidence before guiding treatment.
We evaluated nine head-to-head comparisons. Findings from the
comparisons of vitamin D against potent or very potent corticos-
teroids were mixed, and they varied depending on which vitamin
D and which corticosteroid were analysed. Combination treat-
ment with vitamin D/corticosteroid was usually more effective
than monotherapy with the same vitamin D, and it was always
more effective than the same corticosteroid used alone.
Twelve complex regimens (i.e. treatment sequences that do not
consist of a simple head-to-head comparison between two active
treatments) were compared with vitamin D. Seven of the com-
plex regimens were more effective than vitamin D, achieving an
additional benefit of between 0.27 points and 0.72 points on an
equivalent 6-point IAGI. A comparison of three long-term reg-
imens found no significant difference in effect, but some were
better tolerated (see below). These studies were interpreted inde-
pendently, reflecting the differing management regimens. None
of the studies presented have been replicated precisely. Therefore,
while supportive evidence for findings can be drawn from similar
studies, trial findings for complex regimens should be interpreted
with caution when informing clinical decisions.
Treatments for inverse psoriasis
The review included four placebo-controlled comparisons of treat-
ments for psoriasis of the sensitive areas of the body. As there were
no effectiveness data for tacrolimus, the review evaluated bene-
fits for three treatments. All three were significantly more effec-
tive than placebo, with the pooled effect on a 6-point IAGI scale
ranging from 0.98 (pimecrolimus) to 3.25 (betamethasone valer-
ate). Five treatments were compared head-to-head against vitamin
D. Betamethasone valerate, combined treatment with calcipotriol
and hydrocortisone, and calcitriol were all significantly more ef-
fective than calcipotriol alone. On an equivalent 6-point IAGI,
these treatments achieved an additional benefit of 2.22, 0.33, and
0.67 points, respectively.
Treatments for psoriasis of the scalp
We compared 11 treatments for scalp psoriasis with placebo. All
but two were significantly more effective than vehicle alone; the
most effective was the very potent corticosteroid, clobetasol pro-
pionate, which delivered a benefit of almost 2 points (1.88) on
an equivalent 6-point IAGI scale. When compared head-to-head,
vitamin D was significantly less effective than both potent and
very potent corticosteroids. On an equivalent 6-point IAGI scale,
the additional benefit was between 0.48 and 0.67 points. Combi-
nation therapy with calcipotriol and betamethasone dipropionate
was significantly more effective than either product used alone.
Adverse effects
Randomised evidence found that vitaminDwas significantlymore
likely than potent corticosteroids to cause local adverse effects
(15% versus 8%, P = 0.006), and participants were (borderline)
more likely to withdraw for this reason (2% versus 1%, P = 0.059).
These findingswere supported by indirect comparisons of placebo-
controlled trials. Participants tolerated combined treatment with
vitamin D/corticosteroid on either the body or the scalp as well
as potent corticosteroids and significantly better than vitamin D
alone. No comparison of topical agents found a significant differ-
ence in systemic adverse effects.
Studies of longer-term adverse events found that up to 40% of
those using vitaminDanalogues experienced cutaneous effects and
that up to 14% of participants stopped using vitamin D analogues
for this reason. There was some evidence to suggest that using
vitamin D analogues at high doses could cause systemic adverse
effects.
Two of the major cutaneous adverse effects of topical corticos-
teroids are dermal and epidermal atrophy (Hengge2006;Kragballe
2006). Only 25 of the 78 RCTs of corticosteroids included in the
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review explicitly assessed cutaneous atrophy, and in these the du-
ration of the trials, skin sites assessed, and methods employed re-
duced the chance of detection. The studies either did not support
the methods used to assess atrophy (14/25 trials), physicians un-
dertook them (10/25), study participants self-reported them (5/
25), or a combination of the aforementioned. Where physician
assessments were conducted, the methods used were not explicit
(for example, whether microscopy or ultrasound was used). Two
of the 25 trials featured an independent ’adjudication committee’,
which assessed whether atrophy was likely to be treatment-related
(Kragballe 2006; Poulin 2010). Trial duration of the 25 trials was
typically between 4 and 8 weeks, but there were 2 6-month stud-
ies (Katz 1991a; Poulin 2010) and 2 52-week studies (Kragballe
2006; Luger 2008).
Two trials that assessed atrophy did not report whether or not
any cases of atrophy occurred (Huang 2009; Koo 2006). Ten
RCTs reported cases of atrophy, and these were trials of either very
potent corticosteroids (Cook-Bolden 2010; Decroix 2004; Lowe
2005; Poulin 2010; Reygagne 2005) or combination treatment
with potent corticosteroids (Guenther 2002 (H); Kragballe 2004;
Kragballe 2006; Papp 2003 (H) and Papp 2003 (P); Yang 2009).
Three of the 10 were trials of scalp psoriasis (Cook-Bolden 2010;
Poulin 2010; Reygagne 2005), all of which investigated clobetasol
propionate.
Some studies reviewed as part of our search for additional studies of
adverse events of longer-termuse of topical corticosteroids revealed
atrophy and damage to basal laminae, the extent of which appeared
to be correlated with dosage and duration of use. Research of
very potent steroids on the skin of normal volunteers (Kao 2003).
Longer-term use with topical retinoids caused cutaneous effects in
around 30% of participants, but systemic effects were not assessed.
Concordance/adherence
Thirty-four of the 177 RCTs assessed adherence (’compliance’),
and 26 trials reported findings. Trials used various methods such
as self-report by participants, medication weight, and treatment
completion. Most of the 26 studies that reported findings on ad-
herence found it to be suboptimal. However, Gupta has argued
that the relevant notion is concordance rather than compliance
or adherence (Gupta 2007). Whereas adherence implies that peo-
ple comply with clinicians’ prescribed treatment, concordance in-
volves a negotiated doctor-patient agreement about the treatment
regimen. Van de Kerkhof ’s survey of over 800 European people
with psoriasis found that some chose not to comply, preferring to
apply the ’minimum’ dose needed to achieve the effect theywanted
(van de Kerkhof 2000). If prescribed regimens reflected the wishes
of the person with psoriasis, ’adherence’ rates might be expected to
rise. Nonetheless, poor adherence to treatment regimens is likely
to impair the effectiveness of treatment.
The review identified one study that used an educational pro-
gramme to improve adherence rates in people with psoriasis
(Ferrandiz 1998). This study found no statistically significant dif-
ference in outcomes, a finding which contrasts with evidence con-
cerning an educational programme for atopic dermatitis (Cork
2003). However, whereas the programme in the Ferrandiz 1998
study provided education about the disease, the study by Cork
involved specialist nurses teaching methods for applying topical
treatments. Therefore, the findings from Ferrandiz 1998 may not
generalise to reflect the value of other educational programmes.
Sensitivity analysis
In four comparisons, we used sensitivity analysis to explore
whether within-patient versus between-patient study designs were
associated with different effect sizes. When comparing within-pa-
tient and between-patient study designs, our review found no sta-
tistically significant difference in treatment effect size. If within-
patient studies featured some correlation, due to systemic effects or
cross contamination, then one would expect systematically smaller
effect sizes from within-patient studies. If there is no correlation,
then one would expect the variance to be smaller (as other sources
of between-patient variation have been removed) but the effect
size to be similar. We found no evidence to support a correlation
for within-patient studies, and variances were similar for within
and between-patient studies (Table 3), supporting the pooling of
these, although it is accepted that within-patient designs are ’un-
derweighted’ in meta-analyses.
In the placebo-controlled studies of vitamin D products, there was
little difference when comparing within-patient and between-pa-
tient study findings. On average, within-patient studies identified
a slightly greater effect than between-patient studies (mean differ-
ence: 0.36 points on a 6-point IAGI scale). For placebo-controlled
potent corticosteroids, there was a more pronounced difference in
favour of within-patient studies (mean difference: 0.55 points on a
6-point IAGI scale). In the case of very potent corticosteroids, the
mean effect relative to placebo was slightly larger in the between-
patient studies (mean difference: 0.07 points on a 6-point IAGI
scale), and the analysis of vitamin D against potent corticosteroid
was similar in this respect (a small positive difference in favour of
between-patient studies). These non-statistically significant differ-
ences may be chance findings.
Quality of the evidence
All included trials were randomised, but only 47 studies (27%)
clearly reported themethodused to randomise participants (Figure
3). Just 15 trials (9%) adequately concealed treatment allocation,
but most (74%) masked participants to treatment. Of the 177
studies assessed, 151 reported loss to follow up, and 143 demon-
strated that groups were comparable at baseline. Based on the 100
studies that reported assessable data on baseline severity, it was
apparent that a wide range of severity was included within and be-
tween trials. If the PASI is unreliable for mild-to-moderate disease
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(PASI scores less than 10) (Brownell 2007), it is possible that some
trials may have contributed unreliable PASI data to this review.
Trials varied in their treatment duration and in their outcome
measures (see Included studies section for details). One reason for
the variation in trial treatment duration is that the time taken for
an intervention to be effective differs between treatments. The
analyses and forest plots do not provide information on treatment
duration, but this is an important consideration for clinical deci-
sions. Trials also used different outcome measures; for example,
only 113 studies reported data on the IAGI or IGA, and 65 studies
reported PASI data. In order to maximise the number of stud-
ies contributing data for a particular treatment comparison, we
used a combined end point that incorporated different outcome
measures. This approach is not ideal; although all outcome mea-
sures essentially assess redness, thickness, and scaling (and some-
times area of psoriatic involvement), they differ in their construct.
Therefore, the composite end points should be seen as indicative
rather than definitive.
Medical text books commonly document the risk of skin atro-
phy and tachyphylaxis (diminution of the effects of a drug with
continual use) as problems associated with topical corticosteroids
(Bos 2008). Randomised evidence reported in this review suggests
that maintenance regimens using intermittent dosing are safe and
effective, and no RCT included in the review detected a statisti-
cally significant difference in systemic effects. However, the RCTs
did not clearly report the methods employed (e.g. whether the
investigator used ultrasound) and may have reduced the chance of
detection. We undertook a separate search for longer-term studies
of adverse events, which identified 12 relevant studies of corticos-
teroids. Studies were heterogeneous in terms of design, assessment
methods, comparators considered, and doses used, so we did not
pool data (Higgins 2011). Eight studies assessed atrophy, and six
found some evidence of basal damage and atrophy. We identified
no studies reporting adequate data on tachyphylaxis, despite in-
cluding this term in our searches.
Potential biases in the review process
There are a number of limitations to this review. First, one au-
thor extracted data and a second checked it. Ideally, two authors
should extract data independently (NHSCRD 2001). However,
this approach was not feasible for this review because of funding
constraints. Second, requests for unpublished data from trialists
and sponsors were of variable success; requests were more likely
to be successful when made for more recently published studies,
products still on patent, or both.
This review included 19 comparisons with 10 potential outcomes,
somultiple analysesmay be expected to generate occasional chance
findings. Thus, greater importance is attached where support-
ive findings are found from placebo-controlled and head-to-head
studies as well as linked therapeutic modalities.
Agreements and disagreements with other
studies or reviews
A systematic review by Ashcroft and colleagues focused on head-
to-head trials of one vitamin D analogue, calcipotriol (Ashcroft
2000a). Based on data from 37 studies with over 6000 partici-
pants, the review found that calcipotriol was at least as effective
as potent topical corticosteroids and more effective than calcitriol,
tacalcitol, coal tar, and short contact dithranol. Our review gen-
erally supported these findings. However, we found no significant
difference for the comparison of calcipotriol and calcitriol (SMD
-0.41; 95% CI -1.46 to 0.64), a finding based on 2 head-to-head
trials with 261 participants. Our review also found that calcitriol
is more efficacious than calcipotriol when used for inverse psori-
asis, and it is also better tolerated. Our findings on the effective-
ness of short-contact dithranol compared with calcipotriol were
mixed, but physicians and people with psoriasis may be interested
to know that inpatient treatment with dithranol appears more ef-
fective than calcipotriol (Monastirli 2000). Our review also sup-
ported findings from the review by Ashcroft 2000a that although
calcipotriol caused significantly more skin irritation than potent
topical corticosteroids, skin irritation rarely led to withdrawal of
calcipotriol treatment.
The review byAfifi 2005 concluded that combined treatmentwith
steroids and vitamin D analogues or topical retinoids appeared the
most promising current treatment on account of its superior effi-
cacy and favourable side-effects profile. However, longer-term ad-
verse effects were not addressed by this review. In contrast, the re-
view by Bruner 2003a focused on adverse effects. This review sup-
ported our findings that there is little robust evidence on longer-
term adverse effects; therefore, concluding that since clearance is
not a realistic expectation, “reasonable goals” are needed to avoid
increasing the risk of cutaneous and systemic side-effects through
over use.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence from large numbers of trials indicates that most of the
topical treatments tested in the trials reviewed here alleviate the
symptoms of psoriasis. However, it was not possible to assess the
performance of treatments at different levels of severity of psoriasis.
The evidence suggests that vitamin D products are more effective
than emollient alone. Potent and very potent corticosteroids are
also effective, and very potent corticosteroids are more effective
than either potent corticosteroids or vitamin D products. The ef-
fectiveness of dithranol and tazarotene appears to be similar to that
of vitamin D products. Although vitamin D and corticosteroids
are equally effective for treating psoriasis of the body, corticos-
teroids appear to be more effective than vitamin D for treating
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psoriasis of the scalp. Combined treatment of vitamin D with cor-
ticosteroid is more effective than either vitamin D alone or cor-
ticosteroid alone. Vitamin D is more effective than coal tar, but
findings on the relative effectiveness of vitamin D and dithranol
were mixed. Occlusion enhances the effectiveness of vitamin D,
as does twice-daily rather than once-daily application.
Compared with vitamin D alone, combined therapy that uses two
products separately (vitamin D in the morning and corticosteroid
at night) can achieve similar effects and be as well tolerated as
using a combined product. However, some corticosteroids seem to
perform better than others when used separately (see Analysis 12.5
and Analysis 12.9), and disease severity may also affect treatment
performance, though poor reporting of baseline severity in trials
means that we cannot confirm this. Use of a combined product
may also enhance concordance, and there is evidence to suggest
that adherence is higher when application time is shorter.
Potent corticosteroids are less likely than vitamin D to cause lo-
cal adverse events, and treatment with corticosteroids is less likely
to result in discontinued use because of these adverse events.
Tazarotene is more likely than emollient to cause local adverse
events. Our review found no difference between placebo and
any other topical treatment in the assessment of systemic adverse
events. However, this may reflect an absence of evidence (trials
failing to appropriately assess these events over adequate time pe-
riods) rather than being evidence of absence.
Although current evidence demonstrates that topical steroids are
as effective as and at least as well tolerated as vitamin D analogues,
concern remains about the potential safety problems associated
with corticosteroids (Bos 2008). Concerns include the risk of re-
bound (a worsening of disease following treatment discontinua-
tion), skin atrophy (skin thinning), and tachyphylaxis (decreasing
response to the drug) after long-termuse (Hengge 2006).Methods
to assess rebound have been developed and should be used in fu-
ture research (Carey 2006). Regarding skin thinning, one problem
with psoriasis is that the skin is very thick and a goal of therapy is
to reduce the thickness of lesional (epidermal) skin. Damage to the
surrounding normal skin may occur, and for that reason, people
should use topical corticosteroids for limited periods or sparingly
in delicate areas, such as the face or folds of the skin.
Although topical corticosteroids have been in use for about 50
years, there is a surprising lack of relevant evidence addressing
steroid-associated skin dermal atrophy in people with chronic
plaque psoriasis requiring long-term treatment. It is improbable
that short-term (less than three weeks) courses of topical corti-
costeroids cause dermal skin atrophy, except in delicate areas such
as the face and flexures (groin, axillae, inframammary). However,
treatment may be long-term and continuous for people with more
severe chronic psoriasis. Current assessments of cutaneous dermal
atrophy within trials have largely been limited to clinical observa-
tion or symptom and sign reporting by trial participants (which
will only detect severe atrophy of the dermis). More sensitive and
reliable methods, such as high frequency ultrasound, are routinely
available (Cossmann 2006). Dermal atrophy might be monitored
in part if trials routinely adopted more robust methods, such as
high frequency ultrasound, to assess dermal skin atrophy skin-
thinning, providing useful information for patients and clinicians.
Excessive use of topical corticosteroids can also cause a substantial
thinning of the epidermis (Kao 2003). However, thickening of
the epidermis is part of the problem in psoriasis and so thinning
of the epidermis (not dermis) that has been caused by topical
corticosteroidsmay be of benefit in psoriasis. Evidence drawn from
healthy volunteers or severe long-term cases cannot be generalised.
Specifically, evidence is required concerning the frequency and
spectrum of atrophy in people with chronic psoriasis requiring
long-term treatment.
Topical vitamin D analogues (calcipotriol, tacalcitol) and topical
calcineurin inhibitors (tacrolimus and pimecrolimus) do not cause
cutaneous atrophy. The issue may become a historical one if newer
safer steroids, currently being developed and evaluated for atopic
dermatitis, subsequently demonstrate efficacy and safety in chronic
plaque psoriasis.
We found no evidence on tachyphylaxis, but if treatment response
were to decline, this could lead to over-use, increasing the risk
of percutaneous absorption. As the evidence base on longer-term
adverse effects in psoriasis is inadequate, the preferences of people
with psoriasis and their attitudes to these perceived risks should
inform treatment choice. Further research is required to inform
approaches to long-term maintenance.
Implications for research
Evidence showing that treatments improve the symptoms of pso-
riasis has focused mainly on treatments with relatively short du-
ration. Although improving, there is still relatively limited ran-
domised evidence to tell us about the long-term effect of using
these treatments; good quality head-to-head evidence is therefore
needed to quantify and compare long-term adverse events and to
explore the feasibility of long-term treatment. There are impor-
tant sources of heterogeneity in currently available trial findings,
which it is not possible to explore in anything other than a qual-
itative sense. For example, the properties of the vehicle prepara-
tion are known to deliver wide variation in response to treatment.
This is important when interpreting the findings of this review.
The value of the active ingredient may be worth one point on
a six-point (IAGI) scale, but possibly one to two points are also
being contributed by the vehicle. However, an analysis of vehicle
performance was outside the scope of the review. Trial publica-
tions included in this review span 45 years. Reporting standards
within these trials are generally suboptimal by today’s standards,
and it would be useful to ensure that current trials adhere to CON-
SORT (CONsolidated Standards of Reporting Trials) standards
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to help future reviews to interpret findings appropriately. For ex-
ample, where trials enrol participants with a wide range of baseline
severity, stratifying the randomisation by baseline severity would
be a useful design feature. We are not aware of studies that have
adopted this approach. Trialists might usefully consider including
more homogeneous participant groups in terms of severity, so that
the clinical implications of findings are clearer.
Given the importance of safety to patients and to resolve clinical
uncertainties, it would be valuable to obtain reliable data on the
safety of corticosteroids used long-term at recommended doses,
including step-down or intermittent management. Historically,
these uncertainties have been driven by unrepresentative case series
of non-standard use of steroids. Given the variety of methods used
to assess atrophy and other sequelae, it would be valuable to reach
clinical consensus about reliable assessment methods (Cossmann
2006).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agrup 1981
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 11
Treatment duration: 3 wks; FU: 3 wks
LF: 0 (0%)
BC: not reported
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Stable symmetrical lesions of the same morphology
• Adult
EXCLUSION CRITERIA
• Pregnancy
• Receiving steroid preparations
Interventions • Budesonide ointment 0.025% BD (B)
• Placebo (vehicle) BD (P)
Outcomes 1. Investigator’s preference
2. Patient’s preference
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Agrup 1981 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Alora-Palli 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated list
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 60
Treatment duration: 12 wks; FU: 18 wks
LF: 5 (8.3%)
BC: Yes
Age: 48.5 (15.4SD); range = 19 to 77
Gender (per cent men): 56.7%
Severity: mPASI = 7.09 (3.14SD); PGA = 3.05
Duration (yrs): 16.5 (13.0SD); range = 1 to 62
INCLUSION CRITERIA
• People aged > = 18 with moderate plaque psoriasis
• BSA: 3% to 15% (excluding head, groin, palms, and soles)
EXCLUSION CRITERIA
• Pregnancy or lactation
• Topical or UVB therapy within previous 2 wks
• Systemic corticosteroids, PUVA, or laser phototherapy within previous 4 wks
• Other systemic therapies or biologicals within previous 12 wks
Interventions • Calcipotriol cream 0.005% BD (C)
• Liquid carbonis distillate (LCD) 15% solution BD (T)
Outcomes 1. Per cent change modified PASI (0 to 64.8)
2. Physician’s Global Assessment (PGA): 6-pt (0 = no disease to 5 = very severe).
3. Overall Patient Symptom Score (erythema, thickness, burning, flaking, etc): 7-pt
continuous scale (0 = none to 6 = severe)
4. Success rates
5. Participant satisfaction (cosmetic acceptability)
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Alora-Palli 2010 (Continued)
6. Dermatology Quality of Life Index (DLQI) (0 to 30, where higher scores indicate
poorer QoL)
7. Recurrence rates
◦ loss of PASI 50 response achieved at wk 12
◦ PGA score at wk18 = score at wk 0
Notes NeoStrata company, Inc. sponsored the trial.
There was significant improvement in DLQI scores relative to baseline in both groups
Compliance: 96% of participants in both groups reported they applied the study medi-
cation twice daily on most days
Recurrence rates (loss of PASI50 response): C: 7/9; T: 4/16
Recurrence rates (PGA): C: 14/20; T: 5/22
The trial author supplied unpublished data.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The study was single-blind (investigator).
Randomisation method reported Low risk A computer-generated list was used for ran-
domisation.
Loss to follow up Low risk 8.3%
Baseline assessments Low risk The trial reported demographic and clinical
characteristics.
Baseline comparability demonstrated Low risk This was demonstrated.
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Austad 1998
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 49
Treatment duration: 6 wks; FU: 10 wks
LF: 3 (6.1%)
BC: yes
Age: 42.4 (13.9SD; range = 18 to 68)
Gender (per cent men): 63%
Severity: TSS (0 to 9) = 6.4 (0.5SD; range = 6.0 to 8.0)
Duration: 15.6 (12.3SD; range = 1 to 57)
INCLUSION CRITERIA
• Adults
• Symmetrical plaque psoriasis
• Total Severity Score ≥ 6/9
EXCLUSION CRITERIA
• Widespread psoriasis
• Hypercalcaemia
• Liver or renal disease
• Risk of pregnancy
• Pregnancy
• Relevant concomitant medication or conditions
• Previous adverse response
Interventions • Clobetasol propionate ointment 0.05% BD (2/52), followed by calcipotriol 50
mcg/g BD (4/52) (CP)
• Calcipotriol 50 mcg/g BD (6/52) (C)
Outcomes 1. Overall severity score (0 to 9)
2. Investigator Global Assessment (6-pt: worsened to cleared)
3. Treatment preferences, investigator
4. Treatment preferences, patients
5. Compliance
Notes Glaxo Wellcome Research and Development, Norway, sponsored the trial
Risk of bias
Bias Authors’ judgement Support for judgement
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Austad 1998 (Continued)
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported High risk The trial did not report this.
Loss to follow up Low risk 6.1%
Baseline assessments Low risk The trial did not report these.
Baseline comparability demonstrated Low risk -
Baiocchi 1997
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: block randomisation (4 participants)
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 132
Treatment duration: 8 wks; FU: 8 wks
LF: 2 (1.5%)
BC: yes
Age: 46.8 (15.2SD; range = 18 to 89)
Gender (per cent men): 67.4%
Severity: PASI = 4.4 (2.1SD)
INCLUSION CRITERIA
• Adult
• Symmetrical mild-to-moderate chronic plaque psoriasis
EXCLUSION CRITERIA
• Recent topical or systemic antipsoriatic therapy
• Rapidly worsening psoriasis
• Concurrent vitamin D
• Renal or hepatic disease
• Pregnancy
• Lactation
Interventions • Calcipotriol ointment 50 mcg/g OD (C1)
• Calcipotriol ointment 50 mcg/g BD (C2)
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Baiocchi 1997 (Continued)
Outcomes 1. PASI
2. Severity: erythema, scaling, induration (0 to 4 each)
3. Global improvement score (7-pt: 0% to 90 - 100%)
4. Cosmetic acceptability
Notes The trial did not report on sponsorship.
All participants had a bath with salicylic acid 3 to 4 days before starting study treatments
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 1.5%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Barker 1999 (H)
Methods DESIGN
Within-patient
Participant delivery
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 30
Treatment duration: 8 wks; FU: 8 wks
LF: 4 (13.3%)
BC: demographics similar; clinical characteristics not reported
Age: 47.2 (14.5SD, N = 144) (range = 20 to 75)
Gender (per cent men): 59.7% (86/144)
Severity: not reported
INCLUSION CRITERIA
• Chronic plaque psoriasis
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Barker 1999 (H) (Continued)
• Stable bilateral lesions affecting < 20% total body surface area
• Adult (aged 18 to 85)
EXCLUSION CRITERIA
• Pregnancy
• Concomitant disease
• Known hypersensitivity to vitamin D derivatives
• Systemic treatments within previous 1 mth
• Systemic retinoids within previous 2 mths
• Plaques < 10 cm² or > 150 cm²
Interventions Dose-ranging study including placebo; calcipotriol 50 mcg/g; maxacalcitol 6, 12.5, 25,
and 50 mcg/g OD
Contrast included the following:
• maxacalcitol 25 mcg/g OD
• Calcipotriol 50 mcg/g OD
Outcomes 1. Psoriasis Severity Index (PSI): sum scores for erythema, induration, and scaling (0
to 24)
2. IAGI (6-pt: worse to cleared)
3. PAGI (6-pt: worse to cleared)
4. Investigator side preference
5. Patient side preference
Notes Non-target plaques received emollient or coal tar throughout.
Chugai Pharma Europe sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 13.3%
Baseline assessments Low risk These were partially reported (demograph-
ics only).
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Barker 1999 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (unclear)
WITHDRAWAL/DROPOUT
Described
Participants N: 60
Treatment duration: 8 wks; FU: 8 wks
LF: 6 (10.0%)
BC: demographics similar; clinical characteristics not reported
Age: 47.2 (14.5SD, N = 144) (range = 20 to 75)
Gender (per cent men): 59.7% (86/144)
Severity: not reported
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Stable bilateral lesions affecting < 20% total body surface area
• Adult (aged 18 to 85)
EXCLUSION CRITERIA
• Pregnancy
• Concomitant disease
• Known hypersensitivity to vitamin D derivatives
• Systemic treatments within previous 1 mth
• Systemic retinoids within previous 2 mths
• Plaques < 10 cm² or > 150 cm²
Interventions Dose-ranging study including placebo; calcipotriol 50 mcg/g; maxacalcitol ointment 6,
12.5, 25, and 50 mcg/g OD
Contrast included the following:
• Calcipotriol ointment 50 mcg/g OD (C)
• Placebo ointment (vehicle) (P)
Outcomes 1. Psoriasis Severity Index (PSI): sum scores for erythema, induration and scaling (0
to 24)
2. IAGI (6-pt: worse to cleared)
3. PAGI (6-pt: worse to cleared)
4. Investigator side preference
5. Patient side preference
Notes Non-target plaques received emollient or coal tar throughout the study.
Chugai Pharma Europe sponsored the trial.
Risk of bias
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Barker 1999 (P) (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.0%
Baseline assessments Low risk These were partially reported (demograph-
ics only).
Baseline comparability demonstrated Unclear risk These were partially done.
Barrett 2005
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Not described
Participants N: 420
Treatment duration: 8 wks; FU: 8 wks
LF: unclear
BC: not reported
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• People with mild plaque psoriasis
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol scalp 50 mcg/g solution BD, plus non-medicated shampoo twice/wk
(Johnson’s baby shampoo®) (CP)
• Calcipotriol scalp 50 mcg/g solution BD, plus tar shampoo (Polytar liquid ®)
twice/wk (CT)
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Barrett 2005 (Continued)
At visit 1, all participants were treated with calcipotriol scalp solution twice daily. Par-
ticipants were randomly assigned to treatment with either twice-weekly Polytar® liquid
or a non-medicated shampoo twice weekly
Outcomes 1. Investigator assessment of global improvement (6-pt: worse to cleared)
2. Total Sign Score (scale: 0 to 12)
Notes Leo Pharmaceuticals sponsored the trial. The sponsor supplied unpublished outcomes
data
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial did not report this.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open (impossible to blind par-
ticipants when tar-based products are used)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Bernhard 1991 (1)
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 100
Treatment duration: 2 wks; FU: 2 wks
LF: 4 (4%)
BC: yes
Age: 49 (range = 20 to 77)
Gender (per cent men): 61.5%
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Bernhard 1991 (1) (Continued)
Severity: at least 2 signs or symptoms ≥ 2 on a 4-pt scale
Duration (yrs): 18.2 (range = 1 to 53)
INCLUSION CRITERIA
• Bilateral, comparable psoriasis of at least moderate severity
• Adult
• At least 2 signs or symptoms ≥ 2 on a 4-pt scale
EXCLUSION CRITERIA
• Not reported
Interventions • Halobetasol 0.05% ointment BD (H)
• Placebo (Vehicle) (P)
Outcomes 1. Signs: erythema, plaque elevation, scaling, overall lesion severity
2. Patient Global Assessment (5-pt: poor to excellent)
3. Skin atrophy
Notes Westwood-Squibb Pharmaceuticals (BMS) sponsored the trial with an educational grant
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Bernhard 1991(2)
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 72
Treatment duration: 2 wks; FU: 2 wks
LF: 0 (0%)
BC: yes (demographics); clinical comparability unclear
Age: 53 (range = 23 to 86)
Gender (per cent men): 52.8%
Severity: signs > = 4 on a 7-pt scale; BSA = 1% to 20%
Duration: 22.7 (range = 1 to 62)
INCLUSION CRITERIA
• Plaque psoriasis of at least moderate severity
• Adult
• Signs ≥ 4 on a 7-pt scale
• BSA 1% to 20%
EXCLUSION CRITERIA
• Not reported
Interventions • Halobetasol 0.05% ointment, BD (H)
• Placebo (Vehicle) (P)
Outcomes 1. Signs: erythema, induration, scaling
2. Investigator Global Assessment (5-pt: worse to clear)
Notes Westwood-Squibb Pharmaceuticals (BMS) sponsored the trial with an educational grant
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
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Bernhard 1991(2) (Continued)
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Bernstein 2006
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 200
Treatment duration: 12 wks; FU: 12 wks
LF: 29 (14.5%)
BC: yes
Age: 48.3 (13.9SD)
Gender (per cent men): 46.5%
Severity: PASI (0 to 12) = 6.89 (2.8SD); QLI (0 to 120) = 58.74 (31.5SD)
INCLUSION CRITERIA
• People aged 18 to 80 with mild to moderate plaque psoriasis (BSA < 15%)
• Good general health
EXCLUSION CRITERIA
• Painful/inflamed lesions
• Intertriginous psoriasis
• Hypertrophic lesions
• Severe psoriasis
• Use of topical antipsoriatics within previous 2 wks
• Use of systematic antipsoriatics within previous 4 wks
• Concurrent use of steroids, immunosuppressants, COX2s
• Pregnancy or risk thereof
• Lactation
Interventions • Mahonia aquifolium (Reliéva™) in Novasome cream® BD (MA)
• Placebo (vehicle) BD (P)
Outcomes 1. PASI, assessed by physician on a 4 x 4 cm section of skin “typical of the patient’s
psoriasis involvement” (E+I+S) x per cent involvement (0 to 12)
2. QLI (Quality of Life Index) assessed by participant. 12 questions each scored 0
(not at all) to 10 (very much). Maximum score = 120 (equating to very poor quality of
life)
3. Also covers adverse events.
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Bernstein 2006 (Continued)
Notes Apollo Pharmaceuticals sponsored the trial.
’PASI’ is similar to TSS (range = 0 to 12) as it examines small BSA. However, the PASI
score was also adjusted by area
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 14.5%
Baseline assessments Low risk The trial reported this.
Baseline comparability demonstrated Low risk -
Berth Jones 1992b
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: balanced blocks of 4 using computer-generated randomnum-
bers
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 478
Treatment duration: 8 wks; FU: 8 wks
LF: for PASI: 56 (11.7%); for Response: 20 (4.2%)
BC: yes
Age: 44 (range = 18 to 85)
Gender (per cent men): 55%
Severity: PASI = 9.3
Duration (yrs): 18 (12SD)
INCLUSION CRITERIA
• Outpatients
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Berth Jones 1992b (Continued)
• Adults
• Chronic stable plaque psoriasis
EXCLUSION CRITERIA
• Previous non-response to study medications
• Recent systemic treatment
• Hypercalcaemia
• Abnormal renal/hepatic function
• Calcium or vitamin D intake
• Relevant concomitant medication
• Pregnancy
• Risk of pregnancy
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Dithranol cream (dose titration 0.1% to 2%) OD (D)
Outcomes 1. PASI
2. Investigator Global Assessment (5-pt: worse to cleared)
3. Patient Global Assessment (5-pt: worse to cleared)
4. Cosmetic acceptability
5. Compliance
Notes Leo Pharmaceutical Products, Denmark, sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Low risk A computer-generated block list was used
for randomisation.
Loss to follow up Low risk 11.7%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Beutner 2006
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 27
Treatment duration: 4 wks; FU: 4 wks
LF: 2 (7.4%)
BC: yes
Age: 51.6 (12.8SD); range = 21 to 75
Gender (per cent men): 67%
Ethnicity (% white): 85%
Severity: overall target severity score (0 to 4) = 2.67 (0.58SD)
INCLUSION CRITERIA
• People aged > = 18 with moderate to severe plaque psoriasis (overall plaque
severity score (0 to 8) > = 5)
• 2 bilateral plaques of equivalent size (5 cmˆ2 to 10 cmˆ2)
EXCLUSION CRITERIA
• Use of topical antipsoriatic therapy or UV exposure within previous 4 wks
• Pregnancy or risk thereof
Interventions • Clobetasol propionate 0.05% spray BD (CP)
• Placebo (vehicle) spray BD (P)
Outcomes 1. Overall target plaque severity score using a collapsed 9-pt scale: none (0 to 1),
mild (2 to 3), moderate (4 to 5), severe (6 to 7), and very severe (8)
2. Signs: scaling, erythema, and plaque elevation (each scored 0 to 8)
3. Adverse events (burning, stinging, pruritus, telangiectasias, skin atrophy)
Notes Galderma Laboratories, L.P. sponsored the study.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Beutner 2006 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.4%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Bourke 1993b
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: participants were randomised into groups A and B, then
randomised to left/right application with sealed envelopes
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 19 (evaluable)
Treatment duration: 8 wks; FU: 8 wks
LF: NR
BC: yes (clinical only)
Age: not reported
Gender (per cent men): not reported
Severity: TSS = 7.9
INCLUSION CRITERIA
• Adult
• Symmetrical chronic plaque psoriasis
• Outpatients
EXCLUSION CRITERIA
• UV or systemic antipsoriatic therapy
Interventions • Calcipotriol BD (C)
• Calcipotriol BD plus polythene film at night (O)
Outcomes 1. Signs: erythema, induration, scale
2. Total Sign Score (0 to 12)
Notes Participants were randomised into groups A (calcipotriol BD) and B (occlusion ON),
then each participant was randomised to left/right application: group A (occlusion ON/
no occlusion); group B (calcipotriol BD or placebo BD). The study reported findings
for group A.
The trial did not report sponsorship.
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Bourke 1993b (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Low risk Envelopes were used.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Bourke 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 24
Treatment duration: 8 wks
LF: 4 (16.7%)
BC: yes (clinical only reported)
Age: not reported
Gender (per cent men): 41.7%
Severity: PASI mean = 14.0
INCLUSION CRITERIA
• Adults
• Symmetrical chronic moderate chronic plaque psoriasis
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Drugs affecting systemic calcium homeostasis
• Recent systemic antipsoriatic or UVB therapy
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Bourke 1997 (Continued)
Interventions • Calcitriol 3 mcg/g BD (CL)
• Calcipotriol 50 mcg/g BD (C)
Outcomes 1. PASI
Notes Solvay-Duphar Ltd sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 16.7%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Brown 2005
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 30
Treatment duration: 12 wks; FU: 12 wks
LF: 6 (20%)
BC: unclear
Age: 55 (12.6SD); range = 20 to 75
Gender (per cent men): 50%
Ethnicity (% white): 46.7%
Severity: TSS (0 to 16) mean = 6.97
INCLUSION CRITERIA
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Brown 2005 (Continued)
• People with mild stable plaque psoriasis
• BSA affected < 15%
• General good health
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Phototherapy, topical therapy, or systemic therapy within previous 4 wks
• Cancer
• History of drug or alcohol abuse
• Concomitant antipsoriatic therapy
Interventions • Kukui nut oil TD (K)
• Placebo (mineral oil, vehicle) TD (P)
Outcomes 1. Investigator assessment of PASI (scale unclear (0 to 64.8)) and Global Severity
Score (5-pt: 0 = none to 4 = very severe)
2. Subject assessment of Global Severity Score (5-pt: 0 = none to 4 = very severe)
3. Total Severity Score (0 to 16; thickness + scaliness + erythema + itch)
4. Compliance also assessed (bottles weighed)
Notes Hawaii Community Foundation sponsored the study.
The trial author supplied unpublished data.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 20%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
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Bruce 1994
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 114
Treatment duration: 6 wks; FU: 6 wks
LF: 15 (13.2%)
BC: yes
Age: 44.1 (14.6SD; range = 20 to 77)
Gender (per cent men): 60.2%
Severity: mean duration of current episode (days) = 142 (range = 0 to 601)
Overall severity score (mean): 4.5
INCLUSION CRITERIA
• Stable plaque psoriasis
• Adults
• At least mild overall severity
• At least moderately severe plaque elevation
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Inadequate contraception
• Sensitivity to test medications
• Recent topical, UV, or systemic treatment
• Recent involvement in other trials
• Planned sun exposure
Interventions • Calcipotriol ointment 0.005% BD (C)
• Fluocinonide ointment 0.05% BD (F)
Outcomes 1. Sign: scaling, erythema, plaque elevation
2. Overall severity (Total Sign Score and per cent involvement)
3. Investigator Global Assessment
Notes Westwood Squibb Pharmaceuticals Inc. sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
109Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bruce 1994 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 13.2%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Buckley 1978
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 10
Treatment duration: 3 wks; FU: 3 wks
LF: 2 (20%)
BC: not reported
Age: 21.4 (range = 9 to 41)
Gender (per cent men): 50%
Severity: not reported
INCLUSION CRITERIA
• Active chronic psoriasis
• Lesions approximately symmetrically distributed
EXCLUSION CRITERIA
• Not reported
Interventions • Dead Sea salts emollient lotion 30% (frequency of application not reported) (D)
• Base emollient lotion (placebo) (P)
Outcomes 1. Jacoby assessment score (0 to 7 score transformed to per cent clinical
improvement)
2. Photographic evaluation
3. Overall patient assessment (relative efficacy, speed of response, irritation, staining,
ease of application)
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Buckley 1978 (Continued)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 20.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Buckley 2008
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 218
Treatment duration: 8 wks; FU: 10 wks
LF: 5 (2.3%)
BC: yes
Age: 48.4 (15.48SD)
Gender (per cent men): 45.0%
Ethnicity: 97.7%
Severity: TSS (0 to 12) = 6.80 (1.58SD)
Duration (yrs): 14.6 (13.87SD); range = 0 to 65
Extent of scalp psoriasis: 3.39 (1.36SD)
INCLUSION CRITERIA
• People aged > = 18 with scalp psoriasis affecting > = 10% scalp
• Amenable to topical treatment with < = 100 g medication/wk
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Buckley 2008 (Continued)
• TSS (0 to 12) > = 4
• Each individual sign score (0 to 4) > = 1
• IGA at least mild (> = 3)
EXCLUSION CRITERIA
• Erythrodermic psoriasis
• Pustular psoriasis
• Systemic or PUVA therapy within previous 4 wks
• UVB or grenz ray therapy on scalp, or topical scalp therapy within previous 2 wks
• Severe renal impairment or severe hepatic disorders
Interventions • Combined gel: calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g
OD (C-B)
• Betamethasone dipropionate 0.5 mg/g gel OD (B)
Participants achieving absence of disease (IGA = 5) at weeks 2 to 5 could withdraw from
the study
Outcomes 1. Signs: redness, thickness, scaliness (each sign scored on 5 pt scale 0 to 4)
2. Total Sign Score (TSS; 13-pt: 0 = none to 12 = very severe symptoms)
3. Investigator’s Global Assessment (IGA): 0 = absence of disease to 5 = very severe
disease.
4. Controlled disease: IGA < = 1
5. Investigator assessment of extent of scalp psoriasis: 0% to 100% (score of 3
corresponds to 30% to 49% involvement)
6. Patient’s assessment of global improvement (PAGI): 7-pt scale: 0 = worse to 6 =
cleared. Reported as dichotomised treatment success: PAGI > = 4
7. Treatment duration
8. Compliance (medication usage)
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the study.
Treatment duration (wks): C-B: 6.1 (2.4 SD), N = 108; B: 6.8 (2.2 SD), N = 110
Compliance (missed < = 20% applications): C-B: 93/108; B: 103/110
The sponsor supplied unpublished data.,
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 2.3%
Baseline assessments Low risk These were reported.
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Buckley 2008 (Continued)
Baseline comparability demonstrated Low risk -
Camarasa 2003
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Conducted in 20 centres; stratification not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 258
Treatment duration: 6 wks; FU: 14 wks
LF: 15 (5.8%)
BC: yes
Age: 43.5 (14.3SD: range = 15 to 83)
Gender (per cent men): 64.3%
Severity: per cent BSA = 25.5 (22.9SD: range = 1 to 95); PASI = 15.4 (10.6SD)
Duration of psoriasis (mths) mean: 199.2 (157.5SD: range = 1 to 745)
INCLUSION CRITERIA
• Adults
• Moderate to severe chronic plaque psoriasis (≥ 2 on global severity score)
EXCLUSION CRITERIA
• Systemic or intralesional therapy or photo(chemo)therapy in previous 2 mths
• Medications or conditions that might interfere with the assessment of study drugs
Concomitant bacterial, fungal, or viral skin conditions
• Clinically relevant abnormalities in laboratory parameters (calcium homeostasis
and renal function)
• Pregnancy or lactation
• Absence of adequate contraception, where appropriate
Interventions • Calcitriol 3 mcg/g ointment BD (C)
• Betamethasone dipropionate 0.05% ointment BD (B)
Outcomes 1. IAGI (6-pt: worsening to clearance)
2. PASI
3. Overall global severity of lesions (5-pt: 0 = none to 4 = very severe)
4. Relapse rate
5. Proportion remaining in remission (non-randomised subgroup analysis)
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Camarasa 2003 (Continued)
Notes There was a 1-wk run-in period without treatment, except tar shampoo and emollients.
Follow up was for responders only (defined as achieving clearance or considerable im-
provement).
The scalp was excluded.
Galderma Laboratories sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 5.8%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Cheesbrough 1992
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 24
Treatment duration: 12 wks; FU: 12 wks
LF: 5 (20.8 %)
BC: yes
Age (mean): 47
Gender (per cent men): 54.2%
Severity: PASI mean = 26
INCLUSION CRITERIA
• Chronic stable plaque psoriasis
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Cheesbrough 1992 (Continued)
EXCLUSION CRITERIA
• Not reported
Interventions • Dead sea salts emollient lotion 30% (frequency of application not reported) (D)
• Base emollient lotion (placebo) (P)
Outcomes 1. PASI
2. Erythema, scaling, thickening, pruritus
3. Adverse events
Notes Finders Dead Sea Salt Co and Dead Sea Salt works supplied the study treatments
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 20.8%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Christensen 1999
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Single-blind at inclusion only (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 171
Treatment duration: 8 wks; FU: 16 wks (N = 95)
LF: 5 (2.9%)
BC: yes
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Christensen 1999 (Continued)
Age: 47.4 (range = 17 to 88)
Gender (per cent men): 62.6%
Severity: mean TSS (0 to 9) = 6.24; mean duration of psoriasis = 18.5 (range = 1 to 58)
INCLUSION CRITERIA
• Outpatients with mild to severe chronic stable chronic plaque psoriasis, not more
than 10% BSA, Total Severity Score (0 to 9) ≥ 4, involving all 3 signs (erythema,
scaling, infiltration)
EXCLUSION CRITERIA
• Systemic treatment within previous 4 wks
• Topical treatment within previous 2 wks; receipt of oral retinoids within previous
2 mths
Interventions • Short-contact dithranol (30 min) 1% to 3%, OD (D)
• Calcipotriol 50 mcg/g BD (C)
Outcomes 1. Total Severity Score (0 to 9)
2. Pruritus (0 to 3)
3. Investigator’s Global Assessment (7-pt: worse to completely clear)
4. Patient’s Global Assessment (6-pt: worse to completely clear)
5. Adverse events
Notes The study did not report sponsorship.
The study also included16-week follow-updata for consentingparticipantswho achieved
at least 50% improvement from baseline (Investigator scale).
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 2.9%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Cook-Bolden 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 81
Treatment duration: 4 wks; FU: 4 wks
LF: 3 (4%)
BC: yes
Age: 43.7 (14.69SD)
Ethnicity (% white): 78%
Gender (per cent men): 39.5%
Duration (yrs): 11.1 (10.5SD)
Severity: GSS = 3 (moderate) (67.9%); GSS = 4 (severe) (32.1%)
INCLUSION CRITERIA
• People aged 18 or over with moderate to severe plaque psoriasis of the scalp (GSS
= 3 or GSS = 4)
EXCLUSION CRITERIA
• Use of chemical hair process, steroid medication, ultraviolet B (UVB) treatment,
or both; calcipotriene; other vitamin D analogues; anthralin/tar; all other anti-psoriasis
medications (previous 2 wks)
• Use of PUVA or other non-biological systemic treatments (previous 4 wks)
• Use of biological therapies (previous 12 wks)
• Pregnancy or risk thereof
• Lactation
Interventions • Clobetasol propionate spray 0.05% BD (CP)
• Placebo (vehicle) spray BD (P)
Max usage/wk: 50 g
Participants achieving GSS = 0 at 2 wks completed (“withdrew” from) the study
Outcomes 1. Global Severity Score (GSS) (6-pt: 0 = none to 5 = very severe), dichotomised as
success (clear/almost clear) and failure
2. Scalp psoriasis sign scores: erythema, scaling, elevation (0 to 4, where 0 = none)
3. Pruritus (4-pt: 0 = no itching to 3 = intense itching that disrupts sleep)
4. Atrophy (0 to 3, where 0 = none)
5. Telangiectasias (0 to 3, where 0 = none)
6. Stinging/burning (0 to 3, where 0 = none)
7. Patient satisfaction with applicator
8. Scalpdex, a scalp dermatitis-specific quality of life instrument; 23 questions, each
scored 0 (never) to 100 (all the time)
9. Compliance: yes if participant achieved 80% to 120% of expected applications
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Cook-Bolden 2010 (Continued)
Notes Galderma Laboratories, LP, sponsored the trial.
Galderma supplied safety data for this study.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4%
Baseline assessments Low risk These were made.
Baseline comparability demonstrated Low risk The trial demonstrated demographic and
clinical comparability
Crosti 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 160
Treatment duration: 6 wks; FU: 10 wks
LF: 8 (5%)
BC: yes
Age: 49.9 (14.2SD)
Gender (per cent men): 68.1%
Severity: mean PASI = 7.6
INCLUSION CRITERIA
• Mild stable chronic plaque psoriasis
• Adult
EXCLUSION CRITERIA
• Recent topical or systemic treatments
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Crosti 1997 (Continued)
• Pregnancy
• Lactation
• Concomitant vitamin D or systemic steroids
• Hepatic or renal failure
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Betamethasone dipropionate + salicylic acid BD (B)
Outcomes 1. PASI
2. Investigator Global Assessment
3. Patient Global Assessment of acceptability of treatment (5-pt: nil to excellent)
Notes The trial did not report sponsorship.
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 5.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Cunliffe 1992
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: balanced blocks of 10 according to a computer-generated
random numbers table
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 409
Treatment duration: 6 wks; FU: 6 wks
LF: 8 (2.0%)
BC: yes
Age: 44.9 (range = 17 to 83)
Gender (per cent men): 55.7%
Severity: mean PASI = 9.0 (range = 0.6 to 41.2); mean duration psoriasis = 16.2 (range
= 0.2 to 57)
INCLUSION CRITERIA
• Stable plaque psoriasis
• Adults
• Outpatients
EXCLUSION CRITERIA
• Risk of pregnancy
• Pregnancy
• Lactation
• Recent systemic antipsoriatic treatment
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Betamethasone 17-valerate 1 mg/g BD (B)
Outcomes 1. PASI
2. Patient overall assessment (5 pt: worse to clear)
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Cunliffe 1992 (Continued)
Randomisation method reported Low risk A computer-generated block list was used
for randomisation.
Loss to follow up Low risk 2.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
De Simone 1993
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Blinding unclear
WITHDRAWAL/DROPOUT
Not described
Participants N: 30
Treatment duration: 6 wks; FU: 10 wks
LF: 0 (0%)
BC: not reported
Age: range = 18 to 84
Gender (per cent men): 70.0%
Severity: PASI range = 2.7 to 24.3
INCLUSION CRITERIA
• Chronic plaque psoriasis
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Hepatic or renal disease
• Recent systemic or topical therapy
• High intake of vitamin D or calcium
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Coal tar 5% in Lassar’s paste (T)
Outcomes 1. Investigator Global Assessment (estimated from PASI score)
Notes The trial did not report sponsorship.
Risk of bias
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De Simone 1993 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Decroix 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator); as cream and lotion were compared, not possible to blind
participants
WITHDRAWAL/DROPOUT
Described
Participants N: 222
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: yes
Age: 48.4 (15.0SD)
Gender (per cent men): 55.9%
Ethnicity (% white): 100%
Severity: DSS (0 to 12) = 8.44 (1.45SD); atrophy (0 to 3) = 1.01; telangiectasia (0 to 3)
= 0.01
INCLUSION CRITERIA
• People aged > = 18 with stable moderate to severe plaque psoriasis
• Target lesion diameter > 3 cm
• Lesion not localised to scalp, face, hands, or feet
• BSA > = 10%;
• (Women participants only) negative pregnancy test
EXCLUSION CRITERIA
• Use of topical treatments and phototherapy within previous 2 wks
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Decroix 2004 (Continued)
• Use of systemic therapies within previous 2 to 16 wks
• Regular sun exposure within previous 2 wks
Interventions • Clobetasol propionate lotion/cream BD (CP)
• Placebo (vehicle lotion) BD (P)
Participants were randomised to clobetasol propionate cream or lotion; results were
aggregated for review purposes
Outcomes 1. Erythema, plaque elevation, scaling pruritus: each scored on 5-pt scale (0 to 4)
2. Dermatological Sum Score (DSS: erythema, elevation, scaling): 0 to 12
3. Global severity (GSS): 0 (none) to 4 (severe)
4. Dichotomised as success (GSS = 0, 0.5, or 1) or failure (GSS = 2 to 4)
5. Investigator’s Assessment of Global Improvement (IAGI): -1 (worse) to 5 (clear)
6. Per cent BSA involvement: rule of nines
7. Safety: telangiectasia (0 to 3), atrophy (0 to 3); adverse events
8. Compliance (assessment method not reported)
9. Cosmetic acceptability (questionnaire survey)
Notes Galderma R&D, Sophia Antipolis, France, sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator);
as the cream and lotion were compared, it
was not possible to blind participants
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Douglas 2002
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1106
Treatment duration: 4 wks; FU: 4 wks
LF: 86 (7.8%)
BC: yes
Age: mean = 47.1 (range = 18 to 89)
Gender (per cent men): 59.8%
Severity: PASI = 10.7 (range = 2.1 to 39.6)
Duration: mean = 18.4 (range = 0 to 65)
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Aged at least 18 years
• Use of systemic antipsoriatic treatment/phototherapy in previous 6 weeks
• Treatment of lesions contraindicated for topical corticosteroid therapy
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Current participation in other trial
• Abnormality of calcium metabolism
• Hypercalcaemia
Interventions • Calcipotriol (50 mcg/g)/betamethasone (0.5 mg/g) combination ointment
(Daviobet®) BD (D)
• Calcipotriol ointment (Daivonex®) 50 mcg/g BD (C)
• Betamethasone dipropionate ointment (Diprosone®) 0.5 mg/g BD (B)
All groups then received 4 weeks of maintenance therapy with calcipotriol BD
Outcomes 1. PASI (modified) (0 to 64.8)
2. Redness, thickness, scaling (0 to 8 each)
3. Investigator Global Assessment (6-pt: worse to cleared)
4. Patient’s assessment of treatment response (6-pt: worse to cleared)
5. Adverse events
Notes Leo Pharmaceuticals sponsored the trial.
4-week follow-up study also reported (open design: all participants received calcipotriol)
Risk of bias
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Douglas 2002 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 7.8%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Dubertret 1992
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 66
Treatment duration: 4 wks; FU: 8 wks
LF: 6 (9.1%)
BC: yes
Age: 43 (range = 21 to 84)
Gender (per cent men): 69.7%
Severity: PASI mean = 14.15
Duration: 13.3 (range = 0.3 to 40.0)
INCLUSION CRITERIA
• Bilateral stable symmetric chronic plaque psoriasis of the arms, limbs, or trunk
• Adult
EXCLUSION CRITERIA
• Guttate or pustular psoriasis
• Psoriasis restricted to the scalp, face, elbows, or knees
• Recent systemic or UV therapy in the previous 10 weeks
• Calcium, vitamin D daily or other medications
• Hepatic or renal impairment
• Pplanned exposure to sun
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Dubertret 1992 (Continued)
Interventions • Calcipotriol ointment 50 mcg/gm BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity [erythema, infiltration, desquamation]
2. Modified PASI
3. Preferred treatment
4. Investigator Global Assessment (5-pt: cleared to worse)
5. Patient Global Assessment (5-pt: cleared to worse)
Notes Leo Pharmaceuticals sponsored the trial.
We contacted Leo for patient outcome data.
There was the SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 9.1%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Durakovic 2001
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 15
Treatment duration: 12 wks; FU: 20 wks
LF: 0 (0%)
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Durakovic 2001 (Continued)
BC: yes
Age: 49 (range = 27 to 76)
Gender (per cent men): 80%
Severity: TSS (0 to 24) = 13.7 (14.7SD)
INCLUSION CRITERIA
• Chronic plaque psoriasis involving at least 5% BSA
• Bilateral lesions of approximately 25 cm²
EXCLUSION CRITERIA
• Systemic treatment within previous 30 days
• Topical treatment within previous 1 day
• History of hepatic or renal failure
• Nephrolithiasis; hypercalcaemia
• Hypercalciuria
• Pregnancy
• Lactation
• Unwillingness in women to use effective contraception
Interventions • Hexafluoro-1,25-dihydroxyvitamin D
5 mcg/g in 0.1g of ointment BD (F6)
• Placebo ointment BD (P)
Outcomes 1. Total Severity Score (0 to 24)
2. PASI (0 to 72)
3. Investigator’s assessment of global improvement (5-pt: worsening to excellent
improvement)
Notes National Institutes of Health and by Penederm Inc. sponsored the trial.
8-week follow up (open design: all participants received study drug) study also reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Durakovic 2004
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 11
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 46 (range = 29 to 65)
Gender (per cent men): 72.7%
Severity: TSS (0 to 12) = 9.30
INCLUSION CRITERIA
• Moderate plaque psoriasis
• BSA ≥ 5%; 2 target lesions with diameter ≥ 5cm
• Severity score (0 to 4) ≥ 2 for each of plaque elevation, scaling, and erythema
EXCLUSION CRITERIA
• Previous topical therapy within previous 2 wks
• Systemic therapy within previous 4 wks
• Pregnancy or risk thereof
• Lactation
• Hepatic failure
• Renal failure
• Hypercalcaemia
• Hypercalciuria
• Hyperphosphataemia
• Concurrent calcium supplements or drugs influencing calcium metabolism
Interventions • Paricalcitol (19-nor-1 alpha,25-dihydroxyvitamin D
) ointment 15 mcg/g OD (PC)
• Placebo ointment OD (P)
Outcomes 1. Global severity score (0 to 12) (erythema, plaque elevation, scaling)
2. Global treatment success rates (IAGI) (4-pt: excellent, moderate, mild, or no
improvement)
Notes The trial was sponsored in part by grant from the National Institutes for Health. US
Abbott Laboratories supplied the study drug
Risk of bias
Bias Authors’ judgement Support for judgement
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Durakovic 2004 (Continued)
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Duweb 2000
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 42
Treatment duration: 6 wks; FU: unclear
LF: 0 (0%)
BC: clinical only
Age: 33.5 (range = 6 to 61)
Gender (per cent men): 69%
Severity: TSS (0 to 12) = 5.2
INCLUSION CRITERIA
• Psoriasis of the scalp
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol 50 mcg/g/ml solution BD (C)
• Betamethasone valerate 1% lotion BD (B)
Outcomes 1. Redness, thickness, scaliness (0 to 4)
2. Total Severity Score (0 to 12)
3. Adverse events
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Duweb 2000 (Continued)
Notes Leo Pharmaceuticals sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk This was partially demonstrated.
Elie 1983
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 40 (55% psoriasis)
Treatment duration: 3 wks; FU: 3 wks
LF: not reported
BC: yes
Age: 36.5 (range = 20 to 63)
Gender (per cent men): 40%
Severity: not reported
INCLUSION CRITERIA
• Moderate to severe psoriasis, seborrhoeic dermatitis, or neurodermatitis of the
scalp
• Adult
EXCLUSION CRITERIA
• None reported
130Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Elie 1983 (Continued)
Interventions • Betamethasone-17,21-dipropionate, 0.05% BD (B)
• Salicylic acid 2% BD (S)
• Betamethasone-17,21-dipropionate, 0.05% + Salicylic acid 2% BD (BS)
• Placebo (vehicle) (P)
Outcomes 1. Investigator Global Assessment (5-pt: very severe to clear)
2. Severity (redness; scaling; pruritis)
3. Area of lesion (cm²)
Notes Schering Canada Inc. sponsored the trial.
This was a scalp trial.
There was SD imputation (TSS/IAGI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Ellis 1988
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation list (1:1)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 165
Treatment duration: 3 wks; FU: 3 wks
LF: 33 (20%)
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Ellis 1988 (Continued)
BC: yes
Age: 49.1 (range = 19 to 82)
Gender (per cent men): 51.6%
Severity: not reported
INCLUSION CRITERIA
• Psoriasis of the scalp
• Adult
• TSS (0 to 12) ≥ 6
• Particpants required to have psoriatic lesions elsewhere
EXCLUSION CRITERIA
• Acute systemic illness
• Active skin infection
• Concomitant antihistamine, topical, or systemic corticosteroid, antimetabolites,
PUVA, or other dermatological treatment
• Recalcitrant psoriasis
• Intolerance or hypersensitivity to topical corticosteroids
• Pregnant or lactating
Interventions • Amcinonide lotion 0.1% OD (A)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; excoriation; scaling; induration, pruritis)
2. Total Sign Score (erythema; scaling; induration, pruritis)
3. Investigator’s Overall Evaluation (7-pt: cleared to exacerbation)
4. Patient’s Overall Evaluation (4-pt: poor to excellent)
5. Patient Acceptability Evaluation
Notes The trial did not report sponsorship.
Compliance was checked by counting returned bottles.
This was a scalp trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 20.0%
Baseline assessments Low risk -
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Ellis 1988 (Continued)
Baseline comparability demonstrated Low risk -
Escobar 1992
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: ’randomised code’
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 25
Treatment duration: 4 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 40.3 (14.1SD); range = 18 to 66
Gender (per cent men): 56.0%
Severity: mean TSS (0 to 12) = 7.83
INCLUSION CRITERIA
• Clinical and histopathological diagnosis of psoriasis
EXCLUSION CRITERIA
• Systemic cytostatic/corticosteroid therapy within previous year
• Renal, hepatic, haematological disease
• NSAIDs, beta adrenergic receptor blockers, antimalarial drugs
Interventions • Fish oil plus 6-hour occlusion OD (FO)
• Liquid paraffin plus 6-hour occlusion OD (LP)
Outcomes 1. Erythema, scaling, thickening (0 to 4)
2. Pruritis (VAS)
3. Patient acceptability
Notes The trial did not report sponsorship.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Escobar 1992 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Farkas 1999
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: computer programme randomised participants in blocks of
10
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 84
Treatment duration: 8 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 45.1 (range = 18 to 69)
Gender (per cent men): 60.7%
Severity: mean PASI = 13.2%; BSA (mean) = 16.5%
INCLUSION CRITERIA
• Chronic stable plaque psoriasis
• Adults
• White participants = 30% BSA
• mPASI > 10
• In- and outpatients
EXCLUSION CRITERIA
• Recent topical, systemic, or UV therapies
• Sensitivity to study medications
• Concurrent medication
• Abnormal hepatic or renal function
• Risk of pregnancy
• Pregnancy
• Lactation
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Farkas 1999 (Continued)
Serious co-morbidity
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Dithranol stick 1.5% or 3% OD (D)
Outcomes 1. PASI (modified to exclude head)
2. Total Sign Score (erythema, infiltration, and desquamation)
3. Investigator Global Assessment
4. Patients evaluation of benefit (10-pt)
5. Investigator evaluation of efficacy and tolerability (1 = very good to 4 = very bad)
6. Patient evaluation of efficacy and tolerability (1 = very good to 4 = very bad)
Notes Hermal sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Low risk A computer-generated block list was used
for randomisation.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Feldman 2010 (1)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
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Feldman 2010 (1) (Continued)
Participants N: 323
Treatment duration: 8 wks; FU: 8 wks
LF: 7 (2.2%)
BC: yes
Age: 47.8 (15.2SD)
Gender (per cent men): 48.3%
Per cent white: 90.7%
Severity: ISGA = mild disease: 26.9%; ISGA = moderate disease: 73.1%; SGA = 3.69
(0.89SD); % BSA = 6.4% (4.9SD)
INCLUSION CRITERIA
• People aged ≥12 with mild to moderate plaque psoriasis
• BSA: 2% to 20%
• ISGA: 2 to 3
EXCLUSION CRITERIA
• Known allergy to any component of formulation
• Hypercalcaemia or history thereof
• Pregnancy or risk thereof
• Topical or systemic therapy within previous 4 wks
• Previous participation in trial of study medication
Interventions • Calcipotriol foam 0.005% BD (C)
• Placebo foam BD (P)
Outcomes 1. Investigator Static Global Assessment (IGSA): scale unclear
2. Treatment success: ISGA < = 1 (clear/almost clear) and minimum improvement
from baseline of 2 points.
3. Subject Global Assessment (SGA) (6-pt: 0 = clear to 5 = severe)
4. Signs: erythema, scaling, thickness (0 to 4)
Notes STUDY 1: nCT00689481
Stiefel Laboratories, a GSK Company, sponsored the trial.
Atrophy was not reported.
We sought data, but they were not received. No usable effectiveness data were reported
or available from sponsor
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 2.2%
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Feldman 2010 (1) (Continued)
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Feldman 2010 (2)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 336
Treatment duration: 8 wks; FU: 8 wks
LF: 6 (1.8%)
BC: yes
Age: 48.7 (14.4SD)
Gender (per cent men): 60.4%
% white: 86.0%
Severity: ISGA = mild disease: 31.8%; ISGA = moderate disease: 68.2%; SGA = 3.69
(0.83SD); % BSA = 6.2% (4.8SD)
INCLUSION CRITERIA
• People aged ≥12 with mild to moderate plaque psoriasis
• BSA: 2% to 20%
• ISGA: 2 to 3
EXCLUSION CRITERIA
• Known allergy to any component of formulation
• Hypercalcaemia or history thereof
• Pregnancy or risk thereof
• Topical or systemic therapy within previous 4 wks
• Previous participation in trial of study medication
Interventions • Calcipotriol foam 0.005% BD (C)
• Placebo foam BD (P)
Outcomes 1. Investigator Static Global Assessment (IGSA): scale unclear
2. Treatment success: ISGA < = 1 (clear/almost clear) and minimum improvement
from baseline of 2 points
3. Subject Global Assessment (SGA) (6-pt: 0 = clear to 5 = severe)
4. Signs: erythema, scaling, thickness (0 to 4)
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Feldman 2010 (2) (Continued)
Notes STUDY 2: nCT00688519
Stiefel Laboratories, a GSK Company, sponsored the trial.
Atrophy was not reported.
We sought data, but they were not received. No usable effectiveness data were reported
or available from sponsor
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.8%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Fleming 2010 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 364
Treatment duration: 8 wks; FU: 10 wks
LF: 2 (0.5%)
BC: yes
Age: 51.1 (14.7SD)
Gender (per cent men): 58.8%
Per cent white: 98.1%
Severity: PASI (0 to 64.8) = 7.8 (4.4SD), range = 1 to 25; IGA = 2.97 (0.66SD), range
= mild (2) to very severe (5)
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Fleming 2010 (H) (Continued)
Duration (yrs): 18.9 (13.8SD)
INCLUSION CRITERIA
• People aged > = 18 with psoriasis vulgaris affecting the trunk and or limbs,
amenable to treatment with < = 100 g topical medication/w
• IGA at least mild
EXCLUSION CRITERIA
• Guttate, erythrodermic, exfoliative or pustular psoriasis
• Use of biological therapy within previous 6 mths
• Use of systemic antipsoriatic therapy, PUVA, or grenz ray therapy with previous 4
wks
• Topical or UVB therapy within previous 2 wks
• Concomitant use of emollients during study
Interventions • Calcipotriol gel 50 mcg/g plus betamethasone dipropionate gel 0.5 mg/g OD (C-
B)
• Calcipotriol gel 50 mcg/g OD (C)
• Betamethasone dipropionate gel 0.5 mg/g OD (B)
Concomitant use of corticosteroids (WHO group I or II), dithranol, tar, and retinoids
on face, scalp, and flexures was permitted
Outcomes 1. Investigator’s Global Assessment (IGA) of disease severity; 6-pt (clear, minimal
disease, mild, moderate, severe, very severe); rescaled as clear (0) to very severe (5)
2. Responder (IGA): If IGA moderate at wk 0: clear/minimal at wk 4 or 8. If IGA
mild at wk 0: clear at wk 4 or 8
3. PASI (modified) (0 to 64.8): change from baseline
4. Treatment success: PASI75
5. Adverse events
6. Compliance
Notes Leo Pharma, Ballerup, Denmark, sponsored the trial.
Compliance: mean weekly us =: C-B: 22.7 g; C: 22.4g; B: 25.9 g
Most participants (73.5% to 80%)were fully compliant and those non-compliantmissed
< 10% applications
Safety data were available for 362/364 participants.
Leo Pharmaceuticals supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation
schedule was used.
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Fleming 2010 (H) (Continued)
Loss to follow up Low risk 0.5%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Fleming 2010 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 364
Treatment duration: 8 wks; FU: 10 wks
LF: 2 (0.5%)
BC: yes
Age: 51.1 (14.7SD)
Gender (per cent men): 58.8%
Per cent white: 98.1%
Severity: PASI (0 to 64.8) = 7.8 (4.4SD), range = 1 to 25; IGA = 2.97 (0.66SD), range
= mild (2) to very severe (5)
Duration (yrs): 18.9 (13.8SD)
INCLUSION CRITERIA
• People aged > = 18 with psoriasis vulgaris affecting the trunk and or limbs,
amenable to treatment with < = 100 g topical medication/w
• IGA at least mild
EXCLUSION CRITERIA
• Guttate, erythrodermic, exfoliative or pustular psoriasis
• Use of biological therapy within previous 6 mths
• Use of systemic antipsoriatic therapy, PUVA, or grenz ray therapy with previous 4
wks
• Topical or UVB therapy within previous 2 wks
• Concomitant use of emollients during study
Interventions • Calcipotriol gel 50 mcg/g plus betamethasone dipropionate gel 0.5 mg/g OD (C-
B)
• Calcipotriol gel 50 mcg/g OD (C)
• Betamethasone dipropionate gel 0.5 mg/g OD (B)
• Placebo gel OD (P)
Concomitant use of corticosteroids (WHO group I or II), dithranol, tar, and retinoids
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Fleming 2010 (P) (Continued)
on face, scalp, and flexures were permitted
Outcomes 1. Investigator’s Global Assessment (IGA) of disease severity; 6-pt (clear, minimal
disease, mild, moderate, severe, very severe); rescaled as clear (0) to very severe (5)
2. Responder (IGA): If IGA moderate at wk 0: clear/minimal at wk 4 or 8. If IGA
mild at wk 0: clear at wk 4 or 8
3. PASI (modified) (0 to 64.8): change from baseline
4. Treatment success: PASI75
5. Adverse events
6. Compliance
Notes Leo Pharma, Ballerup, Denmark, sponsored the trial.
Compliance: mean weekly us =: C-B: 22.7 g; C: 22.4g; B: 25.9 g; P: 26.1 g
Most participants (73.5% to 80%)were fully compliant and those non-compliantmissed
< 10% applications
Safety data were available for 362/364 participants.
Leo Pharmaceuticals supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation
schedule was used.
Loss to follow up Low risk 0.5%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Franz 1999
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 190
Treatment duration: 2 wks; FU: 4 wks
LF: 18 (9.5%)
BC: yes
Age: 49.6
Gender (per cent men): 49.3%
Severity: mean TSS (0 to 12) = 7.92
INCLUSION CRITERIA
• Moderate to severe scalp psoriasis (each of 3 primary signs ≥ 2)
• Scalp involvement ≥10%
• Adults
EXCLUSION CRITERIA
• Systemic psoriatic therapy within previous 4 wks
• Topical scalp preparations within previous 2 wks
Interventions • Betamethasone valerate foam 0.1% BD
• Placebo foam BD
• Betamethasone valerate lotion 0.1% BD
• Placebo lotion BD
Findings reported for foam and lotion combined:
• Betamethasone (B)
• Placebo (P)
Outcomes 1. Erythema, scaling, thickness, pruritis
2. IAGI (7-pt: worse to completely clear)
3. PAGI (7-pt: worse to completely clear)
Notes Connectics Corporation sponsored by the trial.
This was a scalp trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Franz 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 9.5%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Franz 2000
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 188
Treatment duration: 2 wks; FU: 4 wks
LF: 0 (0%)
BC: unclear
Age: not reported
Gender (per cent men): 49.5%
Severity: mean TSS (0 to 12) = 7.25
INCLUSION CRITERIA
• Moderate to severe scalp psoriasis (each of 3 primary signs ≥ 2)
• Scalp involvement ≥10%
• Adults
EXCLUSION CRITERIA
• Not reported
Interventions • Clobetasol propionate foam 0.05% BD
• Placebo foam BD
• Clobetasol propionate lotion 0.05% BD
• Placebo lotion BD
Findings reported for foam and lotion combined:
• Clobetasol (C)
• Placebo (P)
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Franz 2000 (Continued)
Outcomes 1. Signs: erythema, scaling, thickness, pruritis
2. TSS (0 to 12)
3. IAGI (7-pt: worse to completely clear)
4. PAGI (7-pt: worse to completely clear)
Notes Connectics Corporation sponsored by the trial.
This was a scalp trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Geilen 2000
Methods DESIGN
Within-patient
Nurse delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 7
Treatment duration: 3 wks; FU: 3 wks
LF: 0 (0%)
BC: yes
Age: 36 to 67
Gender (per cent men): 100%
Severity: TSS (0 to 8) = 6.72 (0.76SD)
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Geilen 2000 (Continued)
INCLUSION CRITERIA
• Chronic plaque psoriasis
EXCLUSION CRITERIA
• Not reported
Interventions • Mycophenolic acid ointment 1% plus occlusion OD (M)
• Placebo ointment plus occlusion OD (P)
Outcomes 1. TSS (erythema induration) (0 to 8)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Gottlieb 2003
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Conducted in 17 centres; stratification not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 279
Treatment duration: 2 wks; FU: 4 wks
LF: 8 (2.9%)
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Gottlieb 2003 (Continued)
BC: yes (clinical only)
Age: 47 (range = 19 to 82)
Gender (per cent men): 57%
Severity: BSA = 6.7%
INCLUSION CRITERIA
• Aged 18 to over
• Mild to moderate chronic plaque psoriasis of non-scalp regions
• 2 > PSGA > 3; BSA < = 20%
• Target lesion > 2 cm² on trunk or extremities with PGSA between 2 and 3 for
each of erythema, scaling, and plaque thickness
EXCLUSION CRITERIA
• Known allergy to study medications or other topical corticosteroids
• Systemic therapy within previous 8 wks
• Topical corticosteroid therapy or retinoids within previous 4 wks
• Other topical therapy within previous 2 wks
• Expected exposure to strong sunlight/UVB therapy during study period
• Pregnancy or risk thereof
• Lactation
Interventions • Clobetasol foam (OLUX®) 0.05% BD (C)
• Placebo foam BD (P)
Limit of 50 g of medication/wk to non-scalp sites only
Outcomes 1. Signs and symptoms of psoriasis (6-pt scale for each: induration, erythema,
scaling, pruritis)
2. Physician’s Static Global Assessment (PGSA) (6-pt: 0 = clear to 5 = majority of
lesions have individual scores that average 5 on a 6-pt scale)
3. Proportion of patients with PSGA score < = 1 at 2 wks
4. Mean change in Total Sign Scores (0 to 15)
5. Patient Global Assessment (PGA) (6-pt: 0 = no psoriasis; 5 = worst during current
exacerbation)
6. Patient assessment of likely compliance
7. Patient assessment of cosmetic acceptability
Notes Connetics Corporation sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
146Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gottlieb 2003 (Continued)
Loss to follow up Low risk -
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk This was partially demonstrated.
Grattan 1997 (H)
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: pre-determined randomisation schedule
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 25
Treatment duration: 4 wks; FU: 16 weeks
LF: not reported
BC: yes
Age: 44.0 (range = 20 to 72)
Gender (per cent men): 52.0%)
Severity: BSA = 16.1% (range = 4.1% to 47.8%); TSS (target sites) = 6.3 (range = NR)
INCLUSION CRITERIA
• Bilateral stable chronic plaque psoriasis
• Adult
• Hospitalised for routine dithranol treatment
EXCLUSION CRITERIA
• Intolerance of dithranol
• Unstable or pustular psoriasis
• Calcium metabolism disorders
• Systemic psoriasis treatment
• Recent UVB or PUVA therapy
• Pregnancy or lactation
Interventions • Calcipotriol ointment 0.005% BD (C)
• Dithranol in aqueous gel (dose titration 0.1% to 2.0%) BD (D)
Outcomes 1. Severity (erythema; scaling; palpability)
2. Total Severity Score
3. Patient assessment of irritation (VAS)
4. Investigator assessment of skin staining (none, mild, moderate, or severe)
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Grattan 1997 (H) (Continued)
Notes There was inpatient treatment to ensure high level of compliance.
Dermal Laboratories sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Grattan 1997 (P)
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: pre-determined randomisation schedule
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 12
Treatment duration: 4 wks: FU: 16 wks
LF: 0 (0%)
BC: yes
Age: 50.3 (range = 33 to 75)
Gender (per cent men): 33% (4/12)
Severity: BSA 17.1% (range = 4.7% to 45.7%); TSS = 6.3 (range = 5 to 7)
INCLUSION CRITERIA
• Bilateral stable chronic plaque psoriasis
• Adult
• Hospitalised for routine dithranol treatment
EXCLUSION CRITERIA
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Grattan 1997 (P) (Continued)
• Intolerance of dithranol
• Unstable or pustular psoriasis
• Calcium metabolism disorders
• Systemic psoriasis treatment
• Recent UVB or PUVA therapy
• Pregnancy or lactation
Interventions • Dithranol in aqueous gel (dose titration 0.1 to 2.0%) BD (D)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; scaling; palpability)
2. Total Severity Score, patient assessment of irritation (VAS)
3. Investigator assessment of skin staining (none, mild, moderate, or severe)
Notes There was inpatient treatment to ensure high level of compliance.
Dermal Laboratories sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Green 1994
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 49
Treatment duration: 4 wks; FU: 4 wks
LF: 3 (6.1%)
BC: unclear
Age: not reported
Gender (per cent men): not reported
Severity: mean TSS (0 to 12) = 6.7
INCLUSION CRITERIA
• Mild to moderate scalp psoriasis and a history of psoriasis elsewhere on the body
• Adult
EXCLUSION CRITERIA
• Excessively thick scalp psoriasis
• Other scalp disease
• Marked deterioration of scalp psoriasis at entry
• Recent systemic or UV therapy
• Concurrent topical corticosteroid use
• Vitamin D or calcium supplement
• Medications that could affect the course of the disease
• Hypercalcaemia
• Hepatic or renal disease
• At risk of pregnancy
Interventions • Calcipotriol solution 50 mcg/ml BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Signs (erythema; thickness; scaliness; flaking; itching)
2. Total Sign Score (redness, thickness, scaliness)
3. Investigator Global Assessment
4. Patient Global Assessment
Notes Leo Pharmaceutical Products sponsored the trial.
Compliance was assessed by unused medication returned at each visit. The compliance
rate for participants in each group was > 90%.
This was a scalp trial.
Risk of bias
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Green 1994 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 6.1%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Greenspan 1993
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 80
Treatment duration: 3 wks; FU: 3 wks
LF: 9 (11.3%)
BC: unclear
Age: 51.5 (range = 20 to 77)
Gender (per cent men): 43.8%
Severity: not reported
INCLUSION CRITERIA
• Mild to moderate psoriasis
EXCLUSION CRITERIA
• Recent systemic or topical treatment for psoriasis
• Contraindication to low-potency corticosteroids
• Pregnant, nursing, or planning pregnancy
Interventions • Desonide lotion 0.05% TDS (DL)
• Desonide cream 0.05% TDS (DC)
• Placebo (vehicle lotion) (P)
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Greenspan 1993 (Continued)
Outcomes 1. Severity (erythema; scaling; induration; pruritis)
2. Investigator Global Assessment
Notes The trial did not report sponsorship, but 3 of the authors were employed by Owen/
Galderma laboratories.
There was SD imputation (IAGI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 11.3%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Gribetz 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: ’validated system that automates the random assignment of
treatment codes’
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 57
Treatment duration: 8 wks; FU: 8 wks
LF: 6 (10.5%)
BC: yes
Age: 47.8 (range = 21 to 88)
Gender (per cent men): 50.9%
Severity: PGA, per cent moderate = 72%; PGA, per cent severe = 29.8%; TSS = 5.34
(range = 3.0 to 9.0)
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Gribetz 2004 (Continued)
INCLUSION CRITERIA
• Stable chronic plaque psoriasis
• Moderate to severe inverse psoriasis affecting axillae, inguinal, inframammary, or
gluteal cleft regions (duration ≥ 6 mths)
• PGA ≥ 3
• Erythema ≥ 2
• Aged ≥ 18
EXCLUSION CRITERIA
• Clinically significant laboratory abnormalities
• Hypersensitivity to study drug or vehicle
• Systemic, phototherapy, or immuno-modifying agents within previous 30 dys
• Topical therapies within previous 14 dys
• Unstable plaque psoriasis, pustular, drug associated or erythrodermic psoriasis
Interventions • Pimecrolimus cream (Elidel®) 1% BD (PM)
• Placebo cream BD (P)
Outcomes 1. Investigator’s Global Assessment of overall severity (PGA) (5-pt: clear to severe
disease)
2. Target Area Score (TSS) (erythema, induration, scaling) (0 to 9)
3. Patient Self-Assessment (control of psoriasis over previous 1 wk) (4-pt: 0 =
complete control; 3 = uncontrolled)
Notes Novartis Pharmaceuticals Group sponsored the trial.
No instances of skin atrophy were reported.
This was an inverse psoriasis trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Novartis supplied identical tubes identi-
fied only by randomisation number (par-
ticipants and investigators blinded to tube
contents)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was by a validated system
that automated the random assignment of
treatment codes
Loss to follow up Low risk 10.5%
Baseline assessments Low risk These were reported.
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Gribetz 2004 (Continued)
Baseline comparability demonstrated Low risk -
Guenther 2000
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 120
Treatment duration: 8 wks; FU: 20 wks
LF: 14 (11.7%)
BC: yes
Age: 48.5
Gender (per cent men): 60.8%
Severity: not reported
INCLUSION CRITERIA
• Stable chronic plaque psoriasis
• BSA involvement between 5% and 20%
• Adult
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Unreliable contraception
• Unstable plaque psoriasis
• Other types of psoriasis or other concomitant dermatological disorder
• Hypercalaemia
• Uncontrolled systemic disease
• Likelihood of prolonged UV exposure
• Concomitant systemic or topical therapies that might affect psoriasis
• Adherence to washout requirements
Interventions • Tazarotene gel, 0.1% ON, plus mometasone furoate cream 0.1% OM (TM)
• Calcipotriol ointment 0.005% BD (C)
12 weeks’ maintenance for both groups with emollient only.
Outcomes 1. IAGI (0 to 6; exacerbation to complete clearance)
2. Erythema, scaling, thickness (0 to 4 for each)
3. BSA involvement
4. Patient assessments (efficacy, comfort of skin; outlook for long-term control;
overall impression of treatment)
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Guenther 2000 (Continued)
5. Adverse events
Notes Allergan Inc. sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 11.7%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Guenther 2002 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated random numbers table
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 828
Treatment duration: 4 wks; FU: 4 wks
LF: 10 (1.2%)
BC: yes
Age: 48.5 (14.3SD)
Gender (per cent men): 64.0%
Severity: mean PASI = 10.5; mean duration psoriasis = 18.3 yrs
INCLUSION CRITERIA
• Aged 18 to 86
• Chronic plaque psoriasis
• BSA involvement ≥ 10%
EXCLUSION CRITERIA
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Guenther 2002 (H) (Continued)
• Systemic therapy within previous 6 wks
• Topical antipsoriatic therapy within previous 2 wks
• Concurrent use of type III/IV topical corticosteroids
• Recent UV exposure
• Pregnancy
• Lactation
• Concurrent use of other medicines that could affect course of psoriasis
Interventions • Calcipotriol (50 mcg/g) and betamethasone dipropionate (0.5 mg/g) ointment
ON, plus placebo OM (D1)
• Calcipotriol (50 mcg/g) and betamethasone dipropionate (0.5 mg/g) ointment
BD (D2)
• Calcipotriol BD (C)
• Placebo BD (P)
Outcomes 1. PASI (head excluded)
2. IAGI (6-pt: worse to clearance)
3. PAGI (6-pt: worse to clearance)
4. Percentage change in thickness score
5. Speed of response (PASI) at 1 week
6. Adverse events
7. Quality of life: Psoriasis Disability Index; EQ-5D and EQ-VAS (reported in van
de Kerkhof 2004)
Notes Leo Pharmaceuticals sponsored the trial.
The trial was conducted across 57 centres in 8 countries.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 1.2%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Guenther 2002 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated random numbers table
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 828
Treatment duration: 4 wks; FU: 4 wks
LF: 10 (1.2%)
BC: yes
Age: 48.5 (14.3SD)
Gender (per cent men): 64.0%
Severity: mean PASI = 10.5; mean duration psoriasis = 18.3 yrs
INCLUSION CRITERIA
• Aged 18 to 86
• Chronic plaque psoriasis
• BSA involvement ≥ 10%
EXCLUSION CRITERIA
• Systemic therapy within previous 6 wks
• Topical antipsoriatic therapy within previous 2 wks
• Concurrent use of type III/IV topical corticosteroids
• Recent UV exposure
• Pregnancy
• Lactation
• Concurrent use of other medicines that could affect course of psoriasis
Interventions • Calcipotriol (50 mcg/g) and betamethasone diproprionate (0.5 mg/g) ointment
ON, plus placebo, OM (D1)
• Calcipotriol (50 mcg/g) and betamethasone diproprionate (0.5 mg/g) ointment
BD (D2)
• Calcipotriol BD (C)
• Placebo BD (P)
Outcomes 1. PASI (head excluded)
2. IAGI (6-pt: worse to clearance)
3. PAGI (6-pt: worse to clearance)
4. Percentage change in thickness score
5. Speed of response (PASI) at 1 week
6. Adverse events
7. Quality of life: Psoriasis Disability Index; EQ-5D and EQ-VAS (reported in van
de Kerkhof 2004)
Notes Leo Pharmaceuticals sponsored the trial.
The trial was conducted across 57 centres in 8 countries.
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Guenther 2002 (P) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk All study personnel and participants were
blinded to treatment assignment for the du-
ration of the study
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 1.2%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Han 2001
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 208
Treatment duration: 12 wks; FU: 12 wks
LF: 9 (4.3%)
BC: yes
Age: 40.4 (8.9SD)
Gender (per cent men): 59.8%
Severity: TSS (0 to 20) = 16.1 (11.0SD)
Duration (yrs): 9.4 (8.9SD)
INCLUSION CRITERIA
• People with chronic plaque psoriasis
• Aged between 18 and 65
• BSA between 2% and 30%
EXCLUSION CRITERIA
• Known allergy to study drug constituents
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Han 2001 (Continued)
• History of other skin diseases
• Pustular or erythrodermic psoriasis
• Topical treatments within previous 2 wks
• PUVA within previous 4 wks
• UVB within previous 2 wks
• Alcohol or drug abuse
• Renal, hepatic, or immunity disorder
• Pregnancy or risk thereof
• Lactation
• Participation in another clinical trial within previous 4 wks
• Other morbidity likely to affect outcome or raise safety issues
Interventions • Tazarotene gel 0.05% OD (T)
• Calcipotriol ointment 5 mcg/g BD (C)
Outcomes 1. TSS (0 to 20)
2. Proportion of patients achieving effective response
3. Curative rate
Notes The trial did not report sponsorship.
Translation support was received for data extraction.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4.3%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Harrington 1996a
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 413
Treatment duration: 8 wks; FU: 8 wks
LF: 47 (11.4%)
BC: yes, except average age in placebo group higher than for A and B (P = 0.02)
Age: 44.6
Gender (per cent men): 52.8%
Severity: PASI (modified) = 8.3 (range = 0.6 to 59.4)
Duration (yrs): 17.7 (range = 0.04 to 70)
INCLUSION CRITERIA
• Stable chronic plaque psoriasis on trunk or limbs
• Adult
EXCLUSION CRITERIA
• Recent systemic medication or phototherapy for psoriasis
• Hepatic or renal disease
• Raised serum calcium
• Calcium supplements or vitamin D
Interventions • Calcipotriol cream 50 mcg/g BD as follows:
◦ Cream A (dissolved) (CA)
◦ Cream B (suspended) (CB)
• Placebo (vehicle of A) (P)
Outcomes 1. PASI (modified to exclude head)
2. Investigator Global Assessment
3. Patient Global Assessment
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Harrington 1996a (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 11.4%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Helfrich 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear (method inadequately described)
Concealment: unclear (inadequately described)
BLINDING
Double-blind (participant/investigator/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 185
Treatment duration: 8 wks; FU: 8 wks
LF: 3 (1.6%)
BC: yes
Age: 49.0 (range = 19 to 83)
Gender (per cent men): 56.8%
Severity: PGA = 3.2 (range = 3 to 4); PSS = 8.1 (range = 4.7 to 12)
Ethnicity (per cent white): NR
Duration: 17.3 (range = 0.5 to 65)
INCLUSION CRITERIA
• People aged 18 and over with chronic plaque psoriasis affecting 2% to 10% BSA
with severity “appropriate” for topical therapy
• PGA score: > = 3
EXCLUSION CRITERIA
• Topical therapies within previous 2 wks
• Systemic/UV therapy within previous 4 wks
• Biological within previous 6 mths
• Oral vitamin D (> 400 IU/day), oral calcium (> 1200 mg/day) within previous 30
days
• Pregnancy or risk thereof
• Lactation
• Significant medial comorbidity
• Sensitivity to study drug
• Concomitant antipsoriatics therapy, immunosuppressive drugs, lithium,
hydoxycholoroquine, or biologicals
• Non-compliance with dosing of study medication
161Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Helfrich 2007 (Continued)
Interventions • Becocalcidiol ointment 75 mcg/g BD (B2)
• Becocalcidiol ointment 75 mcg/g ON and placebo OM (B1)
• Placebo ointment BD (P)
Max: 8 g ointment/day
Participants were permitted concurrent oral vitamin D (= < 400 IU/day), oral calcium
(< = 1200 mg/day), or both; or tar shampoo for scalp psoriasis
Outcomes 1. Physician’s Static Global Assessment of Overall Lesion Severity (PGA) (6-point
scale: clear to very severe)
2. Psoriasis Symptom Severity (PSS) score (0 to 12): sum of scores for erythema,
scaling, induration (each scored 0 to 4)
3. Adverse events
4. Laboratory evaluations
5. Compliance (participants who missed > 6 consecutive doses discontinued the
study)
Notes QuatRx Pharmaceuticals (product nowowned byDeltanoid Pharmaceuticals) sponsored
the trial
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant and
investigator/assessor)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.6%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated (clinical and demo-
graphic).
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Henneicke-v. Z. 1993
Methods DESIGN
Within-patient (placebo)
Between-patient (active)
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 73
Treatment duration: 8 wks; FU: 8 wks
LF: 21 (28.8%)
BC: yes
Age: 40.5 (median); range = 18 to 71 (N = 52)
Gender (per cent men): 65.8% (N = 73)
Severity: TSS (0 to 12) = 7.4
INCLUSION CRITERIA
• Aged 18 to 71
• Moderate plaque psoriasis
• 9 >TSS ≥ 4
EXCLUSION CRITERIA
• Systemic antipsoriatic drugs within previous 4 wks
• UV therapy within previous wk
• Drug-induced psoriasis
• Cancer
• Pregnancy
• Lactation
• Severe organ dysfunction
• Metabolic disorders
• Abuse of drugs or alcohol
Interventions • Omega-3-polyunsaturated fatty acids ointment 1% BD (O3(1))
• Placebo (vehicle) 1% BD
• Omega-3-polyunsaturated fatty acids ointment 10% BD (O3(10))
• Placebo (vehicle) 10% BD (P)
Outcomes 1. Local psoriasis severity index (TSS equivalent): erythema, induration,
desquamation
2. Area of indicator lesion
3. Pruritis
4. Investigator’s subjective intra-individual comparison (left side better than right
side)
5. Patient’s subjective intra-individual comparison (left side better than right side)
6. Compliance: tube weight compared with expected use
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Henneicke-v. Z. 1993 (Continued)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up High risk 28.8%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Highton 1995
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 277
Treatment duration: 8 wks
LF: 30 (10.8%)
BC: clinical severity comparable, demographics unclear
Age: not reported
Gender (per cent men): not reported
Severity: TSS (0 to 8) = 3.90; BSA = 9.1%
INCLUSION CRITERIA
• Moderately severe stable plaque psoriasis
• Plaque elevation score greater than or equal to 4 (0 to 8)
• Not pregnant or nursing during the duration of the study
EXCLUSION CRITERIA
• Recent topical or systemic psoriasis treatment, prolonged exposure to sunlight,
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Highton 1995 (Continued)
phototherapy
• Photochemotherapy
• Hypercalcemia
• Erythrodermic or pustular psoriasis
• Calcium, vitamin A or D supplements
Interventions • Calcipotriene ointment 0.005% BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; plaque elevation; scaling; overall disease severity)
2. 75% improvement scores
3. Investigator Global Assessment (7-pt: worse to completely clear)
Notes Bristol Myers Squibb sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.8%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Hindsén 2006 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 360
Treatment duration: 2 or 6 wks; FU: 6 or 10 wks
LF: NR
BC: not demonstrated
Age: NR
Gender (per cent men): NR
Severity: NR
INCLUSION CRITERIA
• People with moderately severe plaque psoriasis on elbows, knees, or both
EXCLUSION CRITERIA
• Not stated
Interventions • Calcipotriol ointment 50 mcg/g BD (no occlusion) for 6 wks (C)
• Calcipotriol ointment 50 mcg/g plus occlusion, once/week for 2 wks (CO)
[Placebo ointment plus occlusion, once/week for 2 wks (P)]
Outcomes 1. Total Sign Score (redness, thickness, scaliness) (TSS): 0 to 24
Notes Leo Pharma, Ballerup, sponsored the trial.
It was unclear how participants were blinded to treatment options where 2/3 involved
occlusion
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was reported to be double-blind
(participant/investigator), but it was un-
clear how they blindedparticipants to treat-
ment options where 2/3 involved occlusion
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
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Hindsén 2006 (H) (Continued)
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was not demonstrated.
Hindsén 2006 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 360
Treatment duration: 2 or 6 wks; FU: 6 or 10 wks
LF: NR
BC: not demonstrated
Age: NR
Gender (per cent men): NR
Severity: NR
INCLUSION CRITERIA
• People with moderately severe plaque psoriasis on elbows, knees, or both
EXCLUSION CRITERIA
• Not stated
Interventions • Calcipotriol ointment 50 mcg/g, BD (no occlusion) for 6 wks (C)
• Calcipotriol ointment 50 mcg/g plus occlusion, once/week for 2 wks (CO)
• Placebo ointment plus occlusion, once/week for 2 wks (P)
Outcomes 1. Total Sign Score (redness, thickness, scaliness) (TSS): 0 to 24
Notes Leo Pharma, Ballerup, sponsored the trial.
It was unclear how participants were blinded to treatment options where 2/3 involved
occlusion
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Hindsén 2006 (P) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was reported to be double-blind
(participant/investigator), but it was un-
clear how they blindedparticipants to treat-
ment options where 2/3 involved occlusion
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was not demonstrated.
Holick 2003
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 15
Treatment duration: 8 wks; FU: 8 wks
LF: 0 (0%)
BC: not reported
Age: 56 (range = 25 to 74)
Gender (per cent men): 67 %
Severity: not reported
INCLUSION CRITERIA
• Chronic plaque psoriasis
• 2 symmetrically comparable plaques
• Failure to respond to at least 1 standard treatment
EXCLUSION CRITERIA
• Kidney disease, hypercalcaemia, hypercalciuria
• Systemic therapy within previous 30 days
• Topical therapy within previous 14 days
• Concomitant medications that interfere with calcium metabolism
Interventions • Parathyroid hormone (PTH) (1 to 34) 20 mcg/g in Novasome A® liposomal
cream BD (PTH)
• Novasome A® liposomal cream BD (P)
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Holick 2003 (Continued)
Outcomes 1. Global severity score (0 to 24)
2. PASI (for open trial phase only)
Notes The National Institutes for Health (Department of Health and Human Services) and the
Department of Defense Small Business Innovation Research (SBIR) Program sponsored
the trial through grants.
The trial also reported a uncontrolled open, large area, study for N = 10 (PTH applied
OD for up to 11 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Huang 2009
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 320
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: stated no significant difference in clinical or demographic characteristics (data not
shown)
Age: NR
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Huang 2009 (Continued)
Gender (per cent men): NR
Severity: NR
INCLUSION CRITERIA
• Chinese people aged 18 to 65 with stable plaque psoriasis
• At least 1 area (or arm, leg, body) with mPASI score > = 2 (i.e. % BSA > = 10% of
affected area)
EXCLUSION CRITERIA
• Psoriasis of the face
• Severe disease requiring steroids or other systemic medication
• % BSA > = 30%
• Use of systemics during previous 4 weeks, topicals during previous 2 weeks
• Participation in another trial during previous 3 months
• Iodine deficiency, hypercalcaemia, Cushing’s Syndrome, diabetes, or other
metabolic disease
• Heart disease, kidney disease, liver disease
• Immunesuppression
• Cancer
• Mental disorder
• Failure to consent
• Pregnancy or risk thereof
• Lactation
• Investigator opinion of unsuitability
Interventions • Calcipotriol ointment BD (C)
• Calcipotriol betamethasone ointment ON, placebo OM (C-B)
Participant gave written consent to use < = 100 g/wk.
Outcomes 1. mPASI (0 to 64.8)
2. Treatment success: PASI75
3. TSS (redness, thickness, scaliness) (0 to 12)
4. DLQI
5. Adverse events
6. Laboratory tests: urine, blood, biochemistry, liver function, electrolytes, serum
calcium
7. Atrophy, telangiectasias
Notes The trial did not report sponsorship.
We received translation support from native speaker.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Huang 2009 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Unclear risk The trial authors state these were under-
taken.
Baseline comparability demonstrated Unclear risk The trial authors state that groups were
comparable at baseline (not demonstrated)
Hutchinson 2000
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 114
Treatment duration: 8 wks; FU: 8 wks
LF: 28 (24.6%)
BC: yes
Age: 42.3
Gender (per cent men): 74.4%
Severity: PASI (mean) = 11.8
Duration of psoriasis (mths) (mean): 185.1 (range = 1 to 85)
INCLUSION CRITERIA
• Chronic plaque psoriasis of at least moderate severity
• Aged over 18
• White or Asian origin
EXCLUSION CRITERIA
• Systemic or intralesional therapy or photo-chemotherapy within previous 2 mths
• Topical antipsoriatics within previous wk or concomitant
• Other medications that could affect psoriasis
• Pregnancy
• Inadequate contraception
Interventions • Calcitriol ointment 3 mcg/g BD (C)
• Short contact dithranol 0.25 to 2% OD (D)
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Hutchinson 2000 (Continued)
Outcomes 1. PASI
2. IAGI (6-pt: worse to clearing)
3. Overall global severity (5-pt: none to very severe)
4. Psoriasis Disability Index (quality of life) (scale NR)
5. Cosmetic acceptability (1 = good/none to 3 = not acceptable): staining, irritation
6. Adverse events
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 24.6%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Jarratt 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated list
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Unclear
Participants N: 142
Treatment duration: 4 wks; FU: 6 wks
LF: 1 (0.7%)
BC: yes
Age: 45.1 (15.37SD)
Gender (per cent men): 42.3%
Severity: TSS (0 to 9) = 6.6; GSS (6-pt (rescaled: 0 = very severe to 5 = clear) = 1.65 (0.
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Jarratt 2004 (Continued)
61SD), N = 142
INCLUSION CRITERIA
• Aged 12 or over
• Moderate to severe scalp psoriasis (global severity score ≥ 3)
• Compliance with wash-out periods for systemic therapies (details not reported)
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Known allergy to test products
• Need for systemic therapy or other concomitant antipsoriatics
• Excessive UV exposure
Interventions • Clobetasol propionate shampoo 0.05% OLUX® OD (C)
• Placebo shampoo OD (P)
• Treatments applied OD, left to dry for 15 minutes, then washed out
• Placebo represented by vehicle for clobetasol propionate
Outcomes 1. Global severity score (GSS) (6-pt: 0 = clear to 5 = very severe)
2. Total Severity Score (erythema, thickening, scaling) (TSS) (0 to 9)
3. Individual sign scores for erythema, thickening, scaling pruritis, per cent scalp
involvement (4-pt: 0 = none to 3 = severe)
4. IAGI (5-pt: worse to clear)
5. PAGI (5-pt: worse to clear)
Notes Galderma R&D Inc sponsored the trial.
Missing data imputed using last observation carried forward.
No cases of skin atrophy, teleangiectasia, or acne were reported.
This was a scalp trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk -
Loss to follow up Low risk 0.7%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
173Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jarratt 2006
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 120
Treatment duration: 4 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 48.0 (12.9SD)
Gender (per cent men): 60.0%
Severity: % BSA = 7.69% (6.17%SD); ODS (moderate) = 90.8%; ODS (severe/very
severe) = 9.2%
Ethnicity (per cent white): 94.2%
Duration: NR
INCLUSION CRITERIA
• People aged 18 and over with moderate to severe chronic plaque psoriasis
• BSA > = 2% (excluding face, scalp, groin, axillae, and other intertriginous areas)
• Overall disease severity score (0 to 4) > = 3
EXCLUSION CRITERIA
• Non-compliance with treatment specific wash-out periods on topical and
systemic treatments or phototherapy or natural UV light (periods NS)
• Pregnancy or risk thereof
Interventions • Clobetasol propionate 0.05% spray BD (CP)
• Placebo spray BD (P)
Then 4-week treatment-free follow-up period.
There was 8 hrs between applications, and the treated area was unwashed for 4 hours
after application
Outcomes 1. Scaling, erythema, plaque elevation, pruritus, overall disease severity (ODS) each
scored on 5-pt scale (0 = clear to 4 = severe/very severe)
2. Success rate: ODS < = 2 at wk 2 and ODS < = 1 at wk 4
3. ODS at wk 1 and wk 8
4. Signs at wk 1 and wk 8
5. ODS < = 1 at wk 8
6. Adverse events (atrophy, telangiectasia, burning/stinging, folliculitis); HPA axis
suppression
Notes Galderma Pharmaceuticals sponsored the trial.
The trial also reported CIC data on a safety RCT (2 or 4 wks with clobetasol propionate
0.05% spray, < = 50 g/wk): 8/36 had HPA suppression; all returned to normal within 2
wks of end of treatment (EOT)
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Jarratt 2006 (Continued)
The trialist supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk The trial reported these.
Baseline comparability demonstrated Low risk This was demonstrated.
Jekler 1992
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 30
Treatment duration: 8 wks
LF: 3 (10%)
BC: not reported
Age: 45.2 (14.0SD; N = 27)
Gender (per cent men): 77.8%; N = 27
Severity: severity (mean score, 0 to 3) = 1.9; N = 27
Duration disease (years): 20.5 (14.8SD; N = 27)
Duration exacerbation (mths): 5.1 (6.4SD; N = 27)
INCLUSION CRITERIA
• Chronic plaque-type psoriasis with bilateral lesions of equal clinical severity
• Adult.
EXCLUSION CRITERIA
• Topical or systemic corticosteroids
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Jekler 1992 (Continued)
• Recent phototherapy
Interventions • Dithranol 2% ointment 1 minute therapy OD (D)
• Placebo (vehicle) (P)
Outcomes 1. Severity (pruritis; erythema; scaling; infiltration; overall result)
2. Investigator’s assessment of degree of clearing
3. Patient’s assessment of degree of clearing
Notes E Merck AB sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk The trial did not report this.
Jemec 2008 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: pre-planned computer-generated randomisation code list (2:
4:4:1)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1505
Treatment duration: 8 wks; FU: 8 wks
LF: 32 (2.1%)
BC: yes
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Jemec 2008 (H) (Continued)
Age: 49.0 (15.8SD); range = 17 to 97
Gender (per cent men): 44.8%
Ethnicity (per cent white): 96.3%
Severity: IGA mild disease = 6.5%; IGA moderate disease = 56.2%; IGA severe disease
= 31.6%; IGA very severe disease = 5.7%; TSS (0 to 12) = 6.82 (1.85SD)
Duration (yrs): 16.5 (13.6SD)
INCLUSION CRITERIA
• People aged > = 18 with scalp plaque psoriasis involving > = 10% scalp
• Amenable to topical treatment with < = 100 g medication/wk
• Diagnosis of psoriasis vulgaris on trunk/limbs
• Score at least moderate in 1 sign (erythema, thickness, scaliness) and at least slight
for other signs
• IGA mild to very severe
EXCLUSION CRITERIA
• PUVA or grenz ray or relevant systemic therapy within previous 4 wks
• UVB or topical scalp antipsoriatic therapy or topical very potent (WHO group
IV) corticosteroid on face/body within previous 2 wks
• Biological therapy within previous 6 mths
• Planned initiation of/changes to concomitant medication that could affect scalp
psoriasis
• Planned exposure to sun
• Erythrodermic, exfoliative, or postural psoriasis
• Viral lesions
• Skin infections
• Parasitic infections
• Atrophic skin on scalp
• Known/suspected abnormality of calcium homeostasis
• Severe renal insufficiency
• Severe hepatic disorder
Interventions • Calcipotriol 50 mcg/g gel OD (C)
• Betamethasone dipropionate 0.5 mg/g gel OD (B)
• Combined gel: calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g
OD (C-B)
• Placebo gel OD (P)
Outcomes 1. Total Sign Score (0 to 12)
2. Investigator’s Global Assessment of Disease Severity of the scalp (IGA): 6-pt:
absence of disease to very severe disease
3. Treatment success: IGA absence of disease or very mild disease
4. Patient overall assessment of treatment response on a 7-pt scale (worse,
unchanged, slight improvement, moderate improvement, marked improvement,
almost clear, cleared)
5. Compliance (self-report)
6. Adverse events
7. Laboratory tests (serum calcium, serum albumin)
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
The sponsor supplied unpublished data.
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Jemec 2008 (H) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A preplanned computer-generated ran-
domisation code list was used
Loss to follow up Low risk 2.1%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Jemec 2008 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: pre-planned computer-generated randomisation code list (2:
4:4:1)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1505
Treatment duration: 8 wks; FU: 8 wks
LF: 32 (2.1%)
BC: yes
Age: 49.0 (15.8SD); range = 17 to 97
Gender (per cent men): 44.8%
Ethnicity (% white): 96.3%
Severity: IGA mild disease = 6.5%; IGA moderate disease = 56.2%; IGA severe disease
= 31.6%; IGA very severe disease = 5.7%; TSS (0 to 12) = 6.82 (1.85SD)
Duration (yrs): 16.5 (13.6SD)
INCLUSION CRITERIA
• People aged > = 18 with scalp plaque psoriasis involving > = 10% scalp
• Amenable to topical treatment with < = 100 g medication/wk
• Diagnosis of psoriasis vulgaris on trunk/limbs
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Jemec 2008 (P) (Continued)
• Score at least moderate in 1 sign (erythema, thickness, scaliness) and at least slight
for other signs
• IGA mild to very severe
EXCLUSION CRITERIA
• PUVA or grenz ray or relevant systemic therapy within previous 4 wks
• UVB or topical scalp antipsoriatic therapy or topical very potent (WHO group
IV) corticosteroid on face/body within previous 2 wks
• Biological therapy within previous 6 mths
• Planned initiation of/changes to concomitant medication that could affect scalp
psoriasis
• Planned exposure to sun
• Erythrodermic, exfoliative, or postural psoriasis
• Viral lesions
• Skin infections
• Parasitic infections
• Atrophic skin on scalp
• Known/suspected abnormality of calcium homeostasis
• Severe renal insufficiency
• Severe hepatic disorder
Interventions • Calcipotriol 50 mcg/g gel OD (C)
• Betamethasone dipropionate 0.5 mg/g gel OD (B)
• Combined gel: calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g
OD (C-B)
• Placebo gel OD (P)
Outcomes 1. Total Sign Score (0 to 12)
2. Investigator’s Global Assessment of Disease Severity of the scalp (IGA): 6-pt:
absence of disease to very severe disease
3. Treatment success: IGA absence of disease or very mild disease
4. Patient overall assessment of treatment response on a 7-pt scale (worse,
unchanged, slight improvement, moderate improvement, marked improvement,
almost clear, cleared)
5. Compliance (self-report)
6. Adverse events
7. Laboratory tests (serum calcium, serum albumin)
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Jemec 2008 (P) (Continued)
Randomisation method reported Low risk A preplanned computer-generated ran-
domisation code list was used
Loss to follow up Low risk 2.1%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Ji 2008
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 250
Treatment duration: 12 wks; FU: 12 wks
LF: 7 (2.8%)
BC: yes
Age: 41.7 (12.2SD)
Gender (per cent men): 65.6%
Ethnicity (per cent Asian): 100%
Severity: per cent BSA = 18%, range = 1% to 35%; DSS (0 to 12) = 8.12 (1.97SD),
range = 3 to 12
INCLUSION CRITERIA
• People aged 18 to 65 with stable mild to moderate plaque psoriasis
• BSA < = 35%
• Diameter of target lesions > = 3 cm
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Acute guttate psoriasis
• Erythrodermic, pustular, arthropathic psoriasis
• Hypercalcaemia
• Renal dysfunction
• Calcium nephrolithiasis
• Use of topical antipsoriatic therapy within previous 2 wks
• Use of systemic antipsoriatic therapy within previous 8 wks
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Ji 2008 (Continued)
Interventions • Calcipotriol 50 mcg/g ointment BD (C1)
• Calcitriol 3 mcg/g BD (C2)
Usage restrictions:
◦ < = 210 g/wk calcitriol
◦ < = 100 g/wk calcipotriol
Outcomes 1. Investigator’s Assessment of Global Improvement (IAGI; 4-pt: 0 = worse/no
change to 3 = clear/almost clear)
2. Subject’s Assessment of Global Improvement (PAGI) (4-pt: 0 = worse/no change
to 3 = clear/almost clear)
3. Dermatological Sum Score (DSS): erythema, plaque elevation, scaling: 0 to 12
4. Local: cutaneous safety (investigator): 5-pt: 0 (none) to 4 (very severe); cutaneous
discomfort (subject): 5-pt: 0 (none) to 4 (very severe)
5. Adverse events
6. Systemic: routine blood and urine safety parameters, albumin-adjusted serum
total calcium
7. Compliance (medication usage)
Notes Galderma Laboratories LP sponsored the trial.
The trial was set in China.
We received translation support for data extraction.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 2.8%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Jin 2001
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation:
Not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 96
Treatment duration: 6 wks; FU: 6 wks
LF: 7 (7.3%)
BC: yes
Age: 35.8 (range = 18 to 65)
Gender (per cent men): 57.3%
Severity: TSS (0 to 20) = 9.4
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Aged over 18? (cannot translate)
EXCLUSION CRITERIA
• (cannot translate)
Interventions • Anti-IL-8 monoclonal antibody cream (M)
• Placebo (P)
Outcomes 1. Efficacy rate
2. Cure rate
3. Erythema, infiltration, scaling, pruritis
4. TSS (skin damage, erythema, infiltration, thickness, scaling)
5. IAGI (4-pt: failure to cure)
Notes Biological Technical Medical Trade Limited sponsored the trial
We received translation support for data extraction.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
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Jin 2001 (Continued)
Loss to follow up Low risk 7.3%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Jorizzo 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 89
Treatment duration: 4 wks; FU: 6 wks
LF: Unclear
BC: yes
Age: 49.7 (range = 21 to 84)
Gender (per cent men): 65%
Severity: per cent BSA affected = 8.1%
Duration of psoriasis (range, years): 1 to 57
Duration of exacerbation (range, wks): 3 to 2080
INCLUSION CRITERIA
• Moderate to severe plaque type psoriasis
• Non-hospitalised men or non-pregnant; non-lactating women ≥ 12 yrs
• Baseline morning serum cortisol concentration of 5 to 18 mcg/100 mL
EXCLUSION CRITERIA
• Recent topical antipsoriatic medication or other drug that could alter psoriatic
status
Interventions • Clobetasol propionate emollient 0.05% BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; skin thickening; scaling; pruritis)
2. Total Severity Score (0 to 12)
3. Investigator Global Assessment of improvement (6-pt: worse to cleared)
4. Patient Global Assessment of improvement (5-pt: worse to excellent)
Notes Glaxo Wellcome Inc. sponsored the trial.
There was SD imputation (TSS).
183Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jorizzo 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Jorizzo 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 379
Treatment duration: 6 wks; FU: 6 wks
LF: NR
BC: yes (only clinical comparability demonstrated)
Age: NR
Gender (per cent men): NR
Severity: PASI = 7.9 (5.3SD); IGA moderate = 76.2%; IGA severe = 22.2%
INCLUSION CRITERIA
• People with moderate to severe plaque psoriasis
EXCLUSION CRITERIA
• Not stated
Interventions • Calcipotriene 0.005% ointment (C)
• Calcipotriene 0.005% plus betamethasone dipropionate 0.064% ointment (C-B)
< = 100 g/wk - the daily dose was not specified.
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Jorizzo 2007 (Continued)
Outcomes 1. PASI
2. Investigator Global Assessment (IGA)
3. Controlled disease (IGA: absence. very mild disease)
4. Patient Global Assessment of Improvement (PAGI)
5. Treatment success (PAGI marked improvement/cleared)
Notes Warner-Chilcott sponsored the trial.
This was a conference abstract only.
We sought data but received no response.
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Unclear risk The trial only reported clinical assessments
(demographic characteristics not reported)
Baseline comparability demonstrated Unclear risk This was partially demonstrated (demo-
graphic characteristics not assessed)
Kang 1998
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: identical tubes with computer-generated codes
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 30
Treatment duration: 6 wks
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Kang 1998 (Continued)
LF: 0 (0%)
BC: psoriasis comparable, demographics unclear
Age: 41 (range = 18 to 66)
Gender (per cent men): 66.7%
Severity: TSS (0 to 24) = 12.27
INCLUSION CRITERIA
• Mild to moderate stable plaque-type psoriasis
• Adult
EXCLUSION CRITERIA
• Recent systemic therapy, UV, or topical therapy for psoriasis (excluding emollient)
• Pregnant or breast-feeding women
Interventions • Calcipotriene ointment 0.005% BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Signs (erythema; thickness; scaling)
2. TSS (0 to 24)
3. Investigator Global Assessment (7-pt: worse to clear)
Notes Bristol-Myers Squibb Corporation and from Babcock Dermatologic Endowment (Uni-
versity of Michigan) sponsored the trial through grants
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Participants were assigned by computer-
generated code.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Kanzler 1993
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: identical containers labelled right and left; labelling method
not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 18
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: not reported
Age: 45.4 (range = 21 to 66)
Gender (per cent men): 55.6%
Severity: not reported
INCLUSION CRITERIA
• Bilaterally similar chronic stable plaque psoriasis
EXCLUSION CRITERIA
• Recent topical or systemic therapy
Interventions • Tar (liquor carbonis detergens) 5% BD (T)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; induration; scaling; pruritis)
2. Total Severity Score (0 to 12)
3. Investigator Global Assessment: per cent improvement from baseline, based on
TSS
Notes The trial did not report sponsorship.
Compliance was assessed by unused medication returned at each visit. The compliance
rate for participants in each group was > 90%.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
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Kanzler 1993 (Continued)
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Katz 1987a
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 40
Treatment duration: 12 wks; FU: 12 wks
LF: 2 (5%)
BC: yes
Age: 46.7
Gender (per cent men): 60%
Severity: per cent participants with BSA affected < 10% = 68%
Duration (years): 20.8
INCLUSION CRITERIA
• Plaques psoriasis in remission (> 85% resolution) after 2 to 3 weeks treatment
with Betamethasone dipropionate
Note: 38/59 (64%) achieved remission during the acute phase
EXCLUSION CRITERIA
• Not achieving remission during acute phase treatment
Interventions • Betamethasone dipropionate, intermittent maintenance (3 doses at 12-hour
intervals each weekend) (B)
• Placebo (vehicle) (P)
Outcomes 1. Signs (erythema; induration; scaling)
2. Area adjusted clinical score
3. Relapse (adjusted clinical score > 35% of baseline score)
Notes The trial was supported in part by a grant from Schering Plough Corporation.
There was SD imputation (TSS).
Risk of bias
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Katz 1987a (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 5.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Katz 1991a
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated code
Concealment unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 94
Treatment duration: 24 wks; FU: 24 wks
LF: 4 (4.3%)
BC: yes
Age: 46.0 (range = 21 to 86)
Gender (per cent men): 67.8%
Severity: overall score not reported
INCLUSION CRITERIA
• Plaques psoriasis in remission after 3 to 4 weeks treatment with Betamethasone
dipropionate (erythema score = 1; induration = 0.5; scaling = 0)
Note: 94/123 (76%) achieved remission during acute phase
EXCLUSION CRITERIA
• Recent topical or systemic treatment
• Pregnant
• Nursing
• Intent to conceive
• Not achieving remission during acute phase treatment
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Katz 1991a (Continued)
Interventions • Betamethasone dipropionate, intermittent maintenance (3 doses at 12-hour
intervals once a week) (B)
• Placebo (vehicle) (P)
Outcomes 1. Signs (erythema; induration; scaling)
2. TSS (0 to 9)
3. Area adjusted clinical score
4. Treatment failure (adjusted clinical score ≥ 2.5, or overall disease status moderate
or severe)
5. Overall disease status
6. Patient evaluation of effectiveness.
7. Time to relapse
Notes The trial did not report sponsorship, but the Schering Corporation employed the cor-
responding author
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 4.3%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Katz 1991b
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: identical tubes labelled by computer-generated code
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 110
Treatment duration: 2 wks
LF: 2 (1.8%)
BC: inadequately reported
Age: 51.7 (range = 19 to 84)
Gender (per cent men): 80.6%
Severity: Total Severity Score (0 to 12) (median) = 8
Duration of disease (years): 21 (range 1 to 57)
Duration of exacerbation (years): 15.4 (range < 1 to 57)
INCLUSION CRITERIA
• Comparable bilateral lesions of moderate or greater severity of plaque psoriasis
• Adult
• At least 2 signs or symptoms of at least moderate severity
• Lesions ≥10 cm²
EXCLUSION CRITERIA
• Pustular or erythodermic psoriasis
• Recent topical or systemic medication
• Women at risk of pregnancy
Interventions • Halobetasol propionate cream 0.05% BD (H)
• Placebo (vehicle) (P)
Outcomes 1. Severity (0 to 3) (erythema; plaque elevation; scaling pruritis)
2. Total Severity Score (0 to 12)
3. Patient Global Assessments of effectiveness and overall rating (5-pt: poor to
excellent)
Notes The trial was supported by an educational grant from Westwood-Squibb Pharmaceuti-
cals, a Bristol-Myers Squibb company
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Katz 1991b (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 1.8%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk The trial did not report this.
Kaufmann 2002 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 1603
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: yes
Age: 48.4 (range = 17 to 90)
Gender (per cent men): 60.5%
Severity: PASI mean = 10.0 (range = 1.2 to 49.5)
Duration: 19.2 (range = 0 to 75)
INCLUSION CRITERIA
• People aged 18 and over with chronic plaque psoriasis
• BSA at least 10%
EXCLUSION CRITERIA
• Unstable psoriasis in treatment areas
• Other skin diseases that could confound treatment assessments
• Concomitant antipsoriatic therapy
• Hypercalcaemia
• Application of study corticosteroid to untargeted lesion
• Pregnancy
• Lactation
Interventions • Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination
ointment OD (D)
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Kaufmann 2002 (H) (Continued)
• Calcipotriol 50 mcg/g, in combination vehicle ointment OD (C)
• Betamethasone dipropionate 0.5 mg/g, in combination vehicle ointment OD (B)
• Placebo (combination vehicle) ointment OD (P)
Outcomes 1. PASI, modified (change score)
2. Investigator’s Global Assessment of Disease Severity (6-pt: disease absent to very
severe)
3. Patient’s global assessment of disease severity (6-pt: worse to cleared)
Notes Leo Pharmaceuticals sponsored the trial.
Compliance rates were reported for each regimen.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Kaufmann 2002 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 1603
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: yes
193Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kaufmann 2002 (P) (Continued)
Age: 48.4 (range = 17 to 90)
Gender (per cent men): 60.5%
Severity: PASI mean = 10.0 (range = 1.2 to 49.5)
Duration: 19.2 (range = 0 to 75)
INCLUSION CRITERIA
• People aged 18 and over with chronic plaque psoriasis
• BSA at least 10%
EXCLUSION CRITERIA
• Unstable psoriasis in treatment areas
• Other skin diseases that could confound treatment assessments
• Concomitant antipsoriatic therapy
• Hypercalcaemia
• Application of study corticosteroid to untargeted lesion
• Pregnancy
• Lactation
Interventions • Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination
ointment, OD (D)
• Calcipotriol 50 mcg/g, in combination vehicle ointment OD (C)
• Betamethasone dipropionate 0.5 mg/g, in combination vehicle ointment OD (B)
• Placebo (combination vehicle) ointment OD (P)
Outcomes 1. PASI, modified (change score)
2. Investigator’s Global Assessment of Disease Severity (6-pt: disease absent to very
severe)
3. Patient’s global assessment of disease severity (6-pt: worse to cleared)
Notes Leo Pharmaceuticals sponsored the trial.
Compliance were rates reported for each regimen.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
194Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kim 1994
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (unclear who was blinded)
WITHDRAWAL/DROPOUT
Not described
Participants N: 10
Treatment duration: 8 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 32.1 (range 20 to 52)
Gender (per cent men): 60%
Severity: PASI = 10.49 (1.60SD)
Duration: 6.7 years (range 0.2 to 15)
INCLUSION CRITERIA
• Psoriasis
EXCLUSION CRITERIA
• Not identifiable
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Desoxymethasone ointment 2.5 mg/g BD (D)
Outcomes 1. PASI
2. Erythema, infiltration, desquamation (0 to 9)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (unclear who
was blinded).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were reported.
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Kim 1994 (Continued)
Baseline comparability demonstrated Low risk -
Kiss 1996
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 239
Treatment duration: 8 wks
LF: 29 (12.1%)
BC: not reported
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Moderate scalp psoriasis
• Adult
• Overall disease severity ≥ 4
EXCLUSION CRITERIA
• None reported
Interventions • Calcipotriene solution 0.0025% and 0.005% BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (scaling; erythema; plaque elevation; pruritis)
2. Overall severity (9-pt: none to very severe)
3. Investigator Global Assessment (4-pt: worsened to cleared)
Notes Bristol Myers Squibb Pharmaceuticals sponsored the trial.
Carder 1996 reports finding for subgroup (N = 29).
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Kiss 1996 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 12.1%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Klaber 1994
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation:
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 474
Treatment duration: 4 wks
LF: assessment = 6 (1.3%)
TSS: 29 (6.1%)
BC: yes
Age: 44.1 (range = 18 to 90)
Gender (per cent men): 51.5%
Severity: TSS (0 to 12) = 6.5 (range = 2 to 12)
Duration of scalp psoriasis (yrs): 13.1 (range = 0.1 to 67.0)
INCLUSION CRITERIA
• Adults
• Stable, mild-to-moderate scalp psoriasis
• History of psoriasis on body
EXCLUSION CRITERIA
• More extensive, severe, or infected psoriasis
• Recent systemic antipsoriatic treatment or UV
• Concurrent vitamin D, calcium, or other relevant medication
• Significant hepatic or renal disease
• Hypercalcaemia
• Risk of pregnancy
• Pregnancy
• Lactation
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Klaber 1994 (Continued)
Interventions • Calcipotriol solution 50 mcg/ml BD (C)
• Betamethasone 17-valerate solution 1 mg/ml BD (B)
Outcomes 1. Investigator Global Assessment (5-pt: worse to cleared)
2. Patient Global Assessment (5-pt: worse to cleared)
3. Total Sign Score (erythema, thickness, scaliness) (0 to 12)
4. Assessment of extent of scalp psoriasis
5. Assessment of acceptability
Notes Leo Pharmaceutical Products sponsored the trial.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.3%
Baseline assessments Low risk reported
Baseline comparability demonstrated Low risk -
Klaber 2000b
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 475
Treatment duration: 8 wks; FU: 24 wks (N = 166)
LF: 52 (10.9%)
BC: yes
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Klaber 2000b (Continued)
Age: 45.3
Gender (per cent men): 52.0%
Severity: Total Severity Score (0 to 12) = 5.1
INCLUSION CRITERIA
• Mild or moderate scalp psoriasis
EXCLUSION CRITERIA
• Other forms of psoriasis
• Topical antipsoriatic treatment within previous 2 wks
• Systemic antipsoriatic treatment or UV therapy within previous 4 wks
• Concomitant vitamins, calcium, or other medications that could affect the course
of psoriasis
• Known hypersensitivity to study medications
• Pregnancy
• Inadequate contraception
• Lactation
• Hypercalaemia
• Significant renal or hepatic disease
Interventions • Calcipotriol solution 50 mcg/g (Dovonex®) BD (C)
• Coal tar 1%, coconut oil 1%, salicylic acid 0.5%, shampoo (Capasal ®) OD (T)
Outcomes 1. IAGI (6-pt: worse to cleared)
2. TSS (0 to 12)
3. Patients global assessment of disease severity (VAS)
Notes Leo Pharmaceuticals sponsored the trial.
All participants who achieved at least a slight improvement in scalp psoriasis then received
16 weeks of treatment with calcipotriol BD.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.9%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Koo 2006
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated (1:1:2)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 86
Treatment duration: 2 wks; FU: 2 wks
LF: 0 (0%)
BC: not demonstrated
Age: NR
Gender (per cent men): NR
Severity: NR
INCLUSION CRITERIA
• People aged > = 18 with plaque psoriasis
• Good general health
• Target lesions on trunk and extremities with severity score > = 2 for each sign
(erythema, induration, scaling; 0 to 4)
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Use of investigational drug within previous 30 dys
• Systemic or phototherapy within previous 30 dys
• Use of topical or intralesional therapies (other than emollients) within previous 2
wks
• Guttate, erythrodermic, pustular psoriasis
• BSA > 20% (excluding face/scalp)
• Known hypersensitivity to study medications
• Concomitant topical/systemic medication that might affect target lesions
Concomitant phototherapy
Interventions Part 1
• Calcipotriene 0.005% ointment BD (C)
• Clobetasol propionate foam 0.05% BD (CP)
• Calcipotriene 0.005% ointment plus clobetasol propionate foam 0.05% BD (CC)
Part 2
• Follow-up maintenance study based on responders from combination group (CC)
Outcomes 1. Total Severity Score, based on Psoriasis Grading Scale (erythema, induration,
scaling, each 0 to 4) (TSS; 0 to 12). Scores adjusted for baseline differences. TSS
reported separately for trunk and extremity lesions
2. Remission: per cent reduction in TSS > = 50%, IGA reduction of 3 points, or
PGA reduction of 3 points
3. Investigator Global Severity Assessment (IGA); 7-pt: 0 (clear) to 6 (severe)
200Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Koo 2006 (Continued)
4. Subject Global Severity Assessment (PGA); 7-pt: 0 (clear) to 6 (severe)
5. Adverse events
6. Skin atrophy
7. Safety
Notes Connetics Corporation, Palo Alto, California, US, sponsored the trial
We sought data, but we received no response.
There was SD imputation (IGA/PGA).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was not demonstrated.
Kragballe 1988b
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 30
Treatment duration: 6 wks
LF: 3 (10%)
BC: yes
Age: 39 (range = 18 to 65)
Gender (per cent men): 30.0%
Severity: TSS (0 to 9) = 6.9; per cent BSA = 18.7% (range = 12% to 50%)
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Kragballe 1988b (Continued)
Duration (yrs): 15.3 (range = 1 to 35)
INCLUSION CRITERIA
• Stable symmetrically distributed moderate
• Chronic plaque-type psoriasis
• Outpatients
• Adult
• Women above child bearing age or using adequate contraception
EXCLUSION CRITERIA
• Recent topical, systemic, intralesional, or UV radiation therapy (excluding bland
emollients)
• Non-normal serum levels of calcium and creatinine
• Taking calcium tablets
Interventions • Calcipotriol cream 10 mcg/g, 33 mcg/g, or 100 mcg/g BD C (10); C (33); C
(100)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; thickness; scaling)
2. TSS (0 to 9)
3. Investigator Global Assessment (5-pt: worse to clear)
4. Patient Global Assessment (5-pt: worse to clear)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Kragballe 1991a
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 345
Treatment duration: 6 wks
LF: 3 (0.9%)
BC: yes
Age: 45.2 (range = 18 to 90)
Gender (per cent men): 58.8%
Severity: PASI = 8.35 (range = 0.60 to 48.5)
Duration (yrs): 19.5 (range = 0.5 to 76)
INCLUSION CRITERIA
• Adult
• Symmetrical chronic plaque psoriasis
• Inpatients and outpatients
EXCLUSION CRITERIA
• Unstable psoriasis
• Recent systemic or UV therapy
• Hypercalcaemia
• Impaired renal/hepatic function
• High dose calcium/Vitamin D intake
• Unresponsive to corticosteroids
• Concomitant medication
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Betamethasone valerate ointment 0.1% BD (B)
Outcomes 1. PASI
2. Total Sign Score (erythema, thickness, scaliness) (0 to 12)
3. Patient assessment of response
Notes Leo Pharmaceuticals sponsored the trial
Trial participants were inpatients and outpatients.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Kragballe 1991a (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.9%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Kragballe 1998b
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: not stated
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 699
Treatment duration: 8 wks; FU: 8 wks
LF: 8 (1.1%)
BC: psoriasis comparable, demographics unclear
Age: not stated
Gender (per cent men): not stated
Severity: not stated
INCLUSION CRITERIA
• Adult
• Stable chronic plaque psoriasis on trunk and limbs
EXCLUSION CRITERIA
• Pregnancy
• Risk of pregnancy
• Lactation
• Recent systemic or UV therapy
• Concomitant medication
• Hypercalcaemia or renal disease
• Planned exposure to sun
Interventions • Calcipotriol cream 50 mcg/g BD (C2)
• Calcipotriol cream 50 mcg/g OM, plus clobetasone17-butyrate cream,0.5 mg/g
ON (CL)
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Kragballe 1998b (Continued)
• Calcipotriol cream 50 mcg/g OM, plus betamethasone 17-valerate cream 1 mg/g
ON (CB)
• Calcipotriol cream 50 mcg/g OM, plus vehicle ON (C1)
Outcomes 1. PASI
2. Investigator overall assessment of response (6-pt: worse to clearance)
3. Patient overall assessment of response (6-pt: worse to clearance)
Notes Leo Pharmaceuticals sponsored the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study was double-blind (participant/
assessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.1%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Kragballe 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule, using cen-
tralised telephone voice response system
Concealment: adequate
BLINDING
Double-blind (participant/investigator) (Groups A and B)
Single-blind (investigator) (Group C)
WITHDRAWAL/DROPOUT
Described
Participants N: 972
Treatment duration: 8 wk; FU: 12 wks
LF: 99 (10.2%)
BC: yes
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Kragballe 2004 (Continued)
Age: 47.7 (range = 18 to 97)
Gender (per cent men): 63.8%
Severity: PASI = 10.5 (range = 2 to 49); per cent with moderate disease = 64.3%
Duration (yrs): 18.5 (range = 0 to 70)
INCLUSION CRITERIA
• Aged 18 and over
• Chronic plaque psoriasis amenable to topical treatment
• BSA ≥ 10% of at least 1 body region (arms, trunk, legs)
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Unstable psoriasis or other inflammatory skin disease
• Concurrent systemic or UV therapy
• Concurrent topical therapy for trunk or limbs
• Abnormal calcium homeostasis
Interventions • TCP OD for 8 wks then calcipotriol ointment 50 mcg/g OD for 4 wks (A)
• TCP OD for 4 wks then calcipotriol ointment 50 mcg/g OD (weekdays) and
TCP OD (weekends) for 8 wks (B)
• Calcipotriol ointment 50 mcg/g BD for 12 wks (C)
• TCP: calcipotriol ointment 50 mcg/g, plus betamethasone dipropionate 0.5 mg/g
ointment
Outcomes 1. PASI
2. Investigator’s global assessment of severity (PGA) (6-pt: absence of disease to very
severe disease)
3. Self-reported compliance with trial medication
Notes Leo Pharmaceuticals sponsored the trial.
Request data: none supplied
Reversible skin atrophy: A: 1/322; B: 0/322; C: 0/327
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A centralised telephone voice response sys-
tem was used for the participant assign-
ment, and this removed the opportunity for
investigator bias during randomisation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Groups A and B were double-blind (par-
ticipant/investigator); group C was single-
blind (investigator)
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 10.2%
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Kragballe 2004 (Continued)
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Kragballe 2006
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule (1:1:1)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 634
Treatment duration: 52 wks; FU: 52 wks
LF: 8 (1.3%)
BC: yes
Age: 48.7 (14.2SD)
Gender (per cent men): 61.0%
Ethnicity (per cent white): 97.3%
Severity: per cent IGA moderate = 69.1%; per cent IGA severe = 27.9%; per cent IGA
very severe = 3.0%
Duration (yrs): mean = 19.7; median = 17.0; range = 1 to 65
Use of topical corticosteroids during last decade (mths): 33.8
INCLUSION CRITERIA
• Outpatients aged > = 18 with plaque psoriasis of trunk and limbs
• IGA at least moderate.
EXCLUSION CRITERIA
• Erythrodermic, exfoliative, and pustular psoriasis
• Skin infection, use of systemic or topical antipsoriatic therapy
• Use of PUVA or UVB
• BSA > = 30% (and requiring treatment)
• Calcium metabolic disorder
• Pregnancy
• Lactation
Interventions 1. Calcipotriol ointment 50 mcg/g plus betamethasone dipropionate ointment 0.5
mg/g OD (C-B)
2. Alternating every 4 weeks: calcipotriol ointment 50 mcg/g plus betamethasone
dipropionate ointment 0.5 mg/g OD (4 wks) then calcipotriol 50 mcg/g (4 wks) (A)
3. Calcipotriol ointment 50 mcg/g plus betamethasone dipropionate ointment 0.5
mg/g, OD (4 wks) then calcipotriol ointment 50 mcg/g (48 wks) (C)
< = 100 g/wk
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Kragballe 2006 (Continued)
Outcomes 1. Investigator’s Global Assessment (IGA): 6-pt (absent, very mild, mild, moderate,
severe, very severe)
2. Treatment success: IGA absent, very mild, or mild
3. Independent assessment of adverse events by non-investigator clinicians:
adjudicated corticosteroid reactions
4. Patient Global Assessment (PGA): 3-pt (satisfactory, not satisfactory, not
applicable (not used))
5. Compliance (medication usage)
6. HPA assessed in subgroup of 19 participants
Notes Leo Pharma A/S sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation
schedule was used (1:1:1)
Loss to follow up Low risk 1.3%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Unclear risk The trial only reported mean values (no
measure of spread). They described groups
as “well balanced”
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Kragballe 2009
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule (1:2)
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 312
Treatment duration: 8 wks; FU: 16 wks
LF: 2 (0.6%)
BC: yes
Age: 51.0 (15.4SD); range = 18 to 91
Gender (per cent men): 43.0%
Ethnicity (per cent white): 99.0%
Severity: IGA moderate = 56.7%; IGA severe = 35.9%; IGA very severe = 7.4%; TSS (0
to 12) = 7.3 (1.7SD)
Duration (yrs): 18.7 (14.6SD); range = 0 to 70
INCLUSION CRITERIA
• People with moderately severe scalp psoriasis amenable to treatment with < = 100
g medication/wk (combined product) or 60 mL solution/wk (calcipotriol)
• Psoriasis of trunk/limbs
• Scalp involvement > = 10%
• Clinical signs > = moderate for > = 1 sign and > = slight for remaining signs
• IGA > = moderate
EXCLUSION CRITERIA
• PUVA or grenz ray therapy within previous 4 wks
• Topical scalp treatments or UVB therapy or very potent (WHO group IV)
corticosteroids on body within previous 2 wks
• Biologicals within previous 6 mths
• Systemic therapies within previous 4 wks
• Current diagnosis of unstable forms of psoriasis or other skin diseases
confounding psoriasis assessment
• Skin infections
• Atrophy of the scalp
• Calcium homeostasis abnormality
• Severe renal or hepatic disorder
• Concomitant use of medications that could affect scalp psoriasis
• Pregnancy
• Lactation
Interventions • Calcipotriol solution 50 mcg/g BD (C)
• Calcipotriol gel 50 mcg/g plus betamethasone dipropionate “scalp formulation”
(gel) 0.5 mg/g OD (C-B)
There was no concomitant topical treatment, emollient, or medicated shampoo or con-
ditioner
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Kragballe 2009 (Continued)
Outcomes 1. Investigator’s Global Assessment (IGA): 6-pt (absent (0), very mild, mild,
moderate, severe, very severe (5))
2. Treatment success: IGA clear or minimal
3. Total Sign Score (TSS): 0 to 12
4. Patient Global Assessment of Disease Severity (PGA). 5-pt scale (clear, very mild,
mild, moderate, severe)
5. Patient assessment of itching (4-pt: none, mild, moderate, severe)
6. Compliance: self-report; use of study medication
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation
schedule was used (1:2).
Loss to follow up Low risk 0.6%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Kreuter 2006 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation lists
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 80
Treatment duration: 4 wks; FU: 10 wks
LF: 2 (2.5%)
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Kreuter 2006 (H) (Continued)
BC: yes
Age: 52.4 (14.3SD); range = 28 to 87
Gender (per cent men): 61.3%
Ethnicity: NR
Severity: mPASI = 21.2 (13.4SD); range = 3 to 54; VAS (0 to 10) = 4.8 (2.7SD); range
= 1 to 10
INCLUSION CRITERIA
• People aged > = 18 with inverse psoriasis that had been present for at least 6 mths
• Good general health
EXCLUSION CRITERIA
• Systemic or phototherapies within previous 4 wks
• Topical therapies within previous 2 wks
• Acute guttate or pustular psoriasis
• Pregnancy
• Lactation
• Severe concurrent infectious diseases
• Diseases associated with immunesuppression or malignancy
• Drug dependency
• Mental dysfunction or other factors limiting compliance
Interventions • Calcipotriol 0.005% ointment OD (C)
• Betamethasone valerate 0.1% OD (B)
• Pimecrolimus 1% cream OD (PM)
• Placebo (vehicle for pimecrolimus) OD (P)
No concomitant therapies were permitted (including emollients)
Outcomes 1. mPASI (0 to 72): assessment confined to body area affected. Each sign scored 0 to
4 and then multiplied by area affects (0 (0%) to 6 (90% to 100%))
2. VAS (itching): 0 = absence to 10 = maximum
3. Adverse events
Notes Novartis Pharma GmbH sponsored the trial.
Atrophy was not reported.
We sought unpublished data, but it was reported to be unavailable
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Computer-generated randomisation lists
were used.
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Kreuter 2006 (H) (Continued)
Loss to follow up Low risk 2.5%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Kreuter 2006 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation lists
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 80
Treatment duration: 4 wks; FU: 10 wks
LF: 2 (2.5%)
BC: yes
Age: 52.4 (14.3SD); range = 28 to 87
Gender (per cent men): 61.3%
Ethnicity: NR
Severity: mPASI = 21.2 (13.4SD), range = 3 to 54; VAS (0 to 10) = 4.8 (2.7SD), range
= 1 to 10
INCLUSION CRITERIA
• People aged > = 18 with inverse psoriasis that had been present for at least 6 mths
• Good general health
EXCLUSION CRITERIA
• Systemic or phototherapies within previous 4 wks
• Topical therapies within previous 2 wks
• Acute guttate or pustular psoriasis
• Pregnancy
• Lactation
• Severe concurrent infectious diseases
• Diseases associated with immunesuppression or malignancy
• Drug dependency
• Mental dysfunction or other factors limiting compliance
Interventions • Calcipotriol 0.005% ointment OD (C)
• Betamethasone valerate 0.1% OD (B)
• Pimecrolimus 1% cream OD (PM)
• Placebo (vehicle for pimecrolimus) OD (P)
No concomitant therapies were permitted (including emollients)
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Kreuter 2006 (P) (Continued)
Outcomes 1. mPASI (0 to 72): assessment confined to body area affected. Each sign scored 0 to
4 and then multiplied by area affects (0 (0%) to 6 (90% to 100%))
2. VAS (itching): 0 = absence to 10 = maximum
3. Adverse events
Notes Novartis Pharma GmbH sponsored the trial.
Atrophy was not reported.
We sought unpublished data, but it was reported to be unavailable
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Computer-generated randomisation lists
were used.
Loss to follow up Low risk 2.5%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Krueger 1998
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 45
Treatment duration: 6 wks
LF: 0 (0%)
BC: reported to be similar
Age: 50 (range = 23 to 83)
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Krueger 1998 (Continued)
Gender (per cent men): 84%
Severity: not reported
INCLUSION CRITERIA
• Mild to moderate bilateral psoriatic plaques
• Adult
• Total Severity Score less than or equal to 6.
EXCLUSION CRITERIA
• Pregnant
• Nursing or of likely to conceive
• Recent use of certain topical agents
• Recent systemic retinoids, UV phototherapy, or systemic antipsoriasis drugs
Interventions • Tazarotene gel 0.01% or 0.05% BD (T)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; plaque elevation; scaling)
2. TSS (0 to 12)
3. Investigator Global Assessment (6-pt: no change/worse to completely clear)
Notes Allergan, Inc, California, sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk These were partially done.
Baseline comparability demonstrated Unclear risk These were stated to be similar; compara-
bility was not demonstrated
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Köse 1997
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 43
Treatment duration: 10 days FU: 20 days
LF: 0 (0%)
BC: yes
Age: not stated
Gender (per cent men): not stated
Severity: not stated
INCLUSION CRITERIA
• Psoriasis of the scalp
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment 50 mcg/g occluded ON (CO)
• Clobetasol 17-propionate solution BD (CP)
Outcomes 1. TSS (0 to 9)
Notes The trial did not report sponsorship.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk The trial did not report these.
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Köse 1997 (Continued)
Baseline comparability demonstrated Unclear risk The trial reported baseline comparabil-
ity (demographic/clinical), but it was not
demonstrated
Lahfa 2003
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 125
Treatment duration: 12 wks; FU: 12 wks
LF: 5 (4.0%)
BC: yes
Age: 49.5 (15.1SD)
Gender (per cent men): 55.2%
Ethnicity (per cent white/Caucasoid): 97.6%
Severity: PASI = 6.8; per cent BSA = 13.2 (7.4SD)
Duration (yrs): 16.7
INCLUSION CRITERIA
• People with mild to moderate plaque psoriasis
• BSA < 30%
EXCLUSION CRITERIA
• Skin conditions interfering with assessment
• Co-morbidities that put participant at risk
• Severe psoriasis, including erythrodermic
• Pregnancy or risk thereof
• Lactation
• Topical/UVB therapy within previous 2 wks
• PUVA within previous 4 wks
• Systemic therapy, beta blockers, or lithium within previous 8 wks
Interventions • Calcipotriol 50 mcg/g ointment ON, plus clobetasol propionate 0.05% cream
OM (2 to 4 wks), then calcipotriol ointment BD (to wk 12) (C1)
• Calcitriol 3 mcg/g ointment ON, plus clobetasol propionate 0.05% cream OM
(2 to 4 wks), then calcitriol ointment BD (to wk 12) (C2)
In the initial phase, the participant applied dual therapy until achieving clearance or
marked improvement or until 4wks elapsed, then switched tomonotherapymaintenance
phase
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Lahfa 2003 (Continued)
Outcomes 1. PASI, based on scores from 3 lesions, 1 each on trunk, and upper and lower limbs
2. Investigator’s Assessment of Global Improvement (IAGI): 7-pt (worse to clear,
rescaled 0 to 6)
3. Clinical success: IAGI > = marked improved
4. Relapse (maintenance phase): IAGI < = moderate improvement
5. Patient Assessment of Global Improvement: 7-pt (worse to clear)
6. Adverse events: cutaneous safety including signs and soreness (all scored 0 to 3);
investigator assessment of global safety (poor, good, excellent); patient self report
Notes Galderma Laboratories sponsored the trial.
We sought unpublished data, but it was reported to be unavailable
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Landi 1993
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 40
Treatment duration: 6 wks; FU: 10 wks
LF: 0 (0%)
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Landi 1993 (Continued)
BC: psoriasis comparable, demographics unclear
Age: range = 17 to 84
Gender (per cent men): not stated
Severity: PASI (mean) = 11.6 (range = 3.0 to 35.1)
INCLUSION CRITERIA
• Adult
• Mild and moderate psoriasis
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Clobetasol propionate 0.05% ointment BD (CP)
Outcomes 1. PASI
Notes Leo Pharmaceuticals sponsored the trial.
Landi 1993 reported the findings of a single centre, 1 of 3 centres reported in Landi
1993 (N = 120).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Lane 1983
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 157
Treatment duration: 3 wks; FU: 3 wks
LF: 18 (11.5%)
BC: yes
Age: 39.6
Gender (per cent men): 52.5%
Severity: TSS (0 to 20) = 10.6
INCLUSION CRITERIA
• History and physical finding compatible with psoriasis including scaling
erythema, epidermal thickening, crusting, or both
• All ages > 1 year
• Stable disease.
EXCLUSION CRITERIA
• Recent topical or systemic corticosteroid treatment
• Oral antihistamine
• Antipruritic therapy, UV, or X-ray therapy or any medication affecting the study
• Pregnant
Interventions • Betamethasone dipropionate ointment 0.05% OD (B)
• Diflorasone diacetate ointment 0.05% OD (D)
• Placebo (vehicle) (P)
Outcomes 1. Severity (scaling; erythema; pruritis; thickening; crusting; overall condition)
2. Total Severity Score (0 to 20)
Notes The trial did not report sponsorship.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Lane 1983 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 11.5%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Langley 2011 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated (2:2:1)
Concealment: adequate: treatments dispensed by non-study staff
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 458
Treatment duration: 8 wks; FU: 16 wks
LF: 0 (0%)
BC: yes
Age: 51.6 (14SD)
Gender (per cent men): 62.2%
Ethnicity (per cent white): 93.9%
Severity: mPASI = 9.39, range = 2.4 to 59.4; IGA moderate = 68.3%; IGA severe = 29.
5%; IGA very severe = 2.2%; per cent BSA = 9.3 (8.2SD)
Duration (yrs): 19.8 (13.3SD)
INCLUSION CRITERIA
• Participants with moderately severe plaque psoriasis involving trunk, limbs, or
both
• BSA > = 10% on arms, trunk, limbs, or a mixture of the aforementioned
• Amendable to maximum weekly dose of 100 g of gel or 70 g of ointment
EXCLUSION CRITERIA
• Systemic biological therapy within previous 3 mths
• Other systemic treatment within previous 4 wks
• Concurrent oral vitamin D > 500 IU/day
• UVA or grenz ray therapy within previous 4 wks
• UVB within previous 2 wks
• Pregnancy
• Lactation
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Langley 2011 (H) (Continued)
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Calcipotriol gel 50 mcg/g plus betamethasone dipropionate gel 0.5 mg/g OD (C-
B)
• Placebo (gel vehicle) OD (P)
Participants achieving clear IGA stopped treatment and restarted if psoriasis reappeared
There was follow up of responders only (IGA clear or almost clear)
Outcomes 1. Investigator’s Global Assessment of Disease Severity: 6-pt (clear to very severe)
2. Treatment responder (controlled disease): IGA clear or almost clear at wk 8
3. mPASI (0 to 64.8)
4. PASI 50, PASI 75
5. Patient Global Assessment (PGA) of disease severity: 5-pt (clear to severe)
6. Adverse events
7. Relapse (treatment responders only): > = 50% reduction in PASI improvement
achieved (wk0 to wk8)
8. Time to relapse
9. Rebound (treatment responders only): > 125% reduction in PASI at wk 0
10. Compliance (wk 2 to wk 6): self-report and medication usage
11. Adverse events
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
Participants could not be completely blinded to treatment allocation because of differ-
ences in formulation and packaging (bottles for gel vs. tubes for ointments)
Atrophy was not assessed.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A designated third person performed allo-
cation of the investigational products at all
18 centres
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator);
it was not possible to blind participants to
treatments because of differences in vehicle
formulations
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Langley 2011 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated (2:2:1)
Concealment: adequate: treatments dispensed by non-study staff.
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 458
Treatment duration: 8 wks; FU: 16 wks
LF: 0 (0%)
BC: yes
Age: 51.6 (14SD)
Gender (per cent men): 62.2%
Ethnicity (per cent white): 93.9%
Severity: mPASI = 9.39, range = 2.4 to 59.4; IGA moderate = 68.3%; IGA severe = 29.
5%; IGA very severe = 2.2%; per cent BSA = 9.3 (8.2SD)
Duration (yrs): 19.8 (13.3SD)
INCLUSION CRITERIA
• Participants with moderately severe plaque psoriasis involving trunk, limbs, or
both
• BSA > = 10% on arms, trunk, limbs, or a mixture of the aforementioned
• Amendable to maximum weekly dose of 100 g of gel or 70 g of ointment
EXCLUSION CRITERIA
• Systemic biological therapy within previous 3 mths
• Other systemic treatment within previous 4 wks
• Concurrent oral vitamin D > 500 IU/day
• UVA or grenz ray therapy within previous 4 wks
• UVB within previous 2 wks
• Pregnancy
• Lactation
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Calcipotriol gel 50 mcg/g plus betamethasone dipropionate gel 0.5 mg/g OD (C-
B)
• Placebo (gel vehicle) OD (P)
Participants achieving clear IGA stopped treatment and restarted if psoriasis reappeared
There was follow up of responders only (IGA clear or almost clear)
Outcomes 1. Investigator’s Global Assessment of Disease Severity: 6-pt (clear to very severe)
2. Treatment responder (controlled disease): IGA clear or almost clear at wk 8
3. mPASI (0 to 64.8)
4. PASI 50, PASI 75
5. Patient Global Assessment (PGA) of disease severity: 5-pt (clear to severe)
6. Adverse events
7. Relapse (treatment responders only): > = 50% reduction in PASI improvement
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Langley 2011 (P) (Continued)
achieved (wk0 to wk8)
8. Time to relapse
9. Rebound (treatment responders only): > 125% reduction in PASI at wk 0
10. Compliance (wk 2 to wk 6): self-report and medication usage
11. Adverse events
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
Participants could not be completely blinded to treatment allocation because of differ-
ences in formulation and packaging (bottles for gel vs. tubes for ointments)
Atrophy was not assessed.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A designated third person performed allo-
cation of the investigational products at all
18 centres
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator);
it was not possible to blind participants to
treatments because of differences in vehicle
formulations
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Langner 1992
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
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Langner 1992 (Continued)
Participants N: 29
Treatment duration: 6 wks; FU: 6 wks
LF: 0 (0%)
BC: yes
Age: mean: 40.5 (range = 16-77)
Gender (per cent men): 69.0%
Severity: not reported
INCLUSION CRITERIA
• Severe chronic psoriasis
• Symmetrical lesions
• Adult
• Outpatients
EXCLUSION CRITERIA
• Pregnancy or inadequate contraception
Interventions • Calcitriol ointment 3 mcg/g BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; pustules, desquamation, encrustation, vesiculation and
pruritis)
2. Investigator Global Assessment (6-pt: worse to clear)
Notes The trial did not report sponsorship.
All participants received 2 weeks’ pre-treatment with vehicle BD
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk This was demonstrated.
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Langner 1993
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 32
Treatment duration: 6 wks; FU: 6 wks
LF: 2 (6.3%)
BC: yes
Age: mean: 42.4 (range = 16 to 77)
Gender (per cent men): 62.5%
Severity: global severity score (0 to 4) = 3.5
INCLUSION CRITERIA
• Bilateral
• Symmetrical
• Severe chronic plaque psoriasis
• Outpatients.
EXCLUSION CRITERIA
• Pregnancy or inadequate contraception
• Use of calcium
• Vitamin D or analogues
• Calcium-containing antacids
• Digitalis
• Thiazide diuretics or glucocorticosteroids
Interventions • Calcitriol ointment 15 mcg/g BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; scaling; induration; pruritis)
2. PASI
3. Investigator Global Assessment (6-pt: worse to clear)
Notes The trial did not report sponsorship.
All participants received 2 weeks’ pre-treatment with vehicle BD
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Langner 1993 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 6.3%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Langner 2001 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 44
Treatment duration: 6 wks; FU: 6 wks (14 wks for responders)
LF: 4 (9.1%)
BC: not reported
Age: not reported
Gender (per cent men): 54.5%
Severity: not reported
INCLUSION CRITERIA
• Adults with chronic plaque psoriasis
• BSA = 20%
EXCLUSION CRITERIA
• Pregnancy
• Inadequate contraception
Interventions • Calcitriol ointment 3 mcg/g BD (C)
• Betamethasone valerate ointment 0.1% BD (B)
Outcomes 1. IAGI (5-pt: worse to clearance)
Notes The trial did not report sponsorship.
All participants received 2 weeks’ pre-treatment with vehicle BD
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Langner 2001 (H) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 9.1%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Langner 2001 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 44
Treatment duration: 6 wks; FU: 6 wks (14 wks for responders)
LF: 4 (9.1%)
BC: not reported
Age: not reported
Gender (per cent men): 54.5%
Severity: not reported
INCLUSION CRITERIA
• Adults with chronic plaque psoriasis
• BSA = 20%
EXCLUSION CRITERIA
• Pregnancy
• Inadequate contraception
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Langner 2001 (P) (Continued)
Interventions • Calcitriol ointment 3 mcg/g BD (C)
• Placebo ointment BD (P)
Outcomes 1. IAGI (5-pt: worse to clearance)
Notes The trial did not report sponsorship.
All participants received 2 weeks’ pre-treatment with vehicle BD
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 9.1%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Lassus 1991
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: block randomisation
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 50
Treatment duration: 12 wks; FU: 12 wks
LF: 8 (16%)
BC: yes
Age: 42.8 (range = 22 to 50; N = 42)
Gender (per cent men): 45.2% (N = 42)
Severity: TSS (0 to 12) = 7.72
INCLUSION CRITERIA
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Lassus 1991 (Continued)
• Stable psoriasis of at least 1 years’ duration
• Mild to moderate plaque psoriasis
• Nummular, discoid, or guttate psoriasis
• Stable aged 18 to 50
• Localised lesions
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Antipsoriatic therapy within previous 2 wks
• People declining to abstain from alcohol during treatment period
Interventions • Oleum horwathiensis (Psoricur®) OD (O)
• Placebo OD (P)
Outcomes 1. TSS (0 to 12)
2. Severity (scaling, pruritis, erythema, induration)
3. IAGI (5-pt: poor to healed)
Notes The trial did not report sponsorship.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 16.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Lebwohl 2002
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported (but ratio 3:1 used)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 81
Treatment duration: 2 wks; FU: 4 wks
LF: 5 (6.2%)
BC: yes
Age: not reported
Gender (per cent men): not reported
Severity: pruritis (0 to 4) = 2.11
INCLUSION CRITERIA
• Mild to moderate plaque type psoriasis
• Aged at least 18
• TSS (0 to 12) ≥ 3
• Target lesions in at least 1 of 5 anatomical regions
• BSA ≤ 20%
EXCLUSION CRITERIA
• Investigational medication within previous 4 wks
• Topical antipsoriatic treatment within previous 2 wks
• Systemic antipsoriatic treatment within previous 4 wks
• Concurrent UV treatment or sunbathing
• Pregnancy
• Lactation
• Inadequate contraception
• Men wishing to father children during the study
• Concurrent drug or alcohol abuse
Interventions • Clobetasol propionate foam 0.05% BD (maximum of 50 g/wk) (C)
• Placebo foam BD (P)
Outcomes 1. IAGI (7-pt: worse to completely clear)
2. PAGI (7-pt: worse to completely clear)
3. Total Severity Score: erythema, scaling, thickness, pruritis (0 to 4)
4. Adverse events
5. Medicines consumption (compliance)
Notes Connetics Corporation sponsored the trial.
Only non-scalp sites were treated.
Risk of bias
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Lebwohl 2002 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 6.2%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Lebwohl 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 167
Treatment duration: 8 wks; FU: 8 wks
LF: 30 (18%)
BC: yes
Age: 48.0
Gender (per cent men): 58.7%
Severity: Static Severity Score (SSS) (0 to 6) (median) = 3 (range = 1.5 to 5.0); per cent
with concurrent plaque-type lesions = 85%
INCLUSION CRITERIA
• Age limit unclear (stated as ≥ 2 and ≥ 16)
• Chronic plaque psoriasis affecting intertriginous and facial skin
• Disease stable or slowly worsening for ≥ 1 wk
• Target lesion of moderate erythema and TSS (0 to 12) ≥ 4
EXCLUSION CRITERIA
• Systemic therapy or phototherapy within previous 4 wks
• Topical therapy within previous 2 wks
• Inhaled/intranasal corticosteroids within previous 2 wks
• Other topical agents (excluding sunscreen) within previous 1 dy
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Lebwohl 2004 (Continued)
• Recently diagnosed (< 6 mths) or recent exacerbation of inverse psoriasis
• Uncontrolled chronic co-morbidity
• Pregnancy
• Lactation
• Previous use of tacrolimus ointment for facial or intertriginous psoriasis
Interventions • Tacrolimus ointment 0.1% BD
• Placebo ointment BD
Outcomes 1. Inverse psoriasis severity score (Static Severity Score) (SSS) (6-pt: clear to very
severe)
2. IAGI (’PGA’) (7-pt: exacerbation to clear)
3. Signs (0 to 3 each) (erythema, induration, desquamation; overall severity)
4. Patient satisfaction (per cent agreeing with range of statements)
Notes Fujisawa Healthcare Inc sponsored the trial.
Loss to follow up was reported as 11/167.
Non-study body sites received usual topical treatment.
No adequate effectiveness data were reported or available from the sponsor.
This was an inverse psoriasis trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 18.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Lebwohl 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 418
Treatment duration: 8 wks; FU: 8 wks
LF: 0 (0%)
BC: NR separately (see notes)
Age: NR
Gender (per cent men): NR
Severity: GSS (0 to 5) = 2.81 (0.40SD); DSS (0 to 12) (bony areas) = 6.4 (1.24SD);
(non-bony areas) = 6.4 (1.33SD)
INCLUSION CRITERIA
• People aged > = 12 with mild to moderate plaque psoriasis
• BSA < = 35%
EXCLUSION CRITERIA
• Not stated
Interventions • Calcitriol 3 mcg/g ointment BD (C)
• Placebo ointment BD (P)
Outcomes 1. Global Severity Score (GSS) on a 6-pt scale (0 = clear, 1 = almost clear, 2 = mild, 3
= moderate, 4 = severe, 5 = very severe)
2. Dermatological sum score (DSS) (0 to 12): reported separately for bony and non-
bony areas
3. Investigator Assessment of Global Improvement (IAGI) on a 7-pt scale (clear to
worse)
4. Subject Global Assessment (PAGI), 7-pt (clear to worse)
5. Routine clinical and safety laboratory parameters including calcium homeostasis
(> 10% above upper limit of normal range)
Notes Galderma R&D Inc, Princeton, New Jersey, sponsored the trial
The main publication reports only pooled results and baseline statistics from 2 studies
(Lebwohl 2007; Powers 2005).
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Lebwohl 2007 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was not demonstrated.
Lee 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 142
Treatment duration: 6 wks; FU: 14 wks
LF: 11 (7.7%)
BC: yes (clinical only)
Age: NR
Gender (per cent men): NR
Severity: PASI = 3.75 (2.90SD)
INCLUSION CRITERIA
• People with mild to moderate psoriasis
EXCLUSION CRITERIA
• NR
Interventions • Calcitriol ointment BD (C)
• Diflucortolone valerate OM, plus calcitriol ointment ON (C-D)
Outcomes 1. PASI (scale NR)
Notes Sponsor: NR
The trial was set in Korea.
Risk of bias
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Lee 2007 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.7%
Baseline assessments Unclear risk Clinical assessments were reported; demo-
graphics were unclear
Baseline comparability demonstrated Unclear risk Only clinical comparability was demon-
strated.
Lepaw 1978
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: predetermined schedule using identical containers codedwith
participant number
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 29
Treatment duration: 2 wks; FU: 2 wks
LF: 2 (6.9%)
BC: inadequately reported
Age: 14 to 75
Gender (per cent men): 55.2%
Severity: not reported
INCLUSION CRITERIA
• Bilaterally similar psoriatic lesions of the scalp
• Adults or adolescents
EXCLUSION CRITERIA
• Systemic therapy, topical scalp treatments
Interventions • Halcinonide solution 0.1% TDS (H)
• Placebo (vehicle) TDS (P)
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Outcomes 1. Overall therapeutic response
2. Overall comparative response
Notes The trial did not report sponsorship.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 6.9%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Levine 2010 (H)
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation table
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 168
Treatment duration: 12 wks; FU: 12 wks
LF: 4 (2.4%)
BC: stated, not demonstrated
Age: not reported
Gender (per cent men): not reported
Severity: TLPSS = 6.69 (1.38 SD)
INCLUSION CRITERIA
• People aged 18 and over with moderate plaque psoriasis
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• Bilateral plaques or 2 plaques > = 5 cm distant on same side
• 15 x 15 cm>plaque size > 2 x 2 cm
EXCLUSION CRITERIA
• BSA > 15%
• Participants with only scalp, nail, flexural, palmoplantar, or pustular psoriasis
• Participation in trial within previous 3 mths
• Topical antipsoriatic therapy within previous 2 wks
• Systemic antipsoriatic therapy within previous 1 mth
• Use of systemic niacin or multivitamins within previous 2 wks
• Concomitant use of carbamazepine or primidone
• People starting or modifying treatment with betablockers within previous 1 mth
• Significant hematologic, renal, or liver disease
• Relevant psychiatric or medical illness or surgery
• Hemoglobin < 10.0 g/dL, hematocrit < 30%, white blood cell count < 3000/mcg/
L, platelets < 100,000/mcg/L, aspartate aminotransferase or alanine aminotransferase >
3 x upper limit of normal
• Pregnancy
Interventions Participants were randomised to 2 of 7 treatments:
• calcipotriene 0.005% ointment BD (C)
• placebo ointment BD (P)]
• nicotinamide 1.4% BD (NI)
• calcipotriene 0.005% ointment BD + nicotinamide 0.05% BD (NC005)
• calcipotriene 0.005% ointment BD + nicotinamide 0.1% BD (NC010)
• calcipotriene 0.005% ointment BD + nicotinamide 0.7% BD (NC070)
• calcipotriene 0.005% ointment BD + nicotinamide 1.4% BD (NC140)
Outcomes 1. Total Local Psoriasis Severity Score (0 to 12): sum of erythema, plaque elevation,
scaling (each scored 0 to 4)
2. Efficacy end-point: per cent patients ’clear to almost clear’ (TLPSS = 0 to 2):
◦ ’clear’: no elevation above normal skin, no scaling, and no erythema
◦ ’almost clear’: no elevation above normal skin, surface dryness with some
white coloration, and slight to moderate red colouration
Notes Dermipsor Ltd sponsored the trial.
Compliance rates (medicine usage) were reported for each regimen
The trial author supplied unpublished data.
As participants were randomised to 2 of 7 treatments, some comparisons were within-
patient and others between-patient
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The participants, investigators, study site
personnel, sponsor, and laboratories were
unaware of the treatment assignments;
throughout the study, the study investiga-
tor retained a set of code envelopes that
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Levine 2010 (H) (Continued)
were to be opened by the investigator only
if deemed necessary after a serious adverse
event
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation table
was used.
Loss to follow up Low risk 2.4%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk Clinical comparability was stated (not
demonstrated).
Levine 2010 (P)
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation table
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 168
Treatment duration: 12 wks; FU: 12 wks
LF: 4 (2.4%)
BC: stated, not demonstrated
Age: not reported
Gender (per cent men): not reported
Severity: TLPSS = 6.69 (1.38SD)
INCLUSION CRITERIA
• People aged 18 and over with moderate plaque psoriasis
• Bilateral plaques or 2 plaques > = 5 cm distant on same side
• 15 x 15 cm>plaque size > 2 x 2 cm
EXCLUSION CRITERIA
• BSA > 15%
• Participants with only scalp, nail, flexural, palmoplantar, or pustular psoriasis
• Participation in trial within previous 3 mths
• Topical antipsoriatic therapy within previous 2 wks
• Systemic antipsoriatic therapy within previous 1 mth
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• Use of systemic niacin or multivitamins within previous 2 wks
• Concomitant use of carbamazepine or primidone
• People starting or modifying treatment with betablockers within previous 1 mth
• Significant hematologic, renal, or liver disease
• Relevant psychiatric or medical illness or surgery
• Hemoglobin < 10.0 g/dL, hematocrit < 30%, white blood cell count < 3000/mcg/
L, platelets < 100,000/mcg/L, aspartate aminotransferase or alanine aminotransferase >
3 x upper limit of normal
• Pregnancy
Interventions Participants were randomised to 2 of 7 treatments:
• calcipotriene 0.005% ointment BD (C)
• placebo ointment BD (P)]
• nicotinamide 1.4% BD (NI)
• calcipotriene 0.005% ointment BD + nicotinamide 0.05% BD (NC005)
• calcipotriene 0.005% ointment BD + nicotinamide 0.1% BD (NC010)
• calcipotriene 0.005% ointment BD + nicotinamide 0.7% BD (NC070)
• calcipotriene 0.005% ointment BD + nicotinamide 1.4% BD (NC140)
Outcomes 1. Total Local Psoriasis Severity Score (0 to 12): sum of erythema, plaque elevation,
scaling (each scored 0 to 4)
2. Efficacy end-point: per cent patients ’clear to almost clear’ (TLPSS = 0 to 2):
◦ ’clear’: no elevation above normal skin, no scaling, and no erythema
◦ ’almost clear’: no elevation above normal skin, surface dryness with some
white coloration, and slight to moderate red colouration
Notes Dermipsor Ltd sponsored the trial.
Compliance rates (medicine usage) were reported for each regimen
The trial author supplied unpublished data.
As participants were randomised to 2 of 7 treatments, some comparisons were within-
patient and others between-patient
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The participants, investigators, study site
personnel, sponsor, and laboratories were
unaware of the treatment assignments;
throughout the study, the study investiga-
tor retained a set of code envelopes that
were to be opened by the investigator only
if deemed necessary after a serious adverse
event
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Randomisation method reported Low risk A computer-generated randomisation table
was used.
Loss to follow up Low risk 2.4%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk Clinical comparability was stated (not
demonstrated).
Liao 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 50
Treatment duration: 6 wks; FU: 6 wks
LF: 1 (2.0%)
BC: yes
Age: 39.6 (12.8SD); range 21 to 69
Gender (per cent men): 73.5%
Target lesion: face (89.8%); genitofemoral (10.2%)
Severity: TAS (0 to 12) = 6.2 (3.32SD)
INCLUSION CRITERIA
• People aged 18 to 70 with chronic plaque psoriasis affecting facial and
genitofemoral areas
EXCLUSION CRITERIA
• Topical therapies within previous 1 wk
• UV therapy or sunbathing within previous 2 wks
• Systemic therapy within previous 4 wks
• Concurrent use of oral calcium or Vitamin D supplements, or lithium, beta-
blockers, or ACE inhibitors
Interventions • Calcitriol 3 mcg/g ointment BD (C)
• Tacrolimus 0.3 mg/g ointment BD (T)
No concomitant topical therapies or emollients were permitted. Dosing frequency could
be reduced or medication discontinued depending on level of irritancy
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Outcomes 1. Target Area Score (TAS): 0 to 12 (erythema, plaque elevation, scaling)
2. Physician Global Assessment of improvement (PGA) on a 7-pt scale (worse to
clear)
3. Safety: erythema (0 to 4), perilesional oedema (0 to 4), stinging/burning (0 to 4),
hot sensation (0 to 4), folliculitis/acne (0 to 1)
Notes Galderma, Taiwan, sponsored the trial.
Individual safety measures were reported, but the total number of participants experi-
encing any adverse event were not reported
The trial author supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 2.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Lin 2007
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 14
Treatment duration: 8 wks; FU: 8 wks
LF: 4 (28.6%)
BC: yes
Age: 35.8 (10.4SD), range = 21 to 54
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Gender (per cent men): 78.6%
Severity: PSI (0 to 12) = 9.9 (1.2SD); PASI = 11.7 (4.8SD), range = 5.5 to 19.2; per
cent BSA = 13.6 (6.1SD), range = 3% to 20%
Duration (yrs): 110.8 (9.4SD); range = 2 to 30
INCLUSION CRITERIA
• Adult people with recalcitrant, bilateral chronic plaque psoriasis affecting 5% to
20% of BSA
• Plaques 3 to 20 cm diameter
• Disease duration > = 2 yrs
• Resistant to > = 1 topical therapy
• No other significant medical problem
EXCLUSION CRITERIA
• Systemic therapy within previous 30 days
• Topical therapy within previous 14 days
• Tests positive for HIV, hepatitis B, or hepatitis C
• Known sensitivity to Chinese herbs
• Pregnancy or risk thereof
• Lactation
• Clinically significant laboratory abnormality
Interventions • Indigo naturalis 1.4% ointment,OD (I)
• Placebo ointment (olive oil, yellow wax, petroleum jelly) OD (P)
Outcomes 1. Clearing per cent area of target lesions affected
2. Psoriasis severity Index (TSS, 0 to 12)
3. PASI (range not stated)
4. Safety (immunohistochemical analysis of skin biopsies and blood tests)
Notes The sponsor was not reported.
Assessments were conducted by 2 blinded investigators.
A 3-month uncontrolled follow-study also conducted.
The trial author supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up High risk 28.6%
Baseline assessments Unclear risk These were reported.
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Baseline comparability demonstrated Unclear risk This was demonstrated.
Lin 2008
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 42
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: Yes
Age: 34.6 (11.SD); range = 18 to 58
Gender (per cent men): 76.2%
Severity: PASI (median) = 14.7; per cent BSA (median) = 18%; TSS (0 to 24) = 18.8
(3.03SD)
Duration (yrs): 10 (median); range = 2 to 41
INCLUSION CRITERIA
• People aged 18 to 75 with mild to moderate bilateral symmetric plaque psoriasis
• Disease duration > = 2 yrs
• Resistant to > = 2 topical therapies
• Good general health (no abnormality in blood, renal, and liver function tests)
EXCLUSION CRITERIA
• BSA > 60%
• Pustular or generalised erythrodermic psoriasis
• Concomitant use of medications that could affect psoriasis
• Systemic therapy within previous 30 days
• UV therapy within previous 21 days
• Topical therapy within previous 2 wks
• Tests positive for HIV, hepatitis B, or hepatitis C
• History of alcohol/drug misuse
• History of hepatitis
• Known sensitivity to Chinese herbs or vehicle ingredients
• Pregnancy or risk thereof
• Lactation
• Trial participation within previous 30 days
Interventions • Indigo naturalis 1.4% ointment OD (I)
• Placebo ointment (olive oil, yellow wax, petroleum jelly) OD (P)
Participants achieving clearance before study end point could stop treatment
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Outcomes 1. Global improvement (IAGI); 6-pt: worse to clearance
2. Signs (erythema, induration, scaling), each scored 0 (none) to 8 (very severe)
3. Total sum score (0 to 24)
4. PASI (range unclear): baseline median used to explore response by group
5. Compliance (medication use)
6. Safety
Notes The trial was supported by a grant: CMRPG33024 from Chang Gung Memorial Hos-
pital
Participants were instructed to wash skin thoroughly before visits; assessments were based
on photographs
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk These were reported.
Baseline comparability demonstrated Unclear risk This was demonstrated.
Lister 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 171
Treatment duration: 8 wks; FU: 16 wks
LF: not reported
BC: psoriasis comparable, demographics unclear
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Age: not stated
Gender (per cent men): not stated
Severity: TSS (scale NR) = 6.24
INCLUSION CRITERIA
• Chronic plaque psoriasis
EXCLUSION CRITERIA
• Unclear
Interventions • Dithranol cream 1 to 3% OD (D)
• Calcipotriol BD (C)
Outcomes 1. Total Sign Score (erythema, scaling, induration) (scale NR)
2. Investigator and Patient Global Assessments (scales NR)
3. Relapse rates
Notes Bioglan Laboratories sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient detail.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: consecutive balanced blocks of 7 (3:3:1)
Concealment: unclear
BLINDING
Single-blind (investigator); as cream and lotion were compared, not possible to blind
patients
WITHDRAWAL/DROPOUT
Described
Participants N: 192
Treatment duration: 4 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 48.65; range = 19 to 79
Gender (per cent men): 65.6%
Ethnicity (per cent white): 82.8%
Severity: DSS (0 to 12) = 7.60 (1.55SD)
INCLUSION CRITERIA
• People aged > = 18 with stable moderate to severe plaque psoriasis
• DSS (0 to 12) > = 6
• Target lesion diameter > 3 cm, lesion not located on face, axillae, groin, scalp,
hands, or feet
EXCLUSION CRITERIA
• Contravention of wash-out periods for topicals and systemics (duration not stated)
Interventions • Clobetasol propionate lotion/cream BD (CP)
• Placebo lotion BD (P)
Participants were randomised to clobetasol propionate cream or lotion; results were
aggregated for review purposes
Other affected areas could also be treated.
There was a 4-wk treatment- free follow-up period.
Outcomes 1. Signs: erythema, plaque elevation, scaling, pruritus (0 (none) to 4 (very severe))
2. Dermatological sum score (DSS) (erythema, plaque elevation, scaling): 0 to 12
3. Investigator’s Assessment of Global improvement (IAGI): 7-pt (worse to clear)
4. Global severity score (GSS): dichotomised as success (GSS = 0, 0.5 or 1) or failure
(GSS > = 2)
5. BSA
Notes Galderma R&D, Sophia Antipolis, France, sponsored the trial.
We sought unpublished data, but it was reported to be unavailable
Risk of bias
Bias Authors’ judgement Support for judgement
246Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lowe 2005 (Continued)
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator);
as the cream and lotion were compared, it
was not possible to blind participants
Randomisation method reported Low risk Participants allocated in consecutive bal-
anced blocks of 7 using the following ra-
tios: 3:3:1
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Luger 2008
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 869
Treatment duration: 52 wks; FU: 52 wks
LF: 55 (6.3%)
BC: yes
Age: 48.7 (15.0SD), range = 18 to 86
Gender (per cent men): 44.0%
Ethnicity (per cent white): 96.7%
Severity: IGA moderate = 55.5%; IGA severe = 37.8%; IGA very severe = 6.7%
Duration (yrs): 17.6 (14.2SD)
INCLUSION CRITERIA
• Hospital outpatients aged > = 18 with moderate to severe scalp psoriasis
• Amendable to topical treatment with < = 100 g/wk
• Psoriasis vulgaris on trunk or limbs;
• Area of scalp affected > 10%
• IGA at least moderate severity
EXCLUSION CRITERIA
• Use within previous 28 days of PUVA or grenz ray therapy
• Systemics with a potential impact on scalp psoriasis, or biological therapies; UVB;
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topical therapies; calcium metabolism disorders associated with hypercalcaemia.
Unclear if concurrent use permitted during the trial
Interventions • Calcipotriol 50 mcg/g in scalp formulation (gel) OD PRN (C)
• Calcipotriol gel 50 mcg/g plus betamethasone dipropionate “scalp formulation”
(gel) 0.5 mg/g OD (C-B)
Participants achieving clearance could stop treatment, but remained in the trial, and
restart as needed. The regimen was intended to reflect usual clinical practice
Outcomes 1. Adverse drug reactions
2. Adverse events associated with long-term corticosteroid use
3. Investigator’s Global Assessment of disease severity (IGA) (6-pt: absence of disease
(0) to very severe disease (5))
4. Controlled disease: IGA < = 2
5. Compliance (self-report; failure to use treatment for any reason other than no
treatment required) (tube weight also assessed)
Notes Leo Pharma, Ballerup, Denmark,sponsored the trial.
Adverse eventswere recordedby investigators and reviewedby an adjudication committee
(Data Safety Monitoring Board) comprising of 3 dermatologists blinded to treatment
assignment
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk This was not stated.
Loss to follow up Low risk 6.3%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Maier 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 34
Treatment duration: 8 wks; FU: 8 wks
LF: 10 (29.4%)
BC: yes (clinical only)
Age: NR
Gender (per cent men): 55.9%
Severity: mPASI = 6.3 (2.2SD)
INCLUSION CRITERIA
• People with stable mild to moderate plaque psoriasis
EXCLUSION CRITERIA
• Concomitant antipsoriatic therapy or use within previous 2 wks
Interventions • Herbal skincare products (Dr Michaels® cleansing gel, ointment, and skin
conditioner) BD (H)
• 3 fatty skin care products (not vehicle) BD (P)
Outcomes 1. mPASI (0 to 64.8)
Notes The trial did not state the sponsor.
This was an abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up High risk 29.4%
Baseline assessments Unclear risk Clinical assessments were reported.
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Baseline comparability demonstrated Unclear risk Clinical comparability was demonstrated.
Medansky 1987
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 121
Treatment duration: 3 wks; FU: 3 wks
LF: 6 (5.0%)
BC: yes, except duration of disease (P = 0.04)
Age: 53.8 (range = 16 to 80)
Gender (per cent men): 67.8%
Severity: TSS (0 to 9) = 6.6
Duration (yrs): 17.9 (range = 1 to 52)
INCLUSION CRITERIA
• Aged ≥12; chronic plaque psoriasis, stable, or worsening
• Duration ≥ 1 year
• Total Sign Score ≥ 6
EXCLUSION CRITERIA
• Concomitant medication
• Recent systemic corticosteroids or antimetabolites
• Recent topical corticosteroids
• Pregnancy
• Lactation
• Those needing > 90 g/wk topical steroid
• Other forms of psoriasis
Interventions • Mometasone furoate ointment 0.1% OD (M)
• Vehicle OD (P)
Outcomes 1. Signs (erythema; induration; scaling)
2. Total Sign Score (0 to 9)
3. Investigator Global Assessment (6-pt: no change or worse to cleared or marked
improvement)
Notes The trial was supported in part by a grant from Schering Corporation.
There was SD imputation (TSS).
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Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 67.8%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk Baseline comparability was demonstrated
(only significant difference: duration of dis-
ease)
Medansky 1996
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: “schedule”
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 134
Treatment duration: 3 wks; FU: 3 wks
LF: 6 (4.5%)
BC: unclear
Age: 47 (range = 20 to 81)
Gender (per cent men): not stated
Severity: TSS (0 to 9) = 6.5; per cent unstable psoriasis = 28%
INCLUSION CRITERIA
• Mild-to-moderate symmetrical chronic plaque psoriasis
• Adult
• TSS (0 to 9) ≥ 6
EXCLUSION CRITERIA
• Recent topical or systemic antipsoriatic therapy
• Recent lithium, NSAIDs, or beta-blockers
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Interventions • Diflorasone diacetate ointment, 0.05% BD (D)
• Calcipotriene ointment 0.005% BD (C)
Outcomes 1. Signs (erythema, scaling, induration)
2. Total Sign Score (0 to 9)
3. Physician overall evaluation (7 pt: worse to clear)
4. Physician comparative evaluation
5. Patient comparative evaluation
Notes Dermik Laboratories Inc. sponsored the trial.
Adverse events: itching and burning
There was SD imputation (TSS/IAGI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4.5%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Menter 2009
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open (blinding NS but product vehicles differ)
WITHDRAWAL/DROPOUT
Described
Participants N: 122
Treatment duration: 4 wks; FU: 8 wks
LF: 0 (0%)
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BC: yes
Age: 46.5 (14.2SD)
Gender (per cent men): 61.1%
Duration (yrs): 16.4 (11.50SD)
Severity: ODS = 3.06 (0.43SD)
(participant demographics based on per-protocol sample).
INCLUSION CRITERIA
• People aged 18 to 80 with moderate to severe stable plaque psoriasis
• BSA: 3 to 20%
EXCLUSION CRITERIA
• Known allergy to study ingredients
• Psoriasis affecting scalp, face, or groin only
• Area affected required weekly treatment with > 50 g CP spray or > 100 g C-BD
ointment
Interventions • Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination
ointment OD (C-BD)
• Clobetasol propionate 0.05% spray (CP)
Outcomes 1. Overall disease severity (ODS) on a 5-pt scale: clear (0), almost clear, mild,
moderate, severe/very severe (4)
2. Based on erythema, scaling, and elevation
3. Investigator Global Assessment (IGA) on a 4-pt scale (0 to 3): clear (0), mild,
moderate, severe (3). Based on per cent BSA affected (extent) rather than signs
Notes Galderma Laboratories, LP, sponsored the trial.
Atrophy was not assessed.
Telangiectasia was not assessed.
29 participants were ’non-compliant’ with treatment, but intention-to-treat (ITT) anal-
ysis included all enrolled participants
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open (blinding not reported,
but product vehicles differ)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
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Menter 2009 (Continued)
Baseline comparability demonstrated Low risk This was demonstrated.
Molin 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 421
Treatment duration: 8 wks; FU: 8 wks
LF: 4 (1%)
BC: Psoriasis comparable, demographics not reported
Age: not stated
Gender (per cent men): not stated
Severity: no summary measure reported
INCLUSION CRITERIA
• Adult outpatients
• Mild-to-moderate stable and chronic plaque psoriasis of limbs and trunk
EXCLUSION CRITERIA
• None reported
Interventions • Calcipotriol cream 50 mcg/g BD (C)
• Betamethasone 17-valerate cream 1 mg/g BD (B)
Outcomes 1. PASI (0 to 64.8)
2. Severity scores
3. Investigator Global Assessment of response (5-pt: worse to cleared)
4. Patient Global Assessments of response (5-pt: worse to cleared)
Notes Leo Pharmaceutical Products sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
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Molin 1997 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Monastirli 2000
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 70
Treatment duration: 10 wks; FU: 10 wks
LF: not reported
BC: yes
Age: 45.7
Gender (per cent men): 57.1%
Severity: PASI =
◦ D: 7.31 (1.79SD, N = 35)
◦ C: 6.29 (1.63SD, N = 35)
Duration (yrs): 17
INCLUSION CRITERIA
• Inpatients with chronic plaque psoriasis
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Ineffective contraception
• Systemic treatment within previous 2 mths
• Hepatic or renal disease
• Hypercalcaemia
• Known hypersensitivity to study medications
Interventions • Dithranol 2% 30 minutes OD (D)
• Calcipotriol ointment 50 mcg/g BD (C)
Outcomes 1. PASI (excluding head)
255Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Monastirli 2000 (Continued)
Notes The trial did not report sponsorship.
Treatment was delivered in an inpatient setting.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Mortensen 1993b
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 34
Treatment duration: 3 wks; FU: 4 wks
LF: 0 (0%)
BC: psoriasis comparable, demographics inadequately reported
Age: 43 (range = 26 to 75)
Gender (per cent men): 58.8%
Severity: PASI = 12.2
INCLUSION CRITERIA
• Stable plaque-type psoriasis
• Adult outpatients
• Normal hepatic and renal function
EXCLUSION CRITERIA
• Recent UV or other psoriasis treatments
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Mortensen 1993b (Continued)
• Disease or medication influencing calcium or bone metabolism
Interventions • Calcipotriol ointment 50 mcg/g BD (C) [max 100 g/wk]
• Placebo (vehicle) (P)
Outcomes 1. PASI
2. Investigator Global Assessment: per cent improvement from baseline, based on
PASI
3. Patient Global Assessment : per cent improvement from baseline, based on PASI
Notes Leo Pharmaceuticals, Denmark Duration (yrs) sponsored the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Olsen 1991
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 378
Treatment duration: 2 wks; FU: 3 wks
LF: 1 (0.3%)
BC: yes
257Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Olsen 1991 (Continued)
Age: 46 (range = 18 to 88)
Gender (per cent men): 45%
Severity: 80% moderate (6 ≤ TSS < 7.5), 20% severe (TSS > 7.5)
Duration (yr): 12.0 (9.7SD, N = 377); range = 0.4 to 55.0
INCLUSION CRITERIA
• Moderate to severe scalp psoriasis (TSS (0 to 9) ≥ 6)
• Stable or worsening
• Adult
EXCLUSION CRITERIA
• Recent systemic, topical, or UV treatment for psoriasis.
Interventions • Clobetasol propionate 0.05% BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; induration; scaling, pruritis)
2. TSS (0 to12)
3. Investigator Global Assessment (6-pt: worse to cleared)
4. Patient Global Assessment (4-pt: poor to excellent)
Notes In part, Glaxo Inc. sponsored the trial.
This was a scalp trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.3%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Olsen 1996 (1)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described (for both trials together)
Participants N: 181
Treatment duration: 4 wks; FU: 4 wks
LF: 3 (1.7%)
BC: yes
Age: 49 (range = 15 to 76)
Gender (per cent men): 68.0%
Severity: per cent BSA affected = 12.0% (range = 1% to 80%); per cent BSA treated =
11% (range = 1% to 80%)
Duration (yrs): 19 (range = 1 to 60)
Interventions • Fluticasone propionate 0.005% ointment (F) (max 100 g/wk)
• Placebo (vehicle) (P)
Outcomes 1. Investigator Global Assessment (6-pt: cleared to worse)
2. Severity (erythema; induration; scaling; pruritis)
3. Patient subjective assessment (treatment effect: 1 = excellent to 4 = poor)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.7%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Olsen 1996 (2)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described (for both trials together)
Participants N: 207
Treatment duration: 4 wks; FU: 4 wks
LF: 2 (1.0%)
BC: yes
Age: 45 (range = 12 to 87)
Gender (per cent men): 52.7%
Severity: per cent BSA affected = 12.5% (range = 1% to 80%); per cent BSA treated =
12% (range = 1% to 80%)
Duration (yrs): 16 (range = 0.8 to 52)
Interventions • Fluticasone propionate 0.005% ointment (F) (max 100 g/wk)
• Placebo (vehicle) (P)
Outcomes 1. Investigator Global Assessment (6-pt: cleared to worse)
2. Severity (erythema; induration; scaling; pruritis)
3. Patient subjective assessment (treatment effect: 1 = excellent to 4 = poor)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Oranje 1997
Methods DESIGN
Between-patient
Patient/parent delivery
ALLOCATION
Random
Method of randomisation: computer-generated random number table used by 7/14
centres to randomly select ≤ 3 participants
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 77
Treatment duration: 8 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 10 (range = 2 to 14)
Gender (per cent men): 46.8%
Severity: not reported
INCLUSION CRITERIA
• Mild to moderate chronic plaque psoriasis
• Children aged 2 to 14
EXCLUSION CRITERIA
• Acute guttate, pustular, erythrodermic, or worsening psoriasis
• Psoriasis mainly on the face, scalp, or diaper area
• Systemic treatment
• Recent phototherapy
• Concurrent Vitamin D, calcium, or other intercurrent medication
• Renal, hepatic, or osteoarthritic disease
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Placebo (vehicle) (P)
Outcomes 1. PASI: severity (redness; thickness; scaliness, area)
2. Extent of disease
3. Investigator Global Assessment
4. Patient Global Assessment (by parent/guardian for those aged < 8)
5. Compliance
Notes Leo Pharmaceutical Products, Denmark, sponsored the trial.
The trial participants were children.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Oranje 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Ormerod 1997
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 12
Treatment duration: 2 wks; FU: 2 wks
LF: unclear
BC: unclear
Age: not reported
Gender (per cent men): not reported
Severity: TSS (0 to 24) =12.2
INCLUSION CRITERIA
• Bilaterally similar chronic
• Stable plaque psoriasis.
EXCLUSION CRITERIA
• Recent systemic or UV therapy
Interventions • Betamethasone valerate ointment 0.1% BD (B)
• White soft paraffin BD (P)
Outcomes 1. Signs (erythema; elevation; scaling)
2. Total Sign Score (0 to 24)
Notes Wyeth-Ayerst Research and Glaxo Dermatology sponsored the trial
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Ormerod 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Ormerod 2000
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 17
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: not reported
Age: not reported
Gender (per cent men): not reported
Severity: TSS (0 to 24) = 15.5 (SD: 3.7; N = 17)
INCLUSION CRITERIA
• Stable plaque psoriasis
EXCLUSION CRITERIA
• Pregnancy
• Ineffective contraception
• Lactation
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Ormerod 2000 (Continued)
Interventions • NG-monomethyl-L-arginine (L-NMMA) cream 25% BD
• NG-monomethyl-L-arginine (L-NMMA) cream 5% BD
• Placebo (P)
Outcomes 1. TSS (elevation, erythema, scaling) (0 to 24)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Ormerod 2005
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: randomised in blocks of 4 by the pharmacy department using
’Minitab’
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Unclear
Participants N: 24
Treatment duration: 12 wks; FU: 12 wks
LF: 2 (8.3%)
BC: yes
Age: 47.5 (range = 28 to 78)
Gender (per cent men): 75.0%
Severity: TSS (0 to 24) = 17.0 (3.3SD, N = 22)
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Ormerod 2005 (Continued)
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Aged 18 and over
• No significant co morbidity
• Transminase levels within double normal upper limit
EXCLUSION CRITERIA
• Planned exposure to sunlight over trial duration
• Pregnancy or risk thereof
• Lactation; systemic or UV therapy within previous 4 wks
• Topical therapy within previous 2 wks
• Known allergy to macrolide drugs
• Renal or hepatic disease
• Renal malignancy within previous 5 yrs
Interventions • Topical sirolimus 2.2% for 6 wks then 8% for a further 6 wks (S)
• Placebo (P)
Dosing frequency was not reported.
Outcomes 1. Total Sign Score (TSS) of target plaque (erythema, thickening, scaling) (0 to 24)
Notes Wyeth Research, Philadelphia, sponsored the trial.
No systemic adverse event was considered clinically significant.
The daily dosing frequency was unclear.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 9.3%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Ortonne 1994
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: participants allocated sequentially upon inclusion
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 188
Treatment duration: 6 wks; FU: 6 wks
LF: 32 (17.0%)
BC: yes
Age: 46.0 (range = 20 to 85)
Gender (per cent men) 67.3%
Severity: per cent BSA = 18.9%; PASI = 11.67; per cent unstable psoriasis = 40%
Duration (yrs): 14.9
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Stable or worsening
• BSA 10% to 40%
• PASI 1 to 30; outpatients
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Concurrent disease
• Concomitant therapy
• Hypersensitivity to Vitamin D or analogues
• Planned exposure to sun
Interventions • Calcipotriol ointment BD (C)
• Calcipotriol ointment OM, plus betamethasone dipropionate ointment ON (CB)
Outcomes 1. PASI
2. Investigator Global Assessment
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Ortonne 1994 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Low risk Randomisation was sequential.
Loss to follow up Low risk 17.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Ortonne 2003
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation by blocks of 4 using
RANUNI routine of the SAS system
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 75
Treatment duration: 6 wks; FU: 6 wks
LF: 10 (13.3%)
BC: yes, within-patient design but comparability of lesions at baseline not reported
Age: 44.5 (14.5SD: range = 18.8 to 70.7)
Gender (per cent men): 53%
Severity: not reported
INCLUSION CRITERIA
• People with stable chronic plaque psoriasis, localised on ’sensitive areas’: face,
hairline, retro-auricular, and flexural areas
• Aged 18 to 70
• 1 to 4 bilateral lesions of similar severity
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Concomitant disease
• Acute guttate, pustular, erythrodermic, or arthropathic psoriasis
• History of hypercalcaemia, renal dysfunction
• Calcium-based calculi
• Conditions requiring systemic supplements of vitamin D or calcium
• Previous topical therapy within previous 2 wks (4 wks for retinoids)
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Ortonne 2003 (Continued)
• Previous systemic therapy within previous 4 wks (16 wks for retinoids)
Interventions • Calcitriol ointment 3 mcg/g BD (C1)
• Calcipotriol ointment 50 mcg/g BD (C2)
Outcomes 1. Investigator’s Global Assessment of local safety for each lesion (3-pt: 0 = poor to 2
= excellent)
2. Mean of worst sign scores (0 to 9) (signs: perilesional erythema; perilesional
oedema; stinging/burning)
3. Investigator’s Global Assessment of Improvement (IAGI) (7-pt: worse to clear)
4. Patient’s preference for tolerance, efficacy, and global preference (5-pt: right-hand
side (RHS) > left-hand side (LHS): -2 to LHS > RHS: 2)
Notes The trial did not report sponsorship, but 2 authors worked for Galderma, France
This was an inverse psoriasis trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Low risk A computer-generated block list was used
for randomisation.
Loss to follow up Low risk 13.3%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Ortonne 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 501
Treatment duration: 8 wks; FU: 8 wks
LF: 21 (4.2%)
BC: yes
Age: 51.2 (15.0SD, N = 501)
Gender (per cent men): 54.9%
Severity: PASI = 9.8 (6.1SD, N = 501)
Duration (yrs): 19.4 (14.6SD, N = 501)
INCLUSION CRITERIA
• Stable chronic plaque psoriasis amenable to topical treatment
• Aged 18 and over
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Unstable psoriasis or other inflammatory diseases
• Abnormality of calcium metabolism or hypercalcaemia
• Systemic or phototherapy within previous 4 wks
• Topical therapy within previous 2 wks
• Other topical therapy for trunk or limbs during study period
• Corticosteroid treatment of scalp (WHO: class IV) or facial area (WHO: class III/
IV) during study period
Interventions • TCP ointment ON for 4 wks then calcipotriol ointment 50 mcg/g ON for 4 wks
(A)
• Tacalcitol ointment 4 mcg/g ON for 8 wks (T)
• TCP: calcipotriol 50 mcg/g, plus betamethasone dipropionate 0.5 mg/g ointment
Outcomes 1. PASI: mean % reduction
2. IAGI (6-pt: worse to clearance)
3. PAGI (6-pt: worse to clearance)
Notes Leo Pharmaceutical Products sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
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Ortonne 2004 (Continued)
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 4.2%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Ortonne 2006
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: generated by sponsor; stratified by centre (N = 16);
Concealment: unclear
BLINDING
Single-blind (investigator); as cream and gel were compared, it was not possible to blind
participants
WITHDRAWAL/DROPOUT
Described
Participants N: 124
Treatment duration: 12 wks; FU: 14 wks
LF: 0 (0%)
BC: yes
Age: 48.2 (14.8SD); range = 18 to 82
Gender (per cent men): 68.5%
Ethnicity (per cent white): 96.0%
Severity: per cent BSA = 6.3 ((2.2SD), range = 1% to 10%; LPSI (0 to 12) = 7.2 (1.
7SD), range = 4 to 12; PASI (range NS) = 7.1 (3.7SD), range = 1.4 to 21.8
Duration (yrs): 18.9 (13.9SD); range = 0.7 to 69.3
INCLUSION CRITERIA
• People aged > = 18 with mild to moderate stable plaque psoriasis
• Per cent BSA < = 10%
• Target lesion on extremities or trunk between 40 and 200 cmˆ2
• LPSI > = 5
EXCLUSION CRITERIA
• Intranasal or inhaled corticosteroids, systemic, and topic corticosteroids,
phototherapy, topical antipsoriatic therapies
• Immunosuppriessive drugs, chemotherapy agents, systemic drugs with potential
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Ortonne 2006 (Continued)
to alter tacrolimus concentrations, lithium, beta blockers, antimalarials, other
medicated topical agents
Interventions • Calcipotriol 0.005% ointment BD (C)
• Tacrolimus 0.3% gel BD or 0.5% tacrolimus cream BD (T)
There were10 to 14 hours between applications; lesions were treated for 7 days following
clearance
Participants were randomised to tacrolimus cream or gel; results were aggregated for
review purposes
Outcomes 1. Local Psoriasis Severity Index (LPSI) (erythema, induration, scaling): 0 to 12
2. Physician assessment of clinical response of target lesion: IAGI: 5-pt = 0 (worse)
to 4 (much better)
3. Subject’s assessment of clinical response of target lesion: PAGI: 5-pt = 0 (worse) to
4 (much better)
4. Compliance (median daily medication usage)
5. Cosmetic acceptability (participant)
6. Adverse events and clinical laboratory evaluations
Notes Fujisawa GmbH, Munich, Germany, sponsored the trial.
Vissers 2008 (secondary reference under Ortonne 2006) reports immunohistochemistry
findings for subgroup (N = 18)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator);
as the cream and gel were compared, it was
not possible to blind participants
Randomisation method reported Low risk Randomisation was generated by the spon-
sor and stratified by centre
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Ortonne 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: pre-planned computer-generated schedule
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 408
Treatment duration: 8 wks; FU: 8 wks
LF: 9 (2.2%)
BC: yes
Age: 45.6; range = 18 to 86
Gender (per cent men): 54.7%
Ethnicity (per cent white): 97.8%
Severity: PASI = 9.6, range = 0.9 to 32.7; IGA moderate = 68.6%
Duration (yrs): 17.7; range = 0 to 70
INCLUSION CRITERIA
• People aged > = 18 with chronic plaque psoriasis amenable to topical treatment
• % face affected >10%
• % 1 of more body areas affected > = 10%
• IGA at least mild
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Unstable forms of psoriasis in treatment areas
• Other skin condition that could affect assessment
• PUVA or systemic therapy within previous 4 wks
• UVB or topical therapy on trunk, limbs, or face within previous 2 wks
• Treatment of scalp psoriasis with very potent (WHO group IV) corticosteroids or
vitamin D analogues
• Known or suspected abnormality in calcium homeostasis
Interventions • Calcipotriol 25 mcg/g ointment OD (C25)
• Calcipotriol 25 mcg/g ointment plus hydrocortisone 10 mg/g ointment, OD
(C25H)
• Calcipotriol 50 mcg/g ointment OD (C50)
• Calcipotriol 50 mcg/g ointment plus hydrocortisone 10 mg/g ointment OD
(C50H)
Outcomes Outcomes were assessed for the face and body overall and for the face only:
1. PASI (per cent change from baseline to EOT): face = 0 to 3.6; face + body = 0 to
68.4 [1]
2. Investigator’s Global Assessment of Disease Severity (IGA): 6-pt = absence of
disease to very severe disease
3. Adverse events
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Ortonne 2010 (Continued)
4. Compliance (self-report)
Notes Leo Pharma A/S sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A preplanned computer-generated sched-
ule was used.
Loss to follow up Low risk 2.2%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Papakostantinou 2005
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 22
Treatment duration: 2 wks; FU: 2 wks
LF: 0 (0%)
BC: no
Age: 41.3 (3.94SD)
Gender (per cent men): 45.5%
Severity: NS
INCLUSION CRITERIA
• People with mild or moderate plaque psoriasis
• PASI (0 to 72) < = 10
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Papakostantinou 2005 (Continued)
• Elbow lesions for treatment > = 5 cm diameter
EXCLUSION CRITERIA
• Antipsoriatic therapy within previous 4 wks
Interventions • Theophylline 1% ointment BD (T)
• Vehicle ointment (20% transcutol, 10% oleic acid) BD (P)
Outcomes 1. PASI (0 to 72)
Notes The sponsor was not stated.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details (ab-
stract only).
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Unclear risk The trial did not report this (but this was a
within-patient study, so demographics will
be comparable by definition)
Baseline comparability demonstrated Unclear risk This was not demonstrated (see comment
above).
274Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Papp 2003 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated random code
Concealment: adequate
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 1043
Treatment duration: 4 wks; FU: 4 wks
LF: 15 (1.4%)
BC: yes
Age: 47.1
Gender (per cent men): 58.4%
Severity: mean PASI = 10.8 (range = 1 to 36)
Duration: 18.7 years
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Aged at least 18
• BSA ≥10%
EXCLUSION CRITERIA
• Other types of psoriasis or skin diseases
• Hypercalcaemia
• Systemic antipsoriatic treatment or UV therapy within previous 6 wks
• Topical antipsoriatic therapy within previous 2 wks
• Other concomitant medication that might affect psoriasis
• Contraindications for corticosteroid treatment
• Planned exposure to UV light
• Pregnancy
• Lactation
Interventions • Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination
ointment BD (D)
• Calcipotriol 50 mcg/g in combination vehicle ointment BD (C)
• Betamethasone dipropionate 0.5 mg/g in combination vehicle ointment BD (B)
• Placebo (combination vehicle) ointment BD (P)
Outcomes 1. PASI (head excluded)
2. Total Severity Score (9-pt, absent to very severe)
3. IAGI (6-pt: worse to clearance)
4. PAGI (6-pt: worse to clearance)
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
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Papp 2003 (H) (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Treatments were assigned by computer-
generated code and assigned chronologi-
cally at each centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/
investigator). Treatments were identifiable
only by a code number
Randomisation method reported Low risk Randomisation was computer-generated.
(3:3:3:1)
Loss to follow up Low risk 1.4%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Papp 2003 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated random code
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1043
Treatment duration: 4 wks; FU: 4 wks
LF: 15 (1.4%)
BC: yes
Age: 47.1
Gender (per cent men): 58.4%
Severity: mean PASI = 10.8 (range = 1 to 36)
Duration: 18.7 years
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Aged at least 18
• BSA ≥10%
EXCLUSION CRITERIA
• Other types of psoriasis or skin diseases
• Hypercalcaemia
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Papp 2003 (P) (Continued)
• Systemic antipsoriatic treatment or UV therapy within previous 6 wks
• Topical antipsoriatic therapy within previous 2 wks
• Other concomitant medication that might affect psoriasis
• Contraindications for corticosteroid treatment
• Planned exposure to UV light
• Pregnancy
• Lactation
Interventions • Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g combination
ointment BD (D)
• Calcipotriol 50 mcg/g in combination vehicle ointment BD (C)
• Betamethasone dipropionate 0.5 mg/g in combination vehicle ointment BD (B)
• Placebo (combination vehicle) ointment BD (P)
Outcomes 1. PASI (head excluded)
2. Total Severity Score (9-pt, absent to very severe)
3. IAGI (6-pt: worse to clearance)
4. PAGI (6-pt: worse to clearance)
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Treatments were assigned by computer-
generated code and assigned chronologi-
cally at each centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator), and treatments were identifi-
able only by a code number
Randomisation method reported Low risk Randomisation was computer-generated.
(3:3:3:1)
Loss to follow up Low risk 1.4%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Pariser 1996
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Not described
Participants N: 235
Treatment duration: 8 wks; FU: 8 wks
LF: Unclear
BC: psoriasis comparable, demographics not reported.
Age: 45.1 (range = 18 to 86)
Gender (per cent men): not reported
Severity: TSS (0 to 9) = 4.75
INCLUSION CRITERIA
• Stable plaque-type psoriasis; otherwise healthy, non-pregnant people
• At least 4/9 for plaque elevation
• BSA range = 5% to 20%
EXCLUSION CRITERIA
• None reported
Interventions • Calcipotriene ointment 0.005% OD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (scaling; erythema; plaque elevation)
2. TSS (0 to 9)
3. Investigator Global Assessment (10-pt)
Notes Bristol-Myers Squibb Pharmaceutical Research Institute sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
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Pariser 1996 (Continued)
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Pauporte 2004
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 89
Treatment duration: 3 wks; FU: 4 wks
LF: 4 (4.5%)
BC: yes
Age: 46 (15SD)
Gender (per cent men): 44.8%
Severity: TSS (0 to 9) = 7.15
INCLUSION CRITERIA
• Moderate to severe scalp psoriasis, stable, or slowly exacerbating > 1 wk
• Aged ≥12
• Good general health
• Scalp involvement ≥ 20%
• TSS (0 to 9) ≥ 6
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• People requiring topical or systemic treatments that could affect psoriasis
• Systemic corticosteroids within previous 4 wks
• Topical therapies within previous 1 wk
• Concomitant use of other scalp therapies
Interventions • Fluocinolone acetonide 0.01% topical oil (Derma-Smoothe/FS), plus occlusion
ON or for at least 4 hours (F)
• Placebo oil, plus occlusion ON or for at least 4 hours (P)
Participants washed their hair with a non-medicated shampoo after treatment
Outcomes 1. Total Severity Score (0 to 9) (erythema, thickening, scaling)
2. Investigator’s Assessment of Global Improvement (IAGI) (7-pt: cleared to
exacerbation)
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Pauporte 2004 (Continued)
Notes The trial did not report sponsorship, but the corresponding author worked for Hill
Dermaceuticals Inc, US.
To be eligible for inclusion in the efficacy analysis, participants were permitted to deviate
from the treatment plan < = 2 consecutive days and < = 4/10 days.
No case of skin atrophy or telangiectasia were reported.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 4.5%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Perez 1996
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 84
Treatment duration: 10 wks: FU: 52 wks
LF: 0 (0%)
BC: yes
Age: 46 (range = 19 to 76)
Gender (per cent men): 65.5%
Severity: TSS (0 to 9) = 7.6 (range = 5 to 9)
INCLUSION CRITERIA
• Stable plaque or erythrodermic psoriasis
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Perez 1996 (Continued)
• Unsatisfactory response to at least 1 previous treatment (topical steroids/UVB/
PUVA/MTX)
• Adult
• BSA ≥10%
EXCLUSION CRITERIA
• Pregnant, nursing, or inadequate contraception
• Hepatic or renal impairment
• Recent systemic therapy or phototherapy or topical medications (excluding
emollients)
Interventions • Calcitriol 1.5 mcg/g OD (C)
• Placebo (vehicle) (P)
Outcomes • Severity (erythema; plaque thickness; scaling)
• Total Severity Score (0 to 9)
• Investigator Global Assessment (5-pt, worse to excellent improvement)
• PASI (reported only for participants participating in follow-up study)
Notes The NIH General Clinical Research Center supported the trial.
There was also an uncontrolled follow up study (N = 22) involving large-area adminis-
tration of calcitriol; 12-month results were based on results from 6 participants
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Pinheiro 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 132
Treatment duration: 8 wks; FU: 8 wks
LF: 10 (7.6%)
BC: yes
Age: 48.2 (range = 17 to 90)
Gender (per cent men): 59.1%
Severity: per cent severe = 13.6%
Duration (yrs): 16.9 (range = 0.5 to 60)
INCLUSION CRITERIA
• Chronic plaque psoriasis
• Adult
• BSA ≥100 cm²
EXCLUSION CRITERIA
• Hypersensitivity to trial medications
• Concomitant treatment with Vitamin D/calcium/other relevant agent
• Pregnancy
• Risk of pregnancy
• Lactation
• Unable to comply with protocol
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Coal tar 5%/allantoin 2%/hydrocortisone cream 0.5% BD (T)
Outcomes 1. Signs (redness; thickness; scaliness)
2. Total Sign Score (0 to 12)
3. Investigator Global Assessment (5-pt: worse to cleared)
4. Area of affected skin (area scales)
5. Patient evaluation of overall response (VAS)
Notes Leo Pharmaceuticals sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Pinheiro 1997 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.6%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Poulin 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 217
Treatment duration: 6 mths; FU: 6 mths
LF: 45 (20.7%)
BC: yes
Age: 50.4; range = 18 to 82
Gender (per cent men): 44.7%
Ethnicity (per cent white): 91.2%
Severity: GSS = 0 (clear): 10.1%; GSS = 0 (very mild): 33.7%; GSS = 0 (mild): 56.2%;
< 20% scalp affected = 76.5%; mPASI = 4.2 (4.2SD)
INCLUSION CRITERIA
• People aged > = 18 with moderate to severe scalp psoriasis (GSS = 3 or 4) eligible
for initial phase (4 wks)
• Responders (GSS < = 2) eligible for maintenance phase (6 mths)
• Topical and systemic wash-out periods required but not specified
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• Use of superpotent steroids on body
• Body psoriasis requiring systemic therapy.
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Poulin 2010 (Continued)
Interventions • Open-label initial treatment phase with clobetasol propionate 0.05% shampoo
OD for up to 4 wks (N = 288), then participants with GSS < = 2 were randomised to
maintenance therapy:
◦ clobetasol propionate 0.05% shampoo, 2 x/wk for 6 mths (CP)
◦ placebo (vehicle) shampoo, 2 x/wk for 6 mths (P)
• Participants evaluated every 4 wks for relapse (GSS > 2): relapses received
clobetasol propionate 0.05% shampoo OD for 4 wks
◦ GSS < = 2: participants re-initiated maintenance therapy
◦ GSS > 2: participants exited the study
Outcomes 1. Global Severity Score (GSS) (6-pt: 0 = clear to 5 = very severe)
2. Extent of disease (6-pt, 0 (none) to 5 (80% to 100%)) (investigator)
3. Signs (investigator): erythema, scaling, thickness (each scored 0 to 4)
4. MPASI (0 to 7.2)
5. Per cent with rebound at first relapse (mPASI > = 125% of baseline score)
6. Pruritis (subject) (0 to 3)
7. No. relapses
8. Atrophy (0 to 2)
9. Telangiectasia (0 to 2)
10. Burning (0 to 2)
11. adverse events
12. HPA axis activity
13. Patient satisfaction
Notes Galderma Laboratories, LP, sponsored the trial.
The trial (JDT) reported findings for a subset with moderate scalp psoriasis
The sponsor supplied unpublished safety data. No useable efficacy data were available
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 20.7%
Baseline assessments Low risk These were reported (clinical and demo-
graphic).
Baseline comparability demonstrated Low risk This was demonstrated.
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Powers 2005
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: unclear
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 421
Treatment duration: 8 wks; FU: 8 wks
LF: 0 (0%)
BC: yes (clinically), demographics NR (abstract)
Age: NR
Gender (per cent men): NR
Per cent white: NR
Severity: GSS (0 to 5) = 2.71 (0.45SD)
INCLUSION CRITERIA
• People aged > = 12 with mild to moderate plaque psoriasis
• BSA < = 35%
EXCLUSION CRITERIA
• Not reported
Interventions • Calcitriol 3 mcg/g ointment BD (C)
• Placebo ointment BD (P)
Max 30 g/day
Outcomes 1. Global Severity Score (GSS) (6-pt: 0 = none to 5 = very severe), dichotomised as
success (clear/almost clear) and failure
2. Signs: erythema, scaling, thickness (each scored 0 = absent to 4 = severe)
3. Dermatological Sum Score (DSS) (0 to 12)
4. Pruritus (0 to 4)
5. Investigator Global Improvement score (7-pt: worse to clear)
6. Subject Global Improvement score (7-pt: worse to clear)
7. Routine clinical and safety laboratory parameters including calcium homeostasis
(> 10% above upper limit of normal range)
Notes Galderma Laboratories, LP, sponsored the trial.
The sponsor supplied unpublished data.
This was an abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Powers 2005 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Unclear risk Clinical assessments were reported (demo-
graphic characteristics was unclear)
Baseline comparability demonstrated Unclear risk Clinical comparability was demonstrated
(demographic comparability was unclear)
Reygagne 2005
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation list
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 151
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: yes
Age: 45.3 (17.1SD)(range = 10 to 89)
Gender (per cent men): 47.0%
Per cent white: 98.7%
Severity: TSS (0 to 9) = 4.90 (1.74SD); GSS (0 to 5) = 1.50 (0.60SD)
Per cent scalp affected: 45% (SD28%)
INCLUSION CRITERIA
• People aged at least 12 with moderate to severe scalp psoriasis (GSS (0 to 5) > = 3
• Affected area on scalp > = 2 cmˆ2
EXCLUSION CRITERIA
• Very severe scalp psoriasis requiring systemic treatment
• Known allergy to study medications
• Immuno-compromised
• History of adverse response to topical or systemic steroid therapy
• Use of concomitant antipsoriatic therapy, betablockers, lithium, antimalarials or
NSAIDs
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Reygagne 2005 (Continued)
Interventions • calcipotriol 0.005% solution BD (C)
• clobetasol propionate 0.05% shampoo OD (CP)
Outcomes 1. Global Severity Score (GSS) (6-pt: 0 = none to 5 = very severe)
2. Total Severity Score (10-pt: 0 = none to 9 = severe)
3. Pruritus (0 to 3)
4. Per cent scalp area affected
5. Investigator’s Global Assessment of Improvement (7-pt: worse to cleared)
6. Subject’s Global Assessment of Improvement (7-pt: worse to cleared)
7. Atrophy, telangiectasia; burning sensation (scalp/neck/face) (0 to 3), burning/
stinging sensation (eyes) (0 to 3)
8. Adverse events
Notes Galderma Laboratories, LP, sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Low risk A computer-generated randomisation list
was used.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
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Ruzicka 1998
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 178
Treatment duration: 2 + 4 wks; FU: 14 wks
LF: 7 (3.9%)
BC: psoriasis comparable, demographics not reported
Age: 42 (range = 18 to 80)
Gender (per cent men): 55.6%
Severity: PASI = 6.0
INCLUSION CRITERIA
• Adults
• Chronic plaque-type psoriasis
• BSA ≥ 30%
• Calcium levels, renal, and liver function within normal range
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Recent systemic or UV therapy
Interventions 1. Calcipotriol 0.005% ointment BD 6 weeks (C)
2. Calcipotriol 0.005% ointment BD 2 weeks, then calcipotriol ointment 0.005%
OM plus Betamethasone valerate ointment ON 4 weeks (CB)
Outcomes 1. PASI
2. Investigator Global Assessment (6-pt: deterioration to complete healing)
3. Patient evaluation of overall response (5-pt: scale NR)
Notes The trial did not state sponsorship.
Schering AG employed 1 author.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Ruzicka 1998 (Continued)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 3.9%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Salmhofer 2000
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: NR
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 63
Treatment duration: 4 wks; FU: 8 wks
LF: 5 (7.9%)
BC: yes
Age: 47 (15.4SD, range = 19 to 83)
Gender (per cent men): 54.0%
Severity: PASI = 5.5 (2.65SD)
Duration (months): 141 (124SD)
INCLUSION CRITERIA
• Stable chronic plaque psoriasis
• Aged over 19
• Symmetrical lesions
EXCLUSION CRITERIA
• Other types of psoriasis
• BSA affected > 30%
• Concurrent systemic antipsoriatic therapy
• Pregnancy
• Lactation
• Concurrent infectious disease
• Other concurrent dematoses
• Hypercalcaemia
• Severe hepatic/renal disease
Interventions • Calcipotriol ointment 5 mcg/g BD (C)
• Calcipotriol ointment 5 mcg/g OM plus diflucortolone valerate ointment 0.1%,
ON (D)
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Salmhofer 2000 (Continued)
Outcomes 1. PASI
2. IAGI (7-pt: extreme deterioration to complete healing)
3. PAGI (7-pt: extreme deterioration to complete healing)
Notes Schering Wien GmbH sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.9%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Sanchez 2001
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 28
Treatment duration: 8 wks; FU: 8 wks
LF: 3 (10.7%)
BC: yes
Age: 49.5 (range = 22 to 73)
Gender (per cent men): 50%
Severity: PASI = 7.7 (range = 4 to 10)
INCLUSION CRITERIA
• People with plaque type psoriasis
EXCLUSION CRITERIA
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Sanchez 2001 (Continued)
• Systemic treatment within previous 4 wks
• Topical treatment within previous 2 wks
• Known hypersensitivity to sulphides
• Hypothyroidism
• Lactation
Interventions • Propylthiouracil cream 5% TD
• Calcipotriol ointment 50 mcg/g BD
Outcomes 1. PASI
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.7%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Santoianni 2001
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated list using block randomisation; phar-
macy-dispensed treatments in identical tubes
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 85
Treatment duration: 3 wks; FU: 3 wks
LF: 4 (4.7%)
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Santoianni 2001 (Continued)
BC: clinical only
Age: 51.9 (range = 18.8 to 88.5)
Gender (per cent men): 55.3%
Severity: PASI = 6.2
INCLUSION CRITERIA
• Outpatients with disseminated keratotic plaque psoriasis
• Aged over 18
EXCLUSION CRITERIA
• Not reported
Interventions • Betamethasone 17-valerate 21-acetate plus tretinoine plus salicylic acid OD
• Placebo OD
Outcomes 1. PASI
2. IAGI (5-pt: worse to cured)
3. PAGI (5-pt: no change to excellent)
4. Adverse events
Notes IDI Farmaceuticia SpA sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 4.7%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
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Saraceno 2007
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation schedule; boxes dis-
pensed sequentially
Concealment: inadequate
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 150
Treatment duration: 12 wks; FU: 12 wks
LF: 3 (2.0%)
BC: yes
Age: 47.7 (16.5SD); range = 18 to 83
Gender (per cent men): 66.0%
Severity: per cent BSA = 18.6 (7.6SD), range 2 to 30; PASI = 9.2 (4.8SD), range = 1.6
to 33.0
Duration (yrs): 13.8 (13.4SD); range = 0 to 60.1
INCLUSION CRITERIA
• People aged > = 18 with mild to moderate plaque psoriasis
EXCLUSION CRITERIA
• Topical therapy within previous 2 wks
• Systemic therapy within previous 4 wks
• Severe forms of plaque psoriasis
• Guttate, erythrodermic, and pustular psoriasis
• Cutaneous atrophy
• Suspected abnormality in calcium homeostasis
• Pregnancy
• Lactation
Interventions • Calcipotriol 50 mcg/g cream BD (C)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g formulation (4
weeks) OD then calcipotriol 50 mcg/g cream (8 weeks) BD (C-B)
Outcomes 1. PASI (scale NR)
2. Skindex-29: burden of symptoms; social functioning; quality of life
Notes Prodotti Formenti Srl, Milano, Italy, sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk Consecutive coded treatment boxes were
assigned to participants in a 1:1 ratio. It was
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Saraceno 2007 (Continued)
unclear if boxes were of identical appear-
ance
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Low risk A computer-generated randomisation
schedule was used.
Loss to follow up Low risk 2.0%
Baseline assessments Low risk These were reported (clinical and demo-
graphic).
Baseline comparability demonstrated Low risk This was demonstrated (clinical and demo-
graphic).
Scarpa 1994
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Blinding unclear
WITHDRAWAL/DROPOUT
Not described
Participants N: 160
Treatment duration: 6 wks; FU: 10 wks
LF: not reported
BC: demographics comparable, severity not reported
Age: 50
Gender (per cent men): 68.1%
Severity: not reported
INCLUSION CRITERIA
• Plaque-type psoriasis
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment 50 mg/g BD (C)
• Betamethasone dipropionate ointment 0.05% + salicylic acid 3% BD (B)
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Scarpa 1994 (Continued)
Outcomes 1. Investigator Global Assessment (5-pt: null to excellent)
2. Patient’s overall acceptance (5-pt: null to excellent)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Unclear risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Scarpa 1996
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: block randomisation (6 participants)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 76
Treatment duration: 6 wks; FU: 8 wks
LF: 13 (17.1%)
BC: yes
Age: not reported
Gender (per cent men): not reported
Severity: TSS (0 to 12) = 7.92
INCLUSION CRITERIA
• Chronic plaque psoriasis
EXCLUSION CRITERIA
295Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Scarpa 1996 (Continued)
• Concomitant medications (except emollients, tar shampoo, and salicylic acid)
• Topical or systemic steroids
• Calcium or vitamin D intake
• Antipsoriatic medications
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Betamethasone-17-valerate ointment 0.1% OD (B)
Outcomes 1. Severity (erythema; thickness; scaling)
2. Total Severity Score (0 to 12)
3. Comparison of lesions, based on difference in TSS
4. Investigator Global Assessment (6-pt: worsening to healing)
5. Patient assessment of difference
Notes The trial did not report sponsorship.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 17.1%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
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Scarpa 1997
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported; tubes labelled left or right and with participant
ID number and tube ID number
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 157
Treatment duration: 6 wks; FU: 7 wks
LF: 23 (14.6%)
BC: yes
Age: 49 (15SD; N = 134)
Gender (per cent men): 65.6% (N = 157)
Severity: TSS (0 to 12) = 7.7
INCLUSION CRITERIA
• Stable chronic plaque psoriasis
• Symmetrical lesions
• In- and outpatients
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Inadequate contraception
• Recent systemic, light, or topical therapy
• Severe renal failure
• Liver and cardiac dysfunction
• Hypercalcemia
• Hyperphosphoremia
• AIDS
• Drug addiction
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Placebo (vehicle) OD (P)
Outcomes 1. Signs: scaling; erythema; scaling
2. TSS (0 to 12)
3. Patient compliance (tube count; tube contents)
Notes The trial did not report sponsorship, but Istituto Gentili SpA provided medications and
appeared to have undertaken the randomisation.
There was SD imputation (TSS).
Risk of bias
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Scarpa 1997 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 14.6%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Sears 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 190 participants
Treatment duration: 3 wks; FU: 3 wks
LF: 21 (11%)
BC: yes
Age: 44 (range = 19 to 73)
Gender (per cent men): 47.9%
Severity: TSS (0 to 9) = 6.0
Duration (yrs): 17 (range = 1 to 56)
INCLUSION CRITERIA
• Mild or moderate psoriasis not spontaneously remitting
• Adults aged 18 to 70
• Total Sign Score 3 to 8
EXCLUSION CRITERIA
• Acute systemic illness
• Hypothamic-pituitary-adrenal system disorder, severe hepatic or renal disorder
• Psoriatic infection
• Lactation, pregnancy, or inadequate contraception
• Recent use of any corticosteroid, long-acting antihistamines, retinoids
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Sears 1997 (Continued)
• Drugs exacerbating or influencing psoriasis
• Antimetabolic therapy
• PUVA
• ACE inhibitor
• Intolerant of topical corticosteroids or study medication
Interventions • Hydrocortisone buteprate 0.1% cream BD (H)
• Placebo (vehicle) (P)
Outcomes 1. Signs (erythema; skin thickening; scaling)
2. Total Sign Score (0 to 9)
3. Pruritis
4. Investigator and patient evaluations of efficacy (4-pt: poor to excellent)
5. Investigator Global Assessment (7-pt: exacerbation to cleared)
6. Compliance (actual vs. expected usage)
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 11%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
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Seidenari 1997 (H)
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 14
Treatment duration: 6 wks; FU: 8 wks
LF: 3 (21.4%)
BC: yes
Age: 46 (range 23 to 69, N = 26)
Gender (per cent men): 46.2% (N = 26)
Severity: TSS = 6.31 (1.25SD, N = 11)
INCLUSION CRITERIA
• Symmetrical, stable psoriatic plaques
• Adult
• Inpatient or outpatients
EXCLUSION CRITERIA
• Recent topical, UV, or systemic therapy
• Inadequate contraception
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Betamethasone valerate ointment 0.1% OD (B)
Outcomes 1. Signs: erythema; thickening; scaling
2. Total Sign Score (0 to 12)
Notes Demographic characteristics were summarised over both studies, placebo and active
controls (N = 26)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 21.4%
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Seidenari 1997 (H) (Continued)
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Seidenari 1997 (P)
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 12
Treatment duration: 6 wks; FU: 8 wks
LF: 1 (8%)
BC: yes
Age: 46 (range 23 to 69, N = 26)
Gender (per cent men): 46.2% (N = 26)
Severity: TSS = 6.50 (0.76SD, N = 11)
INCLUSION CRITERIA
• Symmetrical, stable psoriatic plaques
• Adult
• Inpatient or outpatients
EXCLUSION CRITERIA
• Recent topical, UV, or systemic therapy
• Inadequate contraception
Interventions • Tacalcitol ointment 4 mcg/g OD (T)
• Placebo (vehicle) (P)
Outcomes 1. Signs: erythema; thickening; scaling
2. Total Sign Score (0 to 12)
Notes Demographic characteristics were summarised over both studies, placebo and active
controls (N = 26)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Seidenari 1997 (P) (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/as-
sessor).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 8.0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk -
Shuttleworth 1998
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: predetermined randomisation schedule in blocks of 10
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 40
Treatment duration: 4 wks; FU: 4 wks
LF: 3 (7.5%)
BC: yes
Age: 41.4 (12.0SD)
Gender (per cent men):60.0%
Severity: investigator’s overall assessment (0 to 9) = 4.85; patient’s overall assessment (0
to 4) = 2.43
INCLUSION CRITERIA
• Scalp psoriasis
• Aged 18 to 70
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Inadequate contraception
• Known hypersensitivity to study medication
• Participation in other study within previous month
• Concurrent systemic medication likely to affect psoriasis
• Photosensitivity; PUVA within previous 2 wks
• ’helmet’ (diffuse) psoriasis
• Concurrent topical antipsoriatics
• Eye disease
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Shuttleworth 1998 (Continued)
Interventions • Ciclopirox olamine shampoo 1.5% 3 times/wk
• Placebo shampoo 3 times/wk
Outcomes 1. IAGI (7-pt: very much worse to completely cleared)
2. Area affected
3. Investigator’s overall assessment (extent of scalp psoriasis) (10-pt: normal to ≥
75% scaling)
4. Scaling (0 to 4.5)
5. Pruritis
6. Patient overall assessment (5-pt: poor to excellent)
7. Adverse events
Notes Stiefel Laboratories sponsored the trial.
The study was underpowered to detect a statistically significant difference due to recruit-
ment difficulties.
This was a scalp trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 7.5%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Staberg 1989
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 10
Treatment duration: 6 wks; FU: 6 wks
LF: 1 (10%)
BC: yes
Age: 50 (26 to 76)
Gender (per cent men): not reported
Severity: TSS (0 to 9) = 7.3
INCLUSION CRITERIA
• Symmetrical chronic plaque psoriasis
• Inpatients
• Adult
EXCLUSION CRITERIA
• None reported
Interventions • Calcipotriol cream 1200 mcg/g BD (C)
• Placebo cream (P)
Outcomes 1. Signs: infiltration; erythema; scaling
2. Total Sign Score (0 to 9)
Notes Leo Pharmaceutical Products supplied the drugs and undertook the statistical analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.0%
Baseline assessments Low risk These were partially done.
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Staberg 1989 (Continued)
Baseline comparability demonstrated Low risk -
Stein 2001
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: investigator undertook randomisation
Concealment: inadequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 40
Treatment duration: 12 wks; FU: 12 wks
LF: 3 (7.5%)
BC: unclear
Age: range = 20 to 70 +
Gender (per cent men): not reported
Severity: TSS (elbows) (0 to 12) = 7.0
INCLUSION CRITERIA
• Mild to moderate symmetrical plaque psoriasis
• Aged at least 18
EXCLUSION CRITERIA
• Systemic treatment within previous 4 wks
• Topical treatment within previous 2 wks
• Investigational medication within previous 4 wks
Interventions • Betamethasone valerate foam 0.12% (Luxiq®) BD (B)
• Placebo foam BD (P)
Outcomes 1. IAGI (7-pt: worse to completely clear)
2. Composite severity score (sum of change scores in erythema, scaling, thickness) (0
to 12)
3. Pruritis
4. BSA involvement
5. Compliance (weight of containers)
Notes The Connetics Corporation sponsored the trial.
There was SD imputation (IAGI).
Risk of bias
Bias Authors’ judgement Support for judgement
305Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Stein 2001 (Continued)
Allocation concealment (selection bias) High risk Allocation concealment was inadequate:
The investigator undertook randomisation
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.5%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Stuecker 2001
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Blinding unclear
WITHDRAWAL/DROPOUT
Described
Participants N: 13
Treatment duration: 12 wks; FU: 12 wks
LF: 2 (15.4%)
BC: yes
Age: 52.9 (12.2SD, range = 38 to 67)
Gender (per cent men): 76.9%
Severity: PASI = 9.11 (4.88SD, range = 2.20 to 18.70)
Duration: 20.8 (12.7SD)
INCLUSION CRITERIA
• Stable psoriasis vulgaris
• Aged 18 to 70
EXCLUSION CRITERIA
• Topical treatment within previous wk
• Modification of systemic treatment within previous 3 mths
• Pototherapy within previous 6 wks
• Known hypersensitivity to study medications
• Avocado oil allergy
• BSA ≥ 60%
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Stuecker 2001 (Continued)
Interventions • Calcipotriol cream BD
• Vitamin B
cream (with avocado oil) BD
Outcomes 1. PASI (modified to exclude head and neck; each side given weighting of 50%)
2. IAGI (4-pt: poor to very good)
3. PAGI (4-pt: poor to very good)
4. Tolerability
Notes Regeneratio Pharma AG sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 15.4%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Stutz 1996
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated randomisation code to allocate sides
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 15
Treatment duration: 3 wks; FU: 3 wks
LF: 2 (13.3%)
BC: not reported
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Stutz 1996 (Continued)
Age: range = 21 to 68
Gender (per cent men): The trial did not report this.
Severity: TSS (scale not reported) = 2.8 (0.3SD)
INCLUSION CRITERIA
• Mild plaque psoriasis
EXCLUSION CRITERIA
• Prescription treatments within previous 2 wks
Interventions • Polymyxin B cream 200,000 U/g TD
• Placebo cream TD
Outcomes 1. Total severity
2. Erythema, scaling, thickness
Notes Babcock Dermatologic Endowment and the alumni of the Department of Dermatology,
University of Michigan Medical Center, MI, sponsored the trial
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Body sites were selected then assigned a
computer-generated randomisation code
that was concealed from both investigators
and participants
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 13.3%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
308Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sudilovsky 1981
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: identical tubes allocated by random numbers table
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 78 (57% psoriasis)
Treatment duration: 3 wks; FU: 3 wks
LF: 0%
BC: Inadequately reported
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Bilateral lesions of similar severity and duration
EXCLUSION CRITERIA
• Recent corticosteroid medication
• History of poor response to corticosteroids
• Concomitant local or systemic therapy that could affect psoriasis
Interventions • Halcinonide cream 0.1% OD + vehicle cream BD (H)
• Placebo (vehicle) treatment durations (P)
Outcomes 1. Comparative therapeutic response (3-pt: equal response to markedly superior
response)
2. Absolute therapeutic response (4-pt: poor (< 25% improvement) to excellent
(75% to 100% improvement))
3. Investigator Global Assessment: reflects comparative and absolute responses
(methodology unclear)
Notes The Squibb Institute for Medical Research sponsored the trial.
Part of a larger study involving participants with atopic dermatitis and trialling other
dosages; aggregated demographics were reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The part of the study (I or II) and side of
the body chosen for treatment were con-
cealed from investigators and determined
by random numbers table
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Sudilovsky 1981 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Sutton 2001
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 53 participants
Treatment duration: 8 wks; FU: 12 wks
LF: 5 (9.4%)
BC: yes
Age: range = 26 to 67
Gender (per cent men): 58.5%
Severity: duration (yrs) = 2 to 50
INCLUSION CRITERIA
• Psoriasis
• Good general health
EXCLUSION CRITERIA
• Women of childbearing potential
• Systemic retinoids within previous 6 mths
• NSAIDs, cytostatic agents, or folic acid-containing vitamin preparations within
previous mth
• Topical or UV treatments within previous 2 wks
Interventions • Methotrexate gel (Azone®) 1% OD
• Placebo gel OD
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Sutton 2001 (Continued)
Outcomes 1. IAGI (6-pt: worse to cleared)
2. Total Severity Score (erythema, thickness, scaling, pruritis) (0 to 20)
3. Adverse events
Notes Cato Research Ltd and Durham Pharmaceuticals LLC, NC, sponsored the trial.
They treated lesions < = 20% BSA.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 9.4%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Syed 1996
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 60
Treatment duration: 4 wks; FU: 52 wks
LF: 0 (0%)
BC: yes
Age: 25.6 (range = 18 to 50)
Gender (per cent men): 60.0%
Severity: PASI = 9.3 (range = 4.8 to 16.7)
Duration (yrs): 8.5 (range = 1 to 21)
INCLUSION CRITERIA
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Syed 1996 (Continued)
• Mild-to-moderate chronic plaque-type psoriasis
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• Cytotoxic drugs
• Beta-blockers
• Recent systemic medication, UV therapy
• Epilepsy
Interventions • Aloe vera extract 0.5% hydrophilic cream TDS (5 days/wk)
• Placebo cream TDS (5 days/wk)
Outcomes 1. PASI
2. Cure rate
3. Significant clearing
Notes The trial did not report sponsorship.
Concomitant water soluble emollients were permitted.
SDs were imputed (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Syed 2001b
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 60 participants
Treatment duration: 4 wks; FU: 8 wks
LF: 0 (0%)
BC: yes
Age: 29.3 (range = 18 to 70)
Gender (per cent men): 61.7%
Severity: PASI = 9.8 (range = 5.3 to 17.5)
Duration (yrs): 9.6 (range = 1 to 24)
INCLUSION CRITERIA
• Chronic, mild to moderate, plaque type psoriasis
• Outpatients
• PASI > 4 or BSA > 20%
EXCLUSION CRITERIA
• Topical or systemic corticosteroids or cytotoxic drugs or beta-blockers or
phototherapy within previous 3 mths
• Pregnancy
• Lactation
• Alcoholic problems
• Concurrent renal, hepatic, or haematological abnormalities
Interventions • Methotrexate gel (Azone ®) 0.25% BD (5 days/wk)
• Placebo gel BD (5 days/wk)
Outcomes 1. PASI
2. Plaques cleared
3. Adverse events
4. Compliance (≤ 40 topical applications during 4-wk period)
Notes The trial did not report sponsorship.
SDs were imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
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Syed 2001b (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Tham 1994
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated random numbers
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 30
Treatment duration: 6 wks; FU: 6 wks
LF: 3 (10%)
BC: yes
Age: 40 (range = 20 to 74)
Gender (per cent men): 56.7%
Ethnicity: Chinese (70.0%), Indian (16.7%), Malay (10.0%), and Sikh (3.3%)
Severity: PASI = 6.65
Duration (years): 9.7 (range = 2 to 20)
INCLUSION CRITERIA
• Stable symmetrical chronic plaque-type psoriasis
• Adult
EXCLUSION CRITERIA
• Recent systemic or UV therapy
• Hypercalcaemia
• High calcium or vitamin D intake
• Impaired renal or hepatic function
• Previous poor response to tar
• Concomitant medications
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• White soft paraffin OM plus coal tar solution BP in aqueous cream 15% ON (T)
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Tham 1994 (Continued)
Outcomes 1. PASI (modified to exclude head)
2. Severity (erythema; infiltration; desquamation)
3. Investigator Global Assessment (5-pt: worse to cleared)
4. Patient Global Assessment (5-pt: worse to cleared)
Notes Leo Pharmaceutical Products sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was single-blind (investigator).
Randomisation method reported Low risk Randomisation was computer-generated.
Loss to follow up Low risk 10.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Tyring 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule (3:1), stratified by ethnicity;
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 177
Treatment duration: 8 wks; FU: 52 wks
LF: 0 (0%) (at 8 wks)
BC: yes
Age: 44.7 (range = 18 to 76)
Gender (per cent men): 63.3%
Ethnicity: per cent white = 0%; per cent Hispanic/Latino: 56%; per cent black/African
American = 44%
Severity: scalp IGA (moderate) = 80.2%; scalp IGA (severe/very severe) = 19.8%; TSS
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Tyring 2010 (Continued)
(0 to 12) = 6.3, range = 4 to 11
Duration (yrs): 10.8, range = 1 to 50
INCLUSION CRITERIA
• People aged > = 18 with plaque psoriasis affecting the scalp and limbs/trunk
• > = 10% scalp affected
• IGA scalp psoriasis at least moderate
• Ethnicity: Hispanic/Latino/black/African American
EXCLUSION CRITERIA
• Topical or UV therapy within previous 2 wks
• Biological within previous 12 wks
• Systemic therapies within previous 4 wks
• Erythrodermic, exfoliative, or pustular psoriasis
• Skin infections
• Skin diseases confounding evaluation of psoriasis
• Calcium metabolic disorder or hypercalcaemia
• Pregnancy
• Lactation
Interventions • Calcipotriene 50 mcg/g plus betamethasone 0.5 mg/g scalp formulation (gel) OD
(C-B)
• Placebo gel OD (P) (8 wks) then C-B (44 wks)
Maximum of 40 g/wk. Treatment was stopped if scalp psoriasis cleared
Concurrent (scalp) antipsoriatics and ’chemical treatments of the hair’ were not permitted
All participants received C-B ointment for trunk/limbs.
Outcomes 1. Investigator Global Assessment of Disease Severity (IGA): 6-pt = clear (0) to very
severe (5). Based on written definitions for plaque thickness, scaling, and erythema.
2. Success: IGA < = 1
3. Signs (investigator assessment): plaque thickness, scaling and erythema (each
scored 0 (none) to 4 (very severe).
4. Total Sign Score (0 to 12)
5. Response criteria: TSS < = 1; PGA < = 1
6. Signs (each): absent
7. Patient Global Assessment of Disease Severity (PGA): 6-pt = clear (0) to very
severe (5). Based overall severity and impact on daily life
8. Adverse events
9. Blood pressure
10. Laboratory tests: serum calcium, albumin, blood urea nitrogen, creatinine.
11. Compliance (medication usage)
Notes Leo Pharma A/S sponsored the trial
This was part of a 52-wk study: Following 8 wks of double-blind treatment, all partici-
pants received C-B scalp formulation for 44 wks. Data were reported only for the 8-wk
end point
The sponsor supplied unpublished data.
Risk of bias
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Tyring 2010 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk Participants were assigned the next consec-
utive randomisation number available at
the site for his/her ethnic category
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk Randomisation was preplanned according
to a computer-generated randomisation
schedule in a ratio of 3:1, stratified by eth-
nicity
Loss to follow up Unclear risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Unclear risk This was partially demonstrated (reported
means, but not standard, deviations; pro-
portions reported)
Tzung 2005
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 23
Treatment duration: 12 wks; FU: 16 wks
LF: 4 (17.4%)
BC: yes
Age: 60.2; range = 12 to 80
Gender (per cent men): 91.3%
Severity: Signs = mean baseline scores ranged from 2.1 to 2.3 (SD range = 0.71 to 0.80)
INCLUSION CRITERIA
• People with plaque psoriasis attending study centre (veteran’s hospital)
• Ethnicity: Chinese
• Target lesions of at least moderate severity
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Tzung 2005 (Continued)
EXCLUSION CRITERIA
• Topical within previous 2 wks
• Oral systemic therapies within previous 6 wks
• Phototherapy or sun exposure within previous 4 wks
• Unstable psoriasis
• Pregnancy
• Lactation
• Uncontrolled systemic disease
Interventions • Calcipotriol 0.005% ointment BD (C)
• Tazarotene 0.1% gel ON placebo petrolatum ointment OM (T)
Outcomes 1. Adverse events
2. Scaling, plaque elevation, erythema (8 pt: 0 = none to 4 = very severe; 0.5
increments)
3. Patient Assessment of Overall Improvement (PAGI): 5-pt = deterioration to
excellent improvement (> 75%)
Notes The trial did not state the sponsor.
The number of adverse events was described, but the number of participants experiencing
ADRs was not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The study was single-blind (investigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 17.4%
Baseline assessments Low risk Clinical assessments were reported (within-
patient study, so demographics compara-
ble)
Baseline comparability demonstrated Low risk Clinical comparability was demonstrated.
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Vali 2005
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: flip of coin
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 42
Treatment duration: 8 wks; FU: 8 wks
LF: 3 (7.1%)
BC: yes
Age: 32 (12.22SD)
Gender (per cent men): 66.7%
Severity: PASI = 10.86 (5.15SD)
INCLUSION CRITERIA
• People with symmetrical plaque psoriasis
• BSA < 20%
EXCLUSION CRITERIA
• Systemic or topical antipsoriatic therapy within previous 4 wks
• Pregnancy
• Lactation
• Use of medications that could affect course of psoriasis
Interventions • Topical caffeine 10% in Plastibase® TD (C)
• Placebo (Plastibase®) TD (P)
Outcomes 1. modified PASI (’regional PASI’): range unclear
2. Adverse events
Notes The trial did not state the sponsor.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Randomisation was by the flip of a coin.
Loss to follow up Low risk 7.1%
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Vali 2005 (Continued)
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Van de Kerkhof 1989
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 10
Treatment duration: 4 wks; FU: 4 wks
LF: 0 (0%)
BC: yes
Age: range = 28 to 72
Gender (per cent men): 70%
Severity: TSS (0 to 9) = 7.2
INCLUSION CRITERIA
• People with symmetrical chronic stable plaque psoriasis
EXCLUSION CRITERIA
• Topical antipsoriatic therapy within previous 2 wks
• Systemic antipsoriatic therapy within previous 1 mth
• BSA affected < = 15%
Interventions • Calcitriol solution 2 mcg/ml BD (C)
• Placebo (vehicle) (P)
Outcomes 1. Severity (erythema; thickness; scaling)
2. TSS (0 to 9)
Notes The trial did not report sponsorship, but Hoffmann-La Roche, Switzerland , employed
1 of the authors.
The authors stated that allocation was concealed to the investigator, but provided no
justification.
Treatment was given at subtherapeutic dose.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
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Van de Kerkhof 1989 (Continued)
Allocation concealment (selection bias) Low risk A randomisation code was generated cen-
trally and concealed from the investigator
until after trial completion
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Van de Kerkhof 1996a
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 122
Treatment duration: 8 wks; FU: 12 wks
LF: 19 (15.6%)
BC: inadequately reported
Age: 44.8 (13.69SD)
Gender (per cent men): 62.3%
Severity: BSA = 5.6%
Duration (mths): 233.5 (175.9SD)
INCLUSION CRITERIA
• Stable plaque psoriasis
• Not localised on the scalp
• BSA: 5.6%
• Score ≥ 2 for erythema and desquamation and Score sum > 5
• White adults and adolescents
EXCLUSION CRITERIA
• Increased serum calcium or serum phosphate level
• Recent systemic or topical antipsoriatic treatment
• Serious disease
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Van de Kerkhof 1996a (Continued)
• Known allergy to study medication
• Recent participation in another clinical trial
• Expected poor compliance
• Calcium supplements
• Drugs influencing calcium metabolism
• Corticosteroids
• Barbiturates
• Phenytoin
• NSAIDs
• Pregnancy
Interventions • Tacalcitol 4 mcg/g OD (T)
• Placebo (vehicle) (P)
Outcomes 1. Signs: erythema; infiltration; desquamation
2. Total Sign Score (0 to 12)
3. Severity
4. Preference assessment
5. Area of test lesions
6. Investigator Global Assessment (4-pt: poor to very good)
7. Patient Global Assessment (4-pt: poor to very good)
8. Assessment of benefit
9. Post-treatment relapse
Notes Hermal Kurt Herrmann sponsored the trial.
Maximum treatment area: 10% BSA
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 15.6%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk The trial did not report this.
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Van de Kerkhof 2002a
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 88 participants
Treatment duration: 4 wks; FU: 5 wks
LF: 7 (8.0%)
BC: yes
Age: not reported
Gender (per cent men): not reported
Severity: PASI = 16.9 (range = 4.3 to 48.0)
INCLUSION CRITERIA
• Inpatients or outpatients
• Aged 18 or over; chronic plaque psoriasis
• Scalp involvement
EXCLUSION CRITERIA
• Other forms of psoriasis
• Systemic antipsoriatic treatment within previous 6 wks
• UV treatment within previous 6 wks
• Impaired renal or hepatic function
• History of urolithiasis or hypercalciurea
• Arthritis
• Immobilisation
• Hypo- or hyperthyroidism
• Heavy exposure to sunlight
• Pregnancy
• Lactation
• Planning of pregnancy
Interventions • Calcipotriol ointment 50 mcg/g (80 to 100 g/wk) and calcipotriol scalp solution
50 mg/ml (30 to 50 ml/wk) (C)
• Dithranol/tar regimen (D)
Outcomes 1. PASI (scalp assessed separately)
2. TSS (SCALP: erythema, thickness, scaling) (0 to 12)
3. IAGI (6-pt: worse to clearance)
4. PAGI (6-pt: worse to clearance)
5. Adverse events
Notes Leo Pharmaceutical Products sponsored the trial.
The trial included inpatients.
The trial reported medication quantities used: “patients complied well”
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Van de Kerkhof 2002a (Continued)
’High dose’ calcipotriol was given (above recommended dosage)
IAGI/PAGI: combined scalp/body
TSS: scalp only
PASI: body only
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 8.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Van de Kerkhof 2006
Methods DESIGN
Between-patient
Nurse and participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated system using telephone response
Concealment: adequate
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 106
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age (mean): 51.2; range = 25 to 83
Gender (per cent men): 59/100 (reported by de Korte 2008 - this is a secondary reference
under Van de Kerkhof 2006); 6 participants missing)
Ethnicity: NR
Severity: mPASI (mean) = 9.9, range = 2.7 to 27.0
INCLUSION CRITERIA
• Outpatients aged > = 18 with plaque psoriasis involving arms, trunk, legs, or a
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Van de Kerkhof 2006 (Continued)
combination of the aforementioned
• Condition amendable to topical treatment
• Target area treatable with < = 100 g calcipotriol/wk
• PASI extent score > = 2 (i.e. BSA (body region) > = 10%)
• Willing/able to comply with study protocol
EXCLUSION CRITERIA
• Acute guttate, generalised pustular, or erythrodermic exfoliative psoriasis
• Atopic dermatitis, seborrhoeic dermatitis, or other inflammatory skin diseases
• Systemic antipsoriatic therapy (including corticosteroids) or phototherapy within
previous 6 wks
• Topical antipsoriatic therapy (body) within previous 2 wks
• Planned changes in concurrent medication that could affect psoriasis (e.g. beta-
blockers, lithium, etc)
• Pregnancy or risk thereof
• Lactation
• Known or suspected hypercalcaemia
• Hypersensitivity to components of study medication
• Treatment with an investigational drug within previous 3 mths
• Current participation in other clinical trial
• Planned exposure to excessive levels of sun/UV radiation
• Known treatment resistance to study medication
Interventions • Calcipotriol 50 mcg/g ointment BD (C)
• Short-contact dithranol cream (dose titration from 0.1% to 5%; application time
15 to 45 mins) OD; class II or III corticosteroids for treatment of severe skin irritation
(D)
◦ wk1: 5 (daily) visits to outpatient clinic
◦ wk2 onwards: twice-weekly visits PRN
Participants intolerant of 0.1% dithranol used 0.05% dose.
Cases of extensive hyperkeratosis, scales of participants in both treatment groups could
be removed with salicylic acid (5%) in petrolatum before wk 0
Participants achieving clearance exited the study.
Outcomes PRIMARY OUTCOMES
1. mPASI (scalp excluded)
SECONDARY OUTCOMES
1. IAGI: Investigator’s overall assessment of treatment response: 6-pt (worse to
clearance)
2. PAGI: Patient’s overall assessment of treatment response: 6-pt (worse to clearance)
3. Quality of life
4. Adverse events
5. Compliance (per cent using study medication as prescribed)
Notes Leo Pharma sponsored the trial.
Secondary response criteria did not demonstrate a statistically significant difference be-
tween treatments
The sponsor supplied unpublished data.
Risk of bias
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Van de Kerkhof 2006 (Continued)
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The treatment was assignment using a tele-
phone voice response system, to ensure that
the investigators’ decision to randomise the
participant preceded knowledge of the ran-
domised treatment
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Low risk Randomisation was through a computer-
generated system using telephone response
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Unclear risk This was partially demonstrated (de Korte
2008). There were significantly more men
in the dithranol group (72% versus 46%)
. However, de Korte does not provide data
on 6 participants. If all these participants
are assumed to be of the gender that min-
imises between group differences, the dif-
ference is almost statistically significant at
the 5% level (= 0.0502; Fisher’s exact test).
This may indicate a flawed randomisation
process, or it may be chance. The primary
reference does not report variance around
mean PASI baseline estimates, so compara-
bility was unclear
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Van de Kerkhof 2009
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule (1:2:2)
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1417
Treatment duration: 8 wks; FU: 8 wks
LF: 2 (0.1%)
BC: yes
Age: 48.3 (16.4SD); range = 18 to 92
Gender (per cent men): 44.8%
Ethnicity (per cent white): 97.2%
Severity: IGA (0 to 5) = 3.32 (0.71SD), range = 2 to 5; TSS (0 to 12) = 6.8 (1.8SD)
Duration (yrs): 15.9 (13.4SD)
INCLUSION CRITERIA
• People aged > = 18 with scalp psoriasis involving > 10% of the scalp, amenable to
treatment with < = 100 g medication/wk
EXCLUSION CRITERIA
• Concomitant topical scalp therapy (except medicated shampoos and emollients)
• Planned initiation of/changes to concomitant medication that could affect scalp
psoriasis
• Use of topical treatment of the face, trunk or limbs with very potent (WHO
group IV) corticosteroids or UVB within previous 2 wks
• PUVA or grenz ray therapy, planned exposure to the sun, systemic therapy within
previous 4 wks
• Biological therapy within previous 6 mths
• Erythrodermic, exfoliative, or pustular psoriasis
• Presence of viral lesions, fungal, or bacterial skin infections, parasitic infections, or
atrophic skin on the scalp, known/suspected abnormality of calcium homeostasis
associated with clinically significant hypercalcaemia
• Severe renal insufficiency
• Severe hepatic disorders
Interventions • Calcipotriol 50 mcg/g gel OD (C)
• Betamethasone dipropionate 0.5 mg/g gel OD (B)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0. 5 mg/g gel (scalp
formulation) OD (C-B)
Participants achieving IGA = 0 could stop medication during the study
Outcomes 1. Investigator’s Global Assessment of severity of scalp psoriasis (IGA); 6-pt (0 =
absence of disease to 5 = very severe disease)
2. Responder: IGA absence or very mild
3. Total Sign Score (erythema, thickness, scaliness): 13-pt (0 to 12)
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Van de Kerkhof 2009 (Continued)
4. Patient assessment of overall response: 7-pt (worse to clear)
5. Adverse events (local)
6. Laboratory tests for calcium and albumin.
7. Compliance (self report and weight medication used)
Notes Leo Pharma A/S, Ballerup, Denmark, sponsored the trial.
The sponsor supplied unpublished data.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk A computer-generated randomisation
schedule was used (1:2:2)
Loss to follow up Low risk 0.1%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Van der Vleuten 1995
Methods DESIGN
Within-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Described
Participants N: 10
Treatment duration: 2 wks; FU: 2 wks
LF: 0 (0%)
BC: inadequately reported
Age: range = 20 to 72
Gender (per cent men): 40%
Severity: PASI (modified) = 17.1 (2.1SEM)
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Van der Vleuten 1995 (Continued)
Duration (yrs): 3 to 53
INCLUSION CRITERIA
• Adult
• Inpatient
• Severe, disabling psoriasis
• Resistant to topical therapy
EXCLUSION CRITERIA
• Recent or concomitant oral antipsoriatic therapy, no topical or systemic
treatments except corticosteroids for the scalp and face
Interventions • Calcipotriol ointment 50 mcg/g BD
• Dithranol in paste or petroleum 0.05% to 4%, 24-hour application on alternate
days
Outcomes 1. PASI (excludes scalp)
Notes The trial did not report sponsorship.
Treatment was delivered in an inpatient setting.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
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Vanderploeg 1976
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: identical tubes allocated by sequential admission number,
corresponding to a standard randomisation schedule using a double-blind code
Concealment: adequate
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 36
Treatment duration: 3 wks; FU: 3 wks
LF: 3 of 36 (8.3%)
BC: yes
Age: 45.7 (range = 10 to 66; N = 33)
Gender (per cent men): 48.5% (N = 33)
Severity: TSS (0 to 20) = 9.9
INCLUSION CRITERIA
• Psoriasis or atopic dermatitis
EXCLUSION CRITERIA
• Recent systemic or topical steroids
• Concomitant medications
Interventions • Betamethasone dipropionate ointment 0.05% BD (B)
• Vehicle BD (P)
Outcomes 1. Signs: scale; erythema; pruritis; thickness; crusting
2. Total Sign Score (0 to 20)
3. Investigator Global Assessment (5 pt: exacerbation to excellent improvement)
Notes The trial did not report sponsorship.
This was part of a larger trial that included participants with atopic dermatitis (50%
psoriasis).
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The sequential trial admission number cor-
responded to the randomisation schedule;
the randomisation code was ’double blind’
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
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Vanderploeg 1976 (Continued)
Randomisation method reported Low risk Randomisation was sequential.
Loss to follow up Low risk 8.3%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Veien 1997
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: block
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 287
Treatment duration: 8 wks; FU: 12 wks
LF: 0 (0%)
BC: psoriasis comparable, demographics inadequately reported
Age: 45.0
Gender (per cent men): 53.7%
Severity: BSA = 7.9% (range = 1% to 75%); TSS (0 to 12) = 7.59
INCLUSION CRITERIA
• Adult
• Stable plaque psoriasis
• TSS > 5
• Erythema ≥ 2, scaling ≥ 2
EXCLUSION CRITERIA
• Pregnancy
• Lactation
• High serum calcium, serum phosphate, serum creatinine
• Unresponsive to calcipotriol
• Intolerant to study ingredients
• Serious co-morbidity
Interventions • Tacalcitol ointment 4 mcg/g OD plus Tacalcitol vehicle OD (T)
• Calcipotriol ointment 50 mcg/g BD (C)
Outcomes 1. Severity: erythema; infiltration; scaling; pruritus
2. Total Sign Score (TSS): 0 to12
3. Investigator Global Assessment (6-pt: worse to clear)
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Veien 1997 (Continued)
4. Patient Global Assessment (scale “virtually identical” to IAGI; details not
reported)
5. Patient evaluation of global usefulness (VAS)
6. Patient evaluation of cosmetic acceptability
7. Quantity of medication used
8. Rebound (aggravation equal to or worse than pre-treatment severity)
Notes Nycomed Pharma sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk The trial did not report this.
Vladimirov 1994
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 60
Treatment duration: 6 wks; FU: 6 wks
LF: 0 (0%)
BC: inadequately reported
Age: range = 18 to 70
Gender (per cent men): not reported
Severity: PASI = 2.92
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Vladimirov 1994 (Continued)
Duration (yrs): range = 0.2 to 30
INCLUSION CRITERIA
• Adult
• Mild to moderate psoriasis
EXCLUSION CRITERIA
• None reported
Interventions • Calcipotriol cream 50 mcg/g BD (C)
• Betamethasone17-valerate ointment 0.1% BD (B)
Outcomes 1. PASI (range unclear)
2. Investigator Global Assessment (scale NR)
Notes Leo Pharmaceuticals sponsored the trial.
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk The trial did not report this.
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Volden 1992
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 10
Treatment duration: 4 wks; FU: 4 wks
LF: 1 (10%)
BC: yes
Age: not reported
Gender (per cent men): not reported
Severity: BSA = 5% to 15%
Duration (mean years): 20
INCLUSION CRITERIA
• Symmetrical plaque-type psoriasis
• Adult outpatients
EXCLUSION CRITERIA
• Recent active treatment for psoriasis
Interventions • Dithranol 1% in petrolatum (D)
• Placebo (vehicle) (P)
Outcomes 1. Signs: erythema; infiltration; scaling
2. Total Sign Score (0 to 12)
Notes The trial did not report sponsorship, but Hydro Pharma, Swedenone, employed 1 of the
authors
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 10.0%
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Volden 1992 (Continued)
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Wall 1998
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Not described
Participants N: 306
Treatment duration: 3 mths
LF: 28 (7.2%)
BC: yes
Age: 46.7
Gender (per cent men): 47.1%
Severity: duration (yrs) = 18.7
Signs and extent reported, but not by summary measure
INCLUSION CRITERIA
• Adult
• Stable mild-to-moderate chronic plaque psoriasis
• BSA ≥100 cm² but < 40%
• Recent GP visit
EXCLUSION CRITERIA
• Acute guttate or pustular psoriasis
• Psoriasis of scalp or face only
• Recent topical or systemic antipsoriatic therapy
• Pregnancy
• Lactation; concomitant vitamin D or calcium intake
• Hypersensitivity to study medication
• Unlikely to comply with protocol
Interventions • Calcipotriol ointment 50 mcg/g BD (C)
• Dithranol 0.1 to 2% OD (D)
Outcomes 1. Investigator assessment of overall clinical response (5-pt: worse to clear)
2. Patient assessment of overall clinical response (5-pt: worse to clear)
3. Quality of Life:
◦ Psoriasis Disability Index (PDI)
◦ Sickness Impact Profile (SIP)
335Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wall 1998 (Continued)
Notes Leo Pharmaceuticals sponsored the trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 7.2%
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Low risk -
Weinstein 1996
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 324
Treatment duration: 12 wks; FU: 24 wks
LF: 6 (1.9%)
BC: yes
Age: 46.8 (range = 12 to 83)
Gender (per cent men): 67%
Severity: per cent BSA = 6.9 (5.2SD); TSS (0 to 12) = 7.3
Duration (yrs): 17.5 (12.7SD)
INCLUSION CRITERIA
• Stable plaque psoriasis
• BSA ≤ 20%
• 2 target lesions with plaque elevation ≥ 2 and ≥ 2 cm in diameter: 1 on elbow/
knee and 1 on trunk/limbs
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Weinstein 1996 (Continued)
EXCLUSION CRITERIA
• Pustular or exfoliative psoriasis
• Sensitivity to study medication
• Other confounding skin conditions
• Recent use of tar shampoos
• Topical/systemic/light therapies
• Topical corticosteroids/UVB
• PUVA/systemic therapy
• Oral retinoids
• Uncontrolled systemic disease
• Pregnant
• Lactating
• Inadequate contraception
Interventions • Tazarotene gel 0.1% OD
• Tazarotene gel 0.05% OD
• Placebo (vehicle) (P)
Outcomes 1. Signs: plaque elevation; scaling; erythema
2. Total Sign Score (0 to 12)
3. Per cent clearance
4. Patient assessment of cosmetic acceptability
Notes Allergan Inc. sponsored the trial.
The authors stated that concealment of treatment allocationwas achieved for participants
and clinicians, as tubes were identical.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 1.9%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
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Weinstein 2003
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: randomised in blocks of 6
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 1303
Treatment duration: 12 wks; FU: 24 wks
LF: 411 (31.5%)
BC: yes
Age: 48.2 (range = 18 to 84)
Gender (per cent men): 62.6%
Severity: OLA (0 to 5) (mean) = 3.6; BSA affected (mean) = 10.5%
Duration (mean yrs): 18.4
INCLUSION CRITERIA
• Aged ≥18
• BSA ≥ 2%; OLA (0 to 5) ≥ 3
• Acceptable blood or urinary test results
EXCLUSION CRITERIA
• Pregnancy or risk thereof
• Lactation
• UV or topical therapies within previous 2 wks
• PUVA or systemic therapies within previous 4 wks
• Oral retinoid therapy within previous 8 wks
• Expected prolonged exposure to UV light
Interventions • Tazarotene cream 0.05% OD (T1)
• Tazarotene cream 0.1% OD (T2)
• Placebo (P)
Outcomes 1. Overall lesion assessment (OLA) (0 = none to 5 = very severe), as applied to all
treated lesions
2. Clinical success (OLA ≤ 2 at 12 wks)
3. Effectiveness (improvement in OLA from baseline of ≥ 15% relative to placebo
improvement score)
4. Overall plaque elevation, scaling and erythema (each scored 0 = none to 4 = severe)
5. Overall global response to treatment (7-pt: completely cleared to worsened)
6. Target lesion response (7-pt: completely cleared to worsened)
Notes Allergan Inc. sponsored the trial.
The paper reported 2 trials; only study A reported follow-up data after 12 weeks (N =
108)
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Weinstein 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Low risk Block randomisation was used.
Loss to follow up High risk 31.5%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
White 2006 (H)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule
Concealment: unclear
BLINDING
Open (acute phase and maintenance phase for CB-W); double-blind (participant/inves-
tigator) (maintenance phase for CB-C and CB-P)
WITHDRAWAL/DROPOUT
Described
Participants N: 1136
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 50.7; range = 18 to 89
Gender (per cent men): 60.7%
Ethnicity (per cent white): 96.9%
Severity: per centBSA=12.1%;mPASI =8.9 (3.8SD), range =2.4 to 30.9; IGAmoderate
= 76%; IGA severe = 24%
Duration (yrs): 0 to 75
INCLUSION CRITERIA
• People aged > = 18 with plaque psoriasis affecting at least 10% arms, 10% trunk,
10% legs, or a combination of the aforementioned
• IGA at least moderate
EXCLUSION CRITERIA
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White 2006 (H) (Continued)
• Erythrodermic, exfoliative, pustular, or guttate psoriasis
• Skin infections
• Other confounding inflammatory skin disease
• Calcium metabolic disorder
• Pregnancy
• Lactation
• Concurrent antipsoriatic therapy
Interventions • Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
(4 wks), then calcipotriol cream 50 mcg/g OD [8 wks] (CB-C)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
(4 wks), then calcipotriol cream 50 mcg/g OD weekdays, CB ointment OD weekends
(8 wks) (CB-W)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
(4 wks), then placebo cream (calcipotriol vehicle), OD (8 wks) (CB-P)]
Use < = 100 g/wk
Outcomes 1. mPASI (0 to 64.8) - per cent change from baseline: rebound: > 125% of baseline;
relapse: > 50% reduction in maximum improvement from baseline
2. Investigator’s Assessment of disease severity (IGA); 6-pt (absent to very severe)
3. Patient’s assessment of overall response (PAGI); 7-pt (worse to clear)
4. Adverse events
5. Compliance (medication usage; self-reported compliance)
Notes Leo Pharma A/S sponsored the trial.
Atrophy was not assessed.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open in the acute phase and
maintenance phase for CB-W and dou-
ble-blind (participant/investigator) in the
maintenance phase for CB-C and CB-P. It
was not possible to blind the alternating
group (CB-W), as the vehicles were differ-
ent
Randomisation method reported Low risk A preplanned computer-generated ran-
domisation schedule was used (1:1:1)
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
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White 2006 (H) (Continued)
Baseline comparability demonstrated Unclear risk This was partially demonstrated (reported
means, but not standard, deviations; pro-
portions reported)
White 2006 (P)
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated schedule
Concealment: unclear
BLINDING
Open (acute phase and maintenance phase for CB-W); double-blind (participant/inves-
tigator) (maintenance phase for CB-C and CB-P)
WITHDRAWAL/DROPOUT
Described
Participants N: 1136
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 50.7; range = 18 to 89
Gender (per cent men): 60.7%
Ethnicity (per cent white): 96.9%
Severity: per centBSA=12.1%;mPASI =8.9 (3.8SD), range =2.4 to 30.9; IGAmoderate
= 76%; IGA severe = 24%
Duration (yrs): 0 to 75
INCLUSION CRITERIA
• People aged > = 18 with plaque psoriasis affecting at least 10% arms, 10% trunk,
10% legs, or a combination of the aforementioned
• IGA at least moderate
EXCLUSION CRITERIA
• Erythrodermic, exfoliative, pustular, or guttate psoriasis
• Skin infections
• Other confounding inflammatory skin disease
• Calcium metabolic disorder
• Pregnancy
• Lactation
• Concurrent antipsoriatic therapy
Interventions • Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
(4 wks), then calcipotriol cream 50 mcg/g OD [8 wks] (CB-C)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
(4 wks), then calcipotriol cream 50 mcg/g OD weekdays, CB ointment OD weekends
(8 wks) (CB-W)
• Calcipotriol 50 mcg/g plus betamethasone dipropionate 0.5 mg/g ointment OD
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White 2006 (P) (Continued)
(4 wks), then placebo cream (calcipotriol vehicle), OD (8 wks) (CB-P)]
Use < = 100 g/wk
Outcomes 1. mPASI (0 to 64.8) - per cent change from baseline: rebound: > 125% of baseline;
relapse: > 50% reduction in maximum improvement from baseline
2. Investigator’s Assessment of disease severity (IGA); 6-pt (absent to very severe)
3. Patient’s assessment of overall response (PAGI); 7-pt (worse to clear)
4. Adverse events
5. Compliance (medication usage; self-reported compliance)
Notes Leo Pharma A/S sponsored the trial.
Atrophy was not assessed.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
High risk The trial was open in the acute phase and
maintenance phase for CB-W and dou-
ble-blind (participant/investigator) in the
maintenance phase for CB-C and CB-P. It
was not possible to blind the alternating
group (CB-W), as the vehicles were differ-
ent
Randomisation method reported Low risk A preplanned computer-generated ran-
domisation schedule was used (1:1:1)
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Unclear risk This was partially demonstrated (reported
means, but not standard, deviations; pro-
portions reported)
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Wolska 1995
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 52
Treatment duration: 4 wks; FU: 4 wks
LF: 12 (23.1%)
BC: yes
Age: 44.7 (range = 18 to 77; N = 40)
Gender (per cent men): 70%; N = 40
Severity: TSS (0 to 9) (median) = 7.1 (range = 6.0 to 9.0)
INCLUSION CRITERIA
• Plaque type psoriasis
• At least 2 symmetrical lesions, excluding those on neck, head, feet, and hands
• TSS ≥ 6
• Between-plaque TSS scores ≤ 1
• Lesions clinically stable ≥ 1wk
EXCLUSION CRITERIA
• Topical antipsoriatic treatment (tar/dithranol/steroids) within previous 2 wks
• Systemic antipsoriatic treatment (steroids/retinoids/methotrexate/cyclosporin)
within previous 4 wks
• UV treatment within previous 4 wks
• Pregnancy
• Lactation;
• Inadequate contraception
• Impaired renal or hepatic function
Interventions • Platelet aggregation activating factor (PAF) (Ro 24 to 0238) 10% solution BD
• Placebo solution BD
Outcomes 1. TSS (erythema, desquamation, infiltration) (0 to 9)
2. IAGI (6-pt: marked worsening to total clearing)
3. Adverse events
Notes The trial did not report sponsorship.
Inpatients PLS CAN YOU PUT THIS IN A SENTENCE?]
Risk of bias
Bias Authors’ judgement Support for judgement
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Wolska 1995 (Continued)
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/in-
vestigator).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk 23.1%
Baseline assessments Low risk -
Baseline comparability demonstrated Low risk -
Wortzel 1975 (1)
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: sequential admission number
Concealment: adequate
BLINDING
Double-blind (participant/physician)
WITHDRAWAL/DROPOUT
Not described
Participants N: 76
Treatment duration: 3 wks; FU: 3 wks
LF: 0 (0%)
BC: not reported
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Moderately severe to very severe psoriasis and atopic dermatitis
• Outpatients
EXCLUSION CRITERIA
• Not reported
Interventions • Betamethasone dipropionate ointment 0.05 BD (B)
• Placebo BD (P)
Outcomes 1. IAGI (5-pt: worse to excellent)
2. Physician opinion of drug effect (scale unclear, results not reported)
Notes Leo Pharmaceuticals sponsored the trial.
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Wortzel 1975 (1) (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The sequential trial admission number cor-
responded to a treatment unit on a ran-
domisation schedule
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/
physician).
Randomisation method reported Low risk Randomisation was sequential.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Wortzel 1975 (2)
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: sequential admission number
Concealment: adequate
BLINDING
Double-blind (participant/physician)
WITHDRAWAL/DROPOUT
Not described
Participants N: 9
Treatment duration: 3 wks; FU: 3 wks
LF: 0 (0%)
BC: The trial did not report this.
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Moderately severe to very severe psoriasis and atopic dermatitis
• Inpatients
EXCLUSION CRITERIA
• Not reported
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Wortzel 1975 (2) (Continued)
Interventions • Betamethasone dipropionate ointment 0.05 BD (B)
• Placebo BD (P)
Outcomes 1. IAGI (5-pt: worse to excellent)
2. Physician opinion of drug effect (scale unclear, results not reported)
Notes The trial did not report sponsorship.
Concomitant water soluble emollients were permitted.
There was SD imputation (PASI).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk The sequential trial admission number cor-
responded to a treatment unit on a ran-
domisation schedule
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (participant/
physician).
Randomisation method reported Low risk Randomisation was sequential.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Unclear risk The trial did not report this.
Wozel 2001
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (unclear)
WITHDRAWAL/DROPOUT
Described
Participants N: 38
Treatment duration: 2 wks; FU: 6 wks
LF: 0 (0%)
BC: yes (statistical significance not reported)
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Wozel 2001 (Continued)
Age: not reported
Gender (per cent men): not reported
Severity: not reported
INCLUSION CRITERIA
• Chronic plaque psoriasis
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment OM plus fluocinolone acetonide ointment 0.025% ON
(CF)
• Calcipotriol ointment OM plus vehicle ointment ON (CP)
• 4 weeks’ maintenance for both groups with calcipotriol ointment BD
Outcomes 1. PASI
Notes The trial did not report sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient detail.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (it was unclear
who was blinded).
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0.0%
Baseline assessments Unclear risk The trial did not report these.
Baseline comparability demonstrated Low risk -
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Yang 2009
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Not stated
WITHDRAWAL/DROPOUT
Described
Participants N: 76
Treatment duration: 6 wks; FU: 6 wks
LF: 0 (0%)
BC: yes
Age: range = 18 to 65
Gender (per cent men): 68.4%
Severity: PASI = 14.3 (5.5SD), range = 4.2 to 19.6
Duration (yrs): range = 0.5 to 34
INCLUSION CRITERIA
• People aged 18 to 65 with plaque psoriasis affecting limbs and body
• PASI < 25
EXCLUSION CRITERIA
• Systemic antipsoriatic therapy within previous 4 wks
• Topical therapy within previous 2 wks
• Use of corticosteroids or vitamin D3 derivatives
• Concurrent infection
• Pregnancy
• Heart, liver, kidney, or mental disorder
• Known sensitivity to study medication
• External injury
Interventions • Calcipotriol cream BD (C)
• Halometasone cream (OM), calcipotriol cream (ON) (2 wks); calcipotriol cream
BD (weekdays), halometasone cream BD (weekends) (2 wks); calcipotriol cream BD (2
wks) (CH)
Treatments were stopped when 90% improvement achieved.
Outcomes 1. mPASI (0 to 64.8)
2. Improvement score (based on change in PASI score x 100%) (IAGI):
◦ Complete recovery: > 90%
◦ Marked improvement: 60% to 89%
◦ Some improvement: 25% to 59%
◦ No effect: <25%
Notes The trial did not state the sponsor.
There was 1 case of skin atrophy in the monotherapy group.
We received translation support for data extraction.
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Yang 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial did not report this.
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Low risk 0%
Baseline assessments Low risk These were reported.
Baseline comparability demonstrated Low risk This was demonstrated.
Zonneveld 1998 (H)
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (but unmatched regimens) (participant/assessor)
WITHDRAWAL/DROPOUT
Not described
Participants N: 70
Treatment duration: 6 wks; FU: 6 wks
LF: not reported
BC: Yes (clinical); demographics not reported
Age: not reported
Gender (per cent men): not reported
Severity: median LPSI ranged from 7.0 (C;T) to 8.0 (P)
INCLUSION CRITERIA
• Chronic plaque psoriasis
• LPSI ≥ 6
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment 0.005% BD (C)
• Tacrolimus ointment 0.3% OD (T)
• Placebo ointment BD (P)
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Zonneveld 1998 (H) (Continued)
Outcomes 1. Local psoriasis severity index (scale NR)
Notes The study was double-blind (but unmatched regimens).
Fujisawa GmbH sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (but unmatched
regimens) (participant/assessor)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk These were partially done.
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Zonneveld 1998 (P)
Methods DESIGN
Between-patient
Delivery unclear
ALLOCATION
Random
Method of randomisation: not reported
Concealment: unclear
BLINDING
Double-blind (but unmatched regimens) (participant/assessor)
WITHDRAWAL/DROPOUT
Not described
Participants N: 70
Treatment duration: 6 wks; FU: 6 wks
LF: not reported
BC: yes (clinical), demographics not reported
Age: not reported
Gender (per cent men): not reported
Severity: median LPSI ranged from 7.0 (C;T) to 8.0 (P)
INCLUSION CRITERIA
• Chronic plaque psoriasis
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Zonneveld 1998 (P) (Continued)
• LPSI ≥ 6
EXCLUSION CRITERIA
• Not reported
Interventions • Calcipotriol ointment 0.005% BD (C)
• Tacrolimus ointment 0.3% OD (T)
• Placebo ointment BD (P)
Outcomes 1. Local psoriasis severity index (scale NR)
Notes The study was double-blind (but unmatched regimens).
Fujisawa GmbH sponsored the trial.
There was SD imputation (TSS).
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk The trial reported insufficient details.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The trial was double-blind (but unmatched
regimens) (participant/assessor)
Randomisation method reported Unclear risk The trial did not report this.
Loss to follow up Unclear risk The trial did not report this.
Baseline assessments Low risk -
Baseline comparability demonstrated Unclear risk This was partially demonstrated.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agrawal 2010 The study did not provide a comparison of interest (compared acitretin gel in 2 formulations)
Akerman 2009 The trialists did not report or make available adequate data
Ambroziak 2002 The study compared steroid against no treatment (rather than against placebo)
Baadsgaard 1995 The study was within-patient, but did not adopt clear left-right design and assessed multiple plaques for
each participant
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(Continued)
Baran 1999 The trialists did not report or make available adequate data
Bianchi 2003 The study compared steroid against no treatment (rather than against placebo)
Brodell 2011a The sponsor did not report or make available adequate data.
Buder 2010 The study assessed multiple plaques for each participant (7 per participant)
Callen 1996 The trialists or sponsor did not report or make available adequate data
Cannavo 2003 This was a nail psoriasis trial, which was removed in the 2011 update
Carroll 2005 The comparator was not strictly placebo (salicylic acid in vehicle)
De Jong 1999 The comparator was not strictly placebo (urea in vehicle).
Elias 1994 It was unclear if it was a valid randomised controlled trial
Esposito 2009 The study did not provide a comparison of interest.
Friedrich 2004 The sponsors did not report or make available adequate data.
Hsia 2010 The study did not assess patient outcomes/tolerability
Insa 2009 The study did not assess patient outcomes/tolerability.
Iraji 2010 The trialists did not report or make available adequate data
Ito 2005 The study was not randomised.
Jansen 1986 No adequate data were reported.
Kaur 2004 The study was not randomised.
Kleyn 2005 The study did not provide a comparison of interest.
Kragballe 1989 Participants were randomised to the 2 substudies, but within the substudies, treatments were appliedwithout
randomisation
Kragballe 1994 This was a dose-ranging study of an unlicensed product not subsequently marketed
Lebwohl 1998b The study did not provide a simple comparison against a vitamin D derivative treatment
Lebwohl 2001 The trialists or sponsor did not report or make available adequate data
Levin 2003 The trialists or sponsor did not report or make available adequate data
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(Continued)
Meyrat 1996 The study did not provide a comparison of interest.
Palazon 2005 The study did not provide a comparison of interest.
Reygagne 2002a The trialists or sponsor did not report or make available adequate data
Rhemus 2006 The study did not provide a comparison of interest (product unlicensed)
Ruzicka 2004 The trialists or sponsor did not report or make available adequate data
Sander 1998 The study did not provide a simple comparison against a vitamin D derivative treatment
Saraswat 2007 The study did not provide a simple comparison against a vitamin D derivative treatment
Scher 2001 This was a nail psoriasis trial, which was removed in the 2011 update
Sefton 1984 The trialists or sponsor did not report or make available adequate data
Sharma 2003 The study used concomitant UV light.
Syed 2001a The trialists did not report or make available adequate data
Tokura 2004 No translation was available.
Tosti 1998 This was a nail psoriasis trial, which was removed in the 2011 update
Tzaneva 2003 The study used concomitant UV light.
van de Kerkhof 1996b The trialists did not report or make available adequate data
Vena 2005 The study was not a randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
353Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bissonnette 2011
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: computer-generated code
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 61
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 50.6 (22 to 65)
Gender (per cent men): 83.6%
Severity: PGA = 3.3 (0.6SD); PASI = 6.0 (2.5SD); BSA = 3.2% (2.0SD)
INCLUSION CRITERIA
• Participants aged 18 to 65 with mild to moderate plaque psoriasis
• BSA: 1% to 15%
• PGA: 2 to 4
• Good general health
EXCLUSION CRITERIA
• Concomitant serious illness/medical condition
• Systemic therapy within previous 12 to 24 wks (depending on drug)
• Phototherapy within previous 4 wks
• Topical antipsoriatic therapy within previous 2 wks
• Other non-plaque forms of psoriasis
Interventions • 1% WBI-1001 in a cream formulation twice daily
• Placebo vehicle twice daily
Outcomes 1. Physician’s Global Assessment (PGA), 6-pt (0 = clear to 5 = very severe)
2. Body surface area (BSA)
3. Psoriasis Area and Severity Index (PASI)
Notes Welichem Biotech Inc. sponsored the trial.
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Callis Duffin 2010
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Not described
Participants N: 200
Treatment duration: 12 wks; FU: 12 wks
LF: NS
BC: NS
Age: NS
Gender (per cent men): NS
Severity: NS
INCLUSION CRITERIA
• Participants aged 18 to 75 with mild to moderate plaque psoriasis
• BSA: 2% to 20%
EXCLUSION CRITERIA
• Lesions solely involving intertriginious areas, the scalp, or the face
• Pustular psoriasis or erythroderma
• Concurrent systemic therapy, topical agents, or UVB therapy within 2 weeks of the first dose of study
medication
• Systemic triazole antifungals except fluconazole
Interventions • INCB018424: Ruxolitinib phosphate cream QD
• Placebo cream QD
Outcomes 1. Total Lesion Score (sum of erythema, scaling, and thickness; points NS)
2. PASI
Notes Incyte Corporation sponsored the trial.
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Calzavara-Pinton 2011
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator/outcome assessor)
WITHDRAWAL/DROPOUT
Described
Participants N: 20
Treatment duration: 8 wks; FU: 16 wks
LF: 2 (10%)
BC: yes
Age: 40.2 (range = 19 to 68)
Gender (per cent men): 40%
Severity: PSI = median 8 (IQR = 7 to 9.25)
INCLUSION CRITERIA
• Participants with mild plaque psoriasis
• Symmetrical plaques
EXCLUSION CRITERIA
• Not stated
Interventions • Budesonide 0.25 mg/g cream OM plus tacalcitol 4 mcg/g ointment ON
• Calcipotriol 50 mcg/g and betamethasone dipropionate 0.5 mg/g once daily
Outcomes 1. Psoriasis Severity Index (erythema + infiltration + scaling) (0 to 12)
2. VAS (adverse events; itching): 0 to 10
3. Patient preference and satisfaction (better/equal/worse)
Notes The sponsor was not stated.
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Henry 2011
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Single-blind (investigator)
WITHDRAWAL
Described
Participants N: 13
Treatment duration: 4 wks; FU: 4 wks
LF: 3 (23.0%)
BC: NS
Age: NS
Gender (per cent men): NS
Severity: NS
INCLUSION CRITERIA
• Participants with mild to moderate plaque psoriasis
EXCLUSION CRITERIA
• NS
Interventions • Clobetasol propionate spray followed by calcitriol ointment twice daily
• Calcitriol ointment followed by clobetasol propionate spray twice daily
Outcomes 1. Signs: erythema, induration, scaling
Notes Galderma sponsored the trial.
This was an abstract only.
Katoh 2003
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Not stated
WITHDRAWAL/DROPOUT
Described
Participants N: 61
Treatment duration: 12 wks; FU: 12 wks
LF: 2 (3%)
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Katoh 2003 (Continued)
BC: yes
Age: 49.2 (14.3SD)
Gender (per cent men): 34%
Severity: PASI = 12.9 (5.3SD)
Ethnicity: Japanese
INCLUSION CRITERIA
• Participants with stable plaque psoriasis
EXCLUSION CRITERIA
• Participants requiring systemic therapy or use of any antipsoriatic treatment within previous 4 wks
Interventions • Calcipotriol 0.005% ointment once daily
• Combination treatment with calcipotriol 0.004% and 0.01% clobetasol propionate ointment once daily
Treatments were applied after bathing.
Participants achieving 50% reduction in baseline PASI then used calcipotriol once daily for a further 12 weeks
Outcomes 1. Eruption score of trunk involvement: sum of erythema, scaling, and induration (0 to 12)
2. PASI
Notes The Japanese Ministry of Education, Science, Sports, and Culture sponsored the trial
Matheson 2011
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Open
WITHDRAWAL/DROPOUT
Not described
Participants N: 32
Treatment duration: 2 wks; FU: 2 wks
LF: NS
BC: no
Age: NS
Gender (per cent men): NS
Severity: NS
INCLUSION CRITERIA
• Participants aged ≥12 with mild to moderate plaque psoriasis
EXCLUSION CRITERIA
• Not stated
Interventions • Calcipotriol ointment 0.005% twice daily
• Calcipotriol foam 0.005% twice daily
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Matheson 2011 (Continued)
Outcomes 1. Safety: adverse events; serum calcium
Notes Stiefel, a GSK company, sponsored the trial.
Paulsen 2005
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 41
Treatment duration: 4 wks; FU: 12 wks
LF: 1 (2%)
BC: yes
Age (median): 44 (23 to 77)
Gender (per cent men): 65%
Severity: duration (yrs; median) = 15 (range = 2 to 60)
INCLUSION CRITERIA
• Participants aged ≥18 with stable mild to moderate plaque psoriasis
• Test plaques similar within each participant (TSS ≤ 1), TSS ≤ 8
EXCLUSION CRITERIA
• Concurrent use of topical steroids or vitamin D or emollients containing aloe vera
• Pregnancy
• Systemic or photo therapy within previous 2 mths
• Topical antipsoriatic therapy within previous 2 wks
• Known allergy to gel
• Severe concomitant disease
• Use of specific drugs
Interventions • Aloe vera gel twice daily
• Placebo gel twice daily
Outcomes 1. PASI
2. Local PASI (TSS) (0 to 9)
3. Patient preference
Notes Psoriasisfonden sponsored the trial.
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Sadeghian 2011
Methods DESIGN
Between-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 60
Treatment duration: 12 wks; FU: 12 wks
LF: 0 (0%)
BC: yes
Age: 32.5 (15.6SD)
Gender (per cent men): 51.7%
Severity: PASI = 3.9 (1.9SD)
INCLUSION CRITERIA
• Participants aged ≥ 5 with plaque psoriasis
• BSA ≤ 10%
EXCLUSION CRITERIA
• Pregnancy
• Non-plaque types of psoriasis
• Participants with scalp and facial lesions
Interventions • Zinc pyrithione 0.25% cream twice daily
• Placebo cream twice daily
Outcomes 1. PASI (0 to 72)
Notes The sponsor was not stated.
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Vahlquist 2004
Methods DESIGN
Within-patient
Participant delivery
ALLOCATION
Random
Method of randomisation: not stated
Concealment: unclear
BLINDING
Double-blind (participant/investigator)
WITHDRAWAL/DROPOUT
Described
Participants N: 12
Treatment duration: 8 wks; FU: x wks
LF: 0 (0%)
BC: no
Age: 43.8 (range = 21 to 58)
Gender (per cent men): 83.3%
Severity: NS
INCLUSION CRITERIA
• Participants with mild to moderate plaque psoriasis
EXCLUSION CRITERIA
• Systemic or topical therapy within previous 4 wks
Interventions • Thyroid hormone analogue (TriAc) 0.1% in hydrophilic ointment twice daily
• Placebo ointment twice daily
Outcomes 1. Psoriasis Severity Index
2. VAS to assess patient preference
Notes -
Yang 1999
Methods This will need to be translated; details to follow at next update
Participants N: 60
Treatment duration: 6 wks; FU: 6 wks
LF: unclear
BC: unclear
Age: range = 14 to 65
Gender (per cent men): unclear
Severity: unclear
INCLUSION CRITERIA
• Unclear
EXCLUSION CRITERIA
• Unclear
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Yang 1999 (Continued)
Interventions • Tacalcitol ointment
• 17 alpha hydrocortisone cream
Outcomes This will need to be translated; details to follow at next update
Notes This will need to be translated; details to follow at next update
Characteristics of ongoing studies [ordered by study ID]
NCT00824980
Trial name or title Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in
the Treatment of Psoriasis - Phase II Single Center Study
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants • Age 18 years of age at pre-study
• Diagnosis of plaque type psoriasis at least 3 month prior to enrolment
• Mild to moderate plaque type psoriasis with at least 2 plaques of approximately 15 cm² for which
topical treatment is indicated
Interventions • Drug: IP10.C8 Gel
• Placebo Gel
Outcomes 1. Psoriasis Area and Severity Index at 4 weeks
Starting date January 2009
Contact information Alexander Narvarini, MD
Telephone: +41 44 255 1111
alexander.navarini@usz.ch
Notes Immune Technologies & Medicine GmbH
http://clinicaltrials.gov/show/NCT00824980
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NCT01018134
Trial name or title A Double-Blind, Vehicle-Controlled, Randomized, Dose Ranging, Multiple-Site Clinical Study to Evaluate
the Efficacy and Safety of Desoximetasone Topical Sprays (0.05%, 0.25%) in Patients With Moderate to
Severe Plaque Psoriasis
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants • Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area
(BSA)
• Have a combined Total Lesion Severity Score (TLSS) of ≥ 7 for the target lesion
• Have a plaque elevation score ≥ 3 of (moderate) for the target lesion
• The target lesion must have an area of at least 5 cm²
• Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the
overall disease severity
Interventions • Drug: desoximetasone 0.05% once daily
• Drug: desoximetasone 0.05% twice daily
• Drug: desoximetasone 0.25% once daily
• Drug: desoximetasone 0.25% once daily
• Drug: vehicle once daily
• Drug: vehicle twice daily
Outcomes 1. Clinical cure: Physician’s Global Assessment (PGA) = 0 or 1 (time frame: 28 days)
2. Lesion treatment success, score of 0 or 1, for each of the 3 signs of erythema, scaling, and plaque
elevation (time frame: day 28)
Starting date November 2009
Contact information Darin B Brimhall, D.O., FACP
Study Director
Novum Pharmaceutical Research Services
Notes Taro Pharmaceuticals USA
http://clinicaltrials.gov/show/NCT01018134
NCT01206387
Trial name or title A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate
the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque
Psoriasis
Methods Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator, outcomes assessor)
Primary purpose: treatment
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NCT01206387 (Continued)
Participants Genders eligible for study: both
Accepts healthy volunteers: no
• Men or non-pregnant, non-lactating women 18 years of age or older
• Have a definite clinical diagnosis of stable plaque psoriasis involving ≥10% of the body surface area
(BSA)
• Have a combined Total Lesion Severity Score (TLSS) of ≥ 7 for the target lesion
• Have a plaque elevation score ≥ 3 of (moderate) for the target lesion
• The target lesion must have an area of at least 5 cm²
• Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the
overall disease severity
Interventions • Drug: desoximetasone spray 0.25%
• Drug: placebo comparator
Outcomes 1. Clinical success (time frame: 28 days) - a participant is considered a clinical success if the Physician’s
Global Assessment (PGA) is 0 (clear) or 1 (almost clear)
2. Treatment success (time frame: 28 days) - a participant is considered a treatment success for the target
lesions if the target lesion has a score of 0 or 1 on the Target Lesion Severity Score (TLSS) for each of the 3
signs and symptoms (erythema, scaling, and plaque elevation)
SECONDARY OUTCOMES
1. Change in PGA (time frame: 28 days) - mean change from baseline to end of treatment in PGA
Starting date August 2010
Contact information Gail Gongas
Telephone: 412 363 3300 ext: 522
GDGongas@novumprs.com
Notes Taro Pharmaceuticals USA
Study ID number: DSXS-0808
http://clinicaltrials.gov/show/NCT01206387
NCT01206660
Trial name or title A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate
the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque
Psoriasis
Methods Study type: Interventional
Study design: Allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator, outcomes assessor)
Primary purpose: treatment
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NCT01206660 (Continued)
Participants Accepts healthy volunteers: no
• Men or non-pregnant, non-lactating women 18 years of age or older
• Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area
(BSA)
• Have a combined Total Lesion Severity Score (TLSS) of ≥ 7 for the target lesion
• Have a plaque elevation score ≥ 3 of (moderate) for the target lesion
• The target lesion must have an area of at least 5 cm²
• Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the
overall disease severity
Interventions • Drug: desoximetasone spray 0.25%
• Drug: placebo
Outcomes PRIMARY OUTCOMES
1. Clinical success (time frame: 28 days) - a participant is considered a clinical success if the Physician’s
Global Assessment (PGA) is 0 (clear) or 1 (almost clear)
2. Treatment success (time frame: 28 days) - a participant is considered a treatment success for the target
lesions if the target lesion has a score of 0 or 1 on the Target Lesion Severity Score (TLSS) for each of the 3
signs and symptoms (erythema, scaling, and plaque elevation)
SECONDARY OUTCOMES
1. Change in PGA (time frame: 28 days)
2. Mean change from baseline to end of treatment in PGA
Starting date August 2010
Contact information Gail Gongas
Telephone: 412 363 3300 ext: 522
GDGongas@novumprs.com
Notes Taro Pharmaceuticals USA
Study ID number: DSXS-0914
http://clinicaltrials.gov/show/NCT01206660
NCT01246583
Trial name or title A Phase 2a, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Of The Pilot
Efficacy, Safety, And Pharmacokinetics Of 2 Ointment Formulations Of CP-690,550 In Subjects With Mild
To Moderate Chronic Plaque Psoriasis
Methods Study type: interventional
Study design: allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, investigator)
Primary purpose: treatment
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NCT01246583 (Continued)
Participants Ages eligible for study: 18 years and older
Genders eligible for study: both
Accepts healthy volunteers: no
INCLUSION CRITERIA
• Mild to moderate chronic plaque psoriasis (psoriasis vulgaris), with the duration of at least 6 months
• A target plaque of at least 9 sq. cm
EXCLUSION CRITERIA
• Demonstrates “rebound” or “flare” of chronic plaque psoriasis
• Non-plaque form of psoriasis
• Currently have or history of psoriatic arthritis
• Current drug-induced psoriasis
• Currently on systemic therapy or was on systemic therapy for psoriasis within the previous 6 months
• Currently on phototherapy for psoriasis or was on phototherapy within the previous 3 months
Interventions • Drug: CP-690,550 ointment 1
• Drug: vehicle 1
• Drug: CP-690,550 ointment 2
• Drug: vehicle 2
Outcomes PRIMARY OUTCOMES
• Per cent change from baseline at week 4 in Target Plaque Severity Score (TPSS)
SECONDARY OUTCOMES
• Proportion of participants with Treatment Area Overall Severity of Psoriasis response of “clear” (0) or
“almost clear”
• Proportion of participants with a difference from baseline of > = 2 steps in Treatment Area Overall
Severity of Psoriasis score
• Per cent change from baseline at weeks 1, 2, 3, and 4 in target plaque area
• Change from baseline at weeks 1, 2, 3, and 4 in TPSS subscores for erythema, induration, and scaling
• Per cent change from baseline in TPSS
• Actual and change from baseline on the treatment area Itch Severity Item (ISI)
• Proportion of participants in each Patient Satisfaction with Study Medication (PSSM) response
category
• Incidence, nature, and severity of observed and reported administration site adverse events over 4
weeks of treatment
• Incidence and severity of burning/stinging of psoriatic or perilesional skin in the treatment area over 4
weeks of treatment
• Incidence and severity of reactions of perilesional skin in the treatment area as measured by Draize
scoring over 4 weeks of treatment
• Incidence and severity of adverse events over 4 weeks of treatment
• Incidence of clinical laboratory abnormalities and change from baseline in clinical laboratory values
over 4 weeks of treatment
• Incidence of clinically significant changes in physical examination from baseline over 4 weeks of
treatment
• Incidence of vital sign (blood pressure and heart rate) abnormalities and change from baseline in vital
sign measures over 4 weeks of treatment
• Incidence of electrocardiogram (ECG) abnormalities and change from baseline in ECG measures over
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NCT01246583 (Continued)
4 weeks of treatment
• Plasma CP-690,550 concentrations, from blood sampling
Starting date November 22 2010
Contact information Pfizer CT.gov Call Center
Notes Pfizer
NCT01247818
Trial name or title A Phase 2 Dose-Randomized, Vehicle-Controlled Study of PH-10-Aqueous Hydrogel for the Treatment of
Plaque Psoriasis
Methods Study type: interventional
Study design: allocation: randomised
End point classification: safety/efficacy study
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment
Participants Accepts healthy volunteers: no
• Men or women, age 18 or older
• Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles,
scalp, and facial or intertriginous areas)
• Fitzpatrick skin type I to VI
• Written informed consent by the participant or legal guardian
Interventions • Drug: PH-10 (0.002% Rose Bengal)
• Drug: PH-10 (0.005% Rose Bengal)
• Drug: PH-10 (0.01% Rose Bengal)
• Drug: vehicle
Outcomes PRIMARY OUTCOMES
• The primary efficacy end point is “Treatment Success,” a static end point assessed at day 29 after initial
PH-10 treatment and defined as 0 or 1 on all Psoriasis Severity Index (PSI) components and 0 or 1 on the
Plaque Response scale (time frame: 28 days)
• The primary safety end point is incidence of adverse experiences, including pain and dermatologic/
skin toxicity (incidence, severity, frequency, duration, and causality) (time frame: 8 weeks)
SECONDARY OUTCOMES
• Psoriasis Severity Index (PSI) score changes at each visit from day 1 pre-treatment (time frame: 8 weeks)
• Plaque Response score changes at each visit from day 1 pre-treatment (time frame: 8 weeks)
• Pruritus Self-Assessment score changes at each visit from day 1 pre-treatment (time frame: 8 weeks)
Starting date December 2010
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NCT01247818 (Continued)
Contact information Eric Wachter, PhD
Provectus Pharmaceuticals
Notes Provectus Pharmaceuticals
http://clinicaltrials.gov/show/NCT01247818
NCT01422434
Trial name or title Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in
Japanese Subjects With Psoriasis Vulgaris
Methods Study type: interventional
Study design: allocation: randomised
End point classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Accepts healthy volunteers: No
Participants having understood and signed a written informed consent form prior to any study related
procedures being carried out
• Japanese participants
• 20 years of age or above of either sex
• Clinical diagnosis of psoriasis vulgaris amenable to topical treatment, involving arms, trunk, legs, or
any of the aforementioned
• A minimum mPASI score for extent of 2 in at least 1 body region (i.e. psoriasis affecting at least 10%
of arms, 10% of trunk, 10% of legs, or any of the aforementioned)
• Psoriasis vulgaris on the trunk/limbs (excluding psoriasis on the genitals/skin folds) of not more than
30% body surface area (BSA)
• A target lesion of a minimum of 5 cm at its longest axis and preferably not located on an elbow or
knee, scoring at least 3 for each of redness, thickness, and scaliness, and at least 10 in total by the physician’s
assessment of severity of the target lesion - a physician’s global assessment of disease severity of psoriasis on
trunk/limbs of mild, moderate, severe, or very severe
• Women of childbearing potential must have a negative result for a urine pregnancy test at day 0 (Visit
1) and must agree to use an adequate method of birth control, as judged by the (sub)investigator, during the
study. The contraceptive method should have started an adequate amount of time before the pregnancy test,
which is dependent on the particular method used and as judged by the (sub)investigator, and must
continue for at least 1 week after the last application of study medication. A woman is defined as not of
child-bearing potential if she is postmenopausal (12 months with no menses without an alter-native medical
cause) or surgically sterile (tubal ligation/section, hysterectomy, or bilateral ovariectomy)
Interventions • Drug: LEO 90105 = calcipotriol + betamethasone dipropionate
• Drug: Dovonex® = calcipotriol
• Drug: Rinderon® - DP = betamethasone dipropionate
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NCT01422434 (Continued)
Outcomes PRIMARY OUTCOMES
1. Change from baseline in Psoriasis Area and Severity Index (PASI) (time frame: week 0, week 4)
SECONDARY OUTCOMES
1. Change from baseline in target lesion assessment (time frame: week 0, week 4
2. Physician’s global assessment of psoriasis (time frame: week 4)
3. Adverse events (time frame: week 4)
Starting date July 2011
Contact information Akira Ozawa, MD, Professor, Principal Investigator
Tokai University School of Medicine
Notes LEO 90105 ointment contains both calcipotriol and betamethasone dipropionate. It has been approved for
the treatment of psoriasis in more than 60 centres, including most European countries, the US, China, Korea,
and Taiwan. This trial will investigate its safety and efficacy in the treatment of Japanese participants with
psoriasis
LEO Pharma
http://clinicaltrials.gov/show/NCT01422434
NCT01465282
Trial name or title A Randomized, Placebo-controlled, Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.
05%, 0.1% and 0.5% w/w Topical CT327 When Applied Twice Daily in Subjects With Psoriasis Vulgaris
Methods Study type: interventional
Study design: allocation: randomised
End point classification: safety/efficacy study
Intervention model: single group assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Accepts healthy volunteers: no
INCLUSION CRITERIA
• Men and women aged at least 18 years.
• Stable psoriasis vulgaris
EXCLUSION CRITERIA
• Participants with guttate, erythrodermic, exfoliative, or pustular psoriasis.
Interventions • Drug: CT327 0.05%
• Drug: CT327 0.1%
• Drug: CT327 0.5%
• Drug: placebo
Outcomes PRIMARY OUTCOMES
1. Efficacy of CT327 ointment (0.05%, 0.1%, and 0.5% w/w) compared with placebo ointment
SECONDARY OUTCOMES
1. Local and systemic toleration
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NCT01465282 (Continued)
Starting date November 1, 2011
Contact information No contacts or locations provided
Notes Creabilis SA
NCT01536886
Trial name or title LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle
and Ointment Vehicle in Subjects With Psoriasis Vulgaris
Methods Allocation: randomised
End point classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Accepts healthy volunteers: no
INCLUSION CRITERIA
• Signed and dated informed consent obtained prior to any trial-related activities (including wash-out
period)
• Age 18 years or above
• Either sex
• Any race or ethnicity
• All skin types
• Women of childbearing potential must have a negative pregnancy test at day 0 (Visit 1)
• Women of childbearing potential must agree to use a highly effective method of birth control during
the study. A highly effective method of birth control is defined as 1 which results in a low failure rate (less
than 1% per year)
• Able to communicate with the investigator and understand and comply with the requirements of the
study
EXCLUSION CRITERIA
• Systemic treatment with biological therapies, whether marketed or not, with a possible effect on
psoriasis vulgaris within the following time periods prior to randomisation:
◦ etanercept - within 4 weeks prior to randomisation
◦ adalimumab, alefacept, infliximab - within 8 weeks prior to randomisation
◦ ustekinumab - within 16 weeks prior to randomisation
◦ other products - 4 weeks/5 half-lives (whichever is longer)
• Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g.
corticosteroids, retinoids, methotrexate, ciclosporin, and other immunosuppressants) within 4 weeks prior
to randomisation
• Participants who have received treatment with any non-marketed drug substance (i.e. a drug which has
not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is
longer) prior to randomisation
• PUVA therapy within 4 weeks prior to randomisation
• UVB therapy within 2 weeks prior to randomisation
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NCT01536886 (Continued)
• Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial
sunlight (including tanning booths, sun lamps, etc) during the study
• Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g.
beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the study
• Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
• Participants with any of the following conditions present on the treatment area: viral (e.g. herpes or
varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in
relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins,
icthyosis, ulcers, and wounds
• Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis) on the treatment
area that may confound the evaluation of psoriasis vulgaris
• Known or suspected disorders of calcium metabolism associated with hypercalcaemia
• Known or suspected severe renal insufficiency or severe hepatic disorders.
• Known or suspected hypersensitivity to component(s) of the investigational products
• Current participation in any other interventional clinical study
• Previously randomised in this study
• Women who are pregnant, wishing to become pregnant during the study, or are breast-feeding
Interventions • Drug: LEO 90100
• Drug: betamethasone plus calcipotriol
• Drug: ointment vehicle
• Drug: LEO 90100 vehicle
Outcomes 1. Investigator’s Global Assessment of Disease Severity (time frame: 4 weeks) Designated as safety issue: no
Starting date May 2012
Contact information Anders Ninn Hansen, MSc Pharm
Telephone: +45 72 26 28 18 ext: 2818
anders.n-hansen@leo-pharma.com
Notes -
NCT01536938
Trial name or title LEO 90100 in the Treatment of Psoriasis Vulgaris
Methods Study type: interventional
Study design: allocation: randomised
End point classification: efficacy study
Intervention model: parallel assignment
Masking: double-blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Accepts healthy volunteers: no
INCLUSION CRITERIA
• Signed and dated informed consent obtained prior to any trial related activities (including wash-out
period)
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NCT01536938 (Continued)
• Age 18 years or above of either sex
• Any race or ethnicity
• All skin types
• Women of childbearing potential must have a negative pregnancy test at day 0 (Visit 1)
• Women of childbearing potential must agree to use a highly effective method of birth control during
the study. A highly effective method of birth control is defined as one which results in a low failure rate (less
than 1% per year)
• Able to communicate with the investigator and understand and comply with the requirements of the
study
EXCLUSION CRITERIA
• Systemic treatment with biological therapies, whether marketed or not, with a possible effect on
psoriasis vulgaris within the following time periods prior to randomisation:
◦ etanercept - within 4 weeks prior to randomisation
◦ adalimumab, alefacept, infliximab - within 8 weeks prior to randomisation
◦ ustekinumab - within 16 weeks prior to randomisation
◦ other products - 4 weeks/5 half-lives (whichever is longer)
• Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g.
corticosteroids, retinoids, methotrexate, ciclosporin, and other immunosuppressants) within 4 weeks prior
to randomisation
• Participants who have received treatment with any non-marketed drug substance (i.e. a drug which has
not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is
longer) prior to randomisation
• PUVA therapy within 4 weeks prior to randomisation
• UVB therapy within 2 weeks prior to randomisation
• Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial
sunlight (including tanning booths, sun lamps, etc) during the study
• Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g.
beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the study
• Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis
• Participants with any of the following conditions present on the treatment area: viral (e.g. herpes or
varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in
relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins,
icthyosis, ulcers, and wounds
• Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis) on the treatment
area that may confound the evaluation of psoriasis vulgaris
• Known or suspected disorders of calcium metabolism associated with hypercalcaemia
• Known or suspected severe renal insufficiency or severe hepatic disorders
• Known or suspected hypersensitivity to component(s) of the investigational products
• Current participation in any other interventional clinical study
• Previously randomised in this study
Interventions • Drug: LEO 90100
• Drug: calcipotriol
• Drug: betamethasone
Outcomes 1. Investigator’s Global Assessment of Disease Severity (time frame: 4 weeks)
(Designated as safety issue: no)
Starting date May 2012
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NCT01536938 (Continued)
Contact information Anders Ninn Hansen, MSc Pharm
Telephone: +45 72 26 28 18 ext: 2818
anders.n-hansen@leo-pharma.com
Notes -
373Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Vitamin D analogues versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 20 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol 10 2287 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.17, -0.68]
1.2 Calcipotriol plus occlusion 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Calcitriol 6 1120 Std. Mean Difference (IV, Random, 95% CI) -1.03 [-1.71, -0.36]
1.4 Tacalcitol 2 433 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.41, -0.26]
1.5 Maxacalcitol 1 103 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-1.91, -0.96]
1.6 Paricalcitol OD 1 22 Std. Mean Difference (IV, Random, 95% CI) -1.66 [-2.66, -0.67]
1.7 Becocalcidiol OD 1 121 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.58, 0.14]
1.8 Becocalcidiol twice daily 1 119 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.04, -0.30]
2 TSS 19 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Calcipotriol 10 1208 Std. Mean Difference (IV, Random, 95% CI) -1.15 [-1.41, -0.89]
2.2 Calcipotriol plus occlusion 1 187 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.44, 0.14]
2.3 Calcitriol 4 1027 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-2.38, -0.07]
2.4 Tacalcitol 3 496 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-0.95, -0.36]
2.5 Maxacalcitol 1 103 Std. Mean Difference (IV, Random, 95% CI) -1.61 [-2.10, -1.12]
2.6 Paricalcitol OD 1 22 Std. Mean Difference (IV, Random, 95% CI) -2.15 [-3.24, -1.06]
2.7 Becocalcidiol OD 1 121 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.37, 0.34]
2.8 Becocalcidiol twice daily 1 119 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.83, -0.10]
3 PASI 9 2422 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.71, -0.45]
3.1 Calcipotriol 8 2195 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-0.75, -0.55]
3.2 Calcipotriol plus occlusion 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Calcitriol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Tacalcitol 1 227 Std. Mean Difference (IV, Random, 95% CI) -0.27 [-0.56, 0.03]
3.5 Maxacalcitol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Paricalcitol OD 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Becocalcidiol OD 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Becocalcidiol twice daily 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 5 1467 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-0.72, -0.36]
4.1 Calcipotriol 2 439 Std. Mean Difference (IV, Random, 95% CI) -0.64 [-0.97, -0.30]
4.2 Calcipotriol plus occlusion 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcitriol 2 801 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-0.76, -0.41]
4.4 Tacalcitol 1 227 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.53, 0.05]
4.5 Maxacalcitol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Paricalcitol OD 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Becocalcidiol OD 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Becocalcidiol twice daily 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
30 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol 17 3269 Std. Mean Difference (IV, Random, 95% CI) -0.96 [-1.15, -0.77]
5.2 Calcipotriol plus occlusion 1 187 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.44, 0.14]
5.3 Calcitriol 7 1140 Std. Mean Difference (IV, Random, 95% CI) -0.92 [-1.54, -0.29]
5.4 Tacalcitol 4 723 Std. Mean Difference (IV, Random, 95% CI) -0.73 [-1.09, -0.37]
5.5 Maxacalcitol 1 103 Std. Mean Difference (IV, Random, 95% CI) -1.43 [-1.91, -0.96]
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5.6 Paricalcitol OD 1 22 Std. Mean Difference (IV, Random, 95% CI) -1.66 [-2.66, -0.67]
5.7 Becocalcidiol OD 1 121 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.58, 0.14]
5.8 Becocalcidiol twice daily 1 119 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.04, -0.30]
6 Total withdrawals 25 4715 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.05, 0.00]
6.1 Calcipotriol 14 3132 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.06, 0.00]
6.2 Calcipotriol plus occlusion 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Calcitriol 5 339 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.02]
6.4 Tacalcitol 4 857 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.14, 0.05]
6.5 Maxacalcitol 1 120 Risk Difference (M-H, Random, 95% CI) 0.11 [-0.01, 0.23]
6.6 Paricalcitol OD 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
6.7 Becocalcidiol OD 1 124 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.12, 0.11]
6.8 Becocalcidiol twice daily 1 121 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.13, 0.10]
7 Withdrawals due to adverse
events
23 4463 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
7.1 Calcipotriol 12 2880 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.04, 0.00]
7.2 Calcipotriol plus occlusion 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Calcitriol 5 339 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.02]
7.4 Tacalcitol 4 857 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.01, 0.02]
7.5 Maxacalcitol 1 120 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.08, 0.06]
7.6 Paricalcitol OD 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
7.7 Becocalcidiol OD 1 124 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.02, 0.08]
7.8 Becocalcidiol twice daily 1 121 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.01, 0.11]
8 Withdrawals due to treatment
failure
14 2752 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.05, 0.00]
8.1 Calcipotriol 7 1770 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.08, 0.01]
8.2 Calcipotriol plus occlusion 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Calcitriol 4 281 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.12, 0.05]
8.4 Tacalcitol 1 314 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
8.5 Maxacalcitol 1 120 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.11, 0.04]
8.6 Paricalcitol OD 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
8.7 Becocalcidiol OD 1 124 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.07, 0.04]
8.8 Becocalcidiol twice daily 1 121 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.09, 0.02]
9 Adverse events (local) 19 4402 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.01, 0.02]
9.1 Calcipotriol 11 2652 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.03, 0.05]
9.2 Calcipotriol plus occlusion 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Calcitriol 4 917 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.03, 0.02]
9.4 Tacalcitol 2 566 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.03, 0.03]
9.5 Maxacalcitol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.6 Paricalcitol OD 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
9.7 Becocalcidiol OD 1 124 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.06, 0.08]
9.8 Becocalcidiol twice daily 1 121 Risk Difference (M-H, Random, 95% CI) 0.10 [0.00, 0.19]
10 Adverse events (systemic) 14 2463 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.1 Calcipotriol 8 1182 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.2 Calcipotriol plus
occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Calcitriol 3 647 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.4 Tacalcitol 1 244 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
10.5 Maxacalcitol 1 120 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
10.6 Paricalcitol OD 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
10.7 Becocalcidiol OD 1 124 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
10.8 Becocalcidiol twice daily 1 124 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
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Comparison 2. Corticosteroid (potent) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 11 1904 Std. Mean Difference (IV, Random, 95% CI) 1.00 [-1.18, -0.82]
1.1 Betamethasone
dipropionate OD
2 739 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-0.98, -0.64]
1.2 Betamethasone
dipropionate twice daily
4 537 Std. Mean Difference (IV, Random, 95% CI) -1.35 [-1.56, -1.15]
1.3 Betamethasone
dipropionate, maintenance
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Betamethasone valerate 1 74 Std. Mean Difference (IV, Random, 95% CI) -1.41 [-1.92, -0.90]
1.5 Budesonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.6 Desonide 1 76 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-1.34, -0.28]
1.7 Diflorasone diacetate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.8 Fluticasone propionate 2 383 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.14, -0.72]
1.9 Hydrocortisone buteprate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Mometasone furoate 1 95 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.17, -0.34]
2 TSS 7 611 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.01, -0.52]
2.1 Betamethasone
dipropionate OD
1 93 Std. Mean Difference (IV, Random, 95% CI) -0.74 [-1.16, -0.32]
2.2 Betamethasone
dipropionate twice daily
1 33 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.48, -0.06]
2.3 Betamethasone
dipropionate, maintenance
1 38 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.62, -0.27]
2.4 Betamethasone valerate 1 22 Std. Mean Difference (IV, Random, 95% CI) -1.09 [-2.00, -0.18]
2.5 Budesonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.6 Desonide 1 76 Std. Mean Difference (IV, Random, 95% CI) -1.16 [-1.70, -0.61]
2.7 Diflorasone diacetate 1 93 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.73, 0.09]
2.8 Fluticasone propionate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Hydrocortisone buteprate 1 161 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.77, -0.15]
2.10 Mometasone furoate 1 95 Std. Mean Difference (IV, Random, 95% CI) -1.12 [-1.55, -0.68]
3 PASI 3 1158 Std. Mean Difference (IV, Random, 95% CI) -0.97 [-1.31, -0.62]
3.1 Betamethasone
dipropionate OD
2 739 Std. Mean Difference (IV, Random, 95% CI) -0.79 [-1.44, -0.14]
3.2 Betamethasone
dipropionate twice daily
1 419 Std. Mean Difference (IV, Random, 95% CI) -1.21 [-1.44, -0.97]
3.3 Betamethasone
dipropionate, maintenance
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Betamethasone valerate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Budesonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Desonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Diflorasone diacetate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Fluticasone propionate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.9 Hydrocortisone buteprate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.10 Mometasone furoate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.1 Betamethasone
dipropionate OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4.2 Betamethasone
dipropionate twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Betamethasone
dipropionate, maintenance
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Betamethasone valerate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Budesonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Desonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Diflorasone diacetate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Fluticasone propionate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.9 Hydrocortisone buteprate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.10 Mometasone furoate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
15 2311 Std. Mean Difference (IV, Random, 95% CI) -0.89 [-1.06, -0.72]
5.1 Betamethasone
dipropionate OD
3 832 Std. Mean Difference (IV, Random, 95% CI) -0.80 [-0.96, -0.64]
5.2 Betamethasone
dipropionate twice daily
4 537 Std. Mean Difference (IV, Random, 95% CI) -1.35 [-1.56, -1.15]
5.3 Betamethasone
dipropionate, maintenance
1 38 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.62, -0.27]
5.4 Betamethasone valerate 2 96 Std. Mean Difference (IV, Random, 95% CI) -1.33 [-1.78, -0.89]
5.5 Budesonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.6 Desonide 1 76 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-1.34, -0.28]
5.7 Diflorasone diacetate 1 93 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.73, 0.09]
5.8 Fluticasone propionate 2 383 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.14, -0.72]
5.9 Hydrocortisone buteprate 1 161 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.77, -0.15]
5.10 Mometasone furoate 1 95 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.17, -0.34]
6 Total withdrawals 9 1673 Risk Difference (M-H, Random, 95% CI) -0.14 [-0.22, -0.05]
6.1 Betamethasone
dipropionate OD
2 756 Risk Difference (M-H, Random, 95% CI) -0.16 [-0.28, -0.04]
6.2 Betamethasone
dipropionate twice daily
1 421 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.12, 0.01]
6.3 Betamethasone
dipropionate, maintenance
2 134 Risk Difference (M-H, Random, 95% CI) -0.45 [-0.60, -0.30]
6.4 Betamethasone valerate 1 80 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
6.5 Budesonide 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
6.6 Desonide 1 80 Risk Difference (M-H, Random, 95% CI) -0.18 [-0.38, 0.02]
6.7 Diflorasone diacetate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.8 Fluticasone propionate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.9 Hydrocortisone buteprate 1 180 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.09, 0.10]
6.10 Mometasone furoate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
9 1292 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.05, 0.02]
7.1 Betamethasone
dipropionate OD
1 633 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.11, -0.02]
7.2 Betamethasone
dipropionate twice daily
1 33 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
7.3 Betamethasone
dipropionate, maintenance
2 134 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
7.4 Betamethasone valerate 1 80 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.02, 0.17]
7.5 Budesonide 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
7.6 Desonide 1 80 Risk Difference (M-H, Random, 95% CI) -0.1 [-0.24, 0.04]
7.7 Diflorasone diacetate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7.8 Fluticasone propionate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.9 Hydrocortisone buteprate 1 190 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.04]
7.10 Mometasone furoate 1 120 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.11, 0.01]
8 Withdrawals due to treatment
failure
6 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Betamethasone
dipropionate OD
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Betamethasone
dipropionate twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Betamethasone
dipropionate, maintenance
2 130 Risk Difference (M-H, Random, 95% CI) -0.46 [-0.61, -0.31]
8.4 Betamethasone valerate 1 80 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
8.5 Budesonide 1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
8.6 Desonide 1 80 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
8.7 Diflorasone diacetate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.8 Fluticasone propionate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.9 Hydrocortisone buteprate 1 190 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
8.10 Mometasone furoate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 10 2117 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.08, -.00]
9.1 Betamethasone
dipropionate OD
2 756 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.15, -0.04]
9.2 Betamethasone
dipropionate twice daily
2 454 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.12, 0.03]
9.3 Betamethasone
dipropionate, maintenance
2 134 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
9.4 Betamethasone valerate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.5 Budesonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.6 Desonide 1 80 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
9.7 Diflorasone diacetate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.8 Fluticasone propionate 1 383 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.05, 0.05]
9.9 Hydrocortisone buteprate 1 190 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.18, 0.07]
9.10 Mometasone furoate 1 120 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.23, 0.02]
10 Adverse events (systemic) 4 675 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.01, 0.01]
10.1 Betamethasone
dipropionate OD
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Betamethasone
dipropionate twice daily
1 421 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.3 Betamethasone
dipropionate, maintenance
2 134 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.07, 0.10]
10.4 Budesonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Desonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.6 Diflorasone diacetate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.7 Fluticasone propionate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.8 Hydrocortisone
buteprate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.9 Betamethasone valerate 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.10 Mometasone furoate 1 120 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
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Comparison 3. Corticosteroid (very potent) versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 5 540 Std. Mean Difference (IV, Random, 95% CI) -1.87 [-2.38, -1.36]
1.1 Clobetasol propionate 4 471 Std. Mean Difference (IV, Random, 95% CI) -1.89 [-2.53, -1.24]
1.2 Halcinonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Halobetasol 1 69 Std. Mean Difference (IV, Random, 95% CI) -1.81 [-2.37, -1.24]
2 TSS 3 545 Std. Mean Difference (IV, Random, 95% CI) -1.35 [-1.80, -0.89]
2.1 Clobetasol propionate 3 545 Std. Mean Difference (IV, Random, 95% CI) -1.35 [-1.80, -0.89]
2.2 Halcinonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Halobetasol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Clobetasol propionate 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Halcinonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Halobetasol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 3 487 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-1.42, -1.02]
4.1 Clobetasol propionate 1 79 Std. Mean Difference (IV, Random, 95% CI) -1.01 [-1.55, -0.47]
4.2 Halcinonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Halobetasol 2 408 Std. Mean Difference (IV, Random, 95% CI) -1.25 [-1.46, -1.04]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
10 1493 Std. Mean Difference (IV, Random, 95% CI) -1.56 [-1.87, -1.26]
5.1 Clobetasol propionate 7 1016 Std. Mean Difference (IV, Random, 95% CI) -1.65 [-2.10, -1.20]
5.2 Halcinonide 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Halobetasol 3 477 Std. Mean Difference (IV, Random, 95% CI) -1.36 [-1.65, -1.07]
6 Total withdrawals 8 1181 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.10, 0.01]
6.1 Clobetasol propionate 7 1037 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.13, 0.01]
6.2 Halcinonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Halobetasol 1 144 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
7 Withdrawals due to adverse
events
10 1601 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
7.1 Clobetasol propionate 7 1037 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
7.2 Halcinonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Halobetasol 3 564 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
8 Withdrawals due to treatment
failure
8 1189 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
8.1 Clobetasol propionate 6 845 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.03, 0.01]
8.2 Halcinonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Halobetasol 2 344 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
9 Adverse events (local) 8 1265 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.02, 0.02]
9.1 Clobetasol propionate 6 845 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.03, 0.03]
9.2 Halcinonide 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Halobetasol 2 420 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
10 Adverse events (systemic) 6 1056 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
10.1 Clobetasol propionate 3 480 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.02, 0.01]
10.2 Halcinonide 1 156 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
10.3 Halobetasol 2 420 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
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Comparison 4. Dithranol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 3 94 Std. Mean Difference (IV, Random, 95% CI) -1.06 [-1.66, -0.46]
3 PASI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
3 94 Std. Mean Difference (IV, Random, 95% CI) -1.06 [-1.66, -0.46]
6 Total withdrawals 4 124 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
7 Withdrawals due to adverse
events
3 104 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
8 Withdrawals due to treatment
failure
2 44 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
9 Adverse events (local) 3 94 Risk Difference (M-H, Random, 95% CI) 0.26 [-0.30, 0.82]
10 Adverse events (systemic) 1 20 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.35, 0.35]
Comparison 5. Vitamin D combination products versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 5 2264 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-1.76, -1.12]
1.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
4 1416 Std. Mean Difference (IV, Random, 95% CI) -1.21 [-1.50, -0.91]
1.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
2 848 Std. Mean Difference (IV, Random, 95% CI) -1.90 [-2.09, -1.71]
2 TSS 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Combination calcipotriol/
betamethasone dipropionate,
once daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Combination calcipotriol/
betamethasone dipropionate,
twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 5 2263 Std. Mean Difference (IV, Random, 95% CI) -1.24 [-1.53, -0.95]
3.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
4 1414 Std. Mean Difference (IV, Random, 95% CI) -1.14 [-1.57, -0.70]
3.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
2 849 Std. Mean Difference (IV, Random, 95% CI) -1.41 [-1.86, -0.97]
4 PAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
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4.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Combination calcipotriol/
betamethasone dipropionate,
twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
5 2264 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-1.76, -1.12]
5.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
4 1416 Std. Mean Difference (IV, Random, 95% CI) -1.21 [-1.50, -0.91]
5.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
2 848 Std. Mean Difference (IV, Random, 95% CI) -1.90 [-2.09, -1.71]
6 Total withdrawals 5 2340 Risk Difference (M-H, Random, 95% CI) -0.12 [-0.17, -0.07]
6.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
4 1483 Risk Difference (M-H, Random, 95% CI) -0.15 [-0.22, -0.09]
6.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
2 857 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.12, -0.03]
7 Withdrawals due to adverse
events
3 1723 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.11, -0.04]
7.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
3 1280 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.11, -0.03]
7.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
1 443 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.14, -0.05]
8 Withdrawals due to treatment
failure
1 802 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.12, -0.06]
8.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
1 359 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.13, -0.05]
8.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
1 443 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.13, -0.05]
9 Adverse events (local) 5 2334 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.08, -0.02]
9.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
4 1479 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.11, -0.02]
9.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
2 855 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.08, 0.01]
10 Adverse events (systemic) 1 412 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.1 Combination
calcipotriol/betamethasone
dipropionate, once daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Combination
calcipotriol/betamethasone
dipropionate, twice daily
1 412 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
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Comparison 6. Other treatment versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 8 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Anti-IL-8 monoclonal
antibody cream
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Caffeine (topical) 10%,
TD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Calcipotriene 0.005%
ointment + nicotinamide 0.
05% or 0.1% or 0.7% or 1.
4%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.6 Dead Sea salts emollient
lotion
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.7 Fish oil plus occlusion 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Indigo naturalis 1.4%
ointment
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.11 Kukui nut oil, TD 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.12 Mahonia aquifolium
(Reliéva™), twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.13 Methotrexate gel 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.14 Mycophenolic acid
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.15 NG-monomethyl-L-
arginine (L-NMMA) cream
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.16 Nicotinamide 1.4%,
twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.17 Oleum horwathiensis
(Psoricur®)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.18 Omega-3-
polyunsaturated fatty acids
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.19 Platelet aggregation
activating factor (PAF)(Ro
24-0238)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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1.20 Polymyxin B cream 200,
000 U/g
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.22 Sirolimus (topical), 2.
2% for 6 wks, then 8% for a
further 6 wks
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.23 Tacrolimus ointment 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.24 Tar 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.25 Tazarotene 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.26 Theophylline 1%
ointment, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Anti-IL-8 monoclonal
antibody cream
1 89 Std. Mean Difference (IV, Random, 95% CI) -0.70 [-1.13, -0.27]
2.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Caffeine (topical) 10%,
TD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Std. Mean Difference (IV, Random, 95% CI) -0.48 [-0.81, -0.15]
2.6 Dead Sea salts emollient
lotion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Fish oil plus occlusion 1 50 Std. Mean Difference (IV, Random, 95% CI) -1.05 [-1.64, -0.46]
2.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Hexafluoro-1,25-
dihydroxyvitamin D3, twice
daily
1 30 Std. Mean Difference (IV, Random, 95% CI) -1.13 [-1.91, -0.35]
2.10 Indigo naturalis 1.4%
ointment
2 88 Std. Mean Difference (IV, Random, 95% CI) -1.64 [-2.13, -1.15]
2.11 Kukui nut oil, TD 1 24 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.48, 1.14]
2.12 Mahonia aquifolium
(Reliéva™), twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.13 Methotrexate gel 1 82 Std. Mean Difference (IV, Random, 95% CI) -0.48 [-0.92, -0.04]
2.14 Mycophenolic acid
ointment
1 14 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-2.67, -0.22]
2.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.60, 0.75]
2.16 Nicotinamide 1.4%,
twice daily
1 96 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.60, 0.20]
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2.17 Oleum horwathiensis
(Psoricur®)
1 42 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.40, -0.14]
2.18 Omega-3-
polyunsaturated fatty acids
ointment
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.19 Platelet aggregation
activating factor (PAF)(Ro 24-
0238)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.20 Polymyxin B cream
200,000 U/g
1 30 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.59, 0.85]
2.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Std. Mean Difference (IV, Random, 95% CI) -2.31 [-3.26, -1.36]
2.22 Sirolimus (topical), 2.2%
for 6 wks, then 8% for a further
6 wks
1 44 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.98, 0.21]
2.23 Tacrolimus ointment 1 47 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.52, 0.63]
2.24 Tar 1 36 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-1.11, 0.22]
2.25 Tazarotene 1 318 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.11, -0.62]
2.26 Theophylline 1%
ointment, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 9 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Anti-IL-8 monoclonal
antibody cream
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Caffeine (topical) 10%,
TD
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Calcipotriene 0.005%
ointment + nicotinamide 0.
05% or 0.1% or 0.7% or 1.
4%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Dead Sea salts emollient
lotion, 30%
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Fish oil plus occlusion 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Herbal skin care
(Dr Michaels® cleansing
gel, ointment and skin
conditioner), twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.9 Hexafluoro-1,25-
dihydroxyvitamin D3, twice
daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.10 Indigo naturalis 1.4%
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.11 Kukui nut oil, twice daily 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.12 Mahonia aquifolium
(Reliéva™), twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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3.13 Methotrexate gel 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.14 Mycophenolic acid
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.15 NG-monomethyl-L-
arginine (L-NMMA) cream
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.16 Nicotinamide 1.4%,
twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.17 Oleum horwathiensis
(Psoricur®)
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.18 Omega-3-
polyunsaturated fatty acids
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.19 Platelet aggregation
activating factor (PAF)(Ro 24-
0238)
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.20 Polymyxin B cream 200,
000 U/g
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.22 Sirolimus (topical), 2.
2% for 6 wks, then 8% for a
further 6 wks
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.23 Tacrolimus ointment 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.24 Tar 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.25 Tazarotene 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.26 Theophylline 1%
ointment, twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 2 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Anti-IL-8 monoclonal
antibody cream
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Caffeine (topical) 10%,
TD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcipotriene 0.005%
ointment + nicotinamide 0.
05% or 0.1% or 0.7% or 1.
4%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Dead Sea salts emollient
lotion, 30%
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Fish oil plus occlusion 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4.9 Hexafluoro-1,25-
dihydroxyvitamin D3, twice
daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.10 Indigo naturalis 1.4%
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.11 Kukui nut oil, TD 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.12 Mahonia aquifolium
(Reliéva™), twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.13 Methotrexate gel 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.14 Mycophenolic acid
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.15 NG-monomethyl-L-
arginine (L-NMMA) cream
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.16 Nicotinamide 1.4%,
twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.17 Oleum horwathiensis
(Psoricur®)
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.18 Omega-3-
polyunsaturated fatty acids
ointment
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.19 Platelet aggregation
activating factor (PAF)(Ro 24-
0238)
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.20 Polymyxin B cream 200,
000 U/g
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.22 Sirolimus (topical), 2.
2% for 6 wks, then 8% for a
further 6 wks
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.23 Tacrolimus ointment 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.24 Tar 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.25 Tazarotene 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.26 Theophylline 1%
ointment, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 60 Std. Mean Difference (IV, Random, 95% CI) -1.58 [-2.16, -0.99]
5.2 Anti-IL-8 monoclonal
antibody cream
1 89 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-1.01, -0.16]
5.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 81 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-1.21, -0.31]
5.4 Caffeine (topical) 10%,
TD
1 78 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.84, 0.06]
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5.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Std. Mean Difference (IV, Random, 95% CI) -0.48 [-0.81, -0.15]
5.6 Dead Sea salts emollient
lotion, 30%
1 19 Std. Mean Difference (IV, Random, 95% CI) 0.57 [-0.36, 1.51]
5.7 Fish oil plus occlusion 1 50 Std. Mean Difference (IV, Random, 95% CI) -1.05 [-1.64, -0.46]
5.8 Herbal skin care
(Dr Michaels® cleansing
gel, ointment and skin
conditioner), twice daily
1 24 Std. Mean Difference (IV, Random, 95% CI) -2.96 [-4.19, -1.74]
5.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-1.35, 0.12]
5.10 Indigo naturalis 1.4%
ointment
2 88 Std. Mean Difference (IV, Random, 95% CI) -2.09 [-2.62, -1.56]
5.11 Kukui nut oil, TD 1 24 Std. Mean Difference (IV, Random, 95% CI) 0.0 [-0.80, 0.80]
5.12 Mahonia aquifolium
(Reliéva™), twice daily
1 200 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.06, -0.48]
5.13 Methotrexate gel 2 142 Std. Mean Difference (IV, Random, 95% CI) -1.05 [-2.04, -0.06]
5.14 Mycophenolic acid
ointment
1 14 Std. Mean Difference (IV, Random, 95% CI) -1.44 [-2.67, -0.22]
5.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.60, 0.75]
5.16 Nicotinamide 1.4%,
twice daily
1 96 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.60, 0.20]
5.17 Oleum horwathiensis
(Psoricur®)
1 42 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.63, 0.58]
5.18 Omega-3-
polyunsaturated fatty acids
ointment
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.19 Platelet aggregation
activating factor (PAF)(Ro
24-0238)
1 80 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.50, 0.37]
5.20 Polymyxin B cream
200,000 U/g
1 30 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.59, 0.85]
5.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Std. Mean Difference (IV, Random, 95% CI) -2.31 [-3.26, -1.36]
5.22 Sirolimus (topical), 2.2%
for 6 wks, then 8% for a further
6 wks
1 44 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.98, 0.21]
5.23 Tacrolimus ointment 1 47 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.52, 0.63]
5.24 Tar 1 36 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-1.11, 0.22]
5.25 Tazarotene 1 318 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.11, -0.62]
5.26 Theophylline 1%
ointment, twice daily
1 22 Std. Mean Difference (IV, Random, 95% CI) -2.87 [-4.13, -1.62]
6 Total withdrawals 23 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
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6.2 Anti-IL-8 monoclonal
antibody cream
1 96 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.12, 0.08]
6.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 85 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.09, 0.09]
6.4 Caffeine (topical) 10%,
TD
1 78 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
6.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.01, 0.08]
6.6 Dead Sea salts emollient
lotion
1 24 Risk Difference (M-H, Random, 95% CI) 0.25 [-0.06, 0.56]
6.7 Fish oil plus occlusion 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
6.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
6.10 Indigo naturalis 1.4%
ointment
2 112 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.15, 0.15]
6.11 Kukui nut oil, TD 1 30 Risk Difference (M-H, Random, 95% CI) -0.13 [-0.42, 0.15]
6.12 Mahonia aquifolium
(Reliéva™), twice daily
1 200 Risk Difference (M-H, Random, 95% CI) -0.23 [-0.32, -0.14]
6.13 Methotrexate gel 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
6.14 Mycophenolic acid
ointment
1 14 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.24, 0.24]
6.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
6.16 Nicotinamide 1.4%,
twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.08]
6.17 Oleum horwathiensis 1 50 Risk Difference (M-H, Random, 95% CI) 0.16 [-0.04, 0.36]
6.18
Omega-3-polyunsaturated fatty
acids ointment
1 146 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.15, 0.15]
6.19 Platelet aggregation
activating factor (PAF)(Ro
24-0238)
1 104 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
6.20 Polymyxin B cream
200,000 U/g
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.24, 0.24]
6.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
6.22 Sirolimus (topical) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.23 Tacrolimus ointment 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.24 Tar 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.25 Tazarotene 2 1627 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.01, 0.09]
6.26 Theophylline 1%
ointment, twice daily
1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
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7 Withdrawals due to adverse
events
19 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
7.2 Anti-IL-8 monoclonal
antibody cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 85 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.07, 0.06]
7.4 Caffeine (topical) 10%,
TD
1 78 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
7.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
7.6 Dead Sea salts emollient
lotion
1 24 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.18, 0.35]
7.7 Fish oil plus occlusion 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
7.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
7.10 Indigo naturalis 1.4%
ointment
2 112 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
7.11 Kukui nut oil, TD 1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
7.12 Mahonia aquifolium
(Reliéva™), twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.13 Methotrexate gel 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
7.14 Mycophenolic acid
ointment
1 14 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.24, 0.24]
7.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
7.16 Nicotinamide 1.4%,
twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
7.17 Oleum horwathiensis 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
7.18
Omega-3-polyunsaturated fatty
acids ointment
1 146 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
7.19 Platelet aggregation
activating factor (PAF)(Ro 24-
0238)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.20 Polymyxin B cream 200,
000 U/g
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
7.22 Sirolimus (topical) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7.23 Tacrolimus ointment 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.24 Tar 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.25 Tazarotene 2 1627 Risk Difference (M-H, Random, 95% CI) 0.07 [0.05, 0.10]
7.26 Theophylline 1%
ointment, twice daily
1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
8 Withdrawals due to treatment
failure
18 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
8.2 Anti-IL-8 monoclonal
antibody cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 85 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.08]
8.4 Caffeine (topical) 10%,
TD
1 78 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
8.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
8.6 Dead Sea salts emollient
lotion
1 24 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.12, 0.29]
8.7 Fish oil plus occlusion 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
8.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
8.10 Indigo naturalis 1.4%
ointment
1 28 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.13, 0.13]
8.11 Kukui nut oil, TD 1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
8.12 Mahonia aquifolium
(Reliéva™), twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.13 Methotrexate gel 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
8.14 Mycophenolic acid
ointment
1 14 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.24, 0.24]
8.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
8.16 Nicotinamide 1.4%,
twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
8.17 Oleum horwathiensis 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
8.18
Omega-3-polyunsaturated fatty
acids ointment
1 146 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
8.19 Platelet aggregation
activating factor (PAF)(Ro 24-
0238)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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8.20 Polymyxin B cream 200,
000 U/g
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
8.22 Sirolimus (topical) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.23 Tacrolimus ointment 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.24 Tar 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.25 Tazarotene 2 1627 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.04, 0.01]
8.26 Theophylline 1%
ointment, twice daily
1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
9 Adverse events (local) 21 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
9.2 Anti-IL-8 monoclonal
antibody cream
1 92 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.10, 0.14]
9.3 Betamethasone 17-valerate
21-acetate plus tretinoin plus
salicylic acid
1 85 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.07, 0.06]
9.4 Caffeine (topical) 10%,
TD
1 78 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.03, 0.13]
9.5 Calcipotriene 0.005%
ointment + nicotinamide
0.05% or 0.1% or 0.7% or
1.4%, twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.13 [-0.02, 0.27]
9.6 Dead Sea salts emollient
lotion
1 24 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.18, 0.35]
9.7 Fish oil plus occlusion 1 50 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.06, 0.14]
9.8 Herbal skin care
(Dr Michaels® cleansing
gel, ointment and skin
conditioner), twice daily
1 24 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.44, 0.27]
9.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Risk Difference (M-H, Random, 95% CI) 0.13 [-0.06, 0.33]
9.10 Indigo naturalis 1.4%
ointment
2 88 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
9.11 Kukui nut oil, TD 1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
9.12 Mahonia aquifolium
(Reliéva™), twice daily
1 200 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.06, 0.02]
9.13 Methotrexate gel 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
9.14 Mycophenolic acid
ointment
1 14 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.24, 0.24]
9.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
9.16 Nicotinamide 1.4%,
twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.10 [-0.07, 0.28]
9.17 Oleum horwathiensis 1 50 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.06, 0.14]
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9.18
Omega-3-polyunsaturated fatty
acids ointment
1 146 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.05]
9.19 Platelet aggregation
activating factor (PAF)(Ro
24-0238)
1 104 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.19, 0.19]
9.20 Polymyxin B cream 200,
000 U/g
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
9.22 Sirolimus (topical) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.23 Tacrolimus ointment 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.24 Tar 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.25 Tazarotene 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.26 Theophylline 1%
ointment, twice daily
1 22 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.16, 0.16]
10 Adverse events (systemic) 12 Risk Difference (M-H, Random, 95% CI) Subtotals only
10.1 Aloe vera extract 0.5%
hydrophilic cream, three times
per day
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Anti-IL-8 monoclonal
antibody cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Betamethasone
17-valerate 21-acetate plus
tretinoin plus salicylic acid
1 85 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
10.4 Caffeine (topical) 10%,
TD
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Calcipotriene 0.005%
ointment + nicotinamide 0.
05% or 0.1% or 0.7% or 1.
4%, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.6 Dead Sea salts emollient
lotion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.7 Fish oil plus occlusion 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.8 Herbal skin care (Dr
Michaels® cleansing gel,
ointment and skin conditioner)
, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.9 Hexafluoro-1,25-
dihydroxyvitamin D3
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
10.10 Indigo naturalis 1.4%
ointment
2 88 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
10.11 Kukui nut oil, TD 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.12 Mahonia aquifolium
(Reliéva™), twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.13 Methotrexate gel 2 166 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
10.14 Mycophenolic acid
ointment
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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10.15
NG-monomethyl-L-arginine
(L-NMMA) cream
1 34 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
10.16 Nicotinamide 1.4%,
twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.17 Oleum horwathiensis 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
10.18 Omega-3-
polyunsaturated fatty acids
ointment
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.19 Platelet aggregation
activating factor (PAF)(Ro
24-0238)
1 104 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
10.20 Polymyxin B cream
200,000 U/g
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.21 PTH (1-34) in
Novasome A® liposomal
cream, twice daily
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
10.22 Sirolimus (topical) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.23 Tacrolimus ointment 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.24 Tar 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.25 Tazarotene 2 414 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.26 Theophylline 1%
ointment, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Vitamin D analogues versus corticosteroid (potent)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol vs.
betamethasone dipropionate
3 1728 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.28, 0.58]
1.2 Calcipotriol vs.
betamethasone valerate
1 412 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.21, 0.17]
1.3 Calcipotriol vs.
desoxymetasone
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Calcipotriol vs. diflorasone
diacetate
1 256 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.02, 0.52]
1.5 Calcipotriol vs.
fluocinonide
1 99 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.99, -0.18]
1.6 Calcitriol vs.
betamethasone dipropionate
1 258 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.04, 0.45]
1.7 Calcitriol vs.
betamethasone valerate
1 30 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.91, 0.53]
1.8 Tacalcitol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Calcipotriol vs.
betamethasone dipropionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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2.2 Calcipotriol vs.
betamethasone valerate
1 684 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.41, -0.11]
2.3 Calcipotriol vs.
desoxymetasone
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Calcipotriol vs. diflorasone
diacetate
1 256 Std. Mean Difference (IV, Random, 95% CI) 0.40 [0.15, 0.65]
2.5 Calcipotriol vs.
fluocinonide
1 89 Std. Mean Difference (IV, Random, 95% CI) -0.50 [-0.92, -0.07]
2.6 Calcitriol vs.
betamethasone dipropionate
1 258 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.02, 0.51]
2.7 Calcitriol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.8 Tacalcitol vs.
betamethasone valerate
2 148 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.09, 0.74]
3 PASI 9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Calcipotriol vs.
betamethasone dipropionate
3 1728 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.22, 0.51]
3.2 Calcipotriol vs.
betamethasone valerate
4 1505 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.22, -0.02]
3.3 Calcipotriol vs.
desoxymetasone
1 20 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.73, 1.02]
3.4 Calcipotriol vs. diflorasone
diacetate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Calcipotriol vs.
fluocinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Calcitriol vs.
betamethasone dipropionate
1 258 Std. Mean Difference (IV, Random, 95% CI) 0.39 [0.14, 0.63]
3.7 Calcitriol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Tacalcitol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 2 1080 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.38, -0.14]
4.1 Calcipotriol vs.
betamethasone dipropionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol vs.
betamethasone valerate
2 1080 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.38, -0.14]
4.3 Calcipotriol vs.
desoxymetasone
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Calcipotriol vs. diflorasone
diacetate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcipotriol vs.
fluocinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Calcitriol vs.
betamethasone dipropionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Calcitriol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Tacalcitol vs.
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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5.1 Calcipotriol vs.
betamethasone dipropionate
3 1728 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.28, 0.58]
5.2 Calcipotriol vs.
betamethasone valerate
4 1557 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.26, 0.02]
5.3 Calcipotriol vs.
desoxymetasone
1 20 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.73, 1.02]
5.4 Calcipotriol vs. diflorasone
diacetate
1 256 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.02, 0.52]
5.5 Calcipotriol vs.
fluocinonide
1 99 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.99, -0.18]
5.6 Calcitriol vs.
betamethasone dipropionate
1 258 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.04, 0.45]
5.7 Calcitriol vs.
betamethasone valerate
1 30 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.91, 0.53]
5.8 Tacalcitol vs.
betamethasone valerate
2 148 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.09, 0.74]
6 Total withdrawals 11 3995 Risk Difference (M-H, Random, 95% CI) 0.02 [0.00, 0.03]
6.1 Calcipotriol vs.
betamethasone dipropionate
3 1739 Risk Difference (M-H, Random, 95% CI) 0.03 [0.01, 0.06]
6.2 Calcipotriol vs.
betamethasone valerate
3 1520 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.01, 0.04]
6.3 Calcipotriol vs.
desoxymetasone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Calcipotriol vs. diflorasone
diacetate
1 268 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
6.5 Calcipotriol vs.
fluocinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.6 Calcitriol vs.
betamethasone dipropionate
1 258 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.08, 0.03]
6.7 Calcitriol vs.
betamethasone valerate
1 30 Risk Difference (M-H, Random, 95% CI) 0.07 [-0.10, 0.23]
6.8 Tacalcitol vs.
betamethasone valerate
2 180 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
7 Withdrawals due to adverse
events
9 3058 Risk Difference (M-H, Random, 95% CI) 0.01 [-.00, 0.01]
7.1 Calcipotriol vs.
betamethasone dipropionate
1 956 Risk Difference (M-H, Random, 95% CI) 0.02 [0.00, 0.04]
7.2 Calcipotriol vs.
betamethasone valerate
3 1520 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.00, 0.01]
7.3 Calcipotriol vs.
desoxymetasone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Calcipotriol vs. diflorasone
diacetate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.5 Calcipotriol vs.
fluocinonide
1 114 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.06, 0.03]
7.6 Calcitriol vs.
betamethasone dipropionate
1 258 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.03]
7.7 Calcitriol vs.
betamethasone valerate
1 30 Risk Difference (M-H, Random, 95% CI) 0.07 [-0.10, 0.23]
7.8 Tacalcitol vs.
betamethasone valerate
2 180 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
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8 Withdrawals due to treatment
failure
5 1500 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
8.1 Calcipotriol vs.
betamethasone dipropionate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Calcipotriol vs.
betamethasone valerate
2 1099 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
8.3 Calcipotriol vs.
desoxymetasone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Calcipotriol vs. diflorasone
diacetate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.5 Calcipotriol vs.
fluocinonide
1 113 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
8.6 Calcitriol vs.
betamethasone dipropionate
1 258 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.03, 0.05]
8.7 Calcitriol vs.
betamethasone valerate
1 30 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.12, 0.12]
8.8 Tacalcitol vs.
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 9 3778 Risk Difference (M-H, Random, 95% CI) 0.07 [0.02, 0.11]
9.1 Calcipotriol vs.
betamethasone dipropionate
3 1739 Risk Difference (M-H, Random, 95% CI) 0.07 [0.04, 0.09]
9.2 Calcipotriol vs.
betamethasone valerate
3 1516 Risk Difference (M-H, Random, 95% CI) 0.12 [-0.02, 0.26]
9.3 Calcipotriol vs.
desoxymetasone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.4 Calcipotriol vs. diflorasone
diacetate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.5 Calcipotriol vs.
fluocinonide
1 113 Risk Difference (M-H, Random, 95% CI) 0.10 [-0.02, 0.22]
9.6 Calcitriol vs.
betamethasone dipropionate
1 258 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.05, 0.06]
9.7 Calcitriol vs.
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.8 Tacalcitol vs.
betamethasone valerate
1 152 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.07, 0.04]
10 Adverse events (systemic) 6 2547 Risk Difference (M-H, Random, 95% CI) -.00 [-0.00, 0.00]
10.1 Calcipotriol vs.
betamethasone dipropionate
1 621 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.2 Calcipotriol vs.
betamethasone valerate
3 1516 Risk Difference (M-H, Random, 95% CI) -.00 [-0.00, 0.00]
10.3 Calcipotriol vs.
desoxymetasone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Calcipotriol vs.
diflorasone diacetate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Calcipotriol vs.
fluocinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.6 Calcitriol vs.
betamethasone dipropionate
1 258 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.04, 0.03]
10.7 Calcitriol vs.
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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10.8 Tacalcitol vs.
betamethasone valerate
1 152 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
Comparison 8. Vitamin D analogues versus corticosteroid (very potent)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Calcipotriol vs. Clobetasol
propionate
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Calcipotriol vs. Clobetasol
propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Calcipotriol vs. Clobetasol
propionate
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Calcipotriol vs. Clobetasol
propionate
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
2 82 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.57, 0.44]
5.1 Calcipotriol vs. Clobetasol
propionate
2 82 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.57, 0.44]
6 Total withdrawals 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
6.1 Calcipotriol vs. Clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
1 Risk Difference (M-H, Random, 95% CI) Totals not selected
7.1 Calcipotriol vs. Clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Withdrawals due to treatment
failure
1 Risk Difference (M-H, Random, 95% CI) Totals not selected
8.1 Calcipotriol vs. Clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
9.1 Calcipotriol vs. Clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
10.1 Calcipotriol vs.
Clobetasol propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Vitamin D combined with corticosteroid versus corticosteroid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
3 1926 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.52, -0.27]
1.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 65 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-1.22, -0.15]
2 TSS 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 3 1876 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.55, -0.33]
3.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
3 1876 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.55, -0.33]
3.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
3 1926 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.52, -0.27]
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5.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 122 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.09, 0.81]
5.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 65 Std. Mean Difference (IV, Random, 95% CI) -0.69 [-1.22, -0.15]
6 Total withdrawals 5 2135 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
6.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
3 1948 Risk Difference (M-H, Random, 95% CI) -.00 [-0.03, 0.03]
6.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 122 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
6.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 65 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
7 Withdrawals due to adverse
events
3 Risk Difference (M-H, Random, 95% CI) Totals not selected
7.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Withdrawals due to treatment
failure
2 Risk Difference (M-H, Random, 95% CI) Totals not selected
8.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 4 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
3 1946 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.00, 0.04]
9.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
1 122 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.13, 0.06]
9.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
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10.1 Calcipotriol +
betamethasone dipropionate vs.
betamethasone dipropionate
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Calcipotriol +
betamethasone dipropionate
vs. clobetasol propionate
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Calcipotriol + clobetasol
propionate vs. clobetasol
propionate
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 10. Vitamin D alone or in combination versus dithranol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol vs. dithranol 4 994 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.85, -0.01]
1.2 Calcitriol vs. dithranol 1 114 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.13, 0.88]
1.3 Tacalcitol vs. dithranol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Calcipotriol vs. dithranol 2 210 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-1.16, 0.08]
2.2 Calcitriol vs. dithranol 1 114 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.24, 0.50]
2.3 Tacalcitol vs. dithranol 1 84 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.60, 0.25]
3 PASI 5 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Calcipotriol vs. dithranol 3 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Calcitriol vs. dithranol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Tacalcitol vs. dithranol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Calcipotriol vs. dithranol 2 544 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.90, 0.80]
4.2 Calcitriol vs. dithranol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Tacalcitol vs. dithranol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
8 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Calcipotriol vs. dithranol 6 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Calcitriol vs. dithranol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Tacalcitol vs. dithranol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Total withdrawals 7 615 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.06, 0.01]
6.1 Calcipotriol vs. dithranol 5 417 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.07, 0.04]
6.2 Calcitriol vs. dithranol 1 114 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.25, 0.06]
6.3 Tacalcitol vs. dithranol 1 84 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.16, 0.11]
7 Withdrawals due to adverse
events
7 1265 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.06, -0.00]
7.1 Calcipotriol vs. dithranol 6 1151 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.06, 0.00]
7.2 Calcitriol vs. dithranol 1 114 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.13, 0.02]
7.3 Tacalcitol vs. dithranol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Withdrawals due to treatment
failure
5 788 Risk Difference (M-H, Random, 95% CI) -.00 [-0.02, 0.02]
8.1 Calcipotriol vs. dithranol 4 674 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.02, 0.02]
8.2 Calcitriol vs. dithranol 1 114 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.08, 0.04]
8.3 Tacalcitol vs. dithranol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9 Adverse events (local) 9 1543 Risk Difference (M-H, Random, 95% CI) -0.32 [-0.43, -0.20]
9.1 Calcipotriol vs. dithranol 7 1345 Risk Difference (M-H, Random, 95% CI) -0.25 [-0.32, -0.17]
9.2 Calcitriol vs. dithranol 1 114 Risk Difference (M-H, Random, 95% CI) -0.67 [-0.80, -0.54]
9.3 Tacalcitol vs. dithranol 1 84 Risk Difference (M-H, Random, 95% CI) -0.36 [-0.52, -0.20]
10 Adverse events (systemic) 4 746 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
10.1 Calcipotriol vs. dithranol 2 548 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
10.2 Calcitriol vs. dithranol 1 114 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
10.3 Tacalcitol vs. dithranol 1 84 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
Comparison 11. Vitamin D alone or in combination versus other vitamin D analogue
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol vs. calcitriol 1 246 Std. Mean Difference (IV, Random, 95% CI) 0.0 [-0.25, 0.25]
1.2 Calcipotriol vs. tacalcitol 1 226 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.73, -0.21]
1.3 Calcipotriol vs.
maxacalcitol
1 52 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.12, 0.98]
2 TSS 3 589 Std. Mean Difference (IV, Random, 95% CI) -0.31 [-0.55, -0.06]
2.1 Calcipotriol vs. calcitriol 1 250 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.57, -0.07]
2.2 Calcipotriol vs. tacalcitol 1 287 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-0.68, -0.22]
2.3 Calcipotriol vs.
maxacalcitol
1 52 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.41, 0.68]
3 PASI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Calcipotriol vs. calcitriol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Calcipotriol vs. tacalcitol 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Calcipotriol vs.
maxacalcitol
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Calcipotriol vs. calcitriol 1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol vs. tacalcitol 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcipotriol vs.
maxacalcitol
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
4 539 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.62, 0.27]
5.1 Calcipotriol vs. calcitriol 2 261 Std. Mean Difference (IV, Random, 95% CI) -0.41 [-1.46, 0.64]
5.2 Calcipotriol vs. tacalcitol 1 226 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.73, -0.21]
5.3 Calcipotriol vs.
maxacalcitol
1 52 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.12, 0.98]
6 Total withdrawals 3 334 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.08]
6.1 Calcipotriol vs. calcitriol 2 274 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.09]
6.2 Calcipotriol vs. tacalcitol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Calcipotriol vs.
maxacalcitol
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.17, 0.17]
7 Withdrawals due to adverse
events
3 334 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.01, 0.06]
7.1 Calcipotriol vs. calcitriol 2 274 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.01, 0.07]
7.2 Calcipotriol vs. tacalcitol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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7.3 Calcipotriol vs.
maxacalcitol
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
8 Withdrawals due to treatment
failure
3 334 Risk Difference (M-H, Random, 95% CI) -.00 [-0.02, 0.01]
8.1 Calcipotriol vs. calcitriol 2 274 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.08, 0.07]
8.2 Calcipotriol vs. tacalcitol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Calcipotriol vs.
maxacalcitol
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
9 Adverse events (local) 2 537 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.05, 0.12]
9.1 Calcipotriol vs. calcitriol 1 250 Risk Difference (M-H, Random, 95% CI) 0.07 [0.01, 0.14]
9.2 Calcipotriol vs. tacalcitol 1 287 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.09, 0.07]
9.3 Calcipotriol vs.
maxacalcitol
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 3 597 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.1 Calcipotriol vs. calcitriol 1 250 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
10.2 Calcipotriol vs. tacalcitol 1 287 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.3 Calcipotriol vs.
maxacalcitol
1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
Comparison 12. Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol twice daily vs.
calcipotriol OM, BMD ON
1 154 Std. Mean Difference (IV, Random, 95% CI) 0.56 [0.23, 0.88]
1.2 Calcipotriol OD vs.
combined calcipotriol + BMD
OD
2 1194 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.31, 1.02]
1.3 Calcipotriol twice daily vs.
combined calcipotriol + BMD
OD
1 377 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.06, 0.48]
1.4 Calcipotriol twice daily vs.
combined calcipotriol + BMD
twice daily
3 1804 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.40, 0.93]
1.5 Calcipotriol twice daily vs.
calcipotriol OM, BMV ON
2 510 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.19, 0.74]
1.6 Calcipotriol twice daily vs.
calcipotriol OM, clobetasone
butyrate ON
1 344 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.05, 0.48]
1.7 Calcipotriol twice daily
vs. calcipotriol twice daily +
clobetasol propionate twice
daily
1 65 Std. Mean Difference (IV, Random, 95% CI) 0.88 [0.34, 1.42]
1.8 Calcipotriol twice
daily vs. calcipotriol OM,
diflucortolone valerate ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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1.9 Calcipotriol OD vs.
calcipotriol OM, fluocinonide
acetonide ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Calcipotriol OD vs.
combined calcipotriol +
hydrocortisone OD
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.06, 0.33]
1.11 Calcitriol twice daily vs.
diflucortolone valerate OM,
calcitriol ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.12 Tacalcitol OD vs.
combined calcipotriol + BMD
OD
1 334 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.26, 0.70]
2 TSS 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Calcipotriol twice daily vs.
calcipotriol OM, BMD ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol OD vs.
combined calcipotriol + BMD
OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Calcipotriol twice daily vs.
combined calcipotriol + BMD
OD
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Calcipotriol twice daily vs.
combined calcipotriol + BMD
twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Calcipotriol twice daily vs.
calcipotriol OM, BMV ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.6 Calcipotriol twice daily vs.
calcipotriol OM, clobetasone
butyrate ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Calcipotriol twice daily
vs. calcipotriol twice daily +
clobetasol propionate twice
daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.8 Calcipotriol twice
daily vs. calcipotriol OM,
diflucortolone valerate ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Calcipotriol OD vs.
calcipotriol OM, fluocinonide
acetonide ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.10 Calcipotriol OD vs.
combined calcipotriol +
hydrocortisone OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.11 Calcitriol twice daily vs.
diflucortolone valerate OM,
calcitriol ON
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.12 Tacalcitol OD vs.
combined calcipotriol + BMD
OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 16 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Calcipotriol twice daily vs.
calcipotriol OM, BMD ON
1 124 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.10, 0.82]
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3.2 Calcipotriol OD vs.
combined calcipotriol + BMD
OD
2 1191 Std. Mean Difference (IV, Random, 95% CI) 0.67 [0.23, 1.11]
3.3 Calcipotriol twice daily vs.
combined calcipotriol + BMD
OD
4 1204 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.38, 0.67]
3.4 Calcipotriol twice daily vs.
combined calcipotriol + BMD
twice daily
3 1744 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.46, 0.83]
3.5 Calcipotriol twice daily vs.
calcipotriol OM, BMV ON
2 515 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.07, 0.93]
3.6 Calcipotriol twice daily vs.
calcipotriol OM, clobetasone
butyrate ON
1 344 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.04, 0.38]
3.7 Calcipotriol twice daily
vs. calcipotriol twice daily +
clobetasol propionate twice
daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Calcipotriol twice
daily vs. calcipotriol OM,
diflucortolone valerate ON
1 116 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.29, 0.44]
3.9 Calcipotriol OD vs.
calcipotriol OM, fluocinonide
acetonide ON
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.11, 1.18]
3.10 Calcipotriol OD vs.
combined calcipotriol +
hydrocortisone OD
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.11, 0.28]
3.11 Calcitriol twice daily vs.
diflucortolone valerate OM,
calcitriol ON
1 142 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.09, 0.57]
3.12 Tacalcitol OD vs.
combined calcipotriol + BMD
OD
1 334 Std. Mean Difference (IV, Random, 95% CI) 0.47 [0.25, 0.69]
4 PAGI 2 399 Std. Mean Difference (IV, Random, 95% CI) 0.49 [0.29, 0.69]
4.1 Calcipotriol twice daily vs.
calcipotriol OM, BMD ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol OD vs.
combined calcipotriol + BMD
OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcipotriol twice daily vs.
combined calcipotriol + BMD
OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Calcipotriol twice daily vs.
combined calcipotriol + BMD
twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcipotriol twice daily vs.
calcipotriol OM, BMV ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Calcipotriol twice daily vs.
calcipotriol OM, clobetasone
butyrate ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4.7 Calcipotriol twice daily
vs. calcipotriol twice daily +
clobetasol propionate twice
daily
1 65 Std. Mean Difference (IV, Random, 95% CI) 0.70 [0.16, 1.23]
4.8 Calcipotriol twice
daily vs. calcipotriol OM,
diflucortolone valerate ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.9 Calcipotriol OD vs.
calcipotriol OM, fluocinonide
acetonide ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.10 Calcipotriol OD vs.
combined calcipotriol +
hydrocortisone OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.11 Calcitriol twice daily vs.
diflucortolone valerate OM,
calcitriol ON
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.12 Tacalcitol OD vs.
combined calcipotriol + BMD
OD
1 334 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.24, 0.68]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol twice daily vs.
calcipotriol OM, BMD ON
1 154 Std. Mean Difference (IV, Random, 95% CI) 0.56 [0.23, 0.88]
5.2 Calcipotriol OD vs.
combined calcipotriol + BMD
OD
2 1194 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.31, 1.02]
5.3 Calcipotriol twice daily vs.
combined calcipotriol + BMD
OD
4 1204 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.20, 0.66]
5.4 Calcipotriol twice daily vs.
combined calcipotriol + BMD
twice daily
3 1804 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.40, 0.93]
5.5 Calcipotriol twice daily vs.
calcipotriol OM, BMV ON
2 510 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.19, 0.74]
5.6 Calcipotriol twice daily vs.
calcipotriol OM, clobetasone
butyrate ON
1 344 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.05, 0.48]
5.7 Calcipotriol twice daily
vs. calcipotriol twice daily +
clobetasol propionate twice
daily
1 65 Std. Mean Difference (IV, Random, 95% CI) 0.88 [0.34, 1.42]
5.8 Calcipotriol twice
daily vs. calcipotriol OM,
diflucortolone valerate ON
1 116 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.29, 0.44]
5.9 Calcipotriol OD vs.
calcipotriol OM, fluocinonide
acetonide ON
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.11, 1.18]
5.10 Calcipotriol OD vs.
combined calcipotriol +
hydrocortisone OD
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.06, 0.33]
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5.11 Calcitriol twice daily vs.
diflucortolone valerate OM,
calcitriol ON
1 142 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.09, 0.57]
5.12 Tacalcitol OD vs.
combined calcipotriol + BMD
OD
1 334 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.26, 0.70]
6 Total withdrawals 15 5494 Risk Difference (M-H, Random, 95% CI) 0.03 [0.02, 0.05]
6.1 Talcipotriol vs. calcipotriol
and corticosteroid
13 4985 Risk Difference (M-H, Random, 95% CI) 0.03 [0.01, 0.05]
6.2 Calcitriol vs. calcitriol and
corticosteroid
1 142 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.08, 0.10]
6.3 Tacalcitol vs. calcipotriol
and corticosteroid
1 367 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.01, 0.11]
7 Withdrawals due to adverse
events
13 4081 Risk Difference (M-H, Random, 95% CI) 0.02 [0.01, 0.03]
7.1 Calcipotriol vs.
calcipotriol and corticosteroid
11 3572 Risk Difference (M-H, Random, 95% CI) 0.02 [0.01, 0.03]
7.2 Calcitriol vs. calcitriol and
corticosteroid
1 142 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.02, 0.07]
7.3 Tacalcitol vs. calcipotriol
and corticosteroid
1 367 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.03]
8 Withdrawals due to treatment
failure
7 1925 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.00, 0.02]
8.1 Calcipotriol vs.
calcipotriol and corticosteroid
7 1925 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.00, 0.02]
8.2 Calcitriol vs. calcitriol and
corticosteroid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Tacalcitol vs. calcipotriol
and corticosteroid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 15 5581 Risk Difference (M-H, Random, 95% CI) 0.06 [0.05, 0.08]
9.1 Calcipotriol vs.
calcipotriol and corticosteroid
13 5084 Risk Difference (M-H, Random, 95% CI) 0.06 [0.04, 0.08]
9.2 Calcitriol vs. calcitriol and
corticosteroid
1 131 Risk Difference (M-H, Random, 95% CI) 0.10 [0.02, 0.19]
9.3 Tacalcitol vs. calcipotriol
and corticosteroid
1 366 Risk Difference (M-H, Random, 95% CI) 0.09 [0.02, 0.15]
10 Adverse events (systemic) 6 2099 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.00, 0.00]
10.1 Calcipotriol vs.
calcipotriol and corticosteroid
5 1968 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.00, 0.00]
10.2 Calcitriol vs. calcitriol
and corticosteroid
1 131 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
10.3 Tacalcitol vs. calcipotriol
and corticosteroid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 13. Vitamin D alone or in combination versus other treatments: complex regimens
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 577 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.29, 0.04]
1.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 585 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.04, 0.29]
1.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 92 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.18, 1.02]
1.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily
(2wks)
1 76 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.05, 0.86]
1.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.54, 0.16]
1.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.12, 0.41]
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1.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy)+ combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.37, 0.66]
1.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy)+ combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.11, 0.40]
1.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 596 Std. Mean Difference (IV, Random, 95% CI) 0.24 [0.08, 0.40]
1.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 493 Std. Mean Difference (IV, Random, 95% CI) 0.54 [0.36, 0.72]
2 TSS 1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (w/
dy) & combined calcipotriol +
BMD (w/e) (8 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2wks);
then calcipotriol (4 wks)
1 92 Std. Mean Difference (IV, Random, 95% CI) 0.63 [0.21, 1.05]
2.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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2.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy)
, halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks)
; then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 649 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.19, 0.11]
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3.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
1 143 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.04, 0.62]
3.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 650 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.05, 0.25]
3.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.01, 1.32]
3.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Std. Mean Difference (IV, Random, 95% CI) 1.13 [0.64, 1.62]
3.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Std. Mean Difference (IV, Random, 95% CI) -0.27 [-0.62, 0.09]
3.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Std. Mean Difference (IV, Random, 95% CI) 0.25 [0.10, 0.39]
3.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.45, 0.74]
3.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.16, 0.45]
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3.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 645 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.01, 0.30]
3.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 501 Std. Mean Difference (IV, Random, 95% CI) 0.49 [0.31, 0.67]
4 PAGI 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 577 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.30, 0.02]
4.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 585 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.06, 0.26]
4.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy)
, halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.13, 0.42]
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4.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Std. Mean Difference (IV, Random, 95% CI) 0.71 [0.56, 0.85]
4.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.29, 0.58]
4.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 596 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.07, 0.39]
4.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 493 Std. Mean Difference (IV, Random, 95% CI) 0.54 [0.36, 0.72]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 577 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.29, 0.04]
5.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
1 143 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.04, 0.62]
5.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 585 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.04, 0.29]
5.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 92 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.18, 1.02]
5.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.01, 1.32]
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5.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.05, 0.86]
5.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.54, 0.16]
5.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.12, 0.41]
5.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy)+ combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.37, 0.66]
5.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.11, 0.40]
5.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 596 Std. Mean Difference (IV, Random, 95% CI) 0.24 [0.08, 0.40]
5.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 493 Std. Mean Difference (IV, Random, 95% CI) 0.54 [0.36, 0.72]
6 Total withdrawals 9 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 649 Risk Difference (M-H, Random, 95% CI) 0.05 [0.00, 0.10]
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6.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
1 150 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.09, 0.17]
6.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 649 Risk Difference (M-H, Random, 95% CI) 0.08 [0.03, 0.13]
6.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 98 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
6.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.10, 0.10]
6.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
6.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.12, 0.11]
6.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Risk Difference (M-H, Random, 95% CI) 0.08 [0.03, 0.14]
6.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Risk Difference (M-H, Random, 95% CI) 0.11 [0.06, 0.17]
6.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.01, 0.07]
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6.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 644 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.01, 0.07]
6.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 501 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.01, 0.12]
7 Withdrawals due to adverse
events
8 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
1 150 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.09, 0.01]
7.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (w/
dy) & combined calcipotriol +
BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 98 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
7.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.10, 0.10]
7.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
7.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.06, 0.03]
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7.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 759 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.01, 0.02]
7.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 753 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.02]
7.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 760 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.03, 0.01]
7.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks)
; then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 501 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.01, 0.05]
8 Withdrawals due to treatment
failure
6 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
1 150 Risk Difference (M-H, Random, 95% CI) 0.21 [0.10, 0.33]
8.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (w/
dy) & combined calcipotriol +
BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 98 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
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8.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.10, 0.10]
8.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
8.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.04, 0.10]
8.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy)+ combined calcipotriol
+ BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks)
; then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 501 Risk Difference (M-H, Random, 95% CI) 0.05 [0.02, 0.08]
9 Adverse events (local) 8 Risk Difference (M-H, Random, 95% CI) Subtotals only
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9.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
1 649 Risk Difference (M-H, Random, 95% CI) 0.11 [0.06, 0.17]
9.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol
(w/dy) & combined calcipotriol
+ BMD (w/e) (8 wks)
1 649 Risk Difference (M-H, Random, 95% CI) 0.11 [0.05, 0.17]
9.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
1 98 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.08, 0.12]
9.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
1 38 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.14, 0.14]
9.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy),
halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
1 76 Risk Difference (M-H, Random, 95% CI) 0.26 [0.07, 0.45]
9.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
1 125 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.10, 0.06]
9.8 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
1 752 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.07, 0.02]
9.9 Combined calcipotriol +
BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 743 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.03, 0.05]
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9.10 Combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
1 749 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.00, 0.08]
9.11 Combined calcipotriol +
BMD (8 wks); then calcipotriol
(4 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (w/dy) &
combined calcipotriol + BMD
(w/e) (8 wks)
1 644 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.05, 0.04]
9.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 501 Risk Difference (M-H, Random, 95% CI) 0.06 [0.01, 0.11]
10 Adverse events (systemic) 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(8 wks); then calcipotriol (4
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (8
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Calcipotriol (12 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (w/
dy) & combined calcipotriol +
BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Calcipotriol (6 wks) vs.
clobetasol propionate (2 wks);
then calcipotriol (4 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Calcipotriol (6 wks) vs.
calcipotriol OM, fluocinonide
acetonide ON (2 wks); then
calcipotriol twice daily (4 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.6 Calcipotriol (6 wks)
vs. halometasone OM,
calcipotriol ON (2 wks); then
calcipotriol twice daily (w/dy)
, halometasone (w/e) (2 wks);
then calcipotriol twice daily (2
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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10.7 Calcipotriol ON,
clobetasol propionate OM (2 to
4 wks); then calcipotriol twice
daily (to wk 12) vs. calcitriol
ON, clobetasol propionate OM
(2 to 4 wks); then calcitriol
twice daily (to wk 12)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.8 Combined calcipotriol
+ BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
ointment twice daily (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.9 Combined calcipotriol
+ BMD (4 wks); then placebo
ointment twice daily (8 wks)
vs. combined calcipotriol +
BMD (4 wks); then calcipotriol
(w/dy) + combined calcipotriol
+ BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.10 Combined calcipotriol
+ BMD (4 wks); then
calcipotriol ointment twice
daily (8 wks) vs. combined
calcipotriol + BMD (4 wks)
; then calcipotriol (w/dy) +
combined calcipotriol + BMD
(w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.11 Combined calcipotriol
+ BMD (8 wks); then
calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (w/
dy) & combined calcipotriol +
BMD (w/e) (8 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.12 Tacalcitol (8 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 14. Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
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1.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Alternating: combined
calcipotriol + BMD (4 wks)
; then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Alternating: combined
calcipotriol + BMD (4 wks)
; then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Alternating: combined
calcipotriol + BMD (4 wks)
; then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Total withdrawals 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
6.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
1 Risk Difference (M-H, Random, 95% CI) Totals not selected
422Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Withdrawals due to treatment
failure
1 Risk Difference (M-H, Random, 95% CI) Totals not selected
8.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
9.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.3 Alternating: combined
calcipotriol + BMD (4 wks);
then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 0 Risk Difference (M-H, Random, 95% CI) Subtotals only
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10.1 Combined calcipotriol +
BMD (52 wks) vs. alternating:
combined calcipotriol + BMD
(4 wks); then calcipotriol (4
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Combined calcipotriol +
BMD (52 wks) vs. combined
calcipotriol + BMD (4 wks);
then calcipotriol (48 wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Alternating: combined
calcipotriol + BMD (4 wks)
; then calcipotriol (4 wks) vs.
combined calcipotriol + BMD
(4 wks); then calcipotriol (48
wks)
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 15. Vitamin D analogues versus other treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol vs. coal tar 3 139 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-1.74, 0.68]
1.2 Calcipotriol vs. coal tar
polytherapy
2 209 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-0.87, -0.31]
1.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Calcipotriol vs.
calcipotriol + nicotinamide 1.
4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 200 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.33, 0.22]
1.6 Calcipotriol vs.
propylthiouracil cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.7 Calcipotriol vs. tazarotene 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.8 Calcipotriol vs. tacrolimus
ointment
1 124 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.60, 0.16]
1.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Calcipotriol vs. vitamin
B12 cream
1 26 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.33, 0.24]
1.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
2 728 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.38, -0.09]
1.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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2.1 Calcipotriol vs. coal tar 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol vs. coal tar
polytherapy
1 132 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-0.86, -0.16]
2.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.49, 0.31]
2.4 Calcipotriol vs.
calcipotriol+nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.14, 0.52]
2.5 Calcipotriol vs.
corticosteroid + salicylic acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.6 Calcipotriol vs.
propylthiouracil cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Calcipotriol vs. tacrolimus
ointment
2 171 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-1.51, 0.81]
2.8 Calcipotriol vs. tazarotene 1 199 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.33, 0.23]
2.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.10 Calcipotriol vs. vitamin
B12 cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
2 247 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-2.04, 1.68]
3 PASI 9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Calcipotriol vs. coal tar 2 109 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-1.54, 1.35]
3.2 Calcipotriol vs. coal tar
polytherapy
1 87 Std. Mean Difference (IV, Random, 95% CI) -0.63 [-1.06, -0.20]
3.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Calcipotriol vs.
calcipotriol + nicotinamide 1.
4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.36, 0.26]
3.6 Calcipotriol vs.
propylthiouracil cream
1 27 Std. Mean Difference (IV, Random, 95% CI) -2.24 [-3.23, -1.25]
3.7 Calcipotriol vs. tacrolimus
ointment
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Calcipotriol vs. tazarotene 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.10 Calcipotriol vs. vitamin
B12 cream
1 26 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.78, 0.75]
3.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
3 989 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.25, 0.00]
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3.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Calcipotriol vs. coal tar 1 54 Std. Mean Difference (IV, Random, 95% CI) -1.51 [-2.12, -0.90]
4.2 Calcipotriol vs. coal tar
polytherapy
1 87 Std. Mean Difference (IV, Random, 95% CI) -0.56 [-0.99, -0.13]
4.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Calcipotriol vs.
calcipotriol + nicotinamide 1.
4%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 186 Std. Mean Difference (IV, Random, 95% CI) -0.49 [-0.79, -0.20]
4.6 Calcipotriol vs.
propylthiouracil cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Calcipotriol vs. tacrolimus
ointment
1 124 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.51, 0.24]
4.8 Calcipotriol vs. tazarotene 1 38 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.99, 0.29]
4.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.10 Calcipotriol vs. vitamin
B12 cream
1 26 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.33, 0.24]
4.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
19 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol vs. coal tar 3 139 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-1.74, 0.68]
5.2 Calcipotriol vs. coal tar
polytherapy
2 209 Std. Mean Difference (IV, Random, 95% CI) -0.59 [-0.87, -0.31]
5.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.49, 0.31]
5.4 Calcipotriol vs.
calcipotriol + nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.14, 0.52]
5.5 Calcipotriol vs.
corticosteroid + salicylic acid
2 360 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.26, 0.15]
5.6 Calcipotriol vs.
propylthiouracil cream
1 27 Std. Mean Difference (IV, Random, 95% CI) -2.24 [-3.23, -1.25]
5.7 Calcipotriol vs. tacrolimus
ointment
2 171 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.28, 0.17]
5.8 Calcipotriol vs. tazarotene 2 237 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.35, 0.16]
5.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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5.10 Calcipotriol vs. vitamin
B12 cream
1 26 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-1.33, 0.24]
5.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
3 988 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.32, -0.07]
5.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
2 247 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-2.04, 1.68]
6 Total withdrawals 15 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Calcipotriol vs. coal tar 2 120 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.12, 0.08]
6.2 Calcipotriol vs. coal tar
polytherapy
2 220 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.10, 0.04]
6.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.05, 0.09]
6.4 Calcipotriol vs.
calcipotriol + nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.06, 0.07]
6.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.09, 0.17]
6.6 Calcipotriol vs.
propylthiouracil cream
1 28 Risk Difference (M-H, Random, 95% CI) 0.07 [-0.16, 0.30]
6.7 Calcipotriol vs. tacrolimus
ointment
1 124 Risk Difference (M-H, Random, 95% CI) -0.13 [-0.25, -0.01]
6.8 Calcipotriol vs. tazarotene 2 254 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.10, 0.01]
6.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
1 120 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.15, 0.08]
6.10 Calcipotriol vs. vitamin
B12 cream
1 26 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.14, 0.14]
6.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
3 1001 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.03, 0.05]
6.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
15 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Calcipotriol vs. coal tar 2 120 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.04, 0.06]
7.2 Calcipotriol vs. coal tar
polytherapy
2 210 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.07, 0.03]
7.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
7.4 Calcipotriol vs.
calcipotriol + nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
7.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.00, 0.10]
7.6 Calcipotriol vs.
propylthiouracil cream
1 28 Risk Difference (M-H, Random, 95% CI) 0.07 [-0.16, 0.30]
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7.7 Calcipotriol vs. tacrolimus
ointment
1 124 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.08, 0.11]
7.8 Calcipotriol vs. tazarotene 2 254 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.16, 0.05]
7.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
1 120 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.10, 0.07]
7.10 Calcipotriol vs. vitamin
B12 cream
1 26 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.14, 0.14]
7.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
3 998 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.01, 0.02]
7.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8 Withdrawals due to treatment
failure
12 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Calcipotriol vs. coal tar 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
8.2 Calcipotriol vs. coal tar
polytherapy
1 88 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.06, 0.07]
8.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
8.4 Calcipotriol vs.
calcipotriol + nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
8.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.07, 0.02]
8.6 Calcipotriol vs.
propylthiouracil cream
1 28 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.25, 0.11]
8.7 Calcipotriol vs. tacrolimus
ointment
1 124 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.07, 0.03]
8.8 Calcipotriol vs. tazarotene 1 208 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
8.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
1 120 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
8.10 Calcipotriol vs. vitamin
B12 cream
1 26 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.14, 0.14]
8.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
3 998 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.01, 0.01]
8.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 11 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Calcipotriol vs. coal tar 2 120 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.06, 0.10]
9.2 Calcipotriol vs. coal tar
polytherapy
1 122 Risk Difference (M-H, Random, 95% CI) 0.06 [-0.09, 0.20]
9.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
1 96 Risk Difference (M-H, Random, 95% CI) -0.15 [-0.32, 0.03]
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9.4 Calcipotriol vs.
calcipotriol + nicotinamide
(0.05%, 0.1%, 0.7%, or
1.4%), twice daily
1 192 Risk Difference (M-H, Random, 95% CI) -0.17 [-0.30, -0.03]
9.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Risk Difference (M-H, Random, 95% CI) 0.09 [0.02, 0.15]
9.6 Calcipotriol vs.
propylthiouracil cream
1 28 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.25, 0.11]
9.7 Calcipotriol vs. tacrolimus
ointment
1 124 Risk Difference (M-H, Random, 95% CI) -0.19 [-0.37, -0.01]
9.8 Calcipotriol vs. tazarotene 1 204 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.11, 0.06]
9.9 Calcipotriol vs. tazarotene
gel plus mometasone furoate
cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.10 Calcipotriol vs. vitamin
B12 cream
1 26 Risk Difference (M-H, Random, 95% CI) 0.23 [-0.06, 0.52]
9.11 Head-to-head vitamin D
alone or in combination: twice
daily vs OD
2 731 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.06, 0.05]
9.12 Head-to-head vitamin D
alone or in combination: no
occlusion vs. occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 8 Risk Difference (M-H, Random, 95% CI) Subtotals only
10.1 Calcipotriol vs. coal tar 1 60 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
10.2 Calcipotriol vs. coal tar
polytherapy
1 88 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
10.3 Calcipotriol vs.
nicotinamide 1.4%, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Calcipotriol vs.
calcipotriol + nicotinamide 1.
4%, twice daily
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Calcipotriol vs.
corticosteroid + salicylic acid
1 160 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.02, 0.02]
10.6 Calcipotriol vs.
propylthiouracil cream
1 28 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.13, 0.13]
10.7 Calcipotriol vs.
tacrolimus ointment
1 124 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.04, 0.04]
10.8 Calcipotriol vs.
tazarotene
1 183 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.05, 0.03]
10.9 Calcipotriol vs.
tazarotene gel plus mometasone
furoate cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.10 Calcipotriol vs. vitamin
B12 cream
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.11 Head-to-head vitamin
D alone or in combination:
twice daily vs OD
1 264 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.12 Head-to-head vitamin
D alone or in combination: no
occlusion vs. occlusion
1 38 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.10, 0.10]
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Comparison 16. Flexural/facial psoriasis: placebo-controlled trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
1.1 Betamethasone valerate 0.
1%, OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Calcipotriol ointment,
OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.3 Pimecrolimus cream, 1%
OD/twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Tacrolimus ointment 0.
1%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 TSS 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Betamethasone valerate 0.
1%, OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol ointment,
OD
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Pimecrolimus cream, 1%
OD/twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 Tacrolimus ointment 0.
1%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 PASI 1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Betamethasone valerate
0.1%, OD
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Calcipotriol ointment,
OD
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Pimecrolimus cream, 1%
OD/twice daily
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Tacrolimus ointment 0.
1%, twice daily
0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Betamethasone valerate 0.
1%, OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol ointment,
OD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Pimecrolimus cream, 1%
OD/twice daily
1 47 Std. Mean Difference (IV, Random, 95% CI) -0.65 [-1.24, -0.06]
4.4 Tacrolimus ointment 0.
1%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Betamethasone valerate
0.1%, OD
1 36 Std. Mean Difference (IV, Random, 95% CI) -2.83 [-3.79, -1.88]
5.2 Calcipotriol ointment,
OD
1 38 Std. Mean Difference (IV, Random, 95% CI) -1.08 [-1.77, -0.40]
5.3 Pimecrolimus cream, 1%
OD/twice daily
2 86 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.30, -0.41]
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5.4 Tacrolimus ointment 0.
1%, twice daily
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Total withdrawals 3 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Betamethasone valerate
0.1%, OD
1 40 Risk Difference (M-H, Random, 95% CI) 0.10 [-0.08, 0.28]
6.2 Calcipotriol ointment,
OD
1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.14, 0.14]
6.3 Pimecrolimus cream, 1%
OD/twice daily
2 97 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.16, 0.04]
6.4 Tacrolimus ointment
0.1%, twice daily
1 167 Risk Difference (M-H, Random, 95% CI) -0.17 [-0.30, -0.03]
7 Withdrawals due to adverse
events
3 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Betamethasone valerate
0.1%, OD
1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
7.2 Calcipotriol ointment,
OD
1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
7.3 Pimecrolimus cream, 1%
OD/twice daily
2 97 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.05, 0.05]
7.4 Tacrolimus ointment
0.1%, twice daily
1 167 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.06, 0.03]
8 Withdrawals due to treatment
failure
3 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Betamethasone valerate
0.1%, OD
1 40 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.18, 0.08]
8.2 Calcipotriol ointment,
OD
1 40 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.18, 0.08]
8.3 Pimecrolimus cream, 1%
OD/twice daily
2 97 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.13, 0.04]
8.4 Tacrolimus ointment
0.1%, twice daily
1 167 Risk Difference (M-H, Random, 95% CI) -0.11 [-0.19, -0.02]
9 Adverse events (local) 3 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Betamethasone valerate
0.1%, OD
1 40 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.18, 0.08]
9.2 Calcipotriol ointment,
OD
1 40 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.11, 0.21]
9.3 Pimecrolimus cream 1%,
OD/twice daily
2 97 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.15, 0.31]
9.4 Tacrolimus ointment
0.1%, twice daily
1 167 Risk Difference (M-H, Random, 95% CI) -0.17 [-0.30, -0.03]
10 Adverse events (systemic) 1 Risk Difference (M-H, Random, 95% CI) Totals not selected
10.1 Betamethasone valerate
0.1%, OD
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Calcipotriol ointment,
OD
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Pimecrolimus cream 1%,
OD/twice daily
0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Tacrolimus ointment
0.1%, twice daily
1 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 17. Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Calcipotriol vs. BMV 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.11, 0.50]
1.3 Calcipotriol vs. calcitriol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 Calcipotriol vs.
pimecrolimus
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.5 Calcitriol vs. tacrolimus 1 49 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.15, 0.98]
2 TSS 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Calcipotriol vs. BMV 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Calcipotriol vs.
calcipotriol + hydrocortisone
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Calcipotriol vs. calcitriol 1 150 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.28, 0.94]
2.4 Calcipotriol vs.
pimecrolimus
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 Calcitriol vs. tacrolimus 1 49 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.27, 0.85]
3 PASI 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Calcipotriol vs. BMV 1 36 Std. Mean Difference (IV, Random, 95% CI) 2.02 [1.20, 2.84]
3.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.32 [0.12, 0.51]
3.3 Calcipotriol vs. calcitriol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Calcipotriol vs.
pimecrolimus
1 39 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-1.17, 0.11]
3.5 Calcitriol vs. tacrolimus 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 0 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Calcipotriol vs. BMV 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Calcipotriol vs.
calcipotriol + hydrocortisone
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 Calcipotriol vs. calcitriol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Calcipotriol vs.
pimecrolimus
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 Calcitriol vs. tacrolimus 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Calcipotriol vs. BMV 1 36 Std. Mean Difference (IV, Random, 95% CI) 2.02 [1.20, 2.84]
5.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.11, 0.50]
5.3 Calcipotriol vs. calcitriol 1 150 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.28, 0.94]
5.4 Calcipotriol vs.
pimecrolimus
1 39 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-1.17, 0.11]
5.5 Calcitriol vs. tacrolimus 1 49 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.15, 0.98]
6 Total withdrawals 4 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Calcipotriol vs. BMV 1 40 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.28, 0.08]
6.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.03, 0.11]
6.3 Calcipotriol vs. calcitriol 1 150 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.11, 0.11]
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6.4 Calcipotriol vs.
pimecrolimus
1 40 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.08, 0.18]
6.5 Calcitriol vs. tacrolimus 1 50 Risk Difference (M-H, Random, 95% CI) 0.12 [-0.02, 0.26]
7 Withdrawals due to adverse
events
4 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Calcipotriol vs. BMV 1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
7.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Risk Difference (M-H, Random, 95% CI) 0.06 [0.02, 0.11]
7.3 Calcipotriol vs. calcitriol 1 150 Risk Difference (M-H, Random, 95% CI) 0.09 [0.01, 0.18]
7.4 Calcipotriol vs.
pimecrolimus
1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
7.5 Calcitriol vs. tacrolimus 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
8 Withdrawals due to treatment
failure
4 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Calcipotriol vs. BMV 1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
8.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 408 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.01, 0.05]
8.3 Calcipotriol vs. calcitriol 1 150 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
8.4 Calcipotriol vs.
pimecrolimus
1 40 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.09, 0.09]
8.5 Calcitriol vs. tacrolimus 1 50 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.07, 0.07]
9 Adverse events (local) 3 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 calcipotriol vs. BMV 1 40 Risk Difference (M-H, Random, 95% CI) 0.10 [-0.05, 0.25]
9.2 Calcipotriol vs.
calcipotriol + hydrocortisone
1 404 Risk Difference (M-H, Random, 95% CI) 0.15 [0.08, 0.23]
9.3 Calcipotriol vs. calcitriol 1 150 Risk Difference (M-H, Random, 95% CI) 0.09 [0.02, 0.17]
9.4 Calcipotriol vs.
pimecrolimus
1 40 Risk Difference (M-H, Random, 95% CI) -0.15 [-0.38, 0.08]
9.5 Calcitriol vs. tacrolimus 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10 Adverse events (systemic) 0 Risk Difference (M-H, Random, 95% CI) Subtotals only
10.1 Calcipotriol vs. BMV 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.2 Calcipotriol vs.
calcipotriol + hydrocortisone
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.3 Calcipotriol vs. calcitriol 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Calcipotriol vs.
pimecrolimus
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Calcitriol vs. tacrolimus 0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 18. Scalp psoriasis: placebo-controlled trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Vitamin D: calcipotriol 2 457 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.28, -0.16]
1.2 Potent steroid:
betamethasone dipropionate
2 712 Std. Mean Difference (IV, Random, 95% CI) -1.09 [-1.29, -0.90]
1.3 Potent steroid:
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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1.4 Very potent steroid:
amcinonide
1 132 Std. Mean Difference (IV, Random, 95% CI) -1.42 [-1.80, -1.04]
1.5 Very potent steroid:
clobetasol propionate
2 458 Std. Mean Difference (IV, Random, 95% CI) -1.73 [-1.99, -1.48]
1.6 Very potent steroid:
halcinonide
1 54 Std. Mean Difference (IV, Random, 95% CI) -1.11 [-1.69, -0.53]
1.7 Vitamin D in
combination: calcipotriol +
BMD
2 854 Std. Mean Difference (IV, Random, 95% CI) -0.97 [-1.61, -0.32]
1.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -1.48 [-2.50, -0.47]
1.9 Other treatment:
ciclopirox olamine shampoo
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.10 Other treatment:
fluocinolone acetonide, plus
occlusion
1 84 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-1.69, -0.76]
1.11 Other treatment: salicylic
acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.79, 0.06]
2 TSS 11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Vitamin D: calcipotriol 2 457 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.64, -0.25]
2.2 Potent steroid:
betamethasone dipropionate
2 712 Std. Mean Difference (IV, Random, 95% CI) -1.00 [-1.19, -0.81]
2.3 Potent steroid:
betamethasone valerate
1 172 Std. Mean Difference (IV, Random, 95% CI) -1.40 [-1.75, -1.05]
2.4 Very potent steroid:
amcinonide
1 126 Std. Mean Difference (IV, Random, 95% CI) -1.58 [-1.98, -1.18]
2.5 Very potent steroid:
clobetasol propionate
3 707 Std. Mean Difference (IV, Random, 95% CI) -1.53 [-1.77, -1.28]
2.6 Very potent steroid:
halcinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 Vitamin D in
combination: calcipotriol +
BMD
2 854 Std. Mean Difference (IV, Random, 95% CI) -0.92 [-1.42, -0.43]
2.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -1.15 [-2.11, -0.19]
2.9 Other treatment:
ciclopirox olamine shampoo
1 37 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.82, 0.68]
2.10 Other treatment:
fluocinolone acetonide, plus
occlusion
1 84 Std. Mean Difference (IV, Random, 95% CI) -0.89 [-1.34, -0.44]
2.11 Other treatment: salicylic
acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -0.57 [-1.47, 0.32]
3 PASI 0 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Vitamin D: calcipotriol 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Potent steroid:
betamethasone dipropionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Potent steroid:
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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3.4 Very potent steroid:
amcinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Very potent steroid:
clobetasol propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Very potent steroid:
halcinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 Vitamin D in
combination: calcipotriol +
BMD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.9 Other treatment:
ciclopirox olamine shampoo
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.10 Other treatment:
fluocinolone acetonide, plus
occlusion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.11 Other treatment: salicylic
acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Vitamin D: calcipotriol 2 450 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-1.28, -0.05]
4.2 Potent steroid:
betamethasone dipropionate
1 685 Std. Mean Difference (IV, Random, 95% CI) -1.23 [-1.43, -1.03]
4.3 Potent steroid:
betamethasone valerate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 Very potent steroid:
amcinonide
1 132 Std. Mean Difference (IV, Random, 95% CI) -0.97 [-1.33, -0.61]
4.5 Very potent steroid:
clobetasol propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 Very potent steroid:
halcinonide
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 Vitamin D in
combination: calcipotriol +
BMD
2 841 Std. Mean Difference (IV, Random, 95% CI) -1.00 [-1.79, -0.22]
4.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.9 Other treatment:
ciclopirox olamine shampoo
1 37 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.86, 0.64]
4.10 Other treatment:
fluocinolone acetonide, plus
occlusion
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.11 Other treatment: salicylic
acid
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Vitamin D: calcipotriol 2 457 Std. Mean Difference (IV, Random, 95% CI) -0.72 [-1.28, -0.16]
5.2 Potent steroid:
betamethasone dipropionate
2 712 Std. Mean Difference (IV, Random, 95% CI) -1.09 [-1.29, -0.90]
5.3 Potent steroid:
betamethasone valerate
1 172 Std. Mean Difference (IV, Random, 95% CI) -1.40 [-1.75, -1.05]
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5.4 Very potent steroid:
amcinonide
1 132 Std. Mean Difference (IV, Random, 95% CI) -1.42 [-1.80, -1.04]
5.5 Very potent steroid:
clobetasol propionate
4 788 Std. Mean Difference (IV, Random, 95% CI) -1.57 [-1.81, -1.34]
5.6 Very potent steroid:
halcinonide
1 54 Std. Mean Difference (IV, Random, 95% CI) -1.11 [-1.69, -0.53]
5.7 Vitamin D in
combination: calcipotriol +
BMD
2 854 Std. Mean Difference (IV, Random, 95% CI) -0.97 [-1.61, -0.32]
5.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -1.48 [-2.50, -0.47]
5.9 Other treatment:
ciclopirox olamine shampoo
1 37 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.82, 0.68]
5.10 Other treatment:
fluocinolone acetonide, plus
occlusion
1 84 Std. Mean Difference (IV, Random, 95% CI) -1.22 [-1.69, -0.76]
5.11 Other treatment: salicylic
acid
1 20 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.79, 0.06]
6 Total withdrawals 13 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Vitamin D: calcipotriol 3 517 Risk Difference (M-H, Random, 95% CI) -0.02 [-0.08, 0.05]
6.2 Potent steroid:
betamethasone dipropionate
1 692 Risk Difference (M-H, Random, 95% CI) -0.14 [-0.21, -0.06]
6.3 Potent steroid:
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 Very potent steroid:
amcinonide
1 165 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.11, 0.11]
6.5 Very potent steroid:
clobetasol propionate
5 1006 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.10, 0.04]
6.6 Very potent steroid:
halcinonide
1 58 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.13, 0.13]
6.7 Vitamin D in
combination: calcipotriol +
BMD
2 854 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.16, -0.03]
6.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6.9 Other treatment:
ciclopirox olamine shampoo
1 40 Risk Difference (M-H, Random, 95% CI) -0.15 [-0.38, 0.09]
6.10 Other treatment:
fluocinolone acetonide, plus
occlusion
1 89 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.13, 0.04]
6.11 Other treatment: salicylic
acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Withdrawals due to adverse
events
13 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Vitamin D: calcipotriol 3 517 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.02, 0.05]
7.2 Potent steroid:
betamethasone dipropionate
2 712 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.08, -0.00]
7.3 Potent steroid:
betamethasone valerate
1 172 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
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7.4 Very potent steroid:
amcinonide
1 165 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.04]
7.5 Very potent steroid:
clobetasol propionate
5 1006 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
7.6 Very potent steroid:
halcinonide
1 58 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.06, 0.06]
7.7 Vitamin D in
combination: calcipotriol +
BMD
1 677 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.08, 0.00]
7.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
1 20 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.17, 0.17]
7.9 Other treatment:
ciclopirox olamine shampoo
1 40 Risk Difference (M-H, Random, 95% CI) -0.18 [-0.42, 0.05]
7.10 Other treatment:
fluocinolone acetonide, plus
occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.11 Other treatment: salicylic
acid
1 20 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.17, 0.17]
8 Withdrawals due to treatment
failure
9 Risk Difference (M-H, Random, 95% CI) Subtotals only
8.1 Vitamin D: calcipotriol 2 457 Risk Difference (M-H, Random, 95% CI) -0.05 [-0.11, 0.00]
8.2 Potent steroid:
betamethasone dipropionate
1 692 Risk Difference (M-H, Random, 95% CI) -0.10 [-0.16, -0.05]
8.3 Potent steroid:
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 Very potent steroid:
amcinonide
1 165 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.05, 0.02]
8.5 Very potent steroid:
clobetasol propionate
5 1006 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.05, 0.02]
8.6 Very potent steroid:
halcinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.7 Vitamin D in
combination: calcipotriol +
BMD
1 677 Risk Difference (M-H, Random, 95% CI) -0.11 [-0.17, -0.06]
8.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.9 Other treatment:
ciclopirox olamine shampoo
1 40 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.28, 0.10]
8.10 Other treatment:
fluocinolone acetonide, plus
occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
8.11 Other treatment: salicylic
acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 12 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Vitamin D: calcipotriol 3 510 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.05, 0.04]
9.2 Potent steroid:
betamethasone dipropionate
2 703 Risk Difference (M-H, Random, 95% CI) -0.07 [-0.13, -0.01]
9.3 Potent steroid:
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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9.4 Very potent steroid:
amcinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9.5 Very potent steroid:
clobetasol propionate
4 817 Risk Difference (M-H, Random, 95% CI) 0.00 [-0.03, 0.04]
9.6 Very potent steroid:
halcinonide
1 58 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.12, 0.06]
9.7 Vitamin D in
combination: calcipotriol +
BMD
2 831 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.13, 0.02]
9.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
1 20 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.17, 0.17]
9.9 Other treatment:
ciclopirox olamine shampoo
1 40 Risk Difference (M-H, Random, 95% CI) -0.06 [-0.24, 0.13]
9.10 Other treatment:
fluocinolone acetonide, plus
occlusion
1 89 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.08]
9.11 Other treatment: salicylic
acid
1 20 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.17, 0.17]
10 Adverse events (systemic) 4 Risk Difference (M-H, Random, 95% CI) Subtotals only
10.1 Vitamin D: calcipotriol 1 408 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.2 Potent steroid:
betamethasone dipropionate
1 692 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.3 Potent steroid:
betamethasone valerate
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.4 Very potent steroid:
amcinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.5 Very potent steroid:
clobetasol propionate
2 385 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.03, 0.02]
10.6 Very potent steroid:
halcinonide
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.7 Vitamin D in
combination: calcipotriol +
BMD
2 843 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.8 Other treatment:
betamethasone-17,21-
dipropionate plus salicylic acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.9 Other treatment:
ciclopirox olamine shampoo
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.10 Other treatment:
fluocinolone acetonide, plus
occlusion
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
10.11 Other treatment:
salicylic acid
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 19. Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IAGI 9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.32, 0.64]
1.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 510 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.20, 0.55]
1.3 Vitamin D vs.
corticosteroid (very potent)
: calcipotriol vs. clobetasol
propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.26, -0.10]
1.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
4 2581 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.44, 0.84]
1.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
2 748 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.73, 0.25]
2 TSS 10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.28, 0.63]
2.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 487 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.09, 0.27]
2.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
1 151 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.05, 0.69]
2.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.27, -0.11]
2.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
3 1978 Std. Mean Difference (IV, Random, 95% CI) 0.70 [0.56, 0.84]
2.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
3 925 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.84, 0.24]
3 PASI 0 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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3.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Vitamin D vs.
corticosteroid (very potent)
: calcipotriol vs. clobetasol
propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 PAGI 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1654 Std. Mean Difference (IV, Random, 95% CI) 0.56 [0.31, 0.81]
4.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
1 468 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.22, 0.59]
4.3 Vitamin D vs.
corticosteroid (very potent)
: calcipotriol vs. clobetasol
propionate
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2414 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.25, -0.09]
4.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
3 1952 Std. Mean Difference (IV, Random, 95% CI) 0.84 [0.61, 1.08]
4.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Combined end point
(IAGI/TSS/PASI/PAGI)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.32, 0.64]
5.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 510 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.20, 0.55]
5.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
1 151 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.05, 0.69]
5.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.26, -0.10]
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5.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
4 2581 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.44, 0.84]
5.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
3 835 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-0.92, 0.02]
6 Total withdrawals 10 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Risk Difference (M-H, Random, 95% CI) 0.07 [-0.04, 0.18]
6.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 516 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.00, 0.08]
6.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
2 194 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.07, 0.18]
6.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.04, 0.06]
6.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
4 2847 Risk Difference (M-H, Random, 95% CI) 0.11 [0.05, 0.18]
6.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
1 475 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.07, 0.09]
7 Withdrawals due to adverse
events
10 Risk Difference (M-H, Random, 95% CI) Subtotals only
7.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Risk Difference (M-H, Random, 95% CI) 0.04 [-0.01, 0.09]
7.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 516 Risk Difference (M-H, Random, 95% CI) 0.03 [0.01, 0.06]
7.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
2 194 Risk Difference (M-H, Random, 95% CI) 0.05 [-0.05, 0.15]
7.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.01, 0.01]
7.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
4 2847 Risk Difference (M-H, Random, 95% CI) 0.06 [0.02, 0.09]
7.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
1 445 Risk Difference (M-H, Random, 95% CI) 0.08 [0.02, 0.14]
8 Withdrawals due to treatment
failure
8 Risk Difference (M-H, Random, 95% CI) Subtotals only
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8.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1676 Risk Difference (M-H, Random, 95% CI) 0.03 [-0.01, 0.07]
8.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 516 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.01, 0.03]
8.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
2 194 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.02, 0.04]
8.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2444 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.02, -0.00]
8.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
3 2535 Risk Difference (M-H, Random, 95% CI) 0.05 [0.01, 0.10]
8.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
0 0 Risk Difference (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Adverse events (local) 10 Risk Difference (M-H, Random, 95% CI) Subtotals only
9.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1652 Risk Difference (M-H, Random, 95% CI) 0.07 [0.04, 0.11]
9.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
2 516 Risk Difference (M-H, Random, 95% CI) 0.17 [0.01, 0.33]
9.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
2 194 Risk Difference (M-H, Random, 95% CI) 0.19 [0.10, 0.28]
9.4 VitaminD + corticosteroid
vs. corticosteroid: calcipotriol +
BMD vs. BMD
3 2415 Risk Difference (M-H, Random, 95% CI) -0.00 [-0.02, 0.01]
9.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
4 2801 Risk Difference (M-H, Random, 95% CI) 0.09 [0.06, 0.12]
9.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
1 445 Risk Difference (M-H, Random, 95% CI) 0.24 [0.15, 0.33]
10 Adverse events (systemic) 6 Risk Difference (M-H, Random, 95% CI) Subtotals only
10.1 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMD
2 1666 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.00, 0.00]
10.2 Vitamin D vs.
corticosteroid (potent):
calcipotriol vs. BMV
1 474 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
10.3 Vitamin D vs.
corticosteroid (very potent):
calcipotriol vs. clobetasol
propionate
1 151 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.03, 0.03]
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10.4 Vitamin D +
corticosteroid vs. corticosteroid:
calcipotriol + BMD vs. BMD
2 2216 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.00, 0.00]
10.5 Vitamin D vs. vitamin D
+ corticosteroid: calcipotriol vs.
calcipotriol + BMD
3 1970 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.00, 0.00]
10.6 Vitamin D vs. other
treatments: calcipotriol vs. coal
tar polytherapy
1 445 Risk Difference (M-H, Random, 95% CI) 0.0 [-0.01, 0.01]
Analysis 1.1. Comparison 1 Vitamin D analogues versus placebo, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 1 IAGI
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol
Barker 1999 (P) 26 -3.19 (1.27) 28 -1.86 (0.89) 7.8 % -1.20 [ -1.79, -0.62 ]
Dubertret 1992 62 -2.66 (0.87) 62 -1.84 (0.75) 10.6 % -1.00 [ -1.38, -0.63 ]
Fleming 2010 (P) 74 2.3 (0.81) 28 2.64 (0.62) 9.7 % -0.44 [ -0.88, 0.00 ]
Guenther 2002 (P) 227 -3.3 (1.12) 206 -1.88 (1.14) 12.7 % -1.25 [ -1.46, -1.05 ]
Harrington 1996a 290 -2.06 (0.8) 71 -1.37 (0.91) 12.0 % -0.84 [ -1.10, -0.57 ]
Kang 1998 15 -3.87 (1.36) 15 -1.47 (0.99) 4.9 % -1.96 [ -2.86, -1.07 ]
Kaufmann 2002 (P) 480 2.2417 (0.9) 157 2.68 (0.89) 13.0 % -0.49 [ -0.67, -0.31 ]
Kragballe 1988b 27 -2.4 (0.88) 27 -1.17 (0.62) 7.4 % -1.59 [ -2.21, -0.97 ]
Oranje 1997 43 -2.53 (1.05) 34 -1.91 (1.19) 9.4 % -0.55 [ -1.01, -0.09 ]
Papp 2003 (P) 308 -2.81 (1.21) 107 -1.92 (1.07) 12.5 % -0.76 [ -0.98, -0.53 ]
Subtotal (95% CI) 1552 735 100.0 % -0.93 [ -1.17, -0.68 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 49.09, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 7.37 (P < 0.00001)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
-10 -5 0 5 10
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(. . . Continued)
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Langner 1992 29 -4.1 (1.05) 29 -3 (1.04) 16.2 % -1.04 [ -1.59, -0.49 ]
Langner 1993 32 -3.97 (1.33) 32 -3.28 (1.14) 16.5 % -0.55 [ -1.05, -0.05 ]
Langner 2001 (P) 15 -2.4 (1.18) 14 -2.14 (0.66) 14.9 % -0.26 [ -0.99, 0.47 ]
Lebwohl 2007 202 -3.1 (1.4) 199 -2.42 (1.37) 17.8 % -0.49 [ -0.69, -0.29 ]
Perez 1996 84 -3.2 (0.85) 84 -1.14 (0.38) 16.8 % -3.11 [ -3.57, -2.66 ]
Powers 2005 199 -2.92 (1.27) 201 -2.01 (1.27) 17.8 % -0.72 [ -0.92, -0.51 ]
Subtotal (95% CI) 561 559 100.0 % -1.03 [ -1.71, -0.36 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 114.17, df = 5 (P<0.00001); I2 =96%
Test for overall effect: Z = 3.01 (P = 0.0026)
4 Tacalcitol
Langley 2011 (P) 163 2.28 (0.89) 64 2.75 (0.78) 50.0 % -0.54 [ -0.84, -0.25 ]
Van de Kerkhof 1996a 103 -1.66 (0.88) 103 -0.75 (0.72) 50.0 % -1.13 [ -1.42, -0.83 ]
Subtotal (95% CI) 266 167 100.0 % -0.84 [ -1.41, -0.26 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 7.57, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.87 (P = 0.0042)
5 Maxacalcitol
Barker 1999 (P) 75 -3.52 (1.23) 28 -1.86 (0.89) 100.0 % -1.43 [ -1.91, -0.96 ]
Subtotal (95% CI) 75 28 100.0 % -1.43 [ -1.91, -0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.88 (P < 0.00001)
6 Paricalcitol OD
Durakovic 2004 11 -2.45 (1.09) 11 -0.69 (0.94) 100.0 % -1.66 [ -2.66, -0.67 ]
Subtotal (95% CI) 11 11 100.0 % -1.66 [ -2.66, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
7 Becocalcidiol OD
Helfrich 2007 63 2.33 (0.84) 58 2.5 (0.68) 100.0 % -0.22 [ -0.58, 0.14 ]
Subtotal (95% CI) 63 58 100.0 % -0.22 [ -0.58, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
8 Becocalcidiol twice daily
Helfrich 2007 61 2.02 (0.74) 58 2.5 (0.68) 100.0 % -0.67 [ -1.04, -0.30 ]
Subtotal (95% CI) 61 58 100.0 % -0.67 [ -1.04, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 21.65, df = 6 (P = 0.00), I2 =72%
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Analysis 1.2. Comparison 1 Vitamin D analogues versus placebo, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 2 TSS
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol
Barker 1999 (P) 26 2.8 (2.3) 28 8.3 (3.2) 8.0 % -1.93 [ -2.59, -1.28 ]
Dubertret 1992 61 3.15 (1.94) 61 4.68 (1.94) 12.2 % -0.78 [ -1.15, -0.42 ]
Highton 1995 124 1.7 (1.2) 123 3.15 (1.2) 13.7 % -1.20 [ -1.48, -0.93 ]
Hinds n 2006 (P) 114 5.2 (3.3) 92 10.4 (4.4) 13.2 % -1.35 [ -1.66, -1.05 ]
Kang 1998 15 4.53 (3.33) 15 10.8 (3.33) 5.7 % -1.83 [ -2.70, -0.96 ]
Kragballe 1988b 27 4.63 (1.88) 27 6.73 (1.37) 8.8 % -1.26 [ -1.85, -0.67 ]
Levine 2010 (P) 48 3.52 (1.95) 48 4.08 (1.93) 11.6 % -0.29 [ -0.69, 0.12 ]
Pariser 1996 167 2.27 (1.33) 168 3.63 (1.33) 14.3 % -1.02 [ -1.25, -0.79 ]
Staberg 1989 9 1.3 (1.6) 9 4.6 (2.2) 4.1 % -1.63 [ -2.74, -0.53 ]
Zonneveld 1998 (P) 23 2.6 (1.73) 23 4.6 (1.73) 8.3 % -1.14 [ -1.76, -0.51 ]
Subtotal (95% CI) 614 594 100.0 % -1.15 [ -1.41, -0.89 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 32.32, df = 9 (P = 0.00018); I2 =72%
Test for overall effect: Z = 8.66 (P < 0.00001)
2 Calcipotriol plus occlusion
Hinds n 2006 (P) 95 9.7 (4.8) 92 10.4 (4.4) 100.0 % -0.15 [ -0.44, 0.14 ]
Subtotal (95% CI) 95 92 100.0 % -0.15 [ -0.44, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Calcitriol
Lebwohl 2007 209 1.94 (0.89) 209 2.17 (0.83) 26.1 % -0.27 [ -0.46, -0.07 ]
Perez 1996 84 2.8 (1.5) 84 7.1 (0.1) 24.9 % -4.03 [ -4.56, -3.50 ]
Powers 2005 210 1.94 (0.85) 211 2.37 (0.79) 26.1 % -0.52 [ -0.72, -0.33 ]
Van de Kerkhof 1989 10 6 (1.49) 10 6.1 (1.49) 22.9 % -0.06 [ -0.94, 0.81 ]
Subtotal (95% CI) 513 514 100.0 % -1.22 [ -2.38, -0.07 ]
Heterogeneity: Tau2 = 1.33; Chi2 = 173.88, df = 3 (P<0.00001); I2 =98%
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Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.07 (P = 0.038)
4 Tacalcitol
Scarpa 1997 134 3.44 (1.94) 134 4.34 (1.94) 47.8 % -0.46 [ -0.71, -0.22 ]
Seidenari 1997 (P) 11 2.92 (1.93) 11 4.52 (1.38) 9.5 % -0.92 [ -1.81, -0.03 ]
Van de Kerkhof 1996a 103 -4 (2.06) 103 -2.3 (2.06) 42.6 % -0.82 [ -1.11, -0.54 ]
Subtotal (95% CI) 248 248 100.0 % -0.66 [ -0.95, -0.36 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.98, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 4.38 (P = 0.000012)
5 Maxacalcitol
Barker 1999 (P) 75 3.13 (3.24) 28 8.38 (3.2) 100.0 % -1.61 [ -2.10, -1.12 ]
Subtotal (95% CI) 75 28 100.0 % -1.61 [ -2.10, -1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.47 (P < 0.00001)
6 Paricalcitol OD
Durakovic 2004 11 2.7 (1.7) 11 7.6 (2.6) 100.0 % -2.15 [ -3.24, -1.06 ]
Subtotal (95% CI) 11 11 100.0 % -2.15 [ -3.24, -1.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
7 Becocalcidiol OD
Helfrich 2007 63 4.86 (2.23) 58 4.89 (1.62) 100.0 % -0.02 [ -0.37, 0.34 ]
Subtotal (95% CI) 63 58 100.0 % -0.02 [ -0.37, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
8 Becocalcidiol twice daily
Helfrich 2007 61 4.03 (2.04) 58 4.89 (1.62) 100.0 % -0.46 [ -0.83, -0.10 ]
Subtotal (95% CI) 61 58 100.0 % -0.46 [ -0.83, -0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Chi2 = 62.06, df = 7 (P = 0.00), I2 =89%
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Analysis 1.3. Comparison 1 Vitamin D analogues versus placebo, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 3 PASI
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol
Dubertret 1992 65 6.3 (6.45) 65 9.16 (8.34) 9.2 % -0.38 [ -0.73, -0.03 ]
Fleming 2010 (P) 74 4.3 (2.8) 28 5.5 (3.5) 6.6 % -0.40 [ -0.83, 0.04 ]
Guenther 2002 (P) 227 4.2 (3.3) 207 7.7 (5.5) 17.2 % -0.78 [ -0.97, -0.58 ]
Harrington 1996a 296 -4.3 (5.13) 70 -0.8 (5.4) 12.9 % -0.67 [ -0.94, -0.41 ]
Kaufmann 2002 (P) 480 -0.46 (0.31) 157 -0.23 (0.34) 18.0 % -0.72 [ -0.91, -0.54 ]
Mortensen 1993b 17 6.53 (2.49) 17 9.04 (4.71) 3.1 % -0.65 [ -1.34, 0.04 ]
Oranje 1997 43 -0.52 (0.45) 34 -0.37 (0.4) 6.2 % -0.35 [ -0.80, 0.11 ]
Papp 2003 (P) 308 -0.49 (0.32) 107 -0.29 (0.31) 15.3 % -0.63 [ -0.85, -0.40 ]
Subtotal (95% CI) 1510 685 88.4 % -0.65 [ -0.75, -0.55 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 7.65, df = 7 (P = 0.36); I2 =8%
Test for overall effect: Z = 12.44 (P < 0.00001)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Tacalcitol
Langley 2011 (P) 163 5.35 (4.44) 64 6.47 (3.56) 11.6 % -0.27 [ -0.56, 0.03 ]
Subtotal (95% CI) 163 64 11.6 % -0.27 [ -0.56, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
5 Maxacalcitol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Paricalcitol OD
Subtotal (95% CI) 0 0 Not estimable
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Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Becocalcidiol OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Becocalcidiol twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1673 749 100.0 % -0.58 [ -0.71, -0.45 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.87, df = 8 (P = 0.09); I2 =42%
Test for overall effect: Z = 8.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 5.94, df = 1 (P = 0.01), I2 =83%
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Analysis 1.4. Comparison 1 Vitamin D analogues versus placebo, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 4 PAGI
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol
Harrington 1996a 291 -2.27 (0.97) 71 -1.51 (1.07) 20.2 % -0.77 [ -1.03, -0.50 ]
Oranje 1997 43 -2.37 (1.02) 34 -1.91 (1.24) 10.7 % -0.41 [ -0.86, 0.05 ]
Subtotal (95% CI) 334 105 30.9 % -0.64 [ -0.97, -0.30 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.80, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 3.67 (P = 0.00025)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Lebwohl 2007 202 -3.02 (1.37) 199 -2.32 (1.43) 25.4 % -0.50 [ -0.70, -0.30 ]
Powers 2005 199 -2.84 (1.33) 201 -1.95 (1.3) 25.1 % -0.68 [ -0.88, -0.47 ]
Subtotal (95% CI) 401 400 50.5 % -0.59 [ -0.76, -0.41 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.49, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 6.65 (P < 0.00001)
4 Tacalcitol
Langley 2011 (P) 163 2.25 (0.93) 64 2.48 (0.99) 18.6 % -0.24 [ -0.53, 0.05 ]
Subtotal (95% CI) 163 64 18.6 % -0.24 [ -0.53, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
5 Maxacalcitol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Paricalcitol OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Becocalcidiol OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
8 Becocalcidiol twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 898 569 100.0 % -0.54 [ -0.72, -0.36 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.99, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 6.02 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.54, df = 2 (P = 0.10), I2 =56%
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Analysis 1.5. Comparison 1 Vitamin D analogues versus placebo, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol
Barker 1999 (P) 26 -3.19 (1.27) 28 -1.86 (0.89) 4.7 % -1.20 [ -1.79, -0.62 ]
Dubertret 1992 62 -2.66 (0.87) 62 -1.84 (0.75) 6.5 % -1.00 [ -1.38, -0.63 ]
Fleming 2010 (P) 74 2.3 (0.81) 28 2.64 (0.62) 5.9 % -0.44 [ -0.88, 0.00 ]
Guenther 2002 (P) 227 -3.3 (1.12) 206 -1.88 (1.14) 7.8 % -1.25 [ -1.46, -1.05 ]
Harrington 1996a 290 -2.06 (0.8) 71 -1.37 (0.91) 7.4 % -0.84 [ -1.10, -0.57 ]
Highton 1995 124 1.7 (1.2) 123 3.15 (1.2) 7.3 % -1.20 [ -1.48, -0.93 ]
Hinds n 2006 (P) 114 5.2 (3.3) 92 10.4 (4.4) 7.1 % -1.35 [ -1.66, -1.05 ]
-4 -2 0 2 4
Favours vitamin D analogue Favours placebo
(Continued . . . )
450Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kang 1998 15 -3.87 (1.36) 15 -1.47 (0.99) 2.9 % -1.96 [ -2.86, -1.07 ]
Kaufmann 2002 (P) 480 2.2417 (0.9) 157 2.68 (0.89) 8.0 % -0.49 [ -0.67, -0.31 ]
Kragballe 1988b 27 -2.4 (0.88) 27 -1.17 (0.62) 4.5 % -1.59 [ -2.21, -0.97 ]
Levine 2010 (P) 48 3.52 (1.95) 48 4.08 (1.93) 6.2 % -0.29 [ -0.69, 0.12 ]
Mortensen 1993b 17 6.53 (2.49) 17 9.04 (4.71) 4.0 % -0.65 [ -1.34, 0.04 ]
Oranje 1997 43 -2.53 (1.05) 34 -1.91 (1.19) 5.7 % -0.55 [ -1.01, -0.09 ]
Papp 2003 (P) 308 -2.81 (1.21) 107 -1.92 (1.07) 7.7 % -0.76 [ -0.98, -0.53 ]
Pariser 1996 167 2.27 (1.33) 168 3.63 (1.33) 7.7 % -1.02 [ -1.25, -0.79 ]
Staberg 1989 9 1.3 (1.6) 9 4.6 (2.2) 2.2 % -1.63 [ -2.74, -0.53 ]
Zonneveld 1998 (P) 23 2.6 (1.73) 23 4.6 (1.73) 4.4 % -1.14 [ -1.76, -0.51 ]
Subtotal (95% CI) 2054 1215 100.0 % -0.96 [ -1.15, -0.77 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 76.86, df = 16 (P<0.00001); I2 =79%
Test for overall effect: Z = 9.98 (P < 0.00001)
2 Calcipotriol plus occlusion
Hinds n 2006 (P) 95 9.7 (4.8) 92 10.4 (4.4) 100.0 % -0.15 [ -0.44, 0.14 ]
Subtotal (95% CI) 95 92 100.0 % -0.15 [ -0.44, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
3 Calcitriol
Langner 1992 29 -4.1 (1.05) 29 -3 (1.04) 14.2 % -1.04 [ -1.59, -0.49 ]
Langner 1993 32 -3.97 (1.33) 32 -3.28 (1.14) 14.5 % -0.55 [ -1.05, -0.05 ]
Langner 2001 (P) 15 -2.4 (1.18) 14 -2.14 (0.66) 13.1 % -0.26 [ -0.99, 0.47 ]
Lebwohl 2007 202 -3.1 (1.4) 199 -2.42 (1.37) 15.7 % -0.49 [ -0.69, -0.29 ]
Perez 1996 84 -3.2 (0.85) 84 -1.14 (0.38) 14.7 % -3.11 [ -3.57, -2.66 ]
Powers 2005 199 -2.92 (1.27) 201 -2.01 (1.27) 15.7 % -0.72 [ -0.92, -0.51 ]
Van de Kerkhof 1989 10 6 (1.49) 10 6.1 (1.49) 12.1 % -0.06 [ -0.94, 0.81 ]
Subtotal (95% CI) 571 569 100.0 % -0.92 [ -1.54, -0.29 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 116.83, df = 6 (P<0.00001); I2 =95%
Test for overall effect: Z = 2.87 (P = 0.0041)
4 Tacalcitol
Langley 2011 (P) 163 2.28 (0.89) 64 2.75 (0.78) 29.0 % -0.54 [ -0.84, -0.25 ]
Scarpa 1997 134 3.44 (1.94) 134 4.34 (1.94) 30.8 % -0.46 [ -0.71, -0.22 ]
Seidenari 1997 (P) 11 2.92 (1.93) 11 4.52 (1.38) 11.3 % -0.92 [ -1.81, -0.03 ]
Van de Kerkhof 1996a 103 -1.66 (0.88) 103 -0.75 (0.72) 28.9 % -1.13 [ -1.42, -0.83 ]
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Study or subgroup Vitamin D analogue Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 411 312 100.0 % -0.73 [ -1.09, -0.37 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 13.06, df = 3 (P = 0.005); I2 =77%
Test for overall effect: Z = 3.98 (P = 0.000069)
5 Maxacalcitol
Barker 1999 (P) 75 -3.52 (1.23) 28 -1.86 (0.89) 100.0 % -1.43 [ -1.91, -0.96 ]
Subtotal (95% CI) 75 28 100.0 % -1.43 [ -1.91, -0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.88 (P < 0.00001)
6 Paricalcitol OD
Durakovic 2004 11 -2.45 (1.09) 11 -0.69 (0.94) 100.0 % -1.66 [ -2.66, -0.67 ]
Subtotal (95% CI) 11 11 100.0 % -1.66 [ -2.66, -0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.27 (P = 0.0011)
7 Becocalcidiol OD
Helfrich 2007 63 2.33 (0.84) 58 2.5 (0.68) 100.0 % -0.22 [ -0.58, 0.14 ]
Subtotal (95% CI) 63 58 100.0 % -0.22 [ -0.58, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
8 Becocalcidiol twice daily
Helfrich 2007 61 2.02 (0.74) 58 2.5 (0.68) 100.0 % -0.67 [ -1.04, -0.30 ]
Subtotal (95% CI) 61 58 100.0 % -0.67 [ -1.04, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 41.16, df = 7 (P = 0.00), I2 =83%
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Analysis 1.6. Comparison 1 Vitamin D analogues versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol
Barker 1999 (P) 4/30 2/30 2.1 % 0.07 [ -0.08, 0.22 ]
Dubertret 1992 4/66 4/66 4.6 % 0.0 [ -0.08, 0.08 ]
Feldman 2010 (1) 24/214 14/109 4.9 % -0.02 [ -0.09, 0.06 ]
Feldman 2010 (2) 19/223 15/113 5.1 % -0.05 [ -0.12, 0.02 ]
Fleming 2010 (P) 6/79 12/40 2.0 % -0.22 [ -0.38, -0.07 ]
Guenther 2002 (P) 23/231 34/208 5.7 % -0.06 [ -0.13, 0.00 ]
Harrington 1996a 30/326 17/87 4.2 % -0.10 [ -0.19, -0.01 ]
Kang 1998 0/15 0/15 2.9 % 0.0 [ -0.12, 0.12 ]
Kaufmann 2002 (P) 39/480 25/157 5.7 % -0.08 [ -0.14, -0.02 ]
Levine 2010 (P) 2/48 0/48 5.4 % 0.04 [ -0.03, 0.11 ]
Mortensen 1993b 0/17 0/17 3.3 % 0.0 [ -0.11, 0.11 ]
Oranje 1997 6/43 3/34 2.3 % 0.05 [ -0.09, 0.19 ]
Papp 2003 (P) 27/308 12/108 5.4 % -0.02 [ -0.09, 0.04 ]
Staberg 1989 0/10 0/10 1.6 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 2090 1042 55.0 % -0.03 [ -0.06, 0.00 ]
Total events: 184 (Vitamin D analogue), 138 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 23.15, df = 13 (P = 0.04); I2 =44%
Test for overall effect: Z = 1.84 (P = 0.066)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Langner 1992 1/32 1/32 4.3 % 0.0 [ -0.09, 0.09 ]
Langner 1993 0/29 0/29 5.6 % 0.0 [ -0.06, 0.06 ]
Langner 2001 (P) 1/15 3/14 0.9 % -0.15 [ -0.40, 0.10 ]
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Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Perez 1996 0/84 0/84 8.3 % 0.0 [ -0.02, 0.02 ]
Van de Kerkhof 1989 0/10 0/10 1.6 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 170 169 20.8 % 0.00 [ -0.02, 0.02 ]
Total events: 2 (Vitamin D analogue), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 Tacalcitol
Langley 2011 (P) 21/184 27/91 3.5 % -0.18 [ -0.29, -0.08 ]
Scarpa 1997 23/157 23/157 4.7 % 0.0 [ -0.08, 0.08 ]
Seidenari 1997 (P) 1/12 1/12 1.1 % 0.0 [ -0.22, 0.22 ]
Van de Kerkhof 1996a 19/122 19/122 4.1 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 475 382 13.3 % -0.05 [ -0.14, 0.05 ]
Total events: 64 (Vitamin D analogue), 70 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.22, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 1.01 (P = 0.31)
5 Maxacalcitol
Barker 1999 (P) 16/90 2/30 2.9 % 0.11 [ -0.01, 0.23 ]
Subtotal (95% CI) 90 30 2.9 % 0.11 [ -0.01, 0.23 ]
Total events: 16 (Vitamin D analogue), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
6 Paricalcitol OD
Durakovic 2004 0/11 0/11 1.9 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 1.9 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Becocalcidiol OD
Helfrich 2007 56/64 53/60 3.1 % -0.01 [ -0.12, 0.11 ]
Subtotal (95% CI) 64 60 3.1 % -0.01 [ -0.12, 0.11 ]
Total events: 56 (Vitamin D analogue), 53 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
8 Becocalcidiol twice daily
Helfrich 2007 53/61 53/60 3.0 % -0.01 [ -0.13, 0.10 ]
Subtotal (95% CI) 61 60 3.0 % -0.01 [ -0.13, 0.10 ]
Total events: 53 (Vitamin D analogue), 53 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
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Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2961 1754 100.0 % -0.02 [ -0.05, 0.00 ]
Total events: 375 (Vitamin D analogue), 320 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 53.54, df = 26 (P = 0.001); I2 =51%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Chi2 = 6.83, df = 6 (P = 0.34), I2 =12%
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Analysis 1.7. Comparison 1 Vitamin D analogues versus placebo, Outcome 7 Withdrawals due to adverse
events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol
Barker 1999 (P) 0/30 1/30 1.7 % -0.03 [ -0.12, 0.05 ]
Dubertret 1992 2/66 1/66 4.1 % 0.02 [ -0.04, 0.07 ]
Feldman 2010 (1) 7/214 1/109 7.7 % 0.02 [ -0.01, 0.05 ]
Feldman 2010 (2) 2/223 3/113 7.2 % -0.02 [ -0.05, 0.01 ]
Guenther 2002 (P) 6/227 21/208 4.7 % -0.07 [ -0.12, -0.03 ]
Harrington 1996a 8/326 8/174 6.5 % -0.02 [ -0.06, 0.01 ]
Highton 1995 6/139 8/138 4.0 % -0.01 [ -0.07, 0.04 ]
Kang 1998 0/15 0/15 1.0 % 0.0 [ -0.12, 0.12 ]
Kaufmann 2002 (P) 15/480 12/157 5.0 % -0.05 [ -0.09, 0.00 ]
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Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Levine 2010 (P) 0/48 0/48 5.7 % 0.0 [ -0.04, 0.04 ]
Mortensen 1993b 0/17 0/17 1.2 % 0.0 [ -0.11, 0.11 ]
Staberg 1989 0/10 0/10 0.5 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 1795 1085 49.2 % -0.02 [ -0.04, 0.00 ]
Total events: 46 (Vitamin D analogue), 55 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 20.47, df = 11 (P = 0.04); I2 =46%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Langner 1992 0/29 0/29 2.9 % 0.0 [ -0.06, 0.06 ]
Langner 1993 1/32 1/32 1.8 % 0.0 [ -0.09, 0.09 ]
Langner 2001 (P) 1/15 3/14 0.2 % -0.15 [ -0.40, 0.10 ]
Perez 1996 0/84 0/84 9.4 % 0.0 [ -0.02, 0.02 ]
Van de Kerkhof 1989 0/10 0/10 0.5 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 170 169 14.8 % 0.00 [ -0.02, 0.02 ]
Total events: 2 (Vitamin D analogue), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.53, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
4 Tacalcitol
Langley 2011 (P) 4/184 4/91 4.6 % -0.02 [ -0.07, 0.02 ]
Scarpa 1997 1/157 0/157 11.0 % 0.01 [ -0.01, 0.02 ]
Seidenari 1997 (P) 0/12 0/12 0.7 % 0.0 [ -0.15, 0.15 ]
Van de Kerkhof 1996a 1/122 0/122 9.6 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 475 382 25.8 % 0.00 [ -0.01, 0.02 ]
Total events: 6 (Vitamin D analogue), 4 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.30, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
5 Maxacalcitol
Barker 1999 (P) 2/90 1/30 2.5 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 90 30 2.5 % -0.01 [ -0.08, 0.06 ]
Total events: 2 (Vitamin D analogue), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
6 Paricalcitol OD
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Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Durakovic 2004 0/11 0/11 0.6 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 0.6 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Becocalcidiol OD
Helfrich 2007 2/64 0/60 4.0 % 0.03 [ -0.02, 0.08 ]
Subtotal (95% CI) 64 60 4.0 % 0.03 [ -0.02, 0.08 ]
Total events: 2 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
8 Becocalcidiol twice daily
Helfrich 2007 3/61 0/60 3.1 % 0.05 [ -0.01, 0.11 ]
Subtotal (95% CI) 61 60 3.1 % 0.05 [ -0.01, 0.11 ]
Total events: 3 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 2666 1797 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 61 (Vitamin D analogue), 64 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 37.74, df = 24 (P = 0.04); I2 =36%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 6.56, df = 6 (P = 0.36), I2 =9%
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Analysis 1.8. Comparison 1 Vitamin D analogues versus placebo, Outcome 8 Withdrawals due to
treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol
Barker 1999 (P) 0/30 1/30 4.9 % -0.03 [ -0.12, 0.05 ]
Feldman 2010 (1) 4/214 3/109 8.8 % -0.01 [ -0.04, 0.03 ]
Feldman 2010 (2) 3/223 1/113 9.8 % 0.00 [ -0.02, 0.03 ]
Guenther 2002 (P) 2/227 19/208 8.4 % -0.08 [ -0.12, -0.04 ]
Harrington 1996a 9/326 22/174 7.4 % -0.10 [ -0.15, -0.05 ]
Levine 2010 (P) 0/48 0/48 8.5 % 0.0 [ -0.04, 0.04 ]
Staberg 1989 0/10 0/10 1.9 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 1078 692 49.6 % -0.03 [ -0.08, 0.01 ]
Total events: 18 (Vitamin D analogue), 46 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 39.89, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Langner 1993 0/32 1/32 5.2 % -0.03 [ -0.11, 0.05 ]
Langner 2001 (P) 0/15 3/14 1.2 % -0.21 [ -0.44, 0.02 ]
Perez 1996 0/84 0/84 9.8 % 0.0 [ -0.02, 0.02 ]
Van de Kerkhof 1989 0/10 0/10 1.9 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 141 140 18.0 % -0.03 [ -0.12, 0.05 ]
Total events: 0 (Vitamin D analogue), 4 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 8.79, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.74 (P = 0.46)
4 Tacalcitol
Scarpa 1997 0/157 0/157 10.3 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 157 157 10.3 % 0.0 [ -0.01, 0.01 ]
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(. . . Continued)
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Maxacalcitol
Barker 1999 (P) 0/90 1/30 5.5 % -0.03 [ -0.11, 0.04 ]
Subtotal (95% CI) 90 30 5.5 % -0.03 [ -0.11, 0.04 ]
Total events: 0 (Vitamin D analogue), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
6 Paricalcitol OD
Durakovic 2004 0/11 0/11 2.1 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 2.1 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Becocalcidiol OD
Helfrich 2007 1/64 2/60 7.2 % -0.02 [ -0.07, 0.04 ]
Subtotal (95% CI) 64 60 7.2 % -0.02 [ -0.07, 0.04 ]
Total events: 1 (Vitamin D analogue), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.53)
8 Becocalcidiol twice daily
Helfrich 2007 0/61 2/60 7.2 % -0.03 [ -0.09, 0.02 ]
Subtotal (95% CI) 61 60 7.2 % -0.03 [ -0.09, 0.02 ]
Total events: 0 (Vitamin D analogue), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Total (95% CI) 1602 1150 100.0 % -0.03 [ -0.05, 0.00 ]
Total events: 19 (Vitamin D analogue), 55 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 81.93, df = 15 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Chi2 = 4.30, df = 6 (P = 0.64), I2 =0.0%
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Analysis 1.9. Comparison 1 Vitamin D analogues versus placebo, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol
Dubertret 1992 14/66 16/66 1.0 % -0.03 [ -0.17, 0.11 ]
Fleming 2010 (P) 8/79 10/40 0.9 % -0.15 [ -0.30, 0.00 ]
Guenther 2002 (P) 45/227 26/208 4.4 % 0.07 [ 0.00, 0.14 ]
Harrington 1996a 81/326 20/87 2.1 % 0.02 [ -0.08, 0.12 ]
Highton 1995 28/139 21/138 2.6 % 0.05 [ -0.04, 0.14 ]
Kang 1998 2/15 0/15 0.5 % 0.13 [ -0.06, 0.33 ]
Kaufmann 2002 (P) 54/480 21/157 5.7 % -0.02 [ -0.08, 0.04 ]
Levine 2010 (P) 9/48 11/48 0.8 % -0.04 [ -0.20, 0.12 ]
Oranje 1997 7/43 8/34 0.6 % -0.07 [ -0.25, 0.11 ]
Papp 2003 (P) 53/308 17/108 3.2 % 0.01 [ -0.07, 0.10 ]
Staberg 1989 1/10 1/10 0.3 % 0.0 [ -0.26, 0.26 ]
Subtotal (95% CI) 1741 911 22.3 % 0.01 [ -0.03, 0.05 ]
Total events: 302 (Vitamin D analogue), 151 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.41, df = 10 (P = 0.26); I2 =19%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Langner 1992 0/29 0/29 5.0 % 0.0 [ -0.06, 0.06 ]
Lebwohl 2007 11/209 14/209 10.1 % -0.01 [ -0.06, 0.03 ]
Powers 2005 10/210 11/211 12.0 % 0.00 [ -0.05, 0.04 ]
Van de Kerkhof 1989 0/10 0/10 0.7 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 458 459 27.8 % -0.01 [ -0.03, 0.02 ]
Total events: 21 (Vitamin D analogue), 25 (Placebo)
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Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
4 Tacalcitol
Langley 2011 (P) 32/184 14/91 2.5 % 0.02 [ -0.07, 0.11 ]
Scarpa 1997 1/134 2/157 40.1 % -0.01 [ -0.03, 0.02 ]
Subtotal (95% CI) 318 248 42.5 % 0.00 [ -0.03, 0.03 ]
Total events: 33 (Vitamin D analogue), 16 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.21 (P = 0.83)
5 Maxacalcitol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Paricalcitol OD
Durakovic 2004 0/11 0/11 0.8 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 0.8 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Becocalcidiol OD
Helfrich 2007 3/64 2/60 4.4 % 0.01 [ -0.06, 0.08 ]
Subtotal (95% CI) 64 60 4.4 % 0.01 [ -0.06, 0.08 ]
Total events: 3 (Vitamin D analogue), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
8 Becocalcidiol twice daily
Helfrich 2007 8/61 2/60 2.3 % 0.10 [ 0.00, 0.19 ]
Subtotal (95% CI) 61 60 2.3 % 0.10 [ 0.00, 0.19 ]
Total events: 8 (Vitamin D analogue), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 2653 1749 100.0 % 0.00 [ -0.01, 0.02 ]
Total events: 367 (Vitamin D analogue), 196 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 18.36, df = 19 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 4.61, df = 5 (P = 0.46), I2 =0.0%
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Analysis 1.10. Comparison 1 Vitamin D analogues versus placebo, Outcome 10 Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 1 Vitamin D analogues versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol
Barker 1999 (P) 0/30 0/30 0.8 % 0.0 [ -0.06, 0.06 ]
Dubertret 1992 0/66 0/66 3.7 % 0.0 [ -0.03, 0.03 ]
Harrington 1996a 0/326 0/87 11.9 % 0.0 [ -0.02, 0.02 ]
Kang 1998 0/15 0/15 0.2 % 0.0 [ -0.12, 0.12 ]
Mortensen 1993b 0/17 0/17 0.3 % 0.0 [ -0.11, 0.11 ]
Oranje 1997 0/43 0/34 1.3 % 0.0 [ -0.05, 0.05 ]
Papp 2003 (P) 0/308 0/108 17.5 % 0.0 [ -0.01, 0.01 ]
Staberg 1989 0/10 0/10 0.1 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 815 367 35.8 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 7 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcitriol
Langner 1992 0/29 0/29 0.8 % 0.0 [ -0.06, 0.06 ]
Perez 1996 0/84 0/84 6.0 % 0.0 [ -0.02, 0.02 ]
Powers 2005 0/210 0/211 36.9 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 323 324 43.6 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
4 Tacalcitol
Van de Kerkhof 1996a 0/122 0/122 12.5 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 122 122 12.5 % 0.0 [ -0.02, 0.02 ]
-1 -0.5 0 0.5 1
Favours vitamin D analogue Favours placebo
(Continued . . . )
462Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Vitamin D analogue Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Maxacalcitol
Barker 1999 (P) 0/90 0/30 1.4 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 90 30 1.4 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Paricalcitol OD
Durakovic 2004 0/11 0/11 0.1 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 0.1 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Becocalcidiol OD
Helfrich 2007 0/64 0/60 3.3 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 64 60 3.3 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Becocalcidiol twice daily
Helfrich 2007 0/64 0/60 3.3 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 64 60 3.3 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1489 974 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 15 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 6 (P = 1.00), I2 =0.0%
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Analysis 2.1. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 1 IAGI
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone dipropionate OD
Fleming 2010 (P) 78 2.03 (1.06) 28 2.64 (0.62) 8.8 % -0.63 [ -1.07, -0.19 ]
Kaufmann 2002 (P) 476 1.8992 (0.94) 157 2.68 (0.89) 15.4 % -0.84 [ -1.03, -0.65 ]
Subtotal (95% CI) 554 185 24.2 % -0.81 [ -0.98, -0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 9.23 (P < 0.00001)
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 312 -3.44 (1.05) 107 -1.92 (1.07) 13.9 % -1.44 [ -1.68, -1.20 ]
Vanderploeg 1976 17 -3.24 (0.97) 16 -2.06 (0.93) 4.4 % -1.21 [ -1.96, -0.46 ]
Wortzel 1975 (1) 39 -2.97 (1.09) 37 -1.7 (1.15) 7.9 % -1.12 [ -1.61, -0.64 ]
Wortzel 1975 (2) 5 -2.2 (1.1) 4 -1.25 (0.5) 1.4 % -0.94 [ -2.38, 0.49 ]
Subtotal (95% CI) 373 164 27.6 % -1.35 [ -1.56, -1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.79, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 12.96 (P < 0.00001)
3 Betamethasone dipropionate, maintenance
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Betamethasone valerate
Stein 2001 37 -3.1 (1.195) 37 -1.4 (1.195) 7.4 % -1.41 [ -1.92, -0.90 ]
Subtotal (95% CI) 37 37 7.4 % -1.41 [ -1.92, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.39 (P < 0.00001)
5 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Desonide
Greenspan 1993 56 -2.8 (0.98) 20 -2 (0.98) 7.1 % -0.81 [ -1.34, -0.28 ]
Subtotal (95% CI) 56 20 7.1 % -0.81 [ -1.34, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
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Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Olsen 1996 (1) 88 -2.9 (1.37) 90 -1.7 (1.18) 11.9 % -0.94 [ -1.25, -0.63 ]
Olsen 1996 (2) 105 -2.8 (1.22) 100 -1.7 (1.15) 12.5 % -0.92 [ -1.21, -0.64 ]
Subtotal (95% CI) 193 190 24.4 % -0.93 [ -1.14, -0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 8.63 (P < 0.00001)
9 Hydrocortisone buteprate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Mometasone furoate
Medansky 1987 50 -1.96 (0.9) 45 -1.24 (1) 9.3 % -0.75 [ -1.17, -0.34 ]
Subtotal (95% CI) 50 45 9.3 % -0.75 [ -1.17, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00041)
Total (95% CI) 1263 641 100.0 % -1.00 [ -1.18, -0.82 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 23.60, df = 10 (P = 0.01); I2 =58%
Test for overall effect: Z = 10.87 (P < 0.00001)
Test for subgroup differences: Chi2 = 21.05, df = 5 (P = 0.00), I2 =76%
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Analysis 2.2. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 2 TSS
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone dipropionate OD
Lane 1983 46 4.5 (2.8) 47 6.6 (2.8) 15.4 % -0.74 [ -1.16, -0.32 ]
Subtotal (95% CI) 46 47 15.4 % -0.74 [ -1.16, -0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
2 Betamethasone dipropionate twice daily
Vanderploeg 1976 17 3.2 (2.8) 16 5.4 (2.8) 8.3 % -0.77 [ -1.48, -0.06 ]
Subtotal (95% CI) 17 16 8.3 % -0.77 [ -1.48, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.034)
3 Betamethasone dipropionate, maintenance
Katz 1987a 19 0.83 (1.33) 19 2.12 (1.33) 8.9 % -0.95 [ -1.62, -0.27 ]
Subtotal (95% CI) 19 19 8.9 % -0.95 [ -1.62, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
4 Betamethasone valerate
Ormerod 1997 11 4.92 (2.53) 11 7.75 (2.45) 5.7 % -1.09 [ -2.00, -0.18 ]
Subtotal (95% CI) 11 11 5.7 % -1.09 [ -2.00, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
5 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Desonide
Greenspan 1993 56 3.07 (0.96) 20 4.11 (0.65) 11.7 % -1.16 [ -1.70, -0.61 ]
Subtotal (95% CI) 56 20 11.7 % -1.16 [ -1.70, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.16 (P = 0.000032)
7 Diflorasone diacetate
Lane 1983 46 5.7 (2.8) 47 6.6 (2.8) 15.8 % -0.32 [ -0.73, 0.09 ]
Subtotal (95% CI) 46 47 15.8 % -0.32 [ -0.73, 0.09 ]
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Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
8 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hydrocortisone buteprate
Sears 1997 78 -2 (1.69) 83 -1.3 (1.32) 19.3 % -0.46 [ -0.77, -0.15 ]
Subtotal (95% CI) 78 83 19.3 % -0.46 [ -0.77, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0039)
10 Mometasone furoate
Medansky 1987 50 2.7 (1.33) 45 4.2 (1.33) 14.9 % -1.12 [ -1.55, -0.68 ]
Subtotal (95% CI) 50 45 14.9 % -1.12 [ -1.55, -0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.05 (P < 0.00001)
Total (95% CI) 323 288 100.0 % -0.77 [ -1.01, -0.52 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 13.13, df = 7 (P = 0.07); I2 =47%
Test for overall effect: Z = 6.19 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.13, df = 7 (P = 0.07), I2 =47%
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Analysis 2.3. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 3 PASI
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone dipropionate OD
Fleming 2010 (P) 78 3.9 (3.8) 28 5.5 (3.5) 25.5 % -0.43 [ -0.86, 0.01 ]
Kaufmann 2002 (P) 476 -0.57 (0.3) 157 -0.23 (0.34) 38.4 % -1.09 [ -1.28, -0.90 ]
Subtotal (95% CI) 554 185 63.9 % -0.79 [ -1.44, -0.14 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 7.58, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 312 -0.63 (0.27) 107 -0.29 (0.31) 36.1 % -1.21 [ -1.44, -0.97 ]
Subtotal (95% CI) 312 107 36.1 % -1.21 [ -1.44, -0.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.11 (P < 0.00001)
3 Betamethasone dipropionate, maintenance
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Desonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: not applicable
9 Hydrocortisone buteprate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Mometasone furoate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 866 292 100.0 % -0.97 [ -1.31, -0.62 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 9.79, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 5.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =29%
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Analysis 2.5. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone dipropionate OD
Fleming 2010 (P) 78 2.03 (1.06) 28 2.64 (0.62) 6.5 % -0.63 [ -1.07, -0.19 ]
Kaufmann 2002 (P) 476 1.8992 (0.94) 157 2.68 (0.89) 9.9 % -0.84 [ -1.03, -0.65 ]
Lane 1983 46 4.5 (2.8) 47 6.6 (2.8) 6.7 % -0.74 [ -1.16, -0.32 ]
Subtotal (95% CI) 600 232 23.2 % -0.80 [ -0.96, -0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 9.86 (P < 0.00001)
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 312 -3.44 (1.05) 107 -1.92 (1.07) 9.2 % -1.44 [ -1.68, -1.20 ]
Vanderploeg 1976 17 -3.24 (0.97) 16 -2.06 (0.93) 3.6 % -1.21 [ -1.96, -0.46 ]
Wortzel 1975 (1) 39 -2.97 (1.09) 37 -1.7 (1.15) 6.0 % -1.12 [ -1.61, -0.64 ]
Wortzel 1975 (2) 5 -2.2 (1.1) 4 -1.25 (0.5) 1.3 % -0.94 [ -2.38, 0.49 ]
Subtotal (95% CI) 373 164 20.1 % -1.35 [ -1.56, -1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.79, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 12.96 (P < 0.00001)
3 Betamethasone dipropionate, maintenance
Katz 1987a 19 0.83 (1.33) 19 2.12 (1.33) 4.2 % -0.95 [ -1.62, -0.27 ]
Subtotal (95% CI) 19 19 4.2 % -0.95 [ -1.62, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
4 Betamethasone valerate
Ormerod 1997 11 4.92 (2.53) 11 7.75 (2.45) 2.7 % -1.09 [ -2.00, -0.18 ]
Stein 2001 37 -3.1 (1.195) 37 -1.4 (1.195) 5.7 % -1.41 [ -1.92, -0.90 ]
Subtotal (95% CI) 48 48 8.4 % -1.33 [ -1.78, -0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 5.85 (P < 0.00001)
5 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
6 Desonide
Greenspan 1993 56 -2.8 (0.98) 20 -2 (0.98) 5.5 % -0.81 [ -1.34, -0.28 ]
Subtotal (95% CI) 56 20 5.5 % -0.81 [ -1.34, -0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.00 (P = 0.0027)
7 Diflorasone diacetate
Lane 1983 46 5.7 (2.8) 47 6.6 (2.8) 6.9 % -0.32 [ -0.73, 0.09 ]
Subtotal (95% CI) 46 47 6.9 % -0.32 [ -0.73, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
8 Fluticasone propionate
Olsen 1996 (1) 88 -2.9 (1.37) 90 -1.7 (1.18) 8.2 % -0.94 [ -1.25, -0.63 ]
Olsen 1996 (2) 105 -2.8 (1.22) 100 -1.7 (1.15) 8.6 % -0.92 [ -1.21, -0.64 ]
Subtotal (95% CI) 193 190 16.8 % -0.93 [ -1.14, -0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 8.63 (P < 0.00001)
9 Hydrocortisone buteprate
Sears 1997 78 -2 (1.69) 83 -1.3 (1.32) 8.2 % -0.46 [ -0.77, -0.15 ]
Subtotal (95% CI) 78 83 8.2 % -0.46 [ -0.77, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.89 (P = 0.0039)
10 Mometasone furoate
Medansky 1987 50 -1.96 (0.9) 45 -1.24 (1) 6.8 % -0.75 [ -1.17, -0.34 ]
Subtotal (95% CI) 50 45 6.8 % -0.75 [ -1.17, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00041)
Total (95% CI) 1463 848 100.0 % -0.89 [ -1.06, -0.72 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 43.03, df = 15 (P = 0.00016); I2 =65%
Test for overall effect: Z = 10.07 (P < 0.00001)
Test for subgroup differences: Chi2 = 40.04, df = 8 (P = 0.00), I2 =80%
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Analysis 2.6. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 6 Total withdrawals
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone dipropionate OD
Fleming 2010 (P) 5/83 12/40 10.6 % -0.24 [ -0.39, -0.09 ]
Kaufmann 2002 (P) 22/476 25/157 14.8 % -0.11 [ -0.17, -0.05 ]
Subtotal (95% CI) 559 197 25.4 % -0.16 [ -0.28, -0.04 ]
Total events: 27 (Corticosteroid (potent)), 37 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.38, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 2.58 (P = 0.010)
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 17/313 12/108 14.6 % -0.06 [ -0.12, 0.01 ]
Subtotal (95% CI) 313 108 14.6 % -0.06 [ -0.12, 0.01 ]
Total events: 17 (Corticosteroid (potent)), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
3 Betamethasone dipropionate, maintenance
Katz 1987a 6/20 16/20 6.2 % -0.50 [ -0.77, -0.23 ]
Katz 1991a 16/48 35/46 9.3 % -0.43 [ -0.61, -0.25 ]
Subtotal (95% CI) 68 66 15.5 % -0.45 [ -0.60, -0.30 ]
Total events: 22 (Corticosteroid (potent)), 51 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.88 (P < 0.00001)
4 Betamethasone valerate
Stein 2001 3/40 3/40 12.3 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 40 40 12.3 % 0.0 [ -0.12, 0.12 ]
Total events: 3 (Corticosteroid (potent)), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Budesonide
Agrup 1981 0/11 0/11 10.2 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 10.2 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Desonide
Greenspan 1993 4/60 5/20 8.5 % -0.18 [ -0.38, 0.02 ]
Subtotal (95% CI) 60 20 8.5 % -0.18 [ -0.38, 0.02 ]
Total events: 4 (Corticosteroid (potent)), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hydrocortisone buteprate
Sears 1997 10/84 11/96 13.4 % 0.00 [ -0.09, 0.10 ]
Subtotal (95% CI) 84 96 13.4 % 0.00 [ -0.09, 0.10 ]
Total events: 10 (Corticosteroid (potent)), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
10 Mometasone furoate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1135 538 100.0 % -0.14 [ -0.22, -0.05 ]
Total events: 83 (Corticosteroid (potent)), 119 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 38.78, df = 8 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.13 (P = 0.0018)
Test for subgroup differences: Chi2 = 32.44, df = 6 (P = 0.00), I2 =82%
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Analysis 2.7. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 7 Withdrawals due to
adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone dipropionate OD
Kaufmann 2002 (P) 5/476 12/157 16.9 % -0.07 [ -0.11, -0.02 ]
Subtotal (95% CI) 476 157 16.9 % -0.07 [ -0.11, -0.02 ]
Total events: 5 (Corticosteroid (potent)), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.04 (P = 0.0024)
2 Betamethasone dipropionate twice daily
Vanderploeg 1976 0/17 0/16 6.9 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 16 6.9 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Betamethasone dipropionate, maintenance
Katz 1987a 0/20 0/20 8.8 % 0.0 [ -0.09, 0.09 ]
Katz 1991a 0/48 0/46 17.3 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 68 66 26.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
4 Betamethasone valerate
Stein 2001 3/40 0/40 8.8 % 0.08 [ -0.02, 0.17 ]
Subtotal (95% CI) 40 40 8.8 % 0.08 [ -0.02, 0.17 ]
Total events: 3 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
5 Budesonide
Agrup 1981 0/11 0/11 4.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 4.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Desonide
Greenspan 1993 0/60 2/20 4.9 % -0.10 [ -0.24, 0.04 ]
Subtotal (95% CI) 60 20 4.9 % -0.10 [ -0.24, 0.04 ]
Total events: 0 (Corticosteroid (potent)), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hydrocortisone buteprate
Sears 1997 1/94 0/96 19.5 % 0.01 [ -0.02, 0.04 ]
Subtotal (95% CI) 94 96 19.5 % 0.01 [ -0.02, 0.04 ]
Total events: 1 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
10 Mometasone furoate
Medansky 1987 0/61 3/59 13.0 % -0.05 [ -0.11, 0.01 ]
Subtotal (95% CI) 61 59 13.0 % -0.05 [ -0.11, 0.01 ]
Total events: 0 (Corticosteroid (potent)), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
Total (95% CI) 827 465 100.0 % -0.01 [ -0.05, 0.02 ]
Total events: 9 (Corticosteroid (potent)), 17 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 20.46, df = 8 (P = 0.01); I2 =61%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 15.38, df = 7 (P = 0.03), I2 =54%
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Analysis 2.8. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 8 Withdrawals due to
treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone dipropionate OD
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Betamethasone dipropionate twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Betamethasone dipropionate, maintenance
Katz 1987a 5/20 15/20 31.5 % -0.50 [ -0.77, -0.23 ]
Katz 1991a 16/46 35/44 68.5 % -0.45 [ -0.63, -0.27 ]
Subtotal (95% CI) 66 64 100.0 % -0.46 [ -0.61, -0.31 ]
Total events: 21 (Corticosteroid (potent)), 50 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 6.04 (P < 0.00001)
4 Betamethasone valerate
Stein 2001 0/40 0/40 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 40 40 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Budesonide
Agrup 1981 0/11 0/11 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Desonide
Greenspan 1993 0/60 0/20 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 60 20 100.0 % 0.0 [ -0.07, 0.07 ]
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hydrocortisone buteprate
Sears 1997 0/94 0/96 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 94 96 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
10 Mometasone furoate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 35.94, df = 4 (P = 0.00), I2 =89%
-1 -0.5 0 0.5 1
Favours corticosteroid (potent) Favours placebo
477Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.9. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone dipropionate OD
Fleming 2010 (P) 7/83 10/40 5.1 % -0.17 [ -0.31, -0.02 ]
Kaufmann 2002 (P) 23/476 21/157 14.1 % -0.09 [ -0.14, -0.03 ]
Subtotal (95% CI) 559 197 19.2 % -0.10 [ -0.15, -0.04 ]
Total events: 30 (Corticosteroid (potent)), 31 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 3.43 (P = 0.00060)
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 27/313 17/108 11.4 % -0.07 [ -0.15, 0.00 ]
Vanderploeg 1976 0/17 0/16 7.5 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 330 124 18.9 % -0.05 [ -0.12, 0.03 ]
Total events: 27 (Corticosteroid (potent)), 17 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.19 (P = 0.23)
3 Betamethasone dipropionate, maintenance
Katz 1987a 0/20 0/20 9.3 % 0.0 [ -0.09, 0.09 ]
Katz 1991a 0/48 0/46 16.6 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 68 66 25.9 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
4 Betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Desonide
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(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greenspan 1993 3/60 1/20 7.6 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 60 20 7.6 % 0.0 [ -0.11, 0.11 ]
Total events: 3 (Corticosteroid (potent)), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Fluticasone propionate
Olsen 1996 (1) 13/193 12/190 15.2 % 0.00 [ -0.05, 0.05 ]
Subtotal (95% CI) 193 190 15.2 % 0.00 [ -0.05, 0.05 ]
Total events: 13 (Corticosteroid (potent)), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
9 Hydrocortisone buteprate
Sears 1997 21/94 27/96 6.5 % -0.06 [ -0.18, 0.07 ]
Subtotal (95% CI) 94 96 6.5 % -0.06 [ -0.18, 0.07 ]
Total events: 21 (Corticosteroid (potent)), 27 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
10 Mometasone furoate
Medansky 1987 5/61 11/59 6.7 % -0.10 [ -0.23, 0.02 ]
Subtotal (95% CI) 61 59 6.7 % -0.10 [ -0.23, 0.02 ]
Total events: 5 (Corticosteroid (potent)), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.090)
Total (95% CI) 1365 752 100.0 % -0.04 [ -0.08, 0.00 ]
Total events: 99 (Corticosteroid (potent)), 99 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 20.56, df = 9 (P = 0.01); I2 =56%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Chi2 = 11.95, df = 6 (P = 0.06), I2 =50%
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Analysis 2.10. Comparison 2 Corticosteroid (potent) versus placebo, Outcome 10 Adverse events
(systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 2 Corticosteroid (potent) versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone dipropionate OD
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Betamethasone dipropionate twice daily
Papp 2003 (P) 0/313 0/108 81.6 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 313 108 81.6 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Betamethasone dipropionate, maintenance
Katz 1987a 0/20 1/20 0.9 % -0.05 [ -0.18, 0.08 ]
Katz 1991a 2/48 0/46 3.2 % 0.04 [ -0.03, 0.11 ]
Subtotal (95% CI) 68 66 4.1 % 0.01 [ -0.07, 0.10 ]
Total events: 2 (Corticosteroid (potent)), 1 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.27 (P = 0.78)
4 Budesonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Desonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
-1 -0.5 0 0.5 1
Favours corticosteroid (potent) Favours placebo
(Continued . . . )
480Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup
Corticosteroid
(potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
7 Fluticasone propionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Hydrocortisone buteprate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Mometasone furoate
Medansky 1987 0/61 0/59 14.4 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 61 59 14.4 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Corticosteroid (potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 442 233 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 2 (Corticosteroid (potent)), 1 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.96), I2 =0.0%
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Analysis 3.1. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 1 IAGI
Study or subgroup
Corticosteroid
(very potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Clobetasol propionate
Beutner 2006 25 0.24 (0.44) 25 2.24 (1.05) 16.6 % -2.45 [ -3.19, -1.70 ]
Decroix 2004 189 -4.94 (1.08) 33 -2.23 (1.69) 21.9 % -2.27 [ -2.70, -1.85 ]
Jarratt 2006 60 1.1 (0.95) 60 2.72 (0.64) 21.7 % -1.99 [ -2.43, -1.55 ]
Lebwohl 2002 60 -2.85 (1.47) 19 -1.58 (1.17) 20.1 % -0.89 [ -1.43, -0.36 ]
Subtotal (95% CI) 334 137 80.4 % -1.89 [ -2.53, -1.24 ]
Heterogeneity: Tau2 = 0.36; Chi2 = 18.67, df = 3 (P = 0.00032); I2 =84%
Test for overall effect: Z = 5.74 (P < 0.00001)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991(2) 36 -2.97 (0.97) 33 -1.3 (0.85) 19.6 % -1.81 [ -2.37, -1.24 ]
Subtotal (95% CI) 36 33 19.6 % -1.81 [ -2.37, -1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.26 (P < 0.00001)
Total (95% CI) 370 170 100.0 % -1.87 [ -2.38, -1.36 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 18.76, df = 4 (P = 0.00088); I2 =79%
Test for overall effect: Z = 7.21 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.85), I2 =0.0%
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Analysis 3.2. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 2 TSS
Study or subgroup
Corticosteroid
(very potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Clobetasol propionate
Gottlieb 2003 139 -4.01 (2.43) 140 -1.51 (2.43) 39.5 % -1.03 [ -1.28, -0.78 ]
Jorizzo 1997 35 -4.3 (1.98) 39 -1.6 (1.98) 28.7 % -1.35 [ -1.86, -0.84 ]
Lowe 2005 163 2.43 (2.03) 29 5.93 (1.85) 31.8 % -1.74 [ -2.17, -1.31 ]
Subtotal (95% CI) 337 208 100.0 % -1.35 [ -1.80, -0.89 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 8.10, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 5.83 (P < 0.00001)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 337 208 100.0 % -1.35 [ -1.80, -0.89 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 8.10, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 4 PAGI
Study or subgroup
Corticosteroid
(very potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Clobetasol propionate
Lebwohl 2002 60 -3.07 (1.4) 19 -1.68 (1.25) 13.4 % -1.01 [ -1.55, -0.47 ]
Subtotal (95% CI) 60 19 13.4 % -1.01 [ -1.55, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991 (1) 96 -2.92 (1.18) 96 -1.47 (1.29) 41.7 % -1.17 [ -1.47, -0.86 ]
Katz 1991b 108 -2.46 (1.45) 108 -0.72 (1.14) 44.9 % -1.33 [ -1.62, -1.03 ]
Subtotal (95% CI) 204 204 86.6 % -1.25 [ -1.46, -1.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 11.54 (P < 0.00001)
Total (95% CI) 264 223 100.0 % -1.22 [ -1.42, -1.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 12.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.68, df = 1 (P = 0.41), I2 =0.0%
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Analysis 3.5. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Corticosteroid
(very potent) Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Clobetasol propionate
Beutner 2006 25 0.24 (0.44) 25 2.24 (1.05) 7.2 % -2.45 [ -3.19, -1.70 ]
Decroix 2004 189 -4.94 (1.08) 33 -2.23 (1.69) 10.3 % -2.27 [ -2.70, -1.85 ]
Gottlieb 2003 139 -4.01 (2.43) 140 -1.51 (2.43) 11.9 % -1.03 [ -1.28, -0.78 ]
Jarratt 2006 60 1.1 (0.95) 60 2.72 (0.64) 10.1 % -1.99 [ -2.43, -1.55 ]
Jorizzo 1997 35 -4.3 (1.98) 39 -1.6 (1.98) 9.4 % -1.35 [ -1.86, -0.84 ]
Lebwohl 2002 60 -2.85 (1.47) 19 -1.58 (1.17) 9.2 % -0.89 [ -1.43, -0.36 ]
Lowe 2005 163 2.43 (2.03) 29 5.93 (1.85) 10.2 % -1.74 [ -2.17, -1.31 ]
Subtotal (95% CI) 671 345 68.3 % -1.65 [ -2.10, -1.20 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 43.69, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 7.21 (P < 0.00001)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991 (1) 96 -2.92 (1.18) 96 -1.47 (1.29) 11.4 % -1.17 [ -1.47, -0.86 ]
Bernhard 1991(2) 36 -2.97 (0.97) 33 -1.3 (0.85) 8.9 % -1.81 [ -2.37, -1.24 ]
Katz 1991b 108 -2.46 (1.45) 108 -0.72 (1.14) 11.5 % -1.33 [ -1.62, -1.03 ]
Subtotal (95% CI) 240 237 31.7 % -1.36 [ -1.65, -1.07 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.78, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 9.18 (P < 0.00001)
Total (95% CI) 911 582 100.0 % -1.56 [ -1.87, -1.26 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 49.13, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 10.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
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Analysis 3.6. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 6 Total withdrawals
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clobetasol propionate
Beutner 2006 2/27 2/27 9.1 % 0.0 [ -0.14, 0.14 ]
Decroix 2004 5/189 4/33 11.1 % -0.09 [ -0.21, 0.02 ]
Gottlieb 2003 4/139 4/140 18.3 % 0.00 [ -0.04, 0.04 ]
Jarratt 2006 0/60 0/60 18.9 % 0.0 [ -0.03, 0.03 ]
Jorizzo 1997 6/44 15/45 7.1 % -0.20 [ -0.37, -0.03 ]
Lebwohl 2002 3/61 2/20 8.9 % -0.05 [ -0.19, 0.09 ]
Lowe 2005 9/163 8/29 7.4 % -0.22 [ -0.39, -0.05 ]
Subtotal (95% CI) 683 354 80.8 % -0.06 [ -0.13, 0.01 ]
Total events: 29 (Corticosteroid (very potent)), 35 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 33.33, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991(2) 0/72 0/72 19.2 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 72 72 19.2 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 755 426 100.0 % -0.05 [ -0.10, 0.01 ]
Total events: 29 (Corticosteroid (very potent)), 35 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 43.07, df = 7 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 2.43, df = 1 (P = 0.12), I2 =59%
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Analysis 3.7. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 7 Withdrawals due to
adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clobetasol propionate
Beutner 2006 0/27 0/27 1.7 % 0.0 [ -0.07, 0.07 ]
Decroix 2004 1/189 0/33 4.4 % 0.01 [ -0.04, 0.05 ]
Gottlieb 2003 0/139 1/140 20.7 % -0.01 [ -0.03, 0.01 ]
Jarratt 2006 0/60 0/60 7.8 % 0.0 [ -0.03, 0.03 ]
Jorizzo 1997 1/44 1/45 2.1 % 0.00 [ -0.06, 0.06 ]
Lebwohl 2002 0/61 0/20 1.7 % 0.0 [ -0.07, 0.07 ]
Lowe 2005 1/163 0/29 3.5 % 0.01 [ -0.04, 0.05 ]
Subtotal (95% CI) 683 354 41.9 % 0.00 [ -0.02, 0.01 ]
Total events: 3 (Corticosteroid (very potent)), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 6 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991 (1) 0/100 0/100 21.3 % 0.0 [ -0.02, 0.02 ]
Bernhard 1991(2) 0/72 0/72 11.1 % 0.0 [ -0.03, 0.03 ]
Katz 1991b 0/110 0/110 25.7 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 282 282 58.1 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 965 636 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 3 (Corticosteroid (very potent)), 2 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 9 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.82)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
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Analysis 3.8. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 8 Withdrawals due to
treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clobetasol propionate
Beutner 2006 0/27 0/27 3.2 % 0.0 [ -0.07, 0.07 ]
Decroix 2004 0/189 1/33 3.2 % -0.03 [ -0.10, 0.04 ]
Gottlieb 2003 0/139 1/140 28.6 % -0.01 [ -0.03, 0.01 ]
Jarratt 2006 0/60 0/60 13.3 % 0.0 [ -0.03, 0.03 ]
Jorizzo 1997 1/44 6/45 1.3 % -0.11 [ -0.22, 0.00 ]
Lebwohl 2002 0/61 0/20 3.2 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 520 325 52.9 % -0.01 [ -0.03, 0.01 ]
Total events: 1 (Corticosteroid (very potent)), 8 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.11, df = 5 (P = 0.21); I2 =30%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991 (1) 0/100 0/100 29.1 % 0.0 [ -0.02, 0.02 ]
Bernhard 1991(2) 0/72 0/72 17.9 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 172 172 47.1 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 692 497 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 1 (Corticosteroid (very potent)), 8 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 8.09, df = 7 (P = 0.32); I2 =13%
Test for overall effect: Z = 0.70 (P = 0.49)
Test for subgroup differences: Chi2 = 0.52, df = 1 (P = 0.47), I2 =0.0%
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Analysis 3.9. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clobetasol propionate
Beutner 2006 1/27 0/27 2.7 % 0.04 [ -0.06, 0.13 ]
Decroix 2004 2/189 0/33 13.2 % 0.01 [ -0.03, 0.05 ]
Gottlieb 2003 7/139 10/140 8.0 % -0.02 [ -0.08, 0.03 ]
Jarratt 2006 14/60 13/60 1.1 % 0.02 [ -0.13, 0.17 ]
Jorizzo 1997 5/44 5/45 1.5 % 0.00 [ -0.13, 0.13 ]
Lebwohl 2002 17/61 6/20 0.5 % -0.02 [ -0.25, 0.21 ]
Subtotal (95% CI) 520 325 27.0 % 0.00 [ -0.03, 0.03 ]
Total events: 46 (Corticosteroid (very potent)), 34 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 5 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Halobetasol
Bernhard 1991 (1) 0/100 0/100 67.0 % 0.0 [ -0.02, 0.02 ]
Katz 1991b 7/110 7/110 6.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 210 210 73.0 % 0.0 [ -0.02, 0.02 ]
Total events: 7 (Corticosteroid (very potent)), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 730 535 100.0 % 0.00 [ -0.02, 0.02 ]
Total events: 53 (Corticosteroid (very potent)), 41 (Placebo)
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(. . . Continued)
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 3.10. Comparison 3 Corticosteroid (very potent) versus placebo, Outcome 10 Adverse events
(systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 3 Corticosteroid (very potent) versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Clobetasol propionate
Gottlieb 2003 0/139 1/140 23.4 % -0.01 [ -0.03, 0.01 ]
Jarratt 2006 0/60 0/60 8.8 % 0.0 [ -0.03, 0.03 ]
Lebwohl 2002 17/61 6/20 0.2 % -0.02 [ -0.25, 0.21 ]
Subtotal (95% CI) 260 220 32.3 % -0.01 [ -0.02, 0.01 ]
Total events: 17 (Corticosteroid (very potent)), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
2 Halcinonide
Sudilovsky 1981 0/78 0/78 14.7 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 78 78 14.7 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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(. . . Continued)
Study or subgroup
Corticosteroid
(very potent) Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Halobetasol
Bernhard 1991 (1) 0/100 0/100 24.0 % 0.0 [ -0.02, 0.02 ]
Katz 1991b 0/110 0/110 29.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 210 210 53.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Corticosteroid (very potent)), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 548 508 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 17 (Corticosteroid (very potent)), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Chi2 = 0.26, df = 2 (P = 0.88), I2 =0.0%
-0.5 -0.25 0 0.25 0.5
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Analysis 4.2. Comparison 4 Dithranol versus placebo, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 2 TSS
Study or subgroup Dithranol Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Buckley 1978 8 -0.54 (0.29) 8 -0.26 (0.14) 22.7 % -1.16 [ -2.25, -0.08 ]
Grattan 1997 (P) 12 1.2 (1.77) 12 4.1 (1.59) 27.3 % -1.66 [ -2.62, -0.71 ]
Jekler 1992 27 0.99 (0.47) 27 1.3 (0.42) 50.0 % -0.69 [ -1.24, -0.14 ]
Total (95% CI) 47 47 100.0 % -1.06 [ -1.66, -0.46 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 3.19, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 3.45 (P = 0.00056)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Dithranol versus placebo, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Dithranol Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Buckley 1978 8 -0.54 (0.29) 8 -0.26 (0.14) 22.7 % -1.16 [ -2.25, -0.08 ]
Grattan 1997 (P) 12 1.2 (1.77) 12 4.1 (1.59) 27.3 % -1.66 [ -2.62, -0.71 ]
Jekler 1992 27 0.99 (0.47) 27 1.3 (0.42) 50.0 % -0.69 [ -1.24, -0.14 ]
Total (95% CI) 47 47 100.0 % -1.06 [ -1.66, -0.46 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 3.19, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 3.45 (P = 0.00056)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 Dithranol versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 6 Total withdrawals
Study or subgroup Dithranol Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buckley 1978 2/10 2/10 7.3 % 0.0 [ -0.35, 0.35 ]
Grattan 1997 (P) 0/12 0/12 40.9 % 0.0 [ -0.15, 0.15 ]
Jekler 1992 3/30 3/30 38.8 % 0.0 [ -0.15, 0.15 ]
Volden 1992 1/10 1/10 12.9 % 0.0 [ -0.26, 0.26 ]
Total (95% CI) 62 62 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 6 (Dithranol), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Dithranol versus placebo, Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Dithranol Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grattan 1997 (P) 0/12 0/12 13.7 % 0.0 [ -0.15, 0.15 ]
Jekler 1992 0/30 0/30 76.4 % 0.0 [ -0.06, 0.06 ]
Volden 1992 0/10 0/10 9.9 % 0.0 [ -0.17, 0.17 ]
Total (95% CI) 52 52 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Dithranol), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 Dithranol versus placebo, Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Dithranol Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grattan 1997 (P) 0/12 0/12 58.1 % 0.0 [ -0.15, 0.15 ]
Volden 1992 0/10 0/10 41.9 % 0.0 [ -0.17, 0.17 ]
Total (95% CI) 22 22 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Dithranol), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 Dithranol versus placebo, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup Dithranol Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buckley 1978 5/7 2/7 29.5 % 0.43 [ -0.04, 0.90 ]
Jekler 1992 0/30 0/30 37.1 % 0.0 [ -0.06, 0.06 ]
Volden 1992 4/10 0/10 33.4 % 0.40 [ 0.08, 0.72 ]
Total (95% CI) 47 47 100.0 % 0.26 [ -0.30, 0.82 ]
Total events: 9 (Dithranol), 2 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 25.44, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Dithranol versus placebo, Outcome 10 Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 4 Dithranol versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup Dithranol Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Buckley 1978 2/10 2/10 100.0 % 0.0 [ -0.35, 0.35 ]
Total (95% CI) 10 10 100.0 % 0.0 [ -0.35, 0.35 ]
Total events: 2 (Dithranol), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Vitamin D combination products versus placebo, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 1 IAGI
Study or subgroup
Vitamin D
combina-
tion Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Fleming 2010 (P) 150 1.85 (1.05) 28 2.64 (0.62) 14.5 % -0.79 [ -1.20, -0.38 ]
Guenther 2002 (P) 150 -3.59 (1) 206 -1.88 (1.14) 17.2 % -1.58 [ -1.82, -1.33 ]
Kaufmann 2002 (P) 490 1.5 (0.9) 157 2.68 (0.89) 17.8 % -1.31 [ -1.51, -1.12 ]
Langley 2011 (P) 171 1.84 (0.93) 64 2.75 (0.78) 16.3 % -1.02 [ -1.32, -0.72 ]
Subtotal (95% CI) 961 455 65.7 % -1.21 [ -1.50, -0.91 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 14.26, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 7.96 (P < 0.00001)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 234 -3.79 (0.97) 206 -1.88 (1.14) 17.4 % -1.81 [ -2.03, -1.59 ]
Papp 2003 (P) 301 -3.84 (0.91) 107 -1.92 (1.07) 16.9 % -2.01 [ -2.27, -1.75 ]
Subtotal (95% CI) 535 313 34.3 % -1.90 [ -2.09, -1.71 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.27, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 19.38 (P < 0.00001)
Total (95% CI) 1496 768 100.0 % -1.44 [ -1.76, -1.12 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 47.32, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 8.73 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.67, df = 1 (P = 0.00), I2 =93%
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Analysis 5.3. Comparison 5 Vitamin D combination products versus placebo, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 3 PASI
Study or subgroup
Vitamin D
combina-
tion Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Fleming 2010 (P) 147 3.1 (2.8) 28 5.5 (3.5) 13.9 % -0.82 [ -1.23, -0.40 ]
Guenther 2002 (P) 150 3 (2.5) 207 7.7 (5.5) 17.4 % -1.04 [ -1.27, -0.82 ]
Kaufmann 2002 (P) 490 -0.71 (0.26) 157 -0.23 (0.34) 17.8 % -1.70 [ -1.91, -1.50 ]
Langley 2011 (P) 171 3.58 (2.98) 64 6.47 (3.56) 16.1 % -0.92 [ -1.21, -0.62 ]
Subtotal (95% CI) 958 456 65.2 % -1.14 [ -1.57, -0.70 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 31.51, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 5.13 (P < 0.00001)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 234 2.7 (2.5) 207 7.7 (5.5) 17.8 % -1.19 [ -1.40, -0.99 ]
Papp 2003 (P) 301 -0.73 (0.25) 107 -0.29 (0.31) 17.0 % -1.65 [ -1.89, -1.40 ]
Subtotal (95% CI) 535 314 34.8 % -1.41 [ -1.86, -0.97 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 7.65, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 6.25 (P < 0.00001)
Total (95% CI) 1493 770 100.0 % -1.24 [ -1.53, -0.95 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 40.35, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 8.39 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
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Analysis 5.4. Comparison 5 Vitamin D combination products versus placebo, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 4 PAGI
Study or subgroup
Vitamin D
combina-
tion Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Langley 2011 (P) 171 1.82 (0.94) 64 2.48 (0.99) -0.69 [ -0.98, -0.40 ]
2 Combination calcipotriol/betamethasone dipropionate, twice daily
-10 -5 0 5 10
Favours vitamin D combination Favours placebo
500Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Vitamin D combination products versus placebo, Outcome 5 Combined end
point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D
combina-
tion Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Fleming 2010 (P) 150 1.85 (1.05) 28 2.64 (0.62) 14.5 % -0.79 [ -1.20, -0.38 ]
Guenther 2002 (P) 150 -3.59 (1) 206 -1.88 (1.14) 17.2 % -1.58 [ -1.82, -1.33 ]
Kaufmann 2002 (P) 490 1.5 (0.9) 157 2.68 (0.89) 17.8 % -1.31 [ -1.51, -1.12 ]
Langley 2011 (P) 171 1.84 (0.93) 64 2.75 (0.78) 16.3 % -1.02 [ -1.32, -0.72 ]
Subtotal (95% CI) 961 455 65.7 % -1.21 [ -1.50, -0.91 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 14.26, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 7.96 (P < 0.00001)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 234 -3.79 (0.97) 206 -1.88 (1.14) 17.4 % -1.81 [ -2.03, -1.59 ]
Papp 2003 (P) 301 -3.84 (0.91) 107 -1.92 (1.07) 16.9 % -2.01 [ -2.27, -1.75 ]
Subtotal (95% CI) 535 313 34.3 % -1.90 [ -2.09, -1.71 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.27, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 19.38 (P < 0.00001)
Total (95% CI) 1496 768 100.0 % -1.44 [ -1.76, -1.12 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 47.32, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 8.73 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.67, df = 1 (P = 0.00), I2 =93%
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Analysis 5.6. Comparison 5 Vitamin D combination products versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D
combina-
tion Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Fleming 2010 (P) 13/162 12/40 7.8 % -0.22 [ -0.37, -0.07 ]
Guenther 2002 (P) 11/152 34/208 19.3 % -0.09 [ -0.16, -0.03 ]
Kaufmann 2002 (P) 13/490 25/157 20.5 % -0.13 [ -0.19, -0.07 ]
Langley 2011 (P) 12/183 27/91 12.9 % -0.23 [ -0.33, -0.13 ]
Subtotal (95% CI) 987 496 60.5 % -0.15 [ -0.22, -0.09 ]
Total events: 49 (Vitamin D combination), 98 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.83, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 4.69 (P < 0.00001)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 19/237 34/208 20.1 % -0.08 [ -0.14, -0.02 ]
Papp 2003 (P) 16/304 12/108 19.4 % -0.06 [ -0.12, 0.01 ]
Subtotal (95% CI) 541 316 39.5 % -0.07 [ -0.12, -0.03 ]
Total events: 35 (Vitamin D combination), 46 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
Total (95% CI) 1528 812 100.0 % -0.12 [ -0.17, -0.07 ]
Total events: 84 (Vitamin D combination), 144 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.27, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.18, df = 1 (P = 0.04), I2 =76%
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Analysis 5.7. Comparison 5 Vitamin D combination products versus placebo, Outcome 7 Withdrawals due
to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D
combina-
tion Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Guenther 2002 (P) 0/151 21/208 25.4 % -0.10 [ -0.14, -0.06 ]
Kaufmann 2002 (P) 3/490 12/157 25.5 % -0.07 [ -0.11, -0.03 ]
Langley 2011 (P) 3/183 4/91 23.5 % -0.03 [ -0.07, 0.02 ]
Subtotal (95% CI) 824 456 74.4 % -0.07 [ -0.11, -0.03 ]
Total events: 6 (Vitamin D combination), 37 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.36, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 3.21 (P = 0.0013)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 1/235 21/208 25.6 % -0.10 [ -0.14, -0.05 ]
Subtotal (95% CI) 235 208 25.6 % -0.10 [ -0.14, -0.05 ]
Total events: 1 (Vitamin D combination), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.54 (P < 0.00001)
Total (95% CI) 1059 664 100.0 % -0.07 [ -0.11, -0.04 ]
Total events: 7 (Vitamin D combination), 58 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.67, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 4.58 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.98, df = 1 (P = 0.32), I2 =0.0%
-1 -0.5 0 0.5 1
Favours vitamin D combination Favours placebo
503Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.8. Comparison 5 Vitamin D combination products versus placebo, Outcome 8 Withdrawals due
to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D
combina-
tion Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Guenther 2002 (P) 0/151 19/208 49.5 % -0.09 [ -0.13, -0.05 ]
Subtotal (95% CI) 151 208 49.5 % -0.09 [ -0.13, -0.05 ]
Total events: 0 (Vitamin D combination), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 1/235 19/208 50.5 % -0.09 [ -0.13, -0.05 ]
Subtotal (95% CI) 235 208 50.5 % -0.09 [ -0.13, -0.05 ]
Total events: 1 (Vitamin D combination), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.26 (P = 0.000020)
Total (95% CI) 386 416 100.0 % -0.09 [ -0.12, -0.06 ]
Total events: 1 (Vitamin D combination), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 6.14 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 5.9. Comparison 5 Vitamin D combination products versus placebo, Outcome 9 Adverse events
(local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D
combina-
tion Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Fleming 2010 (P) 12/160 10/40 4.8 % -0.18 [ -0.32, -0.03 ]
Guenther 2002 (P) 15/151 26/208 19.7 % -0.03 [ -0.09, 0.04 ]
Kaufmann 2002 (P) 29/490 21/157 25.0 % -0.07 [ -0.13, -0.02 ]
Langley 2011 (P) 16/182 14/91 12.4 % -0.07 [ -0.15, 0.02 ]
Subtotal (95% CI) 983 496 61.9 % -0.07 [ -0.11, -0.02 ]
Total events: 72 (Vitamin D combination), 71 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.92, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.95 (P = 0.0032)
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Guenther 2002 (P) 25/235 26/208 23.2 % -0.02 [ -0.08, 0.04 ]
Papp 2003 (P) 30/304 17/108 15.0 % -0.06 [ -0.14, 0.02 ]
Subtotal (95% CI) 539 316 38.1 % -0.03 [ -0.08, 0.01 ]
Total events: 55 (Vitamin D combination), 43 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 1522 812 100.0 % -0.05 [ -0.08, -0.02 ]
Total events: 127 (Vitamin D combination), 114 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.56, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 0.97, df = 1 (P = 0.32), I2 =0.0%
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Analysis 5.10. Comparison 5 Vitamin D combination products versus placebo, Outcome 10 Adverse events
(systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 5 Vitamin D combination products versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup
Vitamin D
combina-
tion Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combination calcipotriol/betamethasone dipropionate, once daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D combination), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Combination calcipotriol/betamethasone dipropionate, twice daily
Papp 2003 (P) 0/304 0/108 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 304 108 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D combination), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 304 108 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D combination), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours vitamin D combination Favours placebo
506Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.1. Comparison 6 Other treatment versus placebo, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 1 IAGI
Study or subgroup Other treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
2 Anti-IL-8 monoclonal antibody cream
Jin 2001 45 -1.27 (1.01) 44 -0.73 (0.79) -0.59 [ -1.01, -0.16 ]
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 42 -2.36 (0.69) 39 -1.79 (0.8) -0.76 [ -1.21, -0.31 ]
4 Caffeine (topical) 10%, TD
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
6 Dead Sea salts emollient lotion
7 Fish oil plus occlusion
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 15 -3.3 (0.71) 15 -2.8 (0.86) -0.62 [ -1.35, 0.12 ]
10 Indigo naturalis 1.4% ointment
Lin 2008 34 -4.18 (1.22) 34 -1.68 (1.09) -2.14 [ -2.74, -1.53 ]
11 Kukui nut oil, TD
Brown 2005 13 1.7 (0.9) 11 1.7 (0.8) 0.0 [ -0.80, 0.80 ]
12Mahonia aquifolium (Reli va ), twice daily
13 Methotrexate gel
Sutton 2001 39 -2.34 (1.2) 41 -1.78 (0.72) -0.56 [ -1.01, -0.12 ]
14 Mycophenolic acid ointment
15 NG-monomethyl-L-arginine (L-NMMA) cream
16 Nicotinamide 1.4%, twice daily
17 Oleum horwathiensis (Psoricur )
Lassus 1991 19 -2.21 (1.69) 23 -2.17 (1.72) -0.02 [ -0.63, 0.58 ]
18 Omega-3-polyunsaturated fatty acids ointment
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Wolska 1995 40 -3.13 (0.79) 40 -3.08 (0.73) -0.07 [ -0.50, 0.37 ]
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
20 Polymyxin B cream 200,000 U/g
21 PTH (1-34) in Novasome A liposomal cream, twice daily
22 Sirolimus (topical), 2.2% for 6 wks, then 8% for a further 6 wks
23 Tacrolimus ointment
24 Tar
25 Tazarotene
26 Theophylline 1% ointment, twice daily
-10 -5 0 5 10
Favours other treatment Favours placebo
Analysis 6.2. Comparison 6 Other treatment versus placebo, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 2 TSS
Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Anti-IL-8 monoclonal antibody cream
Jin 2001 45 4.78 (3.2) 44 7.09 (3.31) 100.0 % -0.70 [ -1.13, -0.27 ]
Subtotal (95% CI) 45 44 100.0 % -0.70 [ -1.13, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.0013)
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
-10 -5 0 5 10
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Caffeine (topical) 10%, TD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 144 3.15 (1.94) 48 4.08 (1.93) 100.0 % -0.48 [ -0.81, -0.15 ]
Subtotal (95% CI) 144 48 100.0 % -0.48 [ -0.81, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
6 Dead Sea salts emollient lotion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Fish oil plus occlusion
Escobar 1992 25 1.74 (1.94) 25 3.81 (1.94) 100.0 % -1.05 [ -1.64, -0.46 ]
Subtotal (95% CI) 25 25 100.0 % -1.05 [ -1.64, -0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hexafluoro-1,25-dihydroxyvitamin D3, twice daily
Durakovic 2001 15 2.4 (4.9) 15 8.1 (4.9) 100.0 % -1.13 [ -1.91, -0.35 ]
Subtotal (95% CI) 15 15 100.0 % -1.13 [ -1.91, -0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0044)
10 Indigo naturalis 1.4% ointment
Lin 2007 10 3.7 (2) 10 7.2 (1.4) 19.7 % -1.94 [ -3.05, -0.84 ]
Lin 2008 34 6.3 (4.28) 34 12.8 (3.92) 80.3 % -1.57 [ -2.11, -1.02 ]
Subtotal (95% CI) 44 44 100.0 % -1.64 [ -2.13, -1.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 6.56 (P < 0.00001)
11 Kukui nut oil, TD
Brown 2005 13 5.55 (2.26) 11 4.77 (2.26) 100.0 % 0.33 [ -0.48, 1.14 ]
Subtotal (95% CI) 13 11 100.0 % 0.33 [ -0.48, 1.14 ]
Heterogeneity: not applicable
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 0.81 (P = 0.42)
12Mahonia aquifolium (Reli va ), twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
13 Methotrexate gel
Sutton 2001 41 -2.98 (3.93) 41 -1.32 (2.77) 100.0 % -0.48 [ -0.92, -0.04 ]
Subtotal (95% CI) 41 41 100.0 % -0.48 [ -0.92, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
14 Mycophenolic acid ointment
Geilen 2000 7 5.13 (0.73) 7 6.32 (0.81) 100.0 % -1.44 [ -2.67, -0.22 ]
Subtotal (95% CI) 7 7 100.0 % -1.44 [ -2.67, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.021)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 17 9.12 (3.55) 17 8.82 (4.22) 100.0 % 0.08 [ -0.60, 0.75 ]
Subtotal (95% CI) 17 17 100.0 % 0.08 [ -0.60, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 48 3.69 (1.93) 48 4.08 (1.93) 100.0 % -0.20 [ -0.60, 0.20 ]
Subtotal (95% CI) 48 48 100.0 % -0.20 [ -0.60, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
17 Oleum horwathiensis (Psoricur )
Lassus 1991 19 -0.74 (0.23) 23 -0.56 (0.23) 100.0 % -0.77 [ -1.40, -0.14 ]
Subtotal (95% CI) 19 23 100.0 % -0.77 [ -1.40, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
18 Omega-3-polyunsaturated fatty acids ointment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: not applicable
20 Polymyxin B cream 200,000 U/g
Stutz 1996 15 2.5 (1.5) 15 2.3 (1.5) 100.0 % 0.13 [ -0.59, 0.85 ]
Subtotal (95% CI) 15 15 100.0 % 0.13 [ -0.59, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 15 -0.67 (0.23) 15 -0.18 (0.18) 100.0 % -2.31 [ -3.26, -1.36 ]
Subtotal (95% CI) 15 15 100.0 % -2.31 [ -3.26, -1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.76 (P < 0.00001)
22 Sirolimus (topical), 2.2% for 6 wks, then 8% for a further 6 wks
Ormerod 2005 22 9.1 (4.8) 22 11.2 (5.8) 100.0 % -0.39 [ -0.98, 0.21 ]
Subtotal (95% CI) 22 22 100.0 % -0.39 [ -0.98, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
23 Tacrolimus ointment
Zonneveld 1998 (P) 24 4.7 (1.73) 23 4.6 (1.73) 100.0 % 0.06 [ -0.52, 0.63 ]
Subtotal (95% CI) 24 23 100.0 % 0.06 [ -0.52, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
24 Tar
Kanzler 1993 18 -3.25 (2.03) 18 -2.36 (1.86) 100.0 % -0.45 [ -1.11, 0.22 ]
Subtotal (95% CI) 18 18 100.0 % -0.45 [ -1.11, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
25 Tazarotene
Weinstein 1996 211 3.8 (1.73) 107 5.3 (1.73) 100.0 % -0.86 [ -1.11, -0.62 ]
Subtotal (95% CI) 211 107 100.0 % -0.86 [ -1.11, -0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.00 (P < 0.00001)
26 Theophylline 1% ointment, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 63.44, df = 16 (P = 0.00), I2 =75%
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Analysis 6.3. Comparison 6 Other treatment versus placebo, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 3 PASI
Study or subgroup Other treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 30 2.2 (3.76) 30 8.2 (3.76) -1.58 [ -2.16, -0.99 ]
2 Anti-IL-8 monoclonal antibody cream
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 42 2.28 (3.03) 39 3.94 (3.03) -0.54 [ -0.99, -0.10 ]
4 Caffeine (topical) 10%, TD
Vali 2005 39 4.41 (4.83) 39 6.29 (4.71) -0.39 [ -0.84, 0.06 ]
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
6 Dead Sea salts emollient lotion, 30%
Cheesbrough 1992 8 24 (11.1) 11 18.5 (7.5) 0.57 [ -0.36, 1.51 ]
7 Fish oil plus occlusion
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Maier 2004 14 -0.89 (0.15) 10 -0.22 (0.29) -2.96 [ -4.19, -1.74 ]
9 Hexafluoro-1,25-dihydroxyvitamin D3, twice daily
10 Indigo naturalis 1.4% ointment
11 Kukui nut oil, twice daily
Brown 2005 13 3.9 (3) 11 4 (2.7) -0.03 [ -0.84, 0.77 ]
12Mahonia aquifolium (Reli va ), twice daily
Bernstein 2006 100 -3.39 (3.59) 100 -0.09 (4.85) -0.77 [ -1.06, -0.48 ]
13 Methotrexate gel
Syed 2001b 30 2.2 (3.76) 30 8.2 (3.76) -1.58 [ -2.16, -0.99 ]
14 Mycophenolic acid ointment
15 NG-monomethyl-L-arginine (L-NMMA) cream
16 Nicotinamide 1.4%, twice daily
17 Oleum horwathiensis (Psoricur )
18 Omega-3-polyunsaturated fatty acids ointment
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
20 Polymyxin B cream 200,000 U/g
21 PTH (1-34) in Novasome A liposomal cream, twice daily
22 Sirolimus (topical), 2.2% for 6 wks, then 8% for a further 6 wks
23 Tacrolimus ointment
24 Tar
25 Tazarotene
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 11 -0.5 (0.19) 11 -0.09 (0.04) -2.87 [ -4.13, -1.62 ]
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Analysis 6.4. Comparison 6 Other treatment versus placebo, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 4 PAGI
Study or subgroup Other treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
2 Anti-IL-8 monoclonal antibody cream
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 42 -2.55 (0.993) 39 -1.69 (1.127) -0.80 [ -1.26, -0.35 ]
4 Caffeine (topical) 10%, TD
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
6 Dead Sea salts emollient lotion, 30%
7 Fish oil plus occlusion
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
9 Hexafluoro-1,25-dihydroxyvitamin D3, twice daily
10 Indigo naturalis 1.4% ointment
11 Kukui nut oil, TD
Brown 2005 13 1.7 (0.9) 11 1.7 (0.9) 0.0 [ -0.80, 0.80 ]
12Mahonia aquifolium (Reli va ), twice daily
13 Methotrexate gel
14 Mycophenolic acid ointment
15 NG-monomethyl-L-arginine (L-NMMA) cream
16 Nicotinamide 1.4%, twice daily
17 Oleum horwathiensis (Psoricur )
18 Omega-3-polyunsaturated fatty acids ointment
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
20 Polymyxin B cream 200,000 U/g
21 PTH (1-34) in Novasome A liposomal cream, twice daily
22 Sirolimus (topical), 2.2% for 6 wks, then 8% for a further 6 wks
23 Tacrolimus ointment
24 Tar
25 Tazarotene
26 Theophylline 1% ointment, twice daily
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Analysis 6.5. Comparison 6 Other treatment versus placebo, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 30 2.2 (3.76) 30 8.2 (3.76) 100.0 % -1.58 [ -2.16, -0.99 ]
Subtotal (95% CI) 30 30 100.0 % -1.58 [ -2.16, -0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.29 (P < 0.00001)
2 Anti-IL-8 monoclonal antibody cream
Jin 2001 45 -1.27 (1.01) 44 -0.73 (0.79) 100.0 % -0.59 [ -1.01, -0.16 ]
Subtotal (95% CI) 45 44 100.0 % -0.59 [ -1.01, -0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 42 -2.36 (0.69) 39 -1.79 (0.8) 100.0 % -0.76 [ -1.21, -0.31 ]
Subtotal (95% CI) 42 39 100.0 % -0.76 [ -1.21, -0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.29 (P = 0.0010)
4 Caffeine (topical) 10%, TD
Vali 2005 39 4.41 (4.83) 39 6.29 (4.71) 100.0 % -0.39 [ -0.84, 0.06 ]
Subtotal (95% CI) 39 39 100.0 % -0.39 [ -0.84, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.088)
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 144 3.15 (1.94) 48 4.08 (1.93) 100.0 % -0.48 [ -0.81, -0.15 ]
Subtotal (95% CI) 144 48 100.0 % -0.48 [ -0.81, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
6 Dead Sea salts emollient lotion, 30%
Cheesbrough 1992 8 24 (11.1) 11 18.5 (7.5) 100.0 % 0.57 [ -0.36, 1.51 ]
Subtotal (95% CI) 8 11 100.0 % 0.57 [ -0.36, 1.51 ]
Heterogeneity: not applicable
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.20 (P = 0.23)
7 Fish oil plus occlusion
Escobar 1992 25 1.74 (1.94) 25 3.81 (1.94) 100.0 % -1.05 [ -1.64, -0.46 ]
Subtotal (95% CI) 25 25 100.0 % -1.05 [ -1.64, -0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.46 (P = 0.00053)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Maier 2004 14 -0.89 (0.15) 10 -0.22 (0.29) 100.0 % -2.96 [ -4.19, -1.74 ]
Subtotal (95% CI) 14 10 100.0 % -2.96 [ -4.19, -1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.74 (P < 0.00001)
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 15 -3.3 (0.71) 15 -2.8 (0.86) 100.0 % -0.62 [ -1.35, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % -0.62 [ -1.35, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
10 Indigo naturalis 1.4% ointment
Lin 2007 10 3.7 (2) 10 7.2 (1.4) 22.9 % -1.94 [ -3.05, -0.84 ]
Lin 2008 34 -4.18 (1.22) 34 -1.68 (1.09) 77.1 % -2.14 [ -2.74, -1.53 ]
Subtotal (95% CI) 44 44 100.0 % -2.09 [ -2.62, -1.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 7.75 (P < 0.00001)
11 Kukui nut oil, TD
Brown 2005 13 1.7 (0.9) 11 1.7 (0.8) 100.0 % 0.0 [ -0.80, 0.80 ]
Subtotal (95% CI) 13 11 100.0 % 0.0 [ -0.80, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12Mahonia aquifolium (Reli va ), twice daily
Bernstein 2006 100 -3.39 (3.59) 100 -0.09 (4.85) 100.0 % -0.77 [ -1.06, -0.48 ]
Subtotal (95% CI) 100 100 100.0 % -0.77 [ -1.06, -0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.25 (P < 0.00001)
13 Methotrexate gel
Sutton 2001 41 -2.34 (1.2) 41 -1.78 (0.72) 51.8 % -0.56 [ -1.00, -0.12 ]
Syed 2001b 30 2.2 (3.76) 30 8.2 (3.76) 48.2 % -1.58 [ -2.16, -0.99 ]
Subtotal (95% CI) 71 71 100.0 % -1.05 [ -2.04, -0.06 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 7.37, df = 1 (P = 0.01); I2 =86%
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.07 (P = 0.038)
14 Mycophenolic acid ointment
Geilen 2000 7 5.13 (0.73) 7 6.32 (0.81) 100.0 % -1.44 [ -2.67, -0.22 ]
Subtotal (95% CI) 7 7 100.0 % -1.44 [ -2.67, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.021)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 17 9.12 (3.55) 17 8.82 (4.22) 100.0 % 0.08 [ -0.60, 0.75 ]
Subtotal (95% CI) 17 17 100.0 % 0.08 [ -0.60, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 48 3.69 (1.93) 48 4.08 (1.93) 100.0 % -0.20 [ -0.60, 0.20 ]
Subtotal (95% CI) 48 48 100.0 % -0.20 [ -0.60, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
17 Oleum horwathiensis (Psoricur )
Lassus 1991 19 -2.21 (1.69) 23 -2.17 (1.72) 100.0 % -0.02 [ -0.63, 0.58 ]
Subtotal (95% CI) 19 23 100.0 % -0.02 [ -0.63, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
18 Omega-3-polyunsaturated fatty acids ointment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Wolska 1995 40 -3.13 (0.79) 40 -3.08 (0.73) 100.0 % -0.07 [ -0.50, 0.37 ]
Subtotal (95% CI) 40 40 100.0 % -0.07 [ -0.50, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
20 Polymyxin B cream 200,000 U/g
Stutz 1996 15 2.5 (1.5) 15 2.3 (1.5) 100.0 % 0.13 [ -0.59, 0.85 ]
Subtotal (95% CI) 15 15 100.0 % 0.13 [ -0.59, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 15 -0.67 (0.23) 15 -0.18 (0.18) 100.0 % -2.31 [ -3.26, -1.36 ]
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Study or subgroup Other treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 15 15 100.0 % -2.31 [ -3.26, -1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.76 (P < 0.00001)
22 Sirolimus (topical), 2.2% for 6 wks, then 8% for a further 6 wks
Ormerod 2005 22 9.1 (4.8) 22 11.2 (5.8) 100.0 % -0.39 [ -0.98, 0.21 ]
Subtotal (95% CI) 22 22 100.0 % -0.39 [ -0.98, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
23 Tacrolimus ointment
Zonneveld 1998 (P) 24 4.7 (1.73) 23 4.6 (1.73) 100.0 % 0.06 [ -0.52, 0.63 ]
Subtotal (95% CI) 24 23 100.0 % 0.06 [ -0.52, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
24 Tar
Kanzler 1993 18 -3.25 (2.03) 18 -2.36 (1.86) 100.0 % -0.45 [ -1.11, 0.22 ]
Subtotal (95% CI) 18 18 100.0 % -0.45 [ -1.11, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
25 Tazarotene
Weinstein 1996 211 3.8 (1.73) 107 5.3 (1.73) 100.0 % -0.86 [ -1.11, -0.62 ]
Subtotal (95% CI) 211 107 100.0 % -0.86 [ -1.11, -0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.00 (P < 0.00001)
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 11 -0.5 (0.19) 11 -0.09 (0.04) 100.0 % -2.87 [ -4.13, -1.62 ]
Subtotal (95% CI) 11 11 100.0 % -2.87 [ -4.13, -1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 126.78, df = 24 (P = 0.00), I2 =81%
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Analysis 6.6. Comparison 6 Other treatment versus placebo, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 6 Total withdrawals
Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Anti-IL-8 monoclonal antibody cream
Jin 2001 3/48 4/48 100.0 % -0.02 [ -0.12, 0.08 ]
Subtotal (95% CI) 48 48 100.0 % -0.02 [ -0.12, 0.08 ]
Total events: 3 (Other treatment), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 2/44 2/41 100.0 % 0.00 [ -0.09, 0.09 ]
Subtotal (95% CI) 44 41 100.0 % 0.00 [ -0.09, 0.09 ]
Total events: 2 (Other treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
4 Caffeine (topical) 10%, TD
Vali 2005 3/39 3/39 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 39 39 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 3 (Other treatment), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 5/144 0/48 100.0 % 0.03 [ -0.01, 0.08 ]
Subtotal (95% CI) 144 48 100.0 % 0.03 [ -0.01, 0.08 ]
Total events: 5 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
6 Dead Sea salts emollient lotion
Cheesbrough 1992 4/12 1/12 100.0 % 0.25 [ -0.06, 0.56 ]
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 12 12 100.0 % 0.25 [ -0.06, 0.56 ]
Total events: 4 (Other treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
7 Fish oil plus occlusion
Escobar 1992 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
10 Indigo naturalis 1.4% ointment
Lin 2007 4/14 4/14 20.1 % 0.0 [ -0.33, 0.33 ]
Lin 2008 8/42 8/42 79.9 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 56 56 100.0 % 0.0 [ -0.15, 0.15 ]
Total events: 12 (Other treatment), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
11 Kukui nut oil, TD
Brown 2005 2/15 4/15 100.0 % -0.13 [ -0.42, 0.15 ]
Subtotal (95% CI) 15 15 100.0 % -0.13 [ -0.42, 0.15 ]
Total events: 2 (Other treatment), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
12Mahonia aquifolium (Reli va ), twice daily
Bernstein 2006 3/100 26/100 100.0 % -0.23 [ -0.32, -0.14 ]
Subtotal (95% CI) 100 100 100.0 % -0.23 [ -0.32, -0.14 ]
Total events: 3 (Other treatment), 26 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 4.89 (P < 0.00001)
13 Methotrexate gel
Syed 2001b 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
14 Mycophenolic acid ointment
Geilen 2000 0/7 0/7 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 7 7 100.0 % 0.0 [ -0.24, 0.24 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 0/17 0/17 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 1/48 0/48 100.0 % 0.02 [ -0.04, 0.08 ]
Subtotal (95% CI) 48 48 100.0 % 0.02 [ -0.04, 0.08 ]
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
17 Oleum horwathiensis
Lassus 1991 6/25 2/25 100.0 % 0.16 [ -0.04, 0.36 ]
Subtotal (95% CI) 25 25 100.0 % 0.16 [ -0.04, 0.36 ]
Total events: 6 (Other treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
18 Omega-3-polyunsaturated fatty acids ointment
Henneicke-v. Z. 1993 21/73 21/73 100.0 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 73 73 100.0 % 0.0 [ -0.15, 0.15 ]
Total events: 21 (Other treatment), 21 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wolska 1995 12/52 12/52 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 52 52 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 12 (Other treatment), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
20 Polymyxin B cream 200,000 U/g
Stutz 1996 2/15 2/15 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.24, 0.24 ]
Total events: 2 (Other treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
22 Sirolimus (topical)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
23 Tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
24 Tar
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
25 Tazarotene
Weinstein 1996 55/216 27/108 21.5 % 0.00 [ -0.10, 0.10 ]
Weinstein 2003 286/860 125/443 78.5 % 0.05 [ 0.00, 0.10 ]
Subtotal (95% CI) 1076 551 100.0 % 0.04 [ -0.01, 0.09 ]
Total events: 341 (Other treatment), 152 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.71 (P = 0.087)
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 0/11 0/11 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.7. Comparison 6 Other treatment versus placebo, Outcome 7 Withdrawals due to adverse
events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Anti-IL-8 monoclonal antibody cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 1/44 1/41 100.0 % 0.00 [ -0.07, 0.06 ]
Subtotal (95% CI) 44 41 100.0 % 0.00 [ -0.07, 0.06 ]
Total events: 1 (Other treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 Caffeine (topical) 10%, TD
Vali 2005 0/39 0/39 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 39 39 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 0/144 0/48 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 144 48 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Dead Sea salts emollient lotion
Cheesbrough 1992 2/12 1/12 100.0 % 0.08 [ -0.18, 0.35 ]
Subtotal (95% CI) 12 12 100.0 % 0.08 [ -0.18, 0.35 ]
Total events: 2 (Other treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
7 Fish oil plus occlusion
Escobar 1992 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.0 (P = 1.0)
10 Indigo naturalis 1.4% ointment
Lin 2007 0/14 0/14 11.1 % 0.0 [ -0.13, 0.13 ]
Lin 2008 0/42 0/42 88.9 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 56 56 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
11 Kukui nut oil, TD
Brown 2005 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12Mahonia aquifolium (Reli va ), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
13 Methotrexate gel
Syed 2001b 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
14 Mycophenolic acid ointment
Geilen 2000 0/7 0/7 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 7 7 100.0 % 0.0 [ -0.24, 0.24 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 0/17 0/17 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 0/48 0/48 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 48 48 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
17 Oleum horwathiensis
Lassus 1991 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
18 Omega-3-polyunsaturated fatty acids ointment
Henneicke-v. Z. 1993 0/73 0/73 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 73 73 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
20 Polymyxin B cream 200,000 U/g
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
22 Sirolimus (topical)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
23 Tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
24 Tar
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
25 Tazarotene
Weinstein 1996 24/216 3/108 23.2 % 0.08 [ 0.03, 0.14 ]
Weinstein 2003 97/860 20/443 76.8 % 0.07 [ 0.04, 0.10 ]
Subtotal (95% CI) 1076 551 100.0 % 0.07 [ 0.05, 0.10 ]
Total events: 121 (Other treatment), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 0/11 0/11 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.8. Comparison 6 Other treatment versus placebo, Outcome 8 Withdrawals due to treatment
failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Anti-IL-8 monoclonal antibody cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 1/44 0/41 100.0 % 0.02 [ -0.04, 0.08 ]
Subtotal (95% CI) 44 41 100.0 % 0.02 [ -0.04, 0.08 ]
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4 Caffeine (topical) 10%, TD
Vali 2005 0/39 0/39 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 39 39 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 0/144 0/48 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 144 48 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Dead Sea salts emollient lotion
Cheesbrough 1992 1/12 0/12 100.0 % 0.08 [ -0.12, 0.29 ]
Subtotal (95% CI) 12 12 100.0 % 0.08 [ -0.12, 0.29 ]
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
7 Fish oil plus occlusion
Escobar 1992 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
10 Indigo naturalis 1.4% ointment
Lin 2007 0/14 0/14 100.0 % 0.0 [ -0.13, 0.13 ]
Subtotal (95% CI) 14 14 100.0 % 0.0 [ -0.13, 0.13 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
11 Kukui nut oil, TD
Brown 2005 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12Mahonia aquifolium (Reli va ), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
13 Methotrexate gel
Syed 2001b 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
-1 -0.5 0 0.5 1
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
14 Mycophenolic acid ointment
Geilen 2000 0/7 0/7 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 7 7 100.0 % 0.0 [ -0.24, 0.24 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 0/17 0/17 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 0/48 0/48 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 48 48 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
17 Oleum horwathiensis
Lassus 1991 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
18 Omega-3-polyunsaturated fatty acids ointment
Henneicke-v. Z. 1993 0/73 0/73 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 73 73 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
-1 -0.5 0 0.5 1
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
20 Polymyxin B cream 200,000 U/g
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
22 Sirolimus (topical)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
23 Tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
24 Tar
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
25 Tazarotene
Weinstein 1996 9/216 6/108 21.6 % -0.01 [ -0.06, 0.04 ]
Weinstein 2003 40/860 28/443 78.4 % -0.02 [ -0.04, 0.01 ]
Subtotal (95% CI) 1076 551 100.0 % -0.02 [ -0.04, 0.01 ]
Total events: 49 (Other treatment), 34 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 0/11 0/11 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 6.9. Comparison 6 Other treatment versus placebo, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 9 Adverse events (local)
Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Syed 1996 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Anti-IL-8 monoclonal antibody cream
Jin 2001 5/46 4/46 100.0 % 0.02 [ -0.10, 0.14 ]
Subtotal (95% CI) 46 46 100.0 % 0.02 [ -0.10, 0.14 ]
Total events: 5 (Other treatment), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 1/44 1/41 100.0 % 0.00 [ -0.07, 0.06 ]
Subtotal (95% CI) 44 41 100.0 % 0.00 [ -0.07, 0.06 ]
Total events: 1 (Other treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
4 Caffeine (topical) 10%, TD
Vali 2005 2/39 0/39 100.0 % 0.05 [ -0.03, 0.13 ]
Subtotal (95% CI) 39 39 100.0 % 0.05 [ -0.03, 0.13 ]
Total events: 2 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Levine 2010 (P) 51/144 11/48 100.0 % 0.13 [ -0.02, 0.27 ]
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 144 48 100.0 % 0.13 [ -0.02, 0.27 ]
Total events: 51 (Other treatment), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
6 Dead Sea salts emollient lotion
Cheesbrough 1992 2/12 1/12 100.0 % 0.08 [ -0.18, 0.35 ]
Subtotal (95% CI) 12 12 100.0 % 0.08 [ -0.18, 0.35 ]
Total events: 2 (Other treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
7 Fish oil plus occlusion
Escobar 1992 1/25 0/25 100.0 % 0.04 [ -0.06, 0.14 ]
Subtotal (95% CI) 25 25 100.0 % 0.04 [ -0.06, 0.14 ]
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Maier 2004 3/14 3/10 100.0 % -0.09 [ -0.44, 0.27 ]
Subtotal (95% CI) 14 10 100.0 % -0.09 [ -0.44, 0.27 ]
Total events: 3 (Other treatment), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 2/15 0/15 100.0 % 0.13 [ -0.06, 0.33 ]
Subtotal (95% CI) 15 15 100.0 % 0.13 [ -0.06, 0.33 ]
Total events: 2 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
10 Indigo naturalis 1.4% ointment
Lin 2007 0/10 0/10 9.3 % 0.0 [ -0.17, 0.17 ]
Lin 2008 0/34 0/34 90.7 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 44 44 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
11 Kukui nut oil, TD
Brown 2005 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12Mahonia aquifolium (Reli va ), twice daily
Bernstein 2006 1/100 3/100 100.0 % -0.02 [ -0.06, 0.02 ]
Subtotal (95% CI) 100 100 100.0 % -0.02 [ -0.06, 0.02 ]
Total events: 1 (Other treatment), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
13 Methotrexate gel
Syed 2001b 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
14 Mycophenolic acid ointment
Geilen 2000 0/7 0/7 100.0 % 0.0 [ -0.24, 0.24 ]
Subtotal (95% CI) 7 7 100.0 % 0.0 [ -0.24, 0.24 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 0/17 0/17 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
16 Nicotinamide 1.4%, twice daily
Levine 2010 (P) 16/48 11/48 100.0 % 0.10 [ -0.07, 0.28 ]
Subtotal (95% CI) 48 48 100.0 % 0.10 [ -0.07, 0.28 ]
Total events: 16 (Other treatment), 11 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
17 Oleum horwathiensis
Lassus 1991 1/25 0/25 100.0 % 0.04 [ -0.06, 0.14 ]
Subtotal (95% CI) 25 25 100.0 % 0.04 [ -0.06, 0.14 ]
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
18 Omega-3-polyunsaturated fatty acids ointment
Henneicke-v. Z. 1993 1/73 0/73 100.0 % 0.01 [ -0.02, 0.05 ]
Subtotal (95% CI) 73 73 100.0 % 0.01 [ -0.02, 0.05 ]
Total events: 1 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Wolska 1995 23/52 23/52 100.0 % 0.0 [ -0.19, 0.19 ]
Subtotal (95% CI) 52 52 100.0 % 0.0 [ -0.19, 0.19 ]
Total events: 23 (Other treatment), 23 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
20 Polymyxin B cream 200,000 U/g
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
22 Sirolimus (topical)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
23 Tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
24 Tar
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
25 Tazarotene
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
26 Theophylline 1% ointment, twice daily
Papakostantinou 2005 0/11 0/11 100.0 % 0.0 [ -0.16, 0.16 ]
Subtotal (95% CI) 11 11 100.0 % 0.0 [ -0.16, 0.16 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Review: Topical treatments for chronic plaque psoriasis
Comparison: 6 Other treatment versus placebo
Outcome: 10 Adverse events (systemic)
Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aloe vera extract 0.5% hydrophilic cream, three times per day
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Anti-IL-8 monoclonal antibody cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Betamethasone 17-valerate 21-acetate plus tretinoin plus salicylic acid
Santoianni 2001 0/44 0/41 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 44 41 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Caffeine (topical) 10%, TD
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriene 0.005% ointment + nicotinamide 0.05% or 0.1% or 0.7% or 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Dead Sea salts emollient lotion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Fish oil plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
-1 -0.5 0 0.5 1
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Herbal skin care (Dr Michaels cleansing gel, ointment and skin conditioner), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Hexafluoro-1,25-dihydroxyvitamin D3
Durakovic 2001 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
10 Indigo naturalis 1.4% ointment
Lin 2007 0/10 0/10 9.3 % 0.0 [ -0.17, 0.17 ]
Lin 2008 0/34 0/34 90.7 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 44 44 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
11 Kukui nut oil, TD
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
12Mahonia aquifolium (Reli va ), twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
13 Methotrexate gel
Sutton 2001 0/53 0/53 75.1 % 0.0 [ -0.04, 0.04 ]
Syed 2001b 0/30 0/30 24.9 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 83 83 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
14 Mycophenolic acid ointment
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
15 NG-monomethyl-L-arginine (L-NMMA) cream
Ormerod 2000 0/17 0/17 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 17 17 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
16 Nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
17 Oleum horwathiensis
Lassus 1991 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
18 Omega-3-polyunsaturated fatty acids ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
19 Platelet aggregation activating factor (PAF)(Ro 24-0238)
Wolska 1995 0/52 0/52 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 52 52 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
20 Polymyxin B cream 200,000 U/g
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
21 PTH (1-34) in Novasome A liposomal cream, twice daily
Holick 2003 0/15 0/15 100.0 % 0.0 [ -0.12, 0.12 ]
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Study or subgroup Other treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 15 15 100.0 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
22 Sirolimus (topical)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
23 Tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
24 Tar
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
25 Tazarotene
Krueger 1998 0/45 0/45 10.1 % 0.0 [ -0.04, 0.04 ]
Weinstein 1996 0/216 0/108 89.9 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 261 153 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
26 Theophylline 1% ointment, twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Other treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
-1 -0.5 0 0.5 1
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Analysis 7.1. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 1 IAGI
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. betamethasone dipropionate
Fleming 2010 (H) 74 2.3 (0.81) 78 2.03 (1.06) 16.6 % 0.28 [ -0.04, 0.60 ]
Kaufmann 2002 (H) 480 2.24 (0.9) 476 1.9 (0.94) 45.3 % 0.37 [ 0.24, 0.50 ]
Papp 2003 (H) 308 -2.81 (1.21) 312 -3.44 (1.05) 38.1 % 0.56 [ 0.40, 0.72 ]
Subtotal (95% CI) 862 866 100.0 % 0.43 [ 0.28, 0.58 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.03, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 5.57 (P < 0.00001)
2 Calcipotriol vs. betamethasone valerate
Molin 1997 205 -2.41 (0.94) 207 -2.39 (0.92) 100.0 % -0.02 [ -0.21, 0.17 ]
Subtotal (95% CI) 205 207 100.0 % -0.02 [ -0.21, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Medansky 1996 128 -4.1 (1.11) 128 -4.4 (1.11) 100.0 % 0.27 [ 0.02, 0.52 ]
Subtotal (95% CI) 128 128 100.0 % 0.27 [ 0.02, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
5 Calcipotriol vs. fluocinonide
Bruce 1994 52 -4.04 (1.31) 47 -3.3 (1.2) 100.0 % -0.58 [ -0.99, -0.18 ]
Subtotal (95% CI) 52 47 100.0 % -0.58 [ -0.99, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0046)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 128 -3.31 (1.12) 130 -3.55 (1.21) 100.0 % 0.21 [ -0.04, 0.45 ]
Subtotal (95% CI) 128 130 100.0 % 0.21 [ -0.04, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
7 Calcitriol vs. betamethasone valerate
-2 -1 0 1 2
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Langner 2001 (H) 15 -2.4 (1.18) 15 -2.2 (0.86) 100.0 % -0.19 [ -0.91, 0.53 ]
Subtotal (95% CI) 15 15 100.0 % -0.19 [ -0.91, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
8 Tacalcitol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 29.74, df = 5 (P = 0.00), I2 =83%
-2 -1 0 1 2
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Analysis 7.2. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 2 TSS
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. betamethasone dipropionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. betamethasone valerate
Kragballe 1991a 342 2.31 (1.95) 342 2.82 (1.95) 100.0 % -0.26 [ -0.41, -0.11 ]
Subtotal (95% CI) 342 342 100.0 % -0.26 [ -0.41, -0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00067)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
-2 -1 0 1 2
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Medansky 1996 128 2.7 (1.5) 128 2.1 (1.5) 100.0 % 0.40 [ 0.15, 0.65 ]
Subtotal (95% CI) 128 128 100.0 % 0.40 [ 0.15, 0.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.16 (P = 0.0016)
5 Calcipotriol vs. fluocinonide
Bruce 1994 44 1.92 (1.48) 45 2.66 (1.48) 100.0 % -0.50 [ -0.92, -0.07 ]
Subtotal (95% CI) 44 45 100.0 % -0.50 [ -0.92, -0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 128 1.58 (0.82) 130 1.36 (0.82) 100.0 % 0.27 [ 0.02, 0.51 ]
Subtotal (95% CI) 128 130 100.0 % 0.27 [ 0.02, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.032)
7 Calcitriol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 63 3.06 (1.95) 63 2.3 (1.95) 85.5 % 0.39 [ 0.03, 0.74 ]
Seidenari 1997 (H) 11 2.77 (1.48) 11 1.92 (1.43) 14.5 % 0.56 [ -0.29, 1.42 ]
Subtotal (95% CI) 74 74 100.0 % 0.41 [ 0.09, 0.74 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 37.57, df = 4 (P = 0.00), I2 =89%
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Analysis 7.3. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 3 PASI
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. betamethasone dipropionate
Fleming 2010 (H) 74 4.3 (2.8) 78 3.9 (3.8) 16.5 % 0.12 [ -0.20, 0.44 ]
Kaufmann 2002 (H) 480 -0.46 (0.31) 476 -0.57 (0.3) 45.4 % 0.36 [ 0.23, 0.49 ]
Papp 2003 (H) 308 -0.49 (0.32) 312 -0.63 (0.27) 38.2 % 0.47 [ 0.31, 0.63 ]
Subtotal (95% CI) 862 866 100.0 % 0.36 [ 0.22, 0.51 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.97, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 4.81 (P < 0.00001)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 201 -5.5 (5.84) 200 -5.32 (6.02) 26.7 % -0.03 [ -0.23, 0.17 ]
Kragballe 1991a 316 2.5 (2.86) 316 3.06 (3.38) 41.9 % -0.18 [ -0.33, -0.02 ]
Molin 1997 205 3.1 (2.8) 207 3.5 (4.3) 27.4 % -0.11 [ -0.30, 0.08 ]
Vladimirov 1994 32 0.97 (3.61) 28 1.54 (3.61) 4.0 % -0.16 [ -0.66, 0.35 ]
Subtotal (95% CI) 754 751 100.0 % -0.12 [ -0.22, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.38, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
3 Calcipotriol vs. desoxymetasone
Kim 1994 10 3.69 (1.9) 10 3.4 (1.93) 100.0 % 0.15 [ -0.73, 1.02 ]
Subtotal (95% CI) 10 10 100.0 % 0.15 [ -0.73, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 128 5.4 (5.06) 130 3.67 (3.79) 100.0 % 0.39 [ 0.14, 0.63 ]
Subtotal (95% CI) 128 130 100.0 % 0.39 [ 0.14, 0.63 ]
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0021)
7 Calcitriol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Tacalcitol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 34.88, df = 3 (P = 0.00), I2 =91%
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Analysis 7.4. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 4 PAGI
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. betamethasone dipropionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 198 -2.52 (0.9) 198 -2.27 (1) 36.7 % -0.26 [ -0.46, -0.06 ]
Kragballe 1991a 342 -2.94 (0.64) 342 -2.77 (0.7) 63.3 % -0.25 [ -0.40, -0.10 ]
Subtotal (95% CI) 540 540 100.0 % -0.26 [ -0.38, -0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcitriol vs. betamethasone dipropionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcitriol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Tacalcitol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Total (95% CI) 540 540 100.0 % -0.26 [ -0.38, -0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000027)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours vitamin D analogue Favours corticosteroid (potent)
Analysis 7.5. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 5 Combined end
point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. betamethasone dipropionate
Fleming 2010 (H) 74 2.3 (0.81) 78 2.03 (1.06) 16.6 % 0.28 [ -0.04, 0.60 ]
Kaufmann 2002 (H) 480 2.24 (0.9) 476 1.9 (0.94) 45.3 % 0.37 [ 0.24, 0.50 ]
Papp 2003 (H) 308 -2.81 (1.21) 312 -3.44 (1.05) 38.1 % 0.56 [ 0.40, 0.72 ]
Subtotal (95% CI) 862 866 100.0 % 0.43 [ 0.28, 0.58 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.03, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 5.57 (P < 0.00001)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 201 -5.5 (5.84) 200 -5.32 (6.02) 28.2 % -0.03 [ -0.23, 0.17 ]
Kragballe 1991a 342 2.31 (1.95) 342 2.82 (1.95) 36.4 % -0.26 [ -0.41, -0.11 ]
Molin 1997 205 -2.41 (0.94) 207 -2.39 (0.92) 28.6 % -0.02 [ -0.21, 0.17 ]
Vladimirov 1994 32 0.97 (3.61) 28 1.54 (3.61) 6.8 % -0.16 [ -0.66, 0.35 ]
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 780 777 100.0 % -0.12 [ -0.26, 0.02 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.13, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 1.68 (P = 0.093)
3 Calcipotriol vs. desoxymetasone
Kim 1994 10 3.69 (1.9) 10 3.4 (1.93) 100.0 % 0.15 [ -0.73, 1.02 ]
Subtotal (95% CI) 10 10 100.0 % 0.15 [ -0.73, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
4 Calcipotriol vs. diflorasone diacetate
Medansky 1996 128 -4.1 (1.11) 128 -4.4 (1.11) 100.0 % 0.27 [ 0.02, 0.52 ]
Subtotal (95% CI) 128 128 100.0 % 0.27 [ 0.02, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
5 Calcipotriol vs. fluocinonide
Bruce 1994 52 -4.04 (1.31) 47 -3.3 (1.2) 100.0 % -0.58 [ -0.99, -0.18 ]
Subtotal (95% CI) 52 47 100.0 % -0.58 [ -0.99, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0046)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 128 -3.31 (1.12) 130 -3.55 (1.21) 100.0 % 0.21 [ -0.04, 0.45 ]
Subtotal (95% CI) 128 130 100.0 % 0.21 [ -0.04, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
7 Calcitriol vs. betamethasone valerate
Langner 2001 (H) 15 -2.4 (1.18) 15 -2.2 (0.86) 100.0 % -0.19 [ -0.91, 0.53 ]
Subtotal (95% CI) 15 15 100.0 % -0.19 [ -0.91, 0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 63 3.06 (1.95) 63 2.3 (1.95) 85.5 % 0.39 [ 0.03, 0.74 ]
Seidenari 1997 (H) 11 2.77 (1.48) 11 1.92 (1.43) 14.5 % 0.56 [ -0.29, 1.42 ]
Subtotal (95% CI) 74 74 100.0 % 0.41 [ 0.09, 0.74 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
Test for subgroup differences: Chi2 = 44.40, df = 7 (P = 0.00), I2 =84%
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Analysis 7.6. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 6 Total
withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. betamethasone dipropionate
Fleming 2010 (H) 6/79 5/83 3.6 % 0.02 [ -0.06, 0.09 ]
Kaufmann 2002 (H) 39/480 22/476 22.6 % 0.04 [ 0.00, 0.07 ]
Papp 2003 (H) 27/308 17/313 13.2 % 0.03 [ -0.01, 0.07 ]
Subtotal (95% CI) 867 872 39.4 % 0.03 [ 0.01, 0.06 ]
Total events: 72 (Vitamin D analogue), 44 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 21/205 17/204 6.8 % 0.02 [ -0.04, 0.08 ]
Kragballe 1991a 15/345 15/345 23.3 % 0.0 [ -0.03, 0.03 ]
Molin 1997 14/210 7/211 12.5 % 0.03 [ -0.01, 0.07 ]
Subtotal (95% CI) 760 760 42.6 % 0.01 [ -0.01, 0.04 ]
Total events: 50 (Vitamin D analogue), 39 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 1.70, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Medansky 1996 6/134 6/134 8.8 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 134 134 8.8 % 0.0 [ -0.05, 0.05 ]
Total events: 6 (Vitamin D analogue), 6 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol vs. fluocinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 6/128 9/130 6.6 % -0.02 [ -0.08, 0.03 ]
Subtotal (95% CI) 128 130 6.6 % -0.02 [ -0.08, 0.03 ]
Total events: 6 (Vitamin D analogue), 9 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
7 Calcitriol vs. betamethasone valerate
Langner 2001 (H) 1/15 0/15 0.8 % 0.07 [ -0.10, 0.23 ]
Subtotal (95% CI) 15 15 0.8 % 0.07 [ -0.10, 0.23 ]
Total events: 1 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 13/76 13/76 1.5 % 0.0 [ -0.12, 0.12 ]
Seidenari 1997 (H) 3/14 3/14 0.2 % 0.0 [ -0.30, 0.30 ]
Subtotal (95% CI) 90 90 1.7 % 0.0 [ -0.11, 0.11 ]
Total events: 16 (Vitamin D analogue), 16 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1994 2001 100.0 % 0.02 [ 0.00, 0.03 ]
Total events: 151 (Vitamin D analogue), 114 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 6.50, df = 10 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
Test for subgroup differences: Chi2 = 4.58, df = 5 (P = 0.47), I2 =0.0%
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Analysis 7.7. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 7 Withdrawals
due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. betamethasone dipropionate
Kaufmann 2002 (H) 15/480 5/476 15.2 % 0.02 [ 0.00, 0.04 ]
Subtotal (95% CI) 480 476 15.2 % 0.02 [ 0.00, 0.04 ]
Total events: 15 (Vitamin D analogue), 5 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 4/205 2/204 9.2 % 0.01 [ -0.01, 0.03 ]
Kragballe 1991a 2/345 1/345 51.5 % 0.00 [ -0.01, 0.01 ]
Molin 1997 6/210 3/211 6.5 % 0.01 [ -0.01, 0.04 ]
Subtotal (95% CI) 760 760 67.2 % 0.00 [ 0.00, 0.01 ]
Total events: 12 (Vitamin D analogue), 6 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Bruce 1994 0/57 1/57 2.2 % -0.02 [ -0.06, 0.03 ]
Subtotal (95% CI) 57 57 2.2 % -0.02 [ -0.06, 0.03 ]
Total events: 0 (Vitamin D analogue), 1 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 2/128 1/130 7.2 % 0.01 [ -0.02, 0.03 ]
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(. . . Continued)
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 128 130 7.2 % 0.01 [ -0.02, 0.03 ]
Total events: 2 (Vitamin D analogue), 1 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
7 Calcitriol vs. betamethasone valerate
Langner 2001 (H) 1/15 0/15 0.2 % 0.07 [ -0.10, 0.23 ]
Subtotal (95% CI) 15 15 0.2 % 0.07 [ -0.10, 0.23 ]
Total events: 1 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 0/76 0/76 7.7 % 0.0 [ -0.03, 0.03 ]
Seidenari 1997 (H) 0/14 0/14 0.3 % 0.0 [ -0.13, 0.13 ]
Subtotal (95% CI) 90 90 8.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1530 1528 100.0 % 0.01 [ 0.00, 0.01 ]
Total events: 30 (Vitamin D analogue), 13 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 6.49, df = 8 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Test for subgroup differences: Chi2 = 4.28, df = 5 (P = 0.51), I2 =0.0%
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Analysis 7.8. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 8 Withdrawals
due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. betamethasone dipropionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 6/205 6/204 7.3 % 0.00 [ -0.03, 0.03 ]
Kragballe 1991a 1/345 2/345 80.5 % 0.00 [ -0.01, 0.01 ]
Subtotal (95% CI) 550 549 87.8 % 0.00 [ -0.01, 0.01 ]
Total events: 7 (Vitamin D analogue), 8 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Bruce 1994 0/57 0/56 6.7 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 57 56 6.7 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 4/128 3/130 4.9 % 0.01 [ -0.03, 0.05 ]
Subtotal (95% CI) 128 130 4.9 % 0.01 [ -0.03, 0.05 ]
Total events: 4 (Vitamin D analogue), 3 (Corticosteroid (potent))
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
7 Calcitriol vs. betamethasone valerate
Langner 2001 (H) 0/15 0/15 0.5 % 0.0 [ -0.12, 0.12 ]
Subtotal (95% CI) 15 15 0.5 % 0.0 [ -0.12, 0.12 ]
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Tacalcitol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 750 750 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 11 (Vitamin D analogue), 11 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi2 = 0.29, df = 3 (P = 0.96), I2 =0.0%
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Analysis 7.9. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 9 Adverse events
(local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. betamethasone dipropionate
Fleming 2010 (H) 8/79 7/83 9.4 % 0.02 [ -0.07, 0.11 ]
Kaufmann 2002 (H) 54/480 23/476 13.3 % 0.06 [ 0.03, 0.10 ]
Papp 2003 (H) 53/308 27/313 12.1 % 0.09 [ 0.03, 0.14 ]
Subtotal (95% CI) 867 872 34.9 % 0.07 [ 0.04, 0.09 ]
Total events: 115 (Vitamin D analogue), 57 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 64/205 18/204 10.5 % 0.22 [ 0.15, 0.30 ]
Kragballe 1991a 37/345 35/345 12.6 % 0.01 [ -0.04, 0.05 ]
Molin 1997 49/207 21/210 10.8 % 0.14 [ 0.07, 0.21 ]
Subtotal (95% CI) 757 759 33.9 % 0.12 [ -0.02, 0.26 ]
Total events: 150 (Vitamin D analogue), 74 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.01; Chi2 = 28.15, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.72 (P = 0.085)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Bruce 1994 10/57 4/56 7.4 % 0.10 [ -0.02, 0.22 ]
Subtotal (95% CI) 57 56 7.4 % 0.10 [ -0.02, 0.22 ]
Total events: 10 (Vitamin D analogue), 4 (Corticosteroid (potent))
Heterogeneity: not applicable
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.70 (P = 0.088)
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 7/128 7/130 11.9 % 0.00 [ -0.05, 0.06 ]
Subtotal (95% CI) 128 130 11.9 % 0.00 [ -0.05, 0.06 ]
Total events: 7 (Vitamin D analogue), 7 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
7 Calcitriol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 2/76 3/76 11.8 % -0.01 [ -0.07, 0.04 ]
Subtotal (95% CI) 76 76 11.8 % -0.01 [ -0.07, 0.04 ]
Total events: 2 (Vitamin D analogue), 3 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
Total (95% CI) 1885 1893 100.0 % 0.07 [ 0.02, 0.11 ]
Total events: 284 (Vitamin D analogue), 145 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.00; Chi2 = 45.38, df = 8 (P<0.00001); I2 =82%
Test for overall effect: Z = 2.75 (P = 0.0059)
Test for subgroup differences: Chi2 = 10.77, df = 4 (P = 0.03), I2 =63%
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Analysis 7.10. Comparison 7 Vitamin D analogues versus corticosteroid (potent), Outcome 10 Adverse
events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 7 Vitamin D analogues versus corticosteroid (potent)
Outcome: 10 Adverse events (systemic)
Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. betamethasone dipropionate
Papp 2003 (H) 0/308 0/313 34.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 308 313 34.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. betamethasone valerate
Cunliffe 1992 1/205 1/204 7.3 % 0.00 [ -0.01, 0.01 ]
Kragballe 1991a 0/345 0/345 41.9 % 0.0 [ -0.01, 0.01 ]
Molin 1997 0/207 0/210 15.4 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 757 759 64.7 % 0.00 [ 0.00, 0.00 ]
Total events: 1 (Vitamin D analogue), 1 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
3 Calcipotriol vs. desoxymetasone
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. diflorasone diacetate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. fluocinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcitriol vs. betamethasone dipropionate
Camarasa 2003 2/128 3/130 1.2 % -0.01 [ -0.04, 0.03 ]
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Study or subgroup Vitamin D analogue
Corticosteroid
(potent)
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 128 130 1.2 % -0.01 [ -0.04, 0.03 ]
Total events: 2 (Vitamin D analogue), 3 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
7 Calcitriol vs. betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Tacalcitol vs. betamethasone valerate
Scarpa 1996 7/76 7/76 0.2 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 76 76 0.2 % 0.0 [ -0.09, 0.09 ]
Total events: 7 (Vitamin D analogue), 7 (Corticosteroid (potent))
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1269 1278 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 10 (Vitamin D analogue), 11 (Corticosteroid (potent))
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 5 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 0.19, df = 3 (P = 0.98), I2 =0.0%
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Analysis 8.1. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 1 IAGI
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 21 3.16 (1.18) 21 2.93 (1.18) 0.19 [ -0.42, 0.80 ]
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Analysis 8.3. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 3 PASI
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. Clobetasol propionate
Landi 1993 20 1.33 (1.4) 20 2.02 (2.6) -0.32 [ -0.95, 0.30 ]
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Analysis 8.4. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 4 PAGI
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 21 3.29 (1.3) 21 2.74 (1.3) 0.42 [ -0.20, 1.03 ]
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Analysis 8.5. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 5
Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 21 3.16 (1.18) 21 2.93 (1.18) 51.1 % 0.19 [ -0.42, 0.80 ]
Landi 1993 20 1.33 (1.4) 20 2.02 (2.6) 48.9 % -0.32 [ -0.95, 0.30 ]
Total (95% CI) 41 41 100.0 % -0.06 [ -0.57, 0.44 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours vitamin D analogue Favours corticosteroid (v potent)
560Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.6. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 6 Total
withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 0/21 0/21 0.0 [ -0.09, 0.09 ]
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Analysis 8.7. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 7
Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 0/21 0/21 0.0 [ -0.09, 0.09 ]
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Analysis 8.8. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 8
Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. Clobetasol propionate
Koo 2006 0/21 0/21 0.0 [ -0.09, 0.09 ]
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Analysis 8.9. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 9 Adverse
events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. Clobetasol propionate
Landi 1993 0/20 1/20 -0.05 [ -0.18, 0.08 ]
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Analysis 8.10. Comparison 8 Vitamin D analogues versus corticosteroid (very potent), Outcome 10
Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 8 Vitamin D analogues versus corticosteroid (very potent)
Outcome: 10 Adverse events (systemic)
Study or subgroup Vitamin D analogue
Corticosteroid
(v potent)
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. Clobetasol propionate
Landi 1993 0/20 1/20 -0.05 [ -0.18, 0.08 ]
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Analysis 9.1. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 1
IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 1 IAGI
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 369 -3.72 (0.96) 363 -3.25 (1.1) 38.7 % -0.46 [ -0.60, -0.31 ]
Fleming 2010 (H) 150 1.85 (1.05) 78 2.03 (1.06) 17.0 % -0.17 [ -0.44, 0.10 ]
Kaufmann 2002 (H) 490 1.5 (0.9) 476 1.9 (0.94) 44.3 % -0.43 [ -0.56, -0.31 ]
Subtotal (95% CI) 1009 917 100.0 % -0.40 [ -0.52, -0.27 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.44, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 6.12 (P < 0.00001)
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 44 2.11 (1.18) 21 2.93 (1.18) 100.0 % -0.69 [ -1.22, -0.15 ]
Subtotal (95% CI) 44 21 100.0 % -0.69 [ -1.22, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 1.07, df = 1 (P = 0.30), I2 =6%
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Analysis 9.2. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 2 TSS
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 62 1.65 (0.91) 60 1.25 (0.86) 0.45 [ 0.09, 0.81 ]
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
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Analysis 9.3. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 3
PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 3 PASI
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 342 2.5 (2.5) 343 3.9 (3.7) 37.9 % -0.44 [ -0.59, -0.29 ]
Fleming 2010 (H) 147 3.1 (2.8) 78 3.9 (3.8) 14.1 % -0.25 [ -0.53, 0.02 ]
Kaufmann 2002 (H) 490 -0.71 (0.26) 476 -0.57 (0.3) 48.0 % -0.50 [ -0.63, -0.37 ]
Subtotal (95% CI) 979 897 100.0 % -0.44 [ -0.55, -0.33 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.58, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 7.95 (P < 0.00001)
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 979 897 100.0 % -0.44 [ -0.55, -0.33 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.58, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 7.95 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 4
PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 4 PAGI
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 44 2.37 (1.3) 21 2.74 (1.3) -0.28 [ -0.80, 0.24 ]
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Analysis 9.5. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 5
Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 369 -3.72 (0.96) 363 -3.25 (1.1) 38.7 % -0.46 [ -0.60, -0.31 ]
Fleming 2010 (H) 150 1.85 (1.05) 78 2.03 (1.06) 17.0 % -0.17 [ -0.44, 0.10 ]
Kaufmann 2002 (H) 490 1.5 (0.9) 476 1.9 (0.94) 44.3 % -0.43 [ -0.56, -0.31 ]
Subtotal (95% CI) 1009 917 100.0 % -0.40 [ -0.52, -0.27 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.44, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 6.12 (P < 0.00001)
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 62 1.65 (0.91) 60 1.25 (0.86) 100.0 % 0.45 [ 0.09, 0.81 ]
Subtotal (95% CI) 62 60 100.0 % 0.45 [ 0.09, 0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 44 2.11 (1.18) 21 2.93 (1.18) 100.0 % -0.69 [ -1.22, -0.15 ]
Subtotal (95% CI) 44 21 100.0 % -0.69 [ -1.22, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 20.80, df = 2 (P = 0.00), I2 =90%
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Analysis 9.6. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 6
Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 28/372 21/365 19.3 % 0.02 [ -0.02, 0.05 ]
Fleming 2010 (H) 13/162 5/83 5.7 % 0.02 [ -0.05, 0.09 ]
Kaufmann 2002 (H) 13/490 22/476 44.7 % -0.02 [ -0.04, 0.00 ]
Subtotal (95% CI) 1024 924 69.7 % 0.00 [ -0.03, 0.03 ]
Total events: 54 (Vitamin D combined with corticosteroid), 48 (Corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.86, df = 2 (P = 0.15); I2 =48%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 0/62 0/60 25.1 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 62 60 25.1 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D combined with corticosteroid), 0 (Corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 0/44 0/21 5.2 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 44 21 5.2 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Vitamin D combined with corticosteroid), 0 (Corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 1130 1005 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 54 (Vitamin D combined with corticosteroid), 48 (Corticosteroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.87, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 0.00, df = 2 (P = 1.00), I2 =0.0%
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Analysis 9.7. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 7
Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Kaufmann 2002 (H) 3/490 5/476 0.00 [ -0.02, 0.01 ]
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 0/62 0/60 0.0 [ -0.03, 0.03 ]
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 0/44 0/21 0.0 [ -0.07, 0.07 ]
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Analysis 9.8. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 8
Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 0/62 0/60 0.0 [ -0.03, 0.03 ]
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Koo 2006 0/44 0/21 0.0 [ -0.07, 0.07 ]
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Analysis 9.9. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 9
Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 30/372 17/365 36.2 % 0.03 [ 0.00, 0.07 ]
Fleming 2010 (H) 12/160 7/83 8.5 % -0.01 [ -0.08, 0.06 ]
Kaufmann 2002 (H) 29/490 23/476 55.3 % 0.01 [ -0.02, 0.04 ]
Subtotal (95% CI) 1022 924 100.0 % 0.02 [ 0.00, 0.04 ]
Total events: 71 (Vitamin D combined with corticosteroid), 47 (Corticosteroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
Menter 2009 4/62 6/60 100.0 % -0.04 [ -0.13, 0.06 ]
Subtotal (95% CI) 62 60 100.0 % -0.04 [ -0.13, 0.06 ]
Total events: 4 (Vitamin D combined with corticosteroid), 6 (Corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D combined with corticosteroid), 0 (Corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 1.09, df = 1 (P = 0.30), I2 =8%
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Analysis 9.10. Comparison 9 Vitamin D combined with corticosteroid versus corticosteroid, Outcome 10
Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 9 Vitamin D combined with corticosteroid versus corticosteroid
Outcome: 10 Adverse events (systemic)
Study or subgroup
Vitamin D
combined with
corticosteroid Corticosteroid
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol + betamethasone dipropionate vs. betamethasone dipropionate
Douglas 2002 0/372 0/365 0.0 [ -0.01, 0.01 ]
2 Calcipotriol + betamethasone dipropionate vs. clobetasol propionate
3 Calcipotriol + clobetasol propionate vs. clobetasol propionate
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Analysis 10.1. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 1 IAGI
Study or subgroup Vitamin D analogue Dithranol
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 231 -2.81 (0.6) 227 -2.29 (0.97) 27.1 % -0.64 [ -0.83, -0.46 ]
Christensen 1999 89 -3.4 (1.52) 77 -2.6 (1.52) 24.8 % -0.52 [ -0.83, -0.21 ]
Van de Kerkhof 2006 46 -2.96 (1.53) 40 -3.6 (1.19) 22.0 % 0.46 [ 0.03, 0.89 ]
Wall 1998 153 -2.48 (0.88) 131 -1.69 (0.96) 26.1 % -0.86 [ -1.10, -0.61 ]
Subtotal (95% CI) 519 475 100.0 % -0.43 [ -0.85, -0.01 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 28.06, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.00 (P = 0.045)
2 Calcitriol vs. dithranol
Hutchinson 2000 60 -2.19 (0.52) 54 -2.44 (0.45) 100.0 % 0.51 [ 0.13, 0.88 ]
Subtotal (95% CI) 60 54 100.0 % 0.51 [ 0.13, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0076)
3 Tacalcitol vs. dithranol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 10.68, df = 1 (P = 0.00), I2 =91%
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Analysis 10.2. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 2 TSS
Study or subgroup Vitamin D analogue Dithranol
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. dithranol
Christensen 1999 89 2.38 (1.65) 77 3.72 (1.65) 58.0 % -0.81 [ -1.13, -0.49 ]
Grattan 1997 (H) 22 1.8 (2) 22 2.2 (2.6) 42.0 % -0.17 [ -0.76, 0.42 ]
Subtotal (95% CI) 111 99 100.0 % -0.54 [ -1.16, 0.08 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 3.48, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Calcitriol vs. dithranol
Hutchinson 2000 60 1.65 (0.76) 54 1.54 (0.95) 100.0 % 0.13 [ -0.24, 0.50 ]
Subtotal (95% CI) 60 54 100.0 % 0.13 [ -0.24, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
3 Tacalcitol vs. dithranol
Farkas 1999 42 -6.1 (2.4) 42 -5.7 (2.1) 100.0 % -0.18 [ -0.60, 0.25 ]
Subtotal (95% CI) 42 42 100.0 % -0.18 [ -0.60, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 3.53, df = 2 (P = 0.17), I2 =43%
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Analysis 10.3. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 3 PASI
Study or subgroup Vitamin D analogue Dithranol
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 214 3.4 (2.7) 208 4.7 (4.4) -0.36 [ -0.55, -0.16 ]
Monastirli 2000 35 2.58 (1.18) 35 0.34 (0.51) 2.44 [ 1.81, 3.06 ]
Van de Kerkhof 2006 54 -0.56 (0.37) 52 -0.63 (0.3) 0.21 [ -0.18, 0.59 ]
2 Calcitriol vs. dithranol
Hutchinson 2000 60 4.2 (3.9) 54 5.2 (5.5) -0.21 [ -0.58, 0.16 ]
3 Tacalcitol vs. dithranol
Farkas 1999 42 4.16 (3.22) 42 4.38 (3.05) -0.07 [ -0.50, 0.36 ]
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Analysis 10.4. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 4 PAGI
Study or subgroup Vitamin D analogue Dithranol
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 231 -2.72 (0.74) 227 -2.31 (1) 52.6 % -0.47 [ -0.65, -0.28 ]
Van de Kerkhof 2006 46 -2.89 (1.68) 40 -3.53 (1.43) 47.4 % 0.40 [ -0.02, 0.83 ]
Subtotal (95% CI) 277 267 100.0 % -0.05 [ -0.90, 0.80 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 13.35, df = 1 (P = 0.00026); I2 =93%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Calcitriol vs. dithranol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Tacalcitol vs. dithranol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 5 Combined
end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D analogue Dithranol
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 231 -2.81 (0.6) 227 -2.29 (0.97) -0.64 [ -0.83, -0.46 ]
Christensen 1999 89 -3.4 (1.52) 77 -2.6 (1.52) -0.52 [ -0.83, -0.21 ]
Grattan 1997 (H) 22 1.8 (2) 22 2.2 (2.6) -0.17 [ -0.76, 0.42 ]
Monastirli 2000 35 2.58 (1.18) 35 0.34 (0.51) 2.44 [ 1.81, 3.06 ]
Van de Kerkhof 2006 46 -2.96 (1.53) 40 -3.6 (1.19) 0.46 [ 0.03, 0.89 ]
Wall 1998 153 -2.48 (0.88) 131 -1.69 (0.96) -0.86 [ -1.10, -0.61 ]
2 Calcitriol vs. dithranol
Hutchinson 2000 60 -2.19 (0.52) 54 -2.44 (0.45) 0.51 [ 0.13, 0.88 ]
3 Tacalcitol vs. dithranol
Farkas 1999 42 -6.1 (2.4) 42 -5.7 (2.1) -0.18 [ -0.60, 0.25 ]
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Analysis 10.6. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 6 Total
withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D analogue Dithranol
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. dithranol
Christensen 1999 0/89 5/82 37.4 % -0.06 [ -0.12, -0.01 ]
Grattan 1997 (H) 3/25 3/25 3.6 % 0.0 [ -0.18, 0.18 ]
Monastirli 2000 0/35 0/35 39.7 % 0.0 [ -0.05, 0.05 ]
Van de Kerkhof 2006 17/54 11/52 4.2 % 0.10 [ -0.06, 0.27 ]
Van der Vleuten 1995 0/10 0/10 3.8 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 213 204 88.7 % -0.01 [ -0.07, 0.04 ]
Total events: 20 (Vitamin D analogue), 19 (Dithranol)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.25, df = 4 (P = 0.18); I2 =36%
Test for overall effect: Z = 0.48 (P = 0.63)
2 Calcitriol vs. dithranol
Hutchinson 2000 12/60 16/54 4.6 % -0.10 [ -0.25, 0.06 ]
Subtotal (95% CI) 60 54 4.6 % -0.10 [ -0.25, 0.06 ]
Total events: 12 (Vitamin D analogue), 16 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
3 Tacalcitol vs. dithranol
Farkas 1999 4/42 5/42 6.6 % -0.02 [ -0.16, 0.11 ]
Subtotal (95% CI) 42 42 6.6 % -0.02 [ -0.16, 0.11 ]
Total events: 4 (Vitamin D analogue), 5 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 315 300 100.0 % -0.02 [ -0.06, 0.01 ]
Total events: 36 (Vitamin D analogue), 40 (Dithranol)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.70, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 0.95, df = 2 (P = 0.62), I2 =0.0%
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Analysis 10.7. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 7Withdrawals
due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D analogue Dithranol
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 4/239 12/239 33.0 % -0.03 [ -0.07, 0.00 ]
Lister 1997 2/89 6/82 14.7 % -0.05 [ -0.11, 0.01 ]
Monastirli 2000 0/35 0/35 18.7 % 0.0 [ -0.05, 0.05 ]
Van de Kerkhof 2006 7/54 3/52 6.1 % 0.07 [ -0.04, 0.18 ]
Van der Vleuten 1995 0/10 0/10 2.6 % 0.0 [ -0.17, 0.17 ]
Wall 1998 9/161 20/145 13.9 % -0.08 [ -0.15, -0.02 ]
Subtotal (95% CI) 588 563 88.9 % -0.03 [ -0.06, 0.00 ]
Total events: 22 (Vitamin D analogue), 41 (Dithranol)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.71, df = 5 (P = 0.17); I2 =35%
Test for overall effect: Z = 1.69 (P = 0.092)
2 Calcitriol vs. dithranol
Hutchinson 2000 1/60 4/54 11.1 % -0.06 [ -0.13, 0.02 ]
Subtotal (95% CI) 60 54 11.1 % -0.06 [ -0.13, 0.02 ]
Total events: 1 (Vitamin D analogue), 4 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
3 Tacalcitol vs. dithranol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 648 617 100.0 % -0.03 [ -0.06, 0.00 ]
Total events: 23 (Vitamin D analogue), 45 (Dithranol)
Heterogeneity: Tau2 = 0.00; Chi2 = 8.14, df = 6 (P = 0.23); I2 =26%
Test for overall effect: Z = 2.19 (P = 0.029)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
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Analysis 10.8. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 8Withdrawals
due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D analogue Dithranol
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 3/239 3/239 77.5 % 0.0 [ -0.02, 0.02 ]
Monastirli 2000 0/35 0/35 10.6 % 0.0 [ -0.05, 0.05 ]
Van de Kerkhof 2006 7/54 4/52 2.3 % 0.05 [ -0.06, 0.17 ]
Van der Vleuten 1995 0/10 0/10 1.0 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 338 336 91.4 % 0.00 [ -0.02, 0.02 ]
Total events: 10 (Vitamin D analogue), 7 (Dithranol)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Calcitriol vs. dithranol
Hutchinson 2000 1/60 2/54 8.6 % -0.02 [ -0.08, 0.04 ]
Subtotal (95% CI) 60 54 8.6 % -0.02 [ -0.08, 0.04 ]
Total events: 1 (Vitamin D analogue), 2 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 Tacalcitol vs. dithranol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 398 390 100.0 % 0.00 [ -0.02, 0.02 ]
Total events: 11 (Vitamin D analogue), 9 (Dithranol)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.52, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 10.9. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 9 Adverse
events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D analogue Dithranol
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 84/239 127/239 12.7 % -0.18 [ -0.27, -0.09 ]
Christensen 1999 11/89 23/82 11.9 % -0.16 [ -0.28, -0.04 ]
Grattan 1997 (H) 1/22 11/22 8.9 % -0.45 [ -0.68, -0.23 ]
Lister 1997 11/89 23/82 11.9 % -0.16 [ -0.28, -0.04 ]
Monastirli 2000 5/35 16/35 9.6 % -0.31 [ -0.52, -0.11 ]
Van de Kerkhof 2006 21/53 37/52 10.2 % -0.32 [ -0.50, -0.14 ]
Wall 1998 28/161 71/145 12.4 % -0.32 [ -0.42, -0.22 ]
Subtotal (95% CI) 688 657 77.7 % -0.25 [ -0.32, -0.17 ]
Total events: 161 (Vitamin D analogue), 308 (Dithranol)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.28, df = 6 (P = 0.06); I2 =51%
Test for overall effect: Z = 6.65 (P < 0.00001)
2 Calcitriol vs. dithranol
Hutchinson 2000 3/60 39/54 11.6 % -0.67 [ -0.80, -0.54 ]
Subtotal (95% CI) 60 54 11.6 % -0.67 [ -0.80, -0.54 ]
Total events: 3 (Vitamin D analogue), 39 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 10.01 (P < 0.00001)
3 Tacalcitol vs. dithranol
Farkas 1999 2/42 17/42 10.7 % -0.36 [ -0.52, -0.20 ]
Subtotal (95% CI) 42 42 10.7 % -0.36 [ -0.52, -0.20 ]
Total events: 2 (Vitamin D analogue), 17 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
Total (95% CI) 790 753 100.0 % -0.32 [ -0.43, -0.20 ]
Total events: 166 (Vitamin D analogue), 364 (Dithranol)
Heterogeneity: Tau2 = 0.02; Chi2 = 51.76, df = 8 (P<0.00001); I2 =85%
Test for overall effect: Z = 5.48 (P < 0.00001)
Test for subgroup differences: Chi2 = 31.08, df = 2 (P = 0.00), I2 =94%
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Analysis 10.10. Comparison 10 Vitamin D alone or in combination versus dithranol, Outcome 10 Adverse
events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 10 Vitamin D alone or in combination versus dithranol
Outcome: 10 Adverse events (systemic)
Study or subgroup Vitamin D analogue Dithranol
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. dithranol
Berth Jones 1992b 0/239 1/239 81.5 % 0.00 [ -0.02, 0.01 ]
Van der Vleuten 1995 0/35 0/35 3.7 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 274 274 85.2 % 0.00 [ -0.02, 0.01 ]
Total events: 0 (Vitamin D analogue), 1 (Dithranol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.49)
2 Calcitriol vs. dithranol
Hutchinson 2000 0/60 0/54 9.5 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 60 54 9.5 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Tacalcitol vs. dithranol
Farkas 1999 0/42 0/42 5.3 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 42 42 5.3 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Vitamin D analogue), 0 (Dithranol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 376 370 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 1 (Dithranol)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.96), I2 =0.0%
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Analysis 11.1. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 1 IAGI
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. calcitriol
Ji 2008 122 -2.15 (0.76) 124 -2.15 (0.73) 100.0 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 122 124 100.0 % 0.0 [ -0.25, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. tacalcitol
Veien 1997 113 -3.8 (0.9) 113 -3.3 (1.2) 100.0 % -0.47 [ -0.73, -0.21 ]
Subtotal (95% CI) 113 113 100.0 % -0.47 [ -0.73, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 26 -3.19 (1.27) 26 -3.73 (1.22) 100.0 % 0.43 [ -0.12, 0.98 ]
Subtotal (95% CI) 26 26 100.0 % 0.43 [ -0.12, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 11.22, df = 2 (P = 0.00), I2 =82%
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Analysis 11.2. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 2 TSS
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. calcitriol
Ji 2008 125 1.87 (2.07) 125 2.54 (2.08) 41.1 % -0.32 [ -0.57, -0.07 ]
Subtotal (95% CI) 125 125 41.1 % -0.32 [ -0.57, -0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.011)
2 Calcipotriol vs. tacalcitol
Veien 1997 145 -5.05 (2.26) 142 -4.03 (2.26) 43.3 % -0.45 [ -0.68, -0.22 ]
Subtotal (95% CI) 145 142 43.3 % -0.45 [ -0.68, -0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 26 2.8 (2.3) 26 2.4 (3.5) 15.6 % 0.13 [ -0.41, 0.68 ]
Subtotal (95% CI) 26 26 15.6 % 0.13 [ -0.41, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 296 293 100.0 % -0.31 [ -0.55, -0.06 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.77, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 2.47 (P = 0.014)
Test for subgroup differences: Chi2 = 3.77, df = 2 (P = 0.15), I2 =47%
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Analysis 11.3. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 3 PASI
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. calcitriol
Bourke 1997 7 4.7 (2.4) 8 8.8 (4.2) -1.11 [ -2.22, 0.01 ]
2 Calcipotriol vs. tacalcitol
3 Calcipotriol vs. maxacalcitol
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Analysis 11.4. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 4 PAGI
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. calcitriol
Ji 2008 125 -2.1 (0.76) 125 -2.13 (0.72) 0.04 [ -0.21, 0.29 ]
2 Calcipotriol vs. tacalcitol
3 Calcipotriol vs. maxacalcitol
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Analysis 11.5. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. calcitriol
Bourke 1997 7 4.7 (2.4) 8 8.8 (4.2) 11.0 % -1.11 [ -2.22, 0.01 ]
Ji 2008 122 -2.15 (0.76) 124 -2.15 (0.73) 33.0 % 0.0 [ -0.25, 0.25 ]
Subtotal (95% CI) 129 132 44.0 % -0.41 [ -1.46, 0.64 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 3.61, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Calcipotriol vs. tacalcitol
Veien 1997 113 -3.8 (0.9) 113 -3.3 (1.2) 32.6 % -0.47 [ -0.73, -0.21 ]
Subtotal (95% CI) 113 113 32.6 % -0.47 [ -0.73, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.48 (P = 0.00050)
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 26 -3.19 (1.27) 26 -3.73 (1.22) 23.4 % 0.43 [ -0.12, 0.98 ]
Subtotal (95% CI) 26 26 23.4 % 0.43 [ -0.12, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
Total (95% CI) 268 271 100.0 % -0.17 [ -0.62, 0.27 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 13.94, df = 3 (P = 0.003); I2 =78%
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Chi2 = 8.33, df = 2 (P = 0.02), I2 =76%
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Analysis 11.6. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcitriol
Bourke 1997 4/12 4/12 2.6 % 0.0 [ -0.38, 0.38 ]
Ji 2008 11/125 8/125 85.0 % 0.02 [ -0.04, 0.09 ]
Subtotal (95% CI) 137 137 87.6 % 0.02 [ -0.04, 0.09 ]
Total events: 15 (Vitamin D alone or in combination), 12 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Calcipotriol vs. tacalcitol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 4/30 4/30 12.4 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 30 30 12.4 % 0.0 [ -0.17, 0.17 ]
Total events: 4 (Vitamin D alone or in combination), 4 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 167 167 100.0 % 0.02 [ -0.04, 0.08 ]
Total events: 19 (Vitamin D alone or in combination), 16 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 11.7. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcitriol
Bourke 1997 0/12 0/12 5.5 % 0.0 [ -0.15, 0.15 ]
Ji 2008 6/125 2/125 63.8 % 0.03 [ -0.01, 0.08 ]
Subtotal (95% CI) 137 137 69.4 % 0.03 [ -0.01, 0.07 ]
Total events: 6 (Vitamin D alone or in combination), 2 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Calcipotriol vs. tacalcitol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 0/30 0/30 30.6 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 30.6 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 167 167 100.0 % 0.02 [ -0.01, 0.06 ]
Total events: 6 (Vitamin D alone or in combination), 2 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 11.8. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcitriol
Bourke 1997 1/12 2/12 0.3 % -0.08 [ -0.35, 0.18 ]
Ji 2008 0/125 0/125 93.9 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 137 137 94.2 % -0.01 [ -0.08, 0.07 ]
Total events: 1 (Vitamin D alone or in combination), 2 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Calcipotriol vs. tacalcitol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 0/30 0/30 5.8 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 5.8 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 167 167 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 1 (Vitamin D alone or in combination), 2 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 11.9. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcitriol
Ji 2008 14/125 5/125 52.8 % 0.07 [ 0.01, 0.14 ]
Subtotal (95% CI) 125 125 52.8 % 0.07 [ 0.01, 0.14 ]
Total events: 14 (Vitamin D alone or in combination), 5 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
2 Calcipotriol vs. tacalcitol
Veien 1997 17/145 18/142 47.2 % -0.01 [ -0.09, 0.07 ]
Subtotal (95% CI) 145 142 47.2 % -0.01 [ -0.09, 0.07 ]
Total events: 17 (Vitamin D alone or in combination), 18 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.81)
3 Calcipotriol vs. maxacalcitol
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 270 267 100.0 % 0.03 [ -0.05, 0.12 ]
Total events: 31 (Vitamin D alone or in combination), 23 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 2.56, df = 1 (P = 0.11), I2 =61%
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Analysis 11.10. Comparison 11 Vitamin D alone or in combination versus other vitamin D analogue,
Outcome 10 Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 11 Vitamin D alone or in combination versus other vitamin D analogue
Outcome: 10 Adverse events (systemic)
Study or subgroup
Vitamin D alone
or in
combination
Other
vitamin D
analogue
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcitriol
Ji 2008 0/125 0/125 42.1 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 125 125 42.1 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. tacalcitol
Veien 1997 0/142 0/145 55.3 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 142 145 55.3 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Calcipotriol vs. maxacalcitol
Barker 1999 (H) 0/30 0/30 2.6 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 2.6 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 297 300 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other vitamin D analogue)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 1.00), I2 =0.0%
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Analysis 12.1. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 1 IAGI
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol twice daily vs. calcipotriol OM, BMD ON
Ortonne 1994 80 -3.6 (1) 74 -4.1 (0.76) 100.0 % 0.56 [ 0.23, 0.88 ]
Subtotal (95% CI) 80 74 100.0 % 0.56 [ 0.23, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
2 Calcipotriol OD vs. combined calcipotriol + BMD OD
Fleming 2010 (H) 74 2.3 (0.81) 150 1.85 (1.05) 43.9 % 0.46 [ 0.18, 0.74 ]
Kaufmann 2002 (H) 480 2.24 (0.9) 490 1.5 (0.9) 56.1 % 0.82 [ 0.69, 0.95 ]
Subtotal (95% CI) 554 640 100.0 % 0.66 [ 0.31, 1.02 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.24, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 3.68 (P = 0.00023)
3 Calcipotriol twice daily vs. combined calcipotriol + BMD OD
Guenther 2002 (H) 227 -3.3 (1.12) 150 -3.59 (1) 100.0 % 0.27 [ 0.06, 0.48 ]
Subtotal (95% CI) 227 150 100.0 % 0.27 [ 0.06, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.55 (P = 0.011)
4 Calcipotriol twice daily vs. combined calcipotriol + BMD twice daily
Douglas 2002 365 -3.1 (1.09) 369 -3.7 (0.96) 34.3 % 0.58 [ 0.44, 0.73 ]
Guenther 2002 (H) 227 -3.3 (1.12) 234 -3.79 (0.97) 32.4 % 0.47 [ 0.28, 0.65 ]
Papp 2003 (H) 308 -2.8 (1.21) 301 -3.8 (0.91) 33.3 % 0.93 [ 0.76, 1.10 ]
Subtotal (95% CI) 900 904 100.0 % 0.66 [ 0.40, 0.93 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 15.28, df = 2 (P = 0.00048); I2 =87%
Test for overall effect: Z = 4.89 (P < 0.00001)
5 Calcipotriol twice daily vs. calcipotriol OM, BMV ON
Kragballe 1998b 172 -2.98 (1.23) 174 -3.04 (1.15) 53.0 % 0.05 [ -0.16, 0.26 ]
Ruzicka 1998 86 -3.3 (1.4) 78 -4 (1.23) 47.0 % 0.53 [ 0.22, 0.84 ]
Subtotal (95% CI) 258 252 100.0 % 0.27 [ -0.19, 0.74 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 6.16, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.15 (P = 0.25)
6 Calcipotriol twice daily vs. calcipotriol OM, clobetasone butyrate ON
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kragballe 1998b 172 -2.98 (1.23) 172 -3.29 (1.09) 100.0 % 0.27 [ 0.05, 0.48 ]
Subtotal (95% CI) 172 172 100.0 % 0.27 [ 0.05, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
7 Calcipotriol twice daily vs. calcipotriol twice daily + clobetasol propionate twice daily
Koo 2006 21 3.16 (1.18) 44 2.11 (1.18) 100.0 % 0.88 [ 0.34, 1.42 ]
Subtotal (95% CI) 21 44 100.0 % 0.88 [ 0.34, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
8 Calcipotriol twice daily vs. calcipotriol OM, diflucortolone valerate ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Calcipotriol OD vs. calcipotriol OM, fluocinonide acetonide ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol OD vs. combined calcipotriol + hydrocortisone OD
Ortonne 2010 202 2.01 (0.95) 206 1.88 (0.94) 100.0 % 0.14 [ -0.06, 0.33 ]
Subtotal (95% CI) 202 206 100.0 % 0.14 [ -0.06, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
11 Calcitriol twice daily vs. diflucortolone valerate OM, calcitriol ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Tacalcitol OD vs. combined calcipotriol + BMD OD
Langley 2011 (H) 163 2.28 (0.89) 171 1.84 (0.93) 100.0 % 0.48 [ 0.26, 0.70 ]
Subtotal (95% CI) 163 171 100.0 % 0.48 [ 0.26, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.34 (P = 0.000014)
Test for subgroup differences: Chi2 = 20.45, df = 8 (P = 0.01), I2 =61%
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Analysis 12.2. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 2 TSS
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol twice daily vs. calcipotriol OM, BMD ON
2 Calcipotriol OD vs. combined calcipotriol + BMD OD
3 Calcipotriol twice daily vs. combined calcipotriol + BMD OD
Huang 2009 149 -0.071 (0.08) 152 -0.09 (0.07) 0.25 [ 0.03, 0.48 ]
4 Calcipotriol twice daily vs. combined calcipotriol + BMD twice daily
5 Calcipotriol twice daily vs. calcipotriol OM, BMV ON
6 Calcipotriol twice daily vs. calcipotriol OM, clobetasone butyrate ON
7 Calcipotriol twice daily vs. calcipotriol twice daily + clobetasol propionate twice daily
8 Calcipotriol twice daily vs. calcipotriol OM, diflucortolone valerate ON
9 Calcipotriol OD vs. calcipotriol OM, fluocinonide acetonide ON
10 Calcipotriol OD vs. combined calcipotriol + hydrocortisone OD
11 Calcitriol twice daily vs. diflucortolone valerate OM, calcitriol ON
12 Tacalcitol OD vs. combined calcipotriol + BMD OD
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Analysis 12.3. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 3 PASI
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol twice daily vs. calcipotriol OM, BMD ON
Ortonne 1994 65 -0.74 (0.22) 59 -0.83 (0.16) 100.0 % 0.46 [ 0.10, 0.82 ]
Subtotal (95% CI) 65 59 100.0 % 0.46 [ 0.10, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.53 (P = 0.011)
2 Calcipotriol OD vs. combined calcipotriol + BMD OD
Fleming 2010 (H) 74 4.3 (2.8) 147 3.1 (2.8) 45.9 % 0.43 [ 0.14, 0.71 ]
Kaufmann 2002 (H) 480 -0.46 (0.31) 490 -0.71 (0.26) 54.1 % 0.87 [ 0.74, 1.01 ]
Subtotal (95% CI) 554 637 100.0 % 0.67 [ 0.23, 1.11 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 7.91, df = 1 (P = 0.005); I2 =87%
Test for overall effect: Z = 3.00 (P = 0.0027)
3 Calcipotriol twice daily vs. combined calcipotriol + BMD OD
Guenther 2002 (H) 227 4.2 (3.3) 150 3 (2.5) 29.4 % 0.40 [ 0.19, 0.61 ]
Huang 2009 149 -0.7 (0.21) 152 -0.79 (0.18) 26.0 % 0.46 [ 0.23, 0.69 ]
Jorizzo 2007 186 -0.43 (0.3) 193 -0.64 (0.3) 29.5 % 0.70 [ 0.49, 0.91 ]
Saraceno 2007 73 4.07 (3.33) 74 2.5 (2.5) 15.2 % 0.53 [ 0.20, 0.86 ]
Subtotal (95% CI) 635 569 100.0 % 0.52 [ 0.38, 0.67 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.43, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 7.16 (P < 0.00001)
4 Calcipotriol twice daily vs. combined calcipotriol + BMD twice daily
Douglas 2002 332 4.4 (3.9) 342 2.5 (2.5) 34.8 % 0.58 [ 0.43, 0.74 ]
Guenther 2002 (H) 227 4.2 (3.3) 234 2.7 (2.5) 31.5 % 0.51 [ 0.33, 0.70 ]
Papp 2003 (H) 308 -0.49 (0.32) 301 -0.73 (0.25) 33.6 % 0.83 [ 0.67, 1.00 ]
Subtotal (95% CI) 867 877 100.0 % 0.64 [ 0.46, 0.83 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 7.59, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 6.68 (P < 0.00001)
5 Calcipotriol twice daily vs. calcipotriol OM, BMV ON
Kragballe 1998b 172 4.04 (3.39) 174 3.42 (3.05) 52.6 % 0.19 [ -0.02, 0.40 ]
Ruzicka 1998 87 1.9 (1.59) 82 1 (0.82) 47.4 % 0.70 [ 0.39, 1.01 ]
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 259 256 100.0 % 0.43 [ -0.07, 0.93 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 7.08, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.70 (P = 0.089)
6 Calcipotriol twice daily vs. calcipotriol OM, clobetasone butyrate ON
Kragballe 1998b 172 4.04 (3.39) 172 3.5 (2.86) 100.0 % 0.17 [ -0.04, 0.38 ]
Subtotal (95% CI) 172 172 100.0 % 0.17 [ -0.04, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
7 Calcipotriol twice daily vs. calcipotriol twice daily + clobetasol propionate twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Calcipotriol twice daily vs. calcipotriol OM, diflucortolone valerate ON
Salmhofer 2000 58 1.9 (1.4) 58 1.8 (1.2) 100.0 % 0.08 [ -0.29, 0.44 ]
Subtotal (95% CI) 58 58 100.0 % 0.08 [ -0.29, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
9 Calcipotriol OD vs. calcipotriol OM, fluocinonide acetonide ON
Wozel 2001 19 8.94 (5.08) 19 6.3 (4.57) 100.0 % 0.53 [ -0.11, 1.18 ]
Subtotal (95% CI) 19 19 100.0 % 0.53 [ -0.11, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
10 Calcipotriol OD vs. combined calcipotriol + hydrocortisone OD
Ortonne 2010 202 4.38 (3.93) 206 4.05 (3.87) 100.0 % 0.08 [ -0.11, 0.28 ]
Subtotal (95% CI) 202 206 100.0 % 0.08 [ -0.11, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
11 Calcitriol twice daily vs. diflucortolone valerate OM, calcitriol ON
Lee 2007 73 -0.26 (0.33) 69 -0.34 (0.33) 100.0 % 0.24 [ -0.09, 0.57 ]
Subtotal (95% CI) 73 69 100.0 % 0.24 [ -0.09, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
12 Tacalcitol OD vs. combined calcipotriol + BMD OD
Langley 2011 (H) 163 5.35 (4.44) 171 3.58 (2.98) 100.0 % 0.47 [ 0.25, 0.69 ]
Subtotal (95% CI) 163 171 100.0 % 0.47 [ 0.25, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.23 (P = 0.000024)
Test for subgroup differences: Chi2 = 29.92, df = 10 (P = 0.00), I2 =67%
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Analysis 12.4. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 4 PAGI
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol twice daily vs. calcipotriol OM, BMD ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol OD vs. combined calcipotriol + BMD OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol twice daily vs. combined calcipotriol + BMD OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol twice daily vs. combined calcipotriol + BMD twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol twice daily vs. calcipotriol OM, BMV ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcipotriol twice daily vs. calcipotriol OM, clobetasone butyrate ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol twice daily vs. calcipotriol twice daily + clobetasol propionate twice daily
Koo 2006 21 3.29 (1.3) 44 2.37 (1.3) 14.2 % 0.70 [ 0.16, 1.23 ]
Subtotal (95% CI) 21 44 14.2 % 0.70 [ 0.16, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.010)
8 Calcipotriol twice daily vs. calcipotriol OM, diflucortolone valerate ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: not applicable
9 Calcipotriol OD vs. calcipotriol OM, fluocinonide acetonide ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol OD vs. combined calcipotriol + hydrocortisone OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Calcitriol twice daily vs. diflucortolone valerate OM, calcitriol ON
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Tacalcitol OD vs. combined calcipotriol + BMD OD
Langley 2011 (H) 163 2.25 (0.93) 171 1.82 (0.94) 85.8 % 0.46 [ 0.24, 0.68 ]
Subtotal (95% CI) 163 171 85.8 % 0.46 [ 0.24, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.14 (P = 0.000035)
Total (95% CI) 184 215 100.0 % 0.49 [ 0.29, 0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.67, df = 1 (P = 0.41), I2 =0.0%
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Analysis 12.5. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol twice daily vs. calcipotriol OM, BMD ON
Ortonne 1994 80 -3.6 (1) 74 -4.1 (0.76) 100.0 % 0.56 [ 0.23, 0.88 ]
Subtotal (95% CI) 80 74 100.0 % 0.56 [ 0.23, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
2 Calcipotriol OD vs. combined calcipotriol + BMD OD
Fleming 2010 (H) 74 2.3 (0.81) 150 1.85 (1.05) 43.9 % 0.46 [ 0.18, 0.74 ]
Kaufmann 2002 (H) 480 2.24 (0.9) 490 1.5 (0.9) 56.1 % 0.82 [ 0.69, 0.95 ]
Subtotal (95% CI) 554 640 100.0 % 0.66 [ 0.31, 1.02 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.24, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 3.68 (P = 0.00023)
3 Calcipotriol twice daily vs. combined calcipotriol + BMD OD
Guenther 2002 (H) 227 -3.3 (1.12) 150 -3.59 (1) 27.0 % 0.27 [ 0.06, 0.48 ]
Huang 2009 149 -0.071 (0.08) 152 -0.09 (0.07) 25.8 % 0.25 [ 0.03, 0.48 ]
Jorizzo 2007 186 -0.43 (0.3) 193 -0.64 (0.3) 26.9 % 0.70 [ 0.49, 0.91 ]
Saraceno 2007 73 4.07 (3.33) 74 2.5 (2.5) 20.3 % 0.53 [ 0.20, 0.86 ]
Subtotal (95% CI) 635 569 100.0 % 0.43 [ 0.20, 0.66 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 11.46, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 3.68 (P = 0.00023)
4 Calcipotriol twice daily vs. combined calcipotriol + BMD twice daily
Douglas 2002 365 -3.1 (1.09) 369 -3.7 (0.96) 34.3 % 0.58 [ 0.44, 0.73 ]
Guenther 2002 (H) 227 -3.3 (1.12) 234 -3.79 (0.97) 32.4 % 0.47 [ 0.28, 0.65 ]
Papp 2003 (H) 308 -2.8 (1.21) 301 -3.8 (0.91) 33.3 % 0.93 [ 0.76, 1.10 ]
Subtotal (95% CI) 900 904 100.0 % 0.66 [ 0.40, 0.93 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 15.28, df = 2 (P = 0.00048); I2 =87%
Test for overall effect: Z = 4.89 (P < 0.00001)
5 Calcipotriol twice daily vs. calcipotriol OM, BMV ON
Kragballe 1998b 172 -2.98 (1.23) 174 -3.04 (1.15) 53.0 % 0.05 [ -0.16, 0.26 ]
Ruzicka 1998 86 -3.3 (1.4) 78 -4 (1.23) 47.0 % 0.53 [ 0.22, 0.84 ]
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 258 252 100.0 % 0.27 [ -0.19, 0.74 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 6.16, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.15 (P = 0.25)
6 Calcipotriol twice daily vs. calcipotriol OM, clobetasone butyrate ON
Kragballe 1998b 172 -2.98 (1.23) 172 -3.29 (1.09) 100.0 % 0.27 [ 0.05, 0.48 ]
Subtotal (95% CI) 172 172 100.0 % 0.27 [ 0.05, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
7 Calcipotriol twice daily vs. calcipotriol twice daily + clobetasol propionate twice daily
Koo 2006 21 3.16 (1.18) 44 2.11 (1.18) 100.0 % 0.88 [ 0.34, 1.42 ]
Subtotal (95% CI) 21 44 100.0 % 0.88 [ 0.34, 1.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.18 (P = 0.0015)
8 Calcipotriol twice daily vs. calcipotriol OM, diflucortolone valerate ON
Salmhofer 2000 58 1.9 (1.4) 58 1.8 (1.2) 100.0 % 0.08 [ -0.29, 0.44 ]
Subtotal (95% CI) 58 58 100.0 % 0.08 [ -0.29, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
9 Calcipotriol OD vs. calcipotriol OM, fluocinonide acetonide ON
Wozel 2001 19 8.94 (5.08) 19 6.3 (4.57) 100.0 % 0.53 [ -0.11, 1.18 ]
Subtotal (95% CI) 19 19 100.0 % 0.53 [ -0.11, 1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
10 Calcipotriol OD vs. combined calcipotriol + hydrocortisone OD
Ortonne 2010 202 2.01 (0.95) 206 1.88 (0.94) 100.0 % 0.14 [ -0.06, 0.33 ]
Subtotal (95% CI) 202 206 100.0 % 0.14 [ -0.06, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
11 Calcitriol twice daily vs. diflucortolone valerate OM, calcitriol ON
Lee 2007 73 -0.26 (0.33) 69 -0.34 (0.33) 100.0 % 0.24 [ -0.09, 0.57 ]
Subtotal (95% CI) 73 69 100.0 % 0.24 [ -0.09, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
12 Tacalcitol OD vs. combined calcipotriol + BMD OD
Langley 2011 (H) 163 2.28 (0.89) 171 1.84 (0.93) 100.0 % 0.48 [ 0.26, 0.70 ]
Subtotal (95% CI) 163 171 100.0 % 0.48 [ 0.26, 0.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.34 (P = 0.000014)
Test for subgroup differences: Chi2 = 23.13, df = 11 (P = 0.02), I2 =52%
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Analysis 12.6. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Talcipotriol vs. calcipotriol and corticosteroid
Douglas 2002 37/369 28/372 11.3 % 0.03 [ -0.02, 0.07 ]
Fleming 2010 (H) 6/79 13/162 3.7 % 0.00 [ -0.08, 0.07 ]
Guenther 2002 (H) 23/231 30/389 8.6 % 0.02 [ -0.02, 0.07 ]
Huang 2009 7/160 6/160 10.0 % 0.01 [ -0.04, 0.05 ]
Kaufmann 2002 (H) 39/480 13/490 22.2 % 0.05 [ 0.03, 0.08 ]
Koo 2006 0/21 0/44 4.0 % 0.0 [ -0.07, 0.07 ]
Kragballe 1998b 19/174 23/351 6.8 % 0.04 [ -0.01, 0.10 ]
Ortonne 2010 34/202 27/206 4.0 % 0.04 [ -0.03, 0.11 ]
Papp 2003 (H) 27/308 16/304 11.5 % 0.04 [ -0.01, 0.08 ]
Ruzicka 1998 5/87 6/82 3.5 % -0.02 [ -0.09, 0.06 ]
Salmhofer 2000 5/63 5/63 2.2 % 0.0 [ -0.09, 0.09 ]
Saraceno 2007 14/75 3/75 2.0 % 0.15 [ 0.05, 0.25 ]
Wozel 2001 0/19 0/19 2.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 2268 2717 91.8 % 0.03 [ 0.01, 0.05 ]
Total events: 216 (Vitamin D alone or in combination), 170 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.84, df = 12 (P = 0.31); I2 =13%
Test for overall effect: Z = 3.64 (P = 0.00028)
2 Calcitriol vs. calcitriol and corticosteroid
Lee 2007 6/73 5/69 2.5 % 0.01 [ -0.08, 0.10 ]
Subtotal (95% CI) 73 69 2.5 % 0.01 [ -0.08, 0.10 ]
Total events: 6 (Vitamin D alone or in combination), 5 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.83)
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Tacalcitol vs. calcipotriol and corticosteroid
Langley 2011 (H) 21/184 12/183 5.6 % 0.05 [ -0.01, 0.11 ]
Subtotal (95% CI) 184 183 5.6 % 0.05 [ -0.01, 0.11 ]
Total events: 21 (Vitamin D alone or in combination), 12 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 2525 2969 100.0 % 0.03 [ 0.02, 0.05 ]
Total events: 243 (Vitamin D alone or in combination), 187 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.41, df = 14 (P = 0.42); I2 =3%
Test for overall effect: Z = 4.36 (P = 0.000013)
Test for subgroup differences: Chi2 = 0.60, df = 2 (P = 0.74), I2 =0.0%
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Analysis 12.7. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcipotriol and corticosteroid
Guenther 2002 (H) 6/227 1/386 14.2 % 0.02 [ 0.00, 0.05 ]
Huang 2009 1/160 1/160 18.3 % 0.0 [ -0.02, 0.02 ]
Kaufmann 2002 (H) 15/480 3/490 18.6 % 0.03 [ 0.01, 0.04 ]
Koo 2006 0/21 0/44 2.0 % 0.0 [ -0.07, 0.07 ]
Kragballe 1998b 8/174 6/351 7.3 % 0.03 [ -0.01, 0.06 ]
Ortonne 1994 6/97 3/91 2.6 % 0.03 [ -0.03, 0.09 ]
Ortonne 2010 19/202 6/206 4.3 % 0.06 [ 0.02, 0.11 ]
Ruzicka 1998 1/87 1/82 7.7 % 0.00 [ -0.03, 0.03 ]
Salmhofer 2000 1/63 0/63 4.9 % 0.02 [ -0.03, 0.06 ]
Saraceno 2007 2/75 0/75 4.7 % 0.03 [ -0.02, 0.07 ]
Wozel 2001 0/19 0/19 1.1 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 1605 1967 85.8 % 0.02 [ 0.01, 0.03 ]
Total events: 59 (Vitamin D alone or in combination), 21 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.91, df = 10 (P = 0.14); I2 =33%
Test for overall effect: Z = 3.01 (P = 0.0026)
2 Calcitriol vs. calcitriol and corticosteroid
Lee 2007 2/73 0/69 4.4 % 0.03 [ -0.02, 0.07 ]
Subtotal (95% CI) 73 69 4.4 % 0.03 [ -0.02, 0.07 ]
Total events: 2 (Vitamin D alone or in combination), 0 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
3 Tacalcitol vs. calcipotriol and corticosteroid
Langley 2011 (H) 4/184 3/183 9.8 % 0.01 [ -0.02, 0.03 ]
Subtotal (95% CI) 184 183 9.8 % 0.01 [ -0.02, 0.03 ]
Total events: 4 (Vitamin D alone or in combination), 3 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 1862 2219 100.0 % 0.02 [ 0.01, 0.03 ]
Total events: 65 (Vitamin D alone or in combination), 24 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 15.27, df = 12 (P = 0.23); I2 =21%
Test for overall effect: Z = 3.36 (P = 0.00077)
Test for subgroup differences: Chi2 = 0.94, df = 2 (P = 0.62), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
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Analysis 12.8. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcipotriol and corticosteroid
Guenther 2002 (H) 2/227 1/386 53.0 % 0.01 [ -0.01, 0.02 ]
Koo 2006 0/21 0/44 1.9 % 0.0 [ -0.07, 0.07 ]
Kragballe 1998b 3/174 2/351 21.1 % 0.01 [ -0.01, 0.03 ]
Ortonne 2010 8/202 4/206 8.5 % 0.02 [ -0.01, 0.05 ]
Salmhofer 2000 0/63 0/63 9.9 % 0.0 [ -0.03, 0.03 ]
Saraceno 2007 2/75 1/75 4.6 % 0.01 [ -0.03, 0.06 ]
Wozel 2001 0/19 0/19 1.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 781 1144 100.0 % 0.01 [ 0.00, 0.02 ]
Total events: 15 (Vitamin D alone or in combination), 8 (vitamin D and corticosteroid)
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(. . . Continued)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Calcitriol vs. calcitriol and corticosteroid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Tacalcitol vs. calcipotriol and corticosteroid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 781 1144 100.0 % 0.01 [ 0.00, 0.02 ]
Total events: 15 (Vitamin D alone or in combination), 8 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.099)
Test for subgroup differences: Not applicable
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Analysis 12.9. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcipotriol and corticosteroid
Douglas 2002 44/369 30/372 15.4 % 0.04 [ 0.00, 0.08 ]
Fleming 2010 (H) 8/79 12/160 5.0 % 0.03 [ -0.05, 0.10 ]
Guenther 2002 (H) 45/227 40/386 8.3 % 0.09 [ 0.03, 0.15 ]
Huang 2009 25/160 17/160 5.6 % 0.05 [ -0.02, 0.12 ]
Kaufmann 2002 (H) 54/480 29/490 22.1 % 0.05 [ 0.02, 0.09 ]
Kragballe 1998b 54/173 71/347 4.7 % 0.11 [ 0.03, 0.19 ]
Ortonne 1994 24/94 11/88 2.5 % 0.13 [ 0.02, 0.24 ]
Ortonne 2010 63/200 40/204 4.3 % 0.12 [ 0.03, 0.20 ]
Papp 2003 (H) 53/308 30/304 10.2 % 0.07 [ 0.02, 0.13 ]
Ruzicka 1998 13/87 6/82 3.5 % 0.08 [ -0.02, 0.17 ]
Salmhofer 2000 6/63 8/63 2.6 % -0.03 [ -0.14, 0.08 ]
Saraceno 2007 8/75 7/75 3.4 % 0.01 [ -0.08, 0.11 ]
Wozel 2001 1/19 1/19 1.6 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 2334 2750 89.1 % 0.06 [ 0.04, 0.08 ]
Total events: 398 (Vitamin D alone or in combination), 302 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.26, df = 12 (P = 0.35); I2 =9%
Test for overall effect: Z = 5.92 (P < 0.00001)
2 Calcitriol vs. calcitriol and corticosteroid
Lee 2007 8/67 1/64 4.4 % 0.10 [ 0.02, 0.19 ]
Subtotal (95% CI) 67 64 4.4 % 0.10 [ 0.02, 0.19 ]
Total events: 8 (Vitamin D alone or in combination), 1 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
3 Tacalcitol vs. calcipotriol and corticosteroid
Langley 2011 (H) 32/184 16/182 6.5 % 0.09 [ 0.02, 0.15 ]
Subtotal (95% CI) 184 182 6.5 % 0.09 [ 0.02, 0.15 ]
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Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 32 (Vitamin D alone or in combination), 16 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 2585 2996 100.0 % 0.06 [ 0.05, 0.08 ]
Total events: 438 (Vitamin D alone or in combination), 319 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.60, df = 14 (P = 0.41); I2 =4%
Test for overall effect: Z = 6.94 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.46, df = 2 (P = 0.48), I2 =0.0%
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Analysis 12.10. Comparison 12 Vitamin D alone or in combination versus vitamin D + corticosteroid,
Outcome 10 Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 12 Vitamin D alone or in combination versus vitamin D + corticosteroid
Outcome: 10 Adverse events (systemic)
Study or subgroup
Vitamin D alone
or in
combination
vitamin D and
corticosteroid
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. calcipotriol and corticosteroid
Douglas 2002 0/369 0/372 56.2 % 0.0 [ -0.01, 0.01 ]
Huang 2009 3/160 3/160 1.8 % 0.0 [ -0.03, 0.03 ]
Papp 2003 (H) 0/308 0/304 38.4 % 0.0 [ -0.01, 0.01 ]
Ruzicka 1998 11/87 7/82 0.2 % 0.04 [ -0.05, 0.13 ]
Salmhofer 2000 0/63 0/63 1.7 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 987 981 98.2 % 0.00 [ 0.00, 0.00 ]
Total events: 14 (Vitamin D alone or in combination), 10 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.63, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Calcitriol vs. calcitriol and corticosteroid
Lee 2007 0/67 0/64 1.8 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 67 64 1.8 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D alone or in combination), 0 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Tacalcitol vs. calcipotriol and corticosteroid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (vitamin D and corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1054 1045 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 14 (Vitamin D alone or in combination), 10 (vitamin D and corticosteroid)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.32, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 1.00), I2 =0.0%
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Analysis 13.1. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 1 IAGI
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 283 1.62 (0.86) 294 1.73 (0.92) 100.0 % -0.12 [ -0.29, 0.04 ]
Subtotal (95% CI) 283 294 100.0 % -0.12 [ -0.29, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 283 1.62 (0.86) 302 1.51 (0.89) 100.0 % 0.13 [ -0.04, 0.29 ]
Subtotal (95% CI) 283 302 100.0 % 0.13 [ -0.04, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 46 -3.17 (0.82) 46 -3.67 (0.84) 100.0 % 0.60 [ 0.18, 1.02 ]
Subtotal (95% CI) 46 46 100.0 % 0.60 [ 0.18, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily
(2wks)
Yang 2009 36 -1.86 (0.93) 40 -2.23 (0.86) 100.0 % 0.41 [ -0.05, 0.86 ]
Subtotal (95% CI) 36 40 100.0 % 0.41 [ -0.05, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Lahfa 2003 64 -4.69 (1.3) 61 -4.44 (1.28) 100.0 % -0.19 [ -0.54, 0.16 ]
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Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 64 61 100.0 % -0.19 [ -0.54, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 376 2.49 (0.99) 383 2.23 (0.96) 100.0 % 0.27 [ 0.12, 0.41 ]
Subtotal (95% CI) 376 383 100.0 % 0.27 [ 0.12, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy)+ combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 376 2.49 (0.99) 377 1.98 (0.99) 100.0 % 0.51 [ 0.37, 0.66 ]
Subtotal (95% CI) 376 377 100.0 % 0.51 [ 0.37, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.95 (P < 0.00001)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy)+
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 383 2.23 (0.96) 377 1.98 (0.99) 100.0 % 0.26 [ 0.11, 0.40 ]
Subtotal (95% CI) 383 377 100.0 % 0.26 [ 0.11, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.52 (P = 0.00044)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 294 1.73 (0.92) 302 1.51 (0.89) 100.0 % 0.24 [ 0.08, 0.40 ]
Subtotal (95% CI) 294 302 100.0 % 0.24 [ 0.08, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 247 -2.45 (1.31) 246 -3.16 (1.33) 100.0 % 0.54 [ 0.36, 0.72 ]
Subtotal (95% CI) 247 246 100.0 % 0.54 [ 0.36, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 54.06, df = 9 (P = 0.00), I2 =83%
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Analysis 13.2. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 2 TSS
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol (6 wks) vs. clobetasol propionate (2wks); then calcipotriol (4 wks)
Austad 1998 46 2.5 (1.3) 46 1.7 (1.2) 100.0 % 0.63 [ 0.21, 1.05 ]
Subtotal (95% CI) 46 46 100.0 % 0.63 [ 0.21, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.96 (P = 0.0030)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
Subtotal (95% CI) 0 0 Not estimable
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Favours vitamin D regimen Favours complex regimen
(Continued . . . )
612Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 3 PASI
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 327 -0.659 (0.331) 322 -0.65 (0.317) 100.0 % -0.04 [ -0.19, 0.11 ]
Subtotal (95% CI) 327 322 100.0 % -0.04 [ -0.19, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Saraceno 2007 71 3.04 (3.76) 72 2.11 (2.56) 100.0 % 0.29 [ -0.04, 0.62 ]
Subtotal (95% CI) 71 72 100.0 % 0.29 [ -0.04, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 327 -0.659 (0.331) 323 -0.69 (0.285) 100.0 % 0.10 [ -0.05, 0.25 ]
Subtotal (95% CI) 327 323 100.0 % 0.10 [ -0.05, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 19 6.5 (3.86) 19 4.27 (2.64) 100.0 % 0.66 [ 0.01, 1.32 ]
Subtotal (95% CI) 19 19 100.0 % 0.66 [ 0.01, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Yang 2009 36 4.5 (2.5) 40 2.3 (1.2) 100.0 % 1.13 [ 0.64, 1.62 ]
Subtotal (95% CI) 36 40 100.0 % 1.13 [ 0.64, 1.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
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Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lahfa 2003 64 -0.82 (0.3) 61 -0.74 (0.3) 100.0 % -0.27 [ -0.62, 0.09 ]
Subtotal (95% CI) 64 61 100.0 % -0.27 [ -0.62, 0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 376 -0.33 (0.48) 383 -0.45 (0.49) 100.0 % 0.25 [ 0.10, 0.39 ]
Subtotal (95% CI) 376 383 100.0 % 0.25 [ 0.10, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.39 (P = 0.00070)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 376 -0.33 (0.48) 377 -0.58 (0.35) 100.0 % 0.59 [ 0.45, 0.74 ]
Subtotal (95% CI) 376 377 100.0 % 0.59 [ 0.45, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.98 (P < 0.00001)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 383 -0.45 (0.49) 377 -0.58 (0.35) 100.0 % 0.30 [ 0.16, 0.45 ]
Subtotal (95% CI) 383 377 100.0 % 0.30 [ 0.16, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.17 (P = 0.000030)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 322 -0.646 (0.317) 323 -0.69 (0.285) 100.0 % 0.15 [ -0.01, 0.30 ]
Subtotal (95% CI) 322 323 100.0 % 0.15 [ -0.01, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 252 -0.38 (0.46) 249 -0.59 (0.39) 100.0 % 0.49 [ 0.31, 0.67 ]
Subtotal (95% CI) 252 249 100.0 % 0.49 [ 0.31, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 70.21, df = 10 (P = 0.00), I2 =86%
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Analysis 13.4. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 4 PAGI
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 283 -3.52 (0.97) 294 -3.37 (1.18) 100.0 % -0.14 [ -0.30, 0.02 ]
Subtotal (95% CI) 283 294 100.0 % -0.14 [ -0.30, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 283 -3.52 (0.97) 302 -3.62 (0.98) 100.0 % 0.10 [ -0.06, 0.26 ]
Subtotal (95% CI) 283 302 100.0 % 0.10 [ -0.06, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.22)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
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Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
White 2006 (P) 376 -2.25 (1.79) 383 -2.73 (1.67) 100.0 % 0.28 [ 0.13, 0.42 ]
Subtotal (95% CI) 376 383 100.0 % 0.28 [ 0.13, 0.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.80 (P = 0.00015)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 376 -2.25 (1.79) 377 -3.44 (1.57) 100.0 % 0.71 [ 0.56, 0.85 ]
Subtotal (95% CI) 376 377 100.0 % 0.71 [ 0.56, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.40 (P < 0.00001)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 383 -2.73 (1.67) 377 -3.44 (1.57) 100.0 % 0.44 [ 0.29, 0.58 ]
Subtotal (95% CI) 383 377 100.0 % 0.44 [ 0.29, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.96 (P < 0.00001)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 294 -3.37 (1.18) 302 -3.62 (0.98) 100.0 % 0.23 [ 0.07, 0.39 ]
Subtotal (95% CI) 294 302 100.0 % 0.23 [ 0.07, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0050)
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 247 -2.4 (1.38) 246 -3.15 (1.39) 100.0 % 0.54 [ 0.36, 0.72 ]
Subtotal (95% CI) 247 246 100.0 % 0.54 [ 0.36, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.90 (P < 0.00001)
Test for subgroup differences: Chi2 = 73.44, df = 6 (P = 0.00), I2 =92%
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Analysis 13.5. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 283 1.62 (0.86) 294 1.73 (0.92) 100.0 % -0.12 [ -0.29, 0.04 ]
Subtotal (95% CI) 283 294 100.0 % -0.12 [ -0.29, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Saraceno 2007 71 3.04 (3.76) 72 2.11 (2.56) 100.0 % 0.29 [ -0.04, 0.62 ]
Subtotal (95% CI) 71 72 100.0 % 0.29 [ -0.04, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.71 (P = 0.087)
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 283 1.62 (0.86) 302 1.51 (0.89) 100.0 % 0.13 [ -0.04, 0.29 ]
Subtotal (95% CI) 283 302 100.0 % 0.13 [ -0.04, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 46 -3.17 (0.82) 46 -3.67 (0.84) 100.0 % 0.60 [ 0.18, 1.02 ]
Subtotal (95% CI) 46 46 100.0 % 0.60 [ 0.18, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.80 (P = 0.0051)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 19 6.5 (3.86) 19 4.27 (2.64) 100.0 % 0.66 [ 0.01, 1.32 ]
Subtotal (95% CI) 19 19 100.0 % 0.66 [ 0.01, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Yang 2009 36 -1.86 (0.93) 40 -2.23 (0.86) 100.0 % 0.41 [ -0.05, 0.86 ]
Subtotal (95% CI) 36 40 100.0 % 0.41 [ -0.05, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
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Study or subgroup Vitamin D regimen Complex regimen
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lahfa 2003 64 -4.69 (1.3) 61 -4.44 (1.28) 100.0 % -0.19 [ -0.54, 0.16 ]
Subtotal (95% CI) 64 61 100.0 % -0.19 [ -0.54, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 376 2.49 (0.99) 383 2.23 (0.96) 100.0 % 0.27 [ 0.12, 0.41 ]
Subtotal (95% CI) 376 383 100.0 % 0.27 [ 0.12, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy)+ combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 376 2.49 (0.99) 377 1.98 (0.99) 100.0 % 0.51 [ 0.37, 0.66 ]
Subtotal (95% CI) 376 377 100.0 % 0.51 [ 0.37, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.95 (P < 0.00001)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 383 2.23 (0.96) 377 1.98 (0.99) 100.0 % 0.26 [ 0.11, 0.40 ]
Subtotal (95% CI) 383 377 100.0 % 0.26 [ 0.11, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.52 (P = 0.00044)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 294 1.73 (0.92) 302 1.51 (0.89) 100.0 % 0.24 [ 0.08, 0.40 ]
Subtotal (95% CI) 294 302 100.0 % 0.24 [ 0.08, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.95 (P = 0.0032)
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 247 -2.45 (1.31) 246 -3.16 (1.33) 100.0 % 0.54 [ 0.36, 0.72 ]
Subtotal (95% CI) 247 246 100.0 % 0.54 [ 0.36, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.86 (P < 0.00001)
Test for subgroup differences: Chi2 = 55.51, df = 11 (P = 0.00), I2 =80%
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Analysis 13.6. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 47/327 30/322 100.0 % 0.05 [ 0.00, 0.10 ]
Subtotal (95% CI) 327 322 100.0 % 0.05 [ 0.00, 0.10 ]
Total events: 47 (Vitamin D regimen), 30 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Saraceno 2007 17/75 14/75 100.0 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 75 75 100.0 % 0.04 [ -0.09, 0.17 ]
Total events: 17 (Vitamin D regimen), 14 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 47/327 21/322 100.0 % 0.08 [ 0.03, 0.13 ]
Subtotal (95% CI) 327 322 100.0 % 0.08 [ 0.03, 0.13 ]
Total events: 47 (Vitamin D regimen), 21 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.30 (P = 0.00096)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 3/49 3/49 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 49 49 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 3 (Vitamin D regimen), 3 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 0/19 0/19 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 19 19 100.0 % 0.0 [ -0.10, 0.10 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Yang 2009 0/36 0/40 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 36 40 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Lahfa 2003 8/64 8/61 100.0 % -0.01 [ -0.12, 0.11 ]
Subtotal (95% CI) 64 61 100.0 % -0.01 [ -0.12, 0.11 ]
Total events: 8 (Vitamin D regimen), 8 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 79/376 48/383 100.0 % 0.08 [ 0.03, 0.14 ]
Subtotal (95% CI) 376 383 100.0 % 0.08 [ 0.03, 0.14 ]
Total events: 79 (Vitamin D regimen), 48 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.14 (P = 0.0017)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 79/376 36/377 100.0 % 0.11 [ 0.06, 0.17 ]
Subtotal (95% CI) 376 377 100.0 % 0.11 [ 0.06, 0.17 ]
Total events: 79 (Vitamin D regimen), 36 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 4.43 (P < 0.00001)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 48/383 36/377 100.0 % 0.03 [ -0.01, 0.07 ]
Subtotal (95% CI) 383 377 100.0 % 0.03 [ -0.01, 0.07 ]
Total events: 48 (Vitamin D regimen), 36 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 30/322 21/322 100.0 % 0.03 [ -0.01, 0.07 ]
Subtotal (95% CI) 322 322 100.0 % 0.03 [ -0.01, 0.07 ]
Total events: 30 (Vitamin D regimen), 21 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 51/252 37/249 100.0 % 0.05 [ -0.01, 0.12 ]
Subtotal (95% CI) 252 249 100.0 % 0.05 [ -0.01, 0.12 ]
Total events: 51 (Vitamin D regimen), 37 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Test for subgroup differences: Chi2 = 17.98, df = 11 (P = 0.08), I2 =39%
-1 -0.5 0 0.5 1
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Analysis 13.7. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Saraceno 2007 0/75 3/75 100.0 % -0.04 [ -0.09, 0.01 ]
Subtotal (95% CI) 75 75 100.0 % -0.04 [ -0.09, 0.01 ]
Total events: 0 (Vitamin D regimen), 3 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 0/49 0/49 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 49 49 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 0/19 0/19 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 19 19 100.0 % 0.0 [ -0.10, 0.10 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Yang 2009 0/36 0/40 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 36 40 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Lahfa 2003 0/64 1/61 100.0 % -0.02 [ -0.06, 0.03 ]
Subtotal (95% CI) 64 61 100.0 % -0.02 [ -0.06, 0.03 ]
Total events: 0 (Vitamin D regimen), 1 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 7/376 5/383 100.0 % 0.01 [ -0.01, 0.02 ]
Subtotal (95% CI) 376 383 100.0 % 0.01 [ -0.01, 0.02 ]
Total events: 7 (Vitamin D regimen), 5 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 7/376 8/377 100.0 % 0.00 [ -0.02, 0.02 ]
Subtotal (95% CI) 376 377 100.0 % 0.00 [ -0.02, 0.02 ]
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 7 (Vitamin D regimen), 8 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 5/383 8/377 100.0 % -0.01 [ -0.03, 0.01 ]
Subtotal (95% CI) 383 377 100.0 % -0.01 [ -0.03, 0.01 ]
Total events: 5 (Vitamin D regimen), 8 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.39)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 11/252 6/249 100.0 % 0.02 [ -0.01, 0.05 ]
Subtotal (95% CI) 252 249 100.0 % 0.02 [ -0.01, 0.05 ]
Total events: 11 (Vitamin D regimen), 6 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Chi2 = 5.51, df = 8 (P = 0.70), I2 =0.0%
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Analysis 13.8. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Saraceno 2007 20/75 4/75 100.0 % 0.21 [ 0.10, 0.33 ]
Subtotal (95% CI) 75 75 100.0 % 0.21 [ 0.10, 0.33 ]
Total events: 20 (Vitamin D regimen), 4 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 0/49 0/49 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 49 49 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 0/19 0/19 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 19 19 100.0 % 0.0 [ -0.10, 0.10 ]
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Yang 2009 0/36 0/40 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 36 40 100.0 % 0.0 [ -0.05, 0.05 ]
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Lahfa 2003 4/64 2/61 100.0 % 0.03 [ -0.04, 0.10 ]
Subtotal (95% CI) 64 61 100.0 % 0.03 [ -0.04, 0.10 ]
Total events: 4 (Vitamin D regimen), 2 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy)+
combined calcipotriol + BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 16/252 3/249 100.0 % 0.05 [ 0.02, 0.08 ]
Subtotal (95% CI) 252 249 100.0 % 0.05 [ 0.02, 0.08 ]
Total events: 16 (Vitamin D regimen), 3 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.05 (P = 0.0023)
Test for subgroup differences: Chi2 = 15.88, df = 5 (P = 0.01), I2 =69%
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Analysis 13.9. Comparison 13 Vitamin D alone or in combination versus other treatments: complex
regimens, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 13 Vitamin D alone or in combination versus other treatments: complex regimens
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks)
Kragballe 2004 73/327 35/322 100.0 % 0.11 [ 0.06, 0.17 ]
Subtotal (95% CI) 327 322 100.0 % 0.11 [ 0.06, 0.17 ]
Total events: 73 (Vitamin D regimen), 35 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000071)
2 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (8 wks)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D regimen), 0 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol (12 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol + BMD (w/e) (8 wks)
Kragballe 2004 73/327 37/322 100.0 % 0.11 [ 0.05, 0.17 ]
Subtotal (95% CI) 327 322 100.0 % 0.11 [ 0.05, 0.17 ]
Total events: 73 (Vitamin D regimen), 37 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 3.72 (P = 0.00020)
4 Calcipotriol (6 wks) vs. clobetasol propionate (2 wks); then calcipotriol (4 wks)
Austad 1998 4/49 3/49 100.0 % 0.02 [ -0.08, 0.12 ]
Subtotal (95% CI) 49 49 100.0 % 0.02 [ -0.08, 0.12 ]
Total events: 4 (Vitamin D regimen), 3 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
5 Calcipotriol (6 wks) vs. calcipotriol OM, fluocinonide acetonide ON (2 wks); then calcipotriol twice daily (4 wks)
Wozel 2001 1/19 1/19 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 19 19 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 1 (Vitamin D regimen), 1 (Complex regimen)
Heterogeneity: not applicable
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcipotriol (6 wks) vs. halometasone OM, calcipotriol ON (2 wks); then calcipotriol twice daily (w/dy), halometasone (w/e) (2 wks); then calcipotriol twice daily (2
wks)
Yang 2009 14/36 5/40 100.0 % 0.26 [ 0.07, 0.45 ]
Subtotal (95% CI) 36 40 100.0 % 0.26 [ 0.07, 0.45 ]
Total events: 14 (Vitamin D regimen), 5 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0063)
7 Calcipotriol ON, clobetasol propionate OM (2 to 4 wks); then calcipotriol twice daily (to wk 12) vs. calcitriol ON, clobetasol propionate OM (2 to 4 wks); then
calcitriol twice daily (to wk 12)
Lahfa 2003 3/64 4/61 100.0 % -0.02 [ -0.10, 0.06 ]
Subtotal (95% CI) 64 61 100.0 % -0.02 [ -0.10, 0.06 ]
Total events: 3 (Vitamin D regimen), 4 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
8 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily
(8 wks)
White 2006 (P) 32/373 43/379 100.0 % -0.03 [ -0.07, 0.02 ]
Subtotal (95% CI) 373 379 100.0 % -0.03 [ -0.07, 0.02 ]
Total events: 32 (Vitamin D regimen), 43 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
9 Combined calcipotriol + BMD (4 wks); then placebo ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) + combined
calcipotriol + BMD (w/e) (8 wks)
White 2006 (P) 32/373 28/370 100.0 % 0.01 [ -0.03, 0.05 ]
Subtotal (95% CI) 373 370 100.0 % 0.01 [ -0.03, 0.05 ]
Total events: 32 (Vitamin D regimen), 28 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
10 Combined calcipotriol + BMD (4 wks); then calcipotriol ointment twice daily (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) +
combined calcipotriol + BMD (w/e) (8 wks)
White 2006 (H) 43/379 28/370 100.0 % 0.04 [ 0.00, 0.08 ]
Subtotal (95% CI) 379 370 100.0 % 0.04 [ 0.00, 0.08 ]
Total events: 43 (Vitamin D regimen), 28 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.076)
11 Combined calcipotriol + BMD (8 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (w/dy) % combined calcipotriol +
BMD (w/e) (8 wks)
Kragballe 2004 35/322 37/322 100.0 % -0.01 [ -0.05, 0.04 ]
Subtotal (95% CI) 322 322 100.0 % -0.01 [ -0.05, 0.04 ]
Total events: 35 (Vitamin D regimen), 37 (Complex regimen)
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Study or subgroup Vitamin D regimen Complex regimen
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
12 Tacalcitol (8 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Ortonne 2004 32/252 16/249 100.0 % 0.06 [ 0.01, 0.11 ]
Subtotal (95% CI) 252 249 100.0 % 0.06 [ 0.01, 0.11 ]
Total events: 32 (Vitamin D regimen), 16 (Complex regimen)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 35.10, df = 10 (P = 0.00), I2 =72%
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Analysis 14.1. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 1 IAGI
Study or subgroup Regimen 1 Regimen 2
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 104 1.74 (0.99) 104 1.83 (1.03) -0.09 [ -0.36, 0.18 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 104 1.74 (0.99) 89 1.92 (0.97) -0.18 [ -0.47, 0.10 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 104 1.83 (1.03) 89 1.92 (0.97) -0.09 [ -0.37, 0.19 ]
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Analysis 14.5. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Regimen 1 Regimen 2
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 104 1.74 (0.99) 104 1.83 (1.03) -0.09 [ -0.36, 0.18 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 104 1.74 (0.99) 89 1.92 (0.97) -0.18 [ -0.47, 0.10 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 104 1.83 (1.03) 89 1.92 (0.97) -0.09 [ -0.37, 0.19 ]
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Analysis 14.6. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 6 Total withdrawals
Study or subgroup Regimen 1 Regimen 2
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 64/212 56/213 0.04 [ -0.05, 0.12 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 64/212 70/209 -0.03 [ -0.12, 0.06 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 56/213 70/209 -0.07 [ -0.16, 0.02 ]
-0.5 -0.25 0 0.25 0.5
Favours regimen 1 Favours regimen 2
631Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.7. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Regimen 1 Regimen 2
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 14/212 11/213 0.01 [ -0.03, 0.06 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 14/212 16/209 -0.01 [ -0.06, 0.04 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 11/213 16/209 -0.02 [ -0.07, 0.02 ]
-0.2 -0.1 0 0.1 0.2
Favours regimen 1 Favours regimen 2
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Analysis 14.8. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Regimen 1 Regimen 2
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 32/212 31/213 0.01 [ -0.06, 0.07 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 32/212 42/209 -0.05 [ -0.12, 0.02 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 31/213 42/209 -0.06 [ -0.13, 0.02 ]
-0.5 -0.25 0 0.25 0.5
Favours regimen 1 Favours regimen 2
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Analysis 14.9. Comparison 14 Vitamin D alone or in combination versus other treatment: long-term
studies (> 24 wks), Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 14 Vitamin D alone or in combination versus other treatment: long-term studies (> 24 wks)
Outcome: 9 Adverse events (local)
Study or subgroup Regimen 1 Regimen 2
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Combined calcipotriol + BMD (52 wks) vs. alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks)
Kragballe 2006 45/212 63/213 -0.08 [ -0.17, 0.00 ]
2 Combined calcipotriol + BMD (52 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 45/212 78/209 -0.16 [ -0.25, -0.08 ]
3 Alternating: combined calcipotriol + BMD (4 wks); then calcipotriol (4 wks) vs. combined calcipotriol + BMD (4 wks); then calcipotriol (48 wks)
Kragballe 2006 63/213 78/209 -0.08 [ -0.17, 0.01 ]
-0.5 -0.25 0 0.25 0.5
Favours regimen 1 Favours regimen 2
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Analysis 15.1. Comparison 15 Vitamin D analogues versus other treatment, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 1 IAGI
Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 28 2.2 (1.01) 27 1.6 (1.01) 34.2 % 0.59 [ 0.04, 1.13 ]
De Simone 1993 15 -2.7 (0.88) 15 -1.8 (0.86) 32.0 % -1.01 [ -1.77, -0.24 ]
Tham 1994 27 -2.3 (0.83) 27 -1.2 (0.96) 33.8 % -1.21 [ -1.79, -0.62 ]
Subtotal (95% CI) 70 69 100.0 % -0.53 [ -1.74, 0.68 ]
Heterogeneity: Tau2 = 1.03; Chi2 = 22.54, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 65 -2.66 (0.67) 57 -2.28 (0.92) 59.4 % -0.47 [ -0.83, -0.11 ]
Van de Kerkhof 2002a 41 -3.41 (1.2) 46 -2.48 (1.24) 40.6 % -0.75 [ -1.19, -0.32 ]
Subtotal (95% CI) 106 103 100.0 % -0.59 [ -0.87, -0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 4.15 (P = 0.000034)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. calcipotriol + nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. corticosteroid + salicylic acid
Scarpa 1994 100 -2.72 (1.27) 100 -2.65 (1.18) 100.0 % -0.06 [ -0.33, 0.22 ]
Subtotal (95% CI) 100 100 100.0 % -0.06 [ -0.33, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 Calcipotriol vs. propylthiouracil cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol vs. tazarotene
Subtotal (95% CI) 0 0 Not estimable
-10 -5 0 5 10
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
8 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 40 -3.25 (0.98) 84 -3.01 (1.12) 100.0 % -0.22 [ -0.60, 0.16 ]
Subtotal (95% CI) 40 84 100.0 % -0.22 [ -0.60, 0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 13 -2.08 (0.49) 13 -1.77 (0.6) 100.0 % -0.55 [ -1.33, 0.24 ]
Subtotal (95% CI) 13 13 100.0 % -0.55 [ -1.33, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Guenther 2002 (H) 234 -3.79 (0.97) 150 -3.59 (1) 51.6 % -0.20 [ -0.41, 0.00 ]
Kragballe 1998b 172 -2.98 (1.23) 172 -2.63 (1.34) 48.4 % -0.27 [ -0.48, -0.06 ]
Subtotal (95% CI) 406 322 100.0 % -0.24 [ -0.38, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.14 (P = 0.0017)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.2. Comparison 15 Vitamin D analogues versus other treatment, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 2 TSS
Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. coal tar
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 69 2.7 (2.14) 63 3.8 (2.14) 100.0 % -0.51 [ -0.86, -0.16 ]
Subtotal (95% CI) 69 63 100.0 % -0.51 [ -0.86, -0.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0039)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 48 3.52 (1.95) 48 3.69 (1.93) 100.0 % -0.09 [ -0.49, 0.31 ]
Subtotal (95% CI) 48 48 100.0 % -0.09 [ -0.49, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 Calcipotriol vs. calcipotriol+nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 48 3.52 (1.95) 144 3.15 (1.94) 100.0 % 0.19 [ -0.14, 0.52 ]
Subtotal (95% CI) 48 144 100.0 % 0.19 [ -0.14, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
5 Calcipotriol vs. corticosteroid + salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Calcipotriol vs. propylthiouracil cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 40 3.25 (0.98) 84 3.01 (1.12) 52.1 % 0.22 [ -0.16, 0.60 ]
Zonneveld 1998 (H) 23 2.6 (2.14) 24 4.7 (2.14) 47.9 % -0.96 [ -1.57, -0.36 ]
Subtotal (95% CI) 63 108 100.0 % -0.35 [ -1.51, 0.81 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 10.58, df = 1 (P = 0.001); I2 =91%
Test for overall effect: Z = 0.59 (P = 0.56)
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
8 Calcipotriol vs. tazarotene
Han 2001 101 3.91 (6.08) 98 4.18 (4.39) 100.0 % -0.05 [ -0.33, 0.23 ]
Subtotal (95% CI) 101 98 100.0 % -0.05 [ -0.33, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Bourke 1993b 19 -3.1 (2.6) 19 -5.2 (2.6) 48.7 % 0.79 [ 0.13, 1.45 ]
Hinds n 2006 (H) 114 5.2 (3.3) 95 9.7 (4.8) 51.3 % -1.11 [ -1.40, -0.81 ]
Subtotal (95% CI) 133 114 100.0 % -0.18 [ -2.04, 1.68 ]
Heterogeneity: Tau2 = 1.73; Chi2 = 26.34, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 15.3. Comparison 15 Vitamin D analogues versus other treatment, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 3 PASI
Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 28 -0.37 (0.27) 27 -0.58 (0.37) 50.1 % 0.64 [ 0.10, 1.18 ]
Tham 1994 27 2 (2.1) 27 4.5 (3.6) 49.9 % -0.84 [ -1.39, -0.28 ]
Subtotal (95% CI) 55 54 100.0 % -0.10 [ -1.54, 1.35 ]
Heterogeneity: Tau2 = 1.01; Chi2 = 13.82, df = 1 (P = 0.00020); I2 =93%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Calcipotriol vs. coal tar polytherapy
Van de Kerkhof 2002a 41 -0.57 (0.29) 46 -0.36 (0.36) 100.0 % -0.63 [ -1.06, -0.20 ]
Subtotal (95% CI) 41 46 100.0 % -0.63 [ -1.06, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.87 (P = 0.0041)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. calcipotriol + nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 80 2.6 (3.61) 80 2.78 (3.61) 100.0 % -0.05 [ -0.36, 0.26 ]
Subtotal (95% CI) 80 80 100.0 % -0.05 [ -0.36, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 14 1.11 (1.04) 13 3.83 (1.31) 100.0 % -2.24 [ -3.23, -1.25 ]
Subtotal (95% CI) 14 13 100.0 % -2.24 [ -3.23, -1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
7 Calcipotriol vs. tacrolimus ointment
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
8 Calcipotriol vs. tazarotene
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 13 0.8 (0.66) 13 0.81 (0.69) 100.0 % -0.01 [ -0.78, 0.75 ]
Subtotal (95% CI) 13 13 100.0 % -0.01 [ -0.78, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Baiocchi 1997 130 0.97 (1.3) 130 1.1 (1.4) 26.8 % -0.10 [ -0.34, 0.15 ]
Guenther 2002 (H) 234 2.7 (2.5) 150 3 (2.5) 37.7 % -0.12 [ -0.32, 0.09 ]
Kragballe 1998b 172 4.04 (3.39) 173 4.58 (3.93) 35.5 % -0.15 [ -0.36, 0.06 ]
Subtotal (95% CI) 536 453 100.0 % -0.12 [ -0.25, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.4. Comparison 15 Vitamin D analogues versus other treatment, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 4 PAGI
Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. coal tar
Tham 1994 27 -2.44 (0.89) 27 -1.11 (0.85) 100.0 % -1.51 [ -2.12, -0.90 ]
Subtotal (95% CI) 27 27 100.0 % -1.51 [ -2.12, -0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)
2 Calcipotriol vs. coal tar polytherapy
Van de Kerkhof 2002a 41 -3.29 (1.19) 46 -2.57 (1.36) 100.0 % -0.56 [ -0.99, -0.13 ]
Subtotal (95% CI) 41 46 100.0 % -0.56 [ -0.99, -0.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. calcipotriol + nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. corticosteroid + salicylic acid
Scarpa 1994 89 -3.29 (0.73) 97 -2.87 (0.94) 100.0 % -0.49 [ -0.79, -0.20 ]
Subtotal (95% CI) 89 97 100.0 % -0.49 [ -0.79, -0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00091)
6 Calcipotriol vs. propylthiouracil cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 40 -3.23 (1.05) 84 -3.08 (1.13) 100.0 % -0.13 [ -0.51, 0.24 ]
Subtotal (95% CI) 40 84 100.0 % -0.13 [ -0.51, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
8 Calcipotriol vs. tazarotene
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tzung 2005 19 -3.16 (0.69) 19 -2.89 (0.81) 100.0 % -0.35 [ -0.99, 0.29 ]
Subtotal (95% CI) 19 19 100.0 % -0.35 [ -0.99, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 13 -2.08 (0.49) 13 -1.77 (0.6) 100.0 % -0.55 [ -1.33, 0.24 ]
Subtotal (95% CI) 13 13 100.0 % -0.55 [ -1.33, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.5. Comparison 15 Vitamin D analogues versus other treatment, Outcome 5 Combined end
point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 28 2.2 (1.01) 27 1.6 (1.01) 34.2 % 0.59 [ 0.04, 1.13 ]
De Simone 1993 15 -2.7 (0.88) 15 -1.8 (0.86) 32.0 % -1.01 [ -1.77, -0.24 ]
Tham 1994 27 -2.3 (0.83) 27 -1.2 (0.96) 33.8 % -1.21 [ -1.79, -0.62 ]
Subtotal (95% CI) 70 69 100.0 % -0.53 [ -1.74, 0.68 ]
Heterogeneity: Tau2 = 1.03; Chi2 = 22.54, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 65 -2.66 (0.67) 57 -2.28 (0.92) 59.4 % -0.47 [ -0.83, -0.11 ]
Van de Kerkhof 2002a 41 -3.41 (1.2) 46 -2.48 (1.24) 40.6 % -0.75 [ -1.19, -0.32 ]
Subtotal (95% CI) 106 103 100.0 % -0.59 [ -0.87, -0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 4.15 (P = 0.000034)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 48 3.52 (1.95) 48 3.69 (1.93) 100.0 % -0.09 [ -0.49, 0.31 ]
Subtotal (95% CI) 48 48 100.0 % -0.09 [ -0.49, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
4 Calcipotriol vs. calcipotriol + nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 48 3.52 (1.95) 144 3.15 (1.94) 100.0 % 0.19 [ -0.14, 0.52 ]
Subtotal (95% CI) 48 144 100.0 % 0.19 [ -0.14, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 80 2.6 (3.61) 80 2.78 (3.61) 44.4 % -0.05 [ -0.36, 0.26 ]
Scarpa 1994 100 -2.72 (1.27) 100 -2.65 (1.18) 55.6 % -0.06 [ -0.33, 0.22 ]
Subtotal (95% CI) 180 180 100.0 % -0.05 [ -0.26, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
6 Calcipotriol vs. propylthiouracil cream
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Sanchez 2001 14 1.11 (1.04) 13 3.83 (1.31) 100.0 % -2.24 [ -3.23, -1.25 ]
Subtotal (95% CI) 14 13 100.0 % -2.24 [ -3.23, -1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.42 (P < 0.00001)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 40 -3.25 (0.98) 84 -3.01 (1.12) 55.3 % -0.22 [ -0.60, 0.16 ]
Zonneveld 1998 (H) 23 2.6 (2.14) 24 4.7 (2.14) 44.7 % -0.96 [ -1.57, -0.36 ]
Subtotal (95% CI) 63 108 100.0 % -0.55 [ -1.28, 0.17 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 4.15, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.50 (P = 0.13)
8 Calcipotriol vs. tazarotene
Han 2001 101 3.91 (6.08) 98 4.18 (4.39) 84.2 % -0.05 [ -0.33, 0.23 ]
Tzung 2005 19 -3.16 (0.69) 19 -2.89 (0.81) 15.8 % -0.35 [ -0.99, 0.29 ]
Subtotal (95% CI) 120 117 100.0 % -0.10 [ -0.35, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 13 -2.08 (0.49) 13 -1.77 (0.6) 100.0 % -0.55 [ -1.33, 0.24 ]
Subtotal (95% CI) 13 13 100.0 % -0.55 [ -1.33, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Baiocchi 1997 130 0.97 (1.3) 130 1.1 (1.4) 26.9 % -0.10 [ -0.34, 0.15 ]
Guenther 2002 (H) 234 -3.79 (0.97) 150 -3.59 (1) 37.7 % -0.20 [ -0.41, 0.00 ]
Kragballe 1998b 172 -2.98 (1.23) 172 -2.63 (1.34) 35.3 % -0.27 [ -0.48, -0.06 ]
Subtotal (95% CI) 536 452 100.0 % -0.20 [ -0.32, -0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 3.08 (P = 0.0021)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Bourke 1993b 19 -3.1 (2.6) 19 -5.2 (2.6) 48.7 % 0.79 [ 0.13, 1.45 ]
Hinds n 2006 (H) 114 5.2 (3.3) 95 9.7 (4.8) 51.3 % -1.11 [ -1.40, -0.81 ]
Subtotal (95% CI) 133 114 100.0 % -0.18 [ -2.04, 1.68 ]
Heterogeneity: Tau2 = 1.73; Chi2 = 26.34, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.19 (P = 0.85)
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Study or subgroup Vitamin D analogue Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for subgroup differences: Chi2 = 33.90, df = 10 (P = 0.00), I2 =71%
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Analysis 15.6. Comparison 15 Vitamin D analogues versus other treatment, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 6 Total withdrawals
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 2/30 3/30 54.2 % -0.03 [ -0.17, 0.11 ]
Tham 1994 3/30 3/30 45.8 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 60 60 100.0 % -0.02 [ -0.12, 0.08 ]
Total events: 5 (Vitamin D analogue), 6 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 4/69 6/63 60.5 % -0.04 [ -0.13, 0.05 ]
Van de Kerkhof 2002a 3/41 4/47 39.5 % -0.01 [ -0.12, 0.10 ]
Subtotal (95% CI) 110 110 100.0 % -0.03 [ -0.10, 0.04 ]
Total events: 7 (Vitamin D analogue), 10 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 2/48 1/48 100.0 % 0.02 [ -0.05, 0.09 ]
Subtotal (95% CI) 48 48 100.0 % 0.02 [ -0.05, 0.09 ]
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
4 Calcipotriol vs. calcipotriol + nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 2/48 5/144 100.0 % 0.01 [ -0.06, 0.07 ]
Subtotal (95% CI) 48 144 100.0 % 0.01 [ -0.06, 0.07 ]
Total events: 2 (Vitamin D analogue), 5 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 20/80 17/80 100.0 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 80 80 100.0 % 0.04 [ -0.09, 0.17 ]
Total events: 20 (Vitamin D analogue), 17 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 2/14 1/14 100.0 % 0.07 [ -0.16, 0.30 ]
Subtotal (95% CI) 14 14 100.0 % 0.07 [ -0.16, 0.30 ]
Total events: 2 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 3/40 17/84 100.0 % -0.13 [ -0.25, -0.01 ]
Subtotal (95% CI) 40 84 100.0 % -0.13 [ -0.25, -0.01 ]
Total events: 3 (Vitamin D analogue), 17 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
8 Calcipotriol vs. tazarotene
Han 2001 2/103 7/105 94.1 % -0.05 [ -0.10, 0.01 ]
Tzung 2005 4/23 4/23 5.9 % 0.0 [ -0.22, 0.22 ]
Subtotal (95% CI) 126 128 100.0 % -0.04 [ -0.10, 0.01 ]
Total events: 6 (Vitamin D analogue), 11 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Guenther 2000 6/60 8/60 100.0 % -0.03 [ -0.15, 0.08 ]
Subtotal (95% CI) 60 60 100.0 % -0.03 [ -0.15, 0.08 ]
Total events: 6 (Vitamin D analogue), 8 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 0/13 0/13 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 13 13 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Baiocchi 1997 33/132 34/132 13.3 % -0.01 [ -0.11, 0.10 ]
Guenther 2002 (H) 19/237 11/152 50.8 % 0.01 [ -0.05, 0.06 ]
Kragballe 1998b 19/174 17/174 35.9 % 0.01 [ -0.05, 0.08 ]
Subtotal (95% CI) 543 458 100.0 % 0.01 [ -0.03, 0.05 ]
Total events: 71 (Vitamin D analogue), 62 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.7. Comparison 15 Vitamin D analogues versus other treatment, Outcome 7 Withdrawals due
to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 0/30 0/30 66.1 % 0.0 [ -0.06, 0.06 ]
Tham 1994 1/30 0/30 33.9 % 0.03 [ -0.05, 0.12 ]
Subtotal (95% CI) 60 60 100.0 % 0.01 [ -0.04, 0.06 ]
Total events: 1 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 1/65 3/57 64.3 % -0.04 [ -0.10, 0.03 ]
Van de Kerkhof 2002a 2/41 2/47 35.7 % 0.01 [ -0.08, 0.09 ]
Subtotal (95% CI) 106 104 100.0 % -0.02 [ -0.07, 0.03 ]
Total events: 3 (Vitamin D analogue), 5 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 0/48 0/48 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 48 48 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Calcipotriol vs. calcipotriol + nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 0/48 0/144 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 48 144 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 4/80 0/80 100.0 % 0.05 [ 0.00, 0.10 ]
Subtotal (95% CI) 80 80 100.0 % 0.05 [ 0.00, 0.10 ]
Total events: 4 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.86 (P = 0.063)
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 2/14 1/14 100.0 % 0.07 [ -0.16, 0.30 ]
Subtotal (95% CI) 14 14 100.0 % 0.07 [ -0.16, 0.30 ]
Total events: 2 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 3/40 5/84 100.0 % 0.02 [ -0.08, 0.11 ]
Subtotal (95% CI) 40 84 100.0 % 0.02 [ -0.08, 0.11 ]
Total events: 3 (Vitamin D analogue), 5 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
8 Calcipotriol vs. tazarotene
Han 2001 3/103 5/105 70.0 % -0.02 [ -0.07, 0.03 ]
Tzung 2005 0/23 3/23 30.0 % -0.13 [ -0.28, 0.02 ]
Subtotal (95% CI) 126 128 100.0 % -0.05 [ -0.16, 0.05 ]
Total events: 3 (Vitamin D analogue), 8 (Other treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.98 (P = 0.32)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Guenther 2000 3/60 4/60 100.0 % -0.02 [ -0.10, 0.07 ]
Subtotal (95% CI) 60 60 100.0 % -0.02 [ -0.10, 0.07 ]
Total events: 3 (Vitamin D analogue), 4 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 0/13 0/13 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 13 13 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Baiocchi 1997 7/132 6/132 5.8 % 0.01 [ -0.04, 0.06 ]
Guenther 2002 (H) 1/235 0/151 85.0 % 0.00 [ -0.01, 0.02 ]
Kragballe 1998b 8/174 6/174 9.3 % 0.01 [ -0.03, 0.05 ]
Subtotal (95% CI) 541 457 100.0 % 0.01 [ -0.01, 0.02 ]
Total events: 16 (Vitamin D analogue), 12 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.80 (P = 0.42)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.8. Comparison 15 Vitamin D analogues versus other treatment, Outcome 8 Withdrawals due
to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. coal tar
Tham 1994 0/30 0/30 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. coal tar polytherapy
Van de Kerkhof 2002a 1/41 1/47 100.0 % 0.00 [ -0.06, 0.07 ]
Subtotal (95% CI) 41 47 100.0 % 0.00 [ -0.06, 0.07 ]
Total events: 1 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 0/48 0/48 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 48 48 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Calcipotriol vs. calcipotriol + nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 0/48 0/144 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 48 144 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 1/80 3/80 100.0 % -0.02 [ -0.07, 0.02 ]
Subtotal (95% CI) 80 80 100.0 % -0.02 [ -0.07, 0.02 ]
Total events: 1 (Vitamin D analogue), 3 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 0/14 1/14 100.0 % -0.07 [ -0.25, 0.11 ]
Subtotal (95% CI) 14 14 100.0 % -0.07 [ -0.25, 0.11 ]
Total events: 0 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 0/40 2/84 100.0 % -0.02 [ -0.07, 0.03 ]
Subtotal (95% CI) 40 84 100.0 % -0.02 [ -0.07, 0.03 ]
Total events: 0 (Vitamin D analogue), 2 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
8 Calcipotriol vs. tazarotene
Han 2001 0/103 0/105 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 103 105 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Guenther 2000 1/60 1/60 100.0 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 60 60 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 1 (Vitamin D analogue), 1 (Other treatment)
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 0/13 0/13 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 13 13 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Baiocchi 1997 1/132 1/132 25.4 % 0.0 [ -0.02, 0.02 ]
Guenther 2002 (H) 1/235 0/151 59.8 % 0.00 [ -0.01, 0.02 ]
Kragballe 1998b 3/174 3/174 14.8 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 541 457 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 5 (Vitamin D analogue), 4 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.9. Comparison 15 Vitamin D analogues versus other treatment, Outcome 9 Adverse events
(local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 9 Adverse events (local)
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. coal tar
Alora-Palli 2010 4/30 5/30 19.1 % -0.03 [ -0.21, 0.15 ]
Tham 1994 1/30 0/30 80.9 % 0.03 [ -0.05, 0.12 ]
Subtotal (95% CI) 60 60 100.0 % 0.02 [ -0.06, 0.10 ]
Total events: 5 (Vitamin D analogue), 5 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Calcipotriol vs. coal tar polytherapy
Pinheiro 1997 15/65 10/57 100.0 % 0.06 [ -0.09, 0.20 ]
Subtotal (95% CI) 65 57 100.0 % 0.06 [ -0.09, 0.20 ]
Total events: 15 (Vitamin D analogue), 10 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Levine 2010 (H) 9/48 16/48 100.0 % -0.15 [ -0.32, 0.03 ]
Subtotal (95% CI) 48 48 100.0 % -0.15 [ -0.32, 0.03 ]
Total events: 9 (Vitamin D analogue), 16 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
4 Calcipotriol vs. calcipotriol + nicotinamide (0.05%, 0.1%, 0.7%, or 1.4%), twice daily
Levine 2010 (H) 9/48 51/144 100.0 % -0.17 [ -0.30, -0.03 ]
Subtotal (95% CI) 48 144 100.0 % -0.17 [ -0.30, -0.03 ]
Total events: 9 (Vitamin D analogue), 51 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 7/80 0/80 100.0 % 0.09 [ 0.02, 0.15 ]
Subtotal (95% CI) 80 80 100.0 % 0.09 [ 0.02, 0.15 ]
Total events: 7 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0087)
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Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 0/14 1/14 100.0 % -0.07 [ -0.25, 0.11 ]
Subtotal (95% CI) 14 14 100.0 % -0.07 [ -0.25, 0.11 ]
Total events: 0 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 13/40 43/84 100.0 % -0.19 [ -0.37, -0.01 ]
Subtotal (95% CI) 40 84 100.0 % -0.19 [ -0.37, -0.01 ]
Total events: 13 (Vitamin D analogue), 43 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
8 Calcipotriol vs. tazarotene
Han 2001 10/101 13/103 100.0 % -0.03 [ -0.11, 0.06 ]
Subtotal (95% CI) 101 103 100.0 % -0.03 [ -0.11, 0.06 ]
Total events: 10 (Vitamin D analogue), 13 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Stuecker 2001 4/13 1/13 100.0 % 0.23 [ -0.06, 0.52 ]
Subtotal (95% CI) 13 13 100.0 % 0.23 [ -0.06, 0.52 ]
Total events: 4 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
Guenther 2002 (H) 25/235 15/151 71.9 % 0.01 [ -0.05, 0.07 ]
Kragballe 1998b 54/173 59/172 28.1 % -0.03 [ -0.13, 0.07 ]
Subtotal (95% CI) 408 323 100.0 % 0.00 [ -0.06, 0.05 ]
Total events: 79 (Vitamin D analogue), 74 (Other treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
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(. . . Continued)
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: not applicable
-0.5 -0.25 0 0.25 0.5
Favours vitamin D analogue Favours other treatment
Analysis 15.10. Comparison 15 Vitamin D analogues versus other treatment, Outcome 10 Adverse events
(systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 15 Vitamin D analogues versus other treatment
Outcome: 10 Adverse events (systemic)
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. coal tar
Tham 1994 1/30 1/30 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 30 30 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 1 (Vitamin D analogue), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. coal tar polytherapy
Van de Kerkhof 2002a 0/41 0/47 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 41 47 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Calcipotriol vs. nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
-2 -1 0 1 2
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(. . . Continued)
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
4 Calcipotriol vs. calcipotriol + nicotinamide 1.4%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcipotriol vs. corticosteroid + salicylic acid
Crosti 1997 0/80 0/80 100.0 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 80 80 100.0 % 0.0 [ -0.02, 0.02 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
6 Calcipotriol vs. propylthiouracil cream
Sanchez 2001 0/14 0/14 100.0 % 0.0 [ -0.13, 0.13 ]
Subtotal (95% CI) 14 14 100.0 % 0.0 [ -0.13, 0.13 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Calcipotriol vs. tacrolimus ointment
Ortonne 2006 0/40 0/84 100.0 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 40 84 100.0 % 0.0 [ -0.04, 0.04 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
8 Calcipotriol vs. tazarotene
Han 2001 1/92 2/91 100.0 % -0.01 [ -0.05, 0.03 ]
Subtotal (95% CI) 92 91 100.0 % -0.01 [ -0.05, 0.03 ]
Total events: 1 (Vitamin D analogue), 2 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
9 Calcipotriol vs. tazarotene gel plus mometasone furoate cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Calcipotriol vs. vitamin B12 cream
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Head-to-head vitamin D alone or in combination: twice daily vs OD
-2 -1 0 1 2
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(. . . Continued)
Study or subgroup Vitamin D analogue Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Baiocchi 1997 0/132 0/132 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 132 132 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
12 Head-to-head vitamin D alone or in combination: no occlusion vs. occlusion
Bourke 1993b 0/19 0/19 100.0 % 0.0 [ -0.10, 0.10 ]
Subtotal (95% CI) 19 19 100.0 % 0.0 [ -0.10, 0.10 ]
Total events: 0 (Vitamin D analogue), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
-2 -1 0 1 2
Favours vitamin D analogue Favours other treatment
Analysis 16.1. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 1 IAGI
Study or subgroup Active treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone valerate 0.1%, OD
2 Calcipotriol ointment, OD
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 22 -2.95 (1.33) 25 -1.56 (1.23) -1.07 [ -1.69, -0.45 ]
4 Tacrolimus ointment 0.1%, twice daily
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Analysis 16.2. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 2 TSS
Study or subgroup Active treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone valerate 0.1%, OD
2 Calcipotriol ointment, OD
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 28 -4.1 (1.03) 29 -2.67 (1.03) -1.37 [ -1.95, -0.79 ]
4 Tacrolimus ointment 0.1%, twice daily
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Analysis 16.3. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 3 PASI
Study or subgroup Active treatment Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 17 2.94 (3.76) 19 13.84 (3.76) -2.83 [ -3.79, -1.88 ]
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 19 9.68 (3.76) 19 13.84 (3.76) -1.08 [ -1.77, -0.40 ]
3 Pimecrolimus cream, 1% OD/twice daily
Kreuter 2006 (P) 20 11.45 (3.76) 19 13.84 (3.76) -0.62 [ -1.27, 0.02 ]
4 Tacrolimus ointment 0.1%, twice daily
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Analysis 16.4. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 4 PAGI
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone valerate 0.1%, OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol ointment, OD
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 22 -2.36 (0.85) 25 -1.72 (1.06) 100.0 % -0.65 [ -1.24, -0.06 ]
Subtotal (95% CI) 22 25 100.0 % -0.65 [ -1.24, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
4 Tacrolimus ointment 0.1%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 16.5. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 5 Combined end
point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 17 2.94 (3.76) 19 13.84 (3.76) 100.0 % -2.83 [ -3.79, -1.88 ]
Subtotal (95% CI) 17 19 100.0 % -2.83 [ -3.79, -1.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.83 (P < 0.00001)
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 19 9.68 (3.76) 19 13.84 (3.76) 100.0 % -1.08 [ -1.77, -0.40 ]
Subtotal (95% CI) 19 19 100.0 % -1.08 [ -1.77, -0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.09 (P = 0.0020)
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 22 -2.95 (1.33) 25 -1.56 (1.23) 52.3 % -1.07 [ -1.69, -0.45 ]
Kreuter 2006 (P) 20 11.45 (3.76) 19 13.84 (3.76) 47.7 % -0.62 [ -1.27, 0.02 ]
Subtotal (95% CI) 42 44 100.0 % -0.86 [ -1.30, -0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 3.77 (P = 0.00016)
4 Tacrolimus ointment 0.1%, twice daily
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 13.67, df = 2 (P = 0.00), I2 =85%
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Analysis 16.6. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 6 Total
withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 6 Total withdrawals
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 3/20 1/20 100.0 % 0.10 [ -0.08, 0.28 ]
Subtotal (95% CI) 20 20 100.0 % 0.10 [ -0.08, 0.28 ]
Total events: 3 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 1/20 1/20 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 1 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 2/28 4/29 39.7 % -0.07 [ -0.22, 0.09 ]
Kreuter 2006 (P) 0/20 1/20 60.3 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 48 49 100.0 % -0.06 [ -0.16, 0.04 ]
Total events: 2 (Active treatment), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
4 Tacrolimus ointment 0.1%, twice daily
Lebwohl 2004 14/112 16/55 100.0 % -0.17 [ -0.30, -0.03 ]
Subtotal (95% CI) 112 55 100.0 % -0.17 [ -0.30, -0.03 ]
Total events: 14 (Active treatment), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 5.96, df = 3 (P = 0.11), I2 =50%
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Analysis 16.7. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 7 Withdrawals
due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 0/28 0/29 66.2 % 0.0 [ -0.07, 0.07 ]
Kreuter 2006 (P) 0/20 0/20 33.8 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 48 49 100.0 % 0.0 [ -0.05, 0.05 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
4 Tacrolimus ointment 0.1%, twice daily
Lebwohl 2004 0/112 1/55 100.0 % -0.02 [ -0.06, 0.03 ]
Subtotal (95% CI) 112 55 100.0 % -0.02 [ -0.06, 0.03 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Chi2 = 0.35, df = 3 (P = 0.95), I2 =0.0%
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Analysis 16.8. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 8 Withdrawals
due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 0/20 1/20 100.0 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 20 20 100.0 % -0.05 [ -0.18, 0.08 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 0/20 1/20 100.0 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 20 20 100.0 % -0.05 [ -0.18, 0.08 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
3 Pimecrolimus cream, 1% OD/twice daily
Gribetz 2004 1/28 2/29 55.3 % -0.03 [ -0.15, 0.08 ]
Kreuter 2006 (P) 0/20 1/20 44.7 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 48 49 100.0 % -0.04 [ -0.13, 0.04 ]
Total events: 1 (Active treatment), 3 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
4 Tacrolimus ointment 0.1%, twice daily
Lebwohl 2004 0/112 6/55 100.0 % -0.11 [ -0.19, -0.02 ]
Subtotal (95% CI) 112 55 100.0 % -0.11 [ -0.19, -0.02 ]
Total events: 0 (Active treatment), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 1.44, df = 3 (P = 0.70), I2 =0.0%
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Analysis 16.9. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 9 Adverse events
(local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 9 Adverse events (local)
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone valerate 0.1%, OD
Kreuter 2006 (P) 0/20 1/20 100.0 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 20 20 100.0 % -0.05 [ -0.18, 0.08 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
2 Calcipotriol ointment, OD
Kreuter 2006 (P) 2/20 1/20 100.0 % 0.05 [ -0.11, 0.21 ]
Subtotal (95% CI) 20 20 100.0 % 0.05 [ -0.11, 0.21 ]
Total events: 2 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 Pimecrolimus cream 1%, OD/twice daily
Gribetz 2004 1/28 1/29 58.3 % 0.00 [ -0.09, 0.10 ]
Kreuter 2006 (P) 5/20 1/20 41.7 % 0.20 [ -0.01, 0.41 ]
Subtotal (95% CI) 48 49 100.0 % 0.08 [ -0.15, 0.31 ]
Total events: 6 (Active treatment), 2 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.99, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.72 (P = 0.47)
4 Tacrolimus ointment 0.1%, twice daily
Lebwohl 2004 14/112 16/55 100.0 % -0.17 [ -0.30, -0.03 ]
Subtotal (95% CI) 112 55 100.0 % -0.17 [ -0.30, -0.03 ]
Total events: 14 (Active treatment), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Chi2 = 5.61, df = 3 (P = 0.13), I2 =47%
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Analysis 16.10. Comparison 16 Flexural/facial psoriasis: placebo-controlled trials, Outcome 10 Adverse
events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 16 Flexural/facial psoriasis: placebo-controlled trials
Outcome: 10 Adverse events (systemic)
Study or subgroup Active treatment Placebo
Risk
Difference
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Betamethasone valerate 0.1%, OD
2 Calcipotriol ointment, OD
3 Pimecrolimus cream 1%, OD/twice daily
4 Tacrolimus ointment 0.1%, twice daily
Lebwohl 2004 0/112 0/55 0.0 [ -0.03, 0.03 ]
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Analysis 17.1. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 1 IAGI
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. BMV
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 202 1.37 (1.16) 206 1.04 (1.02) 100.0 % 0.30 [ 0.11, 0.50 ]
Subtotal (95% CI) 202 206 100.0 % 0.30 [ 0.11, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0024)
3 Calcipotriol vs. calcitriol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. pimecrolimus
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcitriol vs. tacrolimus
Liao 2007 24 -3.67 (1.78) 25 -4.48 (2.02) 100.0 % 0.42 [ -0.15, 0.98 ]
Subtotal (95% CI) 24 25 100.0 % 0.42 [ -0.15, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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Analysis 17.2. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 2 TSS
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. BMV
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Calcipotriol vs. calcipotriol + hydrocortisone
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Calcipotriol vs. calcitriol
Ortonne 2003 75 1.78 (1.5) 75 0.86 (1.5) 100.0 % 0.61 [ 0.28, 0.94 ]
Subtotal (95% CI) 75 75 100.0 % 0.61 [ 0.28, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
4 Calcipotriol vs. pimecrolimus
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Calcitriol vs. tacrolimus
Liao 2007 24 -0.51 (0.35) 25 -0.64 (0.51) 100.0 % 0.29 [ -0.27, 0.85 ]
Subtotal (95% CI) 24 25 100.0 % 0.29 [ -0.27, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.92, df = 1 (P = 0.34), I2 =0.0%
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Analysis 17.3. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 3 PASI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 3 PASI
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. BMV
Kreuter 2006 (H) 19 9.68 (3.26) 17 2.94 (3.26) 100.0 % 2.02 [ 1.20, 2.84 ]
Subtotal (95% CI) 19 17 100.0 % 2.02 [ 1.20, 2.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.83 (P < 0.00001)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 202 0.21 (0.3) 206 0.13 (0.19) 100.0 % 0.32 [ 0.12, 0.51 ]
Subtotal (95% CI) 202 206 100.0 % 0.32 [ 0.12, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.20 (P = 0.0014)
3 Calcipotriol vs. calcitriol
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 19 9.68 (3.26) 20 11.45 (3.26) 100.0 % -0.53 [ -1.17, 0.11 ]
Subtotal (95% CI) 19 20 100.0 % -0.53 [ -1.17, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
5 Calcitriol vs. tacrolimus
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 23.31, df = 2 (P = 0.00), I2 =91%
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Analysis 17.5. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Calcipotriol vs. BMV
Kreuter 2006 (H) 19 9.68 (3.26) 17 2.94 (3.26) 100.0 % 2.02 [ 1.20, 2.84 ]
Subtotal (95% CI) 19 17 100.0 % 2.02 [ 1.20, 2.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.83 (P < 0.00001)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 202 1.37 (1.16) 206 1.04 (1.02) 100.0 % 0.30 [ 0.11, 0.50 ]
Subtotal (95% CI) 202 206 100.0 % 0.30 [ 0.11, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0024)
3 Calcipotriol vs. calcitriol
Ortonne 2003 75 1.78 (1.5) 75 0.86 (1.5) 100.0 % 0.61 [ 0.28, 0.94 ]
Subtotal (95% CI) 75 75 100.0 % 0.61 [ 0.28, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 19 9.68 (3.26) 20 11.45 (3.26) 100.0 % -0.53 [ -1.17, 0.11 ]
Subtotal (95% CI) 19 20 100.0 % -0.53 [ -1.17, 0.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
5 Calcitriol vs. tacrolimus
Liao 2007 24 -3.67 (1.78) 25 -4.48 (2.02) 100.0 % 0.42 [ -0.15, 0.98 ]
Subtotal (95% CI) 24 25 100.0 % 0.42 [ -0.15, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 25.69, df = 4 (P = 0.00), I2 =84%
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Analysis 17.6. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. BMV
Kreuter 2006 (H) 1/20 3/20 100.0 % -0.10 [ -0.28, 0.08 ]
Subtotal (95% CI) 20 20 100.0 % -0.10 [ -0.28, 0.08 ]
Total events: 1 (Vitamin D alone or in combination), 3 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 34/202 27/206 100.0 % 0.04 [ -0.03, 0.11 ]
Subtotal (95% CI) 202 206 100.0 % 0.04 [ -0.03, 0.11 ]
Total events: 34 (Vitamin D alone or in combination), 27 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
3 Calcipotriol vs. calcitriol
Ortonne 2003 10/75 10/75 100.0 % 0.0 [ -0.11, 0.11 ]
Subtotal (95% CI) 75 75 100.0 % 0.0 [ -0.11, 0.11 ]
Total events: 10 (Vitamin D alone or in combination), 10 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 1/20 0/20 100.0 % 0.05 [ -0.08, 0.18 ]
Subtotal (95% CI) 20 20 100.0 % 0.05 [ -0.08, 0.18 ]
Total events: 1 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
5 Calcitriol vs. tacrolimus
Liao 2007 3/25 0/25 100.0 % 0.12 [ -0.02, 0.26 ]
Subtotal (95% CI) 25 25 100.0 % 0.12 [ -0.02, 0.26 ]
Total events: 3 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.096)
Test for subgroup differences: Chi2 = 3.91, df = 4 (P = 0.42), I2 =0.0%
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Analysis 17.7. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. BMV
Kreuter 2006 (H) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 19/202 6/206 100.0 % 0.06 [ 0.02, 0.11 ]
Subtotal (95% CI) 202 206 100.0 % 0.06 [ 0.02, 0.11 ]
Total events: 19 (Vitamin D alone or in combination), 6 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0060)
3 Calcipotriol vs. calcitriol
Ortonne 2003 9/75 2/75 100.0 % 0.09 [ 0.01, 0.18 ]
Subtotal (95% CI) 75 75 100.0 % 0.09 [ 0.01, 0.18 ]
Total events: 9 (Vitamin D alone or in combination), 2 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcitriol vs. tacrolimus
Liao 2007 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 5.25, df = 4 (P = 0.26), I2 =24%
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Analysis 17.8. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Calcipotriol vs. BMV
Kreuter 2006 (H) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 8/202 4/206 100.0 % 0.02 [ -0.01, 0.05 ]
Subtotal (95% CI) 202 206 100.0 % 0.02 [ -0.01, 0.05 ]
Total events: 8 (Vitamin D alone or in combination), 4 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
3 Calcipotriol vs. calcitriol
Ortonne 2003 0/75 0/75 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 75 75 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 0/20 0/20 100.0 % 0.0 [ -0.09, 0.09 ]
Subtotal (95% CI) 20 20 100.0 % 0.0 [ -0.09, 0.09 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Calcitriol vs. tacrolimus
Liao 2007 0/25 0/25 100.0 % 0.0 [ -0.07, 0.07 ]
Subtotal (95% CI) 25 25 100.0 % 0.0 [ -0.07, 0.07 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.98, df = 4 (P = 0.91), I2 =0.0%
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Analysis 17.9. Comparison 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other
treatment, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 17 Flexural/facial psoriasis: vitamin D alone or in combination versus other treatment
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D alone
or in
combination Other treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 calcipotriol vs. BMV
Kreuter 2006 (H) 2/20 0/20 100.0 % 0.10 [ -0.05, 0.25 ]
Subtotal (95% CI) 20 20 100.0 % 0.10 [ -0.05, 0.25 ]
Total events: 2 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 Calcipotriol vs. calcipotriol + hydrocortisone
Ortonne 2010 52/200 22/204 100.0 % 0.15 [ 0.08, 0.23 ]
Subtotal (95% CI) 200 204 100.0 % 0.15 [ 0.08, 0.23 ]
Total events: 52 (Vitamin D alone or in combination), 22 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 4.02 (P = 0.000059)
3 Calcipotriol vs. calcitriol
Ortonne 2003 8/75 1/75 100.0 % 0.09 [ 0.02, 0.17 ]
Subtotal (95% CI) 75 75 100.0 % 0.09 [ 0.02, 0.17 ]
Total events: 8 (Vitamin D alone or in combination), 1 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
4 Calcipotriol vs. pimecrolimus
Kreuter 2006 (H) 2/20 5/20 100.0 % -0.15 [ -0.38, 0.08 ]
Subtotal (95% CI) 20 20 100.0 % -0.15 [ -0.38, 0.08 ]
Total events: 2 (Vitamin D alone or in combination), 5 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
5 Calcitriol vs. tacrolimus
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 6.32, df = 3 (P = 0.10), I2 =53%
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Analysis 18.1. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 1 IAGI
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D: calcipotriol
Green 1994 25 -2.52 (1.08) 24 -1.25 (1.22) 37.9 % -1.09 [ -1.69, -0.48 ]
Jemec 2008 (P) 272 1.85 (1.15) 136 2.41 (1.06) 62.1 % -0.50 [ -0.71, -0.29 ]
Subtotal (95% CI) 297 160 100.0 % -0.72 [ -1.28, -0.16 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 3.25, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Potent steroid: betamethasone dipropionate
Elie 1983 10 -1.8 (1) 10 -0.9 (1) 4.3 % -0.86 [ -1.79, 0.06 ]
Jemec 2008 (P) 556 1.23 (1.07) 136 2.41 (1.06) 95.7 % -1.10 [ -1.30, -0.91 ]
Subtotal (95% CI) 566 146 100.0 % -1.09 [ -1.29, -0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 11.15 (P < 0.00001)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Ellis 1988 65 -4.6 (1.29) 67 -2.8 (1.23) 100.0 % -1.42 [ -1.80, -1.04 ]
Subtotal (95% CI) 65 67 100.0 % -1.42 [ -1.80, -1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.27 (P < 0.00001)
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 0.707317 (0.928545) 41 40 2.6 (0.955416) 20.9 % -1.99 [ -2.53, -1.45 ]
Olsen 1991 188 -3.65 (1.24) 189 -1.7 (1.09) 79.1 % -1.67 [ -1.90, -1.43 ]
Subtotal (95% CI) 229 229 100.0 % -1.73 [ -1.99, -1.48 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.17, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 13.22 (P < 0.00001)
6 Very potent steroid: halcinonide
Lepaw 1978 27 -2.3 (0.95) 27 -1.3 (0.82) 100.0 % -1.11 [ -1.69, -0.53 ]
Subtotal (95% CI) 27 27 100.0 % -1.11 [ -1.69, -0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
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(. . . Continued)
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 541 1.09 (1.02) 136 2.41 (1.06) 52.5 % -1.28 [ -1.48, -1.08 ]
Tyring 2010 135 1.05 (1.15) 42 1.79 (1.28) 47.5 % -0.62 [ -0.98, -0.27 ]
Subtotal (95% CI) 676 178 100.0 % -0.97 [ -1.61, -0.32 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 10.15, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 2.95 (P = 0.0032)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Elie 1983 10 -2.45 (1) 10 -0.9 (1) 100.0 % -1.48 [ -2.50, -0.47 ]
Subtotal (95% CI) 10 10 100.0 % -1.48 [ -2.50, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
9 Other treatment: ciclopirox olamine shampoo
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Other treatment: fluocinolone acetonide, plus occlusion
Pauporte 2004 42 -4.38 (0.99) 42 -2.76 (1.57) 100.0 % -1.22 [ -1.69, -0.76 ]
Subtotal (95% CI) 42 42 100.0 % -1.22 [ -1.69, -0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.12 (P < 0.00001)
11 Other treatment: salicylic acid
Elie 1983 10 -1.8 (1) 10 -0.9 (1) 100.0 % -0.86 [ -1.79, 0.06 ]
Subtotal (95% CI) 10 10 100.0 % -0.86 [ -1.79, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 22.17, df = 8 (P = 0.00), I2 =64%
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Analysis 18.2. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 2 TSS
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D: calcipotriol
Green 1994 25 3.6 (2.7) 24 5.3 (2.5) 11.5 % -0.64 [ -1.22, -0.07 ]
Jemec 2008 (P) 272 3.4 (2.4) 136 4.4 (2.4) 88.5 % -0.42 [ -0.62, -0.21 ]
Subtotal (95% CI) 297 160 100.0 % -0.44 [ -0.64, -0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.43 (P < 0.00001)
2 Potent steroid: betamethasone dipropionate
Elie 1983 10 2.18 (2.27) 10 3.87 (2.27) 4.4 % -0.71 [ -1.62, 0.20 ]
Jemec 2008 (P) 556 2.2 (2.1) 136 4.4 (2.4) 95.6 % -1.02 [ -1.21, -0.82 ]
Subtotal (95% CI) 566 146 100.0 % -1.00 [ -1.19, -0.81 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 10.31 (P < 0.00001)
3 Potent steroid: betamethasone valerate
Franz 1999 115 2.78 (2.27) 57 5.97 (2.27) 100.0 % -1.40 [ -1.75, -1.05 ]
Subtotal (95% CI) 115 57 100.0 % -1.40 [ -1.75, -1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.81 (P < 0.00001)
4 Very potent steroid: amcinonide
Ellis 1988 59 -6.31 (2.27) 67 -2.7 (2.27) 100.0 % -1.58 [ -1.98, -1.18 ]
Subtotal (95% CI) 59 67 100.0 % -1.58 [ -1.98, -1.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.70 (P < 0.00001)
5 Very potent steroid: clobetasol propionate
Franz 2000 125 2.1 (2.27) 63 5.4 (2.27) 30.6 % -1.45 [ -1.78, -1.11 ]
Jarratt 2004 95 3.2 (1.74) 47 5.49 (1.74) 26.3 % -1.31 [ -1.69, -0.93 ]
Olsen 1991 188 2.4 (2.27) 189 6.3 (2.27) 43.1 % -1.71 [ -1.95, -1.48 ]
Subtotal (95% CI) 408 299 100.0 % -1.53 [ -1.77, -1.28 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.73, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 12.14 (P < 0.00001)
6 Very potent steroid: halcinonide
Subtotal (95% CI) 0 0 Not estimable
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(. . . Continued)
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 541 1.9 (2.1) 136 4.4 (2.4) 54.4 % -1.15 [ -1.35, -0.96 ]
Tyring 2010 135 2.1 (2.4) 42 3.7 (2.6) 45.6 % -0.65 [ -1.00, -0.30 ]
Subtotal (95% CI) 676 178 100.0 % -0.92 [ -1.42, -0.43 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 5.95, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 3.69 (P = 0.00023)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Elie 1983 10 1.15 (2.27) 10 3.87 (2.27) 100.0 % -1.15 [ -2.11, -0.19 ]
Subtotal (95% CI) 10 10 100.0 % -1.15 [ -2.11, -0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 28 4.25 (2.49) 9 4.44 (2.65) 100.0 % -0.07 [ -0.82, 0.68 ]
Subtotal (95% CI) 28 9 100.0 % -0.07 [ -0.82, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
10 Other treatment: fluocinolone acetonide, plus occlusion
Pauporte 2004 42 3 (1.71) 42 4.76 (2.18) 100.0 % -0.89 [ -1.34, -0.44 ]
Subtotal (95% CI) 42 42 100.0 % -0.89 [ -1.34, -0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.88 (P = 0.00010)
11 Other treatment: salicylic acid
Elie 1983 10 2.51 (2.27) 10 3.87 (2.27) 100.0 % -0.57 [ -1.47, 0.32 ]
Subtotal (95% CI) 10 10 100.0 % -0.57 [ -1.47, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Chi2 = 68.77, df = 9 (P = 0.00), I2 =87%
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Analysis 18.4. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 4 PAGI
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D: calcipotriol
Green 1994 25 -2.52 (0.96) 24 -1.42 (1.1) 40.0 % -1.05 [ -1.65, -0.45 ]
Jemec 2008 (P) 266 -3.52 (1.86) 135 -2.77 (1.8) 60.0 % -0.41 [ -0.62, -0.20 ]
Subtotal (95% CI) 291 159 100.0 % -0.66 [ -1.28, -0.05 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 3.93, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 2.11 (P = 0.035)
2 Potent steroid: betamethasone dipropionate
Jemec 2008 (P) 550 -4.59 (1.39) 135 -2.77 (1.8) 100.0 % -1.23 [ -1.43, -1.03 ]
Subtotal (95% CI) 550 135 100.0 % -1.23 [ -1.43, -1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 12.09 (P < 0.00001)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Ellis 1988 65 -2.2 (0.89) 67 -1.33 (0.89) 100.0 % -0.97 [ -1.33, -0.61 ]
Subtotal (95% CI) 65 67 100.0 % -0.97 [ -1.33, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.27 (P < 0.00001)
5 Very potent steroid: clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
6 Very potent steroid: halcinonide
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 529 -4.75 (1.31) 135 -2.77 (1.8) 51.7 % -1.39 [ -1.59, -1.19 ]
Tyring 2010 135 1.3 (0.99) 42 1.93 (1.26) 48.3 % -0.59 [ -0.94, -0.24 ]
Subtotal (95% CI) 664 177 100.0 % -1.00 [ -1.79, -0.22 ]
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Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.30; Chi2 = 14.81, df = 1 (P = 0.00012); I2 =93%
Test for overall effect: Z = 2.52 (P = 0.012)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 28 -2 (1) 9 -1.89 (0.93) 100.0 % -0.11 [ -0.86, 0.64 ]
Subtotal (95% CI) 28 9 100.0 % -0.11 [ -0.86, 0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.78)
10 Other treatment: fluocinolone acetonide, plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Other treatment: salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 10.67, df = 4 (P = 0.03), I2 =63%
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Analysis 18.5. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 5 Combined end point
(IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D: calcipotriol
Green 1994 25 -2.52 (1.08) 24 -1.25 (1.22) 37.9 % -1.09 [ -1.69, -0.48 ]
Jemec 2008 (P) 272 1.85 (1.15) 136 2.41 (1.06) 62.1 % -0.50 [ -0.71, -0.29 ]
Subtotal (95% CI) 297 160 100.0 % -0.72 [ -1.28, -0.16 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 3.25, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Potent steroid: betamethasone dipropionate
Elie 1983 10 -1.8 (1) 10 -0.9 (1) 4.3 % -0.86 [ -1.79, 0.06 ]
Jemec 2008 (P) 556 1.23 (1.07) 136 2.41 (1.06) 95.7 % -1.10 [ -1.30, -0.91 ]
Subtotal (95% CI) 566 146 100.0 % -1.09 [ -1.29, -0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 11.15 (P < 0.00001)
3 Potent steroid: betamethasone valerate
Franz 1999 115 2.78 (2.27) 57 5.97 (2.27) 100.0 % -1.40 [ -1.75, -1.05 ]
Subtotal (95% CI) 115 57 100.0 % -1.40 [ -1.75, -1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.81 (P < 0.00001)
4 Very potent steroid: amcinonide
Ellis 1988 65 -4.6 (1.29) 67 -2.8 (1.23) 100.0 % -1.42 [ -1.80, -1.04 ]
Subtotal (95% CI) 65 67 100.0 % -1.42 [ -1.80, -1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.27 (P < 0.00001)
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 0.707317 (0.928545) 41 40 2.6 (0.955416) 14.2 % -1.99 [ -2.53, -1.45 ]
Franz 2000 125 2.1 (2.27) 63 5.4 (2.27) 26.3 % -1.45 [ -1.78, -1.11 ]
Jarratt 2004 95 3.2 (1.74) 47 5.49 (1.74) 22.7 % -1.31 [ -1.69, -0.93 ]
Olsen 1991 188 -3.65 (1.24) 189 -1.7 (1.09) 36.7 % -1.67 [ -1.90, -1.43 ]
Subtotal (95% CI) 449 339 100.0 % -1.57 [ -1.81, -1.34 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.30, df = 3 (P = 0.15); I2 =43%
Test for overall effect: Z = 13.25 (P < 0.00001)
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Study or subgroup Active treatment Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
6 Very potent steroid: halcinonide
Lepaw 1978 27 -2.3 (0.95) 27 -1.3 (0.82) 100.0 % -1.11 [ -1.69, -0.53 ]
Subtotal (95% CI) 27 27 100.0 % -1.11 [ -1.69, -0.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.78 (P = 0.00016)
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 541 1.09 (1.02) 136 2.41 (1.06) 52.5 % -1.28 [ -1.48, -1.08 ]
Tyring 2010 135 1.05 (1.15) 42 1.79 (1.28) 47.5 % -0.62 [ -0.98, -0.27 ]
Subtotal (95% CI) 676 178 100.0 % -0.97 [ -1.61, -0.32 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 10.15, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 2.95 (P = 0.0032)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Elie 1983 10 -2.45 (1) 10 -0.9 (1) 100.0 % -1.48 [ -2.50, -0.47 ]
Subtotal (95% CI) 10 10 100.0 % -1.48 [ -2.50, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 28 4.25 (2.49) 9 4.44 (2.65) 100.0 % -0.07 [ -0.82, 0.68 ]
Subtotal (95% CI) 28 9 100.0 % -0.07 [ -0.82, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
10 Other treatment: fluocinolone acetonide, plus occlusion
Pauporte 2004 42 -4.38 (0.99) 42 -2.76 (1.57) 100.0 % -1.22 [ -1.69, -0.76 ]
Subtotal (95% CI) 42 42 100.0 % -1.22 [ -1.69, -0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.12 (P < 0.00001)
11 Other treatment: salicylic acid
Elie 1983 10 -1.8 (1) 10 -0.9 (1) 100.0 % -0.86 [ -1.79, 0.06 ]
Subtotal (95% CI) 10 10 100.0 % -0.86 [ -1.79, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.068)
Test for subgroup differences: Chi2 = 26.09, df = 10 (P = 0.00), I2 =62%
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Analysis 18.6. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 6 Total withdrawals
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D: calcipotriol
Green 1994 1/25 2/24 23.2 % -0.04 [ -0.18, 0.09 ]
Jemec 2008 (P) 57/272 30/136 58.5 % -0.01 [ -0.10, 0.07 ]
Kiss 1996 3/30 3/30 18.3 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 327 190 100.0 % -0.02 [ -0.08, 0.05 ]
Total events: 61 (Active treatment), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Potent steroid: betamethasone dipropionate
Jemec 2008 (P) 47/556 30/136 100.0 % -0.14 [ -0.21, -0.06 ]
Subtotal (95% CI) 556 136 100.0 % -0.14 [ -0.21, -0.06 ]
Total events: 47 (Active treatment), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.63 (P = 0.00028)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Ellis 1988 13/83 13/82 100.0 % 0.00 [ -0.11, 0.11 ]
Subtotal (95% CI) 83 82 100.0 % 0.00 [ -0.11, 0.11 ]
Total events: 13 (Active treatment), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 4/41 2/40 14.9 % 0.05 [ -0.07, 0.16 ]
Franz 2000 0/125 0/63 24.3 % 0.0 [ -0.02, 0.02 ]
Jarratt 2004 1/95 0/47 23.3 % 0.01 [ -0.03, 0.05 ]
Olsen 1991 5/189 22/189 22.0 % -0.09 [ -0.14, -0.04 ]
Poulin 2010 16/106 29/111 15.6 % -0.11 [ -0.22, 0.00 ]
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 556 450 100.0 % -0.03 [ -0.10, 0.04 ]
Total events: 26 (Active treatment), 53 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 36.71, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 0.79 (P = 0.43)
6 Very potent steroid: halcinonide
Lepaw 1978 2/29 2/29 100.0 % 0.0 [ -0.13, 0.13 ]
Subtotal (95% CI) 29 29 100.0 % 0.0 [ -0.13, 0.13 ]
Total events: 2 (Active treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 61/541 30/136 75.9 % -0.11 [ -0.18, -0.03 ]
Tyring 2010 19/135 8/42 24.1 % -0.05 [ -0.18, 0.08 ]
Subtotal (95% CI) 676 178 100.0 % -0.09 [ -0.16, -0.03 ]
Total events: 80 (Active treatment), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0047)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 1/29 2/11 100.0 % -0.15 [ -0.38, 0.09 ]
Subtotal (95% CI) 29 11 100.0 % -0.15 [ -0.38, 0.09 ]
Total events: 1 (Active treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
10 Other treatment: fluocinolone acetonide, plus occlusion
Pauporte 2004 1/43 3/46 100.0 % -0.04 [ -0.13, 0.04 ]
Subtotal (95% CI) 43 46 100.0 % -0.04 [ -0.13, 0.04 ]
Total events: 1 (Active treatment), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
11 Other treatment: salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 10.25, df = 7 (P = 0.17), I2 =32%
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Analysis 18.7. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 7 Withdrawals due to
adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 7 Withdrawals due to adverse events
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D: calcipotriol
Green 1994 1/25 0/24 11.7 % 0.04 [ -0.07, 0.15 ]
Jemec 2008 (P) 20/272 7/136 55.3 % 0.02 [ -0.03, 0.07 ]
Kiss 1996 0/30 0/30 32.9 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 327 190 100.0 % 0.02 [ -0.02, 0.05 ]
Total events: 21 (Active treatment), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Potent steroid: betamethasone dipropionate
Elie 1983 0/10 0/10 4.6 % 0.0 [ -0.17, 0.17 ]
Jemec 2008 (P) 6/556 7/136 95.4 % -0.04 [ -0.08, 0.00 ]
Subtotal (95% CI) 566 146 100.0 % -0.04 [ -0.08, 0.00 ]
Total events: 6 (Active treatment), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
3 Potent steroid: betamethasone valerate
Franz 1999 0/115 0/57 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 115 57 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Very potent steroid: amcinonide
Ellis 1988 1/83 0/82 100.0 % 0.01 [ -0.02, 0.04 ]
Subtotal (95% CI) 83 82 100.0 % 0.01 [ -0.02, 0.04 ]
Total events: 1 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 0/41 1/40 2.8 % -0.03 [ -0.09, 0.04 ]
Franz 2000 0/125 0/63 20.9 % 0.0 [ -0.02, 0.02 ]
Jarratt 2004 0/95 0/47 11.9 % 0.0 [ -0.03, 0.03 ]
Olsen 1991 0/189 1/189 57.9 % -0.01 [ -0.02, 0.01 ]
Poulin 2010 2/106 4/111 6.5 % -0.02 [ -0.06, 0.03 ]
Subtotal (95% CI) 556 450 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 2 (Active treatment), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.22, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.39)
6 Very potent steroid: halcinonide
Lepaw 1978 0/29 0/29 100.0 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 29 29 100.0 % 0.0 [ -0.06, 0.06 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 8/541 7/136 100.0 % -0.04 [ -0.08, 0.00 ]
Subtotal (95% CI) 541 136 100.0 % -0.04 [ -0.08, 0.00 ]
Total events: 8 (Active treatment), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Elie 1983 0/10 0/10 100.0 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 10 10 100.0 % 0.0 [ -0.17, 0.17 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 0/29 2/11 100.0 % -0.18 [ -0.42, 0.05 ]
Subtotal (95% CI) 29 11 100.0 % -0.18 [ -0.42, 0.05 ]
Total events: 0 (Active treatment), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
10 Other treatment: fluocinolone acetonide, plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
11 Other treatment: salicylic acid
Elie 1983 0/10 0/10 100.0 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 10 10 100.0 % 0.0 [ -0.17, 0.17 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 10.57, df = 9 (P = 0.31), I2 =15%
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Analysis 18.8. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 8 Withdrawals due to
treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D: calcipotriol
Green 1994 0/25 2/24 18.8 % -0.08 [ -0.21, 0.05 ]
Jemec 2008 (P) 19/272 16/136 81.2 % -0.05 [ -0.11, 0.01 ]
Subtotal (95% CI) 297 160 100.0 % -0.05 [ -0.11, 0.00 ]
Total events: 19 (Active treatment), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
2 Potent steroid: betamethasone dipropionate
Jemec 2008 (P) 9/556 16/136 100.0 % -0.10 [ -0.16, -0.05 ]
Subtotal (95% CI) 556 136 100.0 % -0.10 [ -0.16, -0.05 ]
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 9 (Active treatment), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.00031)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Ellis 1988 0/83 1/82 100.0 % -0.01 [ -0.05, 0.02 ]
Subtotal (95% CI) 83 82 100.0 % -0.01 [ -0.05, 0.02 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 0/41 0/40 17.3 % 0.0 [ -0.05, 0.05 ]
Franz 2000 0/125 0/63 22.2 % 0.0 [ -0.02, 0.02 ]
Jarratt 2004 0/95 0/47 20.6 % 0.0 [ -0.03, 0.03 ]
Olsen 1991 2/189 17/189 18.1 % -0.08 [ -0.12, -0.04 ]
Poulin 2010 1/106 0/111 21.9 % 0.01 [ -0.02, 0.03 ]
Subtotal (95% CI) 556 450 100.0 % -0.01 [ -0.05, 0.02 ]
Total events: 3 (Active treatment), 17 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 23.90, df = 4 (P = 0.00008); I2 =83%
Test for overall effect: Z = 0.68 (P = 0.50)
6 Very potent steroid: halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 2/541 16/136 100.0 % -0.11 [ -0.17, -0.06 ]
Subtotal (95% CI) 541 136 100.0 % -0.11 [ -0.17, -0.06 ]
Total events: 2 (Active treatment), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.11 (P = 0.000040)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
-0.5 -0.25 0 0.25 0.5
Favours active treatment Favours placebo
(Continued . . . )
688Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 0/29 1/11 100.0 % -0.09 [ -0.28, 0.10 ]
Subtotal (95% CI) 29 11 100.0 % -0.09 [ -0.28, 0.10 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
10 Other treatment: fluocinolone acetonide, plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Other treatment: salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 17.45, df = 5 (P = 0.00), I2 =71%
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Analysis 18.9. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 9 Adverse events (local)
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D: calcipotriol
Green 1994 5/25 7/24 3.7 % -0.09 [ -0.33, 0.15 ]
Jemec 2008 (P) 35/266 18/135 42.7 % 0.00 [ -0.07, 0.07 ]
Kiss 1996 0/30 0/30 53.6 % 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 321 189 100.0 % 0.00 [ -0.05, 0.04 ]
Total events: 40 (Active treatment), 25 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Potent steroid: betamethasone dipropionate
Elie 1983 0/10 0/10 10.7 % 0.0 [ -0.17, 0.17 ]
Jemec 2008 (P) 29/548 18/135 89.3 % -0.08 [ -0.14, -0.02 ]
Subtotal (95% CI) 558 145 100.0 % -0.07 [ -0.13, -0.01 ]
Total events: 29 (Active treatment), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.47 (P = 0.014)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Very potent steroid: clobetasol propionate
Cook-Bolden 2010 2/41 1/40 19.6 % 0.02 [ -0.06, 0.11 ]
Jarratt 2004 13/94 10/47 7.1 % -0.07 [ -0.21, 0.06 ]
Olsen 1991 21/189 18/189 34.8 % 0.02 [ -0.05, 0.08 ]
Poulin 2010 5/106 6/111 38.5 % -0.01 [ -0.07, 0.05 ]
Subtotal (95% CI) 430 387 100.0 % 0.00 [ -0.03, 0.04 ]
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 41 (Active treatment), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.87, df = 3 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
6 Very potent steroid: halcinonide
Lepaw 1978 0/29 1/29 100.0 % -0.03 [ -0.12, 0.06 ]
Subtotal (95% CI) 29 29 100.0 % -0.03 [ -0.12, 0.06 ]
Total events: 0 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 25/530 18/135 62.1 % -0.09 [ -0.15, -0.03 ]
Tyring 2010 9/128 3/38 37.9 % -0.01 [ -0.11, 0.09 ]
Subtotal (95% CI) 658 173 100.0 % -0.06 [ -0.13, 0.02 ]
Total events: 34 (Active treatment), 21 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.49 (P = 0.14)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Elie 1983 0/10 0/10 100.0 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 10 10 100.0 % 0.0 [ -0.17, 0.17 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
9 Other treatment: ciclopirox olamine shampoo
Shuttleworth 1998 1/29 1/11 100.0 % -0.06 [ -0.24, 0.13 ]
Subtotal (95% CI) 29 11 100.0 % -0.06 [ -0.24, 0.13 ]
Total events: 1 (Active treatment), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
10 Other treatment: fluocinolone acetonide, plus occlusion
Pauporte 2004 1/43 0/46 100.0 % 0.02 [ -0.04, 0.08 ]
Subtotal (95% CI) 43 46 100.0 % 0.02 [ -0.04, 0.08 ]
Total events: 1 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
11 Other treatment: salicylic acid
Elie 1983 0/10 0/10 100.0 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 10 10 100.0 % 0.0 [ -0.17, 0.17 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 8.05, df = 8 (P = 0.43), I2 =1%
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Analysis 18.10. Comparison 18 Scalp psoriasis: placebo-controlled trials, Outcome 10 Adverse events
(systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 18 Scalp psoriasis: placebo-controlled trials
Outcome: 10 Adverse events (systemic)
Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D: calcipotriol
Jemec 2008 (P) 0/272 0/136 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 272 136 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Potent steroid: betamethasone dipropionate
Jemec 2008 (P) 0/556 0/136 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 556 136 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Potent steroid: betamethasone valerate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: not applicable
4 Very potent steroid: amcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
5 Very potent steroid: clobetasol propionate
Olsen 1991 4/83 4/85 13.0 % 0.00 [ -0.06, 0.07 ]
Poulin 2010 0/106 1/111 87.0 % -0.01 [ -0.03, 0.02 ]
Subtotal (95% CI) 189 196 100.0 % -0.01 [ -0.03, 0.02 ]
Total events: 4 (Active treatment), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
6 Very potent steroid: halcinonide
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
7 Vitamin D in combination: calcipotriol + BMD
Jemec 2008 (P) 0/541 0/136 92.6 % 0.0 [ -0.01, 0.01 ]
Tyring 2010 0/128 0/38 7.4 % 0.0 [ -0.04, 0.04 ]
Subtotal (95% CI) 669 174 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
8 Other treatment: betamethasone-17,21-dipropionate plus salicylic acid
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
9 Other treatment: ciclopirox olamine shampoo
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
10 Other treatment: fluocinolone acetonide, plus occlusion
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
11 Other treatment: salicylic acid
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Study or subgroup Active treatment Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Active treatment), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 0.39, df = 3 (P = 0.94), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
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Analysis 19.1. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 1 IAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 1 IAGI
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 272 1.85 (1.15) 556 1.23 (1.07) 49.5 % 0.56 [ 0.42, 0.71 ]
Van de Kerkhof 2009 286 1.73 (1.1) 562 1.3 (1.07) 50.5 % 0.40 [ 0.25, 0.54 ]
Subtotal (95% CI) 558 1118 100.0 % 0.48 [ 0.32, 0.64 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.53, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 5.75 (P < 0.00001)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 24 -2.63 (0.88) 18 -2.83 (0.92) 8.2 % 0.22 [ -0.39, 0.83 ]
Klaber 1994 236 -2.51 (1.14) 232 -2.93 (1.02) 91.8 % 0.39 [ 0.20, 0.57 ]
Subtotal (95% CI) 260 250 100.0 % 0.37 [ 0.20, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000029)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 108 0.79 (0.91) 110 1.05 (1.04) 8.9 % -0.26 [ -0.53, 0.00 ]
Jemec 2008 (H) 541 1.09 (1.02) 556 1.23 (1.07) 45.0 % -0.13 [ -0.25, -0.02 ]
Van de Kerkhof 2009 567 1.08 (1) 562 1.3 (1.07) 46.1 % -0.21 [ -0.33, -0.10 ]
Subtotal (95% CI) 1216 1228 100.0 % -0.18 [ -0.26, -0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 272 1.85 (1.15) 541 1.09 (1.02) 26.4 % 0.71 [ 0.56, 0.86 ]
Kragballe 2009 105 2.2 (1.26) 207 1.17 (1.05) 21.2 % 0.91 [ 0.67, 1.16 ]
Luger 2008 265 1.68 (1.12) 338 1.3 (1.01) 25.8 % 0.36 [ 0.20, 0.52 ]
Van de Kerkhof 2009 286 1.73 (1.1) 567 1.08 (1) 26.6 % 0.63 [ 0.48, 0.77 ]
Subtotal (95% CI) 928 1653 100.0 % 0.64 [ 0.44, 0.84 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 16.99, df = 3 (P = 0.00071); I2 =82%
Test for overall effect: Z = 6.23 (P < 0.00001)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Barrett 2005 161 -3.48 (1.11) 170 -3.49 (1.17) 49.6 % 0.01 [ -0.21, 0.22 ]
Klaber 2000b 208 -2.77 (1.28) 209 -2.07 (1.56) 50.4 % -0.49 [ -0.68, -0.29 ]
Subtotal (95% CI) 369 379 100.0 % -0.24 [ -0.73, 0.25 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 11.30, df = 1 (P = 0.00078); I2 =91%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 106.49, df = 4 (P = 0.00), I2 =96%
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Analysis 19.2. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 2 TSS.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 2 TSS
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 272 3.4 (2.4) 556 2.2 (2.1) 49.5 % 0.54 [ 0.40, 0.69 ]
Van de Kerkhof 2009 286 2.95 (2.1) 562 2.21 (2) 50.5 % 0.36 [ 0.22, 0.51 ]
Subtotal (95% CI) 558 1118 100.0 % 0.45 [ 0.28, 0.63 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.97, df = 1 (P = 0.08); I2 =66%
Test for overall effect: Z = 5.01 (P < 0.00001)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 24 2.1 (2.53) 18 1.49 (2.53) 8.4 % 0.24 [ -0.38, 0.85 ]
Klaber 1994 220 3.29 (5.3) 225 2.93 (4.35) 91.6 % 0.07 [ -0.11, 0.26 ]
Subtotal (95% CI) 244 243 100.0 % 0.09 [ -0.09, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Reygagne 2005 75 2.36 (1.64) 76 1.76 (1.57) 100.0 % 0.37 [ 0.05, 0.69 ]
Subtotal (95% CI) 75 76 100.0 % 0.37 [ 0.05, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.024)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 108 -5.31 (2.47) 110 -4.77 (2.54) 8.9 % -0.21 [ -0.48, 0.05 ]
Jemec 2008 (H) 541 1.9 (2.1) 556 2.2 (2.1) 45.0 % -0.14 [ -0.26, -0.02 ]
Van de Kerkhof 2009 567 1.74 (1.9) 562 2.21 (2) 46.1 % -0.24 [ -0.36, -0.12 ]
Subtotal (95% CI) 1216 1228 100.0 % -0.19 [ -0.27, -0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 4.79 (P < 0.00001)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 272 3.4 (2.4) 541 1.9 (2.1) 38.4 % 0.68 [ 0.53, 0.83 ]
Kragballe 2009 105 4.4 (2.7) 207 2.3 (2.1) 22.2 % 0.90 [ 0.66, 1.15 ]
Van de Kerkhof 2009 286 2.95 (2.1) 567 1.74 (1.9) 39.4 % 0.61 [ 0.47, 0.76 ]
Subtotal (95% CI) 663 1315 100.0 % 0.70 [ 0.56, 0.84 ]
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 3.97, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 9.78 (P < 0.00001)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Barrett 2005 207 -2.8 (2.3) 211 -3.3 (2) 35.2 % 0.23 [ 0.04, 0.42 ]
Klaber 2000b 210 3.1 (2) 210 3.7 (2.2) 35.2 % -0.28 [ -0.48, -0.09 ]
Van de Kerkhof 2002a 41 -0.48 (0.24) 46 -0.17 (0.38) 29.5 % -0.95 [ -1.40, -0.51 ]
Subtotal (95% CI) 458 467 100.0 % -0.30 [ -0.84, 0.24 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 29.12, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 143.01, df = 5 (P = 0.00), I2 =97%
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Analysis 19.4. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 4 PAGI.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 4 PAGI
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 266 -3.52 (1.86) 550 -4.59 (1.39) 49.7 % 0.69 [ 0.54, 0.84 ]
Van de Kerkhof 2009 282 -3.92 (1.54) 556 -4.54 (1.39) 50.3 % 0.43 [ 0.28, 0.57 ]
Subtotal (95% CI) 548 1106 100.0 % 0.56 [ 0.31, 0.81 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 5.80, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 4.35 (P = 0.000014)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Klaber 1994 236 -2.44 (1.07) 232 -2.85 (0.94) 100.0 % 0.41 [ 0.22, 0.59 ]
Subtotal (95% CI) 236 232 100.0 % 0.41 [ 0.22, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.35 (P = 0.000014)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 107 -4.99 (1.09) 109 -4.66 (1.28) 8.9 % -0.28 [ -0.54, -0.01 ]
Jemec 2008 (H) 529 -4.75 (1.31) 550 -4.59 (1.39) 44.8 % -0.12 [ -0.24, 0.00 ]
Van de Kerkhof 2009 563 -4.79 (1.23) 556 -4.54 (1.39) 46.3 % -0.19 [ -0.31, -0.07 ]
Subtotal (95% CI) 1199 1215 100.0 % -0.17 [ -0.25, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 2 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.06 (P = 0.000048)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 266 -3.52 (1.86) 529 -4.75 (1.31) 35.6 % 0.81 [ 0.66, 0.96 ]
Kragballe 2009 105 2.01 (1.14) 207 0.89 (0.9) 28.4 % 1.13 [ 0.88, 1.38 ]
Van de Kerkhof 2009 282 -3.92 (1.54) 563 -4.79 (1.23) 36.0 % 0.65 [ 0.50, 0.79 ]
Subtotal (95% CI) 653 1299 100.0 % 0.84 [ 0.61, 1.08 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 10.80, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 6.96 (P < 0.00001)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 100.98, df = 3 (P = 0.00), I2 =97%
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Analysis 19.5. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 5 Combined end point (IAGI/TSS/PASI/PAGI).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 5 Combined end point (IAGI/TSS/PASI/PAGI)
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 272 1.85 (1.15) 556 1.23 (1.07) 49.5 % 0.56 [ 0.42, 0.71 ]
Van de Kerkhof 2009 286 1.73 (1.1) 562 1.3 (1.07) 50.5 % 0.40 [ 0.25, 0.54 ]
Subtotal (95% CI) 558 1118 100.0 % 0.48 [ 0.32, 0.64 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.53, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 5.75 (P < 0.00001)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 24 -2.63 (0.88) 18 -2.83 (0.92) 8.2 % 0.22 [ -0.39, 0.83 ]
Klaber 1994 236 -2.51 (1.14) 232 -2.93 (1.02) 91.8 % 0.39 [ 0.20, 0.57 ]
Subtotal (95% CI) 260 250 100.0 % 0.37 [ 0.20, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.18 (P = 0.000029)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Reygagne 2005 75 2.36 (1.64) 76 1.76 (1.57) 100.0 % 0.37 [ 0.05, 0.69 ]
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 75 76 100.0 % 0.37 [ 0.05, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.024)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 108 0.79 (0.91) 110 1.05 (1.04) 8.9 % -0.26 [ -0.53, 0.00 ]
Jemec 2008 (H) 541 1.09 (1.02) 556 1.23 (1.07) 45.0 % -0.13 [ -0.25, -0.02 ]
Van de Kerkhof 2009 567 1.08 (1) 562 1.3 (1.07) 46.1 % -0.21 [ -0.33, -0.10 ]
Subtotal (95% CI) 1216 1228 100.0 % -0.18 [ -0.26, -0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 272 1.85 (1.15) 541 1.09 (1.02) 26.4 % 0.71 [ 0.56, 0.86 ]
Kragballe 2009 105 2.2 (1.26) 207 1.17 (1.05) 21.2 % 0.91 [ 0.67, 1.16 ]
Luger 2008 265 1.68 (1.12) 338 1.3 (1.01) 25.8 % 0.36 [ 0.20, 0.52 ]
Van de Kerkhof 2009 286 1.73 (1.1) 567 1.08 (1) 26.6 % 0.63 [ 0.48, 0.77 ]
Subtotal (95% CI) 928 1653 100.0 % 0.64 [ 0.44, 0.84 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 16.99, df = 3 (P = 0.00071); I2 =82%
Test for overall effect: Z = 6.23 (P < 0.00001)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Barrett 2005 161 -3.48 (1.11) 170 -3.49 (1.17) 35.5 % 0.01 [ -0.21, 0.22 ]
Klaber 2000b 208 -2.77 (1.28) 209 -2.07 (1.56) 36.0 % -0.49 [ -0.68, -0.29 ]
Van de Kerkhof 2002a 41 -0.48 (0.24) 46 -0.17 (0.38) 28.5 % -0.95 [ -1.40, -0.51 ]
Subtotal (95% CI) 410 425 100.0 % -0.45 [ -0.92, 0.02 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 19.63, df = 2 (P = 0.00005); I2 =90%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Chi2 = 112.96, df = 5 (P = 0.00), I2 =96%
-4 -2 0 2 4
Favours vitamin D alone or in combination Favours other active treatment
700Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 19.6. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 6 Total withdrawals.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 6 Total withdrawals
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 57/272 47/556 49.3 % 0.13 [ 0.07, 0.18 ]
Van de Kerkhof 2009 38/286 66/562 50.7 % 0.02 [ -0.03, 0.06 ]
Subtotal (95% CI) 558 1118 100.0 % 0.07 [ -0.04, 0.18 ]
Total events: 95 (Vitamin D alone or in combination), 113 (Other active treatment)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.09, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 0/24 0/18 18.3 % 0.0 [ -0.09, 0.09 ]
Klaber 1994 20/240 9/234 81.7 % 0.04 [ 0.00, 0.09 ]
Subtotal (95% CI) 264 252 100.0 % 0.04 [ 0.00, 0.08 ]
Total events: 20 (Vitamin D alone or in combination), 9 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Ko¨se 1997 0/21 0/22 50.7 % 0.0 [ -0.09, 0.09 ]
Reygagne 2005 11/75 3/76 49.3 % 0.11 [ 0.02, 0.20 ]
Subtotal (95% CI) 96 98 100.0 % 0.05 [ -0.07, 0.18 ]
Total events: 11 (Vitamin D alone or in combination), 3 (Other active treatment)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.86, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.84 (P = 0.40)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 14/108 9/110 21.2 % 0.05 [ -0.03, 0.13 ]
Jemec 2008 (H) 61/541 47/556 39.4 % 0.03 [ -0.01, 0.06 ]
Van de Kerkhof 2009 48/567 66/562 39.4 % -0.03 [ -0.07, 0.00 ]
Subtotal (95% CI) 1216 1228 100.0 % 0.01 [ -0.04, 0.06 ]
Total events: 123 (Vitamin D alone or in combination), 122 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 7.10, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 0.33 (P = 0.74)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jemec 2008 (H) 57/272 61/541 26.3 % 0.10 [ 0.04, 0.15 ]
Kragballe 2009 23/105 17/207 20.3 % 0.14 [ 0.05, 0.22 ]
Luger 2008 175/440 92/429 25.4 % 0.18 [ 0.12, 0.24 ]
Van de Kerkhof 2009 38/286 48/567 28.0 % 0.05 [ 0.00, 0.09 ]
Subtotal (95% CI) 1103 1744 100.0 % 0.11 [ 0.05, 0.18 ]
Total events: 293 (Vitamin D alone or in combination), 218 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 13.97, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 3.45 (P = 0.00056)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Klaber 2000b 72/238 69/237 100.0 % 0.01 [ -0.07, 0.09 ]
Subtotal (95% CI) 238 237 100.0 % 0.01 [ -0.07, 0.09 ]
Total events: 72 (Vitamin D alone or in combination), 69 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi2 = 7.36, df = 5 (P = 0.20), I2 =32%
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Analysis 19.7. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 7 Withdrawals due to adverse events.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 7 Withdrawals due to adverse events
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 20/272 6/556 47.1 % 0.06 [ 0.03, 0.09 ]
Van de Kerkhof 2009 8/286 7/562 52.9 % 0.02 [ -0.01, 0.04 ]
Subtotal (95% CI) 558 1118 100.0 % 0.04 [ -0.01, 0.09 ]
Total events: 28 (Vitamin D alone or in combination), 13 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.74, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 0/24 0/18 9.3 % 0.0 [ -0.09, 0.09 ]
Klaber 1994 11/240 2/234 90.7 % 0.04 [ 0.01, 0.07 ]
Subtotal (95% CI) 264 252 100.0 % 0.03 [ 0.01, 0.06 ]
Total events: 11 (Vitamin D alone or in combination), 2 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.016)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Ko¨se 1997 0/21 0/22 46.5 % 0.0 [ -0.09, 0.09 ]
Reygagne 2005 7/75 0/76 53.5 % 0.09 [ 0.02, 0.16 ]
Subtotal (95% CI) 96 98 100.0 % 0.05 [ -0.05, 0.15 ]
Total events: 7 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.07, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.01 (P = 0.31)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 1/108 2/110 7.4 % -0.01 [ -0.04, 0.02 ]
Jemec 2008 (H) 8/541 6/556 39.5 % 0.00 [ -0.01, 0.02 ]
Van de Kerkhof 2009 4/567 7/562 53.2 % -0.01 [ -0.02, 0.01 ]
Subtotal (95% CI) 1216 1228 100.0 % 0.00 [ -0.01, 0.01 ]
Total events: 13 (Vitamin D alone or in combination), 15 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jemec 2008 (H) 20/272 8/541 25.7 % 0.06 [ 0.03, 0.09 ]
Kragballe 2009 9/105 2/207 18.2 % 0.08 [ 0.02, 0.13 ]
Luger 2008 44/440 9/429 26.3 % 0.08 [ 0.05, 0.11 ]
Van de Kerkhof 2009 8/286 4/567 29.8 % 0.02 [ 0.00, 0.04 ]
Subtotal (95% CI) 1103 1744 100.0 % 0.06 [ 0.02, 0.09 ]
Total events: 81 (Vitamin D alone or in combination), 23 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 14.23, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 3.13 (P = 0.0017)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Klaber 2000b 35/230 16/215 100.0 % 0.08 [ 0.02, 0.14 ]
Subtotal (95% CI) 230 215 100.0 % 0.08 [ 0.02, 0.14 ]
Total events: 35 (Vitamin D alone or in combination), 16 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 2.62 (P = 0.0088)
Test for subgroup differences: Chi2 = 23.39, df = 5 (P = 0.00), I2 =79%
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Analysis 19.8. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 8 Withdrawals due to treatment failure.
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 8 Withdrawals due to treatment failure
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 19/272 9/556 46.4 % 0.05 [ 0.02, 0.09 ]
Van de Kerkhof 2009 8/286 9/562 53.6 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 558 1118 100.0 % 0.03 [ -0.01, 0.07 ]
Total events: 27 (Vitamin D alone or in combination), 18 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.09, df = 1 (P = 0.02); I2 =80%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 0/24 0/18 4.7 % 0.0 [ -0.09, 0.09 ]
Klaber 1994 4/240 2/234 95.3 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 264 252 100.0 % 0.01 [ -0.01, 0.03 ]
Total events: 4 (Vitamin D alone or in combination), 2 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Ko¨se 1997 0/21 0/22 14.9 % 0.0 [ -0.09, 0.09 ]
Reygagne 2005 1/75 0/76 85.1 % 0.01 [ -0.02, 0.05 ]
Subtotal (95% CI) 96 98 100.0 % 0.01 [ -0.02, 0.04 ]
Total events: 1 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 0/108 2/110 7.9 % -0.02 [ -0.05, 0.01 ]
Jemec 2008 (H) 2/541 9/556 53.7 % -0.01 [ -0.02, 0.00 ]
Van de Kerkhof 2009 7/567 9/562 38.4 % 0.00 [ -0.02, 0.01 ]
Subtotal (95% CI) 1216 1228 100.0 % -0.01 [ -0.02, 0.00 ]
Total events: 9 (Vitamin D alone or in combination), 20 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Jemec 2008 (H) 19/272 2/541 32.8 % 0.07 [ 0.04, 0.10 ]
Luger 2008 51/440 14/429 31.8 % 0.08 [ 0.05, 0.12 ]
Van de Kerkhof 2009 8/286 7/567 35.4 % 0.02 [ -0.01, 0.04 ]
Subtotal (95% CI) 998 1537 100.0 % 0.05 [ 0.01, 0.10 ]
Total events: 78 (Vitamin D alone or in combination), 23 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 16.89, df = 2 (P = 0.00021); I2 =88%
Test for overall effect: Z = 2.21 (P = 0.027)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Chi2 = 11.94, df = 4 (P = 0.02), I2 =66%
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Analysis 19.9. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 9 Adverse events (local).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 9 Adverse events (local)
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 35/266 29/548 48.6 % 0.08 [ 0.03, 0.12 ]
Van de Kerkhof 2009 36/282 32/556 51.4 % 0.07 [ 0.03, 0.11 ]
Subtotal (95% CI) 548 1104 100.0 % 0.07 [ 0.04, 0.11 ]
Total events: 71 (Vitamin D alone or in combination), 61 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Duweb 2000 2/24 0/18 43.3 % 0.08 [ -0.05, 0.22 ]
Klaber 1994 84/240 26/234 56.7 % 0.24 [ 0.17, 0.31 ]
Subtotal (95% CI) 264 252 100.0 % 0.17 [ 0.01, 0.33 ]
Total events: 86 (Vitamin D alone or in combination), 26 (Other active treatment)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.25, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 2.11 (P = 0.035)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Ko¨se 1997 4/21 2/22 18.4 % 0.10 [ -0.11, 0.31 ]
Reygagne 2005 17/75 1/76 81.6 % 0.21 [ 0.12, 0.31 ]
Subtotal (95% CI) 96 98 100.0 % 0.19 [ 0.10, 0.28 ]
Total events: 21 (Vitamin D alone or in combination), 3 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 4.26 (P = 0.000021)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Buckley 2008 1/108 2/110 27.5 % -0.01 [ -0.04, 0.02 ]
Jemec 2008 (H) 25/530 29/548 38.6 % -0.01 [ -0.03, 0.02 ]
Van de Kerkhof 2009 35/563 32/556 33.8 % 0.00 [ -0.02, 0.03 ]
Subtotal (95% CI) 1201 1214 100.0 % 0.00 [ -0.02, 0.01 ]
Total events: 61 (Vitamin D alone or in combination), 63 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 35/266 25/530 30.4 % 0.08 [ 0.04, 0.13 ]
Kragballe 2009 20/104 7/206 12.4 % 0.16 [ 0.08, 0.24 ]
Luger 2008 93/431 50/419 26.1 % 0.10 [ 0.05, 0.15 ]
Van de Kerkhof 2009 36/282 35/563 31.1 % 0.07 [ 0.02, 0.11 ]
Subtotal (95% CI) 1083 1718 100.0 % 0.09 [ 0.06, 0.12 ]
Total events: 184 (Vitamin D alone or in combination), 117 (Other active treatment)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.17, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 5.89 (P < 0.00001)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Klaber 2000b 137/230 77/215 100.0 % 0.24 [ 0.15, 0.33 ]
Subtotal (95% CI) 230 215 100.0 % 0.24 [ 0.15, 0.33 ]
Total events: 137 (Vitamin D alone or in combination), 77 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 5.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 74.84, df = 5 (P = 0.00), I2 =93%
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Analysis 19.10. Comparison 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments,
Outcome 10 Adverse events (systemic).
Review: Topical treatments for chronic plaque psoriasis
Comparison: 19 Scalp psoriasis: vitamin D alone or in combination versus other treatments
Outcome: 10 Adverse events (systemic)
Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMD
Jemec 2008 (H) 0/272 0/556 48.6 % 0.0 [ -0.01, 0.01 ]
Van de Kerkhof 2009 0/282 0/556 51.4 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 554 1112 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Vitamin D vs. corticosteroid (potent): calcipotriol vs. BMV
Klaber 1994 0/240 0/234 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 240 234 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Vitamin D vs. corticosteroid (very potent): calcipotriol vs. clobetasol propionate
Reygagne 2005 0/75 0/76 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 75 76 100.0 % 0.0 [ -0.03, 0.03 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Vitamin D + corticosteroid vs. corticosteroid: calcipotriol + BMD vs. BMD
Jemec 2008 (H) 0/541 0/556 49.0 % 0.0 [ 0.00, 0.00 ]
Van de Kerkhof 2009 0/563 0/556 51.0 % 0.0 [ 0.00, 0.00 ]
Subtotal (95% CI) 1104 1112 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
5 Vitamin D vs. vitamin D + corticosteroid: calcipotriol vs. calcipotriol + BMD
Jemec 2008 (H) 0/272 0/541 44.9 % 0.0 [ -0.01, 0.01 ]
Kragballe 2009 0/105 0/207 6.8 % 0.0 [ -0.01, 0.01 ]
Van de Kerkhof 2009 0/282 0/563 48.3 % 0.0 [ -0.01, 0.01 ]
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Study or subgroup
Vitamin D alone
or in
combination
Other
active
treatment
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 659 1311 100.0 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
6 Vitamin D vs. other treatments: calcipotriol vs. coal tar polytherapy
Klaber 2000b 0/230 0/215 100.0 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 230 215 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (Vitamin D alone or in combination), 0 (Other active treatment)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.0, df = 5 (P = 1.00), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours vitamin D alone or in combination Favours other active treatment
A D D I T I O N A L T A B L E S
Table 1. List of acronyms
Acronym Full name
BC baseline comparability demonstrated (clinical/demographic)
BD twice daily
BMD betamethasone dipropionate
BMV betamethasone valerate
BSA Body Surface Area
Btw-patient Between-patient
CI confidence interval
dys days
EQ-5D EuroQOL
FU follow up (includes treatment period)
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Table 1. List of acronyms (Continued)
I² heterogeneity statistic
IAGI Investigator Assessment of Global Improvement (change score)
IGA Investigator Global Assessment (static score)
IQR interquartile range
ISGA Investigator’s Static Global Assessment Score
LAE local adverse effects
LCD liquor carbonis distillate
LF loss to follow up (per cent of participants randomised, not contributing to primary outcome measure)
MEMS Medication Event Monitoring System
mPASI modified Psoriasis Area Severity Index
NA not available/not applicable
NR not reported
OD once daily
OM once in the morning
ON once at night
ODS overall disease severity
PAGI Patient Assessment of Global Improvement (change score)
PASI Psoriasis Area Severity Index
PDI Psoriasis Disability Index
PGA Patient Global Assessment (static score)
PMAQ-3w Medication Adherence Questionnaire, version 3W
pt point
QOL quality of life
RD risk difference
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Table 1. List of acronyms (Continued)
SD standard deviation
SMD standardised mean difference
TCP two-compound product
TD three times daily
TLPSS Total Local Psoriasis Severity Score
TSS Total Severity Score/total sum score
UV ultra violet
VDRE Vitamin D-Responsive Element
wks weeks
yrs years
Table 2. Overview of outcome measures on effectiveness
Outcome Acronym Construct Scale, minimum Scale, maximum Notes
* Investigator’s As-
sessment of Over-
all Global Improve-
ment
IAGI Improvement
from baseline variably
defined.Common tax-
onomy ranges from
worse to cleared
4-pt 7-pt Calculated means and
standard deviations by
assigning zero to
’worse’ (or equivalent).
Higher scores indicate
greater improvement
Inves-
tigator’s Global As-
sessment of Disease
Severity
IGA Static equivalent of the
IAGI
4-pt 7-pt Calculated means and
standard deviations by
assigning zero to ’clear’
(or equivalent).
Higher scores indicate
more severe disease
Total Severity Score TSS Redness (ery-
thema), thickness (in-
filtration) and scaling
(sometimes also itch-
ing (pruritis)) of target
plaque(s). Scored sep-
arately then summed
0 to 3 0 to 24 Also known as the Lo-
cal Psoriasis Severity
Index or the Total Sum
Score. Higher scores
indicate more severe
disease
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Table 2. Overview of outcome measures on effectiveness (Continued)
Psoriasis Area and
Severity Index
PASI Redness, thickness,
and scaliness of the le-
sions (each graded on a
0 to 4 scale), weighted
by the area of involve-
ment (0 to 6) and
summed
0 to 68 (without head) 0 to 72 (including
head)
Higher scores indicate
more severe disease
* Patient’s
Assessment of Over-
all Global Improve-
ment
PAGI Assessed as IAGI 4-pt 7-pt Less often reported
than IAGI.Majority of
included trials use 5-pt
scale
Patient’s Global As-
sessment of Disease
Severity
PGA Assessed as IGA 4-pt 5-pt Rarely reported (5/
177 studies)
* IAGI/PAGI data are entered as a negative values; thus, a reduction denotes a positive improvement for the active treatment consistent
with TSS and PASI measures
Table 3. Summary of imputed standard deviation values
Type of
study/score
Placebo
IAGI
(change)
/IGA (end
point)
Placebo
TSS
Placebo
PASI
Placebo
PAGI
(change)
/PGA (end
point)
H2H
IAGI
(change)
/IGA (end
point)
H2H
TSS
H2H
PASI
H2H
PAGI
(change)/
PGA (end
point)
Between-
patient (end
point)
0.93 1.33 3.76 1.13 1.01 1.65 3.61 1.12
Within-
patient (end
point)
1.08 1.49 7.17 NA NA 1.50 2.58 NA
Between-
patient
(change)
1.17 1.52 5.75 1.31 1.10 1.73 7.85 1.20
Within-
patient
(change)
1.02 1.58 NA 1.53 0.96 1.94 NA 0.83
Within-
patient (%
change)
NA 0.18 NA NA NA NA NA NA
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Table 3. Summary of imputed standard deviation values (Continued)
Between-
patient (%
change)
NA NA 0.37 NA NA 0.13 0.33 NA
Scalp
between-
patient (end
point)
1.08 1.74 NA 1.06 1.06 1.94 NA 1.18
Scalp
within-
patient (end
point)
1.33 NA NA NA NA NA NA NA
Scalp
between-
patient
(change)
1.20 NA NA 1.28 1.30 1.75 NA 1.20
Scalp
between-
patient (%
change)
NA NA NA NA NA 0.25 NA NA
NA: not available; H2H: head-to-head; IGA [PGA]: Investigator [Patient] Global Assessment of Disease Severity;
IAGI [PAGI]: Investigator (patient) Assessment of Global Improvement; TSS: Total Severity Score; PASI: Psoriasis Area and Severity
Index
Table 4. Overview of analyses: evidence of effectiveness outcomes
Comparison No. Comparison Label No. studies
(NB: a study may con-
tribute to
more than one compari-
son)
Per cent studies with
between-patient design
No.
participants
01 Vitamin D analogues vs.
placebo
30 60% 4986
02 Corticosteroid (potent)
vs. placebo
13 85% 2216
03 Corticosteroid (very po-
tent) vs. placebo
10 70% 1264
04 Dithranol vs. placebo 3 0% 47
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Table 4. Overview of analyses: evidence of effectiveness outcomes (Continued)
05 Vitamin D combination
products vs. placebo
5 100% 2058
06 Other treatment vs.
placebo
26 46% 1450
07 Vitamin D analogues vs.
corticosteroid (potent)
14 64% 3542
08 Vitamin D analogues vs.
corticosteroid (very po-
tent)
2 100% 82
09 VitaminDcombinedwith
corticosteroid vs. corticos-
teroid
5 100% 2113
10 Vitamin D alone or in
combination vs. dithranol
8 88% 1284
11 Vitamin D alone or in
combination vs. other vi-
tamin D analogue
4 75% 513
12 Vitamin D alone or in
combination vs. vitamin
D + corticosteroid
17 94% 5856
13 Vitamin
Dalone or in combination
vs. other treatments: com-
plex regimens
9 89% 2936
14 Vitamin
Dalone or in combination
vs. other treatment: long-
term studies (> 24 wks)
1 100% 297
15 Vitamin D analogues vs.
other treatment
19 68% 2364
16 Flexural/facial psoriasis:
placebo-controlled trials
2 100% 122
17 Flexural/facial pso-
riasis: vitamin D alone or
in combination vs. other
treatment
4 75% 588
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Table 4. Overview of analyses: evidence of effectiveness outcomes (Continued)
18 Scalp psoriasis: placebo-
controlled trials
14 93% 3011
19 Scalp psoriasis: vitamin D
alone or in combination
vs. other treatments
12 100% 5413
Table 5. Analysis 01: Trial characteristics and outcomes: vitamin D vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
OD/BD
Effect size [CI] (SMD -0.93;
95% CI -1.17 to
-0.68)
(SMD -1.15;
95% CI -1.41 to
-0.89)
(SMD -0.65;
95% CI -0.75 to
-0.55)
(SMD -0.64;
95% CI -0.97 to
-0.30)
(SMD -0.96;
95% CI -1.15 to
-0.77)
02 Calcipotriol
plus occlusion
Effect size [CI] NA (SMD -0.15;
95% CI -0.44 to
0.14)
- - (SMD -0.15;
95% CI -0.44 to
0.14)
03 Calcitriol
OD/BD
Effect size [CI] (SMD -1.03;
95% CI -1.71 to
-0.36)
(SMD -1.22;
95% CI -2.38 to
-0.07)
- (SMD -0.59;
95% CI -0.76 to
-0.41)
(SMD -0.92;
95% CI -1.54 to
-0.29)
04 Tacalcitol
OD
Effect size [CI] (SMD -0.84;
95% CI -1.41 to
-0.26)
(SMD -0.66;
95% CI -0.95 to
-0.36)
(SMD -0.27;
95% CI -0.56 to
0.03)
(SMD -0.24;
95% CI -0.53 to
0.05)
(SMD -0.73;
95% CI -1.09 to
-0.37)
05 Maxacalcitol
OD
Effect size [CI] (SMD -1.43;
95% CI -1.91 to
-0.96)
(SMD -1.61;
95% CI -2.10 to
-1.12)
- - (SMD -1.43;
95% CI -1.91 to
-0.96)
06 Paricalcitol
OD
Effect size [CI] (SMD -1.66;
95% CI -2.66 to
-0.67)
(SMD -2.15;
95% CI -3.24 to
-1.06)
- - (SMD -1.66;
95% CI -2.66 to
-0.67)
07 Becocalcidiol
OD
Effect size [CI] (SMD -0.22;
95% CI -0.58 to
0.14)
(SMD -0.02;
95% CI -0.37 to
0.34)
- - (SMD -0.22;
95% CI -0.58 to
0.14)
08 Becocalcidiol
BD
Effect size [CI] (SMD -0.67;
95% CI -1.04 to
-0.30)
(SMD -0.46;
95% CI -0.83 to
-0.10)
- - (SMD -0.67;
95% CI -1.04 to
-0.30)
All treatments Effect size [CI];
I² statistic
(SMD -0.95;
95% CI -1.17 to
-0.74):
I² statistic: 89.
(SMD
-1.04; 95% CI -
1.33 to -0.74) I²
statistic: 93.0%
(SMD -0.58;
95% CI -0.71 to
-0.45):
(SMD -0.54;
95% CI -0.72 to
-0.36):
(SMD -0.90;
95% CI -1.07 to
-0.72);
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Table 5. Analysis 01: Trial characteristics and outcomes: vitamin D vs. placebo (Continued)
0% I² statistic: 42.
3%
I² statistic: 55.
5%
I² statistic: 87.
5%
- No. participants 3771 2647 2357 1467 4986
- Between-patient
design
13 9 8 5 18
- Within-patient
design
7 10 1 0 12
- Treatment dura-
tion
4 wks to 12 wks 4 wks to 12 wks 3 wks to 8 wks 8 wks to 8 wks 3 wks to 12 wks
Sensitivity analy-
ses
Within-patient
trials
- - - - (SMD -1.11;
95% CI -1.58 to
-0.64)
- Between-patient
trials
- - - - (SMD -0.80;
95% CI -0.96 to
-0.63)
- Calcitriol, Perez
1996 removed
- - - (SMD -0.60;
95% CI -0.78 to
-0.41)
- Calcipotriol BD - - - - (SMD -1.02;
95% CI -1.23 to
-0.82)
- Calcipotriol OD - - - - (SMD -0.76;
95% CI -1.13 to
-0.40)
- correlation coef-
ficient (rho) = 0
All trials
- - - - (SMD -0.85;
95% CI -1.00 to
-0.71);
I² statistic: 87.
8%
- rho = 0
Btw-patient tri-
als
rho = 0.25
Within-patient
trials
- - - - (SMD -0.87;
95% CI -1.01 to
-0.72);
I² statistic: 88.
8%
- rho = 0
Btw-patient tri-
- - - - (SMD -0.88;
95% CI -1.03 to
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Table 5. Analysis 01: Trial characteristics and outcomes: vitamin D vs. placebo (Continued)
als
rho = 0.50
Within-patient
trials
-0.73);
I² statistic = 90.
3%
- rho = 0
Btw-patient tri-
als
rho = 0.75
Within-patient
trials
- - - - (SMD -0.91;
95% CI -1.07 to
-0.75);
I² statistic: 93.
2%
For acronyms, see Table 1.
Table 6. Analysis 02: Trial characteristics and outcomes: potent steroids vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Betametha-
sone dipropi-
onate OD
Effect size [CI] (SMD -0.81;
95% CI -0.98 to
-0.64)
(SMD -0.74;
95% CI -1.16 to
-0.32)
(SMD -0.79;
95% CI -1.44 to
-0.14)
- (SMD -0.
80; 95% CI -0.96
to -0.64)
02 Betametha-
sone dipropi-
onate BD
Effect size [CI] (SMD -1.35;
95% CI -1.56 to
-1.15)
(SMD -0.77;
95% CI -1.48 to
-0.06)
(SMD -1.21;
95% CI -1.44 to
-0.97)
- (SMD -1.
35; 95% CI -1.56
to -1.15)
03 Betametha-
sone dipro-
pionate, mainte-
nance
Effect size [CI] (SMD -0.95;
95% CI -1.62 to
-0.27)
- - (SMD -0.
95; 95% CI -1.62
to -0.27)
04 Betametha-
sone valerate
Effect size [CI] (SMD -1.41;
95% CI -1.92 to
-0.90)
(SMD -1.09;
95% CI -2.00 to
-0.18)
- - (SMD -1.
33; 95% CI -1.78
to -0.89)
05 Budesonide Effect size [CI] - - - - -
06 Desonide Effect size [CI] (SMD -0.81;
95% CI -1.34 to
-0.28)
(SMD -1.16;
95% CI -1.70 to
-0.61)
- - (SMD -0.
81; 95% CI -1.34
to -0.28)
07 Diflorasone
diacetate
Effect size [CI] - (SMD -0.32;
95% CI -0.73 to
0.09)
- - (SMD -0.
32; 95% CI -0.73
to 0.09)
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Table 6. Analysis 02: Trial characteristics and outcomes: potent steroids vs. placebo (Continued)
08 Fluticasone
propionate
Effect size [CI] (SMD -0.93;
95% CI -1.14 to
-0.72)
- - - (SMD -0.
93; 95% CI -1.14
to -0.72)
09 Hydrocorti-
sone buteprate
Effect size [CI] - (SMD -0.46;
95% CI -0.77 to
-0.15)
- - (SMD -0.
46; 95% CI -0.77
to -0.15)
10 Mometasone
furoate
Effect size [CI] (SMD -0.75;
95% CI -1.17 to
-0.34)
(SMD -1.12;
95% CI -1.55 to
-0.68)
- - (SMD -0.
75; 95% CI -1.17
to -0.34)
All treatments Effect size [CI];
I² statistic
(SMD
-1.00; 95% CI -
1.18 to -0.82); I²
statistic: 57.6%
(SMD
-0.77; 95% CI -
1.01 to -0.52); I²
statistic: 46.7%
(SMD
-0.97; 95% CI -
1.31 to -0.62); I²
statistic: 79.6%
- (SMD -0.89;
95% CI -1.06 to -
0.72); I² statistic:
65.1%
- No. participants 1867 553 1158 0 2216
- Between-patient
design
8 6 3 0 11
- Within-patient
design
1 1 0 0 2
- Treatment dura-
tion
3 wks to 12 wks 2 wks to 12 wks 4 wks to 8 wks - 2 wks to 12 wks
Sensitivity analy-
ses
Within-patient
trials
- - - - (SMD -1.
33; 95% CI -1.78
to -0.89)
- Between-patient
trials
- - - - (SMD -0.
85; 95% CI -1.03
to -0.67)
- correlation coef-
ficient (rho) = 0
All trials
- - - - (SMD -0.
89; 95% CI -1.06
to -0.72) I² statis-
tic: 77.7%
- rho = 0
Btw-patient tri-
als
rho = 0.25
Within-patient
trials
- - - - (SMD -0.
89; 95% CI -1.06
to -0.72) I² statis-
tic: 78.0%
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Table 6. Analysis 02: Trial characteristics and outcomes: potent steroids vs. placebo (Continued)
- rho = 0
Btw-patient tri-
als
rho = 0.50
Within-patient
trials
- - - - (SMD -0.
90; 95% CI -1.07
to -0.73) I² statis-
tic: 78.6%
- rho = 0
Btw-patient tri-
als
rho = 0.75
Within-patient
trials
- - - - (SMD -0.
91; 95% CI -1.08
to -0.74) I² statis-
tic: 80.2%
For acronyms, see Table 1. Both within-patient trials compared betamethasone valerate with placebo.
Table 7. Analysis 03: Trial characteristics and outcomes: v. potent steroids vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end
point
01 Clobetasol
propionate
Effect size [CI] (SMD -1.89;
95% CI -2.53 to
-1.24)
(SMD -1.35;
95% CI -1.80 to
-0.89)
- (SMD -1.01; 95%
CI -1.55 to -0.47)
(SMD -1.65; 95%
CI -2.10 to -1.20)
02 Halcinonide Effect size [CI] - - - - -
03 Halobetasol Effect size [CI] (SMD -1.81;
95% CI -2.37 to
-1.24)
- - (SMD -1.25; 95%
CI -1.46 to -1.04)
(SMD -1.36; 95%
CI -1.65 to -1.07)
All treatments Effect size [CI],
N, I²
(SMD
-1.87; 95% CI -
2.38 to -1.36); I²
statistic: 78.7%
(SMD
-1.35; 95% CI -
1.80 to -0.89); I²
statistic: 75.3%
- (SMD -1.22; 95%
CI -1.42 to -1.02); I²
statistic: 0%
(SMD -1.56; 95%
CI -1.87 to -1.26); I²
statistic: 81.7%
- No. participants 515 545 0 283 1264
- Between-patient
design
4 3 0 1 7
- Within-patient
design
1 0 0 2 3
- Treatment dura-
tion
2 wks to 4 wks 2 wks to 4 wks 2 wks to 2 wks 2 wks to 4 wks
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Table 7. Analysis 03: Trial characteristics and outcomes: v. potent steroids vs. placebo (Continued)
Sensitivity analy-
ses
Within-patient
trials
- - - - (SMD -1.52; 95%
CI -2.02 to -1.02)
- Between-patient
trials
- - - - (SMD -1.58; 95%
CI -1.99 to -1.17)
- correlation coef-
ficient (rho) = 0
All trials
- - - - (SMD -1.52; 95%
CI -1.80 to -1.24) I²
statistic: 81.6%
- rho = 0
Btw-patient tri-
als
rho = 0.25
Within-patient
trials
- - - - (SMD -1.52; 95%
CI -1.80 to -1.25) I²
statistic: 82.2%
- rho = 0
Btw-patient tri-
als
rho = 0.50
Within-patient
trials
- - - - (SMD -1.53; 95%
CI -1.80 to -1.26) I²
statistic: 83.3%
- rho = 0
Btw-patient tri-
als
rho = 0.75
Within-patient
trials
- - - - (SMD -1.55; 95%
CI -1.80 to -1.29) I²
statistic: 85.9%
For acronyms, see Table 1.
Table 8. Analysis 05: Trial characteristics and outcomes: vitamin D combination vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end
point
01 Combination
calcipotriol/
betamethasone
dipropionate,
OD
Effect size [CI] (SMD -1.21;
95% CI -1.50 to
-0.91)
- (SMD -1.14; 95%
CI -1.57 to -0.70)
(SMD -0.69; 95%
CI -0.98 to -0.40)
(SMD -1.21; 95%
CI -1.50 to -0.91)
02 Combination
calcipotriol/
betamethasone
dipropionate,
Effect size [CI] (SMD -1.90;
95% CI -2.09 to
-1.71)
- (SMD -1.41; 95%
CI -1.86 to -0.97)
- (SMD -1.90; 95%
CI -2.09 to -1.71)
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Table 8. Analysis 05: Trial characteristics and outcomes: vitamin D combination vs. placebo (Continued)
BD
All treatments Effect size [CI],
N, I² statistic
(SMD
-1.44; 95% CI -
1.76 to -1.12); I²
statistic: 89.4%
- (SMD -1.24; 95%
CI -1.53 to -0.95);
I² statistic: 87.6%
(SMD -0.69; 95%
CI -0.98 to -0.40);
I² statistic: NA
(SMD -1.44; 95%
CI -1.76 to -1.12);
I² statistic: 89.4%
- No. participants 2058 0 2056 235 2058
- Between-patient
design
5 0 5 1 5
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
4 wks to 8 wks - 4 wks to 8 wks 8 wks 4 wks to 8 wks
For acronyms, see Table 1.
Table 9. Analysis 06: Trial characteristics and outcomes: other treatments vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Aloe vera ex-
tract
Effect size [CI] - - (SMD -1.58;
95% CI -2.16 to
-0.99)
- (SMD -1.58;
95% CI -2.16 to
-0.99)
02 Anti-
IL-8monoclonal
antibody cream
Effect size [CI] (SMD -0.59;
95% CI -1.01 to
-0.16)
(SMD -0.70;
95% CI -1.13 to
-0.27)
- - (SMD -0.59;
95% CI -1.01 to
-0.16)
03 Betametha-
sone 17-valerate
21-acetate plus
tretinoine plus
salicylic acid
Effect size [CI] (SMD -0.76;
95% CI -1.21 to
-0.31)
- (SMD -0.54;
95% CI -0.99 to
-0.10)
(SMD -0.80;
95% CI -1.26 to
-0.35)
(SMD -0.76;
95% CI -1.21 to
-0.31)
04Caffeine (top-
ical) 10%, TD
Effect size [CI] - - (SMD -0.39;
95% CI -0.84 to
0.06)
- (SMD -0.39;
95% CI -0.84 to
0.06)
05 Calcipotriene
0.
005% ointment
+ nicotinamide
0.05% or 0.1%
Effect size [CI] - (SMD -0.48;
95% CI -0.81 to
-0.15)
- - (SMD -0.48;
95% CI -0.81 to
-0.15)
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Table 9. Analysis 06: Trial characteristics and outcomes: other treatments vs. placebo (Continued)
or 0.7% or 1.
4%, BD
06 Dead sea salts
emollient lotion
Effect size [CI] - - (SMD 0.57;
95% CI -0.36 to
1.51)
- (SMD 0.57;
95% CI -0.36 to
1.51)
07 Fish oil plus
occlusion
Effect size [CI] - (SMD -1.05;
95% CI -1.64 to
-0.46)
- - (SMD -1.05;
95% CI -1.64 to
-0.46)
08
Herbal skin care
(Dr Michaels®
cleans-
ing gel, ointment
and skin condi-
tioner), BD
Effect size [CI] (SMD -2.96;
95% CI -4.19 to
-1.74)
- (SMD -2.96;
95% CI -4.19 to
-1.74)
09 Hexafluoro-
1,25-dihydrox-
yvitamin D3
Effect size [CI] (SMD -0.62;
95% CI -1.35 to
0.12)
(SMD -1.13;
95% CI -1.91 to
-0.35)
- - (SMD -0.62;
95% CI -1.35 to
0.12)
10 Indigo natu-
ralis 1.4% oint-
ment
Effect size [CI] (SMD -2.14;
95% CI -2.74 to
-1.53)
(SMD -1.64;
95% CI -2.13 to
-1.15)
- - (SMD -2.09;
95% CI -2.62 to
-1.56)
11Kukui nut oil,
TD
Effect size [CI] (SMD 0.00;
95% CI -0.80 to
0.80)
(SMD 0.33;
95% CI -0.48 to
1.14)
(SMD -0.03;
95% CI -0.84 to
0.77)
(SMD 0.00;
95% CI -0.80 to
0.80)
(SMD 0.00;
95% CI -0.80 to
0.80)
12 Ma-
honia aquifolium
(Reliéva™), BD
Effect size [CI] - - - - (SMD -0.77;
95% CI -1.06 to
-0.48)
13 Methotrexate
gel
Effect size [CI] (SMD -0.56;
95% CI -1.01 to
-0.12)
(SMD -0.48;
95% CI -0.92 to
-0.04)
(SMD -1.58;
95% CI -2.16 to
-0.99)
- (SMD -1.05;
95% CI -2.04 to
-0.06)
14 Mycopheno-
lic acid ointment
Effect size [CI] - (SMD -1.44;
95% CI -2.67 to
-0.22)
- - (SMD -1.44;
95% CI -2.67 to
-0.22)
15 NG-
monomethyl-L-
arginine (L-
NMMA) cream
Effect size [CI] - (SMD 0.08;
95% CI -0.60 to
0.75)
- - (SMD 0.08;
95% CI -0.60 to
0.75)
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Table 9. Analysis 06: Trial characteristics and outcomes: other treatments vs. placebo (Continued)
16
Nicotinamide 1.
4%, BD
Effect size [CI] - (SMD -0.20;
95% CI -0.60 to
0.20)
- - (SMD -0.20;
95% CI -0.60 to
0.20)
17 Oleum hor-
wathiensis
Effect size [CI] (SMD -0.02;
95% CI -0.63 to
0.58)
(SMD -0.77;
95% CI -1.40 to
-0.14)
- - (SMD -0.02;
95% CI -0.63 to
0.58)
18 Omega-3-
polyunsat-
urated fatty acids
ointment
Effect size [CI] - - - - -
19Platelet aggre-
gation activating
factor (PAF) (Ro
24-0238)
Effect size [CI] (SMD -0.07;
95% CI -0.50 to
0.37)
- - (SMD -0.07;
95% CI -0.50 to
0.37)
20 Polymyxin B
cream, 200,000
U/g
Effect size [CI] - (SMD 0.13;
95% CI -0.59 to
0.85)
- - (SMD 0.13;
95% CI -0.59 to
0.85)
21 PTH
(1-34) in Nova-
some A® liposo-
mal cream, BD
Effect size [CI] - (SMD -2.31;
95% CI -3.26 to
-1.36)
- - (SMD -2.31;
95% CI -3.26 to
-1.36)
22
Sirolimus (topi-
cal), 2.2% for 6
wks, then 8% for
a further 6 wks
Effect size [CI] - (SMD -0.39;
95% CI -0.98 to
0.21)
- - (SMD -0.39;
95% CI -0.98 to
0.21)
23 Tacrolimus
ointment
Effect size [CI] - (SMD 0.06;
95% CI -0.52 to
0.63)
- - (SMD 0.06;
95% CI -0.52 to
0.63)
24 Tar Effect size [CI] - (SMD -0.45;
95% CI -1.11 to
0.22)
- - (SMD -0.45;
95% CI -1.11 to
0.22)
25 Tazarotene Effect size [CI] - (SMD -0.86;
95% CI -1.11 to
-0.62)
- - (SMD -0.86;
95% CI -1.11 to
-0.62)
26 Theophylline
1% ointment,
BD
Effect size [CI] - - (SMD -2.87;
95% CI -4.13 to
-1.62)
- (SMD -2.87;
95% CI -4.13 to
-1.62)
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Table 9. Analysis 06: Trial characteristics and outcomes: other treatments vs. placebo (Continued)
All treatments (not pooled) - - - - -
- No. participants 364 907 529 105 1450
- Between-patient
design
4 5 8 2 12
- Within-patient
design
4 12 1 0 14
- Treatment dura-
tion
3 wks to 12 wks 3 wks to 12 wks 2 wks to 12 wks 3 wks to 12 wks 2 wks to 12 wks
For acronyms, see Table 1.
Table 10. Analysis 07: Trial characteristics and outcomes: vitamin D vs. potent steroids
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Cal-
cipotriol vs. be-
tamethasone
dipropionate
Effect size [CI] (SMD
0.43; 95% CI 0.
28 to 0.58)
- (SMD
0.36; 95% CI 0.
22 to 0.51)
- (SMD
0.43; 95% CI 0.
28 to 0.58)
02 Calcipotriol
vs. betametha-
sone valerate
Effect size [CI] (SMD -0.02;
95% CI -0.21 to
0.17)
(SMD -0.26;
95% CI -0.41 to
-0.11)
(SMD -0.12;
95% CI -0.22 to
-0.02)
(SMD -0.26;
95% CI -0.38 to
-0.14)
(SMD -0.12;
95% CI -0.26 to
0.02)
03 Calcipotriol
vs. desoxymeta-
sone
Effect size [CI] - - (SMD 0.15;
95% CI -0.73 to
1.02)
- (SMD 0.15;
95% CI -0.73 to
1.02)
04
Calcipotriol vs.
diflorasone diac-
etate
Effect size [CI] (SMD
0.27; 95% CI 0.
02 to 0.52)
(SMD
0.40; 95% CI 0.
15 to 0.65)
- - (SMD
0.27; 95% CI 0.
02 to 0.52)
05 Calcipotriol
vs. fluocinonide
Effect size [CI] (SMD -0.58;
95% CI -0.99 to
-0.18)
(SMD -0.50;
95% CI -0.92 to
-0.07)
- - (SMD -0.58;
95% CI -0.99 to
-0.18)
06 Calcitriol vs.
betamethasone
dipropionate
Effect size [CI] (SMD 0.21;
95% CI -0.04 to
0.45)
(SMD
0.27; 95% CI 0.
02 to 0.51)
(SMD
0.39; 95% CI 0.
14 to 0.63)
- (SMD 0.21;
95% CI -0.04 to
0.45)
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Table 10. Analysis 07: Trial characteristics and outcomes: vitamin D vs. potent steroids (Continued)
07 Calcitriol vs.
betamethasone
valerate
Effect size [CI] (SMD -0.19;
95% CI -0.91 to
0.53)
- - - (SMD -0.19;
95% CI -0.91 to
0.53)
08 Tacalcitol vs.
betamethasone
valerate
Effect size [CI] - (SMD
0.41; 95% CI 0.
09 to 0.74)
- - (SMD
0.41; 95% CI 0.
09 to 0.74)
All treatments Effect size [CI];
I² statistic
(SMD 0.17;
95% CI -0.04 to
0.37); I² statistic:
83.4%
(SMD 0.11;
95% CI -0.22 to
0.44); I² statistic:
86.7%
(SMD 0.12;
95% CI -0.07 to
0.32); I² statistic:
86.2%
(SMD
-0.26; 95% CI -
0.38 to -0.14); I²
statistic: 0%
(SMD 0.11;
95% CI -0.07 to
0.30); I² statistic:
85.6%
- No. participants 2655 891 3185 738 3542
- Between-patient
design
7 2 7 1 9
- Within-patient
design
1 4 2 1 5
- Treatment dura-
tion
3 wks to 8 wks 3 wks to 6 wks 4 wks to 8 wks 6 wks 3 wks to 8 wks
Sensitivity analy-
ses
Within-patient
trials
- - - - (SMD 0.17;
95% CI -0.20 to
0.54)
- Between-patient
trials
- - - - (SMD 0.10;
95% CI -0.11 to
0.31)
- correlation coef-
ficient (rho) = 0
All trials
- - - - (SMD 0.10;
95% CI -0.08 to
0.28);
I² statistic: 90.
5%
- rho = 0
Btw-patient tri-
als
rho = 0.25
Within-patient
trials
- - - - (SMD 0.10;
95% CI -0.07 to
0.28)
I² statistic: 91.
3%
- rho = 0
Btw-patient tri-
als
rho = 0.50
- - - - (SMD 0.11;
95% CI -0.07 to
0.29)
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Table 10. Analysis 07: Trial characteristics and outcomes: vitamin D vs. potent steroids (Continued)
Within-patient
trials
I² statistic: 92.
4%
- rho = 0
Btw-patient tri-
als
rho = 0.75
Within-patient
trials
- - - - (SMD 0.12;
95% CI -0.06 to
0.30)
I² statistic: 94.
3%
For acronyms, see Table 1.
Table 11. Analysis 08: Trial characteristics and outcomes: vitamin D vs. v. potent steroids
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end
point
01
Calcipotriol vs.
clobetasol propi-
onate
Effect size [CI] (SMD 0.19;
95% CI -0.42 to
0.80)
- (SMD -0.32; 95%
CI -0.95 to 0.30)
(SMD 0.42; 95%
CI -0.20 to 1.03)
(SMD -0.06; 95%
CI -0.57 to 0.44); I²
statistic: 25.7%
All treatments No. participants 42 0 40 42 82
- Between-patient
design
1 0 1 1 2
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
2 wks - 6 wks 2 wks 2 wks to 6 wks
Table 12. Analysis 09: Trial characteristics and outcomes: vitamin D + steroid vs. steroid
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
+ betamethasone
dipropionate vs.
betamethasone
dipropionate
Effect size [CI] (SMD -0.40;
95% CI -0.52 to
-0.27)
- (SMD -0.44;
95% CI -0.55 to
-0.33)
- (SMD -0.40;
95% CI -0.52 to
-0.27)
02 Calcipotriol
+ betamethasone
dipropionate vs.
Effect size [CI] - (SMD
0.45; 95% CI 0.
09 to 0.81)
- - (SMD
0.45; 95% CI 0.
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Table 12. Analysis 09: Trial characteristics and outcomes: vitamin D + steroid vs. steroid (Continued)
clobetasol propi-
onate
09 to 0.81)
03 Calcipotriol +
clobetasol propi-
onate vs. clobeta-
sol propionate
Effect size [CI] (SMD -0.69;
95% CI -1.22 to
-0.15)
- - (SMD -0.28;
95% CI -0.80 to
0.24)
(SMD -0.69;
95% CI -1.22 to
-0.15)
- Effect size [CI],
I²
(SMD
-0.41; 95% CI -
0.53 to -0.29); I²
statistic: 32.0%
(SMD 0.45;
95% CI 0.09 to
0.81): I² statistic:
NA
(SMD
-0.44; 95% CI -
0.55 to -0.33) I²
statistic: 22.4%
(SMD -0.28;
95% CI -0.80 to
0.24) I² statistic:
NA
(SMD
-0.26; 95% CI -
0.52 to -0.00); I²
statistic: 84.4%
- No. participants 1991 122 1876 65 2113
- Between-patient
design
4 1 3 1 5
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
2 wks to 8 wks 4 wks 4 wks to 8 wks 2 wks 2 wks to 8 wks
Table 13. Analysis 10: Trial characteristics and outcomes: vitamin D vs. dithranol
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
vs. dithranol
Effect size [CI] (SMD -0.43;
95% CI -0.85 to
-0.01)
(SMD -0.54;
95% CI -1.16 to
0.08)
(SMD 0.73;
95% CI -0.55 to
2.00)
(SMD -0.05;
95% CI -0.90 to
0.80)
(SMD 0.07;
95% CI -0.57 to
0.71)
02 Calcitriol vs.
dithranol
Effect size [CI] (SMD
0.51; 95% CI 0.
13 to 0.88)
(SMD 0.13;
95% CI -0.24 to
0.50)
(SMD -0.21;
95% CI -0.58 to
0.16)
- (SMD
0.51; 95% CI 0.
13 to 0.88)
03 Tacalcitol vs.
dithranol
Effect size [CI] - (SMD -0.18;
95% CI -0.60 to
0.25)
(SMD -0.07;
95% CI -0.50 to
0.36)
- (SMD -0.18;
95% CI -0.60 to
0.25)
All treatments Effect size [CI],
I² statistic
(SMD
-0.24; 95% CI -
0.72 to 0.25); I²
statistic:93.0%
(SMD
-0.27; 95% CI -
0.73 to 0.20); I²
statistic: 80.6%
(SMD 0.36;
95% CI -0.33 to
1.04); I² statistic:
94.5%
(SMD
-0.05; 95% CI -
0.90 to 0.80); I²
statistic: 92.5%
(SMD 0.09;
95% CI -0.44 to
0.63); I² statistic:
94.9%
- No. participants 1108 386 796 544 1284
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Table 13. Analysis 10: Trial characteristics and outcomes: vitamin D vs. dithranol (Continued)
- Between-patient
design
5 3 5 2 7
- Within-patient
design
0 1 0 0 1
- Treatment dura-
tion
8 wks to 12 wks 4 wks to 8 wks 8 wks to 12 wks 8 wks to 12 wks 4 wks to 12 wks
Table 14. Analysis 11: Trial characteristics and outcomes: vitamin D vs. vitamin D
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
vs. calcitriol
Effect size [CI] (SMD 0.00;
95% CI -0.25 to
0.25)
(SMD -0.32;
95% CI -0.57 to
-0.07)
(SMD -1.11;
95% CI -2.22 to
0.01)
(SMD 0.04;
95% CI -0.21 to
0.29)
(SMD -0.41;
95% CI -1.46 to
0.64)
02 Calcipotriol
vs. tacalcitol
Effect size [CI] (SMD -0.47;
95% CI -0.73 to
-0.21)
(SMD -0.45;
95% CI -0.68 to
-0.22)
- - (SMD -0.47;
95% CI -0.73 to
-0.21)
03 Calcipotriol
vs. maxacalcitol
Effect size [CI] (SMD 0.43;
95% CI -0.12 to
0.98)
(SMD 0.13;
95% CI -0.41 to
0.68)
- - (SMD 0.43;
95% CI -0.12 to
0.98)
All treatments Effect size [CI],
I²
(SMD
-0.06; 95% CI -
0.51 to 0.38); I²
statistic: 82.2%
(SMD
-0.31; 95% CI -
0.55 to -0.06); I²
statistic: 46.9%
(SMD
-1.11; 95% CI -
2.22 to 0.01); I²
statistic: NA
(SMD 0.04;
95% CI -0.21 to
0.29); I² statistic:
NA
(SMD
-0.17; 95% CI -
0.62 to 0.27); I²
statistic: 78.5%
- No. participants 498 563 15 250 513
- Between-patient
design
2 2 1 1 3
- Within-patient
design
1 1 0 0 1
- Treatment dura-
tion
8 wks to 12 wks 8 wks to 12 wks 8 wks 12 wks 8 wks to 12 wks
Sensitivity analy-
ses
TSS data from Ji
2008 used
in combined end
point:
01 Calcipotriol
- - - (SMD -0.52;
95% CI -1.19 to
0.15; I² statistic:
44.9%)
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Table 14. Analysis 11: Trial characteristics and outcomes: vitamin D vs. vitamin D (Continued)
vs. calcitriol
- TSS data from Ji
2008 used
in combined end
point:
all treatments
- - - (SMD -0.28;
95% CI -0.66 to
0.10; I² statistic:
70.6%)
Table 15. Analysis 12: Trial characteristics and outcomes: vitamin D vs. vitamin D + steroid
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Cal-
cipotriol BD vs.
calcipotriol OM,
BMD ON
Effect size [CI] (SMD
0.56; 95% CI 0.
23 to 0.88)
- (SMD
0.46; 95% CI 0.
10 to 0.82)
- (SMD
0.56; 95% CI 0.
23 to 0.88)
02 Cal-
cipotriol OD vs.
combined cal-
cipotriol + BMD
OD
Effect size [CI] (SMD
0.66; 95% CI 0.
31 to 1.02)
- (SMD
0.67; 95% CI 0.
23 to 1.11)
- (SMD
0.66; 95% CI 0.
31 to 1.02)
03 Cal-
cipotriol BD vs.
combined cal-
cipotriol + BMD
OD
Effect size [CI] (SMD
0.27; 95% CI 0.
06 to 0.48)
(SMD
0.25; 95% CI 0.
03 to 0.48)
(SMD
0.52; 95% CI 0.
38 to 0.67)
- (SMD
0.43; 95% CI 0.
20 to 0.66)
04 Cal-
cipotriol BD vs.
combined cal-
cipotriol + BMD
BD
Effect size [CI] (SMD
0.66; 95% CI 0.
40 to 0.93)
- (SMD
0.64; 95% CI 0.
46 to 0.83)
- (SMD
0.66; 95% CI 0.
40 to 0.93)
05 Cal-
cipotriol BD vs.
calcipotriol OM,
BMV ON
Effect size [CI] (SMD 0.27;
95% CI -0.19 to
0.74)
- (SMD 0.43;
95% CI -0.07 to
0.93)
- (SMD 0.27;
95% CI -0.19 to
0.74)
06 Cal-
cipotriol BD vs.
calcipotriol OM,
clobetasone bu-
tyrate ON
Effect size [CI] (SMD
0.27; 95% CI 0.
05 to 0.48)
- (SMD 0.17;
95% CI -0.04 to
0.38)
- (SMD
0.27; 95% CI 0.
05 to 0.48)
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Table 15. Analysis 12: Trial characteristics and outcomes: vitamin D vs. vitamin D + steroid (Continued)
07 Cal-
cipotriol BD vs.
calcipotriol BD
+ clobetasol pro-
pionate BD
Effect size [CI] (SMD
0.88; 95% CI 0.
34 to 1.42)
- - (SMD
0.70; 95% CI 0.
16 to 1.23)
(SMD
0.88; 95% CI 0.
34 to 1.42)
08 Cal-
cipotriol BD vs.
calcipotriol OM,
diflucortolone
valerate ON
Effect size [CI] - - (SMD 0.08;
95% CI -0.29 to
0.44)
- (SMD 0.08;
95% CI -0.29 to
0.44)
09 Cal-
cipotriol OD vs.
calcipotriol OM,
fluocinonide
acetonide ON
Effect size [CI] - - (SMD 0.53;
95% CI -0.11 to
1.18)
- (SMD 0.53;
95% CI -0.11 to
1.18)
10
Calcipotriol OD
vs. combined
calcipotriol
+ hydrocortisone
OD
Effect size [CI] (SMD 0.14;
95% CI -0.06 to
0.33)
- (SMD 0.08;
95% CI -0.11 to
0.28)
- (SMD 0.14;
95% CI -0.06 to
0.33)
11 calcitriol BD
vs. diflu-
cortolone valer-
ate OM,
calcitriol ON
Effect size [CI] - - (SMD 0.24;
95% CI -0.09 to
0.57)
- (SMD 0.24;
95% CI -0.09 to
0.57)
12 Tacalci-
tol OD vs. com-
bined cal-
cipotriol + BMD
OD
Effect size [CI] (SMD
0.48; 95% CI 0.
26 to 0.70)
- (SMD
0.47; 95% CI 0.
25 to 0.69)
(SMD
0.46; 95% CI 0.
24 to 0.68)
(SMD
0.48; 95% CI 0.
26 to 0.70)
All treatments Effect size [CI],
I² statistic
(SMD 0.48;
95% CI 0.32 to
0.65), I² statistic:
86.9%
(SMD
0.25; 95% CI 0.
03 to 0.48)
(SMD 0.47;
95% CI 0.34 to
0.59), I² statistic:
82.3%
(SMD 0.49;
95% CI 0.29 to
0.69), I² statistic:
0%
(SMD 0.46;
95% CI 0.33 to
0.59), I² statistic:
83.3%
- No. participants 4791 301 5703 399 5856
- Between-patient
design
11 1 15 2 16
- Within-patient
design
0 0 1 0 1
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Table 15. Analysis 12: Trial characteristics and outcomes: vitamin D vs. vitamin D + steroid (Continued)
- Treatment dura-
tion
2 wks to 8 wks 4 wks 2 wks to 12 wks 2 wks to 8 wks 2 wks to 12 wks
For acronyms, see Table 1.
Table 16. Analysis 13: Trial characteristics and outcomes: vitamin D vs. other treatments: complex regimens
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01
Calcipotriol (12
wks) vs. com-
bined cal-
cipotriol + BMD
(8wks); then cal-
cipotriol (4 wks)
Effect size [CI] (SMD -0.12;
95% CI -0.29 to
0.04)
- (SMD -0.04;
95% CI -0.19 to
0.11)
(SMD -0.14;
95% CI -0.30 to
0.02)
(SMD -0.12;
95% CI -0.29 to
0.04)
02
Calcipotriol (12
wks) vs. com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (8 wks)
Effect size [CI] - - (SMD 0.29;
95% CI -0.04 to
0.62)
- (SMD 0.29;
95% CI -0.04 to
0.62)
03
Calcipotriol (12
wks) vs. com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (w/dy)
& combined cal-
cipotriol + BMD
(w/e) (8 wks)
Effect size [CI] (SMD 0.13;
95% CI -0.04 to
0.29)
- (SMD 0.10;
95% CI -0.05 to
0.25)
(SMD 0.10;
95% CI -0.06 to
0.26)
(SMD 0.13;
95% CI -0.04 to
0.29)
04 Calcipotriol
(6 wks) vs. clobe-
tasol propionate
(2 wks); then cal-
cipotriol (4 wks)
Effect size [CI] (SMD
0.60; 95% CI 0.
18 to 1.02)
(SMD
0.63; 95% CI 0.
21 to 1.05)
- - (SMD
0.60; 95% CI 0.
18 to 1.02)
05 Calcipotriol
(6 wks) vs.
calcipotriol OM,
fluocinonide
Effect size [CI] - - (SMD
0.66; 95% CI 0.
01 to 1.32)
- (SMD
0.66; 95% CI 0.
01 to 1.32)
732Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 16. Analysis 13: Trial characteristics and outcomes: vitamin D vs. other treatments: complex regimens (Continued)
acetonide ON (2
wks); then cal-
cipotriol BD (4
wks)
06 Cal-
cipotriol (6 wks)
vs. halometasone
OM, calcipotriol
ON
(2wks); then cal-
cipotriol BD (w/
dy), halometa-
sone (w/
e) (2 wks); then
calcipotriol BD
(2wks)
Effect size [CI] (SMD 0.41;
95% CI -0.05 to
0.86)
- (SMD
1.13; 95% CI 0.
64 to 1.62)
- (SMD 0.41;
95% CI -0.05 to
0.86)
07 Calcipotriol
ON, clobetasol
propionate OM
(2 to 4 wks);
then calcipotriol
BD (to wk12)
vs. calcitriolON,
clobetasol propi-
onate OM (2 to
4 wks); then cal-
citriol BD (to
wk12)
Effect size [CI] (SMD -0.19;
95% CI -0.54 to
0.16)
- (SMD -0.27;
95% CI -0.62 to
0.09)
- (SMD -0.19;
95% CI -0.54 to
0.16)
08 Combined
calcipotriol
+ BMD (4 wks)
; then placebo
ointment BD (8
wks) vs. com-
bined cal-
cipotriol + BMD
(4 wks); then
calcipotriol oint-
ment BD (8wks)
Effect size [CI] (SMD
0.27; 95% CI 0.
12 to 0.41)
- (SMD
0.25; 95% CI 0.
10 to 0.39)
(SMD
0.28; 95% CI 0.
13 to 0.42)
(SMD
0.27; 95% CI 0.
12 to 0.41)
09 Combined
calcipotriol
+ BMD (4 wks)
; then placebo
ointment BD (8
wks) vs. com-
bined cal-
Effect size [CI] (SMD
0.51; 95% CI 0.
37 to 0.66)
- (SMD
0.59; 95% CI 0.
45 to 0.74)
(SMD
0.71; 95% CI 0.
56 to 0.85)
(SMD
0.51; 95% CI 0.
37 to 0.66)
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Table 16. Analysis 13: Trial characteristics and outcomes: vitamin D vs. other treatments: complex regimens (Continued)
cipotriol + BMD
(4wks); then cal-
cipotriol (w/dy)
+ combined cal-
cipotriol + BMD
(w/e) (8 wks)
10 combined
calcipotriol
+ BMD (4 wks);
then calcipotriol
ointment BD (8
wks) vs. com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (w/dy)
+ combined cal-
cipotriol + BMD
(w/e) (8 wks)
Effect size [CI] (SMD
0.26; 95% CI 0.
11 to 0.40)
- (SMD
0.30; 95% CI 0.
16 to 0.45)
(SMD
0.44; 95% CI 0.
29 to 0.58)
(SMD
0.26; 95% CI 0.
11 to 0.40)
11 Combined
calcipotriol
+ BMD (8 wks);
then calcipotriol
(4 wks) vs. com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (w/dy)
& combined cal-
cipotriol + BMD
(w/e) (8 wks)
Effect size [CI] (SMD
0.24; 95% CI 0.
08 to 0.40)
- (SMD 0.15;
95% CI -0.01 to
0.30)
(SMD
0.23; 95% CI 0.
07 to 0.39)
(SMD
0.24; 95% CI 0.
08 to 0.40)
12 Tacalcitol (8
wks) vs. com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (4 wks)
Effect size [CI] (SMD
0.54; 95% CI 0.
36 to 0.72)
- (SMD
0.49; 95% CI 0.
31 to 0.67)
(SMD
0.54; 95% CI 0.
36 to 0.72)
(SMD
0.54; 95% CI 0.
36 to 0.72)
All treatments (not pooled) - - - - -
- No. participants 2755 46 2991 2508 2936
- Between-patient
design
6 0 8 4 8
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Table 16. Analysis 13: Trial characteristics and outcomes: vitamin D vs. other treatments: complex regimens (Continued)
- Within-patient
design
1 1 0 0 1
- Treatment dura-
tion
6 wks to 12 wks 6 wks 2 wks to 12 wks 8 wks to 12 wks 2 wks to 12 wks
For acronyms, see Table 1.
Table 17. Analysis 14: Trial characteristics and outcomes: vitamin D vs. other treatment: long-term studies (> 24 wks)
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end point
01 Combined
cal-
cipotriol + BMD
(52 wks) vs. al-
ternating: com-
bined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (4 wks)
Effect size [CI] (SMD -0.09;
95% CI -0.36 to
0.18)
- - - (SMD -0.09; 95% CI -0.36 to 0.
18)
02 Combined
cal-
cipotriol+BMD
(52 wks) vs.
combined cal-
cipotriol+ BMD
(4 wks); then
calcipotriol (48
wks)
Effect size [CI] (SMD -0.18;
95% CI -0.47 to
0.10)
- - - (SMD -0.18; 95% CI -0.47 to 0.
10)
03 Alternating:
combined cal-
cipotriol + BMD
(4wks); then cal-
cipotriol (4 wks)
vs. combined
calcipotriol
+ BMD (4 wks);
then calcipotriol
(48 wks)
Effect size [CI] (SMD -0.09;
95% CI -0.37 to
0.19)
- - - (SMD -0.09; 95% CI -0.37 to 0.
19)
All treatments (no pooling) - - - - -
- No. participants 297 0 0 0 297
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Table 17. Analysis 14: Trial characteristics and outcomes: vitamin D vs. other treatment: long-term studies (> 24 wks)
(Continued)
- Between-patient
design
1 0 0 0 1
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
52 wks - - - 52 wks
For acronyms, see Table 1.
Table 18. Analysis 15: Trial characteristics and outcomes: vitamin D/other treatment
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
vs. coal tar
Effect size [CI] (SMD -0.53;
95% CI -1.74 to
0.68)
- (SMD -0.10;
95% CI -1.54 to
1.35)
(SMD -0.10;
95% CI -1.54 to
1.35)
(SMD -0.53;
95% CI -1.74 to
0.68)
02 Calcipotriol
vs. coal tar poly-
therapy
Effect size [CI] (SMD -0.59;
95% CI -0.87 to
-0.31)
(SMD -0.51;
95% CI -0.86 to
-0.16)
(SMD -0.63;
95% CI -1.06 to
-0.20)
(SMD -0.63;
95% CI -1.06 to
-0.20)
(SMD -0.59;
95% CI -0.87 to
-0.31)
03 Calcipotriol
vs. nicotinamide
1.4%, BD
Effect size [CI] - (SMD -0.09;
95% CI -0.49 to
0.31)
- - (SMD -0.09;
95% CI -0.49 to
0.31)
04 Calcipotriol
vs. calcipotriol +
nicotinamide 1.
4%, BD
Effect size [CI] - (SMD 0.19;
95% CI -0.14 to
0.52)
- - (SMD 0.19;
95% CI -0.14 to
0.52)
05 Calcipotriol
vs. corticosteroid
+ salicylic acid
Effect size [CI] (SMD -0.06;
95% CI -0.33 to
0.22)
- (SMD -0.05;
95% CI -0.36 to
0.26)
(SMD -0.49;
95% CI -0.79 to
-0.20)
(SMD -0.05;
95% CI -0.26 to
0.15)
06 Calcipotriol
vs. propylth-
iouracil cream
Effect size [CI] - - (SMD -2.24;
95% CI -3.23 to
-1.25)
- (SMD -2.24;
95% CI -3.23 to
-1.25)
07
Calcipotriol vs.
tacrolimus oint-
ment
Effect size [CI] - (SMD -0.35;
95% CI -1.51 to
0.81)
(SMD -0.13;
95% CI -0.51 to
0.24)
(SMD -0.55;
95% CI -1.28 to
0.17)
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Table 18. Analysis 15: Trial characteristics and outcomes: vitamin D/other treatment (Continued)
08 Calcipotriol
vs. tazarotene
Effect size [CI] (SMD -0.22;
95% CI -0.60 to
0.16)
(SMD -0.05;
95% CI -0.33 to
0.23)
- (SMD -0.35;
95% CI -0.99 to
0.29)
(SMD -0.10;
95% CI -0.35 to
0.16)
09 Calcipotriol
vs. tazarotene gel
plus
mometasone
furoate cream
Effect size [CI] - - - - -
10 Calcipotriol
vs. vitamin B12
cream
Effect size [CI] (SMD -0.55;
95% CI -1.33 to
0.24)
- (SMD -0.01;
95% CI -0.78 to
0.75)
(SMD -0.55;
95% CI -1.33 to
0.24)
(SMD -0.55;
95% CI -1.33 to
0.24)
11 Head-to-
head vitamin D
alone or in com-
bination: dosing
Effect size [CI] (SMD -0.24;
95% CI -0.38 to
-0.09)
- (SMD -0.12;
95% CI -0.25 to
0.00)
- (SMD -0.20;
95% CI -0.32 to
-0.07)
12 Head-to-
head vitamin D
alone or in com-
bination: occlu-
sion
Effect size [CI] - (SMD -0.18;
95% CI -2.04 to
1.68)
- - (SMD -0.18;
95% CI -2.04 to
1.68)
All treatments (not pooled) - - - - -
- No. participants 1386 898 1228 456 2364
- Between-patient
design
8 5 6 3 13
- Within-patient
design
2 2 3 3 6
- Treatment dura-
tion
4 wks to 12 wks 6 wks to 12 wks 4 wks to 12 wks 4 wks to 12 wks 4 wks to 12 wks
For acronyms, see Table 1.
Table 19. Analysis 16: Trial characteristics and outcomes: flexural/facial psoriasis: placebo trials
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
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Table 19. Analysis 16: Trial characteristics and outcomes: flexural/facial psoriasis: placebo trials (Continued)
01 Betametha-
sone valerate 0.
1%, OD
Effect size [CI] - - (SMD -2.83;
95% CI -3.79 to
-1.88)
- (SMD -2.83;
95% CI -3.79 to
-1.88)
02 Calcipotriol
ointment, OD
Effect size [CI] - - (SMD -1.08;
95% CI -1.77 to
-0.40)
- (SMD -1.08;
95% CI -1.77 to
-0.40)
03 Pimecrolimus
cream, 1% OD/
BD
Effect size [CI] (SMD -1.07;
95% CI -1.69 to
-0.45)
(SMD -1.37;
95% CI -1.95 to
-0.79)
(SMD -0.62;
95% CI -1.27 to
0.02)
(SMD -0.65;
95% CI -1.24 to
-0.06)
(SMD -0.86;
95% CI -1.30 to
-0.41)
04
Tacrolimus oint-
ment 0.1%, BD
Effect size [CI] - - - - -
All treatments (no pooling) - - - - -
- No. participants 47 57 75 47 122
- Between-patient
design
1 1 1 1 2
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
8 wks 8 wks 4 wks 8 wks 4 wks to 8 wks
For acronyms, see Table 1.
Table 20. Analysis 17: Trial characteristics and outcomes: flexural/facial psoriasis: vitamin D vs. other treatment
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined
end point
01 Calcipotriol
vs. BMV
Effect size [CI] - - (SMD
2.02; 95% CI 1.
20 to 2.84)
- (SMD 2.02; 95%
CI 1.20 to 2.84)
02 Calcipotriol
vs. calcipotriol +
hydrocortisone
Effect size [CI] (SMD
0.30; 95% CI 0.
11 to 0.50)
- (SMD
0.32; 95% CI 0.
12 to 0.51)
- (SMD 0.30; 95%
CI 0.11 to 0.50)
03 Calcipotriol
vs. calcitriol
Effect size [CI] - (SMD
0.61; 95% CI 0.
28 to 0.94)
- - (SMD 0.61; 95%
CI 0.28 to 0.94)
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Table 20. Analysis 17: Trial characteristics and outcomes: flexural/facial psoriasis: vitamin D vs. other treatment (Continued)
04 Calcipotriol
vs. pimecrolimus
Effect size [CI] - - (SMD -0.53;
95% CI -1.17 to
0.11)
(SMD -0.
53; 95% CI -1.17
to 0.11)
05 Calcitriol vs.
tacrolimus
Effect size [CI] (SMD 0.42;
95% CI -0.15 to
0.98)
(SMD 0.29;
95% CI -0.27 to
0.85)
- - (SMD 0.42; 95%
CI -0.15 to 0.98)
All treatments (no pooling) - - - - -
- No. participants 457 124 464 0 588
- Between-patient
design
2 1 2 0 3
- Within-patient
design
0 1 0 0 1
- Treatment dura-
tion
6 wks to 8 wks 6 wks 4 wks to 8 wks 0 4 wks to 8 wks
For acronyms, see Table 1.
Table 21. Analysis 18: Trial characteristics and outcomes: scalp psoriasis: placebo-controlled trials
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end
point
01 Vitamin D:
calcipotriol
Effect size [CI] (SMD -0.72;
95% CI -1.28 to
-0.16)
(SMD -0.44;
95% CI -0.64 to
-0.25)
- (SMD -0.66; 95%
CI -1.28 to -0.05)
(SMD -0.72; 95%
CI -1.28 to -0.16)
02 Po-
tent steroid: be-
tamethasone
dipropionate
Effect size [CI] (SMD -1.09;
95% CI -1.29 to
-0.90)
(SMD -1.00;
95% CI -1.19 to
-0.81)
- (SMD -1.23; 95%
CI -1.43 to -1.03)
(SMD -1.09; 95%
CI -1.29 to -0.90)
03 Po-
tent steroid: be-
tamethasone
valerate
Effect size [CI] - (SMD -1.40;
95% CI -1.75 to
-1.05)
- - (SMD -1.40; 95%
CI -1.75 to -1.05)
04 Very po-
tent steroid: am-
cinonide
Effect size [CI] (SMD -1.42;
95% CI -1.80 to
-1.04)
(SMD -1.58;
95% CI -1.98 to
-1.18)
- (SMD -0.97; 95%
CI -1.33 to -0.61)
(SMD -1.42; 95%
CI -1.80 to -1.04)
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Table 21. Analysis 18: Trial characteristics and outcomes: scalp psoriasis: placebo-controlled trials (Continued)
05 Very potent
steroid: clobeta-
sol propionate
Effect size [CI] (SMD -1.73;
95% CI -1.99 to
-1.48)
(SMD -1.53;
95% CI -1.77 to
-1.28)
- - (SMD -1.57; 95%
CI -1.81 to -1.34)
06 Very po-
tent steroid: hal-
cinonide
Effect size [CI] (SMD -1.11;
95% CI -1.69 to
-0.53)
- - - (SMD -1.11; 95%
CI -1.69 to -0.53)
07 Vitamin D in
combina-
tion: calcipotriol
+ BMD
Effect size [CI] (SMD -0.97;
95% CI -1.61 to
-0.32)
(SMD -0.92;
95% CI -1.42 to
-0.43)
- (SMD -1.00; 95%
CI -1.79 to -0.22)
(SMD -0.97; 95%
CI -1.61 to -0.32)
08 Other treat-
ment: be-
tamethasone-17,
21-dipropionate
plus salicylic acid
Effect size [CI] (SMD -1.48;
95% CI -2.50 to
-0.47)
(SMD -1.15;
95% CI -2.11 to
-0.19)
- - (SMD -1.48; 95%
CI -2.50 to -0.47)
09 Other treat-
ment: ci-
clopirox olamine
shampoo
Effect size [CI] - (SMD -0.07;
95% CI -0.82 to
0.68)
- (SMD -0.11; 95%
CI -0.86 to 0.64)
(SMD -0.07; 95%
CI -0.82 to 0.68)
10 Other treat-
ment: fluoci-
nolone ace-
tonide, plus oc-
clusion
Effect size [CI] (SMD -1.22;
95% CI -1.69 to
-0.76)
(SMD -0.89;
95% CI -1.34 to
-0.44)
- - (SMD -1.22; 95%
CI -1.69 to -0.76)
11 Other treat-
ment: salicylic
acid
Effect size [CI] (SMD -0.86;
95% CI -1.79 to
0.06)
(SMD -0.57;
95% CI -1.47 to
0.32)
- - (SMD -0.86; 95%
CI -1.79 to 0.06)
All treatments No. participants 2472 2897 0 1875 3011
- Between-patient
design
9 12 0 5 13
- Within-patient
design
1 0 0 0 1
- Treatment dura-
tion
2 wks to 8 wks 2 wks to 8 wks - 3 wks to 8 wks 2 wks to 8 wks
Sensitivity analy-
sis: potent corti-
costeroids
Effect size [CI];
I² statistic
- - - - (SMD -1.18; 95%
CI -1.40 to -0.96); I²
statistic: 19.9%
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Table 21. Analysis 18: Trial characteristics and outcomes: scalp psoriasis: placebo-controlled trials (Continued)
Sensitivity analy-
sis: very potent
corticosteroids
Effect size [CI];
I² statistic
- - - - (SMD -1.51; 95%
CI -1.70 to -1.31); I²
statistic: 37.5%
For acronyms, see Table 1.
Table 22. Analysis 19: Trial characteristics and outcomes: scalp psoriasis: vitamin D vs. other treatment
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end
point
01 Vitamin D
vs. corticosteroid
(potent)
: calcipotriol vs.
BMD
Effect size [CI] (SMD
0.48; 95% CI 0.
32 to 0.64)
(SMD
0.45; 95% CI 0.
28 to 0.63)
- (SMD0.56; 95% CI
0.31 to 0.81)
(SMD0.48; 95%CI
0.32 to 0.64)
02 Vitamin D
vs. corticosteroid
(potent)
: calcipotriol vs.
BMV
Effect size [CI] (SMD
0.37; 95% CI 0.
20 to 0.55)
(SMD 0.09;
95% CI -0.09 to
0.27)
- (SMD0.41; 95% CI
0.22 to 0.59)
(SMD0.37; 95%CI
0.20 to 0.55)
03 Vitamin D
vs. corticosteroid
(very potent)
: calcipotriol vs.
clobetasol propi-
onate
Effect size [CI] - (SMD
0.37; 95% CI 0.
05 to 0.69)
- - (SMD0.37; 95%CI
0.05 to 0.69)
04 Vitamin D +
corticosteroid vs.
cor-
ticosteroid: cal-
cipotriol + BMD
vs. BMD
Effect size [CI] (SMD -0.18;
95% CI -0.26 to
-0.10)
(SMD -0.19;
95% CI -0.27 to
-0.11)
- (SMD -0.17; 95%
CI -0.25 to -0.09)
(SMD -0.18; 95%
CI -0.26 to -0.10)
05VitaminDvs.
vitamin D + cor-
ticosteroid: cal-
cipotriol vs. cal-
cipotriol + BMD
Effect size [CI] (SMD
0.64; 95% CI 0.
44 to 0.84)
(SMD
0.70; 95% CI 0.
56 to 0.84)
- (SMD0.84; 95% CI
0.61 to 1.08)
(SMD0.64; 95%CI
0.44 to 0.84)
06 Vitamin D
vs. other treat-
ments: cal-
cipotriol vs. coal
tar polytherapy
Effect size [CI] (SMD -0.24;
95% CI -0.73 to
0.25)
(SMD -0.30;
95% CI -0.84 to
0.24)
- - (SMD -0.45; 95%
CI -0.92 to 0.02)
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Table 22. Analysis 19: Trial characteristics and outcomes: scalp psoriasis: vitamin D vs. other treatment (Continued)
All treatments No. participants 5175 4877 0 3742 5413
- Between-patient
design
10 11 0 6 12
- Within-patient
design
0 0 0 0 0
- Treatment dura-
tion
4 wks to 52 wks 4 wks to 8 wks 0 4 wks to 8 wks 4 wks to 52 wks
For acronyms, see Table 1.
Table 23. Analysis 04: Trial characteristics and outcomes: dithranol vs. placebo
Subcategory Measure 01 IAGI/IGA 02 TSS 03 PASI 04 PAGI/PGA 05 Combined end point
01 Dithranol Effect size [CI],
N, I² statistic
- (SMD -1.
06; 95% CI -1.66
to -0.46); I² statis-
tic: 37.4%
- - (SMD -1.06; 95% CI -1.66
to -0.46); I² statistic: 37.4%
- No. participants 0 47 0 0 47
- Between-patient
design
0 0 0 0 0
- Within-patient
design
0 3 0 0 3
- Treatment dura-
tion
3 wks to 8 wks - - 3 wks to 8 wks
- correlation coef-
ficient (rho) = 0
All trials
- - - (SMD -0.98; 95% CI -1.56
to -0.41)
I² statistic: 13.9%
- rho = 0
Btw-patient trials
rho = 0.25
Within-patient
trials
- - - - (SMD -1.05; 95% CI -1.67
to -0.44)
I² statistic: 35.4%
- rho = 0
Btw-patient trials
rho = 0.50
Within-patient
- - - - (SMD -1.12; 95% CI -1.75
to -0.48)
I² statistic: 56.9%
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Table 23. Analysis 04: Trial characteristics and outcomes: dithranol vs. placebo (Continued)
trials
- rho = 0
Btw-patient trials
rho = 0.75
Within-patient
trials
- - - - (SMD -1.17; 95% CI -1.81
to -0.52)
I² statistic: 78.5%
For acronyms, see Table 1.
Table 24. Included studies of adverse events
Study Methods Participants Intervention
(s)
Outcomes
(AEs)
Summary
findings
Notes Allocation
concealment
Andres 2006 DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion:
computer-
generated list
Concealment:
unclear
BLIND-
ING: single-
blind (investi-
gator)
WITH-
DRAWAL/
DROPOUT:
described
N: 26
TD: 4 wks;
FU: 4 wks
LF: 0 (0%)
BC: character-
istics reported,
but not
demonstrated
to be compa-
rable (sham-
poo group had
more
severe disease
and higher
proportion of
males)
Age: 34.3 (9.
5SD)
Gender
(per centmen)
: 58%
Severity:
DSS: 5.3 (1.
3SD)
% scalp af-
fected: 63.8%
INCLUSION
CRITERIA:
people
with scalp pso-
riasis affecting
> = 25% scalp;
Clobeta-
sol propionate
0.05% sham-
poo, OD. Ap-
plied
to dry scalp,
rinsed off after
15 minutes
Clobetasol
propionate 0.
05% gel, OD.
Applied to dry
scalp and left
in.
Serum cortisol
atrophogenic-
ity (ul-
trasound mea-
surement of
skin thickness
(epidermis +
dermis) (mm)
, averaged over
3 sites of the
scalp)
ocular sa-
fety (intraocu-
lar pressure)
DSS (10-
pt; sum of ery-
thema, adher-
ent desquama-
tion, and
plaque thick-
ening;
0 (none) to
3 (severe) with
half-point rat-
ings
permitted)
Patient-
reported ocu-
lar stinging (0
to 3)
Compliance
Nei-
ther formula-
tion had an
impact on oc-
ular safety, no
report of ocu-
lar stinging
LAE:
CS: 1/14; CG:
2/14
HPA suppres-
sion:
CS: 0/14; CG:
2/14
Atrophy:
CS: 0/14; CG:
0/14
De-
crease in skin
thickness from
baseline:mean
difference:
CS: 0.04 mm
CG: -0.24
mm
(difference: P
< = 0.025)
Effi-
cacy results of
the 2 formula-
tions were
Exploratory
safety study
Sponsored by
Galderma
Laboratories
Unclear
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Table 24. Included studies of adverse events (Continued)
DSS > = 3
EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; lacta-
tion; ophthal-
mological dis-
order; contact
lens wearer
similar. Com-
pli-
ance with pro-
tocol was good
in both groups
Barnes 2000 DESIGN:
within-patient
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 202
TD: 52 wks;
FU: 52 wks
LF: 64 (32%)
BC: NA
Age: 46 (14.
5SD)
Gender
(per centmen)
: 60%
Severity:
Scalp: TSS (0
to 12): 5.9;
Overall assess-
ment (investi-
gator)
: mild (31%);
moder-
ate (58%); se-
vere (11%)
Body: PASI
(modified): 6.
8 Overall as-
sessment (in-
vestiga-
tor): mild (41.
5%); moder-
ate (55%); se-
vere (3.5%)
INCLUSION
CRITE-
RIA: chronic
plaque psori-
asis on scalp
and body;
adult (≥18);
outpatient
Cal-
cipotriol scalp
solution 50
mcg/ml BD
plus
calcipotriol
cream50mcg/
gBD(up to70
g/wk)
No control
Local AEs:
number
of AEs/partic-
ipant
% severe AEs
withdrawals
due to adverse
events (WA)
Systemic AEs:
serum calcium
serum PTH
uri-
nary calcium/
creatinine ra-
tio
Local AEs:
the most com-
mon local AE
was facial irri-
tation
(60/202 par-
ticipants at wk
2), though the
incidence de-
clined rapidly
over time (1/
141 at wk 46).
20% of local
AEs consid-
ered by inves-
tigator to be
’severe’. 14%
of participants
withdrew be-
cause of ad-
verse events
Systemic AEs:
no significant
changes
observed
Sponsored by
Leo Pharma-
ceuticals
Not applicable
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Table 24. Included studies of adverse events (Continued)
EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; severe
(i.e. requiring
ad-
ditional ther-
apy) or un-
stable psoria-
sis; hyper-
calcaemia; his-
tory
of hypo- or hy-
perparathy-
roidism, renal/
hepatic dis-
ease; systemic
or photothera-
pies within
previous
6 wks; other
medication
that could af-
fect course of
disease
Berth-Jones
1993; Berth-
Jones 1992c
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
NA
STUDY A:
N: 20
TD: 52 wks;
FU: 52 wks
LF: 0 (0%)
BC: NA
Age: 43
Gender
(per centmen)
: 65%
Severity:mean
PASI: 7.6 (3.
5SD)
STUDY B:
N: in-
tervention: 10
{32 controls}
TD: 4 wks;
FU: 4 wks
LF: 0 (0%)
BC: not
Study A: cal-
cipotriol oint-
ment 50 mcg/
g BD up to
100 g/wk
No control
Study B: cal-
cipotriol oint-
ment 50 mcg/
g BD, using
100 g/wk for 4
wks
Control: peo-
ple using al-
ternative ther-
apies
Local AEs:
not assessed
Systemic AEs:
urine calcium
and phosphate
ex-
cretion; serum
total calcium,
phosphate and
alkaline phos-
phatase
Study A:
no significant
trend in urine
calcium excre-
tion
Study B:
significant in-
crease in urine
calcium excre-
tion (rel-
ative to con-
trols and to
baseline)
Sponsorship
not reported
For study B,
baseline com-
pa-
rability of in-
tervention and
control groups
not
demonstrated.
Berth
Jones 1992 re-
ports findings
for study A at
10 mths
Not applicable
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Table 24. Included studies of adverse events (Continued)
demonstrated
Age: 48 {42}
Gender
(per centmen)
: 50% {44%}
Severity:mean
PASI:
18.0 (13.9SD)
{NR}
INCLUSION
CRITERIA:
people
with chronic
plaque psoria-
sis;
aged≥18; un-
der long-term
care of inves-
tigators. Study
A: compliant
patients,
responsive to
calcipotriol.
Study B: more
extensive
disease, failing
to respond to
low doses of
topical agents.
Controls re-
ceived no cal-
cipotriol.
EXCLU-
SION CRI-
TERIA: preg-
nancy
Bleiker 1998 DESIGN: un-
controlled
study
Delivery: un-
clear
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
N: 28
TD: 2 wks;
FU: 26 wks
LF: unclear
BC: NA
Age:
47 (range: 18
to 83)
Gender
(per centmen)
: 50%
STUDY
A: 200 g cal-
cipotriol oint-
ment 50 mcg/
g (wk 1) plus
300 g 50 mcg/
g calcipotriol
(wk 2)
STUDY B:
Calcipotriol
Local AEs:
not assessed
Systemic AEs:
serum
total adjusted
calcium
urinary
calcium
5 participants
developed hy-
percal-
caemia during
treatment, all
had received a
dose > 5 g/kg
9 participants
became hyper-
calciuric dur-
ing treatment;
Sponsorship
not reported
Not applicable
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Table 24. Included studies of adverse events (Continued)
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
not described
Sever-
ity: PASI: 21.4
(range: 8.2 to
53.7)
INCLUSION
CRI-
TERIA: inpa-
tients with se-
vere chronic
plaque psori-
asis (> 15%
BSA)
EXCLU-
SION CRI-
TERIA: renal
impairment,
pregnancy,
lacta-
tion, systemic
treatment, di-
uretics
50
mcg/g PRN <
= 360 g/wk
this was un-
correlated
with dose
Brodell 2011b DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
randomised
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
not described
N: 305
TD: 12 wks;
FU: 12
LF: unclear
BC: NA
Age: 50.3 (13.
7SD); range:
22 to 84
Gender (per
cent men): 61.
8%
Severity:
ODS: all pa-
tients scored as
moderate/
severe/very se-
vere
% BSA: 7.1%
% white: 91.
8%
INCLUSION
CRI-
TERIA: peo-
ple with mod-
erate to severe
plaque psori-
asis; affected;
Clo-
betasol propi-
onate 0.05%
spray BD (2 to
4 wks); treat-
ment respon-
ders (ODS < =
3) then treated
with calcitriol
3 mg/g oint-
ment (8 wks)
Pruri-
tis, telangiec-
tasias, burn-
ing/stinging
(0 to 3), skin
atrophy, folli-
culitis
Overall
disease sever-
ity (ODS) (5-
pt: 0 = clear to
4 = severe/very
severe) based
on erythema,
scaling,
and plaque el-
evation
Treat-
ment success
(change from
baseline ODS
> = 1 at wk 12)
At 4 wks:
skin atrophy
7/285
telangiectasias
2/285
stinging/
Burning 39/
285
folliculitis 11/
285
At 12 wks:
skin atrophy
2/235
telangiectasias
5/235
stinging/
Burning 35/
235
folliculitis 3/
235
Any
adverse event:
100/305
Sponsored by
Galderma lab-
oratories
Not applicable
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aged 18 to 80
EXCLU-
SION
CRITERIA:
not stated
Corbett 1976 DESIGN:
within-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: NR
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
not described
N: 14
TD: 26 wks;
FU: 26 wks
LF: 2 (14.3%)
BC
(clinical): NR
Age: 44 (18.
4SD) Gender
(per centmen)
: 64%
Severity: NR
INCLUSION
CRITERIA:
bilateral psori-
asis involving
< = 15% BSA;
willing to par-
ticipate for 6
months
EXCLU-
SION CRI-
TERIA: NR
Clobeta-
sol propionate
0.05% oint-
ment, BD Be-
tamethasone
valerate 0.1%
ointment, BD
Local AEs:
NR
Systemic AEs:
synacthen test
for function of
pituitary-
adrenal axis at
0, 3, and 6
months
Quantities
used by study
par-
ticipants were
small (mean: 7
g/wk)
No pituitary-
adrenal
suppression
observed
Sponsorship
not reported
Unclear
Gerritsen
2001;
Langner
1996; van de
Kerkhof
1996c
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: NA
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
N: 257
TD: < = 78
wks; FU: <=
78 wks
LF: 4 (1.6%)
BC: NA
Age: 42
(13SD)
Gender (per
cent men): 61.
3%
Severity: BSA:
14.0% (14.
2%SD); PASI:
9.7; 47% had
severe disease
INCLUSION
CRITE-
RIA: chronic
plaque psoria-
Calcitriol 3
mcg/g BD
No control
Local AEs:
serious AEs re-
ported; with-
drawals due to
adverse events
(WA)
Systemic AEs:
laboratory lev-
els for: pro-
tein albumin;
calcium, phos-
phorus,
sodium,
potas-
sium, plasma
calcitriol
Urinary
calcium, cre-
Local AEs:
WA: 7/253;
AEs: 37/353;
no se-
rious local ad-
verse events
Systemic AEs:
WA:
1/253. 4 addi-
tional partic-
ipants experi-
enced hyper-
calcaemia. All
mean
values for all
parameters re-
mainedwithin
normal levels.
Sponsored by
Solvay-
Duphar BV
Excludes scalp
Not applicable
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Table 24. Included studies of adverse events (Continued)
sis; aged ≥18
EXCLU-
SION CRI-
TERIA: non-
compliant;
preg-
nancy; use of
systemic/
phototherapy
within previ-
ous 2 mths;
use of topical
therapy
within previ-
ous 1 wk; con-
comitant dis-
ease; clinically
rel-
evant abnor-
mality in lab-
oratory assess-
ments; known
hypersen-
sitivity to vita-
min D/vehicle
atinine, phos-
phorus; creati-
nine
clearance; uri-
nary calcium/
creatinine ra-
tio
Mean use: 6 g/
day (range: 1
to 24 g/day)
Guzzo 1996 DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: NR
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
described
N: 78
TD: 8 wks;
FU: 8 wks
LF: 2 (2.6%)
BC: no (1 sta-
tistically sig-
nificant differ-
ence (% BSA
higher in in-
tervention
group)
Age: 48
Gender
(per centmen)
: 67%
Severity:mean
BSA: 9%
INCLUSION
CRITERIA:
aged≥18; sta-
ble
plaque psoria-
sis; BSA: 5%
Calcipotriol
50 mcg/g
ointment BD,
up to 120 g/
wk
Placebo
Local AEs: not
assessed
Systemic AEs:
blood and
urine chem-
istry analysis:
parathy-
roid hormone,
serum
calcium,
bone-specific
alkaline phos-
phatase,
urinary hyrox-
yproline, 24-
hr urinary cal-
cium ex-
cretion. Bone
densitometry
No adverse ef-
fects on bone
metabolism or
calcium
Sponsored by
Bristol-Myers
Squibb
Unclear
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Table 24. Included studies of adverse events (Continued)
to 20%
EXCLU-
SION
CRITE-
RIA: hypercal-
caemia, bone,
thyroid
or parathyroid
disease; topi-
cal therapy
within previ-
ous 2
wks; systemic/
phototherapy
within previ-
ous 8 wks
Heng 1990 DESIGN: be-
tween-patient
(retrospective
study)
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
NA
WITH-
DRAWAL/
DROPOUT:
NA
N: 28
TD: 6 mths
to 12 ys; FU:
6 mths to 12
years
LF: NA
BC: demo-
graphic: yes;
clinical: not
demonstrated
Age: 49
(13SD)
Gender
(per centmen)
: 82%
Severity: NR
INCLUSION
CRITERIA:
psoriasis (any
severity; types
include plaque
(16), gen-
eralised, seb-
orrhoeic, gut-
tate, erythro-
dermic)
; previous pro-
longed treat-
ment with
topical fluori-
nated steroids
Previous pro-
longed treat-
ment with
topical fluori-
nated steroids
Con-
trol: ’steroid-
negative’
group - previ-
ous tar/UVB/
sunlight or no
treatment
Lo-
cal AEs: light/
electron mi-
croscopy for
examination
of basal ker-
atinocyte her-
niation
(BKH); layers
of basement
membrane
Systemic AEs:
NR
Local
AEs: light mi-
croscopy re-
vealed no be-
tween-group
differences.
Electron mi-
croscopy re-
vealed multi-
layered, frag-
mented
and disorgan-
ised basal lam-
inae
in the steroid
group, which
appeared to be
corre-
lated with du-
ration of treat-
ment. Frag-
mentation was
not observed
in the control
group
Sponsorship
not reported
Non-
psoriatic con-
trol group also
considered
16/28 partici-
pants had
plaque psoria-
sis
Not applicable
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(range: 6 mths
to 12 years).
Control group
matched for
age and gen-
der
EXCLU-
SION CRI-
TERIA: NR
Katz 1987b DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: NS
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
described
N: 40
TD: 3 wks;
FU: 3 wks
LF: NA
BC:
demographic:
yes; clinical:
yes (gender
imbalance)
Age:
44 (range: 18
to 66)
Gender
(per centmen)
: 53%
Severity: 55%
moderate dis-
ease; 45% se-
vere disease
INCLUSION
CRITERIA:
aged≥ 18; sta-
ble or worsen-
ing, moderate
or
severe chronic
plaque psoria-
sis;
baseline labo-
ratory values
within normal
range (5 to 25
mcg%)
EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; lacta-
Betametha-
sone dipropi-
onate (0.05%)
in opti-
mised vehicle
BD; Clobeta-
sol 17 propi-
onate (0.05%)
ointment BD
Local AEs: not
assessed
Systemic AEs:
morning
plasma corti-
sol levels; 24-
hr urine
steroid levels;
FBC, blood
chemistry, uri-
nalysis
Temporary re-
versible
suppression of
the hypothala-
mic-pituitary-
adrenal axis in
8/40 partici-
pants
Sponsorship
not reported;
1 author from
Schering Cor-
poration
Unclear
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Table 24. Included studies of adverse events (Continued)
tion; hyper-
sensitivity
to study med-
ications; con-
current medi-
cation
that could af-
fect study out-
comes; use of
systemic ther-
apies
within previ-
ous 4 wks; use
of topical ther-
apies within
previous 2 wks
Katz 1989 DESIGN:
within-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: unclear
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
described
N: 30
TD: 2 wks;
FU: 4 wks
LF: 0 (0%)
BC: yes
Age:
55 (range: 36
to 69)
Gender
(per centmen)
: 53%
Severity: NR
INCLUSION
CRITERIA:
bilateral sym-
metric chronic
plaque psori-
asis EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; peo-
ple with overt
signs of atro-
phy
Betametha-
sone dipropi-
onate (0.05%)
in opti-
mised vehicle
BD (BMD)
Clo-
betasol propi-
onate (0.05%)
ointment BD
(CP)
Unin-
volved (non-
psoriatic) area
used as test
area for each
participant
Lo-
cal AEs: skin
surface micro-
scopic exami-
na-
tion with pho-
tographic doc-
umen-
tation; oil and
magnifying (8
x) lens to de-
tect ’preat-
rophy’ (visibil-
ity of subpap-
illary vascular
plexus caused
by thinning of
epidermis and
papillary der-
mis)
Systemic AEs:
NR
Local AEs: no
serious adverse
events ob-
served with ei-
ther treat-
ment. Preatro-
phy identified
in 20% of in-
volved plaques
(BMD: 11/
59; CP: 12/
59) and was
more likely in
females. In the
test area (non-
psoriatic skin)
,
5% of plaques
showed preat-
rophy (BMD:
2/30; CP: 1/
30). Preatro-
phy appeared
to be usually
reversible fol-
lowing
treatment ces-
sation
Sponsored by
Schering Cor-
poration
Unclear
Kimball 2008
Phase II
DESIGN: un-
controlled
patient deliv-
ery
N: 32
TD: 2 wks;
FU: NS
Clobetasol 0.
05% foam BD
Clo-
Maximal
plasma
concen-
Higher but
non-
significant lev-
Supported by
Stiefel Labora-
tories, Inc.
Not applicable
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ALLOCA-
TION:
unclear
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
LF: 1 (3.1%)
BC: NA
Age: 24 to 72
Gender (per
cent men): NS
Severity: NS
% white: 94%
INCLUSION
CRITERIA
people with
mild to mod-
erate plaque
psoriasis; aged
> = 12
EXCLU-
SION CRI-
TERIA: NS
betasol 0.05%
ointment BD
(= 7 g/day, up
to 50 g/wk)
tration of clo-
betasol propi-
onate
els of clobe-
tasol in oint-
ment group
Review of
phase II stud-
ies on AD and
psoriasis (clo-
betasol foam)
Kimball 2008
Phase III
DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: not
stated
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
described
N: 497
TD: 2 wks;
FU: NS
LF: 16 (3%)
BC: NS
Age: NS
Gender (per
cent men): NS
Severity: most
had baseline
ISGA of 3
INCLUSION
CRI-
TERIA: peo-
ple with mild
to moderate
plaque psoria-
sis; aged > = 12
EXCLU-
SION CRI-
TERIA: NS
Clobetasol 0.
05% foam BD
Clo-
betasol 0.05%
ointment BD
Placebo foam
BD
Face, scalp,
and inter-
triginous areas
excluded from
treatment
Treatment-
related adverse
events:
• all
• atrophy
• burning
• pruritis
• folliculitis
ISGA (inves-
tigator’s static
global assess-
ment score)
(scale NR)
Atrophy:
C foam: 2%
(N = 253)
C ointment:
NS (N = 121)
Placebo foam:
1% (N = 123)
Burning:
C foam: 2%
(N = 253)
C ointment:
NS (N = 121)
Placebo foam:
2% (N = 123)
All treatment-
related adverse
events:
C foam: 8%
(N = 253)
C ointment:
2% (N = 121)
Placebo foam:
7% (N = 123)
Supported by
Stiefel Labora-
tories Inc.
Re-
view of phase
III studies on
AD and pso-
riasis (clobeta-
sol foam)
Unclear
Kragballe
1991b
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
N: 15
TD: 26 wks;
FU: 26 wks
LF: 1(6.7%)
BC: NA
Age:
42 (range: 21
Cal-
cipotriol oint-
ment 50 mcg/
g BD (max:
100 g/wk)
Local AEs: pa-
tient report of
adverse events
Investi-
gator report of
adverse events
Local AEs:
AE(L):
3/15 (reported
to be transient
& mild).
Cases of mild
Sponsorship
not reported.
Leo Pharma-
ceuticals
supplied study
medication
Not applicable
753Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 24. Included studies of adverse events (Continued)
random
Method
of randomisa-
tion:NACon-
cealment: NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
to 71)
Gender
(per centmen)
: 53%
Severity:
% BSA: 14%
(range: 5% to
30%)
Most ’moder-
ate’ severity
INCLUSION
CRITE-
RIA: partici-
pants previ-
ously respond-
ing to cal-
cipotriol dur-
ing 8-wk clin-
ical trial, but
who had since
relapsed
EXCLU-
SION
CRITERIA:
hyper-
calcaemia, im-
paired renal/
hepatic func-
tion, daily re-
ceiving > 400
i.u. vitamin D
No control (skin exam-
ination). Skin
biopsies to de-
termine histo-
logic signs of
epidermal and
dermal
atrophy.
Systemic AEs:
lab-
oratory tests:
FBC, serum
alkaline phos-
phatase, aspar-
tate amino-
transferase,
bilirubin, cre-
atinine, total
calcium, total
phosphate
to moderate
atrophy found
in 4/8 partici-
pants
Systemic AEs:
no consistent
changes in lab-
oratory analy-
ses, with no
clinically im-
portant
changes in
serum calcium
Face and scalp
treated
with emollient
or hydrocorti-
sone cream
1% (not cal-
cipotriol)
Lambert 2002 DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
N: 157
TD: 26 wks;
FU: 26 wks
LF: 8 (5.1%)
BC: NA
Age: 44.4 (14.
0SD)
Gender
(per centmen)
: 57%
Severity:mean
BSA: 13%;
mean PASI: 9.
4 (5.4SD)
INCLUSION
CRITE-
RIA: chronic
Tacalci-
tol ointment,
4 mcg/g OD.
No control
Lo-
cal AEs: par-
ticipants asked
about adverse
events. Tolera-
bility assessed
by investigator
(4-pt: 1 = ex-
cellent to 4 =
poor).
Systemic AEs:
Routine
haematology
and biochem-
istry: FBC,
haemoglobin,
Local AEs:
WA: 5/157 (3.
4%) (treat-
ment-related).
AE(L): 26/
157 (transient
skin irritation)
Tolerability at
least moderate
in 95% of par-
ticipants
Systemic AEs:
no serious ad-
verse events
and no hyper-
Sponsored by
Hermal/BHI,
Germany
Scalp
excluded
Similar
study to van
de Kerkhof
2002, but un-
clear whether
Lambert 2002
is a report of a
subgroup or a
distinct study
Not applicable
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DROPOUT:
described
plaque psoria-
sis; aged 18 to
70; BSA 7%
to 20%; labo-
ratory param-
eters normal at
baseline
EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; topi-
cal antipso-
riatic therapy
within previ-
ous 2 wks; sys-
temic antipso-
riatic therapy
within previ-
ous 6
wks; retinoids
within previ-
ous 52 wks.;
history of hy-
perparathy-
roidism; con-
comitant
use of drugs
affecting cal-
cium
metabolism
bilirubin,
creatinine,
alkaline
phosphatase,
aspartate
aminotrans-
ferase, alanine
aminotrans-
ferase, gamma
glutamyl-
transpepti-
dase, calcium,
phosphate,
sodium,
potassium,
glucose, urea,
albumin.
Urinalysis:
calcium,
creatinine,
phosphate
calcaemia
Lebwohl
1998b
DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random.
Method
of randomisa-
tion: unclear
Concealment:
unclear
BLIND-
ING: double-
blind (partici-
pant/
investigator)
N: 40
TD: 26 wks;
FU: 26 wks
LF: 4 (10%)
BC:
no (Group A
had less severe
disease at base-
line)
Age: NR
Gender
(per centmen)
: NR
Severity:
mild to mod-
erate psoriasis
INCLUSION
Initial reg-
imen: all par-
ticipants
received 2 wks
of calcipotriol
(OM),
halobe-
tasol ointment
(ON)
Group A: Cal-
cipotriol oint-
ment 50 mcg/
g (weekdays)
plus halo-
betasol 0.05%
ointment BD
Local AEs:
treatment-
related adverse
events
Systemic AEs:
not assessed
Local AEs:
AE(L) (treat-
ment-
related; all ir-
ritant contact
dermati-
tis): Group A:
4/17GroupB:
1/20 No cuta-
neous atrophy
observed
Sponsored
by Westwood
Squibb Phar-
maceuticals
Unclear
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WITH-
DRAWAL/
DROPOUT:
described
CRITERIA:
people with at
least moderate
improve-
ment in re-
sponse to ini-
tial 2-wk ther-
apy regimen;
aged≥18; sta-
ble dis-
ease; BSA < =
20% (exclud-
ing face/scalp)
; plaque eleva-
tion
at leastmoder-
ate; willing to
comply with
study protocol
EXCLU-
SION
CRITERIA:
history of sen-
sitivity
to study ingre-
dients; topical
antipsoriat-
ics within pre-
vious 2 wks;
UVB/PUVA
within previ-
ous 8 wks; his-
tory of hyper-
calcaemia, re-
current illness
(weekends)
Group B:
Placebo oint-
ment
(weekdays)
plus halo-
betasol 0.05%
ointment BD
(weekends)
Lebwohl 2001 DESIGN: be-
tween-patient
patient deliv-
ery
ALLOCA-
TION:
random
Method
of randomisa-
tion: NR
Concealment:
unclear
BLIND-
N: 50
TD: 26 wks;
FU: 26 wks
LF: NR
BC: NR
Age: 55
Gender
(per centmen)
: NR
Severity: NR
INCLUSION
CRITERIA:
moderate to
Open-label
phase:
tazarotene 0.
1%
gel plus clo-
betasol propi-
onate 0.05%
ointment for
6 wks. Once
daily initially,
then ’tapered’.
Maintenance
Local AEs: no.
steroid-
specific side-
effects
With-
drawals due to
adverse events
(WA) Drug-
related adverse
events
Systemic AEs:
not assessed
Local AEs: no
steroid-
specific side-
effects
WA: 0/50
AE(L) (treat-
ment-related):
TC: 24% TP:
29% P: 0%
Sponsorship:
not reported
No adequate
effective-
ness data re-
ported. Num-
bers of partic-
ipants in each
group NR
Unclear
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Table 24. Included studies of adverse events (Continued)
ING: double-
blind (partici-
pant/
investigator)
WITH-
DRAWAL/
DROPOUT:
not described
severe plaque
psoriasis; BSA
< = 15%. All
participants
participated
in an open-
label treat-
ment phase
for 6 wks
(tazarotene gel
0.1% OM,
clobetasol
propionate
ointment 0.
05% ON)
EXCLU-
SION CRI-
TERIA: topi-
cal antipsori-
atic treatment
within pre-
vious 2 wks;
UV treat-
ment within
previous 4
wks; systemic
antipsoriatic
treatment
within previ-
ous 8 wks
phase (20wks)
:
tazarotene gel,
0.1%, OM (3/
7 days)
, plus clobeta-
sol propionate
0.05% oint-
ment ON (2/
7days) (TC)
Tazarotene
gel, 0.
1%, OM (3/7
days), placebo
ointment OM
(2/7 days)
, placebo oint-
mentON (2/7
days) (TP)
Placebo
gel OM (3/7
days), placebo
ointment ON
(2/7 days) (P)
Menter 2007;
Feldman
2007a
DESIGN: un-
controlled
patient deliv-
ery
ALLOCA-
TION: NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 1423
TD: 4 wks;
FU: 4 wks
LF: 2 (0.1%)
BC: NA
Age: 49.7 (14.
7SD)
Gender (per
cent men): NS
Severity:
Duration (yrs)
: 12.5 (13SD)
BSA: 10.6%
(5.75% SD)
INCLUSION
CRITERIA:
peo-
ple with mod-
Clo-
betasol 0.05%
foam BD, up
to
50 g/wk either
as monother-
apy or adjunc-
tive to existing
therapy
Erythema,
peeling/
scaling,
dryness, sting-
ing/burn-
ing (0 none to
3 severe)
Telangiecta-
sia, skin atro-
phy, pruritus,
folliculitis (ab-
sent/present)
Also as-
sessed efficacy
and QoL
Erythema: 23.
7%
peeling/scal-
ing: 21.0%
dryness: 28.
3%
stinging/
burning: 15.
1%
Telangiecta-
sia, skin atro-
phy, folliculi-
tis: present in
less than 1%
of participants
(findings not
reported sepa-
Clobex Spray
Community-
Based Re-
search Assess-
ment
(COBRA)
Sponsorship
not reported
Not applicable
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Table 24. Included studies of adverse events (Continued)
erate to severe
plaque psoria-
sis; 3% to20%
BSA involve-
ment
EXCLU-
SION CRI-
TERIA: cur-
rent systemic
therapy, pho-
tother-
apy or topical
therapy
rately)
Pruritus: 5.
7%
Miyachi 2002 DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 160
TD: 54 wks;
FU: 54 wks
LF: 6 (3.8%)
BC: NA
Age: 48.2 (16.
1SD)
Gender
(per centmen)
: 82%
Severity:
mean PASI:
22.49 (10.
2SD) IN-
CLUSION
CRITERIA:
inpatients and
outpatients
with BSA
≥10% EX-
CLUSION
CRITERIA:
pregnancy;
lactation;
severe liver
disease, heart
disease, im-
paired renal
function, hy-
percalcaemia;
treatment
with topical,
UV or sys-
temic antipso-
Tacal-
citol ointment
20 mcg/g OD
(max: 10 g/
day)
No control
Local AEs:
treatment-
related adverse
events
Sys-
temic events:
haematologi-
cal tests (FBC)
, blood bio-
chemical tests
(calcium, in-
organic phos-
phorus, albu-
min, protein,
bilirubin, urea
nitrogen, crea-
tinine, GP/
AST, GPT/
ALT, alkaline
phosphatase,
LDH, intact
PTH), urinal-
ysis (glu-
cose, protein)
; serum tacal-
citol and vita-
min D levels
Local AEs:
AE(L): 16/
154
(29 events, all
mild to mod-
erate)
Systemic AEs:
AE(S): 85/154
(155 events, of
which 6 were
considered
treatment-re-
lated). Serum
levels of in-
tact PTH and
tacalcitol de-
creased, sug-
gesting percu-
ta-
neous absorp-
tion of tacalci-
tol. However,
mean levels of
serum calcium
re-
mainedwithin
the standard
level. Data on
individual re-
sponses not re-
ported.
Sponsorship:
not reported
Scalp treated
in 74/154 par-
ticipants
Usual dosing
regimen
for tacalcitol is
4 mcg/g OD
Not applicable
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Table 24. Included studies of adverse events (Continued)
riatics within
previous 2
wks
High-
dose tacalcitol
affected serum
cal-
cium in par-
ticipants with
reduced renal
function
Poyner 1993 DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 203
TD: 48 wks;
FU: 48 wks
LF: 59 (29.
1%)
BC: NA
Age: 43.
8 (range: 17 to
80)
Gender (per
cent men): 52.
7%
Severity
(assessment
methods NR)
: mild (8%)
; moderate
(63%); severe
(30%) IN-
CLUSION
CRITERIA:
aged ≥18;
chronic
plaque pso-
riasis ≥ 100
cm². EX-
CLUSION
CRITERIA:
PUVA within
previous 8
wks; elevated
serum cal-
cium, unsta-
ble disease,
impaired
hepatic/renal
function’
pregnancy;
concomitant
Calcipotriol
50 mcg/g
ointment
No control
Loca AEs: self
report of ad-
verse events.
Withdrawals
due to adverse
events (WA)
Systemic AEs:
biochemical
and haemato-
logical tests
Compliance:
self-reported
usage at each
visit; weighing
of ointment
tubes
Local AEs:
WA: 8/203
AE(L): 83/
203
142 events re-
ported by 83
(41%) partici-
pants with 20.
2%
being lesional/
perilesional ir-
ritation
Systemic AEs:
no significant
changes in
haemato-
logical values.
Mean
serum calcium
did not
change signifi-
cantly over
study period.
Significant fall
in serum urate
in those
treated ≥ 36
wks
Compli-
ance: median
weekly use
(wks 0 to 5):
16.5g; (wks 43
to 48): 11.6g
Sponsored by
Leo Pharma-
ceuticals
Face/scalp ex-
cluded
Not applicable
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Table 24. Included studies of adverse events (Continued)
oral calcium/
vitamin D.
topical an-
tipsoriatics,
lithium, sys-
temic steroids
Ramsay 1994 DESIGN: un-
controlled
open study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 167 TD:
52 wks; FU:
52 wks LF: 39
(23.4%)
BC: NA
Age:
49 (range: 20
to 85)
Gender
(per centmen)
: 60%
Severity: PASI
(modified): 8.
1 (6.7SD)
INCLUSION
CRITERIA:
chronic
plaque psori-
asis; previous
response to
calcipotriol;
managed by
specialists EX-
CLUSION
CRITERIA:
pregnancy or
risk thereof;
abnormal
serum calcium
or phosphate;
impaired
hepatic/renal
function;
concomitant
oral calcium/
vitamin D;
systemic ther-
apy within
previous 8
wks; topi-
cal therapy
within previ-
ous 4 wks
Calcipotriol
50 mcg/g
ointment.
Max dose: 100
g/wk; 2500 g/
pa Face/scalp/
neck excluded
No control
Local AEs: self
report of
adverse events:
mild, moder-
ate, severe; un-
likely, possi-
bly, or proba-
bly treatment-
related
Systemic AEs:
haematol-
ogy (erythro-
cyte, haemo-
globin, leuko-
cyte, platelet
counts) and
biochemistry
(bilirubin,
AST/ALT,
alkaline phos-
phatase, albu-
min, urate,
creatinine,
phosphate, to-
tal calcium)
tests Compli-
ance: self re-
port of num-
ber tubes used
and number
daily doses
AE(L):
52/161 60 (46
considered to
be treatment-
related) events
reported by 52
of 161 partic-
ipants. 1 par-
ticipant devel-
oped a
significant rise
in serum cal-
cium.
No other ab-
normal-
ities in haema-
tology or bio-
chemistry
tests. 118/161
participants
reported con-
tinuous medi-
cation use and
80% to 90%
used
it twice daily.
Mean use: 35.
1 g/wk (’ini-
tially’) to 23.
4 g/wk during
last 6 mths
Sponsored by
Leo Pharma-
ceuticals
Not applicable
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Table 24. Included studies of adverse events (Continued)
Roelofzen
2010
DESIGN: ob-
servational
study using
retrospective
data (medical
records, can-
cer registry)
and prospec-
tive
(survey) data
(treatments/
lifestyle)
. Multivariate
proportional
hazards regres-
sion.
ALLOCA-
TION: NA
BLINDING:
NA
WITH-
DRAWAL/
DROPOUT:
described
N: 4315
TD: pix
lithantracis
(med): 4 mths
(1
to 300 mths)
liquor carbo-
nis deter-
gens (med): 6
mths (1 to 500
mths)
FU: (med) 21
yrs
LF: 329 (7.
6%)
BC: NA
Age (at diag-
nosis): 31 (0 to
95.7)
Gender
(per centmen)
: 52%
Severity:
% BSA < 1%:
9%
% BSA 2% to
9%: 30%
% BSA 10%
to 30%: 39%
% BSA >
30%: 22%
INCLUSION
CRITERIA:
people
with psoriasis
or eczema, di-
agnosed 1960
to 1990 and
treated in 1 of
3 Dutch hos-
pitals;
EXCLU-
SION CRI-
TERIA: peo-
ple who could
not be traced
All
topical, pho-
totherapy, and
systemic ther-
apies. Focus of
study is on
coal tar:
• Liquor
carbonis only
(LCD)
• Pix
lithantiacis
(PL)
Any cancer
Skin cancer
Internal
malignancies
Specific tu-
mour groups:
• haematological
• breast
• lung
• gastrointestinal
• bladder/
urinary tract
• prostate
• female
reproductive
organs
No
statistically
significant in-
creased risk of
any cancer.
Hazard ratios:
Any cancer:
LCD: 0.85
(95% CI 0.60
to 1.19)
PL: 0.64
(95% CI 0.40
to 1.03)
Skin cancer:
LCD: 1.35
(95% CI 0.53
to 3.44)
PL: 0.33
(95% CI 0.07
to 1.69)
Analy-
sis adjusted for
smoking sta-
tus, other
treatments,
skin type, al-
co-
hol consump-
tion. How-
ever, data on
duration of tar
therapy,
smoking sta-
tus and alco-
hol consump-
tion
were missing
for most par-
ticipants
Not
applicable-
Not
applicable-
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Table 24. Included studies of adverse events (Continued)
van
de Kerkhof
1997b
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion:NACon-
cealment: NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 58
TD: < = 60
wks; FU: < =
60 wks
LF: 16 (27.
6%)
BC: NA
Age:
45 (range: 19
to 78)
Gender (per
cent men): 69.
0%
Severity: BSA:
8.6% (3.9SD)
; TSS (0 to 12)
:7.9 (2.1SD)
INCLUSION
CRITERIA:
people with
chronic
plaque pso-
riasis par-
ticipating
in previous
double-blind
study (Van
de Kerkhof
1996b); aged
25 to 80;
normal serum
calcium/phos-
phate. EX-
CLUSION
CRITERIA:
pregnancy or
risk thereof;
topical ther-
apy within
previous 4
wks; systemic
therapy
within previ-
ous 8 wks; se-
rious disease;
known allergy
to study
Part 1: double-
blind study (8
wks): tacalci-
tol 4 mcg/g
ointment OD
Placebo
Part 2: open
follow-
up study (4wk
wash-out pe-
riod): tacalci-
tol 4 mcg/g
ointmentOD,
< = 20 mg/day
and < 2000
g per partici-
pant over
study period.
Participants
could discon-
tinue treat-
ment after 12
wks
No control
Local AEs: oc-
currence of
adverse events
(duration,
severity, and
whether treat-
ment-related)
Participant
and investiga-
tor assess-
ments of toler-
ability (4-pt: v.
good (3) to in-
sufficient (0))
Systemic AEs:
haematology
(erythrocytes,
platelets, hae-
moglobin,
haematocrit)
; blood chem-
istry (serum
calcium, inor-
ganic phos-
phate, cre-
atinine, ASAT,
alkaline phos-
phatase,
LDH)
Local AEs:
WA: 0/58
AE
(L): 10/58 (19
events) AE(L)
(treatment-
related): 8/58
Toler-
ability: inves-
tigator assess-
ment: 2.60 (0.
53SD,N=58)
;
participant as-
sessment: 2.53
(0.63SD, N =
58)
Systemic AEs:
AE(S): 0/58
No case of hy-
percalcaemia
Sponsorship
not reported
Follow-up
study to Van
de Kerkhof
1996b - 3 of
15 centres par-
ticipated
Scalp
excluded
Not applicable
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Table 24. Included studies of adverse events (Continued)
medication;
concomitant
medication
that could
interfere with
study drug
or systemic
calcium
metabolism
van
de Kerkhof
2002c (see
also Lambert
2002)
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
Part 1:
N: 304
TD: 13 wks;
FU: 13 wks
LF: 47 (15.
5%)
BC: NA
Age:
44 (range: 15
to 76)
Gender
(per centmen)
: 57%
Severity:
median PASI
(modified to
exclude head):
9.5 (range: 2.2
to 24.4); TSS
(0 to 12): 6.0
Part 2: n: 197
TD: 65 wks;
FU: 65 wks
LF: 83 (42.
1%)
BC: NA
Age: NR
Gender
(per centmen)
: NR
Severity: NR
INCLUSION
CRITE-
RIA: chronic
plaque psoria-
sis; BSA 7%
to 20% (ex-
Tacal-
citol 4 mcg/
g OD. Treat-
ment discon-
tinued during
remission and
restarted if re-
lapse
No control
Lo-
cal AEs: num-
ber treatment-
related adverse
events; with-
drawals due to
adverse events
(WA); inves-
tigator assess-
ment of tol-
erability; par-
ticipant assess-
ment of toler-
ability
Systemic AEs:
Haema-
tology: serum
calcium,
parathy-
roid hormone
(PTH), calci-
tonin, cal-
citriol Urine:
calcium, crea-
ti-
nine, calcium/
creatinine
ratio. Compli-
ance with
medication
Local AEs:
WA: 18/304
AE(L): 65/
304
Tol-
erability excel-
lent/good in
76% (patient
assessment) to
92% (investi-
gator
assessment) of
participants at
final
assessment.
Systemic AEs:
No clinically
signif-
icant changes
in rou-
tine haematol-
ogy, urinalysis
or
serum chem-
istry. Compli-
ance with
treatment reg-
imen varied
between 82%
and 92%.
However,
54% of those
with
BSA 10% to
20% exceeded
recommended
Sponsored by
Hermal/BHI,
Germany
Scalp
excluded
Not applicable
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Table 24. Included studies of adverse events (Continued)
cluding scalp);
aged 18 to 70;
normal base-
line laboratory
values
Part 2 of
study: respon-
ders to part 1
(≥ 30% re-
duction
in sum score
(TSS) from
baseline)
EXCLU-
SION CRI-
TERIA: top-
ical steroids
in previous 2
wks; systemic
antipsoriat-
ics within
previous 6
wks; retinoids
within previ-
ous 52 wks;
known hy-
persensitivity
to vitamin D
analogues;
serious con-
comitant dis-
ease; disease
that might
interfere
with study
assessments;
concomitant
use of oral
calcium/
vitamin D;
pregnancy or
risk thereof
daily dose of
5 g (up to 13
g daily), but
there was no
effect on cal-
cium home-
ostasis. Dura-
tion of excess
dosing not re-
ported
Vazquez-
Lopez 2004
DESIGN: un-
controlled
study
patient deliv-
ery
N: 20
TD: 26 wks;
FU: 34 wks
LF: 0 (0%)
BC: NA
Clobeta-
sol propionate
0.05% cream,
OD (week-
Local AEs:
clinical (naked
eye) examina-
tion of psori-
Overuse
of topical
steroids
resulted in
Links compli-
ance with ad-
verse events
Not applicable
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Table 24. Included studies of adverse events (Continued)
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
Age: 28.
2 (range: 20 to
55)
Gender
(per centmen)
: 40%
Severity: NR
INCLUSION
CRITERIA:
absence of vis-
i-
ble or dermas-
copic red lines
(linear telang-
iectasias)
EXCLU-
SION CRI-
TERIA: use of
topical
steroids in pre-
vious 2 mths
ends) plus
calcipotriol 50
mcg/g
ointment BD
(weekdays)
No control
atic plaque
and surround-
ing area
Dermo-
scopic exami-
nation of pso-
riatic plaque
and surround-
ing area
Systemic AEs:
NR
Compli-
ance: quantity
and frequency
of study drug
use (tubes
weighed)
appearance
of clinically
unapparent
but dermo-
scopically
apparent
linear telang-
iectasias. 7/20
participants
failed to
adhere to
recommended
steroid dosing
schedules.
Dermoscopic
red lines not
apparent
in 15/20
participants.
Dermoscopic
red lines ap-
parent in 5/20
participants,
of whom 4
had overused
topical steroid
cream. Steroid
discontinued
in participants
with red lines
and there
was complete
resolution
within 2 mths
Study received
no funding
Veraldi 2006 DESIGN: un-
controlled
study
patient deliv-
ery
ALLO-
CATION: se-
quential
recruitment
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
N: 48
TD: 45 dys;
FU: 45 dys
LF: 5 (10.4%)
BC: NA
Age: 48.
9 (range: 21 to
71)
Gender (per
cent men): 62.
5%
Severity: NR
INCLUSION
CRITERIA:
0.
1% tazarotene
gel, short con-
tact therapy
(applied OD
for 20minutes
then rinsed off
with water)
Pruritis (4-pt:
0 = absent to 3
= severe)
Burning (4-pt:
0 = absent to 3
= severe)
At day
45: pruritis (0
to 3): 0.17 (0.
38SD)
14/43 had
mild pruritis
Burn-
ing (0 to 3) 0.
17 (0.38SD)
14/43
14/43 had
mild burning
No par-
Sponsorship
not reported
Not applicable
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Table 24. Included studies of adverse events (Continued)
described people with
chronic stable
plaque psoria-
sis; % BSA < =
20%
EXCLU-
SION
CRITERIA:
use of antipso-
riatic therapy
within previ-
ous
2 wks; concur-
rent use
of other top-
ical, photo or
systemic ther-
apies
ticipant with-
drew because
of irritation on
treated lesion
Wishart 1994 DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION:
groups deter-
mined accord-
ing to BSA af-
fected.
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 30
TD: 6 wks;
FU: 6 wks
LF: 1 (3%)
BC: NA
Age: 42.5 (13.
2SD)
Gender
(per centmen)
: 47%
Severity:
Du-
ration (mths):
202 (176SD)
INCLUSION
CRITERIA:
people
aged >18 with
severe chronic
plaque psoria-
sis; le-
sion severity >
= 3 (GSS 0 to
4)
EXCLU-
SION CRI-
TERIA: preg-
nancy,
other type of
Calcitriol 15
mcg/g
ointment OD
Quan-
tity of study
drug varied by
group:
Group 1 (N =
12): 4% to 8%
BSA
treated (300 to
600 cmˆ2)
Group 2 (N =
10): 8%
to 15% BSA
treated (600 to
1200 cmˆ2)
Group 3 (N =
8): 15%
to 30% BSA
treated (1200
to 2400 cmˆ2)
IAGI (6-pt)
ECG
Haematology,
biochemistry,
urine protein
and glucose.
Serum
calcium, phos-
phorus,
plasma PTH,
serum 25-hy-
drox-
yvitaim D, 1-
alpha,25dihy-
droxy-vi-
taim D, 24 hr
urine tests for
calcium,
creatinine and
phosphorus
Com-
pliance also as-
sessed (medi-
cation weight)
Mean daily us-
age: 74.0 to
306.1 mcg.
No systemic
adverse events,
no skin irrita-
tion.
No
clinically rel-
evant changes
in vital signs,
haematol-
ogy, biochem-
istry, urine or
ECGs
IAGI (0 to 5):
-
3.57 (1.01SD,
N = 30)
Usual
dose is 3 mcg/
g BD, max. 30
g daily
Sponsored by
Solvay
Duphar
Not applicable
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Table 24. Included studies of adverse events (Continued)
psoriasis, con-
current use of
medicines
contain-
ing calcium or
vitamin
D, antacids or
digitalis
per cent men: per cent male; AE(L): number local adverse events/number participants; AE(S): number systemic adverse events/number
participants; AE: adverse events; BC: baseline comparability; BD: twice daily; BSA: body surface area; FU: follow up (includes TD);
N: number enrolled; NA: not applicable; NR: not reported; OD: once daily; PASI: Psoriasis Area and Severity Index; PRN: as
required; TD: treatment duration; TSS: Total Severity Score; WA: withdrawal due to adverse events
Table 25. Excluded studies of adverse events
Study Reason for exclusion
Aste 2004 Follow-up under 12 wks and not focused on adverse events
Bos 2002 Not psoriasis, short review (letter)
Breneman 2007 Not a product included in our review (bexarotene gel 1%)
Carboni 2005 Not focused on adverse events
Feldman 2007a Evaluated add-on clobetasol for participants treated concurrently with topical or systemic therapy
Floden 1975 Inadequate reporting of adverse events
Franssen 1999 Small (N = 54) retrospective study using participant questionnaires - aimed to identify teratogenetic effects
of tar, but many women unable to recall whether tar used in pregnancy
Hong 2010; Hong 2011 Not chronic plaque psoriasis: paediatric dermatology participants had eczema or “eczema-psoriasis overlap
(atopic dermatitis with associated features of psoriasis)”
Jacobi 2008 Small uncontrolled short-term and already reflected in results from main review
Kang 1998 Short-term and already reflected in results from main review
Lebwohl 1996 Follow-up under 12 wks and not focused on adverse events
Park 2002 Case study
Senter 1983 Adverse events not reported
Singh 2000 Short-term (4 weeks) and brief mention of adverse events
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Table 25. Excluded studies of adverse events (Continued)
Stevanovic 1977 Short-term, unclear if psoriasis, small numbers (N = 6)
Traulsen 2003 Participants were healthy volunteers
Uhoda 2003 Not about adverse events
Vissers 2004 Not about adverse events
Table 26. Included studies of compliance
Study Methods Participants Interventions Outcomes
(compliance
Summary
findings
Notes Allocation
concealment
Balkrishnan
2003
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
sin-
gle-blind (par-
ticipants un-
aware of elec-
tronic compli-
ance
assessment)
WITH-
DRAWAL/
DROPOUT:
described
N: 10
TD: 1wk; FU:
1 wk
LF: 0 (0%)
BC: NA
Age: NR
Gender
(per centmen)
: NR
Severity: NR
INCLUSION
CRI-
TERIA: par-
ticipants with
psoriasis who
already
enrolling in a
study with sal-
icylic acid and
top-
ical tacrolimus
ointment
(Protopic)
combination
therapy.
EXCLU-
SION CRI-
TERIA: NR
Topical sali-
cylic acid 6%
No control
Medication
adherence:
(1) MEMS
cap: med-
ication bottle
cap with mi-
croproces-
sor to record
time/date
of every open-
ing of the bot-
tle.
(2) Patient log
(self report) of
compliance
Mean adher-
ence
rate: method
1: 67% (32%
SD); method
2: 92% (7%
SD)
Med-
ication adher-
ence measured
by method 1
(elec-
tronic) much
lower than by
method 2 (pa-
tient log)
Sponsorship
not reported
D
Carroll
2004a; Carroll
2004b;
Carroll 2005
DESIGN:
within-patient
patient deliv-
ery
ALLOCA-
TION:
N: 30
TD: 8 wks;
FU: 12 wks
LF: 6 (20%)
BC: Yes
Age: 43.
Topical sal-
icylic acid 6%
plus 0.
1% tacrolimus
ointment BD
Medication
adherence:
(1) MEMS
cap: med-
ication bottle
Adherence de-
creased
over time. On
the interven-
tion side, a de-
Sponsored by
Fu-
jisawa Health-
care, Inc. and
by Wake
B
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Table 26. Included studies of compliance (Continued)
random
Method
of randomisa-
tion: NR
Concealment:
unclear
BLINDING:
Sin-
gle-blind (par-
ticipants un-
aware of elec-
tronic compli-
ance
assessment)
WITH-
DRAWAL/
DROPOUT:
described
6 (range 18 to
70)
Gender
(per centmen)
: 50%
Severity: TSS
(0 to 8): 5.3
INCLUSION
CRI-
TERIA: par-
ticipants aged
≥18; symmet-
rical plaque-
type
psoriasis; BSA
< = 10%; sym-
metrical target
plaque 1cm²
with each with
a score of at
least 1 for ery-
thema, thick-
ness, and scale
EXCLU-
SION CRI-
TERIA: preg-
nancy or risk
thereof; topi-
cal treatment
within pre-
vious 2 wks;
phototherapy
or sys-
temic therapy
within previ-
ous 4 wks
Topical sal-
icylic acid 6%
plus placebo
BD
cap with mi-
croproces-
sor to record
time/date
of every open-
ing of the bot-
tle.
(2) Patient log
(self report) of
compliance
(3) medica-
tion weights
crease in ad-
herence rate of
10% was as-
sociated with
a 1-point in-
crease in sever-
ity (P < 0.
05). For the
placebo-
treated side,
adherence was
not sig-
nificantly cor-
related
with changes
in severity.
Poor compli-
ance ap-
pears to have
an impact on
treatment out-
comes in pso-
riasis
Mean adher-
ence (method
1):
%
(doses taken/
doses ex-
pected): 55%;
% (days with
twice-
daily dose/to-
tal days):
39.1% Higher
adherence rate
for women
and older par-
ticipants
Forest Univer-
sity School of
Medicine.
Excluded
from effective-
ness review
(comparator is
not placebo)
Feldman 2007 DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
N: 29
TD: 8 wks;
FU: 8 wks
LF: NR
BC: NA
Age: 43.5
Gender
6% salicylic
acid gel BD
No control
Impact of of-
fice vis-
its on partic-
ipants’ adher-
ence to topical
treatment.
Ad-
herence statis-
tically signifi-
cantly higher
at time of of-
fice visit.
Sponsored in
part by Astel-
las Pharma
US, Inc.
The Center
for Dermatol-
ogy Research
D
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Table 26. Included studies of compliance (Continued)
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
sin-
gle-blind (par-
ticipants un-
aware of elec-
tronic compli-
ance
assessment)
WITH-
DRAWAL/
DROPOUT:
described
(per centmen)
: NR
Severity: NR
INCLUSION
CRITERIA:
NR
EXCLU-
SION CRI-
TERIA: NR
Adherence as-
sessed
using MEMS
cap: medica-
tion bottle cap
Mean adher-
ence over the
study dura-
tion was 55%.
Mean applica-
tions/day: 1.1
(range: 0.72 to
1.4)
is funded by
a grant from
GaldermaL-
aboratories,
LP.
(see also
Balkrishnan
2003; Carroll
2004a, 2004b,
2005)
Ferrandiz
1998
DESIGN: be-
tween-patient
patient deliv-
ery (therapy)
Clinician
delivery (pro-
gramme)
ALLOCA-
TION:
random
Method
of randomisa-
tion: NR
Concealment:
unclear
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
described
N: 881
TD: 16 wks;
FU: 16 wks
LF: 127 (12.
6%)
BC: Yes
Age: 43.3 (16.
9SD)
Gender
(per centmen)
: NR
Severity:mean
PASI: 7.0
INCLUSION
CRITERIA:
moderately se-
vere chronic
plaque psoria-
sis;
BSA < = 30%;
aged 18 to 70;
under special-
ist supervision
EXCLU-
SION CRI-
TERIA: preg-
nancy or lacta-
tion; history of
intolerance to
calcipotriol/
Calcipotriol
plus reinforce-
ment
programme
Cal-
cipotriol with-
out reinforce-
ment
programme
Reinforce-
ment thera-
peutic pro-
gramme to en-
hance adher-
ence: derma-
tologist
provided par-
ticipant edu-
cation with
explanation of
disease charac-
teristics and
treatment effi-
cacy and ap-
plication, plus
written infor-
mation card
The reinforce-
ment pro-
gramme had
no effect on
treatment effi-
cacy
Sponsorship
not reported
B
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Table 26. Included studies of compliance (Continued)
excipients;
concurrent vi-
ta-
min D (> 400
units/day) or
calcium
tablets; psoria-
sis mainly on
face or hirsute
areas
Fouere 2005 DESIGN:
questionnaire
survey (obser-
vational cross-
sectional
study)
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open
WITH-
DRAWAL/
DROPOUT:
response rate
not reported
N: 1281
TD: NA; FU:
NA
LF: NA
BC: NA
Age: 51.9 (SD
14.8)
Gender
(per centmen)
: 48%
Severity: 74%
consid-
ered their pso-
riasis as at least
moderately se-
vere
INCLUSION
CRI-
TERIA:mem-
bers of the na-
tional psoria-
sis patient as-
sociations
inFrance,UK,
Belgium, Ger-
many, and the
Netherlands.
EXCLU-
SION
CRITERIA:
not stated
Any antipsori-
atic therapy
Com-
pliance mea-
sured against
PMAQ-3w
scale
(patient med-
ication adher-
ence question-
naire)
: strict adher-
ence to pre-
scribed reg-
imen over pre-
vious 3 days
and last week-
end
Rea-
sons for non-
compliance
Perceived nec-
essary mea-
sures to in-
crease compli-
ance
73% reported
non-compli-
ance with cur-
rent treatment
Main reasons
for non-com-
pliance: lack
of ef-
ficacy, messi-
ness, and time
constraints
To im-
prove compli-
ance, patients
suggested
improved effi-
cacy, less
greasy, sticky
and smelly
treatment,
and fewer
side-effects
Sponsorship
not reported.
70% of re-
spon-
ders used top-
ical therapy
D
Gokdemir
2008
DESIGN:
open uncon-
trolled study
patient deliv-
ery
ALLOCA-
TION: non-
N: 109
TD: 8 wks;
FU: 8 wks
LF: 6 (6%)
BC: NA
Age:
40 (range: 16
Any pre-
scribed antip-
soriatic ther-
apy
Medication
ad-
herence: num-
ber prescribed
doses taken/
number pre-
Mean adher-
ence for topi-
cal
therapy: 72%
(31%SD)
Findings relate
to any treat-
ment for pso-
riasis (not just
topical
therapy)
D
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Table 26. Included studies of compliance (Continued)
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
described
to 70)
Gender
(per centmen)
: 43%
Sever-
ity: PASI: 9.1
(range: 1.2 to
35)
INCLUSION
CRITE-
RIA: chronic
plaque psori-
asis; received
prescribed an-
tipsoriatic
therapy; aged
≥16; attend-
ing outpatient
clinic in Istan-
bul.
EXCLU-
SION CRI-
TERIA: other
types of psori-
asis; hospi-
talised; preg-
nancy
scribed doses
prescribed (see
Zaghloul
2004).
Adherence
rate was corre-
lated
with being un-
married, more
highly edu-
cated, and be-
ing satis-
fiedwith treat-
ment
Main reasons
for non-ad-
herence were
busyness and
’being fed up’
Sponsorship
not reported
Richards 1999 DE-
SIGN: ques-
tionnaire sur-
vey (cross-sec-
tional uncon-
trolled study)
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
open WITH-
DRAWAL/
DROPOUT:
Response rate
N: 120
TD: NA; FU:
NA
LF: NA
BC: NA
Age: 49 (18 to
84)
Gender
(per centmen)
: 54%
Severity: Du-
ration: range:
1 to 63 yrs
INCLUSION
CRITE-
RIA: consec-
utive partici-
pants
attending ter-
tiary pso-
riasis specialty
Any antipsori-
atic therapy
Per cent com-
plying with
treatment (self
report): scale
not reported
39 per cent
reported non-
compliance
(sometimes/
never comply-
ing) with pre-
scribed treat-
ment. The
non-compli-
ant group had
a higher self-
rated disease
severity, were
younger, and
had a younger
age at onset.
The non-
compli-
ant group re-
ported that
Sponsorship
not reported
55% of par-
ticipants were
using topical
therapies
D
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Table 26. Included studies of compliance (Continued)
not reported clinic; psoria-
sis.
EXCLU-
SION
CRITERIA:
not stated
psoriasis had a
greater impact
on daily life
Factors affect-
ing compli-
ance included
the doctor-
participant re-
la-
tionship; opti-
mism with the
treatment pre-
scribed; and a
lim-
ited ’nuisance’
value of treat-
ment in terms
of side-effects
and hassle of
use
van de
Kerkhof 1998
DE-
SIGN: ques-
tionnaire sur-
vey (uncon-
trolled study)
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
NA
WITH-
DRAWAL/
DROPOUT:
Response rate
reported
N: 972
TD: NA; FU:
NA
Response rate:
13%
BC: NA
Age:
45.8 (range: 5
to 87)
Gender
(per centmen)
: 43%
Severity: dura-
tion of psori-
asis > 10 yrs
in 67% of re-
sponders
INCLUSION
CRITERIA:
subscribers to
’Psoriasis’, the
journal of the
Dutch Psoria-
sis Patient Or-
ganisation
EXCLU-
SION CRI-
Any top-
ical antipsori-
atic therapy
Per cent com-
ply-
ing with fre-
quency of ap-
pli-
cation of pre-
scribed topical
therapies
Reason
for non-com-
pliance
29%
of responders
reported that
the prescriber
did not spec-
ify dosage fre-
quency.
Where dosage
frequency was
specified, 33%
(39%)
complied with
twice (once)
daily regimens
Main reasons
for non-ad-
herence were
preference for
less frequent
dosage; greasi-
ness; lack of ef-
ficacy; and
higher-
than expected
efficacy
Sponsorship
not reported.
14-item ques-
tionnaire
mailed in
1996 to 6100
subscribers of
Psoriasis, the
Journal of the
Dutch Psoria-
sis Patient Or-
ganisation
Responders
asked to report
on compli-
ance over past
6 mths
D
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Table 26. Included studies of compliance (Continued)
TERIA: none
stated
van de
Kerkhof 2000
DE-
SIGN: ques-
tionnaire sur-
vey (uncon-
trolled study)
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLINDING:
single-blind
WITH-
DRAWAL/
DROPOUT:
response rate
reported
N: 839
TD: NA; FU:
NA
LF: NA
Response rate:
14%
BC: NA
Age:
48.5 (range: 4
to 91)
Gender
(per centmen)
: 46%
Severity: dura-
tion of psoria-
sis ≥ 11 years
in 62% of re-
sponders
INCLUSION
CRITERIA:
subscribers to
’Psoriasis’, the
Journal of the
Dutch Psoria-
sis Patient Or-
ganisation
EXCLU-
SION CRI-
TERIA: none
stated
Any antipso-
riatic therapy
including top-
ical treat-
ments, photo
(chemo)ther-
apy and sys-
temic therapy
Per cent com-
ply-
ing with du-
ration of pre-
scribed treat-
ment (topical
therapies)
Per cent com-
ply-
ing with fre-
quency of ap-
pli-
cation of pre-
scribed treat-
ment (topical
therapies)
Reason
for non-com-
pliance
Per cent com-
ply-
ing with du-
ration of pre-
scribed treat-
ment (top-
ical therapies):
71%
Per cent com-
ply-
ing with fre-
quency of ap-
pli-
cation of pre-
scribed treat-
ment (top-
ical therapies):
51%
Main reasons
for non-ad-
herence were
prefer-
ence for min-
imum dosage;
time con-
straints; and
lack of confi-
dence in effi-
cacy
Sponsorship
not reported
41-
item question-
naire mailed
to 6100 sub-
scribers of
Psoriasis, the
Journal of the
Dutch Psoria-
sis Patient Or-
ganisation
Responders
asked to report
on compli-
ance over past
6 mths
D
van de
Kerkhof 2001
DESIGN:
within-patient
(see Notes)
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
concealment:
NA
BLINDING:
N: 976
TD: 8 wks;
FU: 8 wks
LF: 93 (9.5%)
BC: NR
Age:
45.6 (range: 7.
4 to 88.4)
Gender
(per centmen)
: 52% Sever-
ity: BSA ≥
10% in 51%
of participants
Calcipotriol
cream
OM plus cal-
cipotriol oint-
ment ON
Calcipotriol
ointment BD
Compliance:
self-reported
number
of days cream/
ointment regi-
men applied
At wk 3, 72%
of participants
ap-
plied the regi-
men on most
days. By wk
8, this statis-
tic had fallen
to 61%
51%
of the 309 par-
ticipants with
Sponsorship
not reported
Control group
comprised ret-
rospective self-
reported expe-
rience of cal-
cipotriol oint-
ment
monother-
apy by 35%
of participants
D
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Table 26. Included studies of compliance (Continued)
open
WITH-
DRAWAL/
DROPOUT:
described
INCLUSION
CRITE-
RIA: psoriasis
(typeNR); eli-
gible for treat-
ment with cal-
cipotriol
EXCLU-
SION
CRITERIA:
concomitant
topical or sys-
temic antipso-
riatic therapy;
co-exist-
ing skin disor-
der other than
psoriasis
previous expe-
rience of cal-
cipotriol oint-
ment
monotherapy
reported that
their compli-
ance with the
cream/oint-
ment regimen
was higher
in the inter-
vention group
Zaghloul
2004
DESIGN: un-
controlled
study
patient deliv-
ery
ALLOCA-
TION: non-
random
Method
of randomisa-
tion: NA
Concealment:
NA
BLIND-
ING: single-
blind (partici-
pants unaware
that study fo-
cused on com-
pliance)
WITH-
DRAWAL/
DROPOUT:
described
N: 294
TD: 12 wks;
FU: 12 wks
LF: 93 (31.
6%)
BC: NA
Age: 45.
1 (range: 20 to
65)
Gender (per
cent men): 44.
3%
Severity: NR
INCLUSION
CRITERIA:
psoriasis (un-
clear if chronic
plaque only)
; aged 18 to
65; prescribed
oral, topical or
combined
treatment
EXCLU-
SION CRI-
TERIA: preg-
nancy,
Topical,
oral, or com-
bined antipso-
riatic medica-
tion
No control
Medication
adherence:
(1) num-
ber prescribed
doses taken/
number pre-
scribed doses
prescribed
(2) patient
self-report
Quality of Life
(DLQI) (0 to
30; higher
score implies
lower quality
of life)
Med-
ication adher-
ence measured
by
method 1 (ob-
jective) much
lower than by
method 2 (pa-
tient self
report). Mean
rate: 60.6%
(33.0%SD)
; (range: 0%
to169%)
Direct correla-
tion observed
between med-
ication adher-
ence and qual-
ity of life
Adherence
rate higher for
par-
ticipants who
Authors
report no rel-
evant financial
interests
D
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Table 26. Included studies of compliance (Continued)
lactation, con-
comitant dis-
ease
were women,
married, em-
ployed, or not
paying for pre-
scriptions
Adherence
greater
for topical (vs.
systemic)
therapy, once
daily, or first-
time use
per cent men: per cent male; AE(L): number local adverse events/number participants; AE(S): number systemic adverse events/number
participants; AE: adverse events; BC: baseline comparability; BD: twice daily; BSA: body surface area; FU: follow up (includes TD);
N: number enrolled; NA: not applicable; NR: not reported; OD: once daily; PASI: Psoriasis Area and Severity Index; PRN: as
required; TD: treatment duration; TSS: Total Severity Score; WA: withdrawal due to adverse events
Table 27. Excluded studies of compliance
Study Reason for exclusion
Atkinson 2004 Adherence not assessed
Chu 2000 Treatment guideline (not primary study)
Gupta 2007 Review/think piece
Lee 2006 Review
Osborne 2002 Study focused on non-responsive participants rather than those that are specifically non-compliant
Richards 2006 Review
Szeimies 2004 Think piece (not primary study)
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A P P E N D I C E S
Appendix 1. Specialised Register search strategy (RCTs)
Searched 04/12/04
Search updated on 17/11/2008: from January 2005 to date
Search updated on 3/02/2011: from November 2008 to date. One additional term added to 1st part: ’taclonex’.
Search updated 29/08/12: from February 2011 to date.
1st part
(*psorias* or *psoriat*) AND (*tar* or *gel* or alphosyl or carbodome or exorex or balneum or cocois or capasal or ceanel or ionil
or meted or pentrax or anthralin or dithr* or micanol or psorin or psoriderm or salicylic or (vitamin and D) or calcipo* or dovo*
or *calcit* or curatoderm or tazarotene or zorac or silkis or acitretin or neotigason or ciclosporin or cyclosporin or methotrexate or
tacrolimus or pimecrolimus or protopic or elidel or retinoid* or macrolactam* or immunosuppressant* or taclonex) AND topical*
2nd part
(*psorias* or *psoriat*) AND ((adrenal and cortex and hormone*) or *steroid* or hydrocort* or cobadex or efcortelan or *derm
or *dermal or *movate or mildison or calmurid or locoid or alclometasone or modrasone or beclo* or betametha* or betacap or
betnovate or bettamousse or dipro* or clobetaso* or desox* or stiedex or diflucortolone or nerisone or fluocino* or synalar or metosyn
or fluocortolone or ultralanum or flurandrenolone or fludroxycortide or haelan or fluticasone or cutivate or halci* or mometasone or
elocon or triamcinolone or *cort or *cortyl)
Appendix 2. CENTRAL (Cochrane Library CD-ROM) and National Research Register (NRR) (CD-
ROM interface) search strategies (RCTs)
CENTRAL (Cochrane Library CD-ROM 2005 issue 1): publication years 2001 to 2005-02-24
Searched on 17/11/08: CENTRAL (The Cochrane Library: http://www.thecochranelibrary.com/)
Searched on 02/02/11: CENTRAL (The Cochrane Library: http://www.thecochranelibrary.com/)
Searched on 23/08/12: CENTRAL (The Cochrane Library: http://www.thecochranelibrary.com/)
National Research Register (CD-ROM interface, issue 2004/4): all projects with a start date of 2001 to 2005
Website browsed on 20/11/08: UK Clinical Research Network Study Portfolio (http://public.ukcrn.org.uk/search/)
Website browsed on 22/02/11: UK Clinical Research Network Study Portfolio (http://public.ukcrn.org.uk/search/)
Website browsed on 10/09/12: UK Clinical Research Network Study Portfolio (http://public.ukcrn.org.uk/search/)
#1 MeSH descriptor Psoriasis explode all trees
#2 (Psorias* or psoriat* or antipsoria*)
#3 MeSH descriptor Coal Tar, this term only
#4 “coal tar”
#5 (alphosyl)
#6 “carbo dome”
#7 (clinitar or exorex or gelcosal or gelcotar)
#8 (pragmatar or psorigel or balneum or polytar)
#9 (psoriderm or tarcortin or cocois)
#10 “T gel”
#11 (capasal or ceanel or clinitar or ionil)
#12 (meted or pentrax)
#13 MeSH descriptor Anthralin, this term only
#14 (Dithranol or dithrocream or micanol or psorin)
#15 (salicylic next acid*)
#16 (vitamin next d next analogue*)
#17 (vitamin next d next derivative*)
#18 (calcipotriol or calcipotriene or dovonex or dovobet)
#19 (tacalcitol or curatoderm or tazarotene or zorac)
#20 MeSH descriptor Calcitriol, this term only
#21 (silkis or maxacalcitol)
777Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
#22 (#3 OR #4 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #
17 OR #18 OR #19 OR #20 OR #21)
#23 MeSH descriptor Acitretin, this term only
#24 MeSH descriptor Cyclosporins explode all trees
#25 MeSH descriptor Methotrexate, this term only
#26 MeSH descriptor Tacrolimus, this term only
#27 (methotrexate or tacrolimus)
#28 (pimecrolimus or elidel or protopic)
#29 (acitretin or neotigason or cyclosporin or ciclosporin)
#30 (#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29)
#31 (topical)
#32 (#30 AND #31)
#33 (topical next retinoid*)
#34 (topical next macrolactam*)
#35 (topical next immunosuppressant*)
#36 MeSH descriptor Dermatologic Agents, this term only
#37 MeSH descriptor Adrenal Cortex Hormones explode all trees
#38 (corticosteroid* or (cortico next steroid*))
#39 MeSH descriptor Hydrocortisone explode all trees
#40 (hydrocortisone or cobadex or dioderm or efcortelan or hydrocortisyl mildison or alphaderm or calmurid)
#41 “hydrocortisone butyrate”
#42 “alclometasone dipropionate”
#43 (modrasone or locoid or propaderm)
#44 MeSH descriptor Beclomethasone, this term only
#45 “beclomethasone dipropionate”
#46 MeSH descriptor Betamethasone explode all trees
#47 “betamethasone esters”
#48 (betamethasone or betacap or betnovate or diprosone)
#49 (diprosalic or bettamousse)
#50 “clobetasol propionate”
#51 “clobetasone butyrate”
#52 (eumovate or trimovate or dermovate)
#53 MeSH descriptor Desoximetasone, this term only
#54 (desoxymethasone or desoximetasone or stiedex)
#55 MeSH descriptor Diflucortolone, this term only
#56 “diflucortolone valerate”
#57 MeSH descriptor Fluocinolone Acetonide explode all trees
#58 “fluocinolone acetonide”
#59 (synalar or fluocinonide or metosyn or nerisone or elocon)
#60 MeSH descriptor Fluocortolone explode all trees
#61 (fluocortolone or ultralanum or flurandrenolone or haelan)
#62 MeSH descriptor Flurandrenolone, this term only
#63 (fludroxycortide)
#64 (fluticasone next propionate)
#65 (cutivate or halcinonide or halciderm)
#66 “mometasone furoate”
#67 MeSH descriptor Triamcinolone explode all trees
#68 “triamcinolone acetonide”
#69 (adcortyl or aureocort or nystadermal or triadcortyl)
#70 MeSH descriptor Steroids explode all trees
#71 (steroid*)
#72 (#33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)
#73 (#41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48)
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#74 (#49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56)
#75 (#57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64)
#76 (#65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71)
#77 (#22 OR #32 OR #72 OR #73 OR #74 OR #75 OR #76)
#78 (( #1 OR #2 ) AND #77), from 2008 to 2011
Appendix 3. MEDLINE (OVID) search strategy (RCTs)
MEDLINE (OvidSP Online http://www.ovid.com/): database updates 2002/07 to 2005/02 week 2
Search updated on 17/11/2008: 1950 to November Week 1 2008
Search updated on 22/02/2011: 1948 to January Week 3 2011
Search updated on 23/08/2012: 1946 to Present
1 randomized controlled trial.pt.
2 randomized controlled trial/
3 Random Allocation/
4 Double-Blind Method/
5 single-blind method/
6 clinical trial.pt.
7 exp clinical trial/
8 ((clinical$ or intervention$) adj5 (trial$ or study or studies)).tw.
9 ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).tw.
10 Placebos/
11 (placebo$ or random$).tw.
12 Research Design/
13 Comparative Study/
14 exp evaluation studies as topic/
15 Follow-Up Studies/
16 Prospective Studies/
17 (control$ or prospectiv$ or volunteer$).tw.
18 Animals/
19 Humans/
20 or/1-17
21 18 not (18 and 19)
22 20 not 21
23 exp Psoriasis/
24 psorias$.tw.
25 psoriat$.tw.
26 or/23-25
27 coal tar/
28 coal tar.tw.
29 alphosyl.tw.
30 carbo dome.tw.
31 clinitar.tw.
32 exorex.tw.
33 gelcosal.tw.
34 gelcotar.tw.
35 pragmatar.tw.
36 psorigel.tw.
37 balneum.tw.
38 polytar.tw.
39 psoriderm.tw.
40 tarcortin.tw.
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41 cocois.tw.
42 (T adj gel).tw.
43 capasal.tw.
44 ceanel.tw.
45 clinitar.tw.
46 ionil.tw.
47 meted.tw.
48 pentrax.tw.
49 Anthralin/
50 dithranol.tw.
51 dithrocream.tw.
52 micanol.tw.
53 psorin.tw.
54 salicylic acid$.tw.
55 (vitamin adj d adj2 analogue$).tw.
56 (vitamin adj d adj2 derivative$).tw.
57 calcipotriol.tw.
58 calcipotriene.tw.
59 dovonex.tw.
60 dovobet.tw.
61 tacalcitol.tw.
62 curatoderm.tw.
63 tazarotene.tw.
64 zorac.tw.
65 Calcitriol/
66 silkis.tw.
67 maxacalcitol.tw.
68 or/27-67
69 Acitretin/
70 acitretin.tw.
71 neotigason.tw.
72 exp Cyclosporins/
73 cyclosporin.tw.
74 ciclosporin.tw.
75 Methotrexate/
76 methotrexate.tw.
77 Tacrolimus/
78 tacrolimus.tw.
79 protopic.tw.
80 pimecrolimus.tw.
81 elidel.tw.
82 or/69-81
83 topical.tw.
84 82 and 83
85 topical retinoid$.tw.
86 topical macrolactam$.tw.
87 topical immunosuppressant$.tw.
88 or/84-87
89 68 or 88
90 antipsoriat$.tw.
91 antipsorias$.tw.
92 26 or 90 or 91
93 exp Psoriasis/th, pc, dt [Therapy, Prevention & Control, Drug Therapy]
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94 Dermatologic Agents/
95 92 and 22
96 93 and 22
97 94 and 92 and 22
98 or/95-97
99 exp Adrenal Cortex Hormones/
100 corticosteroid$.tw.
101 cortico steroid$.tw.
102 exp Hydrocortisone/
103 hydrocortisone.tw.
104 cobadex.tw.
105 dioderm.tw.
106 efcortelan.tw.
107 hydrocortisyl.tw.
108 mildison.tw.
109 alphaderm.tw.
110 calmurid.tw.
111 hydrocortisone butyrate.tw.
112 locoid.tw.
113 alclometasone dipropionate.tw.
114 modrasone.tw.
115 Beclomethasone/
116 beclomet$asone dipropionate.tw.
117 propaderm.tw.
118 exp Betamethasone/
119 betamethasone esters.tw.
120 betamethasone.tw.
121 betacap.tw.
122 betnovate.tw.
123 diprosone.tw.
124 diprosalic.tw.
125 bettamousse.tw.
126 clobetasol propionate.tw.
127 dermovate.tw.
128 clobetasone butyrate.tw.
129 eumovate.tw.
130 trimovate.tw.
131 Desoximetasone/
132 desoxymethasone.tw.
133 desoximetasone.tw.
134 stiedex.tw.
135 Diflucortolone/
136 diflucortolone valerate.tw.
137 nerisone.tw.
138 exp Fluocinolone Acetonide/
139 fluocinolone acetonide.tw.
140 synalar.tw.
141 fluocinonide.tw.
142 metosyn.tw.
143 exp Fluocortolone/
144 fluocortolone.tw.
145 ultralanum.tw.
146 Flurandrenolone/
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147 flurandrenolone.tw.
148 fludroxycortid$.tw.
149 haelan.tw.
150 fluticasone propionate.tw.
151 cutivate.tw.
152 halcinonide.tw.
153 halciderm.tw.
154 mometasone furoate.tw.
155 elocon.tw.
156 exp Triamcinolone/
157 triamcinolone acetonide.tw.
158 adcortyl.tw.
159 aureocort.tw.
160 nystadermal.tw.
161 tri-adcortyl.tw.
162 exp Steroids/
163 steroid$.tw.
164 or/99-163
165 22 and 92 and 164
166 22 and 92 and 89
167 98 or 165 or 166
168 (200811$ or 200812$).ed.
169 (2009$ or 2010$ or 2011$).ed.
170 168 or 169
171 167 and 170
Appendix 4. EMBASE (OVID) search strategy (RCTs)
EMBASE (OvidSP Online http://www.ovid.com/): database updates 2002/08 to 2005/08
Search updated on 17/11/2008: 1980 to 2008 Week 46
Search updated on 31/01/2011: 1980 to 2011 Week 04
Search updated on 23/08/2012: 1996 to 2012 Week 33
1 Coal Tar/
2 dithranol/ or tazarotene/ or 22 Oxacalcitriol/
3 (coal tar or alphosyl or carbo dome or clinitar or exorex or cocois or T gel or capasal or ceanel or ionil or meted or pentrax).ti,ab.
4 (gelcosal or gelcotar or pragmatar or psoriderm or psorigel or balneum or polytar or tarcortin or dithranol or dithrocream).ti,ab.
5 (anthralin or micanol or psorin or salicylic acid$ or vitamin d analogue$ or vitamin d derivative$).ti,ab.
6 (calcipotriol or calcipotriene or dovonex or dovobet or tacalcitol or curatodermor tazarotene or zorac or silkis ormaxacalcitol).ti,ab.
7 vitamin d derivative/ or calcipotriol/ or calcitriol/ or tacalcitol/ or Salicylic Acid/
8 or/1-7
9 Etretin/ or Immunosuppressive Agent/ or Tacrolimus/
10 Cyclosporin/ or Retinoid/ or Pimecrolimus/
11 Methotrexate/
12 ((immunosuppressant$ or acitretin or neotigason or cyclosporin$ or ciclosporin$ or methotrexate or retinoid$ or macrolactam)
adj5 topical$).ti,ab.
13 ((tacrolimus or protopic or pimecrolimus or elidel) adj5 topical$).ti,ab.
14 or/9-11
15 topical.ti,ab. or topical treatment/ or topical drug administration/
16 (14 and 15) or 12 or 13
17 exp Corticosteroid/
18 Hydrocortisone/
19 (corticosteroid$ or cortico steroid$ or hydrocortisone or cobadex or dioderm or efcortelan).ti,ab.
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20 (hydrocortisyl or mildison or alphaderm or calmurid).ti,ab.
21 (locoid or modrasone or beclomethasone dipropionate).ti,ab.
22 (alclometasone diproprionate or propaderm or betamethasone or betacap or betnovate or diprosone).ti,ab.
23 (diprosalic or bettamousse or clobetasol propionate or dermovate or clobetasone butyrate).ti,ab.
24 (eumovate or trimovate or desoxymethasone or desoxymetasone or desoximethasone or desoximetasone or stiedex).ti,ab.
25 (diflucortolone valerate or nerisone or fluocinolone acetonide or synalar or fluocinonide or metosyn).ti,ab.
26 (ultralanum or flurandrenolone or haelan or fluticasone propionate or cutivate or halcinonide or halciderm).ti,ab.
27 (mometasone furoate or elocon or adcortyl or aureocort or nystadermal or tri adcortyl or steroid$).ti,ab.
28 beclometasone/ or psoralon/ or psoraderm/ or psoradexan/ or psorin/
29 Beclometasone Dipropionate/ or Urea/ or hydrocortisone butyrate/ or hydrocortisone plus urea/
30 alclometasone dipropionate/ or betamethasone dipropionate/ or betamethasone valerate/ or diflucortolone/
31 clobetasol propionate/ or clobetasone butyrate/ or desoximetasone/ or diflucortolone valerate/ or fluocinonide/ or Fluticasone
Propionate/
32 fluocinolone/ or halcinonide/ or mometasone furoate.mp. or triamcinolone acetonide/
33 Fluocortolone/
34 Fludroxycortide/
35 Triamcinolone/
36 exp Steroid/
37 exp Steroid Hormone/
38 or/17-37
39 exp Antipsoriasis Agent/
40 8 or 16 or 38 or 39
41 exp Psoriasis/
42 (psorias$ or psoriat$ or antipsorias$ or antipsoriat$).ti,ab.
43 or/41-42
44 40 and 43
45 randomization/
46 Single Blind Procedure/
47 Double Blind Procedure/
48 exp clinical trial/
49 Placebo/
50 Methodology/
51 comparative study/
52 exp drug comparison/
53 evaluation/
54 Follow Up/
55 Prospective Study/
56 Crossover Procedure/
57 (clinical$ adj3 (trial$ or study or studies)).ti,ab.
58 (intervention$ adj3 (trial$ or study or studies)).ti,ab.
59 ((single$ or doubl$ or trebl$ or tripl$) adj3 blind$).ti,ab.
60 ((single$ or doubl$ or trebl$ or tripl$) adj3 mask$).ti,ab.
61 (placebo or placebos or random$ or control$ or prospectiv$ or volunteer$).ti,ab.
62 or/45-61
63 44 and 62
64 (2008$ or 2009$ or 2010$ or 2011$).em.
65 63 and 64
66 from 65 keep 1-2041
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Appendix 5. Science Citation Index (ISI web of Knowledge interface) and Conference Proceedings
Citation Index - Science (ISI web of Knowledge interface) search strategies (RCTs)
Science Citation Index (SCI Web Of Knowledge http://wos.mimas.ac.uk/): publication years 2000 to 2005
Search updated on 17/11/2008: All lines linted as follows: DocType=All document types; Language=All languages; Database=SCI
EXPANDED; Timespan=2005-2008
Search updated on 02/02/2011: All lines linted as follows: Databases=SCI-EXPANDED Timespan=2008-2011
Search updated on 23/08/12: (limited to 2011-01-01 - 2012-08-23)
Conference Proceedings Citation Index - Science (SCI Web Of Knowledge http://wos.mimas.ac.uk/)
Search updated on 02/02/2011: All lines linted as follows: Databases=CPCI-S Timespan=2008-2011
Search updated on 23/08/12: (limited to 2011-01-01 - 2012-08-23)
# 1 Topic=((psoria* OR antipsoria*) AND (trial* OR random* OR control OR controls OR double blind OR doubleblind or
single blind OR singleblind OR placebo* or evaluation*))
# 2 Topic=(coaltar or coal tar or alphosyl or carbo dome or clinitar or exorex or gelcosal or gelcotar or pragmatar)
# 3 Topic=(psorigel or balneum or polytar or psoriderm or tarcortin or cocois or t gel or tgel or capasal or ceanel or clinitar or ionil
or meted or pentrax)
# 4 Topic=(eumovate or trimovate or desoxime$asone or desoxyme$asone or stiedex or diflucortolone or nerisone or fluocinolone
or synalar)
# 5 Topic=(anthralin OR dithranol or dithrocream or micanol or psorin or salicylic acid or salicylic acids or vitamin d or calcipotriol
or calcipotriene or dovonex or dovobet or tacalcitol or curatoderm or tazarotene or zorac)
# 6 Topic=(fluocinonide or metosyn or fluocortolone or ultralanum or flurandrenolone or fludroxycortide or haelan or fluticasone
propionate)
# 7 Topic=(calcitriol or silkis or maxacalcitol)
# 8 Topic=(cutivate or halcinonide or halciderm or mometasone furoate or elocon or triamcinolone or adcortyl or aureocort or
nystadermal or triadcortyl or steroid or steroids or steroidal)
# 9 Topic=((acitretin or neotigason or cyclosporin* or ciclosporin* or methotrexate or tacrolimus or protopic or pimecrolimus or
elidel or retinoid* or macrolactam* or immunosuppressant*) same topical)
# 10 Topic=(adrenal cortex hormone* or corticosteroid* or cortico steroid* or hydrocortisone or cobadex or dioderm or efcortelan
or hydrocortisyl or mildison)
# 11 Topic=(alphaderm or calmurid or locoid or alclometasone dipropionate or modrasone or beclomet$asone or propaderm)
# 12 Topic=(betamethasone or betacap or betnovate or diprosone or diprosalic or bettamousse or clobetasol propionate or dermovate
or clobetasone butyrate)
# 13 #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
# 14 #13 AND #1
Appendix 6. BIOSIS (EDINAinterface) search strategy (RCTs)
BIOSIS (EDINAinterface): publication years 2001 to 2005
((((((((((((((al: betamethasone or betacap or betnovate or diprosone or diprosalic or bettamousse or “clobetasol propionate” or dermovate
or “clobetasone butyrate”) and (sy: 2001-2005)) or ((al: alphaderm or calmurid or locoid or “alclometasone dipropionate” ormodrasone
or beclomethasone beclometasone or propaderm) and (sy: 2001-2005))) or ((al: “adrenal cortex hormone*” or corticosteroid* or “cortico
steroid*” or hydrocortisone or cobadex or dioderm or efcortelan or hydrocortisyl or mildison) and (sy: 2001-2005))) or ((al: (acitretin
or neotigason or cyclosporin* or ciclosporin* or methotrexate or tacrolimus or protopic or pimecrolimus or elidel or retinoid* or
macrolactam* or immunosuppressant*)) and (sy: 2001-2005))) or ((al: cutivate or halcinonide or halciderm or “mometasone furoate” or
elocon or triamcinolone or adcortyl or aureocort or nystadermal or triadcortyl or steroid or steroids or steroidal) and (sy: 2001-2005)))
or ((al: (calcitriol or silkis or maxacalcitol)) and (sy: 2001-2005))) or ((al: fluocinonide or metosyn or fluocortolone or ultralanum or
flurandrenolone or fludroxycortide or haelan or “fluticasone propionate”) and (sy: 2001-2005))) or ((al: anthralin OR dithranol or
dithrocream or micanol or psorin or “salicylic acid” or “salicylic acids” or “vitamin d” or calcipotriol or calcipotriene or dovonex or
dovobet or tacalcitol or curatoderm or tazarotene or zorac) and (sy: 2001-2005))) or ((al: (eumovate or trimovate or desoxime$asone or
desoxyme$asone or stiedex or diflucortolone or nerisone or fluocinolone or synalar)) and (sy: 2001-2005))) or (al: (psorigel or balneum
or polytar or psoriderm or tarcortin or cocois or t gel or tgel or capasal or ceanel or clinitar or ionil or meted or pentrax))) or (al: (coaltar
or coal tar or alphosyl or carbo dome or clinitar or exorex or gelcosal or gelcotar or pragmatar)))) and ((((al: trial* or random* or “double
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blind” or doubleblind or “single blind” or singleblind or evaluation* or placebo* or control or controls) and (sy: 2001-2005)) and ((al:
(psoria* or antipsoria*)) and (sy: 2001-2005)))))
Appendix 7. Dissertation Abstracts (Dialog Classic interface) and Inside Conferences (Dialog
Classic interface) search strategies (RCTs)
Dissertation Abstracts (Dialog Classic interface): all publication years
Inside Conferences (Dialog Classic interface): all publication years
Biosis (Dialog Classic interface): all publication years
Search updated 17/11/2008: 1993-2008/Nov W2
Search updated 01/02/2011: 1993-2011/Jan W4
Search updated on 24/08/2012: 1993-2012/Aug W3
1 s (coal()tar or coaltar or alphosyl or carbo()dome or clinitar or exorex or cocois)/ti,ab,de
2 s (t()gel or tgel or capasal or ceanel or clinitar or ionil or meted or pentrax)/ti,ab,de
3 s (dithranol or gelcosal or gelcotar or pragmatar or psoriderm or psorigel or balneum or 4. polytar or tarcortin or dithrocream)/
ti,ab,de
4 s (micanol or psorin or salicylic()acid? ? or vitamin()d()analogue? or vitamin()d()derivative?)/ti,ab,de
5 s (calcipotriol or calcipotriene or dovonex or dovobet or tacalcitol or curatoderm or tazarotene or zorac)/ti,ab,de
6 s (calcitriol or silkis or maxacalcitol or adrenal()cortex()hormone? ?)/ti,ab,de
7 s ((cyclosporin or ciclosporin or methotrexate or acitretin or neotigason)(4w)topical?)/ti,ab,de
8 s ((retinoid? ? or immunosuppressant? ? or tacrolimus or protopic or pimecrolimus or macorlactam? ?)(4w)topical?)/ti,ab,de
9 s (corticosteroid? ? or cortico()steroid? ? or hydrocortisone or cobadex or dioderm or efcortelan)/ti,ab,de
10 s (hydrocortisyl or mildison or alphaderm or calmurid)/ti,ab,de
11 s (locoid or alclometasone()dipropionate or modrasone or beclomethasone()dipropionate)/ti,ab,de
12 s (propaderm or betamethasone or betacap or betnovate or diprosone)/ti,ab,de
13 s (diprosalic or bettamousse or clobetasol()propionate or dermovate or clobetasone()butyrate)/ti,ab,de
14 s (eumovate or trimovate or desoxymethasone or desoxymetasone or desoximetasone or desoximethasone or stiedex)/ti,ab,de
15 s (diflucortolone()valerate or nerisone or fluocinolone()acetonide or synalar or fluocinonide or metosyn)/ti,ab,de
16 s (fluocortolone or ultralanum or haelan or fluticasone()propionate or cutivate or halcinonide or halciderm or flurandrenolone
or triamcinolone)/ti,ab,de
17 s (mometasone()furoate or elocon or adcortyl or aureocort or nystadermal or triadcortyl or steroid? ? or steroidal)/ti,ab,de
18 s (beclometasone()dipropionate or fludroxycortide or triamcinolone)/ti,ab,de
19 s s1:s18
20 s (psoria? or antipsoria?)/ti,ab,de
21 s (random? or single()blind or singleblind or double()blind or doubleblind)/ti,ab,de
22 s (placebo or comparative()study or evaluation or prospective()study or crossover or trial or trials or triallist? ?)/ti,ab,de
23 s (control or controls? or prospectiv?)/ti,ab,de
24 s s21:s23
25 s s19 and s20 and s24
26 s UD=200812:201102
27 s s25 and s26
28 s rd s27
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Appendix 8. SIGLE (WebSPIRS interface) search strategy (RCTs)
SIGLE (WebSPIRS interface): publication years 2001 to 2005 (database issue 2004/12)
SIGLE has not been updated since 2005, so searches were not rerun.
#1 psoriat* or psorias*(83 records)
#2 (2002 in PY) or (2003 in PY) or (2004 in PY) or (2005 in PY)(49881 records)
#3 ((2002 in PY) or (2003 in PY) or (2004 in PY) or (2005 in PY)) and (psoriat* or psorias*)(5 records)
Appendix 9. MEDLINE (OVID) search strategy (adverse events)
MEDLINE (OvidSP Online http://www.ovid.com/): database updates 1990 to 2005/02 week 2
Search updated on 17/11/08: 1950 to November Week 1 2008
Search updated on 02/02/11: 1948 to January Week 3 2011
Search updated on 23/08/12: 1946 to present
1 (coal adj tar).tw.
2 alphosyl.tw.
3 (carbo adj dome).tw.
4 clinitar.tw.
5 exorex.tw.
6 gelcosal.tw.
7 gelcotar.tw.
8 pragmatar.tw.
9 psorigel.tw.
10 balneum.tw.
11 polytar.tw.
12 psoriderm.tw.
13 tarcortin.tw.
14 cocois.tw.
15 (T adj gel).tw.
16 capasal.tw.
17 ceanel.tw.
18 ionil.tw.
19 meted.tw.
20 pentrax.tw.
21 dithranol.tw.
22 dithrocream.tw.
23 micanol.tw.
24 psorin.tw.
25 (salicylic adj acid$).tw.
26 (vitamin adj d adj2 analogue$).tw.
27 (vitamin adj d adj2 derivative$).tw.
28 calcipotriol.tw.
29 calcipotriene.tw.
30 dovonex.tw.
31 dovobet.tw.
32 tacalcitol.tw.
33 curatoderm.tw.
34 tazarotene.tw.
35 zorac.tw.
36 silkis.tw.
37 maxacalcitol.tw.
38 antipsoriat$.tw.
39 antipsorias$.tw.
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40 corticosteroid$.tw.
41 (cortico adj steroid$).tw.
42 hydrocortisone.tw.
43 cobadex.tw.
44 dioderm.tw.
45 efcortelan.tw.
46 hydrocortisyl.tw.
47 mildison.tw.
48 alphaderm.tw.
49 calmurid.tw.
50 (hydrocortisone adj butyrate).tw.
51 locoid.tw.
52 (alclometasone adj dipropionate).tw.
53 modrasone.tw.
54 (beclomet$asone adj dipropionate).tw.
55 propaderm.tw.
56 (betamethasone adj esters).tw.
57 betamethasone.tw.
58 betacap.tw.
59 betnovate.tw.
60 diprosone.tw.
61 diprosalic.tw.
62 bettamousse.tw.
63 (clobetasol adj propionate).tw.
64 dermovate.tw.
65 (clobetasone adj butyrate).tw.
66 eumovate.tw.
67 trimovate.tw.
68 desoxymethasone.tw.
69 desoximetasone.tw.
70 stiedex.tw.
71 (diflucortolone adj valerate).tw.
72 nerisone.tw.
73 (fluocinolone adj acetonide).tw.
74 synalar.tw.
75 fluocinonide.tw.
76 metosyn.tw.
77 fluocortolone.tw.
78 ultralanum.tw.
79 flurandrenolone.tw.
80 haelan.tw.
81 (fluticasone adj propionate).tw.
82 cutivate.tw.
83 halcinonide.tw.
84 halciderm.tw.
85 (mometasone adj furoate).tw.
86 elocon.tw.
87 (triamcinolone adj acetonide).tw.
88 adcortyl.tw.
89 aureocort.tw.
90 nystadermal.tw.
91 tri-adcortyl.tw.
92 steroid$.tw.
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93 Coal Tar/
94 Anthralin/
95 Calcitriol/
96 exp Cyclosporins/
97 Tacrolimus/
98 Dermatologic Agents/
99 exp Adrenal Cortex Hormones/
100 exp Hydrocortisone/
101 Beclomethasone/
102 exp Betamethasone/
103 Desoximetasone/
104 Diflucortolone/
105 exp Fluocinolone Acetonide/
106 Fluocortolone/
107 Flurandrenolone/
108 Flurandrenolone/
109 exp Triamcinolone/
110 exp Steroids/
111 or/1-110
112 Acitretin/
113 Immunosuppressive Agents/
114 Cyclosporine/
115 Retinoids/
116 Methotrexate/
117 or/112-116
118 topical.ti,ab. or topical treatment/ or topical drug administration/
119 117 and 118
120 ((tacrolimus or protopic or pimecrolimus or elidel or immunosuppressant$ or acitretin or neotigason or cyclosporin$ or
ciclosporin$ or methotrexate or retinoid$ or macrolactam) adj5 topical$).tw.
121 119 or 120 or 111
122 (safe or safety).tw.
123 side effect$.tw.
124 treatment emergent.tw.
125 undesirable effect$.tw.
126 tolerability.tw.
127 toxicity.tw.
128 adrs.tw.
129 (adverse adj3 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).tw.
130 Adverse Drug Reaction Reporting Systems/
131 drug hypersensitivity/
132 hypersensit$.tw.
133 harm$.tw.
134 exp Substance Withdrawal Syndrome/ci [Chemically Induced]
135 rebound.tw.
136 Hypercalcemia/ci [Chemically Induced]
137 exp Urinary Calculi/ci [Chemically Induced]
138 Tachyphylaxis/ci, de [Chemically Induced, Drug Effects]
139 exp Substance Withdrawal Syndrome/ci [Chemically Induced]
140 exp Atrophy/ci [Chemically Induced]
141 exp Telangiectasis/ci [Chemically Induced]
142 cutaneous atrophy.tw.
143 striae.tw.
144 skin atrophy.tw.
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145 exp Abnormalities, Drug-Induced/
146 exp Drug Toxicity/
147 or/122-146
148 Coal Tar/ae [Adverse Effects]
149 Anthralin/ae [Adverse Effects]
150 Calcitriol/ae [Adverse Effects]
151 Acitretin/ae [Adverse Effects]
152 exp Cyclosporins/de, ae [Drug Effects, Adverse Effects]
153 Methotrexate/ae [Adverse Effects]
154 Tacrolimus/ae [Adverse Effects]
155 Dermatologic Agents/ae [Adverse Effects]
156 exp Adrenal Cortex Hormones/ae, de [Adverse Effects, Drug Effects]
157 exp Hydrocortisone/ae [Adverse Effects]
158 Beclomethasone/ae [Adverse Effects]
159 exp Betamethasone/ae [Adverse Effects]
160 Desoximetasone/ae [Adverse Effects]
161 Diflucortolone/ae [Adverse Effects]
162 exp Fluocinolone Acetonide/ae [Adverse Effects]
163 Fluocortolone/ae [Adverse Effects]
164 Flurandrenolone/ae [Adverse Effects]
165 exp Triamcinolone/ae [Adverse Effects]
166 exp Steroids/ae [Adverse Effects]
167 or/148-166
168 147 or 167
169 (psorias$ or psoriat$).tw.
170 exp psoriasis/
171 or/169-170
172 121 and 168 and 171
173 exp animals/ not (exp animals/ and humans/)
174 172 not 173
175 (comment or editorial).pt.
176 174 not 175
177 (2008$ or 2009$ or 2010$ or 2011$).ed.
178 176 and 177
Appendix 10. EMBASE (OVID) search strategy (adverse events)
EMBASE (OvidSP Online http://www.ovid.com/): 1990 to 2005/08
Search updated on 11/12/08: 1980 to 2008 Week 49
Search updated on 02/02/11: 1980 to 2011 week 4
Search updated on 23/08/12: 1996 to 2012 Week 34
Note: A pragmatic approach was taken to reduce irrelevant records and to negate the over indexing of records in EMBASE; EMTREE
terms were focused in this strategy
1 (coal adj tar).ti,ab.
2 alphosyl.ti,ab.
3 (carbo adj dome).ti,ab.
4 clinitar.ti,ab.
5 exorex.ti,ab.
6 gelcosal.ti,ab.
7 gelcotar.ti,ab.
8 pragmatar.ti,ab.
9 psorigel.ti,ab.
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10 balneum.ti,ab.
11 polytar.ti,ab.
12 psoriderm.ti,ab.
13 tarcortin.ti,ab.
14 cocois.ti,ab.
15 (T adj gel).ti,ab.
16 capasal.ti,ab.
17 ceanel.ti,ab.
18 ionil.ti,ab.
19 meted.ti,ab.
20 pentrax.ti,ab.
21 dithranol.ti,ab.
22 dithrocream.ti,ab.
23 micanol.ti,ab.
24 psorin.ti,ab.
25 (salicylic adj acid$).ti,ab.
26 (vitamin adj d adj2 analogue$).ti,ab.
27 (vitamin adj d adj2 derivative$).ti,ab.
28 calcipotriol.ti,ab.
29 calcipotriene.ti,ab.
30 dovonex.ti,ab.
31 dovobet.ti,ab.
32 tacalcitol.ti,ab.
33 curatoderm.ti,ab.
34 tazarotene.ti,ab.
35 zorac.ti,ab.
36 silkis.ti,ab.
37 maxacalcitol.ti,ab.
38 antipsoriat$.ti,ab.
39 antipsorias$.ti,ab.
40 corticosteroid$.ti,ab.
41 (cortico adj steroid$).ti,ab.
42 hydrocortisone.ti,ab.
43 cobadex.ti,ab.
44 dioderm.ti,ab.
45 efcortelan.ti,ab.
46 hydrocortisyl.ti,ab.
47 mildison.ti,ab.
48 alphaderm.ti,ab.
49 calmurid.ti,ab.
50 (hydrocortisone adj butyrate).ti,ab.
51 locoid.ti,ab.
52 (alclometasone adj dipropionate).ti,ab.
53 modrasone.ti,ab.
54 (beclomet$asone adj dipropionate).ti,ab.
55 propaderm.ti,ab.
56 (betamethasone adj esters).ti,ab.
57 betamethasone.ti,ab.
58 betacap.ti,ab.
59 betnovate.ti,ab.
60 diprosone.ti,ab.
61 diprosalic.ti,ab.
62 bettamousse.ti,ab.
790Topical treatments for chronic plaque psoriasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
63 (clobetasol adj propionate).ti,ab.
64 dermovate.ti,ab.
65 (clobetasone adj butyrate).ti,ab.
66 eumovate.ti,ab.
67 trimovate.ti,ab.
68 desoxymethasone.ti,ab.
69 desoximetasone.ti,ab.
70 stiedex.ti,ab.
71 (diflucortolone adj valerate).ti,ab.
72 nerisone.ti,ab.
73 (fluocinolone adj acetonide).ti,ab.
74 synalar.ti,ab.
75 fluocinonide.ti,ab.
76 metosyn.ti,ab.
77 fluocortolone.ti,ab.
78 ultralanum.ti,ab.
79 flurandrenolone.ti,ab.
80 haelan.ti,ab.
81 (fluticasone adj propionate).ti,ab.
82 cutivate.ti,ab.
83 halcinonide.ti,ab.
84 halciderm.ti,ab.
85 (mometasone adj furoate).ti,ab.
86 elocon.ti,ab.
87 (triamcinolone adj acetonide).ti,ab.
88 adcortyl.ti,ab.
89 aureocort.ti,ab.
90 nystadermal.ti,ab.
91 tri-adcortyl.ti,ab.
92 steroid$.ti,ab.
93 *Coal Tar/
94 *alphosyl/
95 *carbo dome/
96 *Salicylic Acid/
97 *capasal/
98 *meted/
99 *Dithranol/
100 *Psorin/
101 *Vitamin d Derivative/
102 *Calcipotriol/
103 *Betamethasone Dipropionate Plus Calcipotriol/
104 *Tacalcitol/
105 *Tazarotene/
106 *Calcitriol/
107 *22 Oxacalcitriol/
108 *Corticosteroid/
109 *Hydrocortisone/
110 *Urea/
111 *Hydrocortisone Butyrate/
112 *Alclometasone Dipropionate/
113 *Beclometasone Dipropionate/
114 *Betamethasone/
115 *Betamethasone Valerate/
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116 *Betamethasone Dipropionate/
117 *Clobetasol Propionate/
118 *Clobetasone Butyrate/
119 *trimovate/
120 *Desoximetasone/
121 *Diflucortolone Valerate/
122 *Fluocinolone Acetonide/
123 *Fluocinonide/
124 *Fluocortolone/
125 *Fludroxycortide/
126 *Fluticasone Propionate/
127 *Halcinonide/
128 *Mometasone Furoate/
129 *Triamcinolone Acetonide/
130 *Triamcinolone/
131 *Mycolog/
132 *exp Steroid/
133 *Cyclosporin Derivative/ or *Cyclosporin/
134 *Tacrolimus/
135 *Dermatological Agent/
136 or/1-135
137 *Tacrolimus/
138 *Pimecrolimus/
139 *Immunosuppressive Agent/
140 *Etretin/
141 *Cyclosporin/
142 *Cyclosporin A/
143 *Methotrexate/
144 *Retinoid/
145 or/137-144
146 topical.ti,ab. or topical treatment/ or topical drug administration/
147 145 and 146
148 ((tacrolimus or protopic or pimecrolimus or elidel or immunosuppressant$ or acitretin or neotigason or cyclosporin$ or
ciclosporin$ or methotrexate or retinoid$ or macrolactam) adj5 topical$).ti,ab.
149 136 or 147 or 148
150 (safe or safety).ti,ab.
151 side effect$.ti,ab.
152 treatment emergent.ti,ab.
153 undesirable effect$.ti,ab.
154 tolerability.ti,ab.
155 toxicity.ti,ab.
156 adrs.ti,ab.
157 (adverse adj3 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).ti,ab.
158 *Safety/ or *Drug Safety/
159 *Side Effect/
160 *Adverse Drug Reaction/
161 *Drug Tolerability/
162 *Toxicity/ or *Drug Toxicity/
163 *Drug Surveillance Program/
164 *Adverse Outcome/
165 hypersensit$.ti,ab.
166 harm$.ti,ab.
167 rebound.ti,ab.
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168 *Drug Hypersensitivity/
169 *Rebound/
170 *Withdrawal Syndrome/
171 *Hypercalcemia/
172 *Urolithiasis/
173 *Tachyphylaxis/
174 *Drug Withdrawal/
175 *Atrophy/
176 *Telangiectasia/
177 cutaneous atrophy.ti,ab.
178 striae.ti,ab.
179 skin atrophy.ti,ab.
180 *Skin Atrophy/
181 *Stria/
182 or/150-181
183 *Coal Tar/ae, to [Adverse Drug Reaction, Drug Toxicity]
184 *alphosyl/ae [Adverse Drug Reaction]
185 *Salicylic Acid/ae, to [Adverse Drug Reaction, Drug Toxicity]
186 *Dithranol/ae, to [Adverse Drug Reaction, Drug Toxicity]
187 *Psorin/ae [Adverse Drug Reaction]
188 *Vitamin d Derivative/ae, to [Adverse Drug Reaction, Drug Toxicity]
189 *Calcipotriol/ae, to [Adverse Drug Reaction, Drug Toxicity]
190 *Betamethasone Dipropionate Plus Calcipotriol/to, ae [Drug Toxicity, Adverse Drug Reaction]
191 *Tacalcitol/ae, to [Adverse Drug Reaction, Drug Toxicity]
192 *Tazarotene/ae, to [Adverse Drug Reaction, Drug Toxicity]
193 *Calcitriol/ae, to [Adverse Drug Reaction, Drug Toxicity]
194 *22 Oxacalcitriol/ae, to [Adverse Drug Reaction, Drug Toxicity]
195 *Corticosteroid/ae, to [Adverse Drug Reaction, Drug Toxicity]
196 *Hydrocortisone/ae, to [Adverse Drug Reaction, Drug Toxicity]
197 *Urea/ae, to [Adverse Drug Reaction, Drug Toxicity]
198 *Hydrocortisone Butyrate/ae, to [Adverse Drug Reaction, Drug Toxicity]
199 *Alclometasone Dipropionate/ae, to [Adverse Drug Reaction, Drug Toxicity]
200 *Beclometasone Dipropionate/ae, to [Adverse Drug Reaction, Drug Toxicity]
201 *Betamethasone/ae, to [Adverse Drug Reaction, Drug Toxicity]
202 *Betamethasone Valerate/ae, to [Adverse Drug Reaction, Drug Toxicity]
203 *Betamethasone Dipropionate/ae, to [Adverse Drug Reaction, Drug Toxicity]
204 *Clobetasol Propionate/ae, to [Adverse Drug Reaction, Drug Toxicity]
205 *Clobetasone Butyrate/ae [Adverse Drug Reaction]
206 *trimovate/ae [Adverse Drug Reaction]
207 *Desoximetasone/ae, to [Adverse Drug Reaction, Drug Toxicity]
208 *Diflucortolone Valerate/to, ae [Drug Toxicity, Adverse Drug Reaction]
209 *Fluocinolone Acetonide/ae, to [Adverse Drug Reaction, Drug Toxicity]
210 *Fluocinonide/ae, to [Adverse Drug Reaction, Drug Toxicity]
211 *Fluocortolone/ae, to [Adverse Drug Reaction, Drug Toxicity]
212 *Fludroxycortide/ae [Adverse Drug Reaction]
213 *Fluticasone Propionate/ae, to [Adverse Drug Reaction, Drug Toxicity]
214 *Halcinonide/ae [Adverse Drug Reaction]
215 *Mometasone Furoate/ae, to [Adverse Drug Reaction, Drug Toxicity]
216 *Triamcinolone Acetonide/ae, to [Adverse Drug Reaction, Drug Toxicity]
217 *Triamcinolone/ae, to [Adverse Drug Reaction, Drug Toxicity]
218 *Mycolog/ae [Adverse Drug Reaction]
219 *exp Steroid/ae, to [Adverse Drug Reaction, Drug Toxicity]
220 *Cyclosporin Derivative/ae, to [Adverse Drug Reaction, Drug Toxicity]
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221 *Cyclosporin/ae, to [Adverse Drug Reaction, Drug Toxicity]
222 *Tacrolimus/ae, to [Adverse Drug Reaction, Drug Toxicity]
223 *Dermatological Agent/ae, to [Adverse Drug Reaction, Drug Toxicity]
224 *Pimecrolimus/ae, to [Adverse Drug Reaction, Drug Toxicity]
225 *Immunosuppressive Agent/ae, to [Adverse Drug Reaction, Drug Toxicity]
226 *Etretin/ae, to [Adverse Drug Reaction, Drug Toxicity]
227 *Cyclosporin A/ae, to [Adverse Drug Reaction, Drug Toxicity]
228 *Methotrexate/ae, to [Adverse Drug Reaction, Drug Toxicity]
229 *Retinoid/ae, to [Adverse Drug Reaction, Drug Toxicity]
230 or/183-229
231 182 or 230
232 (psorias$ or psoriat$).ti,ab.
233 *exp Psoriasis/
234 232 or 233
235 149 and 231 and 234
236 animal/ not (animal/ and human/)
237 235 not 236
238 (“200800” or “200900”).em.
239 (2010$ or 2011$).em.
240 238 or 239
241 237 and 240
Appendix 11. EMBASE (OVID) search strategy (compliance)
EMBASE (OvidSP Online http://www.ovid.com/): 1980 to 2007 Week 49
Not updated in 2011
1 compliance$.ti,ab. (46694)
2 complied.ti,ab. (1455)
3 compliance/ (1674)
4 comply.ti,ab. (3613)
5 (medicat$ adj4 adher$).ti,ab. (1732)
6 (drug$ adj4 adher$).ti,ab. (777)
7 (medicine$ adj4 adher$).ti,ab. (62)
8 (treatment adj4 adher$).ti,ab. (3072)
9 concordance$.ti,ab. (12825)
10 or/1-9 (68155)
11 psor$.ti,ab. (20549)
12 10 and 11 (171)
13 from 12 keep 1-171 (171)
Appendix 12. MEDLINE (OVID) search strategy (compliance)
MEDLINE(OvidSP Online http://www.ovid.com/): 1950 to November Week 2 2007
Not updated in 2011
1. compliance$.ti,ab. (52891)
2. complied.ti,ab. (1748)
3. compliance/ (2982)
4. comply.ti,ab. (4307)
5. (medicat$ adj4 adher$).ti,ab. (2047)
6. (drug$ adj4 adher$).ti,ab. (878)
7. (medicine$ adj4 adher$).ti,ab. (76)
8. (treatment adj4 adher$).ti,ab. (3442)
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9. concordance$.ti,ab. (14973)
10. or/1-9 (78297)
11. psor$.ti,ab. (25210)
12. 10 and 11 (162)
WH A T ’ S N E W
Last assessed as up-to-date: 2 February 2011.
Date Event Description
9 December 2015 Amended Author information (affiliation) updated
H I S T O R Y
Protocol first published: Issue 4, 2004
Review first published: Issue 2, 2009
Date Event Description
2 April 2013 Amended ’Declarations of interest’ section updated.
25 February 2013 New citation required but conclusions have not
changed
This review was updated, but there was no change to
the conclusions
25 February 2013 New search has been performed 48 new RCTs added.
Comparisons revised to reflect new evidence.
Scalp trials moved to separate comparison groups
ready for removal at next update (#18; #19).
Inverse psoriasis trials also moved to separate compar-
ison groups (#16; #17).
Nail trials removed, as now part of separate Cochrane
review
15 December 2008 Amended Review amended to reflect peer review comments
25 June 2008 Amended Converted to new review format.
29 September 2003 New citation required and conclusions have changed Substantive amendment
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C O N T R I B U T I O N S O F A U T H O R S
The following contributions were made by the authors stated.
Link with editorial base and co-ordinate contributions from co-authors (AM).
Draft protocol (AM with contributions from MC, GD, GE, and JM).
Run searches (adherence) (AM).
Identify relevant titles and abstracts from searches, i.e. broad screen (AM and JM).
Obtain copies of trials (AM).
Select which trials to include (AM, JM, and MC as arbitrator when necessary).
Extract data from trials (AM, JM, and HH).
Enter data into RevMan (AM).
Carry out analysis (AM and JM)
Interpret analysis (AM, JM, and HH).
Draft final review (AM with contribution from MC, GD, HH, and JM).
Update review (AM, JM, HH, and MC).
D E C L A R A T I O N S O F I N T E R E S T
Mike Cork: “I gave a lecture for Leo Pharmaceuticals about psoriasis and atopic eczema in 2012.”
Anne R Mason: none declared
Gordon Dooley: none declared
James Mason: none declared
Helen Hancock: none declared
The clinical referee for this review, Dr Phyllis Spuls, stated the following potential conflict of interest on her comments form: “I have
participated in an advisory board of LEO Pharma to give guidance to general practitioners regarding what to do if patients used
calcipotriol, which has been removed from the market. I am involved as a Principal Investigator in many clinical trials with systemic
agents for psoriasis and now in one for the improvement of adherence to Dovobet.”
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External sources
• Grant from Crookes Healthcare Ltd. to do original systematic review (1999), UK.
• Grant from the Psoriasis Association to update review (2011), Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are some differences between the protocol and the review.
1. In our protocol, we stated our intention to adjust for the precision of findings from within-patient studies for within-patient
correlation. However, we were unsuccessful in our attempts to identify estimates of this correlation from published or unpublished
sources. We therefore undertook sensitivity analysis to investigate differences between within-patient and between-patient studies.
2. In our protocol, we listed three primary outcome measures for data extraction. In the review, we also included the Patient Assessment
of Global Improvement.
3. In our protocol, we stated that there would be no language restrictions when searching for publications. However, the search for
longer-term studies of adverse events included a restriction to publications in English.
4. In our protocol, we stated our intention that studies meeting only some of the inclusion criteria stated above would be listed as
excluded studies. However, as large numbers of studies would need to be listed, this was not feasible. Therefore, we listed as excluded
studies only those studies that we deemed potentially eligible for inclusion and for which we retrieved full papers, but which we
subsequently found to fail to meet the inclusion criteria.
5. Throughout the text, we replaced all references to vitamin D3 with ’vitamin D analogues’.
6. Under Types of studies, we relaxed the condition that studies were of at least two weeks duration. In the same section, we added
the following sentence: “If no useful effectiveness, withdrawal or adverse events data were available, either from the published paper or
from sponsors or trialists, we excluded the study.”
7. Under Types of interventions, we added the sentence “The potency of topical corticosteroids was based on classifications from a
previous review (Mason 2002b)”.
8. Under Methods, Selection of studies, and our explanations of the studies excluded, we added the searches for studies exploring
adverse events and compliance studies.
9. Under Methods/Data extraction and management, we added the phrase ’between-patient design’.
10. Under Methods/Assessment of risk of bias in included studies, we removed the phrase ’in each arm’.
11. Under Methods/Unit of analysis issues/’Summarising primary outcomes with standardised mean differences’, we revised the text
in this section to include the PAGI outcome and to provide a fuller explanation of our analytic approach.
12. Under Methods/Unit of analysis issues/Secondary outcomes, we gave an explanation regarding the different method of analysis
used.
13 Under Methods/Data collection and analysis/Sensitivity analysis, we added text to describe the different types of sensitivity analysis
undertaken.
14 We replaced ’standardised weighted mean difference’ with ’standardised mean difference’ throughout the text to reflect Cochrane
terminology.
15. Under Methods/Data and analyses/Subgroup analysis and investigation of heterogeneity, we inserted two paragraphs to explain
our approach to statistical heterogeneity.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Topical; Adrenal Cortex Hormones [adverse effects; ∗therapeutic use]; Bone Density Conservation Agents [adverse
effects; ∗therapeutic use]; Chronic Disease; Facial Dermatoses [drug therapy]; Psoriasis [∗drug therapy]; Randomized Controlled Trials
as Topic; Scalp Dermatoses [drug therapy]; Vitamin D [adverse effects; analogs & derivatives; ∗therapeutic use]
MeSH check words
Humans
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